FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Bryce, TN Norrbrink, C Cardenas, DD Dijkers, M Felix, ER Finnerup, NB Kennedy, P Lundeberg, T Richards, JS Rintala, DH Siddall, P Widerstrom-Noga, E AF Bryce, Thomas N. Norrbrink, Cecilia Cardenas, Diana D. Dijkers, Marcel Felix, Elizabeth R. Finnerup, Nanna B. Kennedy, Paul Lundeberg, Thomas Richards, J. Scott Rintala, Diana H. Siddall, Philip Widerstrom-Noga, Eva TI From the 2006 NIDRR SCI measures meeting - Pain after spinal cord injury: An evidence-based review for clinical practice and research SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Review DE pain; chronic; classification; neuropathic; non-neuropathic; treatment outcome; spinal cord injuries; pain scales; reproducibility of results ID QUALITY-OF-LIFE; LOW-BACK-PAIN; RANDOMIZED CONTROLLED-TRIAL; VISUAL ANALOG SCALE; NEUROPATHIC PAIN; SHORT-FORM; DOUBLE-BLIND; COPING STRATEGIES; OUTCOME MEASURES; LEEDS ASSESSMENT AB Background/Objectives: To examine the reliability, validity, sensitivity, and practicality of various outcome measures for pain after spinal cord injury (SCI), and to provide recommendations for specific measures for use in clinical trials. Data Sources: Relevant articles were obtained through a search of MEDLINE, EMBASE, CINAHL, and PubMed databases from inception through 2006. Study Selection: The authors performed literature searches to find articles containing data relevant to the reliability and validity of each pain outcome measure in SCI and selected non-SCI populations. Data Extraction: After reviewing the articles, an investigator extracted information utilizing a standard template. A second investigator reviewed the chosen articles and the extracted pertinent information to confirm the findings of the first investigator. Data Synthesis: Taking into consideration both the quantity and quality of the studies analyzed, judgments on reliability and validity of the measures were made by the two investigators. Based upon these judgments, recommendations were formulated for use of specific measures in future clinical trials. In addition, for a subset of measures a voting process by a larger group of SCI experts allowed formulation of recommendations including determining which measures should be incorporated into a minimal dataset of measures for clinical trials and which ones need revision and further validity and reliability testing before use. Conclusions: A 0-10 Point Numerical Rating Scale (NRS) is recommended as the outcome measure for pain intensity after SCI, while the 7-Point Guy/Farrar Patient Global Impression of Change (PGIC) scale is recommended as the outcome measure for global improvement in pain. The SF-36 single pain interference question and the Multidimensional Pain Inventory (MPI) or Brief Pain Inventory (BPI) pain interference items are recommended as the outcome measures for pain interference after SCI. Brush or cotton wool and at least one high-threshold von Frey filament are recommended to test mechanical allodynia/hyperalgesia while a Peltier-type thermotester is recommended to test thermal allodynia/hyperalgesia. The International Association for the Study of Pain (IASP) or Bryce-Ragnarsson pain taxonomies are recommended for classification of pain after SCI, while the Neuropathic Pain Scale (NPS) is recommended for measuring change in neuropathic pain and the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) for quantitating neuropathic and nociceptive pain discrimination. C1 Mt Sinai Med Ctr, New York, NY 10021 USA. Dandyryds Hosp Karolinska Inst, Stockholm, Sweden. Miami Univ, Dept Rehabil Med, Miami, FL USA. Univ Miami, Miami VA Med Ctr, Miami Project Cure Paralysis, Miami, FL 33124 USA. Univ Aarhus, Danish Res Pain Ctr, DK-8000 Aarhus, Denmark. Univ Oxford, Oxford OX1 2JD, England. Univ Alabama, Dept Phys Med & Rehabil, Birmingham, AL USA. VA Med Ctr, Houston, TX USA. Univ Sydney, Royal N Shore Hosp, Pain Management Res Inst, Sydney, NSW 2006, Australia. RP Bryce, TN (reprint author), Mt Sinai Med Ctr, Dept Rehabil Med, 5 E 98th St,6th Flr,Box 1240B, New York, NY 10021 USA. EM Thomas.bryce@mssm.edu RI Heinemann, Allen /K-6283-2012 OI Heinemann, Allen /0000-0003-2782-7326; Dijkers, Marcel/0000-0002-8362-5596 NR 124 TC 61 Z9 64 U1 2 U2 6 PU AMER PARAPLEGIA SOC PI JACKSON HWIGHTS PA 75-20 ASTORIA BLVD, JACKSON HWIGHTS, NY 11370-1177 USA SN 1079-0268 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PY 2007 VL 30 IS 5 BP 421 EP 440 PG 20 WC Clinical Neurology SC Neurosciences & Neurology GA 236PE UT WOS:000251314400002 PM 18092558 ER PT J AU Bauman, WA Zhang, RL Spungen, AM AF Bauman, William A. Zhang, Run Lin Spungen, Ann M. TI Original contribution - Provocative stimulation of growth hormone: A monozygotic twin study discordant for spinal cord injury SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Article DE spinal cord injuries; growth hormone; insulin-like growth factor-1; paraplegia; arginine stimulation test; monozygotic twins ID GH-DEFICIENT ADULTS; BODY-COMPOSITION; FACTOR-I; INTRAVENOUS ARGININE; MEN; THERAPY; FAT AB Background/Objective: A blunted growth hormone (GH) response to provocative testing and/or low levels of plasma insulin-like growth factor-I (IGF-I) have been reported in persons with spinal cord injury (SCI). A reduction in activity of the GH-IGF-I axis may have deleterious effects on body composition and function. Provocative testing for GH stimulation was performed to determine the response in monozygotic twins that were discordant for SCI. Methods: GH stimulation testing was performed by the administration of intravenous arginine. Results: Nine SCI twins with paraplegia, a mean age of 39 +/- 9 years, and duration of injury of 14 +/- 9 years were studied. The twins with SCI had a significantly lower body mass index than non-SCI twins (22.5 +/- 4.0 vs 25.1 +/- 4.2 kg /m(2); P < 0.05); percent fat mass was greater in the twins with SCI (30 +/- 11 % vs 22 +/- 10%; P < 0.05). Baseline serum GH was correlated with percent fat only in the SCI twins. The response to GH provocative stimulation was less in the twins with SCI: peak GH response was 5.8 6.6 vs 13.0 7.3 ng/mL (P < 0.05), and sum GH response was 15.7 +/- 15.6 vs 30.2 +/- 17.3 ng/mL (P 0.06). Although baseline serum GH was correlated with stimulated response in the SCI twins, this relationship was not found in the non-SCI twins. Adiposity was positively related to the provocative serum GH response in twins with SCI rather than negatively related, as noted in the non-SCI twins. Conclusions: This study confirms and extends prior work that reported a reduction in stimulated GH release in persons with SCI, which was related to baseline values. C1 James J Peters Vet Affairs Med Ctr, Res Serv, Bronx, NY USA. Mt Sinai Sch Med, Spinal Cord Damage Res Ctr, New York, NY USA. Mt Sinai Sch Med, Dept Med, New York, NY USA. Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA. RP Bauman, WA (reprint author), Vet Affairs Med Ctr, Ctr Med Consequence Spinal Cord Injury, SCI Serv, Rm 1E-02,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM william.bauman@med.va.gov NR 23 TC 7 Z9 7 U1 0 U2 0 PU AMER PARAPLEGIA SOC PI JACKSON HWIGHTS PA 75-20 ASTORIA BLVD, JACKSON HWIGHTS, NY 11370-1177 USA SN 1079-0268 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PY 2007 VL 30 IS 5 BP 467 EP 472 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 236PE UT WOS:000251314400007 PM 18092562 ER PT J AU Zhou, XH Qin, GS AF Zhou, Xiao-Hua Qin, Gengsheng TI A supplement to: "A new confidence interval for the difference between two binomial proportions of paired data" SO JOURNAL OF STATISTICAL PLANNING AND INFERENCE LA English DT Editorial Material C1 Univ Washington, Dept Biostat, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Biostat Unit, HSR&D Ctr Excellence, Seattle, WA 98108 USA. Georgia State Univ, Dept Math & Stat, Atlanta, GA 30303 USA. RP Zhou, XH (reprint author), Univ Washington, Dept Biostat, F600 Hlth Sci Box 357232, Seattle, WA 98195 USA. EM azhou@u.washington.edu NR 5 TC 5 Z9 5 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0378-3758 J9 J STAT PLAN INFER JI J. Stat. Plan. Infer. PD JAN 1 PY 2007 VL 137 IS 1 BP 357 EP 358 DI 10.1016/j.jspi.2006.01.001 PG 2 WC Statistics & Probability SC Mathematics GA 092LT UT WOS:000241099000031 ER PT J AU Saunders, G Forsline, A Jacobs, P AF Saunders, Gabrielle Forsline, Anna Jacobs, Peter TI The attitudes towards loss of hearing questionnaire (ALHQ): A comparison of paper and electronic formats SO JOURNAL OF THE AMERICAN ACADEMY OF AUDIOLOGY LA English DT Article DE counseling; hearing aids; hearing aid outcome; questionnaires ID OF-LIFE DATA; QUALITY; SATISFACTION; COLLECTION; STANDARD AB The purpose of the study was to determine whether scores obtained on the ALHQ when completed in electronic format are the same as when completed in paper format. Four groups of 25 individuals participated. Each completed the ALHQ on two occasions in either its paper version, its electronic version, or both. The variance in ALHQ scores from the first to second administrations was compared across test groups. Data showed that the two forms of the questionnaire yielded equivalent scores but that completion in different modes on both occasions resulted in more variability in scores than completion in the same mode on both occasions. It is concluded that when comparing questionnaire data across administrations, the same response format should be used. Electronic completion took longer than paper completion, but it is concluded that the numerous advantages of electronic administration outweigh the disadvantages of additional completion time. C1 Portland VA Med Ctr, Natl Ctr Rehabil Auditory Res, Portland, OR 97213 USA. RP Saunders, G (reprint author), Portland VA Med Ctr, Natl Ctr Rehabil Auditory Res, 3710 SW US Vet Hosp Rd, Portland, OR 97213 USA. EM Gabrielle.saunders@med.va.gov NR 16 TC 2 Z9 3 U1 0 U2 2 PU AMER ACADEMY OF AUDIOLOGY PI RESTON PA 11730 PLAZA DRIVE, STE 300, RESTON, VA 20190 USA SN 1050-0545 J9 J AM ACAD AUDIOL JI J. Am. Acad. Audiol. PD JAN PY 2007 VL 18 IS 1 BP 66 EP 77 DI 10.3766/jaaa.18.1.6 PG 12 WC Audiology & Speech-Language Pathology; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Otorhinolaryngology GA 123WF UT WOS:000243326200006 PM 17252959 ER PT J AU Badgwell, C Rosen, T AF Badgwell, Christy Rosen, Ted TI Cutaneous sarcoidosis therapy updated SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Review ID TUMOR-NECROSIS-FACTOR; ACTIVE PULMONARY SARCOIDOSIS; HUMAN ALVEOLAR MACROPHAGES; BLOOD MONONUCLEAR-CELLS; FACTOR-ALPHA PRODUCTION; LOW-DOSE METHOTREXATE; PULSED DYE-LASER; LUPUS-PERNIO; REFRACTORY SARCOIDOSIS; TNF-ALPHA AB The widely accepted standard therapy for cutaneous sarcoidosis includes corticosteroids, antimalarials, and methotrexate. However, a better understanding of the basic immunopathogenic properties of sarcoidosis has elucidated number of steps critical to the persistence mid progression of disease that may be vulnerable to treatment by targeted therapy. This article reviews both standard and newer therapeutic options for cutaneous sarcoidosis. C1 Baylor Coll Med, Dept Dermatol, Houston, TX 77030 USA. Houston Vet Affairs Med Ctr, Houston, TX USA. RP Rosen, T (reprint author), 2815 Plumb, Houston, TX 77005 USA. EM vampireted@aol.com NR 142 TC 47 Z9 53 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD JAN PY 2007 VL 56 IS 1 BP 69 EP 83 DI 10.1016/j.jaad.2006.06.019 PG 15 WC Dermatology SC Dermatology GA 124AL UT WOS:000243339100008 PM 17190623 ER PT J AU Enwonwu, CO Ritchie, CS AF Enwonwu, Cyril O. Ritchie, Christine S. TI Nutrition and inflammatory markers SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION LA English DT Article DE nutrition; inflammation; periodontal disease ID ACUTE-PHASE RESPONSE; PERIODONTAL-DISEASE; PATHOGENESIS; NUTRIENTS; CYTOKINES; CHILDREN AB Background: Inflammation underlies many chronic diseases. The goal of nutritional support in such diseases is to provide adequate energy and nutrients to. meet the increased requirements for synthesis of acute phase proteins, inflammatory mediators, antioxidant defenses and the promotion of tissue repair and restoration of cellular function. Conclusions. Systemic inflammation alters utilization of various nutrients (fats, carbohydrates and protein) and promotes increased cellular consumption of key I antioxidant vitamins and minerals. Some nutrients play a direct role in the resolution of inflammation. These relationships necessitate consideration of the adjunctive role of diet in the natural history of periodontitis. Clinical Implications: Little. is known about the role of nutrition in periodontitis. With rapid advances in molecular biology and nutritional genomics in particular, oral health scientists can address this important area of study. C1 Univ Maryland, Sch Med, Baltimore, MD 21201 USA. Birmingham VA Med Ctr, Birmingham, AL USA. Univ Alabama, Dept Med, Div Gerontol Geriatr & Pallat Care, Birmingham, AL 35294 USA. RP Ritchie, CS (reprint author), Univ Maryland, Sch Med, Baltimore, MD 21201 USA. EM critchie@uab.edu NR 33 TC 9 Z9 12 U1 0 U2 4 PU AMER DENTAL ASSN PI CHICAGO PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA SN 0002-8177 J9 J AM DENT ASSOC JI J. Am. Dent. Assoc. PD JAN PY 2007 VL 138 IS 1 BP 70 EP 73 PG 4 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 127PI UT WOS:000243598400019 PM 17197404 ER PT J AU Jervis, LL Shore, J Hutt, E Manson, SM AF Jervis, Lori L. Shore, Jay Hutt, Evelyn Manson, Spero M. TI Suboptimal pharmacotherapy in a tribal nursing home SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION LA English DT Article DE nursing homes; medications; psychiatric disorders; rural; American Indians ID INAPPROPRIATE MEDICATION USE; EXPLICIT CRITERIA; DRUG-USE; DEMENTIA; RESIDENTS; INTERVENTIONS; EPIDEMIOLOGY; POPULATION; DEPRESSION; FACILITIES AB Objective: Suboptimal medication use among nursing home (NH) residents is common. NH residentstend to be older, suffer from multiple conditions, and take numerous medications, increasing their risk of serious complications. This article examines pharmacotherapy in a rural, tribally owned NH. Design: Medical records were reviewed and case studies were conducted by a team composed of a medical anthropologist, psychiatrist, and geriatrician. Setting: A rural, American Indian-owned NH in the US northern plains. Participants: 40 American Indian and 5 EuroAmerican NH residents. Measurements: Minimum Data Set assessments, admission records, care plans, social histories, prescription lists, and behavioral consultation reports. Results: Potential underuse affected almost 75% of residents; undertreatment of depressive and psychotic/agitated symptoms was especially common. Potential inappropriate use, especially of analgesics, psychotropics, and antihistamines, affected 30% of residents. A smaller, but still substantial, number of residents (21%) experienced potential overuse, much of which involved anticonvulsants, antibiotics, cardiovascular, and psychotropic agents. The prescription of 10 or more medications was significantly associated with potential drug interactions, as well as underuse, inappropriate medication use, and overuse. Conclusions: Psychotropic medications were the most potentially problematic medication category, and were strongly implicated in potential underuse, inappropriate use, and overuse. Fewer medications; the discontinuation of drugs known to be potentially problematic for NH residents; modification of psychotropic medication regimens; use of cognitive-enhancing medications where appropriate; implementation of an electronic medical record system; and greater use of nonpharmacological behavioral interventions may have substantially improved residents' treatment regimens. C1 Univ Colorado Denver, Dept Psychiat, Amer Indian & Alaska Nat Programs, Aurora, CO 80045 USA. Hlth Sci Ctr UCDHSC, Aurora, CO USA. Denver VA Med Ctr, Denver, CO USA. UCDHSC, Dept Med, Denver, CO USA. RP Jervis, LL (reprint author), Univ Colorado Denver, Dept Psychiat, Amer Indian & Alaska Nat Programs, POB 6508,MS F800, Aurora, CO 80045 USA. EM lori.jervis@uchsc.edu FU NIA NIH HHS [K01 AG 20232] NR 53 TC 6 Z9 6 U1 2 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-8610 J9 J AM MED DIR ASSOC JI J. Am. Med. Dir. Assoc. PD JAN PY 2007 VL 8 IS 1 BP 1 EP 7 DI 10.1016/j.jamda.2006.03.010 PG 7 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 128HY UT WOS:000243650000001 PM 17210496 ER PT J AU He, JCJ Lu, TC Fleet, M Sunamoto, M Husain, M Fang, W Neves, S Chen, Y Shankland, S Iyengar, R Klotman, PE AF He, John Cijiang Lu, Ting-Chi Fleet, Margaret Sunamoto, Masaaki Husain, Mohammad Fang, Wei Neves, Susana Chen, Yibang Shankland, Stuart Iyengar, Ravi Klotman, Paul E. TI Retinoic acid inhibits HIV-1-induced podocyte proliferation through the cAMP pathway SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID ACUTE PROMYELOCYTIC LEUKEMIA; HIV-ASSOCIATED NEPHROPATHY; SIGNALING PATHWAYS; CROSS-TALK; IN-VIVO; EXPRESSION; RECEPTORS; NEF; ACTIVATION; PROTEIN AB HIV-associated nephropathy is characterized by renal podocyte proliferation and dedifferentiation. This study found that all-trans retinoic acid (atRA) reverses the effects of HIV-1 infection in podocytes. Treatment with atRA reduced cell proliferation rate by causing G1 arrest and restored the expression of the differentiation markers (synaptopodin, nephrin, podocin, and WT-1) in HIV-1-infected podocytes. It is interesting that both atRA and 9-cis RA increased intracellular cAMP levels in podocytes. Podocytes expressed most isoforms of retinoic acid receptors (RAR) and retinoid X receptors (RXR) with the exception of RXR gamma. RAR alpha antagonists blocked atRA-induced cAMP production and its antiproliferative and prodifferentiation effects on podocytes, suggesting that RARa is required. For determination of the effect of increased intracellular cAMP on HIV-infected podocytes, cells were stimulated with either forskolin or 8-bromo-cAMP. Both compounds inhibited cell proliferation significantly and restored synaptopodin expression in HIV-infected podocytes. The effects of atRA were abolished by Rp-cAMP, an inhibitor of the cAMP/protein kinase A pathway and were enhanced by rolipram, an inhibitor of phosphodiesterase 4, suggesting that the antiproliferative and prodifferentiation effects of atRA on HIV-infected podocytes are cAMP dependent. Furthermore, both atRA and forskolin suppressed HIV-induced mitogen-activated protein kinase I and 2 and Stat3 phosphorylation. In vivo, atRA reduced proteinuria, cell proliferation, and glomerulosclerosis in HIV-1-transgenic mice. These findings suggest that atRA reverses the abnormal phenotype in HIV-1-infected podocytes by stimulating RAR alpha-mediated intracellular cAMP production. These results demonstrate the mechanism by which atRA reverses the proliferation of podocytes that is induced by HIV-1. C1 CUNY Mt Sinai Sch Med, Div Nephrol, Dept Med, New York, NY 10029 USA. CUNY Mt Sinai Sch Med, Div Nephrol, Dept Pharmacol & Biochem, New York, NY 10029 USA. James J Peters VA Med Ctr, Bronx, NY USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. RP He, JCJ (reprint author), CUNY Mt Sinai Sch Med, Div Nephrol, Dept Med, Box 1243,1 Gustave L Levy Pl, New York, NY 10029 USA. EM cijiang.he@mssm.edu FU NIDDK NIH HHS [DK-65495, P01DK056492, R01 DK078897, P01 DK056492, K08 DK065495]; NIGMS NIH HHS [GM-54508, F31 GM065065, R01 GM054508, GM-65065] NR 43 TC 55 Z9 58 U1 0 U2 3 PU AMERICAN SOCIETY NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD JAN PY 2007 VL 18 IS 1 BP 93 EP 102 DI 10.1681/ASN.2006070727 PG 10 WC Urology & Nephrology SC Urology & Nephrology GA 126TG UT WOS:000243537800013 PM 17182884 ER PT J AU de Boer, IH Sibley, SD Kestenbaum, B Sampson, JN Young, B Cleary, PA Steffes, MW Weiss, NS Brunzell, JD AF de Boer, Ian H. Sibley, Shalamar D. Kestenbaum, Bryan Sampson, Joshua N. Young, Bessie Cleary, Patricia A. Steffes, Michael W. Weiss, Noel S. Brunzell, John D. CA Diabet Control & Complicat Trial TI Central obesity, incident microalbuminuria, and change in creatinine clearance in the epidemiology of diabetes interventions and complications study SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID CHRONIC KIDNEY-DISEASE; INSULIN-RESISTANCE; METABOLIC SYNDROME; RISK-FACTORS; INTENSIVE TREATMENT; ALBUMIN EXCRETION; RENAL-FUNCTION; WEIGHT-GAIN; NEPHROPATHY; MELLITUS AB Weight gain and central obesity are associated with insulin resistance, hypertension, and dyslipidemia in type 1 diabetes. These metabolic abnormalities are risk factors for kidney disease in the general population, but data addressing the relationship of central obesity with kidney disease in type I diabetes are limited. Whether waist circumference is associated with incident microalbuminuria and change in creatinine clearance was examined among 1279 participants who had type 1 diabetes and were enrolled in the Epidemiology of Diabetes Interventions and Complications Study, the observational extension of the Diabetes Control and Complications Trial (DCCT). Ninety-three of 1105 participants with normal albumin excretion rate (AER) at DCCT closeout developed incident microalbuminuria over 5.8 yr of follow-up. The hazard ratio for incident microalbuminuria that was associated with each 10-cm greater waist circumference at DCCT closeout was 1.34 (95% confidence interval 1.07 to 1.68), after adjustment for DCCT closeout age, gender, duration of diabetes, treatment group, smoking status, glycosylated hemoglobin, and AER. This increased risk was modestly attenuated when additional adjustment was made for levels of BP and serum lipids. Creatinine clearance declined by an average of 0.34 ml/min per 1.73 m(2) each yr over 8 yr of follow-up. Greater rate of decline in creatinine clearance was associated with greater age, conventional insulin therapy during the DCCT, smoking, and greater glycosylated hemoglobin and AER at DCCT closeout but not with waist circumference. In conclusion, waist circumference predicts the subsequent development of microalbuminuria in type 1 diabetes. In contrast, no association of waist circumference with decline in creatinine clearance was observed. C1 Univ Washington, Div Nephrol, Seattle, WA 98195 USA. Univ Washington, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. Univ Washington, Dept Biostat, Seattle, WA 98195 USA. Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Div Gen Internal Med, Seattle, WA 98195 USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA. Univ Minnesota, Div Diabet Endocrinol, Minneapolis, MN USA. George Washington Univ, Ctr Biostat, Rockville, MD USA. RP de Boer, IH (reprint author), Univ Washington, Div Nephrol, Box 356521,BB-1265 Hlth Sci Bldg,1959 NE Pacific, Seattle, WA 98195 USA. EM deboer@u.washington.edu FU NCRR NIH HHS [5 K12 RR023265-03, K12 RR023265, M01 RR001066, M01-RR01066]; NHLBI NIH HHS [HL004136, K30 HL004136]; NIDDK NIH HHS [DK02456, DK007247, DK599445, N01 DK062204, N01 DK062204-007, P01 DK002456, T32 DK007247] NR 36 TC 71 Z9 74 U1 0 U2 5 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 EI 1533-3450 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD JAN PY 2007 VL 18 IS 1 BP 235 EP 243 DI 10.1681/ASN.2006040394 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA 126TG UT WOS:000243537800026 PM 17151331 ER PT J AU Fried, LF Biggs, ML Shlipak, MG Seliger, S Kestenbaum, B Stehman-Breen, C Sarnak, M Siscovick, D Harris, T Cauley, J Newman, AB Robbins, J AF Fried, Linda F. Biggs, Mary Louise Shlipak, Michael G. Seliger, Stephen Kestenbaum, Bryan Stehman-Breen, Catherine Sarnak, Mark Siscovick, David Harris, Tamara Cauley, Jane Newman, Anne B. Robbins, John TI Association of kidney function with incident hip fracture in older adults SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID GLOMERULAR-FILTRATION-RATE; CYSTATIN-C; CARDIOVASCULAR HEALTH; SERUM CREATININE; ELDERLY PERSONS; RENAL-DISEASE; RISK; HOMOCYSTEINE; OSTEOPOROSIS; FAILURE AB Kidney dysfunction is associated with bone loss, and patients with ESRD have an increased risk for hip fracture. However, the association of mild to moderate kidney disease with hip fracture has not been studied previously. The association of kidney function with incident hip fracture was examined among participants in the Cardiovascular Health Study, a community-based cohort of older individuals. The primary measure of kidney function was serum cystatin C, a measure that does not depend on lean mass. Hip fractures were identified using International Classification of Diseases, Ninth Revision codes for hospitalizations. A total of 4699 individuals had cystatin C measured in 1992 to 1993 and did not have a hip fracture before cystatin C measurement. The association of kidney function with hip fracture was analyzed with Cox proportional hazards models. Analyses were conducted separately for men and women. After a mean follow-up of 7.1 yr, 195 incident hip fractures occurred in women and 79 occurred in men. Higher cystatin C levels were associated with a higher risk for fracture in women (hazard ratio [HR] 1.26; 95% confidence interval [CI] 1.14 to 1.38 per SD) and in men (HR 1.27; 95% CI 1.11 to 1.46). After multivariable adjustment, higher cystatin C levels were significantly associated with hip fracture in women (HR 1.16; 95% Cl 1.01, 1.33) but not in men (HR 1.14; 95% CI 0.86 to 1.52), although the magnitude of the association was similar. Kidney dysfunction, as assessed by cystatin C, is associated with an increased risk for hip fracture. Further studies are needed to evaluate potential mediators of this relationship and to assess whether interventions can decrease this risk. C1 Univ Pittsburgh, Sch Med, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Sch Med, Div Geriatr, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. Univ Washington, Dept Med, Seattle, WA USA. Univ Washington, Collaborat Hlth Studies Coordinating Ctr, Seattle, WA 98195 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA USA. Univ Calif San Francisco, VA Med Ctr, San Francisco, CA 94143 USA. Univ Maryland, Sch Med, Div Nephrol, Baltimore, MD 21201 USA. Univ Washington, Sch Med, Div Nephrol, Seattle, WA USA. Amgen Inc, Thousand Oaks, CA USA. Tufts Univ, New England Med Ctr, Dept Med, Boston, MA 02111 USA. NIA, NIH, Bethesda, MD 20892 USA. Univ Calif Davis, Dept Med, Davis, CA 95616 USA. RP Fried, LF (reprint author), Univ Pittsburgh, Sch Med, VA Pittsburgh Healthcare Syst, Univ Dr C,Mailstop 111F-U, Pittsburgh, PA 15240 USA. EM linda.fried@med.va.gov RI Newman, Anne/C-6408-2013; Cauley, Jane/N-4836-2015 OI Newman, Anne/0000-0002-0106-1150; Cauley, Jane/0000-0003-0752-4408 FU NHLBI NIH HHS [N01-HC-15103, N01-HC-35129, N01-HC-85079, N01-HC-85086] NR 25 TC 92 Z9 92 U1 1 U2 7 PU AMERICAN SOCIETY NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD JAN PY 2007 VL 18 IS 1 BP 282 EP 286 DI 10.1681/ASN.2006050546 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 126TG UT WOS:000243537800031 PM 17167115 ER PT J AU Kane, CJ Presti, JC Amling, CL Aronson, WJ Terris, MK Freedland, SJ AF Kane, Christopher J. Presti, Joseph C. Amling, Christopher L. Aronson, William J. Terris, Martha K. Freedland, Stephen J. CA SEARCH Database Study Grp TI Changing nature of high risk patients undergoing radical prostatectomy SO JOURNAL OF UROLOGY LA English DT Article DE prostate; adenocarcinoma; prostate-specific antigen; prostatectomy; outcome assessment (health care) ID EXTERNAL-BEAM RADIATION; CANCER; MANAGEMENT; OUTCOMES; THERAPY; RADIOTHERAPY; RECURRENCE; CAPSURE; TRENDS AB Purpose: We examined the outcomes of radical prostatectomy alone in high risk patients with prostate cancer and evaluated changes in high risk prostate cancer outcomes with time. Materials and Methods: From 1988 to 2003, 251 men with high risk prostate cancer (prostate specific antigen more than 20 ng/ml and/or biopsy Gleason greater than 7) were identified in a cohort of 1,796 (14%) enrolled in the Shared Equal Access Regional Cancer Hospital Database. Temporal changes in clinicopathological characteristics and prostate specific antigen recurrence rates were examined stratified by 4, 4-year periods. Results: With time significantly more men were considered at high risk due to a high biopsy Gleason score relative to prior years; when the most common reason for being considered at high risk was increased PSA (p < 0.001). Only 3% of high risk men from 2000 to 2003 had increased prostate specific antigen and high biopsy Gleason score compared to 23% from 1988 to 1991. With time there were no differences in biochemical recurrence rates (p = 0.147). Men with a high biopsy Gleason score and increased prostate specific antigen had worse outcomes than men with only a high Gleason score or men with only high prostate specific antigen (p = 0.046 and 0.081, respectively). On multivariate analysis that only included preoperative clinical characteristics only prostate specific antigen was an independent predictor of prostate specific antigen failure following radical prostatectomy (p = 0.014). There was a trend, which did not attain statistical significance, for higher biopsy Gleason scores and higher clinical stage to be associated with higher failure rates (p = 0.060 and 0.081, respectively). Conclusions: Patients are designated as high risk by Gleason grade more commonly now than early in the prostate specific antigen era. Outcomes in high risk patients undergoing radical prostatectomy alone have not significantly improved with time. New treatment strategies, such as multimodality therapy, are needed to improve outcomes in high risk patients with prostate cancer. C1 Univ Calif San Francisco, Dept Urol, Sch Med, San Francisco, CA 94143 USA. Vet Adm Med Ctr, Dept Surg, Urol Sect, San Francisco, CA 94121 USA. Stanford Univ, Sch Med, Dept Urol, Stanford, CA 94305 USA. Vet Adm Med Ctr, Dept Surg, Urol Sect, Palo Alto, CA 94304 USA. USN Hosp, Dept Urol, San Diego, CA 92134 USA. Vet Adm Greater Los Angeles Healthcare Syst, Dept Surg, Urol Sect, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, Dept Urol, Los Angeles, CA USA. Vet Adm Med Ctr, Dept Surg, Augusta, GA 30904 USA. Med Coll Georgia, Urol Sect, Augusta, GA 30912 USA. Vet Adm Med Ctr, Dept Surg, Durham, NC 27705 USA. Duke Univ, Sch Med, Dept Surg, Div Urol Surg, Durham, NC USA. Duke Univ, Sch Med, Dept Pathol, Durham, NC USA. Duke Univ, Sch Med, Duke Prostate Ctr, Durham, NC USA. RP Kane, CJ (reprint author), Univ Calif San Francisco, Dept Urol, Sch Med, 1600 Divisadero St,Room A607, San Francisco, CA 94143 USA. OI Terris, Martha/0000-0002-3843-7270 FU NCI NIH HHS [P50 CA92131-01A1, R01CA100938] NR 20 TC 47 Z9 49 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD JAN PY 2007 VL 177 IS 1 BP 113 EP 117 DI 10.1016/j.juro.2006.08.057 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 116ZV UT WOS:000242843200029 PM 17162017 ER PT J AU Lee, SWH Cheah, PY Liong, ML Yuen, KH Schaeffer, AJ Propert, K Krieger, JN AF Lee, Shaun Wen Huey Cheah, Phaik Yeong Liong, Men Long Yuen, Kah Hay Schaeffer, Anthony J. Propert, Kathleen Krieger, John N. CA M Study Grp CPCRN Grp TI Demographic and clinical characteristics of chronic prostatitis: Prospective comparison of the University of Sciences Malaysia Cohort with the United States National Institutes of Health Cohort SO JOURNAL OF UROLOGY LA English DT Article; Proceedings Paper CT 101st Annual Meeting of the American-Urological-Association CY MAY 20-25, 2006 CL Atlanta, GA SP Amer Urolog Assoc DE pelvic pain; prostate; cohort studies; academic medical centers; National Institutes of Health (US) ID PELVIC PAIN SYNDROME; SYMPTOM INDEX; DOUBLE-BLIND; MEN; TRIAL; CIPROFLOXACIN; THERAPY AB Purpose: We compared demographic and clinical characteristics of the University of Sciences Malaysia Chronic Prostatitis Cohort to the United States National Institutes of Health Chronic Prostatitis Cohort. Materials and Methods: Participants met the same definition of chronic prostatitis/chronic pelvic pain syndrome. Each participant had extensive demographic, medical history, previous treatment, clinical and laboratory evaluations. Results: The University of Sciences Malaysia and National Institutes of Health cohorts proved similar in most respects. National Institutes of Health-Chronic Prostatitis Symptom Index total scores, pain and urinary subscores were similar for the 332 University of Sciences Malaysia Chronic Prostatitis Cohort and 488 National Institutes of Health Chronic Prostatitis Cohort. participants. Differences included worse quality of life subscore for the University of Sciences Malaysia Chronic Prostatitis Cohort., differences in the location, number of sites, and types of pain/discomfort between the 2 populations, and that the University of Sciences Malaysia participants had received less previous treatment. Conclusions: The demographic characteristics and clinical presentation of chronic prostatitis/chronic pelvic pain syndrome proved remarkably similar in these diverse populations. Both cohorts experienced major reduction in their quality of life from chronic pelvic pain and urinary symptoms. Comparison of diverse populations using standard clinical, laboratory and assessment. instruments is feasible, and may provide important insights into chronic prostatitis/chronic pelvic pain syndrome and the factors that determine clinical outcome. C1 Univ Washington, Sch Med, VA Puget Sound Hlth Care Syst, Dept Urol Surg, Seattle, WA 98108 USA. Lam Wah Ee Hosp, Dept Urol, George Town, Malaysia. Northwestern Univ, Dept Urol, Chicago, IL 60611 USA. Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. RP Krieger, JN (reprint author), Univ Washington, Sch Med, VA Puget Sound Hlth Care Syst, Dept Urol Surg, 1660 S Columbian Way, Seattle, WA 98108 USA. EM jkrieger@u.washington.edu RI Yuen, Kah Hay /F-9059-2010 OI Lee, Shaun/0000-0001-7361-6576 FU NIDDK NIH HHS [R01 DK53730, R01 DK53732, R01 DK53734, R01 DK53736, R01 DK53746, R01 DK53752, U01 DK065266-02] NR 13 TC 14 Z9 16 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD JAN PY 2007 VL 177 IS 1 BP 153 EP 157 DI 10.1016/j.juro.2006.08.098 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 116ZV UT WOS:000242843200039 PM 17162027 ER PT J AU Carnevale, E Fogel, E Aplin, AC Gelati, M Howson, KM Zhu, WH Nicosia, RF AF Carnevale, Edvige Fogel, Eric Aplin, Alfred C. Gelati, Maurizio Howson, Karen M. Zhu, Wen-Hui Nicosia, Roberto F. TI Regulation of postangiogenic neovessel survival by beta(1) and beta(3) integrins in collagen and fibrin matrices SO JOURNAL OF VASCULAR RESEARCH LA English DT Article DE aorta; vascular regression; angiogenesis; collagen; fibrin; GM6001; endothelium ID ENDOTHELIAL GROWTH-FACTOR; RAT AORTA MODEL; ALPHA(2)BETA(1) INTEGRINS; 3-DIMENSIONAL COLLAGEN; CELL MORPHOGENESIS; LUMEN FORMATION; ANGIOGENESIS; REGRESSION; EXPRESSION; METALLOPROTEINASE AB We used the aortic ring model of angiogenesis to investigate the role of beta(1) and beta(3) integrins in postangiogenic vascular survival in collagen and fibrin matrices. Confocal microscopy studies showed that both beta(1) and beta(3) integrins were expressed in endothelial cells and pericytes of sprouting neovessels. Antibody blocking experiments demonstrated that beta(1) integrins but not beta(3) integrins were required for angiogenic sprouting in collagen. Conversely, in fibrin, blockade of both integrins was needed to inhibit angiogenesis whereas treatment with either antibody alone was ineffective. Antibody-mediated blockade of beta(1) but not beta(3) integrins accelerated vascular regression in collagen. In contrast, both anti-beta(1) and -beta(3) integrin antibodies were required to promote neovessel breakdown in fibrin. These results demonstrate that angiogenic sprouting and postangiogenic neovessel survival in collagen are critically dependent on beta(1) integrins. They also indicate that these processes involve a redundant repertoire of beta(1) and beta(3) integrins when angiogenesis occurs in fibrin. Thus, pharmacologic targeting of integrin receptors aimed at blocking neovessel formation and survival must be tailored to the specific extracellular matrix environment in which angiogenesis takes place. Copyright (c) 2007 S. Karger AG, Basel. C1 VA Puget Sound Hlth Care Syst, Div Pathol & Lab Med S 113 Lab, Seattle, WA 98108 USA. Univ Washington, Dept Pathol, Seattle, WA 98108 USA. Carlo Besta Inst, Lab Neurobiol & Neuroregenerat Med, Milan, Italy. RP Nicosia, RF (reprint author), VA Puget Sound Hlth Care Syst, Div Pathol & Lab Med S 113 Lab, 1660 S Columbian Way, Seattle, WA 98108 USA. EM roberto.nicosia@va.gov RI Gelati, Maurizio/H-2110-2016 OI Gelati, Maurizio/0000-0002-4828-9849 FU NHLBI NIH HHS [HL 52585] NR 31 TC 17 Z9 19 U1 0 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1018-1172 J9 J VASC RES JI J. Vasc. Res. PY 2007 VL 44 IS 1 BP 40 EP 50 DI 10.1159/000097976 PG 11 WC Physiology; Peripheral Vascular Disease SC Physiology; Cardiovascular System & Cardiology GA 127DA UT WOS:000243564300005 PM 17167269 ER PT J AU Martin, JL Marler, MR Harker, JO Josephson, KR Alessi, CA AF Martin, Jennifer L. Marler, Matthew R. Harker, Judith O. Josephson, Karen R. Alessi, Cathy A. TI A multicomponent nonpharmacological intervention improves activity rhythms among nursing home residents with disrupted sleep/wake patterns SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article ID PHASE RESPONSE CURVE; BRIGHT LIGHT THERAPY; ALZHEIMERS-DISEASE; CIRCADIAN-RHYTHMS; INCONTINENCE CARE; PHYSICAL-ACTIVITY; ELDERLY SUBJECTS; OLDER-ADULTS; DISTURBANCES; DEMENTIA AB Background. Sleep and circadian rhythms are disrupted among many nursing home (NH) residents. We examined the impact of a multicomponent nonpharmacological intervention on 24-hour rest/activity rhythms among long-stay NH residents. Methods. The study was a randomized controlled trial in which, following a 3-day baseline, participants received 5 days of either usual care (control condition) or the active intervention. The intervention combined increased exposure to outdoor bright light, efforts to keep residents out of bed during the day, structured physical activity, institution of a bedtime routine, and efforts to reduce nighttime noise and light in residents' rooms. For 100 residents with baseline and follow-up wrist actigraphy data (mean age = 87 years; 76% women), rest/activity rhythms were modeled to determine the rhythm acrophase (peak time), nadir (trough time), midline estimating statistic of rhythm (MESOR) (midpoint), amplitude (height of peak), slope, and the rest period/active period ratio (a). Results. The intervention led to an increase in the duration of the "active" portion of the rhythm, which was primarily accounted for by a shift in the rest/activity rhythm rise to an earlier time. Findings persisted when analyses were adjusted for age, cognitive functioning, medical comorbidities, and behavioral disturbances. Conclusions. These findings suggest that the intervention may effectively improve the robustness of rest/activity rhythms in NH residents. Further research is needed to examine the impact of similar interventions on other measures of circadian rhythms (e.g., body temperature, melatonin) among NH residents. C1 Univ Calif Los Angeles, Multicampus Program Geriatr Med & Gerontol, Los Angeles, CA USA. Geriatr Res Educ & Clin Ctr, VA Greater Los Angeles Healthcare Syst, Sepulveda, CA USA. Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. RP Martin, JL (reprint author), GRECC, VA Sepulveda, 11E,16111 Plummer St, North Hills, CA 91343 USA. EM jennifer.martin@va.gov FU NIA NIH HHS [AG-10415, R29 AG13885] NR 46 TC 47 Z9 48 U1 2 U2 8 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1030 15TH ST NW, STE 250, WASHINGTON, DC 20005202-842 USA SN 1079-5006 J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD JAN PY 2007 VL 62 IS 1 BP 67 EP 72 PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 178KS UT WOS:000247220200010 PM 17301040 ER PT J AU Mckibbin, T Burzynski, J Greene, R Ochoa-Bayona, J Tsai, TW Callander, N Freytes, C AF Mckibbin, Trevor Burzynski, Julianna Greene, Rebecca Ochoa-Bayona, Jose Tsai, T. W. Callander, Natalie Freytes, Cesar TI Paclitaxel and filgrastim for hematopoietic progenitor cell mobilization in patients with hematologic malignancies after failure of a prior mobilization regimen SO LEUKEMIA & LYMPHOMA LA English DT Article DE stem cell mobilization; marrow and stem cell transplantation; paclitaxel; leukapheresis; hematopoietic stem cell ID BONE-MARROW TRANSPLANTATION; COLONY-STIMULATING FACTOR; NON-HODGKINS-LYMPHOMA; HIGH-DOSE CYCLOPHOSPHAMIDE; BLOOD STEM-CELLS; PLUS G-CSF; MULTIPLE-MYELOMA; RANDOMIZED-TRIAL; STEADY-STATE; CHEMOTHERAPY AB Paclitaxel and G-CSF have been evaluated for HPC mobilization in breast cancer and found to have tolerable toxicity with a predictable time to initiate leukapheresis. However, this approach has not been reported in patients with hematologic malignancies failing prior mobilization. We report a case-series of 26 adults given paclitaxel and G-CSF for HPC mobilization after failure of an initial mobilization. Patients received paclitaxel 250 mg/m(2) followed by G-CSF 10-16 mcg/kg/day. Compared to the initial regimen, paclitaxel mobilization produced greater CD34+ cell yields ( median 1.53 x 10(6) CD34+ cells/kg vs. 0.79 x 10(6) CD34+ cells/kg, p = 0.004). Seventy-six percent of patients initiated leukapheresis on day 8, the remainder on day 9 or 10. Three patients developed febrile neutropenia resulting in one death prior to leukapheresis. Overall, 73% of patients proceeded with autologous HPC transplant. This case-series suggests paclitaxel may be an option for HPC mobilization in patients failing prior regimens. C1 [Mckibbin, Trevor; Burzynski, Julianna; Greene, Rebecca] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacotherapy, San Antonio, TX 78229 USA. [Mckibbin, Trevor; Burzynski, Julianna; Greene, Rebecca] Univ Texas, Coll Pharm, Austin, TX USA. [Mckibbin, Trevor; Burzynski, Julianna; Greene, Rebecca; Ochoa-Bayona, Jose; Freytes, Cesar] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Ochoa-Bayona, Jose; Tsai, T. W.; Callander, Natalie; Freytes, Cesar] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX USA. RP Mckibbin, T (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacotherapy, 7703 Floyd Curl Dr, MSC 6220, San Antonio, TX 78229 USA. EM trevor.mckibbin@gmail.com NR 29 TC 3 Z9 3 U1 0 U2 0 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1042-8194 J9 LEUKEMIA LYMPHOMA JI Leuk. Lymphoma PY 2007 VL 48 IS 12 BP 2360 EP 2366 DI 10.1080/10428190701665970 PG 7 WC Oncology; Hematology SC Oncology; Hematology GA 239KI UT WOS:000251516800028 PM 18067011 ER PT S AU Spassieva, S Bielawski, A Anelli, V Obeid, LM AF Spassieva, Stefka Bielawski, Acek Anelli, Viviana Obeid, Lina M. BE Brown, HA TI Combination of C(17) sphingoid base homologues and mass spectrometry analysis as a new approach to study sphingolipid metabolism SO LIPIDOMICS AND BIOACTIVE LIPIDS: LIPIDS AND CELL SIGNALING SE Methods in Enzymology LA English DT Review; Book Chapter ID LONGEVITY ASSURANCE GENES; LONG-CHAIN BASES; FUNCTIONAL-CHARACTERIZATION; CERAMIDE SYNTHESIS; MOLECULAR-CLONING; KINASE-ACTIVITY; FAMILY-MEMBERS; PHOSPHORYLATION; LAG1; BIOSYNTHESIS AB In recent years, sphingolipid metabolites ceramide, sphingosine, and sphingosine-1-phosphate have emerged as important second messengers in addition to their role as precursors of biomembrane components. The investigation of these sphingolipid metabolites requires the development of new, more sensitive methods for assaying the enzymes involved in their production. This chapter describes the utilization of mass spectrometry technology in combination with nonnaturally occurring C(17) sphingoid bases in the in vitro assays of two of the enzymes of the sphingolipid pathway, ceramide synthase and sphingosine kinase. These new in vitro methods provide high sensitivity and extreme accuracy even when crude extracts are used as enzyme sources. C1 Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Spassieva, S (reprint author), Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. OI obeid, lina/0000-0002-0734-0847 FU NCI NIH HHS [P01 CA097132]; NIA NIH HHS [R01 AG016583]; NIGMS NIH HHS [R01 GM062887] NR 31 TC 21 Z9 21 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 0076-6879 BN 978-0-12-373965-0 J9 METHOD ENZYMOL JI Methods Enzymol. PY 2007 VL 434 BP 233 EP 241 DI 10.1016/S0076-6879(07)34012-3 PG 9 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BGX42 UT WOS:000251128300012 PM 17954250 ER PT J AU James, JA Kim-Howard, XR Bruner, BF Jonsson, MK McClain, MT Arbuckle, MT Walker, C Dennis, GJ Merrill, JT Harley, JB AF James, J. A. Kim-Howard, X. R. Bruner, B. F. Jonsson, M. K. McClain, M. T. Arbuckle, M. T. Walker, C. Dennis, G. J. Merrill, J. T. Harley, J. B. TI Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus SO LUPUS LA English DT Article DE hydroxychloroquine; SLE; systemic lupus erythematosus; therapy ID CONNECTIVE-TISSUE DISEASE; REVISED CRITERIA; LONG-TERM; FOLLOW-UP; ANTIBODIES; COHORT; AUTOANTIBODIES; CLASSIFICATION; EXACERBATIONS; ANTIMALARIALS AB Systemic lupus erythematosus (SLE) is a clinically diverse, complex autoimmune disease which may present with coincident onset of many criteria or slow, gradual symptom accrual. Early intervention has been postulated to delay or prevent the development of more serious sequelae. One option for treatment in this setting is hydroxychloroquine. Using 130 US military personnel who later met ACR SLE criteria, a retrospective study of onset, development and progression of SLE with and without pre-classification hydroxychloroquine (n = 26) use was performed. Patients treated with hydroxychloroquine prior to diagnosis had a longer (Wilcoxon signed rank test, P = 0.018) time between the onset of the first clinical symptom and SLE classification (median: 1.08 versus 0.29 years). Patients treated with prednisone before diagnosis also more slowly satisfied the classification criteria (Wilcoxon signed rank test, P = 0.011). The difference in median times between patients who received NSAIDs before diagnosis, as opposed to those who did not, was not different (P = 0.19). Patients treated with hydroxychloroquine also had a lower rate of autoantibody accumulation and a decreased number of autoantibody specificities at and after diagnosis. These findings are consistent with early hydroxychloroquine use being associated with delayed SLE onset. A prospective, blinded trial testing the capacity of hydroxychloroquine to delay or prevent SLE in high risk populations is warranted. C1 Oklahoma Med Res Fdn, Arthritis & Immunol Program, Oklahoma City, OK 73104 USA. Univ Oklahoma Hlth Sci, Dept Med, Oklahoma City, OK 73104 USA. Univ Oklahoma Hlth Sci, Dept Pathol, Oklahoma City, OK 73104 USA. Oklahoma Med Res Fdn, Genet Epidemiol Unit, Oklahoma City, OK 73104 USA. Univ Bergen, Broegelmann Res Lab, N-5020 Bergen, Norway. Walter Reed Army Med Ctr, Dept Rheumatol, Washington, DC 20307 USA. NIAMSD, Bethesda, MD 20892 USA. Oklahoma Med Res Fdn, Clin Pharmacol Program, Oklahoma City, OK 73104 USA. US Dept Vet Affairs, Oklahoma City, OK 73104 USA. RP James, JA (reprint author), Oklahoma Med Res Fdn, Arthritis & Immunol Program, 825 NE 13th St, Oklahoma City, OK 73104 USA. EM jamesj@omrf.ouhsc.edu FU NCRR NIH HHS [RR15577, RR20143]; NIAID NIH HHS [AI31584, AI50350, AI62629]; NIAMS NIH HHS [AR45084, AR45451, AR48045, AR48980, AR49084, P30 AR053483]; PHS HHS [ARC24717, ARC49084] NR 21 TC 59 Z9 62 U1 0 U2 0 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0961-2033 J9 LUPUS JI Lupus PY 2007 VL 16 IS 6 BP 401 EP 409 DI 10.1177/0961203307078579 PG 9 WC Rheumatology SC Rheumatology GA 196GZ UT WOS:000248471000003 PM 17664230 ER PT J AU Ganz, DA Wenger, NS Roth, CP Kamberg, CJ Chang, JT MacLean, CH Young, RT Solomon, DH Higashi, T Min, LL Reuben, DB Shekelle, PG AF Ganz, David A. Wenger, Neil S. Roth, Carol P. Kamberg, Caren J. Chang, John T. MacLean, Catherine H. Young, Roy T. Solomon, David H. Higashi, Takahiro Min, Lillian Reuben, David B. Shekelle, Paul G. TI The effect of a quality improvement initiative on the quality of other aspects of health care - The law of unintended consequences? SO MEDICAL CARE LA English DT Article; Proceedings Paper CT Annual Meeting of the American-Geriatrics-Society CY MAY 03-07, 2006 CL Chicago, IL SP Amer Geriatr Soc DE quality improvement; quality of care; geriatrics; health services research ID VULNERABLE ELDERS; OLDER PATIENTS; MEDICAL-CARE; INDICATORS; COMMUNITY; INFORMATION; DEMENTIA; INCONTINENCE; INTERVENTION; MANAGEMENT AB Problem: Policymakers and clinicians are concerned that initiatives to improve the quality of care for some conditions may have unintended negative consequences for quality in other conditions. Objective: We sought to determine whether a practice redesign intervention that improved care for falls, incontinence, and cognitive impairment by an absolute 15% change also affected quality of care for masked conditions (conditions not targeted by the intervention). Design, Setting, and Participants: Controlled trial in 2 community medical groups, with 357 intervention and 287 control patients age 75 years or older who had difficulty with falls, incontinence, or cognitive impairment. Intervention: Both intervention and control practices implemented case-finding for target conditions, but only intervention practices received a multicomponent practice-change intervention. Quality of care in the intervention practices improved for 2 of the target conditions (falls and incontinence). Main Outcome Measures: Percent of quality indicators satisfied for a set of 9 masked conditions measured by abstraction of medical records. Results: Before the intervention, the overall percent of masked indicators satisfied was 69% in the intervention group and 67% in the control group. During the intervention period, these percentages did not change, and there was no difference between intervention and control groups for the change in quality between the 2 periods (P = 0.86). The intervention minus control difference-in-change for the percent of masked indicators satisfied was 0.2% (bootstrapped 95% confidence interval, -2.7% to 2.9%). Subgroup analyses by clinical condition and by type of care process performed by the clinician did not show consistent results favoring either the intervention or the control group. Conclusion: A practice-based intervention that improved quality of care for targeted conditions by an absolute 15% change did not affect measurable aspects of care on a broad set of masked quality measures encompassing 9 other conditions. C1 Vet Affairs Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. UCLA STAR Program, Los Angeles, CA USA. RAND Hlth, Santa Monica, CA USA. Kyoto Univ, Dept Epidemiol & Hlth Care Res, Kyoto, Japan. RP Ganz, DA (reprint author), Robert Wood Johnson VA Clin Scholars Program, 911 Broxton Plaza,3rd Floor, Los Angeles, CA 90024 USA. EM dganz@mednet.ucla.edu NR 22 TC 34 Z9 34 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD JAN PY 2007 VL 45 IS 1 BP 8 EP 18 DI 10.1097/01.mlr.0000241115.31531.15 PG 11 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 123RO UT WOS:000243313400004 PM 17279017 ER PT J AU Kahn, KL MacLean, CH Liu, HH Rubenstein, LZ Wong, AL Harker, JO Chen, WP Fitzpatrick, DM Bulpitt, KJ Traina, SB Mittman, BS Hahn, BH Paulus, HE AF Kahn, Katherine L. MacLean, Catherine H. Liu, Honghu Rubenstein, Laurence Z. Wong, Andrew L. Harker, Judith O. Chen, Wen-Pin Fitzpatrick, Diane M. Bulpitt, Ken J. Traina, Shana B. Mittman, Brian S. Hahn, Bevra H. Paulus, Harold E. TI The complexity of care for patients with rheumatoid arthritis - Metrics for better understanding chronic disease care SO MEDICAL CARE LA English DT Article DE chronic disease; rheumatoid arthritis; quality ID IMPROVING PRIMARY-CARE; CHRONIC ILLNESS; PUBLIC-HEALTH; QUESTIONNAIRE; MANAGEMENT; MEDICINE; CRITERIA; OUTCOMES; SCALES; SF36 AB Background: Patients with rheumatoid arthritis (RA) provide an important opportunity for understanding care of patients with a serious chronic condition. Objectives: We sought to characterize the complexity of care for patients with RA, including metrics describing the patient, the disease, and use of the health care system across time and place. Methods: We undertook a prospective cohort study of 568 community-dwelling patients with RA by using observational data from clinically detailed telephone interviews at baseline and 2 years later in addition to medical record abstraction. Health status, comorbidity, use of disease-modifying antirheumatic drugs, visits, providers, provider types, encounter settings, and the discontinuity between patients and providers were studied. Results: Within a 12-month window, 568 patients had 8686 outpatient encounters with the health care system with a mean of 3.41 unique providers per patient associated with a mean of 5 primary care and 6 rheumatologist visits. Half did not see a primary care physician, and 20% did not see a rheurnatologist during 6-month periods despite their use of potentially toxic drugs, a mean of 4 comorbidities and progressive RA. Over the course of 24 months, 29% of patients changed their primary care provider, and 15% changed their rheumatologist. Patients were moderately impaired with mean SF-12 physical component score 37 (SD, 9). Conclusion: Patients with RA have frequent encounters with multiple providers and also frequent discontinuity of care. Recognizing the complexity of the care of patients with a chronic disease across multiple dimensions provides an opportunity to better understand challenges and opportunities in delivering high quality care. C1 Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA. RAND Corp, Santa Monica, CA USA. Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Div Rheumatol, Los Angeles, CA USA. Olive View UCLA Med Ctr, Sylmar, CA 91342 USA. RP Kahn, KL (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, 911 Broxton Ave,Box 951736, Los Angeles, CA 90095 USA. EM kkahn@mednet.ucla.edu FU NIAMS NIH HHS [5 P60 AR36834] NR 34 TC 19 Z9 20 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD JAN PY 2007 VL 45 IS 1 BP 55 EP 65 DI 10.1097/01.mlr.0000237425.58554.66 PG 11 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 123RO UT WOS:000243313400008 PM 17279021 ER PT J AU Steinman, MA Rosenthal, GE Landefeld, CS Bertenthal, D Sen, S Kaboli, PJ AF Steinman, Michael A. Rosenthal, Gary E. Landefeld, C. Seth Bertenthal, Daniel Sen, Saunak Kaboli, Peter J. TI Conflicts and concordance between measures of medication prescribing quality SO MEDICAL CARE LA English DT Article; Proceedings Paper CT 28th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 11-14, 2005 CL New Orleans, LA SP Soc Gen Internal Med DE drug therapy; aged; health care evaluation mechanisms; reproducibility of results; quality of health care ID APPROPRIATENESS INDEX; ELDERLY PATIENTS; BEERS CRITERIA; OLDER PATIENTS; POLYPHARMACY; CARE; RELIABILITY; OUTPATIENTS; GUIDELINES; INPATIENTS AB Background: Several instruments commonly are used to assess the quality of medication prescribing. However, little is known about the relationship between these instruments or the concordance of their quality assessments when applied to the same group of patients. Methods: We assessed 3 indicators of prescribing quality in a cohort of 196 veterans age 65 and older who were taking 5 or more medications. These 3 indicators assessed whether each patient was (1) taking any medication from the drugs-to-avoid criteria of Beers et al, (2) taking any medication with a score of 3 or more on the Medication Appropriateness Index (MAI), and/or (3) taking 9 or more medications (polypharmacy). Kappa statistics were used to assess agreement between measures. Results: Mean age was 74.6 years, and patients used a mean of 8.1 medications. Six percent of drugs were rated inappropriate by the Beers drugs-to-avoid criteria, whereas 23% of drugs received an MAI score of 3 or more. Overall agreement between these metrics was 78%, little more than expected by chance (kappa statistic 0.14, P < 0.01). At the level of the patient, the proportion of subjects taking one or more inappropriate drugs was 37% by drugs-to-avoid criteria and 82% by MAI, whereas 37% had polypharmacy of 9 drugs. Prescribing was classified as inappropriate by all 3 metrics in 18% of patients and as appropriate by all 3 metrics in 13%. Together, this level of agreement was slightly better than chance (3-way kappa statistic 0.08, P = 0.03). Agreement remained low in sensitivity analyses using different cutoffs for the Beers criteria, a range of thresholds for MAI scores, and different definitions of polypharmacy, with kappa statistics : 0.30 for all comparisons. Conclusions: Commonly used measures of drug prescribing quality yield widely discordant results. Because the overall quality of prescribing may not be readily inferred from a single measure, multidimensional approaches will likely be necessary for robust assessment of prescribing quality. C1 San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA 94121 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, Hlth Serv Res Enhancement Award Program, San Francisco, CA USA. Iowa City VA Hlth Care Syst, CRIISP, Iowa City, IA USA. Univ Iowa, Dept Internal Med, Div Gen Internal Med, Roy A & Lucille J Carver Coll Med, Iowa City, IA 52242 USA. RP Steinman, MA (reprint author), San Francisco VA Med Ctr, Div Geriatr, 4150 Clemet St,Box 181-G, San Francisco, CA 94121 USA. EM mike.steinman@ucsf.edu FU NIA NIH HHS [AG 00912, AG 10418] NR 26 TC 30 Z9 35 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD JAN PY 2007 VL 45 IS 1 BP 95 EP 99 DI 10.1097/01.mlr.0000241111.11991.62 PG 5 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 123RO UT WOS:000243313400013 PM 17279026 ER PT J AU Sonnenberg, A AF Sonnenberg, Amnon TI Why is academic medicine run by former C-students? SO MEDICAL HYPOTHESES LA English DT Article AB The present paper hypothesizes that the top positions in academic medicine are generally occupied by less talented and skilled physicians who find more time to spare for administrative activities as compared to physicians who are successful in their research projects or enjoy their skills as practicing clinicians. A physician's utility in advancing a medical career can be modeled as the product of two preferences, administration and biomedical work, weighted by time and talent, respectively. It corresponds with a characteristic Cobb-Douglass utility function of economics, which physicians will try to maximize in pursuing their preferences. The utility function becomes maximized if the split between administration and research mirrors the split between free time and talent, respectively. Physicians with few talents and tots of time to spare will accumulate in administration and politics, whereas those with talents and little time will remain committed to biomedical research or clinical practice. (C) 2007 Elsevier Ltd. All rights reserved. C1 Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97239 USA. RP Sonnenberg, A (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, P3-G1,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 7 TC 3 Z9 3 U1 0 U2 0 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 0306-9877 J9 MED HYPOTHESES JI Med. Hypotheses PY 2007 VL 69 IS 1 BP 218 EP 220 DI 10.1016/j.mehy.2007.01.045 PG 3 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 178PP UT WOS:000247232900044 PM 17363180 ER PT J AU Westbrook, SD Kirkpatrick, WR Freytes, CO Toro, JJ Bernardo, S Patterson, TF Redding, SW Lee, SA AF Westbrook, Steven D. Kirkpatrick, William R. Freytes, Cesar O. Toro, Juan J. Bernardo, Stella Patterson, Thomas F. Redding, Spencer W. Lee, Samuel A. TI Candida krusei sepsis secondary to oral colonization in a hemopoietic stem cell transplant recipient SO MEDICAL MYCOLOGY LA English DT Article DE Candida krusei; oral colonization; hemopoietic stem cell transplantation; Candida sepsis ID FLUCONAZOLE AB Yeasts other than Candida albicans have emerged as important causes of fungal infection in hemopoietic stem cell transplant (HSCT) patients, particularly those receiving fluconazole prophylaxis. We report on an autologous hemopoietic stem cell transplant recipient who developed Candida krusei sepsis from pre-existing oral colonization. C1 Univ Texas, Hlth Sci Ctr, Dept Dent Diagnost Sci, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. RP Westbrook, SD (reprint author), Univ Texas, Hlth Sci Ctr, Dept Dent Diagnost Sci, 7703 Floyd Curl Dr,MSC 7919, San Antonio, TX 78229 USA. EM westbrooks@uthscsa.edu FU NIDCR NIH HHS [DE-18096] NR 8 TC 12 Z9 12 U1 0 U2 0 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1369-3786 J9 MED MYCOL JI Med. Mycol. PY 2007 VL 45 IS 2 BP 187 EP 190 DI 10.1080/1369378060116430 PG 4 WC Infectious Diseases; Mycology; Veterinary Sciences SC Infectious Diseases; Mycology; Veterinary Sciences GA 167VC UT WOS:000246479600010 PM 17365656 ER PT J AU An, JB Rettig, MB AF An, Jiabin Rettig, Matthew B. TI Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib SO MOLECULAR CANCER THERAPEUTICS LA English DT Article ID NF-KAPPA-B; PHASE-II TRIAL; TUMOR-SUPPRESSOR GENE; CYCLE ARREST; INDUCED APOPTOSIS; CANCER-THERAPY; PROTEASOME; PS-341; ACTIVATION; TRANSCRIPTION AB In renal cell carcinoma (RCC) models, maximal cytotoxicity of the proteasome inhibitor bortezomib is dependent on efficient blockade of constitutive nuclear factor KB (NF-KB) activity. Signaling through the epidermal growth factor receptor (EGFR) has been shown to result in NF-KB activation. Thus, we sought to investigate whether inhibition of the EGFR sensitizes RCC cells to the cytotoxic effects of bortezomib. We first established that constitutive NF-KB activity is dependent on signaling through the EGFR in RCC cells. Indeed, blockade of EGFR signaling with an EGFR tyrosine kinase inhibitor (TKI) resulted in inhibition of NF-KB activity. Using pharmacologic and genetic approaches, we also showed that EGFR-mediated NF-KB activation occurs through the phosphotidylinositol-3-OH kinase/AKT pathway. Combinations of the EGFR-TKI and bortezomib resulted in synergistic cytotoxic effects when RCC cells were pretreated with the EGFR-TKI, but an antagonistic interaction was observed with bortezomib pretreatment. Evaluation of the effects of drug sequencing on inhibition of NF-KB activity revealed that EGFR-TKI pretreatment markedly augmented the NF-KB inhibitory effect of bortezomib, whereas bortezomib preexposure resulted in suboptimal NF-KB blockade and thus provides a biochemical explanation for the drug interaction results. We conclude that the constitutive NF-KB activity observed in RCC cells is mediated, at least in part, through an EGFR/phosphotidylinositol-3-OH kinase/AKT signaling cascade. Pretreatment with an EGFR-TKI sensitizes to bortezomib-mediated cytotoxicity by inhibiting constitutive NF-KB activity. The combination of bortezomib and a currently approved EGFR inhibitor warrants clinical investigation. C1 VA Greater Los Angeles Healthcare Syst W Los Ange, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. RP Rettig, MB (reprint author), VA Greater Los Angeles Healthcare Syst W Los Ange, 11301 Wilshire Blvd,Bldg 304,Room E1-22, Los Angeles, CA 90073 USA. EM matthew.rettig@med.va.gov NR 54 TC 41 Z9 43 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1535-7163 J9 MOL CANCER THER JI Mol. Cancer Ther. PD JAN PY 2007 VL 6 IS 1 BP 61 EP 69 DI 10.1158/1535-7163.MCT-06-0255 PG 9 WC Oncology SC Oncology GA 129WC UT WOS:000243759800007 PM 17237266 ER PT J AU Glykys, J Peng, ZC Chandra, D Homanics, GE Houser, CR Mody, I AF Glykys, Joseph Peng, Zechun Chandra, Dev Homanics, Gregg E. Houser, Carolyn R. Mody, Istvan TI A new naturally occurring GABA(A) receptor subunit partnership with high sensitivity to ethanol SO NATURE NEUROSCIENCE LA English DT Article ID CA1 PYRAMIDAL NEURONS; DELTA-SUBUNIT; TONIC INHIBITION; DENTATE GYRUS; GRANULE CELLS; A RECEPTORS; ALPHA-1 SUBUNIT; DEFICIENT MICE; KNOCKOUT MICE; RAT-BRAIN AB According to the rules of GABA(A) receptor (GABA(A)R) subunit assembly, alpha 4 and alpha 6 subunits are considered to be the natural partners of delta subunits. These GABA(A)Rs are a preferred target of low, sobriety-impairing concentrations of ethanol. Here we demonstrate a new naturally occurring GABAAR subunit partnership: d subunits of hippocampal interneurons are coexpressed and colocalized with alpha 1 subunits, but not with alpha 4, alpha 6 or any other alpha subunits. Ethanol potentiates the tonic inhibition mediated by such native alpha 1/delta GABA(A)Rs in wild-type and in alpha 4 subunit-deficient (Gabra4(-/-)) mice, but not in delta subunit - deficient (Gabrd(-/-)) mice. We also ruled out any compensatory upregulation of alpha 6 subunits that might have accounted for the ethanol effect in Gabra4(-/-) mice. Thus, alpha 1/delta subunit assemblies represent a new neuronal GABA(A)R subunit partnership present in hippocampal interneurons, mediate tonic inhibitory currents and are highly sensitive to low concentrations of ethanol. C1 Univ Calif Los Angeles, David Geffen Sch Med, Interdept PhD Program Neurosci, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA. Univ Pittsburgh, Dept Anesthesiol, Pittsburgh, PA 15261 USA. Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15261 USA. VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA. RP Mody, I (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Interdept PhD Program Neurosci, Los Angeles, CA 90095 USA. EM mody@ucla.edu OI Homanics, Gregg/0000-0003-3641-8153 FU BLRD VA [I01 BX000404]; NIAAA NIH HHS [AA14003]; NINDS NIH HHS [NS051311, NS30549, NS35958] NR 52 TC 147 Z9 148 U1 1 U2 3 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 1097-6256 J9 NAT NEUROSCI JI Nat. Neurosci. PD JAN PY 2007 VL 10 IS 1 BP 40 EP 48 DI 10.1038/nn1813 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 120PC UT WOS:000243096100014 PM 17159992 ER PT J AU Weisbord, SD Fried, LF Unruh, ML Kimmel, PL Switzer, GE Fine, MJ Arnold, RM AF Weisbord, Steven D. Fried, Linda F. Unruh, Mark L. Kimmel, Paul L. Switzer, Galen E. Fine, Michael J. Arnold, Robert M. TI Associations of race with depression and symptoms in patients on maintenance haemodialysis SO NEPHROLOGY DIALYSIS TRANSPLANTATION LA English DT Article DE depression; haemodialysis; spirituality; symptoms ID QUALITY-OF-LIFE; STAGE RENAL-DISEASE; DIALYSIS PATIENTS; RACIAL-DIFFERENCES; PERCEPTION; BELIEFS; ILLNESS; NEED AB Background. Although studies have shown that African American haemodialysis patients report better overall quality of life than Whites, racial differences in depression and symptom burden remain less well characterized. The aim of this study was to compare these domains between African American and White patients on chronic haemodialysis. Methods. We surveyed African American and White maintenance haemodialysis patients. Depression was assessed using the Beck Depression Inventory (BDI) and Cognitive Depression Index (CDI). Symptoms were evaluated using the Dialysis Symptom Index (DSI). Results. Among the 82 Whites and 78 African Americans enrolled, there were no racial differences in the prevalence of depression (27% in African Americans vs 27% in Whites, P = 1.0), BDI Scores (11.2 vs 10.9, P = 0.6) or CDI scores (6.0 vs 6.0, P = 0.9). Symptom burden was substantial in both African Americans and Whites (median number of symptoms 8.5 and 9.0, respectively) with no racial differences in the overall burden or severity of symptoms. However, based on a single item, African Americans were more likely to describe their religious/spiritual beliefs as 'very important'. Adjustment for demographic and treatment characteristics had no impact on the associations of race with depression or symptoms. Conclusions. Depression and symptoms are highly prevalent in both African American and White haemodialysis patients, without racial differences in these health-related domains. In exploratory analyses, spiritual/religious beliefs appear to be of greater importance to African Americans. The relevance of these observations to the advantages in quality of life and survival among African Americans on haemodialysis warrants further investigation. C1 VA Pittsburgh Healthcare Syst, Renal Sect, Med Specialty Serv Line, Pittsburgh, PA 15240 USA. VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Dept Med, Pittsburgh, PA 15260 USA. George Washington Univ, Sch Med, Div Renal Dis & Hypertens, Washington, DC 20052 USA. Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Sch Med, Ctr Res Hlth Care, Pittsburgh, PA 15260 USA. RP Weisbord, SD (reprint author), VA Pittsburgh Healthcare Syst, Renal Sect, Med Specialty Serv Line, Mailstop 111F-U,7E Room 120, Pittsburgh, PA 15240 USA. EM weisbordsd@upmc.edu FU NCATS NIH HHS [UL1 TR000005]; NIAID NIH HHS [K24 AI 001769] NR 20 TC 25 Z9 28 U1 0 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0931-0509 J9 NEPHROL DIAL TRANSPL JI Nephrol. Dial. Transplant. PD JAN PY 2007 VL 22 IS 1 BP 203 EP 208 DI 10.1093/ndt/gfl521 PG 6 WC Transplantation; Urology & Nephrology SC Transplantation; Urology & Nephrology GA 126FG UT WOS:000243497200035 PM 16998218 ER PT J AU Zhang, F Wang, SP Cao, GD Gao, YQ Chen, J AF Zhang, Feng Wang, Suping Cao, Guodong Gao, Yanqin Chen, Jun TI Signal transducers and activators of transcription 5 contributes to erythropoietin-mediated neuroprotection against hippocampal neuronal death after transient global cerebral ischemia SO NEUROBIOLOGY OF DISEASE LA English DT Article DE STAT5; CA1; ischemia; EPO ID PHOSPHATIDYLINOSITOL 3-KINASE; NEUROTROPHIC FACTOR; STAT5 ACTIVATION; PROTECTS NEURONS; CELL-LINE; BRAIN; APOPTOSIS; EXPRESSION; PROTEINS; RAT AB The signal transducers and activators of transcription (STAT) proteins are a group of transcriptional factors. Among them, STAT5 initiates a pro-survival signaling cascade. So far, little has been known about the role of STAT5 in cerebral ischemia and reperfusion. This study examines the phosphorylation status of STAT5 in hippocampal CA1 in the early stage after transient global cerebral ischemia in rats. Our data show that the phosphorylation of STAT5 was increased in hippocampal CA1 at 1 h and 3 It ischemia. Taking advantage of the neuroprotective effect of erythropoietin (EPO) in CA1, we further demonstrated that the administration of EPO enhanced the phosphorylation of STAT5, with SATA5a being phosphorylated earlier. The enhanced phosphorylation of STAT5 in the EPO-treated group was accompanied by the upregulation of STAT5 downstream gene products, Bcl-xL and XIAP. Consequently, ischemic CA1 neuronal damage was attenuated by the administration of EPO. Both the enhancement of STAT5 phosphorylation and the neuroprotection rendered by EPO were blocked by Tyrphostin, a selective inhibitor for Janus kinase 2, which is an upstream kinase of STAT5. These findings suggest an association between the activation of STAT5 and CA1 neuronal survival after cerebral ischemia. (c) 2006 Elsevier Inc. All rights reserved. C1 Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA. Fudan Univ, Sch Med, State Key Lab Med Neurobiol, Shanghai, Peoples R China. Vet Affairs Pittsburg Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. RP Chen, J (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, S-507 Biomed Sci Tower, Pittsburgh, PA 15213 USA. EM chenj2@upmc.edu RI Gao, Yanqin/I-6790-2016 OI Gao, Yanqin/0000-0002-4915-9819 FU NINDS NIH HHS [NS36736, NS38560, NS43802, NS45048, R01 NS036736, R01 NS043802, R01 NS045048] NR 47 TC 42 Z9 47 U1 0 U2 4 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0969-9961 J9 NEUROBIOL DIS JI Neurobiol. Dis. PD JAN PY 2007 VL 25 IS 1 BP 45 EP 53 DI 10.1016/j.nbd.2006.08.007 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 114KN UT WOS:000242665200006 PM 17008107 ER PT J AU Ramsay, RE Macias, FM Rowan, AJ AF Ramsay, R. Eugene Macias, Flavia M. Rowan, A. James TI Diagnosing epilepsy in the elderly SO NEUROBIOLOGY OF EPILEPSY AND AGING SE INTERNATIONAL REVIEW OF NEUROBIOLOGY LA English DT Review ID CREUTZFELDT-JAKOB-DISEASE; DIFFERENTIAL-DIAGNOSIS; STATUS EPILEPTICUS; CLINICAL CHARACTERISTICS; NONEPILEPTIC SEIZURES; UNPROVOKED SEIZURES; THYROID STORM; DISORDERS; EPIDEMIOLOGY; POPULATION AB Elderly individuals represent the fastest-growing segment of the US population. Seizures are common among elderly persons, and the etiology, clinical presentation, and prognosis of seizure disorders can often between elderly patients and younger individuals. However, published information regarding the diagnosis and management of elipepsy in elderly patients is scarce. Because a number of conditions that are common in elderly patients may resemble epilepsy, diagnosis can be challenging. Cardiovascular conditions, migraines, drug effects, infections, metabolic disturbances, sleep disorders, and psychiatric disorders arc all associated with signs and symptoms that may often mimic epilepsy. New paradigms must be put into practice to establish an accurate diagnosis in the elderly patient; besides an initial evaluation, the patient history and an electroencephalogram should be obtained. Proper diagnosis is essential for proper treatment in the elderly patient. C1 Univ Miami, Sch Med, Dept Neurol, Int Ctr Epilepsy, Miami, FL 33136 USA. Miami VA Med Ctr, Dept Neurol, Miami, FL 33125 USA. Bronx Vet Adm Med Ctr, Dept Neurol, Bronx, NY 10468 USA. CUNY Mt Sinai Sch Med, New York, NY 10029 USA. RP Ramsay, RE (reprint author), Univ Miami, Sch Med, Dept Neurol, Int Ctr Epilepsy, Miami, FL 33136 USA. RI Ramsay, R. Eugene/D-4491-2011 NR 80 TC 9 Z9 11 U1 0 U2 2 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 0074-7742 J9 INT REV NEUROBIOL PY 2007 VL 81 BP 129 EP + DI 10.1016/S0074-7742(06)81008-1 PG 24 WC Neurosciences SC Neurosciences & Neurology GA BGC21 UT WOS:000245980400008 PM 17433921 ER PT J AU Berlowitz, DR Pugh, MJV AF Berlowitz, Dan R. Pugh, Mary Jo V. TI Pharmacoepidemiology in community-dwelling elderly taking antiepileptic drugs SO NEUROBIOLOGY OF EPILEPSY AND AGING SE INTERNATIONAL REVIEW OF NEUROBIOLOGY LA English DT Review ID CARBAMAZEPINE; PRIMIDONE; PHENYTOIN AB This study used the national inpatient, outpatient, and pharmacy databases from the US Veterans Health Administration to examine prescribing patterns for older patients with epilepsy and to determine the factors associated with receiving recommended antiepileptic drugs (AEDs) such as lamotrigine, gabapentin, or carbamazepine. Among patients with epilepsy, the AED monotherapy most prescribed was phenytoin (70%), followed by phenobarbital (17%). While the rate of phenytoin, use was similar for both previously and newly diagnosed patients with epilepsy, phenobarbital was less commonly used in newly diagnosed patients. Multivariable analyses suggested that reveiving outpatient neurological Care was the strongest predictor of receipt of recommended AED regimens in newly diagnosed elderly patients with epilepsy. These data suggest that the challenge remains to narrow the gap between expert recommendations and actual practice if patients with epilepsy arc to fully benefit from the tremendous progress that has been made in the pharmacological management of this disease. C1 Bedford VA Med Ctr, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA 01730 USA. Boston Univ, Sch Publ Hlth, Dept Hlth Sci, Boston, MA 02118 USA. S Texas Vet Hlth Care Syst, VERDICT, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA. RP Berlowitz, DR (reprint author), Bedford VA Med Ctr, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA 01730 USA. OI Pugh, Mary Jo/0000-0003-4196-7763 NR 14 TC 9 Z9 9 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 0074-7742 J9 INT REV NEUROBIOL PY 2007 VL 81 BP 153 EP 163 DI 10.1016/S0074-7742(06)81009-3 PG 11 WC Neurosciences SC Neurosciences & Neurology GA BGC21 UT WOS:000245980400009 PM 17433922 ER PT J AU Pugh, MJV Berlowitz, DR Kazis, L AF Pugh, Mary Jo V. Berlowitz, Dan R. Kazis, Lewis TI The impact of epilepsy on older veterans SO NEUROBIOLOGY OF EPILEPSY AND AGING SE INTERNATIONAL REVIEW OF NEUROBIOLOGY LA English DT Review ID QUALITY-OF-LIFE; HEALTH-STATUS; PEOPLE AB Despite the fact that old age is the time with highest incidence of epilepsy, little is know specifically about the impact of epilepsy on the daily lives of the elderly. Previous studies have explored the impact of epilepsy on health status in a general population, but typically have not included enough older individuals to adequately describe this population. The study on which this chapter is based used a general survey instrument to begin exploration of this tissue in a population of older veterans with epilepsy. Older patients (>= 65 years of age) were identified who had both International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), codes indicating epilepsy and prescriptions of antiepileptic drugs in national Veterans Affairs (VA) administrative and pharmacy databases during fiscal year 1999. Using these databases, patients were further identified as newly or previously diagnosed. Diagnostic data were then linked with data from the 1999 Large Health Survey of Veteran Enrollees, using encrypted identifiers, and the impact of epilepsy on patients of different ages was assessed using individual scales and component summaries of the Veterans SF-36. Results showed that older individuals with epilepsy had lower scores on measures of both physical and mental health than did their counterparts with no epilepsy. Further, scores associated with mental health functioning were significantly lower with newly diagnosed epilepsy than for those with chronic epilepsy, but differences associated with scores on physical functioning were not significant. Thus, while previous studies suggest that the effects of chronic neurological disorders such as epilepsy are most obvious on measures of mental health, these data suggest that older patients experience difficulties in both physical and mental health. C1 S Texas Vet Hlth Care Syst, VERDICT, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA. Bedford VA Med Ctr, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA 01730 USA. Boston Univ, Sch Publ Hlth, Dept Hlth Serv, Boston, MA 02118 USA. RP Pugh, MJV (reprint author), S Texas Vet Hlth Care Syst, VERDICT, San Antonio, TX 78229 USA. OI Kazis, Lewis/0000-0003-1800-5849; Pugh, Mary Jo/0000-0003-4196-7763 NR 26 TC 5 Z9 5 U1 2 U2 2 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 0074-7742 J9 INT REV NEUROBIOL PY 2007 VL 81 BP 221 EP 233 DI 10.1016/S0074-7742(06)81014-7 PG 13 WC Neurosciences SC Neurosciences & Neurology GA BGC21 UT WOS:000245980400014 PM 17433927 ER PT J AU Macias, FM Ramsay, RE Rowan, AJ AF Macias, Flavia M. Ramsay, R. Eugene Rowan, A. James TI Recruitment and retention in clinical trials of the elderly SO NEUROBIOLOGY OF EPILEPSY AND AGING SE INTERNATIONAL REVIEW OF NEUROBIOLOGY LA English DT Review ID OLDER-PEOPLE; STRATEGIES; PREVENTION; PROGRAM AB The recruitment and retention of elderly patients in Clinical trials provide many challenges. Challenges. Factors affecting recruitment, retention, and cost of recruitment are discussed in this chapter. Various methods are described that were used in recruiting and retaining elderly patients in a Veterans Affairs (VA) Administration clinical trial that compared two newer antiepileptic drugs (AEDs), gabapentin and and lamotrigine, to the established standard AED, carbamazepine. Various strategies were utilized in the VA study to improve recruitment, and each strategy's overall effectiveness was monitored. modification of the patient inclusion criteria, by lowering the age of eligibility from 65 to 60 years, added approximately 100 patients to the study. Replacing five trial sites that had poor recruiting records, extending the patient recruitment period by 3 months, and conducting site visits also Improved patient recruitment rates, such that 82.4% of target enrollment (720 patients) was achieved. The main reasons that screened patients were excluded from the study included: lack of seizures during the prior 3 months, unstable medical condition, adequate treatment with an AED, satisfaction with current treatment, and the ability to give informed consent. Retaining patients for 1 year was the primary outcome measure of this trial, with 46.8% of patients completing the year. The most Common reasons for early termination were study drug-related adverse events (43.0%) and lack of seizure control (10.8%). Comorbidities and polypharmacy occurred more frequently in the elderly, and both had a negative influence on recruitment and retention. C1 Miami VA Med Ctr, Dept Neurol, Miami, FL 33125 USA. Univ Miami, Sch Med, Dept Neurol, Int Ctr Epilepsy, Miami, FL 33136 USA. Bronx Vet Adm Med Ctr, Dept Neurol, Bronx, NY 10468 USA. CUNY Mt Sinai Sch Med, New York, NY 10029 USA. RP Macias, FM (reprint author), Miami VA Med Ctr, Dept Neurol, Miami, FL 33125 USA. RI Ramsay, R. Eugene/D-4491-2011 NR 13 TC 10 Z9 10 U1 1 U2 3 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 0074-7742 J9 INT REV NEUROBIOL PY 2007 VL 81 BP 265 EP 272 DI 10.1016/S0074-7742(06)81017-2 PG 8 WC Neurosciences SC Neurosciences & Neurology GA BGC21 UT WOS:000245980400017 PM 17433930 ER PT J AU Schillerstrom, JE Baker, PS Allman, RM Rungruang, B Zamrini, E Royall, DR AF Schillerstrom, Jason E. Baker, Patricia Sawyer Allman, Richard M. Rungruang, Bunja Zamrini, Edward Royall, Donald R. TI Clock drawing phenotypes in community-dwelling African Americans and caucasians: Results from the university of Alabama at Birmingham study of aging SO NEUROEPIDEMIOLOGY LA English DT Article DE aging; executive function; clock drawing task; cognition; African American population; dementia ID EXECUTIVE IMPAIRMENT; COGNITIVE IMPAIRMENT; DEMENTIA PATIENTS; HISPANIC EPESE; PREVALENCE; PATTERNS; SERVICE; HEALTH; CARE AB Background: Two dementia patterns have been described: 'type 1' dementia is characterized by executive function impairment and posterior cortical impairment, and 'type 2' dementia is characterized by executive impairment and relatively preserved posterior cortical function. The Executive Clock Drawing Task ( CLOX) has been used to discriminate between type 1, type 2, and normal cognitive phenotypes. The aim of this study was to describe the prevalence of these phenotypes in community-dwelling African American and Caucasian elders. Methods: 433 African Americans and 477 Caucasians over the age of 65 were recruited. Executive function was assessed using CLOX1, a command-directed clock drawing task. Posterior cortical impairment was assessed using CLOX2, a clock copy task. CLOX scores were combined to estimate the prevalence of type 1 phenotype ( those with poor CLOX1 and CLOX2 performance) versus type 2 phenotype ( those with only poor CLOX1 performance). Results: 351 ( 39%) subjects had poor executive performance. Three hundred ( 33%) subjects had a type 1 phenotype and this pattern was 2.5 times more common among African Americans than Caucasians. One hundred and thirty seven ( 15%) subjects had a type 2 phenotype with no significant difference between African Americans and Caucasians. African American ethnicity was independently associated with poor CLOX1 performance after adjusting for sociodemographic factors, posterior cortical function, and global cognition. CLOX2 performance was not associated with ethnicity. Conclusion: The prevalence of poor executive performance in community-dwelling elders is high. African Americans were more likely to have a type 1 phenotype and these ethnic differences were not explained by sociodemographic variables alone. Copyright (C) 2007 S. Karger AG, Basel. C1 Univ Texas, Hlth Sci Ctr, Dept Psychiat, San Antonio, TX 78229 USA. Univ Alabama, Ctr Aging, Birmingham, AL USA. Univ Alabama, Dept Med, Birmingham, AL 35294 USA. Univ Alabama, Dept Neurol, Birmingham, AL 35294 USA. Birmingham Atlant VA Geriatr Res Educ & Clin Ctr, Birmingham, AL USA. S Texas Vet Hlth Syst, Audie L Murphy Div, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA. RP Schillerstrom, JE (reprint author), Univ Texas, Hlth Sci Ctr, Dept Psychiat, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM schillerstr@uthscsa.edu FU NIA NIH HHS [AG15062, AG 16582, R01 AG015062] NR 23 TC 2 Z9 2 U1 2 U2 3 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0251-5350 J9 NEUROEPIDEMIOLOGY JI Neuroepidemiology PY 2007 VL 28 IS 3 BP 175 EP 180 DI 10.1159/000104095 PG 6 WC Public, Environmental & Occupational Health; Clinical Neurology SC Public, Environmental & Occupational Health; Neurosciences & Neurology GA 207BD UT WOS:000249225700007 PM 17579283 ER PT J AU Hachinski, V Skoog, I Scheltens, P Wallin, A Erkinjuntti, T Nagata, K Pasquier, F Breteler, MMB DeCarli, C Kalaria, RN Li Hsian, CC Royall, DR Roman, GC AF Hachinski, Vladimir Skoog, Ingmar Scheltens, Philip Wallin, Anders Erkinjuntti, Timo Nagata, Ken Pasquier, Florence Breteler, Monique M. B. DeCarli, Charles Kalaria, Rajesh N. Li Hsian, Christopher Chen Royall, Donald R. Roman, Gustavo C. TI Declaration of San Antonio, Texas SO NEUROEPIDEMIOLOGY LA English DT Editorial Material C1 Univ Western Ontario, London, ON, Canada. Vrije Univ Amsterdam, Med Ctr, Alzheimer Ctr, Amsterdam, Netherlands. Univ Gothenburg, Gothenburg, Sweden. Sahlgrens Univ Hosp, S-41345 Gothenburg, Sweden. Univ Helsinki, Memory Res Unit, FIN-00014 Helsinki, Finland. Univ Helsinki, Cent Hosp, FIN-00014 Helsinki, Finland. Res Inst Brain & Blood Vessels, Akita, Japan. Lille Univ Hosp, Memory Clin, Lille, France. Erasmus Univ, Med Ctr, Dept Epidemiol & Biostat, Neuroepidemiol Sect, Rotterdam, Netherlands. Univ Calif Davis, Imaging Dementia & Aging Lab, Dept Neurol, Sacramento, CA 95817 USA. Univ Calif Davis, Ctr Neurosci, Sacramento, CA 95817 USA. Newcastle Gen Hosp, Wolfson Res Ctr, Inst Ageing & Hlth, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England. Chair Sci Comm San Antonio, San Antonio, TX USA. Singapore Gen Hosp, Singapore 0316, Singapore. Natl Inst Neurosci, Singapore, Singapore. Vet Adm Hosp, Geriatr Res Ctr, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, Geriatr Psychiat Div, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, Memory Clin, San Antonio, TX USA. Univ Calif Davis, UC Davis Alzheimers Dis Ctr, Sacramento, CA 95817 USA. RP Hachinski, V (reprint author), Univ Western Ontario, London, ON, Canada. RI DeCarli, Charles/B-5541-2009 NR 0 TC 3 Z9 3 U1 0 U2 2 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0251-5350 J9 NEUROEPIDEMIOLOGY JI Neuroepidemiology PY 2007 VL 28 IS 3 BP 191 EP 192 DI 10.1159/000107278 PG 2 WC Public, Environmental & Occupational Health; Clinical Neurology SC Public, Environmental & Occupational Health; Neurosciences & Neurology GA 207BD UT WOS:000249225700010 ER PT J AU Bryant, M Marta, C Kim, F Haroutunian, V Pfeiffer, SE Bansal, R AF Bryant, M. Marta, C. Kim, F. Haroutunian, V. Pfeiffer, S. E. Bansal, R. TI FGF Receptor-2 in oligodendrocytes and myelin SO NEURON GLIA BIOLOGY LA English DT Meeting Abstract C1 [Bryant, M.; Marta, C.; Pfeiffer, S. E.; Bansal, R.] Univ Connecticut, Sch Med, Dept Neurosci, Farmington, CT USA. [Haroutunian, V.] Bronx Vet Affairs Med Ctr, New York, NY USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1740-925X J9 NEURON GLIA BIOL JI Neuron Glia Biol. PY 2007 VL 2 SU 1 BP S94 EP S94 PG 1 WC Neurosciences SC Neurosciences & Neurology GA 242FB UT WOS:000251708800289 ER PT B AU Harwood, DG Kalechstein, A Sultzer, DL AF Harwood, Dylan G. Kalechstein, Ari Sultzer, David L. BE Kalechstein, A van Gorp, WG TI Substance use and neuropsychological disorders in aging SO NEUROPSYCHOLOGY AND SUBSTANCE USE: STATE-OF-THE-ART AND FUTURE DIRECTIONS SE Studies on Neuropsychology Development and Cognition LA English DT Article; Book Chapter ID SUBCLINICAL HEPATIC-ENCEPHALOPATHY; ALCOHOL-RELATED DEMENTIA; TERM BENZODIAZEPINE USE; CEREBRAL-BLOOD-FLOW; EMISSION COMPUTED-TOMOGRAPHY; WERNICKE-KORSAKOFF-SYNDROME; ISCHEMIC VASCULAR DEMENTIA; ALZHEIMERS-DISEASE; RISK-FACTORS; COGNITIVE PERFORMANCE C1 [Harwood, Dylan G.; Sultzer, David L.] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Angeles Healthcare Syst, Los Angeles, CA 90095 USA. RP Harwood, DG (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Angeles Healthcare Syst, Los Angeles, CA 90095 USA. NR 149 TC 1 Z9 1 U1 0 U2 1 PU TAYLOR & FRANCIS LTD PI LONDON PA 11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND BN 978-0-203-83771-9; 978-1-84169-457-3 J9 STUD NEUROPSYCH DEV PY 2007 BP 323 EP 348 PG 26 WC Psychology, Biological; Substance Abuse; Neurosciences; Psychology SC Psychology; Substance Abuse; Neurosciences & Neurology GA BUX53 UT WOS:000290615100011 ER PT J AU Burgio, K AF Burgio, K. TI Combining behavior and drug therapy to improve drug withdrawal in the treatment of urge incontinence: A randomized trial SO NEUROUROLOGY AND URODYNAMICS LA English DT Meeting Abstract CT 37th Annual Meeting of the International-Continence-Society CY AUG 20-24, 2007 CL Rotterdam, NETHERLANDS SP Int Continence Soc ID URINARY-INCONTINENCE C1 Univ Alabama, Birmingham, AL USA. Birmingham VA Med Ctr, Birmingham, AL USA. NIDDKD, NIH, Bethesda, MD USA. NR 3 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0733-2467 J9 NEUROUROL URODYNAM JI Neurourol. Urodyn. PY 2007 VL 26 IS 5 MA 21 BP 629 EP 630 PG 2 WC Urology & Nephrology SC Urology & Nephrology GA 197DM UT WOS:000248534000022 ER PT J AU Nygaard, I Kreder, K Mueller, E Brubaker, L Goode, P Visco, A Weber, AM Cundiff, G Wei, J AF Nygaard, Ingrid Kreder, Karl Mueller, Elizabeth Brubaker, Linda Goode, Patricia Visco, Anthony Weber, Anne M. Cundiff, Geoff Wei, John CA Pelvic Floor Disorders Network TI Does urethral competence affect urodynamic voiding parameters in women with prolapse? SO NEUROUROLOGY AND URODYNAMICS LA English DT Article DE obstruction; pelvic organ prolapse; urodynamics; voiding ID PELVIC ORGAN PROLAPSE; VAGINAL VAULT PROLAPSE; UTEROVAGINAL PROLAPSE; URINARY-INCONTINENCE; STRESS-INCONTINENCE; CONTINENT WOMEN; COLPOSUSPENSION; PREVALENCE; REPAIR AB Aims: To (1) compare voiding parameters and (2) correlate symptoms and urodynamic findings in women with pelvic organ prolapse (POP) and varying degrees of urethral competence. Methods: We compared three groups of women with stages II-IV POP. Groups 1 and 2 were symptomatically stress continent women participating in the Colpopexy and Urinary Reduction Efforts (CARE) trial; during prolapse reduction before sacrocolpopexy, Group I (n = 67) did not have and Group 2 (n 84) had urodynamic stress incontinence (USI) during prolapse reduction. Group 3 participants (n = 74), recruited specifically for this study, had stress urinary incontinence (SUI) symptoms and planned sacrocolpopexy. Participants completed standardized uroflowmetry, pressure voiding studies, and validated symptom questionnaires. Results: Subjects' median age was 61 years, median parity 3 and 87% had stage III or IV POP. Four-teen percent of women in Group 3 demonstrated USI without, and 70% with, prolapse reduction. Women in Groups 2 and 3 had more detrusor overactivity (DO) than Group 1 (17 and 24% vs. 6%, P = 0.02) and detrusor overactivity incontinence (DOI) (15 and 8% vs. 0%, P = 0.004). Based on the Blaivis-Groutz nomogram, 60% of all women were obstructed. Post-void residual volume (PVR), peak flow rate, detrusor pressure at peak flow, voiding mechanisms, voiding patterns, obstruction and urinary retention did not differ among groups. Women in Group 3 had higher irritative and obstructive symptom scores than Group 1 or 2; neither score differed by presence of DO nor obstruction, respectively. Conclusion: Women with POP have significant rates of urodynamic obstruction and retention, independent of their continence status. Symptoms of obstruction and retention correlate poorly with urodynamic findings. C1 Univ Utah, Dept Obstet & Gynecol, Coll Med, Salt Lake City, UT 84132 USA. Univ Iowa, Dept Urol, Carver Coll Med, Iowa City, IA USA. Loyola Univ, Med Ctr, Dept Urol, Maywood, IL 60153 USA. Loyola Univ, Med Ctr, Dept Obstet & Gynecol, Maywood, IL 60153 USA. Univ Alabama, Birmingham Atlanta Geriatr Res Educ & Clin Ctr, Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. Univ Alabama, Dept Med, Birmingham, AL 35294 USA. Univ N Carolina, Dept Obstet & Gynecol, Chapel Hill, NC USA. NICHHD, Bethesda, MD USA. Univ British Columbia, Dept Obstet & Gynecol, Vancouver, BC V5Z 1M9, Canada. Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA. RP Nygaard, I (reprint author), Univ Utah, Dept Obstet & Gynecol, Coll Med, 30 North 1900 East,Room 2B 242, Salt Lake City, UT 84132 USA. EM Ingrid.nygaard@hsc.utah.edu OI Mueller, Elizabeth R./0000-0003-3069-4069 FU NICHD NIH HHS [U10 HD41248, U10 HD41269, U10 HD41261, U10 HD41267, U10 HD041261, U10 HD41268, U01 HD41249, U10 HD41250, U10 HD41263] NR 18 TC 5 Z9 6 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0733-2467 J9 NEUROUROL URODYNAM JI Neurourol. Urodyn. PY 2007 VL 26 IS 7 BP 1030 EP 1035 DI 10.1002/nau.20436 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 227BV UT WOS:000250633100015 PM 17638306 ER PT J AU Moscato, SR Miller, J Logsdon, K Weinberg, S Chorpenning, L AF Moscato, Susan Randles Miller, Judith Logsdon, Karen Weinberg, Stephen Chorpenning, Lori TI Dedicated education unit: An innovative clinical partner education model SO NURSING OUTLOOK LA English DT Article AB This article describes the implementation and evaluation of the Dedicated Education Unit (DEU) as an innovative model of clinical nursing education. A partnership of nurse executives, staff nurses and faculty transformed patient care units into environments of support for nursing students and staff nurses while continuing the critical work of providing quality care to acutely ill adults. Various methods were used to obtain formative data during the implementation of this model in which staff nurses assumed the role of nursing instructors. Results showed high student and nurse satisfaction and a marked increase in clinical capacity that allowed for increased enrollment. This article reports on a 3-year project to operationalize the DEU concept with 6 nursing units in 3 hospitals. The development of staff nurses as clinical instructors, best practices to teach and evaluate critical thinking in students, and the mix of student learners continue as focus areas. C1 Univ Portland, Sch Nursing, Portland, OR 97203 USA. Duke Univ, Durham, NC 27706 USA. Portland VA Med Ctr, Portland, OR USA. RP Moscato, SR (reprint author), Univ Portland, Sch Nursing, 5000 N Willamette Blvd, Portland, OR 97203 USA. EM moscato@up.edu NR 11 TC 69 Z9 70 U1 0 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0029-6554 J9 NURS OUTLOOK JI Nurs. Outlook PD JAN-FEB PY 2007 VL 55 IS 1 BP 31 EP 37 DI 10.1016/j.outlook.2006.11.001 PG 7 WC Nursing SC Nursing GA 139UX UT WOS:000244459200007 PM 17289465 ER PT J AU Borrero, S Schwarz, EB Reeves, MF Bost, JE Creinin, MD Ibrahim, SA AF Borrero, Sonya Schwarz, Eleanor B. Reeves, Matthew F. Bost, James E. Creinin, Mitchell D. Ibrahim, Said A. TI Race, insurance status, and tubal sterilization SO OBSTETRICS AND GYNECOLOGY LA English DT Article ID UNITED-STATES; CONTRACEPTIVE STERILIZATION; FEMALE STERILIZATION; WOMEN; HEALTH AB OBJECTIVE: To examine the independent effects of race or ethnicity and insurance status on use of tubal sterilization rates. METHODS: This study used cross-sectional data collected by the 2002 National Survey of Family Growth. The survey is designed to represent women and men aged 15-44 years in the household population of the United States. Our main outcome measure was tubal sterilization at any time before interview. A multivariable logistic regression model was used to estimate the effects of race or ethnicity and insurance status on rates of tubal sterilization after adjusting for important confounders. RESULTS: The sample consisted of 7,643 women: 66% were white, 15% were Hispanic, and 14% were African American; 68% had private insurance and 32% had public or no insurance. After adjusting for age, insurance status, parity, income, education, marital status, and religion, African-American women were more likely than white women to undergo tubal sterilization (adjusted odds ratio 1.43, 95% confidence interval 1.08-1.88). After adjusting for age, race or ethnicity, parity, income, education, marital status, and religion, women with public or no insurance were more likely to undergo sterilization compared with women with private insurance (adjusted odds ratio 1.38, 95% confidence interval 1.09-1.74). CONCLUSION: African-American women and women with no or public insurance were more likely to have undergone! tubal sterilization compared with white women and women with private insurance, respectively. Additional research to identify factors that influence women's decision to undergo sterilization is warranted. C1 VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot 151C, Div Gen Internal Med, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Sch Med, Ctr Res Hlth Care, Div Gen Internal Med, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Sch Med, Ctr Res Hlth Care, Magee Womens Res Inst, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Sch Med, Inst Clin Res Educ, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. VA Pittsburgh Healthcare Syst, Ctr Hlth Equity & Promot, Pittsburgh, PA USA. RP Ibrahim, SA (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot 151C, Div Gen Internal Med, Pittsburgh, PA 15240 USA. EM said.ibrahim2@med.va.gov OI Reeves, Matthew/0000-0001-7749-7447; Schwarz, Eleanor Bimla/0000-0002-9912-8236 NR 19 TC 32 Z9 32 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD JAN PY 2007 VL 109 IS 1 BP 94 EP 100 DI 10.1097/01.AOG.0000249604.78234.d3 PG 7 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 171YO UT WOS:000246771500014 PM 17197593 ER PT J AU Garcia, JM Polvino, WJ AF Garcia, Jose M. Polvino, William J. TI Effect on body weight and safety of RC-1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: Results of a phase I, randomized, placebo-controlled, multiple-dose study in healthy volunteers SO ONCOLOGIST LA English DT Article ID TUMOR-BEARING RATS; CANCER-PATIENTS; FOOD-INTAKE; CACHEXIA; APPETITE; PEPTIDE; INTERLEUKIN-6; SECRETION; ANOREXIA; RECEPTOR AB Purpose. RC-1291is a novel, oral ghrelin mimetic and growth hormone (GH) secretagogue being developed to increase appetite and lean muscle mass in patients with cancer-associated anorexia/cachexia. This randomized, double-blind, placebo-controlled, multiple-dose, dose-escalation phase I study in healthy volunteers evaluated RC1291 once daily (qd) and twice daily ( bid) for effect on body weight and safety. Methods. The study was conducted with three sequential groups of volunteers. Panel A subjects ( n = 8) received placebo or RC-1291, 25 mg qd, for 5 days. Panel B subjects received RC-1291, 25 mg bid or 50 mg qd, for 6 days then crossed over to the other dosage for 5 days ( n = 12); three subjects received placebo for all 11 doses to maintain double-blinding. Panel C subjects ( n = 9) received placebo or RC-1291, 75 mg qd, for 6 days. Results. Subjects who received RC-1291, 50 or 75 mg, had significant dose-related weight gain after 6 days versus placebo, with the greatest increases seen with daily dosing. The mean increase in weight from baseline after 50 mg qd was 1.25 +/- 0.725 kg ( p =.0022 versus placebo), and after 75 mg qd it was 1.16 +/- 0.651 kg ( p =.0022 versus placebo). One subject in the 50 mg qd group had moderate transient elevation in aspartate aminotransferase and alanine aminotransferase levels. No other laboratory or clinical adverse events of consequence were reported. Conclusions. Results indicate that RC-1291 produces dose-related increases in body weight with no dose-limiting adverse effects, and may be an effective treatment for anorexia/cachexia. C1 Michael E DeBakey Vet Affairs Med Ctr, Div Endocrinol Diabet & Metab, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. Sapphire Therapeut Inc, Bridgewater, NJ USA. RP Garcia, JM (reprint author), MEDVA Med Ctr, Dept Med, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM Jgarcia1@bcm.tmc.edu NR 33 TC 67 Z9 67 U1 0 U2 2 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 1083-7159 J9 ONCOLOGIST JI Oncologist PY 2007 VL 12 IS 5 BP 594 EP 600 DI 10.1634/theoncologist.12-5-594 PG 7 WC Oncology SC Oncology GA 172JE UT WOS:000246799400014 PM 17522248 ER PT J AU Shalaby, AA Voigt, A El-Saed, A Mains, M Shusterman, V AF Shalaby, Alaa A. Voigt, Andrew El-Saed, Aiman Mains, Martin Shusterman, Vladimir TI Microvolt T-wave alternans during atrial and ventricular pacing SO PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY LA English DT Article; Proceedings Paper CT 15th World Congress in Cardiac Electrophysiology (CARDIOSTIM 2006) CY JUN 14-17, 2006 CL Nice, FRANCE DE risk stratification; microvolt T-wave alternans; ventricular pacing; atrial pacing ID DEFIBRILLATOR IMPLANTATION; MYOCARDIAL-INFARCTION; ARRHYTHMIAS; BENEFIT AB Introduction: Assessment of microvolt T-wave alternans (MTWA) by the spectral analysis (SA) method requires the heart rate to be stable within a certain range. This can be achieved by ventricular pacing (VP). We compared MTWA during short-term VP versus atrial pacing (AP). Methods: Patients presenting for evaluation of risk of sudden cardiac death underwent an invasive electrophysiologic study. The concordance of results of MTWA-VP with MTWA-AP was evaluated, as well as the specificity, sensitivity, negative, and positive predictive values of MTWA-VP versus MTWA-AP. The maximum recorded amplitude of MTWA (MValt) in concordant positive results, as well as noise levels in all, were compared in both pacing modes. Results: We studied 42 consecutive patients, of whom 31 completed both tests (32 by AP, 40 by VP). Compared to AP, VP-MTWA SA had a sensitivity of 93%, specificity of 71%, negative predictive value of 92%, and positive predictive value of 72%. The results were concordant in 25 patients (80%, kappa = 0.62, P < 0.001). The noise level was significantly higher during VP than AP (1.4 +/- 0.8 vs 1 +/- 0.8, P< 0.01), and there was a trend toward a higher amplitude of TWA by VP (10.7 +/- 5.3 vs 7.8 +/- 3.9, P = 0.058). Conclusions: MTWA SA is m ore likely to be completed during VP than AP. Overall there was concordance between both tests. VP generates higher amplitudes and noise, and a higher percentage of nonnegative results. C1 VA Pittsburgh Healthcare Syst, Div Cardiol, Cardiac Electrophysiol Serv, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Med Ctr, Cardiovasc Inst, Pittsburgh, PA USA. Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA. RP Shalaby, AA (reprint author), VA Pittsburgh Healthcare Syst, Div Cardiol, Cardiac Electrophysiol Serv, 111 C Univ Dr, Pittsburgh, PA 15240 USA. EM Alaa.Shalaby@med.va.gov NR 12 TC 11 Z9 12 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0147-8389 J9 PACE JI PACE-Pacing Clin. Electrophysiol. PD JAN PY 2007 VL 30 SU 1 BP S178 EP S182 PG 5 WC Cardiac & Cardiovascular Systems; Engineering, Biomedical SC Cardiovascular System & Cardiology; Engineering GA 135VI UT WOS:000244181600040 PM 17302700 ER PT J AU Gallagher, RM AF Gallagher, Rollin M. TI ISIS and AAPM: Encouraging best practices in spine treatment SO PAIN MEDICINE LA English DT Editorial Material ID PAIN TREATMENT; OUTCOMES C1 Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. RP Gallagher, RM (reprint author), Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. NR 6 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1526-2375 J9 PAIN MED JI Pain Med. PD JAN-FEB PY 2007 VL 8 IS 1 BP 4 EP 5 DI 10.1111/j.1526-4637.2007.00266.x PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 138UY UT WOS:000244390000003 ER PT J AU Gallagher, RM Weiz-Bosna, M Gammaitoni, A AF Gallagher, Rollin M. Weiz-Bosna, Maripat Gammaitoni, Arnold TI Assessment of dosing frequency of sustained-release opioid preparations in patients with chronic nonmalignant pain SO PAIN MEDICINE LA English DT Article DE opioid; prospective study; daily dosing; chronic pain; long-acting ID THERAPY AB Objective. Many patients with moderate to severe chronic nonmalignant pain require dosing of long-acting opioids more frequently than recommended by the product's manufacturer. To accurately quantitate opioid dosing in clinical practice, daily dosing was prospectively assessed in pain clinic patients. Design. A single-center, 30-day, prospective, observational cohort study, approved by the hospital IRB. Patients. Forty-one evaluable adult outpatients receiving treatment with long-acting opioids for moderate to severe chronic nonmalignant pain. Outcome Measures. The primary measure was the daily number of consumed doses of prescribed long-acting opioid. Rescue medication use, average daily pain intensity, and patient-reported adverse events were also recorded. Results. The mean daily number of doses was 3.0 for oxycodone controlled release (CR), 2.9 for morphine CR, and 3.7 for methadone. For transdermal fentanyl, 50% of patients required dosing every 24-48 hours. Ninety-one percent of oxycodone CR-treated patients, 86% of morphine CR-treated patients, and 50% of fentanyl patch-treated patients required dosing more frequently than that recommended by the product's manufacturer. Patients who received oxycodone CR, morphine CR, and transdermal fentanyl required a mean of 2.9, 2.9, and 3.7 rescue doses per day, respectively. Conclusions. Many patients taking common long-acting opioids for chronic nonmalignant pain require dosing more frequently than recommended by product labeling, and take an additional 34 daily doses of rescue opioid, yet they continue to report moderate to severe pain. Newer opioid formulations that can provide sustained analgesia with convenient dosing are needed as well as a better understanding of the many additional factors that may influence opioid use patterns in patients with chronic pain. C1 Philadelphia VA Med Ctr, Pain Med Serv, Philadelphia, PA 19104 USA. Univ Penn, Ctr Pain Med Res & Policy, Philadelphia, PA 19104 USA. Endo Pharmaceut Inc, Chadds Ford, PA USA. RP Gallagher, RM (reprint author), Philadelphia VA Med Ctr, Pain Med Serv, Univ & Woodland Ave, Philadelphia, PA 19104 USA. EM rgallagh@mail.med.upenn.edu NR 8 TC 18 Z9 18 U1 1 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1526-2375 J9 PAIN MED JI Pain Med. PD JAN-FEB PY 2007 VL 8 IS 1 BP 71 EP 74 DI 10.1111/j.1526-4637.2007.00260.x PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 138UY UT WOS:000244390000012 PM 17244106 ER PT J AU Ito, Y Lugea, A Pandol, SJ McCuskey, RS AF Ito, Yoshiya Lugea, Aurelia Pandol, Stephen J. McCuskey, Robert S. TI Substance P mediates cerulein-induced pancreatic microcirculatory dysfunction in mice SO PANCREAS LA English DT Article DE permeability; edema; perfusion; capillary ID NEUTROPHILS; MICROSCOPY; ACTIVATION; EDEMA; RAT; PERMEABILITY; DERANGEMENT; RECEPTOR AB Objectives: The present study was conducted to examine the contribution of substance P to the pancreatic microcirculatory dysfunction during acute pancreatitis. Methods: Pancreatitis was elicited by up to 6 hourly injections of cerulein (50 mu g/kg IP) in male C57B1/6 mice. At 0, 1, 3, and 6 hours after cerulein treatment, the pancreatic microvasculature in anesthetized mice was studied using established high-resolution in vivo microscopic methods. Results: Treatment of mice with cerulein for 6 hours caused a 30% decrease in capillary perfusion and the diameter of the capillaries and an increase in microvascular permeability (20%) and interstitial space (30-fold). The administration of the substance P receptor antagonist (D-Arg1, D-Pro2, D-Trp7,9, Leu11) (2 mg/kg IP) minimized the pancreatic microcirculatory dysfunction 3 hours after cerulein treatment. The superfusion of substance P for 0.5 hours decreased the diameter (by 22%) and increased microvascular permeability (by 23%) along with interstitial space (22-fold increase). Blockade of substance P receptor attenuated substance P-induced pancreatic microcirculatory dysfunction. Conclusions: These results suggest that substance P mediates pancreatic microcirculatory dysfunction during the development of acute pancreatitis. C1 Univ Arizona, Coll Med, Dept Cell Biol & Anat, Tucson, AZ 85724 USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. RP McCuskey, RS (reprint author), Univ Arizona, Coll Med, Dept Cell Biol & Anat, POB 245044, Tucson, AZ 85724 USA. EM mccuskey@email.arizona.edu FU NIAAA NIH HHS [1-U56-AA0114643]; NIDDK NIH HHS [R01 DK-59508]; PHS HHS [P50-A11999] NR 24 TC 7 Z9 11 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-3177 J9 PANCREAS JI Pancreas PD JAN PY 2007 VL 34 IS 1 BP 138 EP 143 DI 10.1097/01.mpa.0000246663.30751.24 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 168CF UT WOS:000246499200018 PM 17198196 ER PT J AU Pandol, SJ Raraty, M AF Pandol, Stephen J. Raraty, Michael TI Pathobiology of alcoholic pancreatitis SO PANCREATOLOGY LA English DT Review DE alcohol; pancreatitis ID KAPPA-B ACTIVATION; ACID ETHYL-ESTER; NONOXIDATIVE ETHANOL METABOLITES; HEPATIC STELLATE CELLS; CERULEIN-INDUCED PANCREATITIS; CYTOSOLIC-FREE CALCIUM; PROTEIN-KINASE-C; ACINAR-CELLS; ANGIOTENSIN-II; TRYPSINOGEN ACTIVATION AB This paper provides a summary of the effects of alcohol abuse on the pathobiologic responses that occur during acute and chronic pancreatitis considering both the human disease and animal/tissue models. The effects are multiple and include ones on cell death leading to necrosis; on inflammation resulting in a sensitized response to pancreatic stress; and fibrosis through effects of ethanol on pancreatic stellate cells and the plasminogen system. Although the effects of alcohol are multiple and complex, it is likely that a combination of a few key effects on these pathobiologic responses drive the increased sensitivity of the pancreas to acute pancreatitis with pancreatic stress and the promotion of chronic pancreatitis with pancreatic injury occurring during acute pancreatitis. Copyright (c) 2007 S. Karger AG, Basel and IAP. C1 Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. Dept Vet Affairs, Los Angeles, CA USA. Univ Liverpool, Royal Liverpool Univ Hosp, Div Surg & Oncol, Liverpool L69 3BX, Merseyside, England. RP Pandol, SJ (reprint author), VA Greater Los Angeles Hlth Care Syst, Bldg 258,Room 340,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM stephen.pandol@va.gov RI Raraty, Michael/B-5328-2013 NR 127 TC 44 Z9 45 U1 1 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1424-3903 J9 PANCREATOLOGY JI Pancreatology PY 2007 VL 7 IS 2-3 BP 105 EP 114 DI 10.1159/000104235 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 192YV UT WOS:000248240900003 PM 17592222 ER PT J AU Gonzalez-Fernandez, MC Lezcano, E Ross, OA Gomez-Esteban, JC Gomez-Busto, F Velasco, F Alvarez-Alvarez, M Rodriguez-Martinez, MB Ciordia, R Zarranz, JJ Farrer, MJ Mata, IF de Pancorbo, MM AF Gonzalez-Fernandez, Maria C. Lezcano, Elena Ross, Owen A. Gomez-Esteban, Juan C. Gomez-Busto, Fernando Velasco, Fernando Alvarez-Alvarez, Maite Rodriguez-Martinez, Maria B. Ciordia, Roberto Zarranz, Juan J. Farrer, Matthew J. Mata, Ignacio F. de Pancorbo, Marian M. TI Lrrk2-associated parkinsonism is a major cause of disease in Northern Spain SO PARKINSONISM & RELATED DISORDERS LA English DT Article DE Parkinson's disease; LRRK2; dardarina; Spain; mutation ID AUTOSOMAL-DOMINANT PARKINSONISM; LRRK2 G2019S; SPANISH PATIENTS; MUTATIONS; COMMON; FAMILIES; FOUNDER; R1441G; GENE AB Herein we describe a comparative clinical and genetic study of Lrrk2-associated parkinsonism in Northern Spain. In our sample from the Basque region, Lrrk2 R1441G and G2019S account for 15 out of 50 kindreds (30%) with familial Parkinson's disease. We observe common founder haplotypes for both R 1441 G and G2019S carriers. Our findings highlight the importance of Lrrk2 parkinsonism in this population and may have important consequences for its extended Diaspora in North, Central and South Americas. (c) 2007 Elsevier Ltd. All rights reserved. C1 [Gonzalez-Fernandez, Maria C.; Alvarez-Alvarez, Maite; Rodriguez-Martinez, Maria B.; de Pancorbo, Marian M.] Univ Basque Country, Dept Biol Celular, Banco de ADN, Serv Gen Invest Genom, Vitoria, Spain. [Gonzalez-Fernandez, Maria C.; Ross, Owen A.; Farrer, Matthew J.; Mata, Ignacio F.] Mayo Clin, Dept Neurosci, Jacksonville, FL USA. [Lezcano, Elena; Gomez-Esteban, Juan C.; Velasco, Fernando; Ciordia, Roberto] Hosp Cruces, Serv Neurol, Baracaldo, Spain. [Gomez-Busto, Fernando] Residencia Tercera Edad San Prudencio Ayuntamient, Serv Geriatr, Vitoria, Spain. [Mata, Ignacio F.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. RP Mata, IF (reprint author), Geriatr Res Educ & Clin Ctr, VA Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA. EM nachofm@u.washington.edu RI Zarranz, Juan Jose/E-2955-2012; Gomez, Juan Carlos/E-3020-2012; Ross, Owen/D-7573-2013 OI MARTINEZ DE PANCORBO, MARIA DE LOS ANGELES/0000-0002-7408-6068; Fernandez Mata, Ignacio/0000-0003-1198-0633; M. de Pancorbo, Marian/0000-0002-8081-0702 FU NINDS NIH HHS [P50 #NS40256] NR 20 TC 28 Z9 28 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1353-8020 J9 PARKINSONISM RELAT D JI Parkinsonism Relat. Disord. PY 2007 VL 13 IS 8 BP 509 EP 515 DI 10.1016/j.parkreldis.2007.04.003 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA 242VE UT WOS:000251753500009 PM 17540608 ER PT S AU Kraemer, B Schellenberg, GD AF Kraemer, Brian Schellenberg, Gerard D. BE Dwyer, DS TI Using Caenorhabditis elegans models of neurodegenerative disease to identify neuroprotective strategies SO PHARMACOLOGY OF NEUROGENESIS AND NEUROENHANCEMENT SE International Review of Neurobiology LA English DT Review ID BETA-AMYLOID PEPTIDE; NECROTIC CELL-DEATH; ALZHEIMERS-DISEASE; C-ELEGANS; ALPHA-SYNUCLEIN; NEURONAL DEGENERATION; OXIDATIVE STRESS; PROTEIN AGGREGATION; INVERTEBRATE MODELS; MUTANT C1 Vet Affairs Puget Sound Hlth Care Syst, Seattle Div, Ctr Geriatr Res Educ & Clin, Seattle, WA 98108 USA. Univ Washington, Div Gerontol & Geriatr Med, Dept Med, Seattle, WA 98195 USA. Univ Washington, Dept Neurol, Seattle, WA 98195 USA. Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA. RP Kraemer, B (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Seattle Div, Ctr Geriatr Res Educ & Clin, Seattle, WA 98108 USA. NR 65 TC 4 Z9 4 U1 0 U2 7 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 0074-7742 BN 978-0-12-373678-9 J9 INT REV NEUROBIOL JI Int. Rev. Neurobiol. PY 2007 VL 77 BP 219 EP 246 DI 10.1016/S0074-7742(06)77007-6 PG 28 WC Neurosciences SC Neurosciences & Neurology GA BFP47 UT WOS:000243623500007 PM 17178476 ER PT J AU Zickmund, S AF Zickmund, Susan TI Deliberation, phronesis, and authenticity: Heidegger's early conception of rhetoric SO PHILOSOPHY AND RHETORIC LA English DT Article ID ARISTOTLE C1 VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Dept Med Commun, Pittsburgh, PA 15206 USA. RP Zickmund, S (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Dept Med Commun, Pittsburgh, PA 15206 USA. NR 15 TC 3 Z9 4 U1 0 U2 1 PU PENN STATE UNIV PRESS PI UNIVERSITY PK PA 820 NORTH UNIV DRIVE, U S B 1, STE C, UNIVERSITY PK, PA 16802 USA SN 0031-8213 J9 PHILOS RHETORIC JI Philos. Rhetor. PY 2007 VL 40 IS 4 BP 406 EP 415 PG 10 WC Literature; Philosophy SC Literature; Philosophy GA 255FT UT WOS:000252643800005 ER PT J AU Quinn, LS AF Quinn, L. S. TI Interleukin-15: A cytokine which modulates fat : lean body composition SO POULTRY SCIENCE LA English DT Meeting Abstract DE interleukin-15; muscle; adipose tissue C1 [Quinn, L. S.] Univ Washington, Seattle, WA 98195 USA. [Quinn, L. S.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU POULTRY SCIENCE ASSOC INC PI SAVOY PA 1111 N DUNLAP AVE, SAVOY, IL 61874-9604 USA SN 0032-5791 J9 POULTRY SCI JI Poult. Sci. PY 2007 VL 86 SU 1 BP 1 EP 1 PG 1 WC Agriculture, Dairy & Animal Science SC Agriculture GA 213UM UT WOS:000249692600003 ER PT B AU Atwood, CW AF Atwood, Charles W., Jr. BE Pagel, JF PandiPerumal, SR TI Obstructive Sleep Apnea Clinical Presentation SO PRIMARY CARE SLEEP MEDICINE SE Current Clinical Practice Series LA English DT Article; Book Chapter ID GENDER-DIFFERENCES; LATENCY TEST; POPULATION; SCALE; PREVALENCE; DIAGNOSIS; IMPACT; SAMPLE; WOMEN; MEN C1 Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Div Pulm Allergy & Crit Care Med, Sleep Disorders Program,Med Ctr,Sleep Med Ctr, Pittsburgh, PA 15260 USA. RP Atwood, CW (reprint author), Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Div Pulm Allergy & Crit Care Med, Sleep Disorders Program,Med Ctr,Sleep Med Ctr, Pittsburgh, PA 15260 USA. NR 30 TC 1 Z9 1 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-59745-421-6 J9 CURR CLIN PRACT PY 2007 BP 89 EP 95 DI 10.1007/978-1-59745-421-6_8 D2 10.1007/978-1-59745-421-6 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA BNF87 UT WOS:000274465800010 ER PT B AU Atwood, CW AF Atwood, Charles W., Jr. BE Pagel, JF PandiPerumal, SR TI Portable Monitoring SO PRIMARY CARE SLEEP MEDICINE SE Current Clinical Practice Series LA English DT Article; Book Chapter ID SLEEP-APNEA C1 Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Div Pulm Allergy & Crit Care Med, Sleep Disorders Program,Med Ctr,Sleep Med Ctr, Pittsburgh, PA 15260 USA. RP Atwood, CW (reprint author), Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Div Pulm Allergy & Crit Care Med, Sleep Disorders Program,Med Ctr,Sleep Med Ctr, Pittsburgh, PA 15260 USA. NR 3 TC 0 Z9 0 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-59745-421-6 J9 CURR CLIN PRACT PY 2007 BP 305 EP 309 DI 10.1007/978-1-59745-421-6_28 D2 10.1007/978-1-59745-421-6 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA BNF87 UT WOS:000274465800030 ER PT J AU Rogers, B Bosker, GW Crawford, RH Faustini, MC Neptune, RR Walden, G Gitter, AJ AF Rogers, Bill Bosker, Gordon W. Crawford, Richard H. Faustini, Mario C. Neptune, Richard R. Walden, Gail Gitter, Andrew J. TI Advanced trans-tibial socket fabrication using selective laser sintering SO PROSTHETICS AND ORTHOTICS INTERNATIONAL LA English DT Article DE amputees; prosthetics; CAD/CAM ID MANUFACTURE; PROSTHESES AB There have been a variety of efforts demonstrating the use of solid freeform fabrication (SFF) for prosthetic socket fabrication though there has been little effort in leveraging the strengths of the technology. SFF encompasses a class of technologies that can create three dimensional objects directly from a geometric database without specific tooling or human intervention. A real strength of SFF is that cost of fabrication is related to the volume of the part, not the part's complexity. For prosthetic socket fabrication this means that a sophisticated socket can be fabricated at essentially the same cost as a simple socket. Adding new features to a socket design becomes a function of software. The work at The University of Texas Health Science Center at San Antonio (UTHSCSA) and University of Texas at Austin (UTA) has concentrated on developing advanced sockets that incorporate structural features to increase comfort as well as built in fixtures to accommodate industry standard hardware. Selective laser sintering (SLS) was chosen as the SFF technology to use for socket fabrication as it was capable of fabricating sockets using materials appropriate for prosthetics. This paper details the development of SLS prosthetic socket fabrication techniques at UTHSCSA/UTA over a six-year period. C1 Univ Texas, Hlth Sci Ctr, Dept Rehabil Med, San Antonio, TX 78284 USA. Univ Texas, Dept Mech Engn, Austin, TX 78712 USA. S Texas Vet Healthcare Syst, PM&R Serv, San Antonio, TX USA. RP Rogers, B (reprint author), Univ Texas, Hlth Sci Ctr, Dept Rehabil Med, San Antonio, TX 78284 USA. EM rogers@uthscsa.edu RI Rogers, Bill/F-7689-2010 NR 16 TC 23 Z9 23 U1 2 U2 13 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0309-3646 J9 PROSTHET ORTHOT INT JI Prosthet. Orthot. Int. PY 2007 VL 31 IS 1 BP 88 EP 100 DI 10.1080/03093640600983923 PG 13 WC Orthopedics; Rehabilitation SC Orthopedics; Rehabilitation GA 168SY UT WOS:000246545500009 PM 17365888 ER PT J AU Henderson, C Flood, C Szmukler, G AF Henderson, Claire Flood, Chris Szmukler, George TI Shared decision making SO PSYCHIATRIC SERVICES LA English DT Letter ID PSYCHIATRIC ADVANCE DIRECTIVES; RANDOMIZED CONTROLLED-TRIAL; JOINT CRISIS PLANS C1 James J Peters VA Med Ctr, Bronx, NY USA. City Univ London, Dept Mental Hlth & Learning Disabil, London, England. Kings Coll London, Inst Psychiat, London, England. RP Henderson, C (reprint author), James J Peters VA Med Ctr, Bronx, NY USA. RI Henderson, Claire/E-4664-2010 OI Henderson, Claire/0000-0002-6998-5659 NR 5 TC 1 Z9 1 U1 0 U2 2 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD JAN PY 2007 VL 58 IS 1 BP 139 EP 140 DI 10.1176/appi.ps.58.1.139-a PG 2 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 124QE UT WOS:000243384200023 PM 17215426 ER PT J AU Ahearn, EP Juergens, T Smith, T Krahn, D Kalin, N AF Ahearn, Eileen P. Juergens, Timothy Smith, Tracey Krahn, Dean Kalin, Ned TI Fear, Anxiety, and the Neuroimaging of PTSD SO PSYCHOPHARMACOLOGY BULLETIN LA English DT Article DE fear; anxiety; neuroimaging; Posttraumatic stress disorder AB The clinical manifestations of Posttraumatic Stress Disorder (PTSD) include both fear and anxiety symptoms. Animal studies provide significant information about the neurobiological pathways involved in fear and anxiety and are relevant to the study of PTSD. These studies are reviewed along with Rauch's proposed neurobiologic model for PTSD. Neuroimaging findings in PTSD are summarized by region. Most neuroimaging studies to date have been provocation studies which present a trauma-related stimulus and measure response. While providing information about PTSD, these complex studies were not designed to target specific emotions. Studies which can specifically elicit fear or anxiety and evaluate associated brain regions, such as the bed nucleus of the stria terminalis (BNST) may provide a clearer understanding of the biologic underpinnings of PTSD and bridge the knowledge between animal neurobiology and human studies. Psychopharmacology Bulletin. 2007;40(3):88-103. C1 [Ahearn, Eileen P.; Juergens, Timothy; Smith, Tracey; Krahn, Dean] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. [Ahearn, Eileen P.; Juergens, Timothy; Smith, Tracey; Krahn, Dean; Kalin, Ned] Univ Wisconsin, Madison, WI USA. RP Ahearn, EP (reprint author), William S Middleton Mem Vet Adm Med Ctr, 2500 Overlook Terrace, Madison, WI 53705 USA. EM eileen.ahearn@va.gov RI Smith, Tracey/J-2030-2014 OI Smith, Tracey/0000-0001-5338-9142 NR 90 TC 3 Z9 3 U1 2 U2 3 PU MEDWORKS MEDIA GLOBAL, LLC PI HERMOS BEACH PA 670 FIFTH STREET, STE A, HERMOS BEACH, CA 90254 USA SN 0048-5764 J9 PSYCHOPHARMACOL BULL JI Psychopharmacol. Bull. PY 2007 VL 40 IS 3 BP 88 EP 103 PG 16 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA V15HK UT WOS:000207792900009 PM 18007571 ER PT J AU Labus, JS Mayer, EA Chang, L Bolus, R Naliboff, BD AF Labus, Jennifer S. Mayer, Emeran A. Chang, Ln Bolus, Roger Naliboff, Bruce D. TI The central role of gastrointestinal-specific anxiety in irritable bowel syndrome: Further validation of the visceral sensitivity index SO PSYCHOSOMATIC MEDICINE LA English DT Article DE gastrointestinal; anxiety; assessment; irritable bowel syndrome ID ASIAN-AMERICAN; PAIN ANXIETY; DEPRESSION; SCALE; FEAR; NEUROTICISM; GUIDELINES; EXPERIENCE; REGRESSION; DISORDERS AB Objectives: The Visceral Sensitivity Index (VSI) was developed as the first instrument to assess gastrointestinal-specific anxiety, the cognitive, affective, and behavioral response to fear of gastrointestinal sensations, symptoms, and the context in which these visceral sensations and symptoms occur. The purpose of the current study was to a) replicate the previously reported psychometric properties of the VSI, b) assess the known-groups and concurrent validity of the instrument, and c) test conceptual hypotheses regarding gastrointestinal-specific anxiety in comparison to other general measures of psychological distress as a crucial mechanism (mediator/moderator) underlying irritable bowel syndrome diagnosis and its symptoms. Methods: Two undergraduate student samples (n > 500) were administered the VSI along with measures assessing presence of lower gastrointestinal symptoms, nongastrointestinal pain, health-service utilization, anxiety, depression, vitality, neuroticism, and anxiety sensitivity. Path analyses tested the hypothesis that gastrointestinal-specific anxiety mediates the relationship between affective variables and irritable bowel syndrome diagnosis and symptoms. A 'known-groups' validity approach elucidated the relevance of gastrointestinal-specific anxiety across a spectrum of irritable bowel syndrome patients. Results: Good concurrent, divergent and discriminant validity was demonstrated. Logistic regression revealed that gastrointestinal-specific anxiety is the key explanatory variable of irritable bowel syndrome diagnostic status. Path analysis demonstrated that gastrointestinal-specific anxiety mediates the relationship between general psychological distress measures and gastrointestinal symptom severity. The VSI was related to gastrointestinal, but not nongastrointestinal, symptom severity. Conclusions: Overall, the VSI demonstrated excellent psychometric properties providing further support for its use in mechanistic studies of the role of anxiety in irritable bowel syndrome presentation. C1 Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurovisceral Sci & Womens Hlth, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Labus, JS (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurovisceral Sci & Womens Hlth, Peter V Ueberroth Bldg,Rm 2338C2,10946 Le Conte A, Los Angeles, CA 90095 USA. EM jlabus@ucla.edu FU NCCIH NIH HHS [R24 AT002681]; NIDDK NIH HHS [P50 DK64539]; NINR NIH HHS [NR 04881] NR 47 TC 87 Z9 88 U1 1 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0033-3174 J9 PSYCHOSOM MED JI Psychosom. Med. PD JAN PY 2007 VL 69 IS 1 BP 89 EP 98 DI 10.1097/PSY.0b013e31802e2f24 PG 10 WC Psychiatry; Psychology; Psychology, Multidisciplinary SC Psychiatry; Psychology GA 131EX UT WOS:000243852200013 PM 17244851 ER PT J AU Nelson, KM Starkebaum, GA Reiber, GE AF Nelson, Karin M. Starkebaum, Gordon A. Reiber, Gayle E. TI Veterans using and uninsured veterans not using veterans affairs (VA) Health Care SO PUBLIC HEALTH REPORTS LA English DT Article ID OUTPATIENT CLINICS; MEDICAL-CARE; COVERAGE; SYSTEM; ENROLLEES; ACCESS; ADULTS; COSTS; HMOS AB The objectives of this study were to: (1) examine veteran reliance on health services provided by the Veterans Health Administration (VA), (2) describe the characteristics of veterans who receive VA care, and (3) report rates of uninsurance among veterans and characteristics of uninsured veterans. The authors analyzed data from the 2000 Behavioral Risk Factor Surveillance System. Using bivariate and multivariate analyses, the association of veteran's demographic characteristics, health insurance coverage, and use of VA services were examined. Veterans not reporting VA coverage and having no other source of health insurance were considered uninsured. Among veteran respondents, 6.2% reported receiving all of their health care at the VA, 6.9% reported receiving some of their health care at the VA, and 86.9% did not use VA health care. Poor, less-educated, and minority veterans were more likely to receive all of their health care at the VA. Veterans younger than age 65 who utilized the VA for all of their health care also reported coverage with either private insurance (42.6%) or Medicare (36.3%). Of the veterans younger than age 65, 8.6% (population estimate: 1.3 million individuals) were uninsured. Uninsured veterans were less likely to be able to afford a doctor or see a doctor within the last year. Veterans who utilized the VA for all of their health care were more likely to be from disadvantaged groups. A large number of veterans who could use VA services were uninsured. They should be targeted for VA enrollment given the detrimental clinical effects of being uninsured. C1 VA Puget Sound Hlth Care Syst, Primary & Specialty Med Care Serv, Seattle, WA 98107 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98107 USA. Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. RP Nelson, KM (reprint author), VA Puget Sound Hlth Care Syst, Primary & Specialty Med Care Serv, 1660 S Columbian Way,S-111 GIMC, Seattle, WA 98107 USA. EM Karin.Nelson@va.gov NR 32 TC 38 Z9 38 U1 0 U2 2 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1101 15TH ST NW, STE 910, WASHINGTON, DC 20005 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD JAN-FEB PY 2007 VL 122 IS 1 BP 93 EP 100 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 133JU UT WOS:000244010000013 PM 17236614 ER PT J AU Breitner, JCS AF Breitner, John C. S. BE Tsuang, MT Stone, WS Lyons, MJ TI Prevention of Alzheimer's Disease Principles and Prospects SO RECOGNITION AND PREVENTION OF MAJOR MENTAL AND SUBSTANCE USE DISORDERS LA English DT Article; Book Chapter ID MILD COGNITIVE IMPAIRMENT; ESTROGEN REPLACEMENT THERAPY; RANDOMIZED CONTROLLED-TRIAL; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; HEALTH INITIATIVE MEMORY; POSTMENOPAUSAL WOMEN; APOLIPOPROTEIN-E; CACHE COUNTY; DOUBLE-BLIND; RISK C1 [Breitner, John C. S.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Breitner, John C. S.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Div Geriatr Psychiat, Seattle, WA 98195 USA. RP Breitner, JCS (reprint author), VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. NR 25 TC 1 Z9 1 U1 0 U2 0 PU AMER PSYCHIATRIC PRESS, INC PI WASHINGTON PA 1400 K ST NW, WASHINGTON, DC 20005 USA BN 978-1-58562-308-2 PY 2007 BP 319 EP 328 PG 10 WC Psychology, Clinical; Substance Abuse; Psychiatry; Psychology SC Psychology; Substance Abuse; Psychiatry GA BWL81 UT WOS:000294204300014 ER PT J AU Tofovic, SP Salah, EM Jackson, EK Melhem, M AF Tofovic, Stevan P. Salah, Ernan M. Jackson, Edwin K. Melhem, Mona TI Early renal injury induced by caffeine consumption in obese, diabetic ZSF(1) rats SO RENAL FAILURE LA English DT Review DE caffeine; metabolic syndrome; proteinuria; renal failure; tempol ID ADENOSINE RECEPTOR; METABOLIC SYNDROME; RENIN SECRETION; US ADULTS; HYPERTENSION; KIDNEY; TEMPOL; FAILURE; HEALTH; RISK AB Our previous studies indicate that prolonged caffeine consumption exacerbates renal failure in nephropathy associated with the metabolic syndrome. Reduced activity of the antioxidant defense system and beneficial effects of antioxidant therapy have been reported in diabetic rats and humans. The purpose of this study was to examine the early renal effects of caffeine consumption and the effects of concomitant antioxidant therapy in young obese, diabetic ZSF1 rats. Eleven-week-old male ZSF1 rats were randomized to drink tap water, caffeine (0.1%), tempol (1 mmol/ L), or a solution containing caffeine and tempol for nine weeks. Caffeine significantly reduced body weight and glycosuria (weeks 2-9), improved glucose tolerance (week 9), had no effect on elevated plasma triglycerides, plasma cholesterol (week 9) and blood pressure (week 9), and significantly increased plasma cholesterol level (weeks 5 and 9). Yet, as early as after two weeks, caffeine greatly augmented proteinuria and increased renal vascular resistance (RVR) and heart rate (HR: week 9). Tempol had no effects on metabolic status and development of proteinuria, did not alter caffeine-induced metabolic changes and early proteinuria, and attenuated caffeine-induced increase in HR and RVR. Immumohistochemical analysis revealed significant glomerular and interstitial inflammation, proliferation, and fibrosis in control animals. Caffeine augmented the influx of glomerular and interstitial macrophages (ED1+ cells) influx, glomerular and tubular proliferative response, and glomerular collagen IV content. Tempol abolished the exacerbation of renal inflammation, proliferation, and fibrosis induced by caffeine. In conclusion, in nephropathy associated with the metabolic syndrome, caffeine-most likely through the interaction with adenosine receptors and interference with anti-inflammatory and/or glomerular hemodynamic effects of adenosine-augments proteinuria and stimulates some of the key proliferative mechanisms involved in glomerular remodeling and sclerosis. Tempol does not prevent early renal injury (i.e., proteinuria) induced by caffeine, yet abolishes late renal inflammatory, proliferative, and fibrotic change induced by chronic caffeine consumption in obese ZSF1 rats. C1 Univ Pittsburgh, Sch Med, Dept Med, Ctr Clin Pharmacol, Pittsburgh, PA 15219 USA. Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA USA. VA Pittsurgh Hlth Syst, Pittsburgh, PA USA. RP Tofovic, SP (reprint author), Univ Pittsburgh, Sch Med, Dept Med, Ctr Clin Pharmacol, 100 Technol Dr,Suite 450, Pittsburgh, PA 15219 USA. EM tofovic@dom.pitt.edu NR 45 TC 7 Z9 7 U1 1 U2 6 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 0886-022X J9 RENAL FAILURE JI Ren. Fail. PY 2007 VL 29 IS 7 BP 891 EP 902 DI 10.1080/08860220701569846 PG 12 WC Urology & Nephrology SC Urology & Nephrology GA 227EY UT WOS:000250641200017 PM 17994459 ER PT J AU El-Serag, HB Graham, DY Rabeneck, L Avid, A Richardson, P Genta, RM AF El-Serag, Hashem B. Graham, David Y. Rabeneck, Linda Avid, Adjula Richardson, Peter Genta, Robert M. TI Prevalence and determinants of histological abnormalities of the gastric cardia in volunteers SO SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY LA English DT Article DE carditis; epidemiology; gastritis; GERD; Helicobacter pylori; metaplasia; risk factors ID HELICOBACTER-PYLORI INFECTION; GASTROESOPHAGEAL-REFLUX DISEASE; INTESTINAL METAPLASIA; INFLAMMATION; JUNCTION; ESOPHAGUS; SYMPTOMS; MUCOSA AB Objective. The findings of studies examining the prevalence and major risk factors of histological abnormalities of the gastric cardia have been inconsistent. Selection bias was possible in these studies depending on whether patients were referred for ulcer or gastroesophageal reflux disease ( GERD). There have been no studies on non-patient populations. The aim of this study was to mitigate the potential effects of selection bias. Material and methods. In a study comprising health-care workers, we distributed symptom questionnaires and invitations to undergo upper endoscopy. A single endoscopist performed standard endoscopy and biopsy examinations ( 2 antral, 2 corporal, and 2 cardiac biopsies). Staining was done using triple stain. Two pathologists, who were blinded to the results of the questionnaires and endoscopy, interpreted and recorded the histological findings. Results. A total of 226 participants underwent endoscopy. Gastric cardia, as defined by the presence of mucous glands, was identified in 191 subjects; mean age of the subjects was 45 years, 117 ( 61%) were women, and 49% were black. Active gastritis of the cardia was present in 58 ( 30.4%), chronic gastritis in 133 ( 69.6%), intestinal metaplasia ( IM) in 29 ( 15.2%), and pancreatic metaplasia in 25 ( 13%). Direct ( organisms) or indirect evidence ( active anywhere or chronic gastritis in antrum or corpus) for Helicobacter pylori was present in all participants with active gastritis, 60% of subjects with chronic gastritis, and approximately half of those with IM of the cardia. Approximately 15% with chronic carditis had neither H. pylori nor GERD symptoms. There were also no significant differences in the prevalence of heartburn or acid regurgitation, or the use of histamine-2-receptor antagonists ( H2RAs) or proton-pump inhibitors ( PPIs) between groups with and without active or chronic gastritis, IM, or pancreatic metaplasia, whereas active or chronic gastritis in the antrum or corpus and H. pylori infection were more frequent ( 1.5- to 2-fold) among those with histological abnormalities of the cardia. Conclusions. Active and chronic gastritis as well as intestinal metaplasia of the gastric cardia are relatively common in health-care worker volunteers. Although GERD symptoms are not significantly associated with these abnormalities, H. pylori infection is a strong risk factor. However, a considerable number of participants with chronic gastritis of the cardia have neither H. pylori nor GERD. C1 Houston Dept Vet Affiars Med Ctr 152, Gastroenterol Sect, Houston, TX 77030 USA. Houston Dept Vet Affiars Med Ctr, Hlth Serv Res, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. Dallas VA Med Ctr, Pathol Sect, Dallas, TX USA. RP El-Serag, HB (reprint author), Houston Dept Vet Affiars Med Ctr 152, Gastroenterol Sect, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM hasheme@bcm.tmc.edu NR 21 TC 6 Z9 6 U1 0 U2 3 PU TAYLOR & FRANCIS AS PI OSLO PA PO BOX 12 POSTHUSET, NO-0051 OSLO, NORWAY SN 0036-5521 J9 SCAND J GASTROENTERO JI Scand. J. Gastroenterol. PY 2007 VL 42 IS 10 BP 1158 EP 1166 DI 10.1080/00365520701299915 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 217NZ UT WOS:000249955900003 PM 17852849 ER PT J AU Herrmann, M Selige, J Raffael, S Sachs, G Brambilla, A Klein, T AF Herrmann, Michael Selige, Jens Raffael, Sandra Sachs, George Brambilla, Andrea Klein, Thomas TI Systematic expression profiling of the gastric H+/K+ ATPase in human tissue SO SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY LA English DT Article DE acid pump antagonist; APA; GERD; H+/ K+ ATPase; K+ -competitive inhibitor; P-CAB; PPI; proton pump inhibitor; reflux disease; TaqMan PCR ID H,K-ATPASE BETA-SUBUNIT; MEDULLARY COLLECTING DUCT; K+-COMPETITIVE INHIBITOR; PROTON PUMP INHIBITORS; ACID-SECRETION; ALPHA-SUBUNIT; FUNCTIONAL-ROLE; H+,K+-ATPASE; NA,K-ATPASE; BINDING AB Objective. The potassium-competitive acid blockers (P-CABs), comprise a new, innovative group of competitive and reversible inhibitors of the gastric H+/K+ ATPase. Our aim was to identify sites of expression of the H+/K+ ATPase that are potential targets of these compounds by examining the expression profile of the gastric H+/K+ ATPase in the human body from a broad range of tissues. Material and methods. Expression profiling was done by quantitative mRNA analysis (TaqMan PCR). Tissues that were mRNA-positive for the alpha subunit were investigated further by Western blot and immunohistochemistry (IHC) for the presence of gastric H+/K+ ATPase protein. Results. In addition to the very high expression levels in the stomach, the adrenal gland, cerebellum and pancreas gave unexpectedly positive mRNA signals for the alpha subunit of gastric H+/K+ ATPase. However, they were negative for mRNA of the beta subunit, and Western blot and IHC were negative for alpha and beta subunit protein. Another group of tissues with low alpha subunit mRNA expression including the frontal cortex, cortex grey matter, testis, thymus and larynx submucosa were also found negative for both alpha and beta subunit protein. In contrast to mouse kidney, no gastric H+/K+ATPase could be detected in human kidney. Conclusions. We therefore conclude that the only organ in humans expressing significant levels of the P-CAB target gastric H+/K+ ATPase is the stomach. C1 ALTANA Pharma AG, Dept Biochem Gastroenterol, D-78467 Constance, Germany. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. AXXAM Srl, Milan, Italy. RP Klein, T (reprint author), ALTANA Pharma AG, Dept Biochem Gastroenterol, Byk Gulden Str 2, D-78467 Constance, Germany. EM thomas.klein@altanapharma.com NR 49 TC 15 Z9 16 U1 0 U2 3 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0036-5521 EI 1502-7708 J9 SCAND J GASTROENTERO JI Scand. J. Gastroenterol. PY 2007 VL 42 IS 11 BP 1275 EP 1288 DI 10.1080/00365520701405579 PG 14 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 217OC UT WOS:000249956200002 PM 17852870 ER PT J AU Chan, ED Kaminska, AM Gill, W Chmura, K Feldman, NE Bai, XY Floyd, CM Fulton, KE Huitt, GA Strand, MJ Iseman, MD Shapiro, L AF Chan, Edward D. Kaminska, Aleksandra M. Gill, Wendy Chmura, Kathryn Feldman, Nicole E. Bai, Xiyuan Floyd, Corinne M. Fulton, Kayte E. Huitt, Gwen A. Strand, Matthew J. Iseman, Michael D. Shapiro, Leland TI Alpha-1-antitrypsin (AAT) anomalies are associated with lung disease due to rapidly growing mycobacteria and AAT inhibits Mycobacterium abscessus infection of macrophages SO SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID IMMUNODEFICIENCY-VIRUS TYPE-1; NONTUBERCULOUS MYCOBACTERIA; CLINICAL-FEATURES; PULMONARY-DISEASE; DEFICIENCY; EPIDEMIOLOGY AB Rapidly growing mycobacteria (RGM) are ubiquitous in the environment but cause lung disease in only a fraction of exposed individuals. This variable susceptibility to disease implies vulnerability to RGM infection due to weakness in host defense. Since most persons who contract RGM lung disease have no known host defense defect, it is likely that uncharacterized host deficiencies exist that predispose to RGM infection. Alpha-1-antitrypsin (AAT) is a host factor that may protect individuals from respiratory infections. Therefore, we assessed AAT protein anomalies as a risk factor for RGM lung disease. In a cohort of 100 patients with RGM lung disease, Mycobacterium (M.) abscessus was the most prevalent organism, isolated in 64 (64%) subjects. Anomalous AAT proteins were present in 27% of the cohort, which is 1.6 times the estimated prevalence of anomalous AAT proteins in the United States population (p = 0.008). In in vitro studies, both AAT and a synthetic inhibitor of serine proteases suppressed M. abscessus infection of monocyte-derived macrophages by up to 65% (p <0.01). AAT may be an anti-RGM host-defense factor, and anomalous AAT phenotypes or AAT deficiency may constitute risk factors for pulmonary disease due to RGM. C1 Univ Colorado Denver & Hlth Sci Ctr, Dept Med, Div Infect Dis, Denver, CO 80262 USA. Natl Jewish Med & Res Ctr, Dept Med, Denver, CO USA. Natl Jewish Med & Res Ctr, Program Cell Biol, Denver, CO USA. Natl Jewish Med & Res Ctr, Div Pulm Sci & Crit Care Med, Denver, CO USA. Denver Vet Affairs Med Ctr, Denver, CO USA. Univ Colorado, Sch Med, Boulder, CO 80309 USA. RP Shapiro, L (reprint author), Univ Colorado Denver & Hlth Sci Ctr, Dept Med, Div Infect Dis, 4200 E 9th Ave,Box B168, Denver, CO 80262 USA. EM leland.shapiro@uchsc.edu FU NHLBI NIH HHS [R01-HL66112] NR 22 TC 45 Z9 49 U1 0 U2 1 PU TAYLOR & FRANCIS AS PI OSLO PA PO BOX 12 POSTHUSET, NO-0051 OSLO, NORWAY SN 0036-5548 J9 SCAND J INFECT DIS JI Scand. J. Infect. Dis. PY 2007 VL 39 IS 8 BP 690 EP 696 DI 10.1080/00365540701225744 PG 7 WC Infectious Diseases SC Infectious Diseases GA 197FY UT WOS:000248541200005 PM 17654345 ER PT J AU Calkins, ME Dobie, DJ Cadenhead, KS Olincy, A Freedman, R Green, MF Greenwood, TA Gur, RE Gur, RC Light, GA Mintz, J Nuechterlein, KH Radant, AD Schork, NJ Seidman, LJ Siever, LJ Silverman, JM Stone, WS Swerdlow, NR Tsuang, DW Tsuang, MT Turetsky, BI Braff, DL AF Calkins, Monica E. Dobie, Dorcas J. Cadenhead, Kristin S. Olincy, Ann Freedman, Robert Green, Michael F. Greenwood, Tiffany A. Gur, Raquel E. Gur, Ruben C. Light, Gregory A. Mintz, Jim Nuechterlein, Keith H. Radant, Allen D. Schork, Nicholas J. Seidman, Larry J. Siever, Larry J. Silverman, Jeremy M. Stone, William S. Swerdlow, Neal R. Tsuang, Debby W. Tsuang, Ming T. Turetsky, Bruce I. Braff, David L. TI The consortium on the genetics of endophenotypes in schizophrenia: Model recruitment, assessment, and endophenotyping methods for a multisite collaboration SO SCHIZOPHRENIA BULLETIN LA English DT Article DE neurophysiology; neurocognitive; genes ID CONTINUOUS PERFORMANCE-TEST; SORTING TEST-PERFORMANCE; QUANTITATIVE TRAIT LOCI; WORKING-MEMORY; SUSTAINED ATTENTION; RELATIVES; DEFICITS; PAIRS; RECOGNITION; MECHANISMS AB Background: The Consortium on the Genetics of Schizophrenia (COGS) is an ongoing, National Institute of Mental Health-funded, 7-site collaboration investigating the occurrence and genetic architecture of quantitative endophenotypes related to schizophrenia. The purpose of this article is to provide a description of the COGS structure and methods, including participant recruitment and assessment. Methods: The hypothesis-driven recruitment strategy ascertains families that include a proband with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition diagnosis of schizophrenia, and at least one unaffected full sibling available for genotyping and endophenotyping, along with parents available for genotyping and (optional depending on age) endophenotyping. The family structure is selected to provide contrast in quantitative endophenotypic traits and thus to maximize the power of the planned genetic analyses. Probands are recruited from many sources including clinician referrals, local National Alliance for the Mentally Ill chapters, and advertising via the media. All participants undergo a standardized protocol that includes clinical characterization, a blood draw for genotyping, and endophenotype assessments (P50 suppression, prepulse inhibition, antisaccade performance, continuous performance tasks, letter-number span, verbal memory, and a computerized neurocognitive battery). Investigators participate in weekly teleconferences to coordinate and evaluate recruitment, clinical assessment, endophenotyping, and continuous quality control of data gathering and analyses. Data integrity is maintained through use of a highly quality-assured, centralized web-based database. Results: As of February 2006, 355 families have been enrolled and 688 participants have been endophenotyped, including schizophrenia probands (n = 154, M:F = 110:44), first-degree biological relatives (n = 343, M:F = 151:192), and community comparison subjects (n = 191, M:F = 81:110). Discussion: Successful multisite genetics collaborations must institute standardized methodological criteria for assessment and recruitment that are clearly defined, well communicated, and uniformly applied. In parallel, studies utilizing endophenotypes require strict adherence to criteria for cross-site data acquisition, equipment calibration and testing and software equivalence, and continuous quality assurance for many measures obtained across sites. This report describes methods and presents the structure of the COGS as a model of multisite endophenotype genetic studies. It also provides demographic information after the first 2 years of data collection on a sample for whom the behavioral data and genetics of endophenotype performance will be fully characterized in future articles. Some issues discussed in the reviews that follow reflect the challenges of evaluating endophenotypes in studies of the genetic architecture of endophenotypes in schizophrenia. C1 Univ Penn, Dept Psychiat, Neuropsychiat Sect, Philadelphia, PA 19104 USA. Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. Univ Colorado, Hlth Sci Ctr, Dept Psychiat, Denver, CO USA. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Geffen Sch Med, Los Angeles, CA 90024 USA. VA Greater Los Angeles Healthcare Syst, Boston, MA USA. Harvard Univ, Sch Med, Dept Psychiat,Beth Israel Deaconess Med Ctr, Massachusetts Mental Hlth Ctr,Publ Psychiat Div, Boston, MA 02115 USA. Harvard Inst Psychiat Epidemiol & Genet, Boston, MA USA. Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. RP Calkins, ME (reprint author), Univ Penn, Dept Psychiat, Neuropsychiat Sect, 10 Gates,3400 Spruce St, Philadelphia, PA 19104 USA. EM mcalkins@bbl.med.upenn.edu; DBraff@ucsd.edu RI Greenwood, Tiffany/F-6356-2012; Tsuang, Debby/L-7234-2016 OI Greenwood, Tiffany/0000-0002-6080-6503; Tsuang, Debby/0000-0002-4716-1894 FU NIMH NIH HHS [R01-MH65558, MH43518, R01 MH043518, R01 MH065554, R01 MH065558, R01 MH065562, R01 MH065571, R01 MH065578, R01 MH065588, R01 MH065707, R01-MH065554, R01-MH065562, R01-MH065571, R01-MH65578, R01-MH65588, R01-MH65707, R37 MH043518] NR 68 TC 99 Z9 101 U1 0 U2 10 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD JAN PY 2007 VL 33 IS 1 BP 33 EP 48 DI 10.1093/schbul/sbl044 PG 16 WC Psychiatry SC Psychiatry GA 120FW UT WOS:000243070900007 PM 17035358 ER PT J AU Thomas, EA Yao, JK AF Thomas, Elizabeth A. Yao, Jeffrey K. TI Clozapine specifically alters the arachidonic acid pathway in mice lacking apolipoprotein D SO SCHIZOPHRENIA RESEARCH LA English DT Article DE apolipoprotein; antipsychotic; clozapine; arachidonic acid; fatty acid; HPLC ID ANTIPSYCHOTIC-DRUG TREATMENT; PSYCHIATRIC-DISORDERS; FATTY-ACID; SCHIZOPHRENIC-PATIENTS; RAT-BRAIN; PATHOPHYSIOLOGY; PHARMACOTHERAPY; PROGESTERONE; METABOLISM; EXPRESSION AB Apolipoprotein D (apoD), a member of the lipocalin superfamily of lipid-binding proteins, exhibits abundant expression within the CNS of many species, including humans; however, its physiological role remains unclear. Treatment with atypical antipsychotic drugs, especially clozapine, results in elevation of apoD expression levels in rodent brain and in human plasma samples. In order to further explore the role of apoD in mechanisms of clozapine function, we have measured a panel of membrane fatty acids and membrane lipids in brain from drug-treated apoD knock-out mice. Mice received clozapine (10 mg/kg/day) in their drinking water for 28 days and forebrain samples were analyzed using high performance liquid chromatography and capillary gas chromatography. We identified significant differences in the levels of membrane fatty acids in response to clozapine treatment specifically in the brains of apoD knock-out mice, but not wild-type (wt) mice. The most striking observations were decreases in the levels of fatty acids related to metabolism of arachidonic acid (AA), which is a known binding partner for apoD. These include the precursor to arachidonic acid, linoleic acid (LA; 18:2n6c), arachidonic acid itself (20:4n6) and the elongation product of arachidonic acid, adrenic acid (22:4n6). We further report increases in LA, eicosadienoic acid and docosahexaenoic acid in apoD knock-out compared to wild-type mice. These findings implicate an important apoD/AA interaction, which may be necessary for clozapine function. (c) 2006 Elsevier B.V. All rights reserved. C1 Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA. VA Pittsburgy Healthcare Syst, Pittsburgh, PA 15206 USA. Univ Pittsburgh, Ctr Med, Pittsburgh, PA 15206 USA. RP Thomas, EA (reprint author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd,MB-10, La Jolla, CA 92037 USA. EM bthomas@scripps.edu FU NIMH NIH HHS [MH58141, MH069696]; NINDS NIH HHS [NS44169] NR 33 TC 14 Z9 15 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD JAN PY 2007 VL 89 IS 1-3 BP 147 EP 153 DI 10.1016/j.schres.2006.08.011 PG 7 WC Psychiatry SC Psychiatry GA 128KC UT WOS:000243655600016 PM 17011169 ER PT J AU Hackett, AS Watnick, SG AF Hackett, Amy S. Watnick, Suzanne G. TI Withdrawal from dialysis in end-stage renal disease: Medical, social, and psychological issues SO SEMINARS IN DIALYSIS LA English DT Article ID LIFE-SUPPORT; RISK-FACTORS; OF-LIFE AB Dialysis withdrawal is common, accounting for over 20% of patient deaths. It is the third leading cause of death among patients receiving dialysis, after cardiovascular disease and infectious complications. Here we present a case of a patient with significant comorbid disease who ultimately elected to withdraw from dialysis. The medical, social and psychological issues encountered by caregivers are reviewed. Additionally we discuss the available data on factors affecting the decision to withdraw, current practice guidelines, and efforts to educate nephrology fellows on end-of-life issues. C1 Oregon Hlth & Sci Univ, Portland VA Med Ctr, VA Dialysis Unit, Div Nephrol & Hypertens, Portland, OR USA. RP Watnick, SG (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, VA Dialysis Unit, Div Nephrol & Hypertens, P3 NEPH,3710 SW US Vet Hosp Rd, Portland, OR USA. EM watnicks@ohsu.edu NR 15 TC 11 Z9 14 U1 2 U2 2 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0894-0959 J9 SEMIN DIALYSIS JI Semin. Dial. PD JAN-FEB PY 2007 VL 20 IS 1 BP 86 EP 90 DI 10.1111/j.1525-139X.2007.00249.x PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 131ZN UT WOS:000243911600018 PM 17244129 ER PT S AU Turner, JN Coaxum, SD Gelasco, AK Garnovskaya, MN Raymond, JR AF Turner, Justin N. Coaxum, Sonya D. Gelasco, Andrew K. Garnovskaya, Maria N. Raymond, John R. BE Chattopadhyay, A TI Calmodulin Is a 5-HT Receptor-Interacting and Regulatory Protein SO SEROTONIN RECEPTORS IN NEUROBIOLOGY SE Frontiers in Neuroscience LA English DT Article; Book Chapter ID 3RD INTRACELLULAR LOOP; INSULIN-STIMULATED PHOSPHORYLATION; CORTICAL PYRAMIDAL NEURONS; CYCLIC-AMP ACCUMULATION; GROWTH-FACTOR-RECEPTOR; KINASE-C; SEROTONIN RECEPTORS; NA+/H+ EXCHANGE; SIGNAL-TRANSDUCTION; RAT HIPPOCAMPUS AB This chapter explores emerging roles for calmodulin as a regulator of 5-HT receptor function and describes recent work suggesting that calmodulin may be a so-called RIP (receptor-interacting protein) that binds to and modifies the functions of G protein-coupled 5-HT receptors. C1 [Turner, Justin N.; Coaxum, Sonya D.; Gelasco, Andrew K.; Garnovskaya, Maria N.; Raymond, John R.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Turner, Justin N.; Coaxum, Sonya D.; Gelasco, Andrew K.; Garnovskaya, Maria N.; Raymond, John R.] Vet Affairs Med Ctr, Ralph H Johnson Dept, Charleston, SC 29403 USA. RP Turner, JN (reprint author), Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. NR 99 TC 2 Z9 2 U1 0 U2 0 PU CRC PRESS-TAYLOR & FRANCIS GROUP PI BOCA RATON PA 6000 BROKEN SOUND PARKWAY NW, STE 300, BOCA RATON, FL 33487-2742 USA SN 2154-5723 J9 FRONT NEUROSCI JI Front. Neurosci. PY 2007 BP 61 EP 80 D2 10.1201/9781420005752 PG 20 WC Neurosciences SC Neurosciences & Neurology GA BKV55 UT WOS:000269396700005 ER PT J AU Alessi, C Martin, J Josephson, K Khan-Hudson, A Vandenberg, T Birath, J Martinez, S AF Alessi, C. Martin, J. Josephson, K. Khan-Hudson, A. Vandenberg, T. Birath, J. Martinez, S. TI Sleep disturbance predicts functional impairment among older people in assisted living facilities SO SLEEP LA English DT Meeting Abstract CT 21st Annual Meeting of the Association-Professional-Sleep-Societies CY JUN 09-14, 2007 CL Minneapolis, MN C1 Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Sepulveda, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACADEMY SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CENTER STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2007 VL 30 SU S MA 305 BP A104 EP A105 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 164HR UT WOS:000246224900307 ER PT J AU Budhiraja, R Zeater, M Parthasarathy, S Quan, S AF Budhiraja, R. Zeater, M. Parthasarathy, S. Quan, S. TI Factors determining adherence to continuous positive airway pressure (CPAP) therapy in veterans with obstructive sleep apnea (OSA) SO SLEEP LA English DT Meeting Abstract CT 21st Annual Meeting of the Association-Professional-Sleep-Societies CY JUN 09-14, 2007 CL Minneapolis, MN C1 So Arizona VA Healthcare Syst, Tucson, AZ USA. US Dept Vet Affairs, Tucson, AZ USA. Univ Arizona, Tucson, AZ USA. RI Parthasarathy, Sairam/L-1612-2013 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACADEMY SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CENTER STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2007 VL 30 SU S MA 487 BP A166 EP A166 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 164HR UT WOS:000246224900488 ER PT J AU Budhiraja, R Zeater, M Parthasarathy, S Quan, S AF Budhiraja, R. Zeater, M. Parthasarathy, S. Quan, S. TI Comparison of features of central sleep apnea and obstructive sleep apnea SO SLEEP LA English DT Meeting Abstract CT 21st Annual Meeting of the Association-Professional-Sleep-Societies CY JUN 09-14, 2007 CL Minneapolis, MN C1 Univ Arizona, Tucson, AZ USA. US Dept Vet Affairs, Tucson, AZ USA. RI Parthasarathy, Sairam/L-1612-2013 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACADEMY SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CENTER STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2007 VL 30 SU S MA 463 BP A158 EP A158 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 164HR UT WOS:000246224900464 ER PT J AU Dzierzewski, J Mccrae, C Marsiske, M Mccoy, K McNamara, J Dautovich, N Ross, A Stripling, A AF Dzierzewski, J. Mccrae, C. Marsiske, M. McCoy, K. McNamara, J. Dautovich, N. Ross, A. Stripling, A. TI Daily variability in objective and subjective sleep and cognition in older adults with insomnia SO SLEEP LA English DT Meeting Abstract CT 21st Annual Meeting of the Association-Professional-Sleep-Societies CY JUN 09-14, 2007 CL Minneapolis, MN C1 Univ Florida, Gainesville, FL USA. Vet Adm, San Antonio, TX USA. Univ Florida, Gainesville, FL 32611 USA. RI Stripling, Ashley/D-8421-2013 NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER ACADEMY SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CENTER STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2007 VL 30 SU S MA 326 BP A112 EP A112 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 164HR UT WOS:000246224900327 ER PT J AU Hannah, C Imran, A Budhiraja, R Quan, S Parthasarathy, S AF Hannah, C. Imran, A. Budhiraja, R. Quan, S. Parthasarathy, S. TI Alternative management strategies for sleep apnea improve access to care in veterans SO SLEEP LA English DT Meeting Abstract CT 21st Annual Meeting of the Association-Professional-Sleep-Societies CY JUN 09-14, 2007 CL Minneapolis, MN C1 US Dept Vet Affairs, Tucson, AZ USA. Univ Arizona, Tucson, AZ 85721 USA. RI Parthasarathy, Sairam/L-1612-2013 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACADEMY SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CENTER STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2007 VL 30 SU S MA 538 BP A182 EP A182 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 164HR UT WOS:000246224900539 ER PT J AU Madan, V Brennan, F Ross, R Horbal, A Dunn, G Mann, G Morrison, A AF Madan, V Brennan, F. Ross, R. Horbal, A. Dunn, G. Mann, G. Morrison, A. TI Long-term effects of cued fear conditioning on rem sleep microarchitecture and phasic events in rats SO SLEEP LA English DT Meeting Abstract CT 21st Annual Meeting of the Association-Professional-Sleep-Societies CY JUN 09-14, 2007 CL Minneapolis, MN C1 Univ Penn, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACADEMY SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CENTER STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2007 VL 30 SU S MA 12 BP A4 EP A5 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 164HR UT WOS:000246224900014 ER PT J AU Martin, J Irwin, M Martinez, S Birath, J Josephson, K Alessi, C AF Martin, J. Irwin, M. Martinez, S. Birath, J. Josephson, k Alessi, C. TI More daytime sleeping is associated with higher proinflammatory cytokine levels in older postacute rehabilitation patients SO SLEEP LA English DT Meeting Abstract CT 21st Annual Meeting of the Association-Professional-Sleep-Societies CY JUN 09-14, 2007 CL Minneapolis, MN C1 Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Los Angeles, CA USA. Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Sepulveda, CA USA. VA Greater Los Angeles Healthcare Syst, Sepulveda, CA USA. RI Irwin, Michael/H-4870-2013 OI Irwin, Michael/0000-0002-1502-8431 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACADEMY SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CENTER STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2007 VL 30 SU S MA 313 BP A107 EP A108 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 164HR UT WOS:000246224900315 ER PT J AU Methippara, M Kumar, S Noor, AM Szymusiak, R McGinty, D AF Methippara, M. Kumar, S. Noor, Alum M. Szymusiak, R. McGinty, D. TI Lateral ventricular perfusion of salubrinal, which arrests protein translation, promotes SWS in rats SO SLEEP LA English DT Meeting Abstract CT 21st Annual Meeting of the Association-Professional-Sleep-Societies CY JUN 09-14, 2007 CL Minneapolis, MN C1 Vet Adm Greater Los Angeles HealthCare Syst, North Hills, CA USA. Univ Patna, Patna 800005, Bihar, India. Univ Calif Los Angeles, Los Angeles, CA 90024 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER ACADEMY SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CENTER STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2007 VL 30 SU S MA 1054 BP A362 EP A362 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 164HR UT WOS:000246224901055 ER PT J AU Parthasarathy, S Lowman, X Kuo, M Quan, S AF Parthasarathy, S. Lowman, X. Kuo, M. Quan, S. TI Preferred tidal volume setting for non-invasive ventilation is different for sleep and wakefulness SO SLEEP LA English DT Meeting Abstract CT 21st Annual Meeting of the Association-Professional-Sleep-Societies CY JUN 09-14, 2007 CL Minneapolis, MN C1 US Dept Vet Affairs, Tucson, AZ USA. Univ Arizona, Tucson, AZ 85721 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER ACADEMY SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CENTER STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2007 VL 30 SU S MA 535 BP A181 EP A181 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 164HR UT WOS:000246224900536 ER PT J AU Parthasarathy, S Fitzgerald, M Goodwin, J Budhiraja, R Resnick, H Quan, S AF Parthasarathy, S. Fitzgerald, M. Goodwin, J. Budhiraja, R. Resnick, H. Quan, S. TI Nocturia and sleep-disordered breathing in the sleep heart health cohort SO SLEEP LA English DT Meeting Abstract CT 21st Annual Meeting of the Association-Professional-Sleep-Societies CY JUN 09-14, 2007 CL Minneapolis, MN C1 US Dept Vet Affairs, Tucson, AZ USA. Loyola Univ, Chicago, IL 60611 USA. Univ Arizona, Tucson, AZ 85721 USA. RI Parthasarathy, Sairam/L-1612-2013 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACADEMY SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CENTER STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2007 VL 30 SU S MA 530 BP A180 EP A180 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 164HR UT WOS:000246224900531 ER PT J AU Goldstein, G Allen, DN Haas, GL AF Goldstein, Gerald Allen, Daniel N. Haas, Gretchen L. BE Fujii, D Ahmed, I TI Schizophrenia SO SPECTRUM OF PSYCHOTIC DISORDERS: NEUROBIOLOGY, ETIOLOGY, AND PATHOGENESIS LA English DT Article; Book Chapter ID COGNITIVE-BEHAVIORAL THERAPY; RANDOMIZED CONTROLLED-TRIAL; LATE-ONSET SCHIZOPHRENIA; DENDRITIC SPINE DENSITY; CEREBRAL-BLOOD-FLOW; PREMORBID ADJUSTMENT; PREFRONTAL CORTEX; FOLLOW-UP; 1ST-EPISODE SCHIZOPHRENIA; FAMILY INTERVENTION C1 [Goldstein, Gerald] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Allen, Daniel N.] Univ Nevada, Las Vegas, NV 89154 USA. [Haas, Gretchen L.] Univ Pittsburgh, Pittsburgh, PA 15260 USA. RP Goldstein, G (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 93 TC 0 Z9 0 U1 1 U2 1 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-85056-8 PY 2007 BP 15 EP 38 D2 10.2277/ 0521850568 PG 24 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA BYQ38 UT WOS:000299729200003 ER PT J AU Ericksen, S Tsuang, D AF Ericksen, Sasha Tsuang, Debby BE Fujii, D Ahmed, I TI Dementia with lewy bodies SO SPECTRUM OF PSYCHOTIC DISORDERS: NEUROBIOLOGY, ETIOLOGY, AND PATHOGENESIS LA English DT Article; Book Chapter ID AUTOSOMAL-DOMINANT PARKINSONISM; CLINICAL DIAGNOSTIC-ACCURACY; SLEEP BEHAVIOR DISORDER; TEMPORAL-LOBE ATROPHY; ALPHA-SYNUCLEIN GENE; ALZHEIMERS-DISEASE; BODY DISEASE; NEURODEGENERATIVE DISEASES; INTERNATIONAL WORKSHOP; VISUAL HALLUCINATIONS C1 [Ericksen, Sasha; Tsuang, Debby] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Tsuang, Debby] Vet Affairs Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA USA. RP Ericksen, S (reprint author), Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. NR 88 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-85056-8 PY 2007 BP 472 EP 489 D2 10.2277/ 0521850568 PG 18 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA BYQ38 UT WOS:000299729200025 ER PT S AU Yehuda, R Bierer, LM AF Yehuda, Rachel Bierer, Linda M. BE DeKloet, ER Vermetten, E TI Transgenerational transmission of cortisol and PTSD risk SO STRESS HORMONES AND POST TRAUMATIC STRESS DISORDER: BASIC STUDIES AND CLINICAL PERSPECTIVES SE Progress in Brain Research LA English DT Review CT Colloquium on Stress Hormones and Post Traumatic Stress Disorder - Basic Studies and Clinical Perspectives CY AUG 28-30, 2006 CL Amsterdam, NETHERLANDS SP Royal Netherlands Acad Arts & Sci, Minist Defence Netherlands DE posttraurnatic stress disorder; glucocorticoid programming; epigenetics; cortisol; intergenerational effects; risk factors ID POSTTRAUMATIC-STRESS-DISORDER; HOLOCAUST SURVIVORS; TRAUMA EXPOSURE; GENE-EXPRESSION; PARENTAL PTSD; MATERNAL-CARE; RESPONSES; VULNERABILITY; VETERANS; TWIN AB Parental posttraumatic stress disorder (PTSD) appears to be a relevant risk factor for the development of PTSD, as evidenced by a greater prevalence of PTSD, but not trauma exposure, in adult offspring of Holocaust survivors with PTSD, compared to children of Holocaust-exposed parents without PTSD. This paper summarizes recent neuroendocrine studies in offspring of parents with PTSD. Offspring of trauma survivors with PTSD show significantly lower 24-h mean urinary cortisol excretion and salivary cortisol levels as well as enhanced plasma cortisol suppression in response to low dose dexamethasone administration than offspring of survivors without PTSD. In all cases, neuroendocrine measures were negatively correlated with severity of parental PTSD symptoms, even after controlling for PTSD and even other symptoms in offspring. Though the majority of our work has focused on adult offspring of Holocaust survivors, recent observations in infants born to mothers who were pregnant on 9/11 demonstrate that low cortisol in relation to parental PTSD appears to be present early in the course of development and may be influenced by in utero factors such as glucocorticoid programming. Since low cortisol levels are particularly associated with the presence of maternal PTSD the findings suggest the involvement of epigenetic mechanisms. C1 [Yehuda, Rachel; Bierer, Linda M.] Mt Sinai Sch Med & Bronx Vet Affairs, Dept Psychiat, Traumat Stress Studies Program, James J Peters VAMC, Bronx, NY 10468 USA. RP Yehuda, R (reprint author), Mt Sinai Sch Med & Bronx Vet Affairs, Dept Psychiat, Traumat Stress Studies Program, James J Peters VAMC, 116-A,OOMH-PTSD,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM Rachel.yehuda@va.gov NR 55 TC 10 Z9 10 U1 2 U2 20 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0079-6123 BN 978-0-444-53140-7 J9 PROG BRAIN RES JI Prog. Brain Res. PY 2007 VL 167 BP 121 EP 135 DI 10.1016/S0079-6123(07)67009-5 PG 15 WC Behavioral Sciences; Endocrinology & Metabolism; Neurosciences; Psychiatry; Psychology SC Behavioral Sciences; Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry; Psychology GA BHE65 UT WOS:000252487200009 ER PT J AU Huckans, MS Loftis, JM Blackwell, AD Linke, A Hauser, P AF Huckans, Marilyn S. Loftis, Jennifer M. Blackwell, Aaron D. Linke, Alex Hauser, Peter TI Interferon alpha therapy for hepatitis C: treatment completion and response rates among patients with substance use disorders SO SUBSTANCE ABUSE TREATMENT PREVENTION AND POLICY LA English DT Article ID ILLICIT-DRUG-USERS; VIRUS-INFECTION; PLUS RIBAVIRIN; MANAGEMENT; VETERANS; MULTICENTER; POPULATION; PREVALENCE; DRINKERS; BARRIERS AB Background: Individuals with substance use disorders (SUDs) are at increased risk for hepatitis C viral infection (HCV), and few studies have explored their treatment responses empirically. The objective of this study was to assess interferon alpha therapy (IFN) completion and response rates among patients with HCV who had a history of comorbid SUDs. More data is needed to inform treatment strategies and guidelines for these patients. Using a medical record database, information was retrospectively collected on 307,437 veterans seen in the Veterans Integrated Service Network 20 (VISN 20) of the Veterans Healthcare Administration (VHA) between 1998 and 2003. For patients treated with any type of IFN (including regular or pegylated IFN) or combination therapy (IFN and ribavirin) who had a known HCV genotype, IFN completion and response rates were compared among patients with a history of SUD (SUD+ Group) and patients without a history of SUD (SUD- Group). Results: Odds ratio analyses revealed that compared with the SUD- Group, the SUD+ Group was equally likely to complete IFN therapy if they had genotypes 2 and 3 (73.1% vs. 68.0%), and if they had genotypes 1 and 4 (39.5% vs. 39.9%). Within the sample of all patients who began IFN therapy, the SUD- and SUD+ groups were similarly likely to achieve an end of treatment response (genotypes 2 and 3, 52.8% vs. 54.3%; genotypes 1 and 4, 24.5% vs. 24.8%) and a sustained viral response (genotypes 2 and 3, 42.6% vs. 41.1%; genotypes 1 and 4: 16.0% vs. 22.3%). Conclusion: Individuals with and without a history of SUD responded to antiviral therapy for HCV at similar rates. Collectively, these findings suggest that patients who have co-morbid SUD and HCV diagnoses can successfully complete a course of antiviral therapy. C1 [Huckans, Marilyn S.; Loftis, Jennifer M.; Blackwell, Aaron D.; Linke, Alex; Hauser, Peter] Portland VA Med Ctr, NW Hepatitis C Resource Ctr, Portland, OR 97201 USA. [Huckans, Marilyn S.; Loftis, Jennifer M.; Blackwell, Aaron D.; Linke, Alex; Hauser, Peter] Portland VA Med Ctr, Behav Hlth & Clin Neurosci Div, Portland, OR USA. [Huckans, Marilyn S.; Loftis, Jennifer M.; Hauser, Peter] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Hauser, Peter] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA. [Hauser, Peter] Oregon Hlth & Sci Univ, Dept Internal Med, Portland, OR 97201 USA. [Loftis, Jennifer M.; Hauser, Peter] Portland VA Med Ctr, JENS Lab, Portland, OR USA. [Blackwell, Aaron D.] Univ Oregon, Dept Anthropol, Eugene, OR 97403 USA. RP Huckans, MS (reprint author), Portland VA Med Ctr, NW Hepatitis C Resource Ctr, Portland, OR 97201 USA. EM marilyn.huckans@va.gov; loftisj@ohsu.edu; ablackwe@uoregon.edu; alex.linke@va.gov; peter.hauser2@va.gov RI Blackwell, Aaron/B-5258-2008 OI Blackwell, Aaron/0000-0002-5871-9865 NR 38 TC 8 Z9 8 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1747-597X J9 SUBST ABUSE TREAT PR JI Subst/ Abus. Treatment Prev. Pol. PY 2007 VL 2 AR 4 DI 10.1186/1747-597X-2-4 PG 8 WC Substance Abuse SC Substance Abuse GA V00DD UT WOS:000206768100004 PM 17222348 ER PT J AU Chandra, D Gupta, S Reddy, RM Gregoric, ID Kar, B AF Chandra, Divay Gupta, Sachin Reddy, Raghu M. Gregoric, Igor D. Kar, Biswajit TI Gastric volvulus after ventricular assist device explantation and cardiac transplantation SO TEXAS HEART INSTITUTE JOURNAL LA English DT Article DE cardiac transplantation; device removal; stomach volvulus; heart assist devices/adverse effects; hernia, diaphragmatic/ diagnosis/etiology/surgery; postoperative complications ID HEART-TRANSPLANTATION; LVAD AB Diaphragmatic herniation has been recognized as a complication of unrepaired diaphragmatic defects after left ventricular assist device explantation and cardiac transplantation. We believe this to be the 1st report of diaphragmatic herniation that resulted in gastric volvulus in a cardiac transplant recipient. The presentation, diagnosis, and treatment of this potentially fatal condition are discussed herein. Nine months after removal of a Thoratec HeartMate (R) II left ventricular assist device and orthotopic cardiac transplantation, the patient presented with intermittent upper abdominal and lower chest discomfort of 3 weeks' duration. Physical examination was notable for fullness in the upper abdomen. Plain radiographs and computed tomographic scans of the chest and abdomen without contrast were unexceptional. Two weeks later, the patient's pain began to worsen rapidly, and an upper gastrointestinal barium study revealed partial herniation of the stomach into the chest and omento-axial gastric volvulus without luminal obstruction. The patient underwent uncomplicated laparotomy for repair of the diaphragmatic defect and reduction of the herniated stomach. This case highlights the need for increased awareness of diaphragmatic herniation as a complication of unrepaired diaphragmatic defects so that diagnosis is not delayed, and underscores the importance of primary repair of all such defects to prevent future complications. C1 Univ Texas, Hlth Sci Ctr, Dept Med, Houston, TX 77030 USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. Baylor Coll Med, Div Pulm & Crit Care Med, Houston, TX 77030 USA. St Lukes Episcopal Hosp, Texas Heart Inst, Dept Cardiothorac Surg & Mech Circulatory Support, Houston, TX 77030 USA. St Lukes Episcopal Hosp, Texas Heart Inst, Dept Cardiol, Houston, TX 77030 USA. Michael E DeBakey Vet Affairs Med Ctr, Div Cardiol, Houston, TX 77030 USA. RP Chandra, D (reprint author), Baylor Coll Med, Dept Med, 1 Baylor Plaza, Houston, TX 77030 USA. EM divaychandra@gmail.com NR 11 TC 4 Z9 4 U1 0 U2 0 PU TEXAS HEART INST PI HOUSTON PA PO BOX 20345, HOUSTON, TX 77225-0345 USA SN 0730-2347 J9 TEX HEART I J JI Tex. Heart Inst. J. PY 2007 VL 34 IS 1 BP 112 EP 114 PG 3 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 152EO UT WOS:000245344000026 PM 17420807 ER PT J AU Li, YF Wheeler, DL Ananthaswamy, HN Verma, AK Oberley, TD AF Li, Yafan Wheeler, Deric L. Ananthaswamy, Honnavara N. Verma, Ajit K. Oberley, Terry D. TI Differential tumor biology effects of double-initiation in a mouse skin chemical carcinogenesis model comparing wild type versus protein kinase Cepsilon overexpression mice SO TOXICOLOGIC PATHOLOGY LA English DT Article DE protein kinase Cepsilon; cell death; papilloma; squamous cell carcinoma ID SQUAMOUS-CELL CARCINOMA; TRANSGENIC MICE; C-EPSILON; IN-SITU; ACTIVATION; EPIDERMIS; PAPILLOMAS AB Our previous studies showed that protein kinase Cepsilon (PKC epsilon) verexpression in mouse skin resulted in metastatic squamous cell carcinoma (SCC) elicited by single 7,12-dimethylbenz(a)anthracene (DMBA)-initiation and 12-O-tetradecanoylphorbol- 13-acetate (TPA)-promotion in the absence of preceding papilloma formation as is typically observed in wild type mice. The present study demonstrates that double-DMBA initiation modulates tumor incidence, multiplicity, and latency period in both wild type and PKC epsilon overexpression transgenic (PKC epsilon-Tg) mice. After 17 weeks (wks) of tumor promotion, a reduction in papilloma multiplicity was observed in double- versus single-DMBA initiated wild type mice. Papilloma multiplicity was inversely correlated with cell death indices of interfollicular keratinocytes, indicating decreased papilloma formation was caused by increased cell death and suggesting the origin of papillomas is in interfollicular epidermis. Double-initiated PKC epsilon-Tg mice had accelerated carcinoma formation and cancer incidence in comparison to single-initiated PKC epsilon-Tg mice. Morphologic analysis of mouse skin following double initiation and tumor promotion showed a similar if not identical series of events to those previously observed following single initiation and tumor promotion: putative preneoplastic cells were observed arising from hyperplastic hair follicles (HF's) with subsequent cancer cell infiltration into the dermis. Single-initiated PKC epsilon-Tg mice exhibited increased mitosis in epidermal cells of HFs during tumor promotion. C1 [Li, Yafan] Univ New Mexico, Hlth Sci Ctr, Coll Pharm, Program Toxicol & Pharmacol, Albuquerque, NM 87131 USA. [Wheeler, Deric L.; Verma, Ajit K.] Univ New Mexico, Sch Med & Publ Hlth, Dept Human Oncol, Albuquerque, NM 87131 USA. [Ananthaswamy, Honnavara N.] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA. [Oberley, Terry D.] VA Hosp, Pathol & Lab Med Serv, Madison, WI USA. [Oberley, Terry D.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol & Lab Med, Madison, WI 53706 USA. RP Oberley, TD (reprint author), Univ Wisconsin, William S Middleton Mem Vet Adm Hosp, Sch Med & Publ Hlth, Dept Pathol & Lab Med, Room A35,2500 Overlook Terrace, Madison, WI 53705 USA. EM toberley@wisc.edu RI Wheeler, Deric/B-7175-2013 OI Wheeler, Deric/0000-0001-5915-3675 FU NCI NIH HHS [CA35368] NR 14 TC 4 Z9 4 U1 0 U2 1 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 0192-6233 J9 TOXICOL PATHOL JI Toxicol. Pathol. PY 2007 VL 35 IS 7 BP 942 EP 951 DI 10.1080/01926230701748164 PG 10 WC Pathology; Toxicology SC Pathology; Toxicology GA 243JO UT WOS:000251792800010 PM 18098040 ER PT J AU Zhou, W Choi, L Lin, PH Dardik, A Eraso, A Lumsden, AB AF Zhou, Wei Choi, Lorraine Lin, Peter H. Dardik, Alan Eraso, Andrea Lumsden, Alan B. TI Percutaneous transhepatic thrombectomy and pharmacologic thrombolysis of mesenteric venous thrombosis SO VASCULAR LA English DT Article DE endovascular; mesenteric venous thrombosis; oral contraceptives; pancreatitis; percutaneous thrombectomy; transhepatic ID PORTAL-VEIN THROMBOSIS; LIVER-TRANSPLANTATION; MANAGEMENT; STENT AB Mesenteric venous occlusion is a rare yet highly morbid condition that is traditionally treated with anticoagulation while surgery serves as the last resort. Percutaneous intervention provides an effective option with relatively low mortality and morbidity. We herein describe use of transhepatic percutaneous thrombectomy and pharmacologic thrombolysis in treating two cases of symptomatic mesenteric venous thrombosis. These cases underscore the fact that transhepatic thrombectomy and thrombolysis are a highly effective strategy for treating acute symptomatic mesenteric venous thrombosis. Several percutaneous techniques are also reviewed. C1 Baylor Coll Med, Michael E DeBakey Med Ctr, Michael E DeBakey Dept Surg, Div Vasc Surg & Endovasc Therapy, Houston, TX 77030 USA. Yale Univ, Sch Med, Dept Surg, VA Connecticut Healthcare Syst, New Haven, CT USA. Michael E DeBakey Med Ctr, Div Radiol, Houston, TX USA. RP Zhou, W (reprint author), Baylor Coll Med, Michael E DeBakey Dept Surg, Div Vasc Surg, 1709 Dryden St,Suite 1500, Houston, TX 77030 USA. EM wzhou1@bcm.edu NR 20 TC 17 Z9 22 U1 0 U2 1 PU B C DECKER INC PI HAMILTON PA 50 KING STREET EAST, 2ND FLOOR, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1708-5381 J9 VASCULAR JI Vascular PD JAN-FEB PY 2007 VL 15 IS 1 BP 41 EP 45 DI 10.2310/6670.2007.00013 PG 5 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 191OX UT WOS:000248141900009 PM 17382054 ER PT J AU Bhatti, S Hakeem, A Ahmad, U Malik, M Kosolcharoen, P Chang, SM AF Bhatti, Sabha Hakeem, Abdul Ahmad, Usman Malik, Maher Kosolcharoen, Peter Chang, Su Min TI Persistent left superior vena cava (PLSVC) with anomalous left hepatic vein drainage into the right atrium: role of imaging and clinical relevance SO VASCULAR MEDICINE LA English DT Article DE anomalous left hepatic vein; central venous access; left superior vena cava; thoracic veins ID PARKINSON-WHITE-SYNDROME; CENTRAL VENOUS CATHETER; CORONARY-SINUS; EXPERIENCE; CLOSURE AB Persistent left superior vena cava (PLSVC) is a very rare and yet the most commonly described thoracic venous anomaly in medical literature. It has a 10-fold higher incidence with congenital heart disease. PLSVC often becomes apparent when an unknown PLSVC is incidentally discovered during central venous line placement, intracardiac electrode/pacemaker placement or cardiopulmonary bypass, where it may cause technical difficulties and life-threatening complications. PLSVC is also associated with disturbances of cardiac impulse formation and conduction including varying degrees of heart blocks, supraventricular arrhythmias and Wolff Parkinson White syndrome. We describe the case of an 86-year-old male with a history of coronary artery disease and chronic atrial fibrillation who presented with worsening dyspnea and syncopal episodes. An ECG was consistent with complete heart block. During lead placement for the pacemaker, a left subclavian approach was unsuccessful. A left venogram was performed through the brachial vein that demonstrated a left superior vena cava. The diagnosis was confirmed with echocardiography using a bubble study and also a chest CT. The anatomy was unique as there was anomalous left hepatic vein drainage into the right atrium. The case provides insight into the diagnostic modalities and clinical considerations of this unusual thoracic venous anomaly. C1 [Bhatti, Sabha; Hakeem, Abdul; Malik, Maher; Kosolcharoen, Peter; Chang, Su Min] Univ Wisconsin Hosp & Clin, Dept Cardiovasc Med, Madison, WI 53792 USA. [Bhatti, Sabha; Hakeem, Abdul; Malik, Maher; Kosolcharoen, Peter; Chang, Su Min] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Ahmad, Usman] Yale Univ, Sch Med, New Haven, CT USA. RP Hakeem, A (reprint author), 2705 Univ Ave 11, Madison, WI 53705 USA. EM a.hakeem@hosp.wisc.edu NR 31 TC 13 Z9 16 U1 0 U2 2 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1358-863X J9 VASC MED JI Vasc. Med. PY 2007 VL 12 IS 4 BP 319 EP 324 DI 10.1177/1358863x07084859 PG 6 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 248VR UT WOS:000252185700007 PM 18048468 ER PT J AU Groeneveld, PW AF Groeneveld, Peter W. TI Medicare requirement for research participation SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter ID COVERAGE C1 Philadelphia Vet Adm Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA 19104 USA. RP Groeneveld, PW (reprint author), Philadelphia Vet Adm Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA 19104 USA. EM peter.groeneveld@va.gov NR 5 TC 2 Z9 2 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD DEC 27 PY 2006 VL 296 IS 24 BP 2923 EP 2924 DI 10.1001/jama.296.24.2923-b PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 120FD UT WOS:000243069000017 PM 17190890 ER PT J AU Itani, KMF Wilson, SE Awad, SS Jensen, EH Finn, TS Abramson, MA AF Itani, Kamal M. F. Wilson, Samuel E. Awad, Samir S. Jensen, Erin H. Finn, Tyler S. Abramson, Murray A. TI Ertapenem versus cefotetan prophylaxis in elective colorectal surgery SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID SURGICAL SITE INFECTION; COMPLICATED INTRAABDOMINAL INFECTIONS; ANTIMICROBIAL PROPHYLAXIS; PLUS METRONIDAZOLE; COMPARE CEFOTETAN; DOUBLE-BLIND; MULTICENTER; PREVENTION; RESECTION AB BACKGROUND: Ertapenem, a long-acting carbapenem, may be an alternative to the recommended prophylactic antibiotic cefotetan. METHODS: In this randomized, double-blind trial, we assessed the efficacy and safety of antibiotic prophylaxis with ertapenem, as compared with cefotetan, in patients undergoing elective colorectal surgery. A successful outcome was defined as the absence of surgical-site infection, anastomotic leakage, or antibiotic use 4 weeks postoperatively. All adverse events were collected until 14 days after the administration of antibiotic prophylaxis. RESULTS: Of the 1002 patients randomly assigned to study groups, 901 (451 in the ertapenem group and 450 in the cefotetan group) qualified for the modified intention-to-treat analysis, and 672 (338 in the ertapenem group and 334 in the cefotetan group) were included in the per-protocol analysis. After adjustment for strata, in the modified intention-to-treat analysis, the rate of overall prophylactic failure was 40.2% in the ertapenem group and 50.9% in the cefotetan group (absolute difference, -10.7%; 95% confidence interval [CI], -17.1 to -4.2); in the per-protocol analysis, the failure rate was 28.0% in the ertapenem group and 42.8% in the cefotetan group (absolute difference, -14.8%; 95% CI, -21.9 to -7.5). Both analyses fulfilled statistical criteria for the superiority of ertapenem. In the modified intention-to-treat analysis, the most common reason for failure of prophylaxis in both groups was surgical-site infection: 17.1% in the ertapenem group and 26.2% in the cefotetan group (absolute difference, -9.1; 95% CI, -14.4 to -3.7). In the treated population, the overall incidence of Clostridium difficile infection was 1.7% in the ertapenem group and 0.6% in the cefotetan group (P=0.22). CONCLUSIONS: Ertapenem is more effective than cefotetan in the prevention of surgical-site infection in patients undergoing elective colorectal surgery but may be associated with an increase in C. difficile infection. C1 Vet Affairs Boston Healthcare Syst, W Roxbury, MA 02132 USA. Boston Univ, Sch Med, Boston, MA 02118 USA. Univ Calif Irvine, Sch Med, Orange, CA 92668 USA. Baylor Coll Med, Houston, TX 77030 USA. Houston Helathcare Syst, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. Merck Res Labs, Upper Gwynedd, PA USA. RP Itani, KMF (reprint author), Vet Affairs Boston Healthcare Syst, 1400 VFW Pkwy,112A, W Roxbury, MA 02132 USA. EM kitani@med.va.gov NR 28 TC 140 Z9 145 U1 1 U2 5 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD DEC 21 PY 2006 VL 355 IS 25 BP 2640 EP 2651 DI 10.1056/NEJMoa054408 PG 12 WC Medicine, General & Internal SC General & Internal Medicine GA 118QG UT WOS:000242956200005 PM 17182989 ER PT J AU Odden, MC Chertow, GM Fried, LF Newman, AB Connelly, S Angleman, S Harris, TB Simonsick, EM Shlipak, MG AF Odden, Michelle C. Chertow, Glenn M. Fried, Linda F. Newman, Anne B. Connelly, Stephanie Angleman, Sara Harris, Tamara B. Simonsick, Eleanor M. Shlipak, Michael G. CA HABC Study TI Cystatin C and measures of physical function in elderly adults - The health, aging, and body composition (HABC) study SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE aging; cystatin C; exercise tolerance; kidney diseases; muscle weakness; walking ID CHRONIC KIDNEY-DISEASE; GLOMERULAR-FILTRATION-RATE; STAGE RENAL-DISEASE; QUALITY-OF-LIFE; EXERCISE CAPACITY; HEMODIALYSIS-PATIENTS; SERUM CREATININE; OLDER-ADULTS; DIALYSIS; RISK AB Most studies of the relation between kidney function and physical function have been conducted in persons with advanced kidney disease and have used creatinine-based measures of kidney function. Cystatin C concentration is a measure of kidney function that is independent of muscle mass, unlike creatinine. Using baseline data on 3,043 elderly adults from the Health, Aging, and Body Composition Study (Blacks and Whites recruited from Pittsburgh, Pennsylvania, and Memphis, Tennessee, in 1997-1998), the authors examined the cross-sectional association between cystatin C level and performance on several tests of physical function. After adjustment for demographic and lifestyle variables, chronic health conditions, and inflammation, each standard-deviation (0.34 mg/liter) increase in cystatin C concentration was associated with 1.32 odds (95% confidence interval (CI): 1.20, 1.46) of not completing a 400-m walk, a 10.9-second (95% CI: 8.1, 13.8) slower 400-m walk time, a 0.11-point (95% CI: 0.09, 0.13) reduction in lower extremity performance score, a 1.12-kg (95% CI: 0.83, 1.40) lower grip strength, and a 4.7-nm (95% CI: 3.5, 5.9) lower knee extension strength. In contrast, when kidney function was measured by estimated glomerular filtration rate, the association of kidney function with physical function was only evident below 60 ml/minute/1.73 m(2). In these older adults, mild decrements in kidney function, as measured by cystatin C concentration, were associated with poorer physical function. C1 Vet Adm Med Ctr, Gen Internal Med Sect, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Nephrol, San Francisco, CA 94143 USA. Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA. VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. NIA, NIH, Bethesda, MD 20892 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA. RP Odden, MC (reprint author), Vet Adm Med Ctr, Gen Internal Med Sect, 111A1,4150 Clement St, San Francisco, CA 94121 USA. EM shlip@itsa.ucsf.edu RI Newman, Anne/C-6408-2013 OI Newman, Anne/0000-0002-0106-1150; Angleman, Sara/0000-0002-9520-5716 FU Intramural NIH HHS; NHLBI NIH HHS [R01 HL073208-01]; NIA NIH HHS [N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106]; NIDDK NIH HHS [R01 DK 066488] NR 42 TC 58 Z9 59 U1 1 U2 9 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD DEC 15 PY 2006 VL 164 IS 12 BP 1180 EP 1189 DI 10.1093/aje/kwj333 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 115DK UT WOS:000242714800006 PM 17035344 ER PT J AU Kahn, KL MacLean, CH Liu, H Rubenstein, LZ Wong, AL Harker, JO Chen, WP Fitzpatrick, DM Bulpitt, KJ Traina, SB Mittman, BS Hahn, BH Paulus, HE AF Kahn, K. L. MacLean, C. H. Liu, H. Rubenstein, L. Z. Wong, A. L. Harker, J. O. Chen, W. P. Fitzpatrick, D. M. Bulpitt, K. J. Traina, S. B. Mittman, B. S. Hahn, B. H. Paulus, H. E. TI Application of explicit process of care measurement to rheumatoid arthritis: Moving from evidence to practice SO ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH LA English DT Article DE rheumatoid arthritis; DMARDs; quality of care ID HEALTH ASSESSMENT QUESTIONNAIRE; MODIFYING ANTIRHEUMATIC DRUGS; DISEASE-ACTIVITY INDEX; MEASURING QUALITY; THERAPY; GUIDELINES; CANCER; RELIABILITY; MANAGEMENT; VALIDITY AB Objective. To construct quality measures with measurement validity and meaning for clinicians. Methods. We conducted a prospective cohort study of rates of change in disease-modifying antirheumatic drug (DMARD) and/or systemic corticosteroid drug or dose for 568 patients with rheumatoid arthritis (RA) across 6,159 clinical encounters within 12 months to examine how changes in clinical specifications change adherence. Results. Rates of DMARD change were sensitive to specifications regarding the intensity of disease activity (severe or moderate), duration of specified disease activity, and length of the observation period. Over 12 months, the proportions of 377 patients with severe disease activity observed for 1-month, 2-month, and 3-month time blocks who had a change in DMARD drug or dose were 36%, 57%, and 74%, respectively. Over 12 months, a change in DMARD drug or dose was observed for 44%, 50%, and 68% of 377 patients with severe disease within 3 months, 6 months, and 12 months, respectively, of the patient meeting criteria for severe disease activity. A change in DMARD drug or dose was observed for 21%, 23%, and 34% of 149 patients with moderate disease activity within 3, 6, and 12 months, respectively, of the patient meeting criteria for moderate disease activity. Conclusion. Rates of pharmacologic interventions for patients with moderate and severe RA disease activity vary substantially by intensity and duration of disease activity and by duration of period for observing change. Lack of precision in explicit process criteria could substantially mislead comparisons of quality of care across comparison groups. C1 Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA. RAND, Santa Monica, CA USA. Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. Kaiser Permanente, W Los Angeles Med Ctr, Los Angeles, CA USA. RP Kahn, KL (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, 911 Broxton Pl,Box 951736, Los Angeles, CA 90095 USA. EM kkahn@mednet.ucla.edu FU NIAMS NIH HHS [5 P60-AR-36834] NR 32 TC 12 Z9 12 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRIT RHEUM-ARTHR JI Arthritis Rheum-Arthritis Care Res. PD DEC 15 PY 2006 VL 55 IS 6 BP 884 EP 891 DI 10.1002/art.22361 PG 8 WC Rheumatology SC Rheumatology GA 117SD UT WOS:000242892400009 PM 17139665 ER PT J AU Taylor, CE Fang, MA AF Taylor, Connie E. Fang, Meika A. TI Septic arthritis caused by Abiotrophia defectiva SO ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH LA English DT Article ID TOTAL KNEE ARTHROPLASTY; GRANULICATELLA; ENDOCARDITIS; INFECTIONS; DIAGNOSIS; ADIACENS; THERAPY; DISEASE C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90733 USA. Univ Calif Los Angeles, Los Angeles, CA USA. RP Fang, MA (reprint author), VA Greater Los Angeles Healthcare Syst, GRECC 11G,11301 Wilshire Blvd, Los Angeles, CA 90733 USA. EM meika.fang@med.va.gov NR 14 TC 5 Z9 5 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRIT RHEUM-ARTHR JI Arthritis Rheum-Arthritis Care Res. PD DEC 15 PY 2006 VL 55 IS 6 BP 976 EP 977 DI 10.1002/art.22348 PG 2 WC Rheumatology SC Rheumatology GA 117SD UT WOS:000242892400022 PM 17139646 ER PT J AU Meyers, BS English, J Gabriele, M Peasley-Miklus, C Heo, M Flint, AJ Mulsant, BH Rothschild, AJ AF Meyers, Barnett S. English, Judith Gabriele, Michelle Peasley-Miklus, Catherine Heo, Moonseong Flint, Alastair J. Mulsant, Benoit H. Rothschild, Anthony J. CA STOP-PD Study Group TI A delusion assessment scale for psychotic major depression: Reliability, validity, and utility SO BIOLOGICAL PSYCHIATRY LA English DT Article DE delusions; depression; impact; conviction; bizarreness; disorganization ID BETA-HYDROXYLASE ACTIVITY; PSYCHIATRIC RATING-SCALE; CLINICAL-FEATURES; SCHIZOPHRENIA; DIMENSIONS; EXPERIENCE; HALLUCINATIONS; METAANALYSIS; DISORDERS; BELIEFS AB Background: Although delusions are the hallmark of major depression with psychotic features, a scale to measure the intensify of beliefs across multiple delusional domains in this condition has been unavailable. The development and assessment of the Delusional Assessment Scale (DAS) are described. Methods: Scale items were selected initially based on previous studies of delusional ideation in schizophrenia. A three-point item to assess mood congruence was added. A 15-item scale was assessed in 92 subjects participating in the four-site collaborative study of the pharmacotherapy of major depression with psychotic features. Maximum likelihood method was used to determine scale factors, The internal consistency of these factors was determined. Comparisons between scale scores and ratings from the Brief Psychiatric Rating Scale (BPRS) (Overall and Gorham 1962) were used to assess convergent and discriminant validity. Results: The data were fit by a five-factor model (impact, conviction, disorganization, bizarreness, and extension). Inter-rater reliability of the five factors ranged from. 77 for conviction and .74 for impact to .37 for disorganization. Internal consistency for each of the five factors was >= .72. Scores on specific domains were signficantly correlated with the BPRS unusual thought content item and positive symptom subscale scores. Conclusions: The DAS is a reliable measure of 5 delusional domains. C1 Cornell Univ, Weill Coll Med, Dept Psychiat, White Plains, NY 10605 USA. New York Presbyterian Hosp, Westchester Div, W Chester, NY USA. Univ Toronto, Univ Hlth Network, Dept Psychiat, Toronto, ON, Canada. Toronto Rehabil Inst, Geriatr Program & Res Inst, Toronto, ON, Canada. VA Pittsburgh Hlth Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. Univ Massachusetts, Sch Med, Dept Psychiat, Worcester, MA 01655 USA. Univ Massachusetts Mem Hlth Care, Worcester, MA USA. RP Meyers, BS (reprint author), Cornell Univ, Weill Coll Med, Dept Psychiat, 21 Bloomingdale Rd, White Plains, NY 10605 USA. EM bmeyers@med.cornell.edu FU NIMH NIH HHS [MH30915, MH48512, MH62446, MH625518, MH62565, MH62624, MH069430] NR 43 TC 25 Z9 25 U1 2 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD DEC 15 PY 2006 VL 60 IS 12 BP 1336 EP 1342 DI 10.1016/j.biopsych.2006.05.033 PG 7 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 115LL UT WOS:000242735700010 PM 17046724 ER PT J AU Carrieri, MP Amass, L Lucas, GM Vlahov, D Wodak, A Woody, GE AF Carrieri, Maria Patrizia Amass, Leslie Lucas, Gregory M. Vlahov, David Wodak, Alex Woody, George E. TI Buprenorphine use: The international experience SO CLINICAL INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT Forum for Collaborative HIV Research CY JUN 03-04, 2004 CL Washington, DC ID ACTIVE ANTIRETROVIRAL THERAPY; HIV-INFECTED PATIENTS; INJECTING DRUG-USERS; HUMAN-IMMUNODEFICIENCY-VIRUS; HIGH-DOSE BUPRENORPHINE; METHADONE-MAINTENANCE TREATMENT; HIGH-DOSAGE BUPRENORPHINE; 2-YEAR FOLLOW-UP; FRENCH GENERAL-PRACTITIONERS; RANDOMIZED CONTROLLED TRIAL/ AB The confluence of the heroin injection epidemic and the human immunodeficiency virus (HIV) infection epidemic has increased the call for expanded access to effective treatments for both conditions. Buprenorphine and methadone are now listed on the World Health Organization's Model Essential Drugs List. In France, which has the most extensive experience, buprenorphine has been associated with a dramatic decrease in deaths due to overdose, and buprenorphine diversion appears to be associated with inadequate dosage, social vulnerability, and prescriptions from multiple providers. Other treatment models (in the United States, Australia, Germany, and Italy) and buprenorphine use in specific populations are also reviewed in the present article. In countries experiencing a dual epidemic of heroin use and HIV infection, such as former states of the Soviet Union and other eastern European and Asian countries, access to buprenorphine and methadone may be one potential tool for reducing the spread of HIV infection among injection drug users and for better engaging them in medical care. C1 INSERM, U379, F-13006 Marseille, France. Friends Res Inst, Los Angeles, CA USA. Johns Hopkins Univ, Baltimore, MD 21218 USA. New York Acad Med, Ctr Urban Epidemiol Studies, New York, NY USA. Univ Penn, Sch Med, Treatment Res Inst, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. St Vincents Hosp, Alcohol & Drug Serv, Sydney, NSW 2010, Australia. RP Carrieri, MP (reprint author), INSERM, U379, 23 Rue S Torrents, F-13006 Marseille, France. EM Pmcarrieri@aol.com RI Lucas, Gregory/B-9225-2009 FU NIDA NIH HHS [DA15616]; PHS HHS [H97HA03794] NR 185 TC 68 Z9 69 U1 5 U2 11 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD DEC 15 PY 2006 VL 43 SU 4 BP S197 EP S215 DI 10.1086/508184 PG 19 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 106UB UT WOS:000242126100006 PM 17109307 ER PT J AU Goetz, MB Ferguson, MR Han, XL McMillan, G Clair, MS Pappa, KA McClernon, DR O'Brien, WA AF Goetz, Matthew Bidwell Ferguson, Monique R. Han, Xueliang McMillan, Greg Clair, Marty St. Pappa, Keith A. McClernon, Daniel R. O'Brien, William A. TI Evolution of HIV resistance mutations in patients maintained on a stable treatment regimen after virologic failure SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE HIV resistance; protease inhibitors; resistance mutations; reverse transcriptase inhibitors ID ACTIVE ANTIRETROVIRAL THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS; THYMIDINE ANALOG MUTATIONS; COMBINATION THERAPY; HIV-1-INFECTED PATIENTS; DRUG-RESISTANCE; NAIVE PATIENTS; RANDOMIZED-TRIAL; TREATMENT INTERRUPTION; INFECTED PATIENTS AB Objective: We compared the rate of emergence of thymidine analogue mutations (TAMs) and major protease inhibitor mutations in adherent patients who remained on stable treatment with a thymidine analogue and/or protease inhibitor after the onset of virologic failure. Design: Follow-up genotypic resistance testing was done using archived 1 plasma obtained from patients having 0 or 1 TAM and/or 0 or 1 major protease inhibitor resistance mutation at the onset of virologic failure. Results: The median duration of observed failure was 691 days. There were 41 thymidine analogue regimens and 34 protease inhibitor regimens; concomitant ritonavir was used 4 times. New major protease inhibitor mutations emerged more rapidly than did new TAMs (P = 0.0019); new TAMs emerged more rapidly in thymidine analogue regimens that did not include lamivudine (P = 0.0073). The emergence of TAMs and major protease inhibitor mutations did not differ if lamivudine was not part of the thymidine analogue regimen. The evolution of CD4(+) cell counts and plasma viral loads (pVLs) during virologic failure was similar regardless of whether or not a new TAM or major protease inhibitor mutations emerged or, for thymidine analogue-containing regimens, whether lamivudine was or was not used. Conclusions: Major protease inhibitor mutations arose more frequently and rapidly than did TAMs in patients with sustained virologic failure who received lamivudine. C1 Vet Affairs Greater Los Angeles Healthcare Syst, Infect Dis Sect 111F, Dept Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. Univ Texas, Med Branch, Dept Med, Galveston, TX 77550 USA. GlaxoSmithKline Inc, Res Triangle Pk, NC USA. Univ Texas, Med Branch, Dept Pathol, Galveston, TX 77550 USA. Univ Texas, Med Branch, Dept Microbiol & Immunol, Galveston, TX 77550 USA. RP Goetz, MB (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Infect Dis Sect 111F, Dept Med, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM matthew.goetz@va.gov OI Goetz, Matthew/0000-0003-4542-992X FU NIAID NIH HHS [R21 AI058194] NR 48 TC 13 Z9 14 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD DEC 15 PY 2006 VL 43 IS 5 BP 541 EP 549 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 116HR UT WOS:000242793600007 PM 17075391 ER PT J AU Eisenberger, NI Jarcho, JM Lieberman, MD Naliboff, BD AF Eisenberger, Naomi I. Jarcho, Johanna M. Lieberman, Matthew D. Naliboff, Bruce D. TI An experimental study of shared sensitivity to physical pain and social rejection SO PAIN LA English DT Article DE pain sensitivity; social exclusion; social pain; dorsal anterior cingulate cortex; social rejection; pain threshold; pain unpleasantness ID SUPPORT; EXCLUSION; RECOVERY; SURGERY; HURT AB Recent evidence points to a possible overlap in the neural systems underlying the distressing experience that accompanies physical pain and social rejection (Eisenberger et al., 2003). The present study tested two hypotheses that stem from this suggested overlap, namely: (1) that baseline sensitivity to physical pain will predict sensitivity to social rejection and (2) that experiences that heighten social distress will heighten sensitivity to physical pain as well. In the current study, participants' baseline cutaneous heat pain unpleasantness thresholds were assessed prior to the completion of a task that manipulated feelings of social distress. During this task, participants played a virtual ball-tossing game, allegedly with two other individuals, in which they were either continuously included (social inclusion condition) or they were left out of the game by either never being included or by being overtly excluded (social rejection conditions). At the end of the game, three pain stimuli were delivered and participants rated the unpleasantness of each. Results indicated that greater baseline sensitivity to pain (lower pain unpleasantness thresholds) was associated with greater self-reported social distress in response to the social rejection conditions. Additionally, for those in the social rejection conditions, greater reports of social distress were associated with greater reports of pain unpleasantness to the thermal stimuli delivered at the end of the game. These results provide additional support for the hypothesis that pain distress and social distress share neurocognitive substrates. Implications for clinical Populations are discussed. (c) 2006 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved. C1 Univ Calif Los Angeles, Cousins Ctr Psychoneuroimmunol, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Davis Geffen Sch Med, Ctr Neurovisceral Sci & Womens Hlth, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Eisenberger, NI (reprint author), Univ Calif Los Angeles, Cousins Ctr Psychoneuroimmunol, Los Angeles, CA USA. EM neisenbe@ucla.edu; jjarcho@psych.ucla.edu OI Jarcho, Johanna/0000-0001-9075-6968 FU NCCIH NIH HHS [R24 AT002681]; NIDDK NIH HHS [P50 DK64539]; NIMH NIH HHS [MH15750, T32 MH019925]; NINR NIH HHS [NR04881] NR 24 TC 89 Z9 94 U1 1 U2 29 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0304-3959 J9 PAIN JI Pain PD DEC 15 PY 2006 VL 126 IS 1-3 BP 132 EP 138 DI 10.1016/j.pain.2006.06.024 PG 7 WC Anesthesiology; Clinical Neurology; Neurosciences SC Anesthesiology; Neurosciences & Neurology GA 119KW UT WOS:000243012200017 PM 16890354 ER PT J AU Kahn, SE Hull, RL Utzschneider, KM AF Kahn, Steven E. Hull, Rebecca L. Utzschneider, Kristina M. TI Mechanisms linking obesity to insulin resistance and type 2 diabetes SO NATURE LA English DT Article ID BETA-CELL FUNCTION; IMPAIRED GLUCOSE-TOLERANCE; HUMAN ADIPOSE-TISSUE; FATTY-ACID CYCLE; NONDIABETIC SUBJECTS; SECRETORY CAPACITY; METABOLIC SYNDROME; INCRETIN HORMONES; HIGH-RISK; MELLITUS AB Obesity is associated with an increased risk of developing insulin resistance and type 2 diabetes. In obese individuals, adipose tissue releases increased amounts of non-esterified fatty acids, glycerol, hormones, proinflammatory cytokines and other factors that are involved in the development of insulin resistance. When insulin resistance is accompanied by dysfunction of pancreatic islet beta-cells - the cells that release insulin failure to control blood glucose levels results. Abnormalities in beta-cell function are therefore critical in defining the risk and development of type 2 diabetes. This knowledge is fostering exploration of the molecular and genetic basis of the disease and new approaches to its treatment and prevention. C1 VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98108 USA. Univ Washington, Seattle, WA 98108 USA. RP Kahn, SE (reprint author), VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, 1660 S Columbian Way, Seattle, WA 98108 USA. EM skahn@u.washington.edu OI Kahn, Steven/0000-0001-7307-9002; Hull, Rebecca/0000-0001-9690-4087 NR 83 TC 1553 Z9 1612 U1 49 U2 398 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0028-0836 J9 NATURE JI Nature PD DEC 14 PY 2006 VL 444 IS 7121 BP 840 EP 846 DI 10.1038/nature05482 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 116LW UT WOS:000242805400040 PM 17167471 ER PT J AU Lieberman, D AF Lieberman, David TI A call to action - Measuring the quality of colonoscopy SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material ID COMPUTED TOMOGRAPHIC COLONOGRAPHY; COLORECTAL-CANCER; VIRTUAL COLONOSCOPY; ASYMPTOMATIC ADULTS; PREVENTION; ADENOMAS; SURVEILLANCE; POLYPECTOMY; RECURRENCE; CELECOXIB C1 Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Div Gastroenterol, Portland, OR 97201 USA. RP Lieberman, D (reprint author), Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Div Gastroenterol, Portland, OR 97201 USA. NR 20 TC 54 Z9 55 U1 0 U2 0 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD DEC 14 PY 2006 VL 355 IS 24 BP 2588 EP 2589 DI 10.1056/NEJMe068254 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 116BZ UT WOS:000242778800013 PM 17167143 ER PT J AU Pekary, AE Stevens, SA Sattin, A AF Pekary, Albert Eugene Stevens, Schetema A. Sattin, Albert TI Circadian rhythms of TRH-like peptide levels in rat brain SO BRAIN RESEARCH LA English DT Article DE thyrotropin-releasing hormone; limbic system; mood regulation ID THYROTROPIN-RELEASING-HORMONE; RAPID MODULATION; CEREBELLUM; TISSUES AB This is the first report of diurnal variations in the levels of thyrotropin-releasing hormone-like peptides (pGlu-X-Pro-NH2, where "X" can be any amino acid residue) in brain regions involved in mood regulation. These peptides have neuroprotective and antidepressant-like properties that may help stabilize chronobiologic systems that are often abnormal in neuropsychiatric disease. We hypothesized that diurnal fluctuations in the levels of these neuropeptides are components of the chronobiologic regulation of autonomic, behavioral and emotional states. Optimal use of these potentially therapeutic agents will benefit from an understanding of their response to, and effect on, normal vegetative, activity and sleep patterns, and the corresponding disordered patterns of mental illness. For these reasons, 16 male, 200 g, Sprague-Dawley rats were maintained for 4 weeks in a stable 12 h lights on, 12 h lights off photoperiod. Levels of TRH and TRH-like peptides were measured at 3.0 h, 10.5 h, 13.5 h and 21.0 h, where the subjective midnight was 0.0 h, by a combination of HPLC and RIA. Highly significant changes in TRH-like peptide levels were observed in the striatum, posterior cingulate, cerebellum, pyriform cortex, nucleus accumbens and medulla oblongata. TRH-like peptide levels, in general, were highly correlated with changes in TRH concentration, within and between brain regions, and may be colocalized in large glutamatergic neurons innervating the rat limbic system. We conclude that TRH-like peptides may be important components of chronobiologic systems involved in maintaining autonomic, behavioral and mood equilibria. Published by Elsevier B.V. C1 VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA. VA Greater Los Angeles Healthcare Syst, Ctr Ulcer Res & Educ, Los Angeles, CA 90073 USA. VA Greater Los Angeles Healthcare Syst, Psychiat Serv, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Inst Brain Res, Los Angeles, CA 90073 USA. RP Pekary, AE (reprint author), VA Greater Los Angeles Healthcare Syst, Res Serv, Bldg 114,Rm 229,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM Eugene.Pekary@va.gov NR 31 TC 15 Z9 16 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 J9 BRAIN RES JI Brain Res. PD DEC 13 PY 2006 VL 1125 BP 67 EP 76 DI 10.1016/j.brainres.2006.10.003 PG 10 WC Neurosciences SC Neurosciences & Neurology GA 122TZ UT WOS:000243251200009 PM 17113044 ER PT J AU Werner, RM Bradlow, ET AF Werner, Rachel M. Bradlow, Eric T. TI Relationship between medicare's hospital compare performance measures and mortality rates SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID QUALITY-OF-CARE; COMMUNITY-ACQUIRED PNEUMONIA; CONGESTIVE-HEART-FAILURE; HEALTH-CARE; MYOCARDIAL-INFARCTION; COMORBIDITY MEASURES; ADMINISTRATIVE DATA; US HOSPITALS; SURVIVAL; THERAPY AB Context In response to concerns about the quality of care in US hospitals, the Centers for Medicare & Medicaid Services began measuring hospital performance and reporting this performance on their Web site, Hospital Compare. It is unknown whether these process performance measures are related to hospital-level outcomes. Objective To determine whether quality measured with the process measures used in Hospital Compare are correlated with and predictive of hospitals' risk-adjusted mortality rates. Design, Setting, and Participants Cross-sectional study of hospital care between January 1 and December 31, 2004, for acute myocardial infarction, heart failure, and pneumonia at acute care hospitals in the United States included on the Hospital Compare Web site. Ten process performance measures included in Hospital Compare were compared with hospital risk-adjusted mortality rates, which were measured using Medicare Part A claims data. Main Outcome Measures Condition-specific inpatient, 30-day, and 1-year risk-adjusted mortality rates. Results A total of 3657 acute care hospitals were included in the study based on their performance as reported in Hospital Compare. Across all acute myocardial infarction performance measures, the absolute reduction in risk-adjusted mortality rates between hospitals performing in the 25th percentile vs those performing in the 75th percentile was 0.005 for inpatient mortality, 0.006 for 30-day mortality, and 0.012 for 1-year mortality ( P <. 001 for each comparison). For the heart failure performance measures, the absolute mortality reduction was smaller, ranging from 0.001 for inpatient mortality ( P=. 03) to 0.002 for 1-year mortality ( P=. 08). For the pneumonia performance measures, the absolute reduction in mortality ranged from 0.001 for 30-day mortality ( P=. 05) to 0.005 for inpatient mortality ( P <. 001). Differences in mortality rates for hospitals performing in the 75th percentile on all measures within a condition vs those performing lower than the 25th percentile on all reported measures for acute myocardial infarction ranged between 0.008 ( P=. 06) and 0.018 ( P=. 008). For pneumonia, the effects ranged between 0.003 ( P=. 09) and 0.014 ( P <. 001); for heart failure, the effects ranged between - 0.013 ( P=. 06) and - 0.038 ( P=. 45). Conclusions Hospital performance measures predict small differences in hospital risk-adjusted mortality rates. Efforts should be made to develop performance measures that are tightly linked to patient outcomes. C1 Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equit Res & Promot, Philadelphia, PA USA. Univ Penn, Dept Mkt, Philadelphia, PA 19104 USA. Univ Penn, Dept Stat, Philadelphia, PA 19104 USA. Univ Penn, Dept Educ, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. RP Werner, RM (reprint author), 1230 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM rwerner@mail.med.upenn.edu NR 62 TC 312 Z9 315 U1 5 U2 20 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD DEC 13 PY 2006 VL 296 IS 22 BP 2694 EP 2702 DI 10.1001/jama.296.22.2694 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 115WY UT WOS:000242765700024 PM 17164455 ER PT J AU Gleason, CE Schmitz, TW Hess, T Koscik, RL Trivedi, MA Ries, ML Carlsson, CM Sager, MA Asthana, S Johnson, SC AF Gleason, C. E. Schmitz, T. W. Hess, T. Koscik, R. L. Trivedi, M. A. Ries, M. L. Carlsson, C. M. Sager, M. A. Asthana, S. Johnson, S. C. TI Hormone effects on fMRI and cognitive measures of encoding: Importance of hormone preparation SO NEUROLOGY LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; HEALTH INITIATIVE MEMORY; ESTROGEN PLUS PROGESTIN; POSTMENOPAUSAL WOMEN; ACTIVATION; IMPAIRMENT; DISEASE AB We compared fMRI and cognitive data from nine hormone therapy (HT)-naive women with data from women exposed to either opposed conjugated equine estrogens (CEE) (n = 10) or opposed estradiol (n = 4). Exposure to either form of HT was associated with healthier fMRI response; however, CEE-exposed women exhibited poorer memory performance than either HT-naive or estradiol-exposed subjects. These preliminary findings emphasize the need to characterize differential neural effects of various HTs. C1 Univ Wisconsin, Dept Med, Sect Geriatr & Gerontol, Madison, WI 53705 USA. Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI 53705 USA. William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA. RP Gleason, CE (reprint author), Univ Wisconsin, Dept Med, Sect Geriatr, 2870 Univ Ave,Suite 106, Madison, WI 53705 USA. EM ceg@medicine.wisc.edu FU NIA NIH HHS [K23 AG024302-03, R01 AG021155-05, R01 AG021155-03, K23 AG024302-01, K23 AG024302, R01 AG021155, R01 AG21155, K23 AG024302-04, R01 AG021155-02, K23 AG024302-02, R01 AG021155-01A2, R01 AG021155-04, K23 AG024302-05] NR 9 TC 24 Z9 24 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD DEC 12 PY 2006 VL 67 IS 11 BP 2039 EP 2041 DI 10.1212/01.wnl.0000247277.81400.43 PG 3 WC Clinical Neurology SC Neurosciences & Neurology GA 115RG UT WOS:000242750900026 PM 17159116 ER PT J AU Scremin, OU Li, MGG Roch, M Booth, R Jenden, DJ AF Scremin, Oscar U. Li, Mingen Grace Roch, Margareth Booth, Ruth Jenden, Donald J. TI Acetylcholine and choline dynamics provide early and late markers of traumatic brain injury SO BRAIN RESEARCH LA English DT Article DE brain injury; acetylcholine; choline ID MAGNETIC-RESONANCE SPECTROSCOPY; TIME-DEPENDENT CHANGES; CEREBRAL-CORTEX; BLOOD-FLOW; GAS-CHROMATOGRAPHY; MASS-SPECTROMETRY; MEMORY DEFICITS; WORKING MEMORY; RAT-BRAIN; ISCHEMIA AB We assessed acetylcholine (ACh) and choline (Ch) dynamics 2.5 h, 1, 4 and 14 days after cerebral cortex impact injury or craniotomy only in adult male Sprague-Dawley rats. Cortical endogenous ACh (D0ACh), endogenous free Ch (D0Ch), deuterium-labeled Ch (D4Ch), and ACh synthesized from D4Ch (D4ACh) were measured by gas-chromatography mass-spectrometry after intravenous injection of D4Ch followed in 1 min by microwave fixation of the brain. D0Ch increased in and around the impact up to 700% of control within 1 day after trauma. Smaller D0Ch increases were found in the cortex contralateral to the impact and in both hemispheres after craniotomy only. D4Ch contents increased to 200% in the impact and surrounding regions 4-14 days post-trauma, with lower increases 2.5 h post-trauma. DOACh decreased at all times post-trauma in the impact center, and initially in the periphery and adjacent regions with a recovery at 14 days. Similar DOACh decreases, although of lesser extent and magnitude were present in the craniotomy only group. D4ACh showed a peak at one day post-trauma in all regions studied in the impact and craniotomy groups. In conclusion, D0Ch tissue level was an early marker of trauma, while 14 days after trauma Ch uptake from blood was enhanced in and around the traumatized cortex. Craniotomy by itself induced a generalized increase in ACh turnover 1 day after this minimal trauma. Choline acetyltransferase activity was reduced in the impact center region but not affected in the adjacent and contralateral regions or by cramotomy. (c) 2006 Elsevier B.V. All rights reserved. C1 Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA. RP Scremin, OU (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, Bldg 115,Room 319, Los Angeles, CA 90073 USA. EM oscremin@ucla.edu NR 53 TC 17 Z9 17 U1 0 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 J9 BRAIN RES JI Brain Res. PD DEC 8 PY 2006 VL 1124 BP 155 EP 166 DI 10.1016/j.brainres.2006.09.062 PG 12 WC Neurosciences SC Neurosciences & Neurology GA 119MQ UT WOS:000243016800018 PM 17084821 ER PT J AU Sumathipala, R Xu, CS Seago, J Mould, AP Humphries, MJ Craig, SE Patel, Y Wijelath, ES Sobel, M Rahman, S AF Sumathipala, Rushika Xu, Cunshuan Seago, Julian Mould, A. Paul Humphries, Martin J. Craig, Sue E. Patel, Yatin Wijelath, Errol S. Sobel, Michael Rahman, Salman TI The "linker" region (amino acids 38-47) of the disintegrin elegantin is a novel inhibitory domain of integrin alpha(5)beta(1)-dependent cell adhesion on fibronectin - Evidence for the negative regulation of fibronectin synergy site biological activity SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID GLYCOPROTEIN-IIB-IIIA; SNAKE-VENOM PROTEINS; RGD SEQUENCE MOTIFS; HETERODIMERIC DISINTEGRIN; DIRECTED MUTAGENESIS; LIGAND RECOGNITION; 10TH-FIII DOMAINS; BINDING-SITES; COMPLEX; FIBRINOGEN AB Disintegrins are a family of potent inhibitors of cell-cell and cell-matrix adhesion. In this study we have identified a region of the disintegrin elegantin, termed the "linker domain" (amino acids 38-47), with inhibitory activity toward alpha(5)beta(1)-mediated cell adhesion on fibronectin (Fn). Using a chimeric structure-function approach in which sequences of the functionally distinct disintegrin kistrin were introduced into the elegantin template at targeted sites, a loss of inhibitory function toward alpha(5)beta(1)-mediated adhesion on Fn was observed when the elegantin linker domain was substituted. Subsequent analysis comparing the inhibitory efficacies of the panel of elegantin-kistrin chimeras toward CHO alpha(5) cell adhesion on recombinant Fn III6-10 fragments showed that the loss of inhibitory activity associated with the disruption of the elegantin linker domain was dependent upon the presence of a functional Fn III9 synergy site within the Fn III6-10 substrate. This suggested that the elegantin linker domain inhibits primarily the activity of the Fn synergy domain in promoting alpha(5)beta(1) integrin-mediated cell adhesion. Construction of a cyclic peptide corresponding to the entire region of the elegantin linker domain showed that this domain has intrinsic alpha(5)beta(1) inhibitory activity comparable with the activity of the RGDS peptide. These data demonstrate a novel biological function for a disintegrin domain that antagonizes integrin-mediated cell adhesion. C1 Kings Coll London, Sch Med, St Thomas Hosp, Div Cardiovasc Med,Lab Thrombosis & Vasc Remodell, London SE1 7EH, England. Univ Manchester, Fac Life Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England. Univ Washington, Sch Med, Div Vasc Surg, Seattle, WA 98108 USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Rahman, S (reprint author), Kings Coll London, Sch Med, St Thomas Hosp, Div Cardiovasc Med,Lab Thrombosis & Vasc Remodell, London SE1 7EH, England. EM salman.rahman@kcl.ac.uk OI Humphries, Martin/0000-0002-4331-6967 NR 37 TC 2 Z9 2 U1 0 U2 2 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD DEC 8 PY 2006 VL 281 IS 49 BP 37686 EP 37696 DI 10.1074/jbc.M603943200 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 111TH UT WOS:000242477100046 PM 16982624 ER PT J AU Kahn, SE Haffner, SM Heise, MA Herman, WH Holman, RR Jones, NP Kravitz, BG Lachin, JM O'Neill, MC Zinman, B Viberti, G AF Kahn, Steven E. Haffner, Steven M. Heise, Mark A. Herman, William H. Holman, Rury R. Jones, Nigel P. Kravitz, Barbara G. Lachin, John M. O'Neill, M. Colleen Zinman, Bernard Viberti, Giancarlo CA ADOPT Study Grp TI Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID TYPE-2 DIABETES-MELLITUS; BETA-CELL FUNCTION; RANDOMIZED CONTROLLED-TRIAL; BLOOD-GLUCOSE CONTROL; INSULIN-RESISTANCE; CONSENSUS STATEMENT; COMPLICATIONS; RISK; SULFONYLUREA; ASSOCIATION AB BACKGROUND: The efficacy of thiazolidinediones, as compared with other oral glucose-lowering medications, in maintaining long-term glycemic control in type 2 diabetes is not known. METHODS: We evaluated rosiglitazone, metformin, and glyburide as initial treatment for recently diagnosed type 2 diabetes in a double-blind, randomized, controlled clinical trial involving 4360 patients. The patients were treated for a median of 4.0 years. The primary outcome was the time to monotherapy failure, which was defined as a confirmed level of fasting plasma glucose of more than 180 mg per deciliter (10.0 mmol per liter), for rosiglitazone, as compared with metformin or glyburide. Prespecified secondary outcomes were levels of fasting plasma glucose and glycated hemoglobin, insulin sensitivity, and (beta)-cell function. RESULTS: Kaplan-Meier analysis showed a cumulative incidence of monotherapy failure at 5 years of 15% with rosiglitazone, 21% with metformin, and 34% with glyburide. This represents a risk reduction of 32% for rosiglitazone, as compared with metformin, and 63%, as compared with glyburide (P<0.001 for both comparisons). The difference in the durability of the treatment effect was greater between rosiglitazone and glyburide than between rosiglitazone and metformin. Glyburide was associated with a lower risk of cardiovascular events (including congestive heart failure) than was rosiglitazone (P<0.05), and the risk associated with metformin was similar to that with rosiglitazone. Rosiglitazone was associated with more weight gain and edema than either metformin or glyburide but with fewer gastrointestinal events than metformin and with less hypoglycemia than glyburide (P<0.001 for all comparisons). CONCLUSIONS: The potential risks and benefits, the profile of adverse events, and the costs of these three drugs should all be considered to help inform the choice of pharmacotherapy for patients with type 2 diabetes. C1 Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. Univ Washington, Seattle, WA 98195 USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. GlaxoSmithKline Inc, King Of Prussia, PA USA. GlaxoSmithKline Inc, Harlow, Essex, England. Univ Michigan, Ann Arbor, MI 48109 USA. Oxford Ctr Diabet Endocrinol & Metab, Oxford, England. George Washington Univ, Ctr Biostat, Rockville, MD USA. Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada. Univ Toronto, Toronto, ON, Canada. Univ London, Kings Coll London Sch Med, London WC1E 7HU, England. RP Kahn, SE (reprint author), Vet Affairs Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA. EM skahn@u.washington.edu RI Zinman, Bernard/E-7266-2013 OI Lachin, John/0000-0001-9838-2841; Kahn, Steven/0000-0001-7307-9002 NR 35 TC 1519 Z9 1594 U1 11 U2 67 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD DEC 7 PY 2006 VL 355 IS 23 BP 2427 EP 2443 DI 10.1056/NEJMoa066224 PG 17 WC Medicine, General & Internal SC General & Internal Medicine GA 113EO UT WOS:000242581400007 PM 17145742 ER PT J AU Mark, GP Kinney, AE Grubb, MC Zhu, XM Finn, DA Mader, SL Berger, SP Bechtholt, AJ AF Mark, Gregory P. Kinney, Anthony E. Grubb, Michele C. Zhu, Xiaoman Finn, Deborah A. Mader, Sarah L. Berger, S. Paul Bechtholt, Anita J. TI Injection of oxotremorine in nucleus accumbens shell reduces cocaine but not food self-administration in rats SO BRAIN RESEARCH LA English DT Article DE muscarinic receptor; mesolimbic dopamine system; progressive ratio; addiction; cholinergic system; acetylcholine; pirenzepine ID MEDIAL PREFRONTAL CORTEX; MUSCARINIC RECEPTORS; CHOLINERGIC MODULATION; PHOSPHOINOSITIDE BREAKDOWN; NICOTINE ADDICTION; DOPAMINE RELEASE; SEEKING BEHAVIOR; ACETYLCHOLINE; NEURONS; BRAIN AB Mesencephalic dopamine neurons form synapses with acetylcholine (ACh)-containing interneurons in the nucleus accumbens (NAcc). Although their involvement in drug reward has not been systematically investigated, these large aspiny interneurons may serve an important integrative function. We previously found that repeated activation of nicotinic cholinergic receptors enhanced cocaine intake in rats but the role of muscarinic receptors in drug reward is less clear. Here we examined the impact of local changes in muscarinic receptor activation within the NAcc on cocaine and food self-administration in rats trained on a progressive ratio (PR) schedule of reinforcement. Animals were given a minimum of 9 continuous days of drug access before testing in order to establish a stable breaking point (BP) for intravenous cocaine infusions (0.75 mg/kg/infusion). Rats in the food group acquired stable responding on the PR schedule within 7 days. On the test day, rats were bilaterally infused in the NAcc with the muscarinic receptor agonist oxotremorine methiodide (OXO: 0.1, 0.3 or 1 nmol/side), OXO plus the M, selective antagonist pirenzepine (PIRENZ; 0.3 nmol/side) or aCSF 15 min before cocaine or food access. OXO dose dependently reduced BP values for cocaine reinforcement (-17%, -44% [p < 0.05] and -91% [p < 0.0001] for 0.1, 0.3 and 1.0 nmol, respectively) and these reductions dissipated by the following session. Pretreatment with PIRENZ blocked the BP-reducing effect of 0.3 nmol OXO. Notably, OXO (0.1, 0.3 and 1.0 nmol/side) injection in the NAcc did not affect BP for food reward. The results suggest that muscarinic ACh receptors in the caudomedial NAcc may play a role in mediating the behavior reinforcing effects of cocaine. (c) 2006 Elsevier B.V. All rights reserved. C1 Oregon Hlth Sci Univ, Sch Med, Dept Behav Neurosci, Portland, OR 97239 USA. Portland VA Med Ctr, Portland, OR 97239 USA. RP Mark, GP (reprint author), Oregon Hlth Sci Univ, Sch Med, Dept Behav Neurosci, L-470,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM markg@ohsu.edu FU NIDA NIH HHS [T32 DA007262, DA11203, DA14639, F32 DA005965, F32 DA05965, R01 DA014639, R29 DA011203, T32 DA07262] NR 61 TC 19 Z9 20 U1 2 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 J9 BRAIN RES JI Brain Res. PD DEC 6 PY 2006 VL 1123 BP 51 EP 59 DI 10.1016/j.brainres.2006.09.029 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 120BQ UT WOS:000243058900007 PM 17045970 ER PT J AU Turk, DC Dworkin, RH Burke, LB Gershon, R Rothman, M Scott, J Allen, RR Atkinson, JH Chandler, J Cleeland, C Cowan, P Dimitrova, R Dionne, R Farrar, JT Haythornthwaite, JA Hertz, S Jadad, AR Jensen, MP Kellstein, D Kerns, RD Manning, DC Martin, S Max, MB McDermott, MP McGrath, P Moulin, DE Nurmikko, T Quessy, S Raja, S Rappaport, BA Rauschkolb, C Robinson, JP Royal, MA Simon, L Stauffer, JW Stucki, G Tollett, J von Stein, T Wallace, MS Wernicke, J White, RE Williams, AC Witter, J Wyrwich, KW AF Turk, Dennis C. Dworkin, Robert H. Burke, Laurie B. Gershon, Richard Rothman, Margaret Scott, Jane Allen, Robert R. Atkinson, J. Hampton Chandler, Julie Cleeland, Charles Cowan, Penny Dimitrova, Rozalina Dionne, Raymond Farrar, John T. Haythornthwaite, Jennifer A. Hertz, Sharon Jadad, Alejandro R. Jensen, Mark P. Kellstein, David Kerns, Robert D. Manning, Donald C. Martin, Susan Max, Mitchell B. McDermott, Michael P. McGrath, Patrick Moulin, Dwight E. Nurmikko, Turo Quessy, Steve Raja, Srinivasa Rappaport, Bob A. Rauschkolb, Christine Robinson, James P. Royal, Mike A. Simon, Lee Stauffer, Joseph W. Stucki, Gerold Tollett, Jane von Stein, Thorsten Wallace, Mark S. Wernicke, Joachim White, Richard E. Williams, Amanda C. Witter, James Wyrwich, Kathleen W. TI Developing patient-reported outcome measures for pain clinical trials: IMMPACT recommendations SO PAIN LA English DT Review ID PATIENTS PERSPECTIVE; END-POINTS; PERCEPTIONS; ASSESSMENTS C1 Univ Washington, Seattle, WA 98195 USA. Univ Rochester, Sch Med & Dent, Rochester, NY USA. US FDA, Rockville, MD 20857 USA. Northwestern Univ, Chicago, IL 60611 USA. Johnson & Johnson, Raritan, NY USA. AstraZeneca, Wilmington, DE USA. Univ Calif San Diego, La Jolla, CA 92093 USA. Merck & Co Inc, Blue Bell, PA USA. Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA. Amer Chron Pain Assoc, Rocklin, CA USA. Allergan Pharmaceut Inc, Irvine, CA 92715 USA. Natl Inst Dent & Craniofacial Res, Bethesda, MD USA. Univ Penn, Philadelphia, PA 19104 USA. Johns Hopkins Univ, Baltimore, MD 21218 USA. Univ Hlth Network, Toronto, ON, Canada. Univ Toronto, Toronto, ON, Canada. Novartis Pharmaceut, E Hanover, NJ USA. VA Connecticut Healthcare Syst, West Haven, CT USA. Yale Univ, New Haven, CT 06520 USA. Celgene Corp, Warren, NJ USA. Pfizer Global Res & Dev, Ann Arbor, MI USA. Dalhousie Univ, Halifax, NS, Canada. London Reg Canc Ctr, London, ON N6A 4L6, Canada. Univ Liverpool, Liverpool L69 3BX, Merseyside, England. GlaxoSmithKline Inc, Res Triangle Pk, NC USA. Johnson & Johnson, Raritan, NJ USA. Alpharma, Elizabeth, NJ USA. Harvard Univ, Sch Med, Boston, MA USA. Alpharma, Piscataway, NJ USA. Univ Munich, Munich, Germany. US Dept Vet Affairs, Washington, DC USA. NeurogesX Inc, San Carlos, CA USA. Eli Lilly & Co, Indianapolis, IN 46285 USA. Endo Pharmaceut Inc, Chadds Ford, PA USA. St Thomas Hosp, London, England. St Louis Univ, St Louis, MO 63103 USA. RP Turk, DC (reprint author), Univ Washington, Seattle, WA 98195 USA. EM Turkdc@u.washington.edu RI Williams, Amanda/C-7816-2009; Farrar, John/A-1037-2007 OI Farrar, John/0000-0001-8656-5157; Yang, Shuman/0000-0002-9638-0890; Williams, Amanda/0000-0003-3761-8704; McGrath, Patrick/0000-0002-9568-2571 NR 23 TC 130 Z9 133 U1 3 U2 8 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0304-3959 J9 PAIN JI Pain PD DEC 5 PY 2006 VL 125 IS 3 BP 208 EP 215 DI 10.1016/j.pain.2006.09.028 PG 8 WC Anesthesiology; Clinical Neurology; Neurosciences SC Anesthesiology; Neurosciences & Neurology GA 114NO UT WOS:000242673100005 PM 17069973 ER PT J AU Myers, JS Bellini, LM Morris, JB Graham, D Katz, J Potts, JR Weiner, C Volpp, KG AF Myers, Jennifer S. Bellini, Lisa M. Morris, Jon B. Graham, Debra Katz, Joel Potts, John R. Weiner, Charles Volpp, Kevin G. TI Internal medicine and general surgery residents' attitudes about the ACGME duty hours regulations: A multicenter study SO ACADEMIC MEDICINE LA English DT Article ID WORK HOURS; PATIENT SAFETY; SLEEP; CARE; REQUIREMENTS; PERCEPTIONS; PERFORMANCE; PHYSICIAN; EDUCATION; OUTCOMES AB Purpose To assess internal medicine and general surgery residents' attitudes about the effects of the Accreditation Council for Graduate Medical Education duty hours regulations on medical errors, quality of patient care, and residency experiences. Method In 2005, the authors surveyed 200 residents who trained both before and after duty hours reform at six residency programs (three internal medicine, three general surgery) at five academic medical centers in the United States. Residents' attitudes about the effects of the duty hours regulations on the quality of patient care, residency education, and quality of life were measured using a survey instrument containing 19 Likert scale questions on a scale of 1 to 5. Survey responses were compared using the Student's t-test. Results The response rate was 80% (159 residents). Residents reported that whereas fatigue-related errors decreased slightly, errors related to reduced continuity of care significantly increased. Additionally, duty hours regulations somewhat decreased opportunities for formal education, bedside learning, and procedures, but there was no consensus that graduates would be less well trained after duty hours reform. Residents, particularly surgical trainees, reported improvements in quality of life and reduced burnout. Conclusions Residents in medicine and surgery had similar opinions about the effects of duty hours reform, including improved quality of life. However, resident opinions suggest that reduced fatigue-related errors have been offset by errors related to decreased continuity of care and that the quality of the educational experience may have declined. Quantifying the degree to which regulating duty hours affected errors related to discontinuity of care should be a focus of future research. C1 Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Dept Surg, Philadelphia, PA 19104 USA. Case Western Reserve Univ, Dept Surg, Cleveland, OH 44106 USA. Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. Univ Texas, Dept Surg, Houston, TX USA. Johns Hopkins Univ, Dept Med, Baltimore, MD USA. Philadelphia VA Med Ctr, Ctr Hlth Equity Res & Policy, Philadelphia, PA USA. Univ Penn, Wharton Sch, Dept Hlth Care Syst, Philadelphia, PA 19104 USA. RP Myers, JS (reprint author), Hosp Univ Penn, Div Gen Internal Med, 3400 Spruce St,Penn Tower Suite 2009, Philadelphia, PA 19104 USA. EM jennifer.myers@uphs.upenn.edu NR 32 TC 61 Z9 61 U1 2 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-2446 J9 ACAD MED JI Acad. Med. PD DEC PY 2006 VL 81 IS 12 BP 1052 EP 1058 DI 10.1097/01.ACM.0000246687.03462.59 PG 7 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 112RE UT WOS:000242543800011 PM 17122468 ER PT J AU Donovan, DM Kivlahan, DR Doyle, SR Longabaugh, R Greenfield, SF AF Donovan, Dennis M. Kivlahan, Daniel R. Doyle, Suzanne R. Longabaugh, Richard Greenfield, Shelly F. TI Concurrent validity of the Alcohol Use Disorders Identification Test (AUDIT) and AUDIT zones in defining levels of severity among out-patients with alcohol dependence in the COMBINE study SO ADDICTION LA English DT Article DE alcohol dependence; Alcohol Use Disorders Identification Test; assessment; AUDIT zones; AUDIT; screening; severity of dependence ID COMPULSIVE DRINKING SCALE; PRIMARY-CARE; DSM-IV; COMBINED PHARMACOTHERAPIES; BEHAVIORAL INTERVENTIONS; ABUSE; CONSUMPTION; INSTRUMENT; WITHDRAWAL; DIAGNOSIS AB Aims To examine among alcohol-dependent out-patient clients the concurrent validity of the Alcohol Use Disorders Identification Test (AUDIT) total score and 'zones' suggested by the World Health Organization for defining levels of severity of alcohol use problems. Design Participants were classified into AUDIT zones (AUDIT total score = 8-15, 16-19, 20-40) and compared on measures of demographics, treatment goals, alcohol consumption, alcohol-related consequences, severity of dependence, physiological dependence, tolerance, withdrawal and biomarkers of alcohol use. Setting Eleven out-patient academic clinical research centers across the United States. Participants Alcohol dependent individuals (n = 1335) entering out-patient treatment in the Combined Pharmacotherapies and Behavioral Interventions (COMBINE) study. Measurements The AUDIT was administered as part of an initial screening. Baseline measures used for concurrent validation included the Structured Clinical Interview for Diagnostic and Statistical Manual, 4th edition (DSM-IV) Disorders, the Alcohol Dependence Scale, the Drinker Inventory of Consequences, the Obsessive-Compulsive Drinking Scale, the University of Rhode Island Change Assessment, the Thoughts about Abstinence Scale, the Form-90, %carbohydrate-deficient transferrin and gamma-glutamyl transferase. Findings Indicators of severity of dependence and alcohol-related problems increased linearly with total score and differed significantly across AUDIT zones. The highest zone, with scores of 20 and above, was markedly different with respect to severity from the other two zones and members of this group endorsed an abstinence goal more strongly. Conclusions The AUDIT total score is a brief measure that appears to provide an index of severity of dependence in a sample of alcohol-dependent individuals seeking out-patient treatment, extending its potential utility beyond its more traditional role as a screening instrument in general populations. C1 Univ Washington, Inst Alcohol & Drug Abuse, Seattle, WA 98105 USA. Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98105 USA. VA Puget Sound Healthcare Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA USA. Brown Univ, Ctr Alcohol & Addict Studies, Providence, RI 02912 USA. Brown Univ, Dept Psychiat & Human Behav, Providence, RI 02912 USA. Harvard Univ, Sch Med, McLean Hosp, Alcohol & Drug Abuse Treatment Program, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. RP Donovan, DM (reprint author), Univ Washington, Inst Alcohol & Drug Abuse, 1107 NE 45th St,Suite 120, Seattle, WA 98105 USA. EM ddonovan@u.washington.edu FU NIAAA NIH HHS [U10AA11715, U10AA11716, U10AA11721, U10AA11727, U10AA11756, U10AA11768, U10AA11773, U10AA11776, U10AA11777, U10AA11783, U10AA11787, U10AA11799] NR 46 TC 64 Z9 67 U1 4 U2 12 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0965-2140 J9 ADDICTION JI Addiction PD DEC PY 2006 VL 101 IS 12 BP 1696 EP 1704 DI 10.1111/j.1360-0443.2006.01606.x PG 9 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA 110IU UT WOS:000242372700008 PM 17156168 ER PT J AU Andziak, B O'Connor, TP Qi, WB DeWaal, EM Pierce, A Chaudhuri, AR Van Remmen, H Buffenstein, R AF Andziak, Blazej O'Connor, Timothy P. Qi, Wenbo DeWaal, Eric M. Pierce, Anson Chaudhuri, Asish R. Van Remmen, Holly Buffenstein, Rochelle TI High oxidative damage levels in the longest-living rodent, the naked mole-rat SO AGING CELL LA English DT Article DE DNA damage; glutathione; longevity; maximum lifespan; naked mole-rats; oxidative stress ID DNA-DAMAGE; TRIOSEPHOSPHATE ISOMERASE; LIPID-PEROXIDATION; MITOCHONDRIAL-DNA; STRESS; LONGEVITY; PROTEIN; 8-HYDROXY-2'-DEOXYGUANOSINE; F-2-ISOPROSTANES; ANTIOXIDANTS AB Oxidative stress is reputed to be a significant contributor to the aging process and a key factor affecting species longevity. The tremendous natural variation in maximum species lifespan may be due to interspecific differences in reactive oxygen species generation, antioxidant defenses and/or levels of accrued oxidative damage to cellular macromolecules (such as DNA, lipids and proteins). The present study tests if the exceptional longevity of the longest living (> 28.3 years) rodent species known, the naked mole-rat (NMR, Heterocephalus glaber), is associated with attenuated levels of oxidative stress. We compare antioxidant defenses (reduced glutathione, GSH), redox status (GSH/GSSG), as well as lipid (malondialdehyde and isoprostanes), DNA (8-OHdG), and protein (carbonyls) oxidation levels in urine and various tissues from both mole-rats and similar-sized mice. Significantly lower GSH and GSH/GSSG in mole-rats indicate poorer antioxidant capacity and a surprisingly more pro-oxidative cellular environment, manifested by 10-fold higher levels of in vivo lipid peroxidation. Furthermore, mole-rats exhibit greater levels of accrued oxidative damage to lipids (twofold), DNA (similar to two to eight times) and proteins (1.5 to 2-fold) than physiologically age-matched mice, and equal to that of same-aged mice. Given that NMRs live an order of magnitude longer than predicted based on their body size, our findings strongly suggest that mechanisms other than attenuated oxidative stress explain the impressive longevity of this species. C1 CUNY City Coll, Dept Biol, New York, NY 10031 USA. Cornell Univ, Weill Med Coll, Dept Med Genet, New York, NY 10021 USA. Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, San Antonio, TX 78284 USA. RP Buffenstein, R (reprint author), CUNY City Coll, Dept Biol, New York, NY 10031 USA. EM rbuffen@sci.ccny.cuny.edu RI Pierce, Anson/D-1079-2012 OI Pierce, Anson/0000-0002-1383-0180 FU NIA NIH HHS [AG 022891, AG 13319]; NIGMS NIH HHS [GM 08168-25] NR 41 TC 169 Z9 171 U1 5 U2 47 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1474-9718 EI 1474-9726 J9 AGING CELL JI Aging Cell PD DEC PY 2006 VL 5 IS 6 BP 463 EP 471 DI 10.1111/j.1474-9726.2006.00237.x PG 9 WC Cell Biology; Geriatrics & Gerontology SC Cell Biology; Geriatrics & Gerontology GA 107VI UT WOS:000242198700003 PM 17054663 ER PT J AU Kaunitz, JD Akiba, Y AF Kaunitz, J. D. Akiba, Y. TI Review article: duodenal bicarbonate - mucosal protection, luminal chemosensing and acid-base balance SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article; Proceedings Paper CT 11th Taishotoyama International Symposium on Gastroenterology CY APR 22-23, 2005 CL Shimoda, JAPAN ID GENE-RELATED PEPTIDE; RAT GASTRIC-MUCOSA; CYSTIC-FIBROSIS; INTRACELLULAR PH; BLOOD-FLOW; ALKALINE SECRETION; EPITHELIAL-CELLS; SENSING PATHWAYS; HCO3-SECRETION; ANTRAL MUCOSA AB The duodenum serves as a buffer zone between the stomach and the jejunum. Over a length of only 25 cm, large volumes of strong acid secreted by the stomach must be converted to the neutral-alkaline chyme of the hindgut lumen, generating large volumes of CO2. The duodenal mucosa consists of epithelial cells connected by low-resistance tight junctions, forming a leaky epithelial barrier. Despite this permeability, the epithelial cells, under intense stress from luminal mineral acid and highly elevated Pco(2), maintain normal functioning. Bicarbonate ion uniquely protects the duodenal epithelial cells from acid-related injury. The specific protective mechanisms likely involve luminal bicarbonate secretion, intracellular pH buffering and interstitial buffering. Furthermore, the duodenum plays an active role in foregut acid-base homeostasis, absorbing large amounts of H+ and CO2. We have studied mucosal protection and acid-base balance using live-animal fluorescence ratio microimaging and by performing H+ and CO2 balance studies on duodenal perfusates. On the basis of these data, we have formulated novel hypotheses with regard to mucosal protection. C1 Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, CURE, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Digest Dis Res Ctr, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90073 USA. RP Kaunitz, JD (reprint author), W Los Angeles VA Med Ctr, Bldg 114,Room 217,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jake@ucla.edu FU NIDDK NIH HHS [R01 DK 54221, P30 DK0413] NR 66 TC 21 Z9 21 U1 0 U2 5 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0269-2813 J9 ALIMENT PHARM THERAP JI Aliment. Pharmacol. Ther. PD DEC PY 2006 VL 24 SU 4 BP 169 EP 176 DI 10.1111/j1365-2036.2006.00041.x PG 8 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA 123PE UT WOS:000243307000025 PM 17209861 ER PT J AU Wood, CG Wei, SJ Hampshire, MK Devine, PA Metz, JM AF Wood, Charles G. Wei, S. Jack Hampshire, Margaret K. Devine, Pamela A. Metz, James M. TI The influence of race on the attitudes of radiation oncology patients towards clinical trial enrollment SO AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS LA English DT Article; Proceedings Paper CT 46th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 17-20, 2004 CL Atlanta, GA SP Amer Soc Therapeut Radiol & Oncol DE population groups; clinical trials; attitude; neoplasms; radiation ID CANCER-TREATMENT TRIALS; AFRICAN-AMERICANS; INFORMED-CONSENT; TUSKEGEE SYPHILIS; PROSTATE-CANCER; BREAST-CANCER; INTERNET USE; PARTICIPATION; INFORMATION; RECRUITMENT AB Objectives: Enrollment of adult cancer patients in clinical trials remains low, particularly in the minority population. Understanding patient attitudes towards clinical trials during the recruitment process may enhance accrual. Unfortunately, data describing patient attitudes towards clinical trials are limited, particularly in the radiation oncology clinic setting. Methods: A piloted questionnaire assessing basic demographics and attitudes toward clinical trials was offered in 2 radiation oncology clinics between April 2003 and October 2003. The questionnaire was completed by 166 patients. The mean age of the patients completing the questionnaire was 56 years (range, 15-84 years). Of the 166 patients included in the analysis, 108 (65%) were White. The most common cancer diagnoses included prostate (19%), head and neck (16%), and breast (14%). Results: There was no statistical difference between Whites and non-Whites regarding their interest in learning about clinical trials (84.3% versus 84.9%, P = 0.92); nor was there a significant difference in the rate of previous or current trial enrollment (21.3% versus 34.0%, P = 0.08). White patients were more likely to gather information about clinical trials from the Internet (30.6% versus 11.3%, P = 0.007), and they were more likely to use physicians as a source of this information (50.0% versus 34.0%, P = 0.05). Non-White patients were more likely to obtain information about clinical trials from other patients (24.5% versus 12.0%, P = 0.04). In addition, more non-White patients believed they had been treated on clinical trials without their knowledge (21.6% versus 9.3%, P = 0.032). Patients differed somewhat in their expectations of clinical trials. More non-Whites indicated that they would need a > 50% chance of benefiting from a trial (64.4% versus 45.0%, P = 0.03) to enroll on that trial, though there were no statistical differences in outlook towards potential toxicities associated with treatment on a clinical trial. Conclusions: Minority patients historically enroll in clinical trials at a significantly lower rate. Our study of radiation oncology patients documents significant differences in attitudes towards clinical trials between Whites and non-Whites. Understanding the differences in attitudes may allow physicians to overcome barriers that would otherwise hinder the enrollment of non-White patients into clinical trials. C1 Hosp Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Dept Radiat Oncol, Philadelphia, PA USA. RP Wood, CG (reprint author), Hosp Univ Penn, Dept Radiat Oncol, 2 Donner Bldg,3400 Spruce St, Philadelphia, PA 19104 USA. EM wood@xrt.upenn.edu NR 58 TC 18 Z9 18 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0277-3732 J9 AM J CLIN ONCOL-CANC JI Am. J. Clin. Oncol.-Cancer Clin. Trials PD DEC PY 2006 VL 29 IS 6 BP 593 EP 599 DI 10.1097/01.coc.0000236213.61427.84 PG 7 WC Oncology SC Oncology GA 114QW UT WOS:000242681700013 PM 17148997 ER PT J AU Jobe, BA Hunter, JG Chang, EY Kim, CY Eisen, GM Robinson, JD Diggs, BS O'Rourke, RW Rader, AE Schipper, P Sauer, DA Peters, JH Lieberman, DA Morris, CD AF Jobe, Blair A. Hunter, John G. Chang, Eugene Y. Kim, Charles Y. Eisen, Glenn M. Robinson, Jedediah D. Diggs, Brian S. O'Rourke, Robert W. Rader, Anne E. Schipper, Paul Sauer, David A. Peters, Jeffrey H. Lieberman, David A. Morris, Cynthia D. TI Office-based unsedated small-caliber endoscopy is equivalent to conventional sedated endoscopy in screening and surveillance for Barrett's esophagus: A randomized and blinded comparison SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID HIGH-GRADE DYSPLASIA; LOS-ANGELES CLASSIFICATION; ESOPHAGOGASTRODUODENOSCOPY EGD; TRANSNASAL ESOPHAGOGASTRODUODENOSCOPY; GASTROINTESTINAL ENDOSCOPY; UNITED-STATES; ADENOCARCINOMA; DIAGNOSIS; CANCER; TRIAL AB OBJECTIVES: A major limitation to screening and surveillance of Barrett's esophagus is the complexity, expense, and risk associated with sedation for upper endoscopy. This study examines the feasibility, accuracy, and patient acceptability of office-based unsedated endoscopy as an alternative. METHODS: Of 274 eligible adults scheduled for endoscopic screening for gastroesophageal reflux symptoms or surveillance of Barrett's esophagus at a tertiary care center, 121 underwent unsedated small-caliber endoscopy and conventional endoscopy in a randomized crossover study. The two procedures were compared with regard to histological detection of Barrett's esophagus and dysplasia and biopsy size. Patients answered questionnaires assessing the tolerability of the procedures. RESULTS: The prevalence of Barrett's esophagus was 26% using conventional endoscopy and 30% using unsedated endoscopy (P= 0.503). The level of agreement between the two approaches was "moderate" (kappa= 0.591). Each modality detected four cases of low-grade dysplasia with concordance on one case. The tissue samples collected with unsedated endoscopy were smaller than with conventional endoscopy (P < 0.001). The majority of subjects rated their experience with both procedures as being well tolerated with minimal or no difficulty. When asked which procedure they would prefer in the future, 71% (81/114) chose unsedated small-caliber endoscopy. CONCLUSIONS: Office-based unsedated small-caliber endoscopy is technically feasible, well tolerated, and accurate in screening for Barrett's esophagus, despite yielding a smaller biopsy specimen. This approach bears the potential to eliminate the infrastructure and cost required for intravenous sedation in this application. C1 Portland VA Med Ctr, Surg Serv, Portland, OR 97207 USA. Oregon Hlth Sci Univ, Dept Surg, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Div Gastroenterol, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Dept Pathol, Portland, OR 97201 USA. Portland VA Med Ctr, Pathol Serv, Portland, OR USA. Univ Rochester, Dept Surg, Rochester, NY USA. Oregon Hlth Sci Univ, Dept Epidemiol & Outcomes Res, Portland, OR 97201 USA. RP Jobe, BA (reprint author), Portland VA Med Ctr, Surg Serv, P3GS,POB 1034, Portland, OR 97207 USA. OI Diggs, Brian/0000-0003-3586-3757 FU NCI NIH HHS [R03 CA105959-01]; NCRR NIH HHS [5 M01 RR000334]; NIDDK NIH HHS [2U01DK057132-06A1, K23 DK066165-01] NR 37 TC 59 Z9 60 U1 1 U2 4 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD DEC PY 2006 VL 101 IS 12 BP 2693 EP 2703 DI 10.1111/j.1572-0241.2006.00890.x PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 110IV UT WOS:000242372800006 PM 17227516 ER PT J AU Bent, S Padula, A Moore, D Patterson, M Mehling, W AF Bent, Stephen Padula, Amy Moore, Dan Patterson, Michael Mehling, Woff TI Vaterian for steep: A systematic re view and meta-anatysis SO AMERICAN JOURNAL OF MEDICINE LA English DT Review DE herb; alternative medicine; insomnia; sleep; meta-analysis; systematic review ID SLEEP QUALITY; VALERIAN EXTRACT; CHRONIC INSOMNIA; CONTROLLED TRIAL; CLINICAL-TRIALS; DOUBLE-BLIND; PLACEBO; METAANALYSIS; VOLUNTEERS; INSTRUMENT AB Insomnia affects approximately one-third of the adult population and contributes to increased rates of absenteeism, health care use, and social disability. Extracts of the roots of valerian (Valeriana officinalis) are widely used for inducing sleep and improving sleep quality. A systematic review of randomized, placebo-controlled trials of valerian for improving sleep quality is presented. An extensive literature search identified 16 eligible studies examining a total of 1093 patients. Most studies had significant methodologic problems, and the valerian doses, preparations, and length of treatment varied considerably. A dichotomous outcome of sleep quality (improved or not) was reported by 6 studies and showed a statistically significant benefit (relative risk of improved sleep = 1.8, 95% confidence interval, 1.2-2.9), but there was evidence of publication bias in this summary measure. The available evidence suggests that valerian might improve sleep quality without producing side effects. Future studies should assess a range of doses of standardized preparations of valerian and include standard measures of sleep quality and safety. (c) 2006 Elsevier Inc. All rights reserved. C1 San Francisco VAMC, Gen Internal Med Sect, Dept Med, San Francisco, CA 94121 USA. Univ Calif San Francisco, Osher Ctr Integrat Med, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Bent, S (reprint author), San Francisco VAMC, Gen Internal Med Sect, Dept Med, 111-A1,4150 Clement St, San Francisco, CA 94121 USA. EM stephen.bent@ucsf.edu FU NCCIH NIH HHS [K08 AT001338]; PHS HHS [1 K08 ATO1338-01] NR 39 TC 94 Z9 96 U1 2 U2 28 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD DEC PY 2006 VL 119 IS 12 BP 1005 EP 1012 DI 10.1016/j.amjmed.2006.02.026 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 111XI UT WOS:000242488800003 PM 17145239 ER PT J AU Feng, SJ Lu, X Resendiz, JC Kroll, MH AF Feng, Shuju Lu, Xin Resendiz, Julio C. Kroll, Michael H. TI Pathological shear stress directly regulates platelet alpha(IIb)beta(3) signaling SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY LA English DT Article DE platelets; mechanoreceptor; integrin; shear stress; signal transduction ID VON-WILLEBRAND-FACTOR; BETA(3) CYTOPLASMIC DOMAIN; PROTEIN-TYROSINE KINASES; INTEGRIN ALPHA(IIB)BETA(3); ACTIN CYTOSKELETON; THROMBUS FORMATION; FACTOR BINDING; ACTIVATION; PHOSPHORYLATION; ADHESION AB Integrin mechano-transduction is a ubiquitous biological process. Mechanical forces are transduced transmembranously by an integrin's ligand-bound extracellular domain through its beta-subunit's cytoplasmic domain connected to the cytoskeleton. This often culminates in the activation of tyrosine kinases directing cell responses. The delicate balance between hemostasis and thrombosis requires exquisitely fine-tuned integrin function, and balance is maintained in vivo despite that the major platelet integrin alpha(IIb)beta(3) is continuously subjected to frictional or shearing forces generated by laminar blood flow. To test the hypothesis that platelet function is regulated by the direct effects of mechanical forces on alpha(IIb)beta(3), we examined alpha(IIb)beta(3)/cytoskeletal interactions in human platelets exposed to shear stress in a cone-plate viscometer. We observed that alpha-actinin, myosin heavy chain, and Syk coimmunoprecipitate with alpha(IIb)beta(3) in resting platelets and that 120 dyn/cm(2) shear stress leads to their disassociation from alpha(IIb)beta(3). Shear-induced disassociation of alpha-actinin and myosin heavy chain from the beta(3) tail is unaffected by blocking von Willebrand factor (VWF) binding to glycoprotein (Gp) Ib-IX-V but abolished by blocking VWF binding to alpha(IIb)beta(3). Syk's disassociation from alpha(IIb)beta(3) is inhibited when VWF binding to either GpIb-IX-V or alpha(IIb)beta(3) is blocked. Shear stress-induced phosphorylation of SLP-76 and its association with tyrosine-phosphorylated adhesion and degranulation-promoting adapter protein are inhibited by blocking ligand binding to alpha(IIb)beta(3) but not by blocking ligand binding to GpIb-IX-V. Chinese hamster ovary cells expressing alpha(IIb)beta(3) with beta(3) truncated of its cytoskeletal binding domains demonstrate diminished shear-dependent adhesion and cohesion. These results support the hypothesis that shear stress directly modulates alpha(IIb)beta(3) function and suggest that shear-induced alpha(IIb)beta(3) mediated signaling contributes to the regulation of platelet aggregation by directing the release of constraining cytoskeletal elements from the beta(3)-tail. C1 Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. Rice Univ, Houston, TX 77251 USA. Wihuri Res Inst, SF-00140 Helsinki, Finland. RP Kroll, MH (reprint author), VA Med Ctr, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM mkroll@bcm.tmc.edu NR 52 TC 17 Z9 17 U1 0 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6143 J9 AM J PHYSIOL-CELL PH JI Am. J. Physiol.-Cell Physiol. PD DEC PY 2006 VL 291 IS 6 BP C1346 EP C1354 DI 10.1152/ajpcell.00559.2005 PG 9 WC Cell Biology; Physiology SC Cell Biology; Physiology GA 104WT UT WOS:000241992000028 PM 16822941 ER PT J AU Payet, MD Goodfriend, TL Bilodeau, L Mackendale, C Chouinard, L Gallo-Payet, N AF Payet, Marcel D. Goodfriend, Theodore L. Bilodeau, Lyne Mackendale, Cherilu Chouinard, Lucie Gallo-Payet, Nicole TI An oxidized metabolite of linoleic acid increases intracellular calcium in rat adrenal glomerulosa cells SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM LA English DT Article DE intracellular calcium ion concentration ID ATRIAL-NATRIURETIC-PEPTIDE; ALDOSTERONE SECRETION; ANGIOTENSIN-II; CA2+ CHANNELS; MEMBRANE PHOSPHOINOSITIDES; CYCLOPIAZONIC ACID; CYTOSOLIC CALCIUM; SMOOTH-MUSCLE; POTASSIUM; ENTRY AB EKODE, an epoxy-keto derivative of linoleic acid, was previously shown to stimulate aldosterone secretion in rat adrenal glomerulosa cells (15). In the present study, we investigated the effect of exogenous EKODE on cytosolic [Ca2+] increase and aimed to elucidate the mechanism involved in this process. Through the use of the fluorescent Ca2+-sensitive dye Fluo-4, EKODE was shown to rapidly increase intracellular [Ca2+] ([Ca2+](i)) along a bell-shaped dose-response relationship with a maximum peak at 5 mu M. Experiments performed in the presence or absence of Ca2+ revealed that this increase in [Ca2+](i) originated exclusively from intracellular pools. EKODE-induced [Ca2+](i) increase was blunted by prior application of angiotensin II, Xestospongin C, and cyclopiazonic acid, indicating that inositol trisphosphate (InsP(3))-sensitive Ca2+ stores can be mobilized by EKODE despite the absence of InsP(3) production. Accordingly, EKODE response was not sensitive to the phospholipase C inhibitor U-73122. EKODE mobilized a Ca2+ store included in the thapsigargin (TG)-sensitive stores, although the interaction between EKODE and TG appears complex, since EKODE added at the plateau response of TG induced a rapid drop in [Ca2+](i). 9-Oxo-octadecadienoic acid, another oxidized derivative of linoleic acid, also increases [Ca2+](i), with a dose-response curve similar to EKODE. However, arachidonic and linoleic acids at 10 mu M failed to increase [Ca2+](i) but did reduce the amplitude of the response to EKODE. It is concluded that EKODE mobilizes Ca2+ from an InsP(3)-sensitive store and that this [Ca2+](i) increase is responsible for aldosterone secretion by glomerulosa cells. Similar bell-shaped dose-response curves for aldosterone and [Ca2+](i) increases reinforce this hypothesis. C1 Univ Sherbrooke, Fac Med, Dept Physiol & Biophys, Sherbrooke, PQ J1H 5N4, Canada. Univ Sherbrooke, Fac Med, Serv Endocrinol, Dept Med, Sherbrooke, PQ J1H 5N4, Canada. Univ Wisconsin, William S Middleton Mem Vet Hosp, Madison, WI USA. Univ Wisconsin, Dept Med, Madison, WI USA. Univ Wisconsin, Dept Pharmacol, Madison, WI USA. RP Payet, MD (reprint author), Univ Sherbrooke, Fac Med, Dept Physiol & Biophys, 3001-12 Ave Nord, Sherbrooke, PQ J1H 5N4, Canada. EM marcel.payet@usherbrooke.ca NR 43 TC 7 Z9 7 U1 0 U2 4 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1849 J9 AM J PHYSIOL-ENDOC M JI Am. J. Physiol.-Endocrinol. Metab. PD DEC PY 2006 VL 291 IS 6 BP E1160 EP E1167 DI 10.1152/ajpendo.00108.2006 PG 8 WC Endocrinology & Metabolism; Physiology SC Endocrinology & Metabolism; Physiology GA 106XN UT WOS:000242135400004 PM 16822961 ER PT J AU Giraud, GD Faber, JJ Jonker, SS Davis, L Anderson, DF AF Giraud, George D. Faber, J. Job Jonker, Sonnet S. Davis, Lowell Anderson, Debra F. TI Effects of intravascular infusions of plasma on placental and systemic blood flow in fetal sheep SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Article DE fetal sheep; blood pressure; placental flow; systemic flow; placental resistance; systemic resistance ID ARTERIAL-PRESSURE; HYPERTENSION; ANGIOTENSIN; CIRCULATION; REDUCTIONS; RESPONSES; VOLUME; OUTPUT; LAMBS AB Six singleton fetal sheep of 118 - 122 days gestational age were instrumented with flow sensors on the brachiocephalic artery, the postductal aorta, and the common umbilical artery and with arterial and venous intravascular catheters. At 125 - 131 days of gestation, we started week-long continuous recordings of flows and pressures. After control measures had been obtained, the fetuses were given continuous intravenous infusions of adult sheep plasma at an initial rate of 229 ml/day. After 1 wk of infusion, fetal plasma protein concentrations had increased from 34 to 78 g/l, arterial and venous pressures had increased from 42 to 64 and from 2.7 to 3.7 mmHg, and systemic resistance ( exclusive of the coronary bed) had increased from 0.047 to 0.075 mmHg center dot min(-1)center dot ml(-1), whereas placental resistance had increased from 0.065 to 0.111 mmHg center dot min(-1)center dot ml(-1). Fetal plasma renin activities fell as early as 1 day after the start of infusion and remained below control (all changes P < 0.05). All flows decreased slightly although these decreases were not statistically significant. Thus the increase in arterial pressure was entirely due to an increase in systemic and placental resistances. C1 Oregon Hlth Sci Univ, Heart Res Ctr L464, Dept Physiol & Pharmacol, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Dept Obstet & Gynecol, Portland, OR 97239 USA. Portland Vet Affairs Med Ctr, Portland, OR USA. RP Giraud, GD (reprint author), Oregon Hlth Sci Univ, Heart Res Ctr L464, Dept Physiol & Pharmacol, Portland, OR 97239 USA. EM giraudg@ohsu.edu OI Jonker, Sonnet/0000-0002-1097-2562 FU NHLBI NIH HHS [R01-HL-45043]; NICHD NIH HHS [5P01-HD-34430, R01-HD-37376] NR 20 TC 6 Z9 6 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD DEC PY 2006 VL 291 IS 6 BP H2884 EP H2888 DI 10.1152/ajpheart.00428.2006 PG 5 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA 103AO UT WOS:000241855900042 PM 16905601 ER PT J AU Frank, JA Wray, CM McAuley, DF Schwendener, R Matthay, MA AF Frank, James A. Wray, Charlie M. McAuley, Danny F. Schwendener, Reto Matthay, Michael A. TI Alveolar macrophages contribute to alveolar barrier dysfunction in ventilator-induced lung injury SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY LA English DT Article DE alveolar epithelial barrier function; ventilator-associated lung injury; acute lung injury; acute respiratory distress syndrome ID RESPIRATORY-DISTRESS-SYNDROME; ISCHEMIA-REPERFUSION INJURY; TIDAL VOLUME VENTILATION; MECHANICAL VENTILATION; IN-VITRO; ENDOTHELIAL INJURY; EPITHELIAL-CELLS; II CELLS; INFLAMMATION; ACTIVATION AB Alveolar macrophages contribute to alveolar barrier dysfunction in ventilator-induced lung injury. Am J Physiol Lung Cell Mol Physiol 291: L1191-L1198, 2006. First published July 28, 2006; doi:10.1152/ajplung.00055.2006.-In patients requiring mechanical ventilation for acute lung injury or acute respiratory distress syndrome ( ARDS), tidal volume reduction decreases mortality, but the mechanisms of the protective effect have not been fully explored. To test the hypothesis that alveolar macrophage activation is an early and critical event in the initiation of ventilator-induced lung injury (VILI), rats were ventilated with high tidal volume (HVT) for 10 min to 4 h. Alveolar macrophage counts in bronchoalveolar lavage (BAL) fluid decreased 45% by 20 min of HVT (P < 0.05) consistent with activation-associated adhesion. Depletion of alveolar macrophages in vivo with liposomal clodronate significantly decreased permeability and pulmonary edema following 4 h of HVT (P < 0.05). BAL fluid from rats exposed to 20 min of HVT increased nitric oxide synthase activity nearly threefold in naive primary alveolar macrophages (P < 0.05) indicating that soluble factors present in the air spaces contribute to macrophage activation in VILI. Media from cocultures of alveolar epithelial cell monolayers and alveolar macrophages exposed to 30 min of stretch in vitro also significantly increased nitrite production in naive macrophages (P < 0.05), but media from stretched alveolar epithelial cells or primary alveolar macrophages alone did not, suggesting alveolar epithelial cell- macrophage interaction was required for the subsequent macrophage activation observed. These data demonstrate that injurious mechanical ventilation rapidly activates alveolar macrophages and that alveolar macrophages play an important role in the initial pathogenesis of VILI. C1 Univ Calif San Francisco, Dept Med, Cardiovasc Res Inst, Duv Pulm & Crit Care,Med ICU,San Francisco Med C, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Anesthesia, Inst Cardiovasc Res, San Francisco, CA 94143 USA. San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. Paul Scherrer Inst, Villigen, Switzerland. RP Frank, JA (reprint author), Univ Calif San Francisco, Dept Med, Cardiovasc Res Inst, Duv Pulm & Crit Care,Med ICU,San Francisco Med C, Box 111D, San Francisco, CA 94121 USA. EM james.frank@ucsf.edu FU NHLBI NIH HHS [HL-51854, HL-69900, K08 HL069900, K08 HL069900-05, R56 HL088440] NR 42 TC 85 Z9 94 U1 1 U2 11 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1040-0605 J9 AM J PHYSIOL-LUNG C JI Am. J. Physiol.-Lung Cell. Mol. Physiol. PD DEC PY 2006 VL 291 IS 6 BP L1191 EP L1198 DI 10.1152/ajplung.00055.2006 PG 8 WC Physiology; Respiratory System SC Physiology; Respiratory System GA 103AM UT WOS:000241855600010 PM 16877636 ER PT J AU Yaeger, D Smith, HG Altshuler, LL AF Yaeger, Deborah Smith, Healy G. Altshuler, Lori L. TI Atypical antipsychotics in the treatment of schizophrenia during pregnancy and the postpartum SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Editorial Material ID BODY-MASS INDEX; MATERNAL OBESITY; PSYCHOTIC DISORDERS; MENTAL-ILLNESS; BREAST-MILK; WOMEN; RISPERIDONE; CHILDREN; MOTHERS; RISK C1 W Los Angeles VA Healthcare Ctr, WC, OOAC, Womens Comprehens Healthcare Ctr,Dept Psychiat, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. RP Yaeger, D (reprint author), W Los Angeles VA Healthcare Ctr, WC, OOAC, Womens Comprehens Healthcare Ctr,Dept Psychiat, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM Deborah.Yaeger@va.gov NR 39 TC 25 Z9 29 U1 4 U2 10 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X J9 AM J PSYCHIAT JI Am. J. Psychiat. PD DEC PY 2006 VL 163 IS 12 BP 2064 EP 2070 DI 10.1176/appi.ajp.163.12.2064 PG 7 WC Psychiatry SC Psychiatry GA 113VL UT WOS:000242626000010 PM 17151155 ER PT J AU Essock, SM Covell, NH Davis, SM Stroup, TS Rosenheck, RA Lieberman, JA AF Essock, Susan M. Covell, Nancy H. Davis, Sonia M. Stroup, T. Scott Rosenheck, Robert A. Lieberman, Jeffrey A. TI Effectiveness of switching antipsychotic medications SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Article ID CHRONIC-SCHIZOPHRENIA; PRESCRIBING PRACTICES; RISPERIDONE; OLANZAPINE; QUETIAPINE; TRIAL; DRUGS AB Objective: Changing antipsychotics is common despite the dearth of information on risks and benefits associated with medication changes. The authors examined phase 1 findings from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study to explore whether it was more advantageous to continue taking the medication being received at baseline or to switch to a different antipsychotic. Method: First, for patients randomly assigned to treatment with olanzapine (N = 314) or risperidone (N = 321), the authors assessed the impact of being assigned to stay with the medication they were receiving at entry into the study versus being assigned to switch to these medications from a different antipsychotic. Second, for patients whose baseline antipsychotic was olanzapine (N = 319), risperidone (N = 271), or quetiapine (N = 94), the authors examined the impact of being randomly assigned to stay with the same antipsychotic versus switch. Finally, the authors assessed the impact of removing the data of 209 patients whose random assignment was to stay with their baseline antipsychotic. The authors followed analysis strategies for CATIE; primary outcome was time until all-cause treatment discontinuation. Results: Individuals randomly assigned to olanzapine and risperidone who were continuing with their baseline medication had significantly longer times until discontinuation than did those assigned to switch antipsychotics. When these "stayers" were removed, differences seen in the original CATIE phase 1 analyses were attenuated, although the original pattern of results remained. Conclusions: Comparisons of medication effectiveness should take into account whether medications being compared were each newly initiated. Further, unless the clinical situation requires a medication change, prescribers may want to take steps to optimize current medication regimens (e. g., dosage adjustments, behavioral or psychosocial interventions) before switching medications. C1 CUNY Mt Sinai Sch Med, Dept Psychiat, Div Hlth Serv Res, New York, NY 10029 USA. James J Peters VA Med Ctr, Mental Illness Res Educ & Clin Ctr, Bronx, NY USA. Quintiles Inc, Res Triangle Pk, NC USA. Univ N Carolina, Chapel Hill, NC USA. Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT USA. VA New England Mental Illness Res & Educ Ctr, West Haven, CT USA. Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA. New York State Psychiat Inst & Hosp, New York, NY 10032 USA. RP Essock, SM (reprint author), CUNY Mt Sinai Sch Med, Dept Psychiat, Div Hlth Serv Res, Box 1230,1 Gustave L Levy Pl, New York, NY 10029 USA. EM susan.essock@mssm.edu RI Stroup, Thomas/F-9188-2014 OI Stroup, Thomas/0000-0002-3123-0672 FU NIMH NIH HHS [N01 MH90001, R01 MH59312, R03 MH 071663] NR 11 TC 115 Z9 117 U1 1 U2 2 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X EI 1535-7228 J9 AM J PSYCHIAT JI Am. J. Psychiat. PD DEC PY 2006 VL 163 IS 12 BP 2090 EP 2095 DI 10.1176/appi.ajp.163.12.2090 PG 6 WC Psychiatry SC Psychiatry GA 113VL UT WOS:000242626000014 PM 17151159 ER PT J AU Kilbourne, AM Switzer, G Hyman, K Crowley-Matoka, M Fine, MJ AF Kilbourne, Amy M. Switzer, Galen Hyman, Kelly Crowley-Matoka, Megan Fine, Michael J. TI Advancing health disparities research within the health care system: A conceptual framework SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID FEE-FOR-SERVICE; MEDICAL OUTCOMES; RACIAL-DIFFERENCES; LUNG-CANCER; BEHAVIORAL-MODEL; CONTROLLED-TRIAL; CLINICAL-TRIALS; QUALITY; RACE/ETHNICITY; INTERVENTIONS AB We provide a frannework for health services-related researchers, practitioners, and policy makers to guide future health disparities research in areas ranging from detecting differences in health and health care to understanding the determinants that underlie disparities to ultimately designing interventions that reduce and eliminate these disparities. To do this, we identified potential selection biases and definitions of vulnerable groups when detecting disparities. The key factors to understanding disparities were multilevel determinants of health disparities, including individual beliefs and preferences, effective patient-provider communication; and the organizational culture of the health care system. We encourage interventions that yield generalizable data on their effectiveness and that promote further engagement of communities, providers, and policymakers to ultimately enhance the application and the impact of health disparities research. C1 VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot 151CU, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. Univ Pittsburgh, Dept Anthropol, Pittsburgh, PA USA. RP Kilbourne, AM (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot 151CU, Univ Dr C, Pittsburgh, PA 15240 USA. EM amy.kilbourne@va.gov FU NIAID NIH HHS [K24 AI001769, 5K24-AI01769-05]; NIMHD NIH HHS [1P60-MD00207, P60 MD000207] NR 51 TC 144 Z9 145 U1 4 U2 22 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD DEC PY 2006 VL 96 IS 12 BP 2113 EP 2121 DI 10.2105/AJPH.077628 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 111SJ UT WOS:000242474500008 PM 17077411 ER PT J AU Kerr, SF Emmons, LH Melby, PC Liu, C Perez, LE Villegas, M Miranda, R AF Kerr, Sara F. Emmons, Louise H. Melby, Peter C. Liu, Chang Perez, Luis E. Villegas, Maria Miranda, Robert TI Leishmania amazonensis infections in Oryzomys acritus and Oryzomys nitidus from Bolivia SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID CUTANEOUS LEISHMANIASIS; PALEARCTIC ORIGIN; BRAZIL; FOCUS; EPIDEMIOLOGY; VECTOR; STATE AB Three of thirteen Oryzomys acritus, Emmons and Patton 2005 (Rodentia: Muridae: Sigmodontinae) and 3 of 17 Oryzomys nitidus, Thomas 1884, collected from Noel Kempff National Park, Bolivia, from 2002 to 2005, tested positive for Leishmania (Leishmania) amazonensis or L. (L.) mexicana and negative for Leishmania (Viannia) spp. using the polymerase chain reaction (PCR). Based on previous records of L. (L.) amazonensis in humans, rodents, and sand flies from Bolivia, and the geographic distributions of L. (L.) amazonensis and L. (L.) mexicana, it was concluded that the Orvzomys were infected with L. (L.) amazonensis. These results identify two additional species of Oryzomys as hosts of L. (L.) amazonensis, and identify an ecological region of Bolivia where L. (L.) amazonensis is enzootic. C1 Univ Incarnate Word, Dept Biol, San Antonio, TX 78209 USA. Smithsonian Inst, Div Mammals, Washington, DC 20013 USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Kerr, SF (reprint author), Univ Incarnate Word, Dept Biol, 4301 Broadway, San Antonio, TX 78209 USA. EM kerr@uiwtx.edu FU NIGMS NIH HHS [GM55337]; PHS HHS [H75/CCH615041] NR 24 TC 8 Z9 9 U1 0 U2 0 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD DEC PY 2006 VL 75 IS 6 BP 1069 EP 1073 PG 5 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 117OC UT WOS:000242881600008 PM 17172367 ER PT J AU Velicer, CM Dublin, S White, E AF Velicer, Christine M. Dublin, Sascha White, Emily TI Cimetidine use and the risk for prostate cancer: Results from the VITAL cohort study SO ANNALS OF EPIDEMIOLOGY LA English DT Article DE cimetidine; histamine-2 (H-2) blocker; prostate cancer ID PROLACTIN; ANTAGONISTS; BREAST; ZINC; RATS AB PURPOSE: The histamine-2 (H-2) blocker cimetidine may alter androgen, zinc, and prolactin levels, which could alter prostate cancer risk. Increased risk for men filling more than 20 cimetidine prescriptions was reported previously. We examined the association between cimetidine use and prostate cancer risk in a cohort in western Washington State. METHODS: Participants were 33,506 men, 50 to 76 years old, enrolled in the VITamins And Lifestyle cohort (VITAL). H-2-blocker use during the prior 10 years was self-reported through baseline questionnaire between October 2000 and December 2002. Men were followed up for subsequent prostate cancer by linkage to the Surveillance, Epidemiology and End Results cancer registry. We identified 548 incident invasive prostate cancer cases diagnosed from baseline to December 31, 2003. RESULTS: Overall, no association between ever use of cimetidine or years of cimetidine use and prostate cancer risk was observed. However, daily cimetidine use for 10 years was associated with increased risk (relative risk, 2.35; 95% confidence interval, 1.05-5.26) compared with nonuse of any H-2 blockers. Use of other H-2 blockers was not associated with prostate cancer. CONCLUSIONS: Additional studies are needed to determine whether long-term daily cimetidine use is associated with increased prostate cancer risk in other populations, and if so, the reason for this association. (c) 2006 Elsevier Inc. All rights reserved. C1 Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. Fred Hutchinson Canc Res Ctr, Canc Prevent Res Program, Seattle, WA 98104 USA. RP Velicer, CM (reprint author), Univ Washington, Dept Epidemiol, Box 357236, Seattle, WA 98195 USA. EM cvelicer@u.washington.edu FU NCI NIH HHS [T32CA09168, CA74846] NR 20 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1047-2797 J9 ANN EPIDEMIOL JI Ann. Epidemiol. PD DEC PY 2006 VL 16 IS 12 BP 895 EP 900 DI 10.1016/j.annepidem.2006.03.003 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 120LK UT WOS:000243086000006 PM 16843010 ER PT J AU Magee, KH Pollack, BP Raugi, GJ AF Magee, Kristin H. Pollack, Brian P. Raugi, Gregory J. TI Pustule-studded plaques after abrasion injury - Blastomycosis-like pyoderma. SO ARCHIVES OF DERMATOLOGY LA English DT Article ID VEGETANS; THERAPY C1 Emory Univ, Atlanta, GA 30322 USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. Univ Washington, Seattle, WA 98195 USA. RP Magee, KH (reprint author), Emory Univ, Atlanta, GA 30322 USA. NR 9 TC 1 Z9 1 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-987X J9 ARCH DERMATOL JI Arch. Dermatol. PD DEC PY 2006 VL 142 IS 12 BP 1643 EP + DI 10.1001/archderm.142.12.1643-a PG 2 WC Dermatology SC Dermatology GA 116LC UT WOS:000242803400018 PM 17178997 ER PT J AU Niquet, J Seo, DW Wasterlain, CG AF Niquet, J. Seo, D. -W. Wasterlain, C. G. TI Mitochondrial pathways of neuronal necrosis SO BIOCHEMICAL SOCIETY TRANSACTIONS LA English DT Article; Proceedings Paper CT 8th International Symposium on Cytochrome P450 Biodiversity and Biotechnology CY JUL 23-27, 2006 CL Swansea Med Sch, Swansea, WALES HO Swansea Med Sch ID APOPTOSIS-INDUCING FACTOR; TRANSIENT CEREBRAL-ISCHEMIA; OXYGEN-GLUCOSE DEPRIVATION; CELL-DEATH; STATUS EPILEPTICUS; INDUCED SEIZURES; GLOBAL-ISCHEMIA; HIPPOCAMPUS; ACTIVATION; MECHANISMS AB We examined the mechanism of neuronal necrosis induced by hypoxia, excitotoxicity or non-excitotoxic hypoxia. our observations showed that neuronal necrosis can be an active process starting with early mitochondrial swelling, followed by cytochrome c release and caspase cascade. Energy failure and/or calcium overloading of mitochondria may trigger this sequence of events. We called this form of necrosis 'programmed necrosis'. We discuss in this paper the contribution of another mitochondrial death factor, apoptosis-inducing factor. C1 Vet Affairs Greater Los Angeles Healthcare Syst 1, Neurol Serv, Epilepsy Res Labs, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. Sungkyunkwan Univ, Samsung Med Ctr, Seoul 135710, South Korea. Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA. RP Wasterlain, CG (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst 1, Neurol Serv, Epilepsy Res Labs, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM wasterla@ucla.edu FU NINDS NIH HHS [R01 NS13515] NR 23 TC 15 Z9 18 U1 0 U2 3 PU PORTLAND PRESS LTD PI LONDON PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND SN 0300-5127 J9 BIOCHEM SOC T JI Biochem. Soc. Trans. PD DEC PY 2006 VL 34 BP 1347 EP 1351 PN 6 PG 5 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 119LJ UT WOS:000243013500081 PM 17073816 ER PT J AU Taha, TA Mullen, TD Obeid, LM AF Taha, Tarek A. Mullen, Thomas D. Obeid, Lina M. TI A house divided: Ceramide, sphingosine, and sphingosine-1-phosphate in programmed cell death SO BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES LA English DT Review DE programmed cell death; ceramide; sphingosine; sphingosine-1-phosphate (S1P); sphingolipid; apoptosis ID PROTEIN-KINASE-C; TUMOR-NECROSIS-FACTOR; RADIATION-INDUCED APOPTOSIS; JURKAT T-CELLS; ACID SPHINGOMYELINASE; CYTOCHROME-C; GLIOMA-CELLS; CANCER-CELLS; HL-60 CELLS; CATHEPSIN-D AB Programmed cell death is an important physiological response to many forms of cellular stress. The signaling cascades that result in programmed cell death are as elaborate as those that promote cell survival, and it is clear that coordination of both protein- and lipid-mediated signals is crucial for proper cell execution. Sphingolipids are a large class of lipids whose diverse members share the common feature of a long-chain sphingoid base, e.g., sphingosine. Many sphingolipids have been shown to play essential roles in both death signaling and survival. Ceramide, an N-acylsphingosine, has been implicated in cell death following a myriad of cellular stresses. Sphingosine itself can induce cell death but via pathways both similar and dissimilar to those of ceramide. Sphingosine-1-phosphate, on the other hand, is an anti-apoptotic molecule that mediates a host of cellular effects antagonistic to those of its pro-apoptotic sphingolipid siblings. Extraordinarily, these lipid mediators are metabolically juxtaposed, suggesting that the regulation of their metabolism is of the utmost importance in determining cell fate. In this review, we briefly examine the role of ceramide, sphingosine, and sphingosine-1-phosphate in programmed cell death and highlight the potential roles that these lipids play in the pathway to apoptosis. (c) 2006 Elsevier B.V. All rights reserved. C1 Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. Ralph H Johnson Vet Adm Hosp, Div Gen Internal Med, Charleston, SC 29401 USA. RP Obeid, LM (reprint author), Med Univ S Carolina, Dept Med, 114 Doughty St,POB 250779, Charleston, SC 29425 USA. EM obeidl@musc.edu OI obeid, lina/0000-0002-0734-0847 FU NCI NIH HHS [P01 CA097132]; NIA NIH HHS [R01 AG016583]; NIGMS NIH HHS [R01 GM062887] NR 129 TC 163 Z9 169 U1 2 U2 8 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0005-2736 J9 BBA-BIOMEMBRANES JI Biochim. Biophys. Acta-Biomembr. PD DEC PY 2006 VL 1758 IS 12 BP 2027 EP 2036 DI 10.1016/j.bbamem.2006.10.018 PG 10 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 122IZ UT WOS:000243220800012 PM 17161984 ER PT J AU Bliziotes, M Eshleman, A Burt-Pichat, B Zhang, XW Hashimoto, J Wiren, K Chenu, C AF Bliziotes, M. Eshleman, A. Burt-Pichat, B. Zhang, X. -W. Hashimoto, J. Wiren, K. Chenu, C. TI Serotonin transporter and receptor expression in osteocytic MLO-Y4 cells SO BONE LA English DT Article; Proceedings Paper CT 24th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research CY SEP 20-24, 2002 CL SAN ANTONIO, TX SP Amer Soc Bone & Mineral Res DE bone; neurotransmitter; transporter; osteoblast; osteocyte ID MESSENGER-RNA EXPRESSION; TRYPTOPHAN-HYDROXYLASE; BONE-FORMATION; ANTIPEPTIDE ANTIBODIES; IMMUNOREACTIVE NERVES; GLUTAMATE RECEPTORS; 5-HT1A RECEPTOR; LONG BONES; FLUID-FLOW; IN-VITRO AB Neurotransmitter regulation of bone metabolism has been a subject of increasing interest and investigation. We reported previously that osteoblastic cells express a functional scrotonin (5-HT) signal transduction system, with mechanisms for responding to and regulating uptake of 5-HT. The clonal murine osteocytic cell line, MLO-Y4, demonstrates expression of the serotonin transporter (5-HTT), and the 5-HT1A, and 5-HT2A receptors by real-time RT-PCR and immunoblot analysis. Immunohistochemistry using antibodies for the 5-HTT, and the 5-HT1A and 5-HT,, receptors reveals expression of all three proteins in both osteoblasts and osteocytes in rat tibia. 5-HTT binding sites were demonstrated in the MLO-Y4 cells with nanomolar affinity for the stable cocaine analog [I-125]RTI-55. Imipramine and fluoxetine, antagonists with specificity for 5-HTT, show the highest potency to antagonize [I-125]RTI-55 binding in the MLO-Y4 cells. GBR-12935, a relatively selective dopamine transporter antagonist, had a much lower potency, as did desipramine, a selective norepinephrine transporter antagonist. The maximal [H-3]5-HT uptake rate in MLO-Y4 cells was 2.85 pmol/15 min/well, with a K-m value of 290 nM. Imipramine and fluoxetine inhibited specific [H-3]5-HT uptake with IC50 values in the nanomolar range. 5-HT rapidly stimulated PGE(2) release from MLO-Y4 cells; the EC50 for 5-HT was 0.1 mu M, with a 3-fold increase seen at 60 min. The rate-limiting enzyme for serotonin synthesis, tryptophan hydroxylase, is expressed in MLO-Y4 cells as well as osteoblastic MC3T3-E1 cells. Thus, osteocytes, as well as osteoblasts, are capable of 5-HT synthesis, and express functional receptor and transporter components of the 5-HT signal transduction system. (c) 2006 Elsevier Inc. All rights reserved. C1 Portland VA Med Ctr, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Portland, OR 97239 USA. Hop Edouard Herriot, INSERM Unit 403, Lyon, France. RP Bliziotes, M (reprint author), Portland VA Med Ctr, P3 ENDO, Portland, OR 97239 USA. EM bliziote@ohsu.edu OI Wiren, Kristine/0000-0002-6159-4450 FU NIAMS NIH HHS [R01 AR052018-01A1, R01 AR052018-02]; NIDDK NIH HHS [DK54415] NR 50 TC 62 Z9 70 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 8756-3282 J9 BONE JI Bone PD DEC PY 2006 VL 39 IS 6 BP 1313 EP 1321 DI 10.1016/j.bone.2006.06.009 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 119KT UT WOS:000243011900019 PM 16884969 ER PT J AU Frutos-Vivar, F Ferguson, ND Estaban, A Epstein, SK Arabi, Y Apezteguia, C Gonzalez, M Hill, NS Nava, S D'Empaire, G Anzueto, A AF Frutos-Vivar, Fernando Ferguson, Niall D. Estaban, Andres Epstein, Scott K. Arabi, Yaseen Apezteguia, Carlos Gonzalez, Marco Hill, Nichola S. Nava, Stefano D'Empaire, Gabriel Anzueto, Antonio TI Risk factors for extubation failure in patients following a successful spontaneous breathing trial SO CHEST LA English DT Article DE artificial respiration; extubation; predictive index; reintubation; ventilator weaning ID VENTILATOR-ASSOCIATED PNEUMONIA; MECHANICAL VENTILATION; OUTCOMES; SUPPORT; DURATION; COUGH AB Background: To assess the factors associated with reintubation in patients who had successfully passed a spontaneous breathing trial. Methods: We used logistic regression and recursive partitioning analyses of prospectively collected clinical data from adults admitted to ICUs of 37 hospitals in eight countries, who had undergone invasive mechanical ventilation for > 48 h and were deemed ready for extubation. Results: Extubation failure occurred in 121 of the 900 patients (13.4%). The logistic regression analysis identified the following associations with reintubation: rapid shallow breathing index (RSBI) [odds ratio (OR), 1.009 per unit; 95% confidence interval (CI), 1.003 to 1.015]; positive fluid balance (OR, 1.70; 95% CI, 1.15 to 2.53); and pneumonia as the reason for initiating mechanical ventilation (OR, 1.77; 95% CI, 1.10 to 2.84). The recursive partitioning analysis allowed the separation of patients into different risk groups for extubation failure: (1) RSBI of > 57 breaths/L/min and positive fluid balance (OR, 3.0; 95% CI, 1.8 to 4.8); (2) RSBI of < 57 breaths/L/min and pneumonia as reason for mechanical ventilation (OR, 2.0; 95% CI, 1.1 to 3.6); (3) RSBI of > 57 breaths/Umin and negative fluid balance (OR, 1.4; 95% CI, 0.8 to 2.5); and (4) RSBI of < 57 breaths/L/min (OR, 1 [reference value]). Conclusions: Among routinely measured clinical variables, RSBI, positive fluid balance 24 h prior to extubation, and pneumonia at the initiation of ventilation were the best predictors of extubation failure. However, the combined predictive ability of these variables was weak. C1 Univ Madrid, Hosp Getafe, Intens Care Unit, Madrid 28905, Spain. Univ Toronto, Univ Hlth Network, Div Respirol, Dept Med, Toronto, ON, Canada. Univ Toronto, Univ Hlth Network, Interdepartmental Div Crit Care Med, Toronto, ON, Canada. Tufts Univ, Sch Med, Caritas St Elizabeths Med Ctr, Dept Med, Boston, MA 02111 USA. King Abdulaziz Med City, Riyadh, Saudi Arabia. Hosp Prof Posadas, Buenos Aires, DF, Argentina. Hosp Gen Medellin, Medellin, Colombia. Tufts Univ, New England Med Ctr, Dept Med, Div Pulm & Crit Care,Sch Med, Boston, MA 02111 USA. Hosp Clin, Caracas, Venezuela. Fdn S Maugeri, Ist Sci Pavia, Resp Intens Care Unit, Pavia, Italy. S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Frutos-Vivar, F (reprint author), Univ Madrid, Hosp Getafe, Intens Care Unit, Carretera Toledo Km 12,500, Madrid 28905, Spain. EM ffrutos@ucigetafe.com OI Frutos-Vivar, Fernando/0000-0002-4648-9636; Ferguson, Niall/0000-0002-6213-5264 NR 26 TC 117 Z9 125 U1 2 U2 5 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD DEC PY 2006 VL 130 IS 6 BP 1664 EP 1671 DI 10.1378/chest.130.6.1664 PG 8 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 117MB UT WOS:000242876200010 PM 17166980 ER PT J AU Mularski, RA Asch, SM Shrank, WH Kerr, EA Setodji, CM Adams, JL Keesey, J McGlynn, EA AF Mularski, Richard A. Asch, Steven M. Shrank, William H. Kerr, Eve A. Setodji, Claude M. Adams, John L. Keesey, Joan McGlynn, Elizabeth A. TI The quality of obstructive lung disease care for adults in the United States as measured by adherence to recommended processes SO CHEST LA English DT Article ID IMPROVING PRIMARY-CARE; OF-CARE; PULMONARY-DISEASE; HEALTH-CARE; STANDARDIZED PATIENTS; CHRONIC ILLNESS; ASTHMA; MANAGEMENT; COPD; PHYSICIANS AB Background: The extent to which patients with obstructive lung disease receive recommended processes of care is largely unknown. We assessed the quality of care delivered to a national sample of the US population. Methods: We extracted medical records for 2 prior years from consenting participants in a random telephone survey in 12 communities and measured the quality of care provided with 45 explicit, process-based quality indicators for asthma and COPD developed using the modified Delphi expert panel methodology. Multivariate logistic regression evaluated effects of patient demographics, insurance, and other characteristics on the quality of health care. Results: We identified 2,394 care events among 260 asthma participants and 1,664 events among 169 COPD participants. Overall, participants received 55.2% of recommended care for obstructive lung disease. Asthma patients received 53.5% of recommended care; routine management was better (66.9%) than exacerbation care (47.8%). COPD patients received 58.0% of recommended care but received better exacerbation care (60.4%) than routine care (46.1%). Variation was seen in mode of care with considerable deficits in documenting recommended aspects of medical history (41.4%) and use of diagnostic studies (40.1%). Modeling demonstrated modest variation between racial groups, geographic areas, insurance types, and other characteristics. Conclusions: Americans with obstructive lung disease received only 55% of recommended care. The deficits and variability in the quality of care for obstructive lung disease present ample opportunity for quality improvement. Future endeavors should assess reasons for low adherence to recommended processes of care and assess barriers in delivery of care. C1 Kaiser Permanente NW, Ctr Hlth Res, Portland, OR 97227 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RAND Hlth, Los Angeles, CA USA. Ann Arbor Healthcare Syst, Ctr Practice Management & Outcomes Res, Ann Arbor, MI USA. Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, Boston, MA USA. RP Mularski, RA (reprint author), Kaiser Permanente NW, Ctr Hlth Res, 3800 N Interstate,WIN 1060, Portland, OR 97227 USA. EM Richard.Mularski@kpchr.org NR 50 TC 68 Z9 68 U1 0 U2 4 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD DEC PY 2006 VL 130 IS 6 BP 1844 EP 1850 DI 10.1378/chest.130.6.1844 PG 7 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 117MB UT WOS:000242876200037 PM 17167007 ER PT J AU Frank, JA Parsons, PE Matthay, MA AF Frank, James A. Parsons, Polly E. Matthay, Michael A. TI Pathogenetic significance of biological markers of ventilator-associated lung injury in experimental and clinical studies SO CHEST LA English DT Review DE ARDS; critical care; ventilation; ventilator-induced lung injury ID RESPIRATORY-DISTRESS-SYNDROME; TIDAL VOLUME VENTILATION; NECROSIS-FACTOR-ALPHA; PULMONARY-EDEMA FLUID; VON-WILLEBRAND-FACTOR; SURFACTANT PROTEIN-A; MECHANICAL VENTILATION; BRONCHOALVEOLAR LAVAGE; INFLAMMATORY CYTOKINES; ENDOTHELIAL INJURY AB For patients with acute lung injury, positive pressure mechanical ventilation is life saving. However, considerable experimental and clinical data have demonstrated that how clinicians set the tidal volume, positive end-expiratory pressure, and plateau airway pressure influences lung injury severity and patient outcomes including mortality. In order to better identify ventilator-associated lung injury (VALI), clinical investigators have sought to measure blood-borne and airspace biological markers of VALI. At the same time, several laboratory-based studies have focused on biological markers of inflammation and organ injury in experimental models in order to clarify the mechanisms of ventilator-induced lung injury (VILI) and VALI. This review summarizes data on biological markers of VALI and VILI from both clinical and experimental studies with an emphasis on markers identified in patients and in the experimental setting. This analysis suggests that measurement of some of these biological markers may be of value in diagnosing VALI and in understanding its pathogenesis. C1 Univ Calif San Francisco, Div Pulm & Crit Care Med, Med Intens Care Unit, San Francisco VA Med Ctr, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA 94143 USA. Univ Vermont, Dept Med, Div Pulm & Crit Care, Burlington, VT USA. RP Frank, JA (reprint author), Univ Calif San Francisco, Div Pulm & Crit Care Med, Med Intens Care Unit, San Francisco VA Med Ctr, 4150 Clement St,Mail Stop 111D, San Francisco, CA 94121 USA. EM james.frank@ucsf.edu FU NHLBI NIH HHS [K08 HL069900-05, R01 HL051856, K08 HL069900, R37 HL051856, HL 51856, R37 HL051856-14, R56 HL088440]; PHS HHS [JL 69900] NR 64 TC 57 Z9 61 U1 1 U2 3 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD DEC PY 2006 VL 130 IS 6 BP 1906 EP 1914 DI 10.1378/chest.130.6.1906 PG 9 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 117MB UT WOS:000242876200045 PM 17167015 ER PT J AU Wecht, JM Weir, JP Bauman, WA AF Wecht, Jill M. Weir, Joseph P. Bauman, William A. TI Blunted heart rate response to vagal withdrawal in persons with tetraplegia SO CLINICAL AUTONOMIC RESEARCH LA English DT Article DE spinal cord injury; head-up tilt; heart rate variability; autonomic nervous system ID BLOOD-PRESSURE VARIABILITY; UP TILT; AUTONOMIC RESPONSES; SPECTRAL-ANALYSIS; INDIVIDUALS; INHIBITION; MECHANISMS; FAILURE; HUMANS; AGE AB Cardiovascular autonomic mechanisms control heart rate (HR) and determination of heart rate variability (HRV) permits the quantitative assessment of relative shifts in autonomic cardiac control during head-up tilt (HUT). The study herein used HRV techniques to determine the vagal and sympathetic contribution to the change in HR during HUT in persons with tetraplegia (T; n = 7) paraplegia (P; n = 7) and a non-spinal cord injured (non-SCI; n = 8) control group. Heart rate (HR) was continuously monitored and cardiovascular autonomic responses were assessed for 5-minutes at supine and at 45 degrees HUT. Change associated with tilt from supine to 45 degrees HUT was calculated for HR (deltaHR), high & low frequency HRV (HF & LF) and the LF/HF ratio. HR and LF power were lower in the T compared to the P and non-SCI groups at 45 degrees HUT, whereas there were no group differences for HF at 45 degrees HUT. The LF/HF ratio was lower in the T compared to the non-SCI group at 45 degrees HUT. The relationship between delta HR and delta HF response differed between groups (significant group x delta HF interaction) such that the slope of this relationship was reduced in the T (-1.026: 95% Cl: -2.623 to 0.571) compared with the non-SCI (-6.985: 95% Cl: -11.25 to 2.72) and P (-5.218: 95% Cl: -8.197 to -2.239) groups. There was no significant interaction effect for the relationships between deltaHR and deltaLF or deltaLF/HF. In summary, although the magnitude of vagal withdrawal was comparable among the groups, the increase in HR was attenuated in the group with tetraplegia, which may reflect reduced sympathetic cardiac modulation or altered SA node responsiveness to vagal withdrawal. C1 James J Peters Med Ctr, Bronx, NY 10468 USA. Vet Affairs Med Ctr, SCI, Bronx, NY USA. Med Serv, Bronx, NY USA. CUNY Mt Sinai Sch Med, New York, NY 10029 USA. Rehabiol Med Serv, New York, NY USA. Des Moines Univ, Osteopath Med Ctr, Des Moines, IA USA. RP Wecht, JM (reprint author), James J Peters Med Ctr, Rm 1E-06,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM jwecht@hotmail.com NR 20 TC 18 Z9 19 U1 0 U2 2 PU DR DIETRICH STEINKOPFF VERLAG PI DARMSTADT PA PO BOX 10 04 62, D-64204 DARMSTADT, GERMANY SN 0959-9851 J9 CLIN AUTON RES JI Clin. Auton. Res. PD DEC PY 2006 VL 16 IS 6 BP 378 EP 383 DI 10.1007/a10286-006-0367-y PG 6 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 125GN UT WOS:000243430500005 PM 17066256 ER PT J AU Yang, YS Koontz, AM Triolo, RJ Mercer, JL Boninger, ML AF Yang, Yu-Sheng Koontz, Alicia M. Triolo, Ronald J. Mercer, Jennifer L. Boninger, Michael L. TI Surface electromyography activity of trunk muscles during wheelchair propulsion SO CLINICAL BIOMECHANICS LA English DT Article DE electromyography; muscle recruitment; spinal cord injury; manual wheelchair; wheelchair propulsion; trunk stability; trunk control ID SPINAL-CORD-INJURY; ISOMETRIC AXIAL ROTATION; SHOULDER MUSCLES; BIOMECHANICS; POSITION; LEVEL; USERS; PAIN; ILIOCOSTALIS; STIMULATION AB Background. Trunk instability due to paralysis can have adverse effects on posture and function in a wheelchair. The purpose of this study was to record trunk muscle recruitment patterns using surface electromyography from unimpaired individuals during wheelchair propulsion under various propulsion speed conditions to be able to design trunk muscle stimulation patterns for actual wheelchair users with spinal cord injury. Methods. Fourteen unimpaired subjects propelled a test wheelchair on a dynamometer system at two steady state speeds of 0.9 m/s and 1.8 m/s and acceleration from rest to their maximum speed. Lower back/abdominal surface electromyography and upper body movements were recorded for each trial. Based on the hand movement during propulsion, the propulsive cycle was further divided into five stages to describe the activation patterns. Findings. Both abdominal and back muscle groups revealed significantly higher activation at early push and pre-push stages when compared to the other three stages of the propulsion phase. With increasing propulsive speed, trunk muscles showed increased activation (P < 0.0001). Back muscle activity was significantly higher than abdominal muscle activity across the three speed conditions (P < 0.0005), with lower back muscles predominating. Interpretation. Abdominal and back muscle groups cocontracted at late recovery phase and early push phase to provide sufficient trunk stability to meet the demands of propulsion. This study provides an indication of the amount and duration of stimulation needed for a future application of electrical stimulation of the trunk musculature for persons with spinal cord injury. (c) 2006 Elsevier Ltd. All rights reserved. C1 VA Pittsburgh Healthcare Syst, Human Engn Res Labs 151R1H, Pittsburgh, PA 15206 USA. Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA 15261 USA. Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15261 USA. Louis Stokes Cleveland VA Med Ctr, Cleveland FES Ctr, Cleveland, OH 44106 USA. Kaohsiung Med Univ, Fac Occupat Therapy, Coll Hlth Sci, Dept Occupat Therapy, Kaohsiung, Taiwan. RP Koontz, AM (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs 151R1H, 7180 Highland Dr, Pittsburgh, PA 15206 USA. EM akoontz@pitt.edu RI Yang, Yu-Sheng/D-4525-2009 OI Yang, Yu-Sheng/0000-0002-2767-9354; Boninger, Michael/0000-0001-6966-919X NR 42 TC 18 Z9 19 U1 2 U2 7 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0268-0033 J9 CLIN BIOMECH JI Clin. Biomech. PD DEC PY 2006 VL 21 IS 10 BP 1032 EP 1041 DI 10.1016/j.clinbiomech.2006.07.006 PG 10 WC Engineering, Biomedical; Orthopedics; Sport Sciences SC Engineering; Orthopedics; Sport Sciences GA 108MN UT WOS:000242244000005 PM 16979271 ER PT J AU Gralnek, IM Dulai, GS Fennerty, MB Spiegel, BMR AF Gralnek, Ian M. Dulai, Gareth S. Fennerty, M. Brian Spiegel, Brennan M. R. TI Esomeprazole versus other proton pump inhibitors in erosive esophagitis: A meta-analysis of randomized clinical trials SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article ID GASTROESOPHAGEAL-REFLUX DISEASE; PANTOPRAZOLE 40 MG; LANSOPRAZOLE 30 MG; ACID CONTROL; OMEPRAZOLE; SYMPTOMS; EFFICACY; EQUIVALENT; RELIEF; SAFETY AB Background & Aims: There are limited data comparing the effectiveness of available proton pump inhibitors (PPIs) in erosive esophagitis (EE). We performed a mesa-analysis to calculate the pooled effect of esomeprazole on healing rates, symptom relief, and adverse events versus competing PPIs in EE. Methods: We performed a structured electronic search of MEDLINE and EMBASE and reviewed published abstracts to identify English-language, randomized clinical trials from 1995-2005, comparing rates of endoscopic healing, symptom relief, and adverse events with esomeprazole versus alternative PPIs in the treatment of gastroesophageal reflux disease (GERD)/EE. We then performed meta-analysis to compare the relative risk (RR) of EE healing, symptom relief, and adverse events between study arms and calculated the absolute risk reduction and number needed to treat (NNT) for each outcome. Results: Meta-analysis was performed on 10 studies (n = 15,316). At 8 weeks, there was a 5% (RR, 1.05; 95% confidence interval, 1.02-1.08) relative increase in the probability of healing of EE with esomeprazole, yielding an absolute risk reduction of 4% and NNT of 25. The calculated NNTs by Los Angeles grade of EE (grades A-D) were 50, 33, 14, and 8, respectively. Last, esomeprazole conferred an 8% (RR, 1.08; 95% confidence interval, 1.05-1.11) relative increase in the probability of GERD symptom relief at 4 weeks. Conclusions: As compared with other PPIs, esomeprazole confers a statistically significant improvement, yet, clinically, only a modest overall benefit in 8-week healing and symptom relief in all-comers with EE. The clinical benefit of esomeprazole appears negligible in less severe erosive disease but might be important in more severe disease. C1 Technion Israel Inst Technol, Rappaport Fac Med, GI Outcomes Unit,Dept Gastroenterol, Rambam Med Ctr, Haifa, Israel. Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, VA Ctr Outcomes Res & Educ, Los Angeles, CA USA. CURE Digest Dis Res Ctr, Los Angeles, CA USA. Oregon Hlth Sci Univ, Portland, OR 97201 USA. So Calif Permanente Med Grp, Bellflower, CA USA. RP Gralnek, IM (reprint author), Technion Israel Inst Technol, Rappaport Fac Med, GI Outcomes Unit,Dept Gastroenterol, Rambam Med Ctr, Haifa, Israel. EM i_gralnek@rambam.health.gov.il FU NIDDK NIH HHS [2P30 DK 041301-17] NR 26 TC 60 Z9 63 U1 1 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD DEC PY 2006 VL 4 IS 12 BP 1452 EP 1458 DI 10.1016/j.cgh.2006.09.013 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 119CN UT WOS:000242989900009 PM 17162239 ER PT J AU Oh, DS Wang, HS Ohning, GV Pisegna, JR AF Oh, David S. Wang, Hank S. Ohning, Gordon V. Pisegna, Joseph R. TI Validation of a new endoscopic technique to assess acid output in Zollinger-Ellison syndrome SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article ID ESOPHAGEAL-PERFORATION; NASOGASTRIC INTUBATION; GASTRIC-SECRETION; ANESTHETIC AGENTS; HYPERGASTRINEMIA; PENTAGASTRIN; AGREEMENT; DIAGNOSIS; STOMACH; BASAL AB Background & Aims: To safely manage the hypersecretory state in patients with Zollinger-Ellison syndrome, both upper endoscopy and gastric analysis are required to titrate optimal medical therapy. Conventional gastric analysis requires more than 1 hour to perform and results in significant patient dissatisfaction. In this study, we have validated endoscopic gastric analysis as a novel technique that can effectively replace conventional gastric analysis. Methods: In a prospective, crossover study. 12 patients with Zollinger-Ellison syndrome underwent gastric analysis, first by the conventional method and then by an endoscopic technique performed on the same day. Acid concentration was determined by titration, volume output was recorded, and acid output was calculated using standard methodologies and formulas. Agreement was assessed following the Bland-Altman method. To assess repeatability, both techniques were repeated on the same day in a subset of patients. Results: Excellent agreement was reported between acid output (95% limits of agreement, -1.27 to 1.61 mEq/h) and acid concentration (95% limits of agreement, -0.01 to 0.01 mEq/mL), although poor agreement was observed between volume output measured. Endoscopic gastric analysis showed greater reproducibility regarding acid and volume output measured. Conclusions: Wee introduce a new, rapid, reproducible, and accurate endoscopic technique to measure acid output in patients with Zollinger-Ellison syndrome who require both annual endoscopy and gastric analysis. The data presented here suggest that endoscopic gastric analysis would be equally effective in determining acid output in other hypersecretory states. Additional analysis of cost effectiveness is needed to evaluate its use as a screening tool in select populations. C1 VA Greater Los Angeles Healthcare Syst, Dept Gastroenterol & Hepatol, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA USA. RP Pisegna, JR (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Gastroenterol & Hepatol, 691-1110,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jpisegna@ucla.edu NR 31 TC 4 Z9 5 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD DEC PY 2006 VL 4 IS 12 BP 1467 EP 1473 DI 10.1016/j.cgh.2006.08.015 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 119CN UT WOS:000242989900011 PM 17101299 ER PT J AU Nodit, L McGrath, KM Zahid, M Jani, N Schoedel, KE Ohori, NP Carty, S Finkelstein, S Khalid, A AF Nodit, Laurentia McGrath, Kevin M. Zahid, Maliha Jani, Niraj Schoedel, Karen E. Ohori, N. Paul Carty, Sally Finkelstein, Sydney Khalid, Asif TI Endoscopic ultrasound-guided fine needle aspirate microsatellite loss analysis and pancreatic endocrine tumor outcome SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article ID NEUROENDOCRINE TUMORS; DELETION; PROGRESSION; MALIGNANCY; NEOPLASMS; PATHOLOGY; CYTOLOGY; MARKER AB Background & Aims: The clinical course of pancreatic endocrine tumor (PET) varies depending on tumor aggressiveness, disease extent, and possibly accumulated molecular alterations. Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) results, although accurate in diagnosing PET, correlate poorly with PET outcome. The role of detecting key molecular abnormalities in predicting PET behavior and clinical outcome from EUS-FNA material remains unknown. Methods: Patients with confirmed PET who underwent EUS-FNA during a 32-month period were included. Patient demographics and clinical data were recorded and follow-up information was obtained by contacting their physician to evaluate disease progression. Representative tumor cells were microdissected from the FNA material. DNA was harvested and amplified, targeting a panel of 17 polymorphic microsatellite markers on chromosomes 1p, 3p, 5q, 9p, 10q, 11q, 17p, 17q, 21q, and 22q. The polymerase chain reaction products were subjected to fluorescent capillary gel electrophoresis to detect microsatellite loss. The fractional allelic loss (FAL) was calculated. Results: Twenty-five patients were studied. Thirteen were classified histologically as benign PET limited to the pancreas and 12 as malignant PET (invasive or metastatic). The mean FAL in the benign and malignant PET was 0.03 and 0.37 (P < .0001), respectively. In addition, the mean FAL was significantly greater in those with disease progression as compared with patients with stable disease (0.45 vs 0.09 respectively, P < .0001). Conclusions: Microsatellite loss analysis of EUS-FNA material from PET can be performed reliably and an FAL value of more than 0.2 is associated with disease progression. This technique may have value in the preoperative assessment and risk stratification of patients with PET. C1 Univ Pittsburgh, Med Ctr, VA Pittsburgh Hlth Care Syst, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA 15213 USA. Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA. Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA USA. Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA. RedPath Integrated Pathol Inc, Pittsburgh, PA USA. RP Khalid, A (reprint author), Univ Pittsburgh, Med Ctr, VA Pittsburgh Hlth Care Syst, Div Gastroenterol Hepatol & Nutr, M2,C-Wing,PUH,200 Lothrop St, Pittsburgh, PA 15213 USA. EM khalida@upmc.edu NR 24 TC 25 Z9 25 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD DEC PY 2006 VL 4 IS 12 BP 1474 EP 1478 DI 10.1016/j.cgh.2006.07.017 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 119CN UT WOS:000242989900012 PM 16996803 ER PT J AU Oates, JC Gilkeson, GS AF Oates, Jim C. Gilkeson, Gary S. TI The biology of nitric oxide and other reactive intermediates in systemic lupus erythematosus SO CLINICAL IMMUNOLOGY LA English DT Review DE nitric oxide; lupus; reactive oxygen species; reactive nitrogen species; 3-nitrotyrosine; lipid peroxidation; apoptosis; autoantigens ID MRL-LPR/LPR MICE; MESSENGER-RNA EXPRESSION; CELL-ADHESION MOLECULE-1; MRL/LPR MICE; DISEASE-ACTIVITY; RENAL-DISEASE; DIMINISHES GLOMERULOSCLEROSIS; PHARMACOLOGICAL INHIBITION; 3-NITROTYROSINE LEVELS; MYCOPHENOLATE-MOFETIL AB Formation of reactive nitrogen and oxygen intermediates (RNI and ROI) is an essential part of the innate immune response. Markers of systemic RNI production are increased in the setting of systemic lupus erythematosus (SLE) activity. Several tines of evidence suggest mechanisms through which the activity of inducible nitric oxide synthase (iNOS) is pathogenic in SLE, including the ability of peroxynitrite (ONOO-, a product of iNOS activity) to modify proteins, lipids, and DNA. These modifications can alter enzyme activity and may increase the immunogenicity of self antigens, leading to a break in immune tolerance. In humans, observational data suggest that overexpression of iNOS and increased production of ONOO- lead to glomerular and vascular pathology. Therapies designed to target iNOS activity or scavenge ROI and RNI are in development and may provide the means to reduce the pathogenic consequences of ROI and RNI in SLE. (c) 2006 Elsevier Inc. All rights reserved. C1 Med Univ S Carolina, Dept Med, Div Rheumatol, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Oates, JC (reprint author), Med Univ S Carolina, Dept Med, Div Rheumatol, 96 Jonathan Lucas St,Suite 912,POB 250637, Charleston, SC 29425 USA. EM oatesjc@musc.edu FU NCRR NIH HHS [M01 RR001070-315777, M01 RR001070-25A1S20263, M01 RR001070-230263, M01 RR001070-260263, M01 RR001070-270263, M01 RR001070-25A1S10263, M01 RR001070-290263, M01 RR001070-25A10263, M01 RR001070-24S50263, M01 RR001070-30A15146, M01 RR001070-280263, M01 RR001070, M01 RR001070-220263, M01 RR001070-240263]; NIAMS NIH HHS [K08 AR002193, K08 AR002193-03, K08 AR002193-05, K08 AR002193-04, K08 AR002193-02, K08 AR002193-01A1] NR 77 TC 35 Z9 35 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1521-6616 J9 CLIN IMMUNOL JI Clin. Immunol. PD DEC PY 2006 VL 121 IS 3 BP 243 EP 250 DI 10.1016/j.clim.2006.06.001 PG 8 WC Immunology SC Immunology GA 111VZ UT WOS:000242484800001 PM 16861040 ER PT J AU Binder, LM Storzbach, D Salinsky, MC AF Binder, Laurence M. Storzbach, Daniel Salinsky, Martin C. TI MMPI-2 profiles of persons with multiple chemical sensitivity SO CLINICAL NEUROPSYCHOLOGIST LA English DT Article; Proceedings Paper CT Meeting of the American-Academy-of-Clinical-Neuropsychology CY JUN 10, 2004 CL Minneapolis, MN ID IDIOPATHIC ENVIRONMENTAL INTOLERANCES; FAKE BAD SCALE; SYMPTOMS; SEIZURES; MODEL AB We compared the MMPI-2 profiles of adults with multiple chemical sensitivity (MCS), epileptic seizures (ES), and nonepileptic seizures (NES). Both NES and MCS are medically unexplained conditions. In previous studies profiles associated with NES were elevated on scales Hs and Hy, compared with profiles associated with ES. We predicted that profiles associated with MCS would be elevated on Hs and Hy compared with the ES group. Patients with ES and NES were diagnosed after intensive EEG monitoring using published criteria. MCS was diagnosed if there was a complaint of illness in response to multiple common odors at levels that are not noxious to most people. All the MCS cases had legal claims for injury related to chemical exposures. The results showed that on MMPI-2 scales Hs, D, and Hy the MCS group had means significantly higher than both the ES and NES groups. Fake Bad Scale scores were elevated in 11 MCS cases, and regression-based estimates of Fake Bad Scale scores showed elevation in the MCS group compared with both seizure groups. We conclude that MMPI-2 data, obtained from people seeking financial compensation, indicate that there is a strong psychological component to MCS symptoms. C1 Oregon Hlth Sci Univ, Beaverton, OR USA. Portland Vet Affairs Med Ctr, Portland, OR USA. RP Binder, LM (reprint author), 4900 SW Griffith Dr Suite 244, Beaverton, OR 97005 USA. EM pdxlarry@aol.com NR 30 TC 5 Z9 5 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1385-4046 J9 CLIN NEUROPSYCHOL JI Clin. Neuropsychol. PD DEC PY 2006 VL 20 IS 4 BP 848 EP 857 DI 10.1080/13854040500246927 PG 10 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA 085IE UT WOS:000240597000018 PM 16980266 ER PT J AU Anzueto, A Guntapalli, K AF Anzueto, Antonio Guntapalli, Kalapatha TI Adjunctive therapy to mechanical ventilation: Surfactant therapy, liquid ventilation, and prone position SO CLINICS IN CHEST MEDICINE LA English DT Article ID RESPIRATORY-DISTRESS-SYNDROME; ACUTE LUNG INJURY; INHALED NITRIC-OXIDE; FREQUENCY OSCILLATORY VENTILATION; TUMOR-NECROSIS-FACTOR; N-ACETYLCYSTEINE; REGIONAL DISTRIBUTION; ADULT PATIENTS; SEVERE SEPSIS; DOUBLE-BLIND AB Acute lung injury and acute respiratory distress syndrome are associated with significant morbidity and mortality in critically ill patients. Although lung protective mechanical ventilation is the only therapy shown to reduce mortality and development of organ failure, several biologic pathways have been identified and provided an opportunity for therapeutic interventions. No pharmacologic or adjunctive treatments are available. Clinical studies demonstrated that prone position results in significant and clinically relevant improvement in oxygenation and ventilation, which persist when patients are returned to supine position; the beneficial response is not limited to patients turned early in disease course. Few complications are associated with prone ventilation. Clinical experience suggests that prone ventilation may protect the lung from potential detrimental effects of mechanical ventilation. Further studies are needed. C1 Univ Texas, Hlth Sci Ctr, San Antonio, TX 78229 USA. Baylor Coll Med, Houston, TX 77030 USA. RP Anzueto, A (reprint author), S Texas Vet Hlth Care Syst, 111E,7400 Merton Mintner Blvd, San Antonio, TX 78229 USA. EM anzueto@uthscsa.edu NR 94 TC 2 Z9 2 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-5231 J9 CLIN CHEST MED JI Clin. Chest Med. PD DEC PY 2006 VL 27 IS 4 BP 637 EP + DI 10.1016/j.ccm.2006.07.004 PG 19 WC Respiratory System SC Respiratory System GA 109NE UT WOS:000242314200010 PM 17085252 ER PT J AU Mick, TM Hollander, E AF Mick, Thomas M. Hollander, Eric TI Impulsive-compulsive sexual behavior SO CNS SPECTRUMS LA English DT Review ID PARAPHILIA-RELATED DISORDERS; SEROTONIN REUPTAKE INHIBITORS; BUSPIRONE HYDROCHLORIDE; ADDICTION; COMORBIDITY; MALES; MEN; HYPERSEXUALITY; CLOMIPRAMINE; DEFINITION AB Impulsive-compulsive sexual behavior is a little studied clinical phenomenon which affects similar to 5% to 6% of the population. In the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-Text Revision, it is classified as an impulse control disorder not otherwise specified or a sexual disorder not otherwise specified. It may be placed in a possible new category in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition called substance and behavioral addictions. This clinical entity is reviewed and the merit of classifying it as an addiction is assessed. Information is presented regarding its diagnostic criteria, epidemiology, types of behavior it can involve, relationship to hypersexuality, comorbidities, treatment, and etiology. The data regarding this disorder and its overlap with chemical addiction is limited. If the two disorders are to be grouped together, further data are needed. C1 Mt Sinai Sch Med, New York, NY 10029 USA. Mt Sinai Med Ctr, Dept Psychiat, New York, NY 10029 USA. James J Peter Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, Bronx, NY USA. Seaver & New York Autism Ctr Excellence, New York, NY USA. RP Mick, TM (reprint author), Mt Sinai Sch Med, 1 Gustave Levy Pl,Box 1230, New York, NY 10029 USA. EM Thomas.Mick@mssm.edu RI Arens, Johannes/F-1296-2010 NR 56 TC 43 Z9 44 U1 0 U2 13 PU M B L COMMUNICATIONS, INC PI NEW YORK PA 333 HUDSON ST, 7TH FLOOR, NEW YORK, NY 10013 USA SN 1092-8529 J9 CNS SPECTRUMS JI CNS Spectr. PD DEC PY 2006 VL 11 IS 12 BP 944 EP 955 PG 14 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 123CD UT WOS:000243273000012 PM 17146408 ER PT J AU Palevsky, PM AF Palevsky, Paul M. TI Off-pump cardiac surgery and acute kidney injury SO CRITICAL CARE MEDICINE LA English DT Editorial Material DE acute kidney injury; cardiac surgery; coronary artery bypass; off pump; estimated glomerular filtration rate ID MORTALITY C1 Univ Pittsburgh, Sch Med, Renal Sect, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15260 USA. RP Palevsky, PM (reprint author), Univ Pittsburgh, Sch Med, Renal Sect, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15260 USA. OI Palevsky, Paul/0000-0002-7334-5400 NR 7 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0090-3493 J9 CRIT CARE MED JI Crit. Care Med. PD DEC PY 2006 VL 34 IS 12 BP 3052 EP 3053 DI 10.1097/01.CCM.0000248904.17516.C4 PG 2 WC Critical Care Medicine SC General & Internal Medicine GA 110QH UT WOS:000242393100036 PM 17130705 ER PT J AU Restrepo, MI Anzueto, A AF Restrepo, Marcos I. Anzueto, Antonio TI The role of new therapies for severe community-acquired pneumonia SO CURRENT OPINION IN INFECTIOUS DISEASES LA English DT Review DE antibiotics; community-acquired pneumonia; Streptococcus pneumoniae ID BACTEREMIC PNEUMOCOCCAL PNEUMONIA; LOWER RESPIRATORY-TRACT; INTENSIVE-CARE-UNIT; RESISTANT STREPTOCOCCUS-PNEUMONIAE; PROGNOSTIC-FACTORS; ANTIMICROBIAL THERAPY; INITIAL MANAGEMENT; ELDERLY-PATIENTS; ADULT PATIENTS; PSEUDOMONAS-AERUGINOSA AB Purpose of review Community-acquired pneumonia (CAP) is associated with significant morbidity and is the most common cause of death from infectious diseases. CAP patients requiring intensive care unit (ICU) admission carry the highest mortality rates. This paper aims to review the current literature regarding epidemiology, risk factors, severity criteria and reasons for admitting the hospitalized patient to the ICU, and the empiric and specific antibiotic therapeutic regimens employed. Recent findings Multiple sets of clinical practice guidelines have been published in the past few years addressing the treatment of CAP. The guidelines all agree that CAP patients admitted to the hospital represent a major concern, and appropriate empiric therapy should be instituted to improve clinical outcomes. Summary The cost, morbidity and mortality of CAP patients requiring ICU admission remain unacceptably high. These are heterogenous groups of patients, so it is important to use risk-stratification based on clinical parameters and prediction tools. Appropriate antibiotic therapy is an important component in the management of both groups of patients. In particular, it is essential to administer an appropriate antimicrobial agent from the initiation of therapy, so that the risks of treatment failure and the morbidity of CAP may be minimized. C1 Univ Texas, Audie L Murphy Div San Antonio, S Texas Vet Healthcare Syst, Hlth Sci Ctr San Antonio,Div Pulm & Crit Care Med, San Antonio, TX 78229 USA. Vet Evidence Based Res Disseminat Implementat Ctr, San Antonio, TX USA. RP Anzueto, A (reprint author), Univ Texas, Audie L Murphy Div San Antonio, S Texas Vet Healthcare Syst, Hlth Sci Ctr San Antonio,Div Pulm & Crit Care Med, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM anzueto@uthscsa.edu NR 105 TC 5 Z9 6 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0951-7375 J9 CURR OPIN INFECT DIS JI Curr. Opin. Infect. Dis. PD DEC PY 2006 VL 19 IS 6 BP 557 EP 564 DI 10.1097/QCO.0b013e3280106b7f PG 8 WC Infectious Diseases SC Infectious Diseases GA 112GI UT WOS:000242513400005 PM 17075331 ER PT J AU Williams, DL Baskin, DG Schwartz, MW AF Williams, Diana L. Baskin, Denis G. Schwartz, Michael W. TI Leptin regulation of the anorexic response to glucagon-like peptide-1 receptor stimulation SO DIABETES LA English DT Article ID CENTRAL-NERVOUS-SYSTEM; CAUDAL BRAIN-STEM; FOOD-INTAKE; LITHIUM-CHLORIDE; EXENATIDE EXENDIN-4; NEURAL ACTIVATION; GENE-EXPRESSION; BODY-WEIGHT; ZUCKER RATS; MEAL SIZE AB Leptin reduces food intake in part by enhancing satiety responses to gastrointestinal signals produced in response to food consumption. Glucagon-like peptide 1 (GLP-1), secreted by the intestine when nutrients enter the gut, is one. such putative satiety signal. To investigate whether leptin enhances the anorexic effects of GLP-1, rats received either saline or a subthreshold dose of leptin before intraperitoneal injection of either GLP-1 or Exendin-4 (Ex4; a GLP-1 receptor agonist). Leptin pretreatment strongly enhanced anorexia and weight loss induced by GLP-1 or Ex4 over 24 h. Conversely, fasting attenuated the anorexic response to GLP-1 or Ex4 treatment via a leptin-dependent mechanism, as demonstrated by our finding that the effect of fasting was reversed by physiological leptin replacement. As expected, Ex4 induced expression of c-Fos protein, a marker of neuronal activation, in hindbrain areas that process afferent input from satiety signals, including the nucleus of the solitary tract and area postrema. Unexpectedly, leptin pretreatment blocked this response. These findings identify physiological variation of plasma leptin levels as a potent regulator of GLP-1 receptor-mediated food intake suppression and suggest that the underlying mechanism is distinct from that which mediates interactions between leptin and other satiety signals. C1 Univ Washington, Harborview Med Ctr, Div Metab Endocrinol & Nutr, Dept Med, Seattle, WA 98104 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA. RP Williams, DL (reprint author), Univ Washington, Harborview Med Ctr, Div Metab Endocrinol & Nutr, Dept Med, 325 9Th Ave,Box 359675, Seattle, WA 98104 USA. EM dianalw@u.washington.edu RI Schwartz, Michael/H-9950-2012; Williams, Diana/C-1699-2014 OI Williams, Diana/0000-0002-3548-7440 FU NIDDK NIH HHS [DK-52989, DK-68340]; NINDS NIH HHS [NS-32273] NR 36 TC 99 Z9 100 U1 1 U2 10 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 J9 DIABETES JI Diabetes PD DEC PY 2006 VL 55 IS 12 BP 3387 EP 3393 DI 10.2337/db06-0558 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 111JG UT WOS:000242446800023 PM 17130484 ER PT J AU Xu, J Lee, WNP Phan, J Saad, MF Reue, K Kurland, IJ AF Xu, Jun Lee, W. N. Paul Phan, Jack Saad, Mohammed F. Reue, Karen Kurland, Irwin J. TI Lipin deficiency impairs diurnal metabolic fuel switching SO DIABETES LA English DT Article ID REVERSES INSULIN-RESISTANCE; MASS ISOTOPOMER ANALYSIS; ADIPOSE-TISSUE; GLUCOSE-PRODUCTION; DIABETES-MELLITUS; HEPATIC STEATOSIS; GENE-EXPRESSION; IN-VIVO; LIPODYSTROPHY; MOUSE AB Fatty liver is a common feature of both obesity and lipodystrophy, reflecting compromised adipose tissue function. The lipin-deficient fatty liver dystrophy (fld) mouse is an exception, as there is lipodystrophy without a fatty liver. Using a combination of indirect calorimetry and stable-isotope flux phenotyping, we determined that fld mice exhibit abnormal fuel utilization throughout the diurnal cycle, with increased glucose oxidation near the end of the fasting period and increased fatty acid oxidation during the feeding period. The mechanisms underlying these alterations include a twofold increase compared with wild-type mice in tissue glycogen storage during the fed state, a 40% reduction in hepatic glucose production in the fasted state, and a 27-fold increase in de novo fatty acid synthesis in liver during the fed state. Thus, the inability to store energy in adipose tissue in the fld mouse leads to a compensatory increase in glycogen storage for use during the fasting period and reliance upon hepatic fatty acid synthesis to provide fuel for peripheral tissues during the fed state. The increase in hepatic fatty acid synthesis and peripheral utilization provides a potential mechanism to ameliorate fatty liver in the fld that would otherwise occur as a consequence of adipose tissue dysfunction. C1 SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA. Harbor UCLA Med Ctr, Dept Pediat, Torrance, CA 90509 USA. Univ Calif Los Angeles, Dept Human Genet, Los Angeles, CA USA. SUNY Stony Brook, Dept Prevent Med, Stony Brook, NY 11794 USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA USA. Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90024 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA. SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA. RP Kurland, IJ (reprint author), SUNY Stony Brook, Dept Med, HSC T-15 Room 060, Stony Brook, NY 11794 USA. EM irwin.kurland@stonybrook.edu FU NHLBI NIH HHS [HL28481]; NIDDK NIH HHS [R01 DK058132-07, DK58132] NR 44 TC 23 Z9 23 U1 0 U2 5 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 J9 DIABETES JI Diabetes PD DEC PY 2006 VL 55 IS 12 BP 3429 EP 3438 DI 10.2337/db06-0260 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 111JG UT WOS:000242446800028 PM 17130489 ER PT J AU van Genugten, RE Utzschneider, KM Tong, J Gerchman, F Zraika, S Udayasankar, J Boyko, EJ Fujimoto, WY Kahn, SE AF van Genugten, Renate E. Utzschneider, Kristina M. Tong, Jenny Gerchman, Fernando Zraika, Sakeneh Udayasankar, Jayalakshmi Boyko, Edward J. Fujimoto, Wilfred Y. Kahn, Steven E. CA Amer Diabet Assoc GENNID Study Grp TI Effects of sex and hormone replacement therapy use on the prevalence of isolated impaired fasting glucose and isolated impaired glucose tolerance in subjects with a family history of type 2 diabetes SO DIABETES LA English DT Article ID HEALTHY POSTMENOPAUSAL WOMEN; PLACEBO-CONTROLLED TRIAL; CORONARY-HEART-DISEASE; INSULIN SENSITIVITY; DOUBLE-BLIND; RISK-FACTORS; ESTROGEN; METABOLISM; RESISTANCE; SECRETION AB Impaired fasting glucose (IFG) is more prevalent in men and impaired glucose tolerance (IGT) more prevalent in women. To explore whether this sex difference is related to female sex hormones, we performed a cross-sectional analysis of data from 2,164 (1,329 women and 835 men) first-degree relatives of individuals with type 2 diabetes. Subjects were categorized based on a 75-g oral glucose tolerance test. Sex and hormone replacement therapy (HRT) effects on the distribution of glucose tolerance were assessed using multinomial logistic regression corrected for familial clustering. Compared with men, women were more likely to have isolated IGT (relative risk 1.8 [95% CI 1.3-2.5]) and less likely to have isolated IFG (0.5 [0.3-0.7]) adjusted for ethnicity, age, waist, fasting insulin, and early insulin release (Delta I0-30/Delta G(0-30)). To evaluate HRT effects, postmenopausal women using (n = 238) or not using (n = 378) HRT were compared. HRT users were more likely to have isolated IGT (2.2 [1.2-4.0]) after adjustment, but the prevalence of isolated IFG did not differ by HRT status. Based on the influence of sex and HRT on the prevalence of isolated IFG and isolated IGT, we conclude that female sex hormones may play an important role in the pathogenesis of IFG and IGT. C1 VA Puget Sound Hlth Care Syst 151, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98108 USA. Univ Washington, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Dept Med, Div Gen Internal Med, Seattle, WA 98108 USA. VA Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA 98108 USA. RP Utzschneider, KM (reprint author), VA Puget Sound Hlth Care Syst 151, Dept Med, Div Metab Endocrinol & Nutr, 1660 S Columbian Way, Seattle, WA 98108 USA. EM kutzschn@u.washington.edu OI Kahn, Steven/0000-0001-7307-9002; Boyko, Edward/0000-0002-3695-192X NR 37 TC 21 Z9 22 U1 0 U2 1 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 J9 DIABETES JI Diabetes PD DEC PY 2006 VL 55 IS 12 BP 3529 EP 3535 DI 10.2337/db06-0577 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 111JG UT WOS:000242446800040 PM 17130501 ER PT J AU Munoz, J Lok, KH Gower, BA Fernandez, JR Hunter, GR Lara-Castro, C De Luca, M Garvey, WT AF Munoz, Julian Lok, Kerry H. Gower, Barbara A. Fernandez, Jose R. Hunter, Gary R. Lara-Castro, Cristina De Luca, Maria Garvey, W. Timothy TI Polymorphism in the transcription factor 7-like 2 (TCF7L2) gene is associated with reduced insulin secretion in nondiabetic women SO DIABETES LA English DT Article ID BETA-CELL FUNCTION; GLUCOSE-TOLERANCE; INTRAVENOUS GLUCOSE; DIABETES-MELLITUS; RESISTANCE; SENSITIVITY; ONSET; RISK AB Recently, the transcription factor 7-like 2 (TCF7L2) gene on chromosome 10q25.2 has been linked with type 2 diabetes among Caucasians, with disease associations noted for single nucleotide polymorphisms.(SNPs) rs12255372 and rs7903146. To investigate mechanisms by which TCF7L2 could contribute to type 2 diabetes, we examined the effects of these SNPs on clinical and metabolic traits affecting glucose homeostasis in 256 nondiabetic female subjects (138 European Americans and 118 African Americans) aged 7-57 years. Outcomes included BMI, percent body fat, insulin sensitivity (S-i), acute insulin response to glucose (AIR(g)), and the disposition index (DI). Homozygosity for the minor allele (TT) of SNP rs12255372 occurred in 9% of individuals and was associated with a 31% reduction in DI values in a recessive model. The at-risk allele TT was also associated with lower AIR(g) adjusted for S-i in both ethnic groups, whereas rs12255372 genotype was not associated with measures of adiposity or with S-i. The T allele of rs12255372 was also associated with increased prevalence of impaired fasting glucose. Genotypes at rs7903146 were not associated with any metabolic trait. Lower S-i and higher AIR(g) observed in the African-American compared with the European-American subgroup could not be explained by the TCF7L2 genotype. Our data suggest that the TCF7L2 gene is an important factor regulating insulin secretion, which could explain its association with type 2 diabetes. C1 Univ Alabama, Dept Nutr Sci, Birmingham, AL 35294 USA. Univ Alabama, Dept Human Studies, Birmingham, AL USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Munoz, J (reprint author), Univ Alabama, Dept Nutr Sci, 1675 Webb Nutr Sci Bldg,Room 241, Birmingham, AL 35294 USA. EM munozj@uab.edu OI De Luca, Maria/0000-0001-6345-7508 FU NCRR NIH HHS [M01 RR00032]; NIDDK NIH HHS [R01 DK49779, P30 DK56336, R01 DK58278, R01 DK067426] NR 18 TC 70 Z9 72 U1 0 U2 3 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 J9 DIABETES JI Diabetes PD DEC PY 2006 VL 55 IS 12 BP 3630 EP 3634 DI 10.2337/db06-0574 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 111JG UT WOS:000242446800053 PM 17130514 ER PT J AU Levin, BE Kang, L Sanders, NM Dunn-Meynell, AA AF Levin, Barry E. Kang, Ling Sanders, Nicole M. Dunn-Meynell, Ambrose A. TI Role of neuronal glucosensing in the regulation of energy homeostasis SO DIABETES LA English DT Article; Proceedings Paper CT 7th Servier-IGIS Symposium CY MAR 30-APR 02, 2006 CL St Jean Cap Ferrat, FRANCE ID VENTROMEDIAL HYPOTHALAMIC NUCLEUS; SENSITIVE K+ CHANNELS; INSULIN-INDUCED HYPOGLYCEMIA; MELANIN-CONCENTRATING HORMONE; CONTROLLING FOOD-INTAKE; DIET-INDUCED OBESITY; ATP CHANNELS; EXTRACELLULAR GLUCOSE; ARCUATE NUCLEUS; RAT-BRAIN AB Glucosensing is a property of specialized neurons in, the brain that regulate their membrane potential and firing rate as a function of ambient glucose levels. These neurons have several similarities to beta- and alpha-cells in the pancreas, which are also responsive to ambient glucose levels. Many use glucokinase as a rate-limiting step in the production of ATP and its effects on membrane potential and ion channel function to sense glucose. Glucosensing neurons are organized in an interconnected distributed network throughout the brain that also receives afferent neural input from glucosensors in the liver, carotid body, and small intestines. In addition to glucose, glucosensing neurons can use other metabolic substrates, hormones, and peptides to regulate their firing rate. Consequently, the output of these "metabolic sensing" neurons represents their integrated response to all of these simultaneous inputs. The efferents of these neurons regulate feeding, neuroendocrine and autonomic function, and thereby energy expenditure and storage. Thus, glucosensing neurons play a critical role in the regulation of energy homeostasis. Defects in the ability to sense glucose and regulatory hormones like leptin and insulin may underlie the predisposition of some individuals to develop diet-induced obesity. C1 Dept Vet Affairs New Jersey Hlth Care Syst, Neurol Serv, E Orange, NJ USA. Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurol & Neurosci, Newark, NJ 07103 USA. Univ Washington, VA Puget Sound Hlth Care Syst, Div Endocrinol & Metab, Seattle, WA 98195 USA. Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Levin, BE (reprint author), VA Med Ctr, Neurol Serv, 127C,385 Tremont Ave, E Orange, NJ 07018 USA. EM levin@umdnj.edu NR 107 TC 21 Z9 21 U1 0 U2 4 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 J9 DIABETES JI Diabetes PD DEC PY 2006 VL 55 SU 2 BP S122 EP S130 DI 10.2337/db06-S016 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 113MM UT WOS:000242602000018 ER PT J AU Ao, Y Go, VLW Toy, N Li, T Wang, Y Song, MK Reeve, JR Liu, YY Yang, H AF Ao, Yan Go, Vay Liang W. Toy, Natalie Li, Tei Wang, Yu Song, Moon K. Reeve, Joseph R., Jr. Liu, Yanyun Yang, Hong TI Brainstem thyrotropin-releasing hormone regulates food intake through vagal-dependent cholinergic stimulation of ghrelin secretion SO ENDOCRINOLOGY LA English DT Article ID GASTRIC-ACID-SECRETION; DORSAL MOTOR NUCLEUS; CAUDAL RAPHE NUCLEI; GENE-EXPRESSION; INTRACISTERNAL TRH; MEDULLARY RAPHE; FOS EXPRESSION; SUBSTANCE-P; RATS; COMPLEX AB The brainstem is essential for mediating energetic response to starvation. Brain stem TRH is synthesized in caudal raphe nuclei innervating brainstem and spinal vagal and sympathetic motor neurons. Intracisternal injection (ic) of a stable TRH analog RX77368 (7.5-25 ng) dose-dependently stimulated solid food intake by 2.4- to 3-fold in freely fed rats, an effect that lasted for 3 h. By contrast, RX77368 at 25 ng injected into the lateral ventricle induced a delayed and insignificant orexigenic effect only in the first hour. In pentobarbital-anesthetized rats, RX77368 (50 ng) ic induced a significant bipeak increase in serum total ghrelin levels from the basal of 8.7 +/- 1.7 ng/ml to 13.4 +/- 2.4 ng/ml at 30 min and 14.5 +/- 2.0 ng/ml at 90 min, which was prevented by either bilateral vagotomy (-60 min) or atropine pretreatment (2 mg/kg, -30 min) but magnified by bilateral adrenalectomy (-60 min). TRH analog ic-induced food intake in freely fed rats was abolished by either peripheral atropine or ghrelin receptor antagonist (D-Lys-3)-GHRP-6 (10 mu mol/kg) or ic Y1 receptor antagonist 122PU91 (10 nmol/5 mu l). Brain stem TRH mRNA and TRH receptor 1 mRNA increased by 57-58 and 33-35% in 24- and 48-h fasted rats and returned to the fed levels after a 3-h refeeding. Natural food intake in overnight fasted rats was significantly reduced by ic TRH antibody, ic Y1 antagonist, and peripheral atropine. These data establish a physiological role of brainstem TRH in vagal-ghrelin-mediated stimulation of food intake, which involves interaction with brainstem Y1 receptors. C1 Vet Affairs Greater Los Angeles Healthcare Syst, CURE, Digest Dis Res Ctr, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Ctr Ulcer Res & Educ, Digest Dis Res Ctr, Los Angeles, CA USA. Univ Calif Los Angeles, Div Digest Dis, Dept Med, Los Angeles, CA USA. Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA USA. RP Yang, H (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, CURE, Digest Dis Res Ctr, Bldg 115,Room 203,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM hoyang@ucla.edu FU NIDDK NIH HHS [DK-41301] NR 51 TC 31 Z9 32 U1 1 U2 2 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0013-7227 J9 ENDOCRINOLOGY JI Endocrinology PD DEC PY 2006 VL 147 IS 12 BP 6004 EP 6010 DI 10.1210/en.2006-0820 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 105QK UT WOS:000242047200056 PM 16959836 ER PT J AU Kuo, T Christensen, R Gelberg, L Rubenstein, L Burke, A AF Kuo, T Christensen, R Gelberg, L Rubenstein, L Burke, A TI Community-research collaboration between researchers and acupuncturists: Integrating a participatory research approach in a statewide survey of licensed acupuncturists in California SO ETHNICITY & DISEASE LA English DT Article DE acupuncture; community participation; mistrust; Oriental Medicine ID UNITED-STATES; COMPLEMENTARY; MEDICINE AB The Licensed Acupuncture Collaborative Study, a job analysis of licensed acupuncturists in California, provides a model for building community-research partnerships between university researchers and communities of non-physician clinicians. The study design used a project-management approach based on the core principles of community-based participatory research: 1) mobilizing shared expertise and resources to address issues of concern; 2) sharing power in the decision-making process; and 3) promoting mutual ownerships of resources and products derived from the collaboration. A project infrastructure involving the sharing of study responsibilities across university researchers, individual acupuncturists, and state community organizations was developed and cultivated over a three-year project period. Essential factors in the success of this project included shared objectives, addressing the concerns about collaboration among academic and community partners, inclusion of nontraditional viewpoints about healthcare policy, and participation by the acupuncturist community in performing the research. These activities helped to overcome mistrust and perceived power differences between researchers and the acupuncturist community. C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Family Med, Los Angeles, CA 90024 USA. Amer Assoc Oriental Med, Los Angeles, CA USA. VA Greater Los Angeles Med Ctr, VAGLAHS Ctr Excellence Study Healthcare Provider, Sepulveda, CA USA. San Francisco State Univ, Dept Hlth Educ, Inst Holist Healing Studies, San Francisco, CA 94132 USA. RP Kuo, T (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Family Med, 10880 Wilshire Blvd,Suite 1800, Los Angeles, CA 90024 USA. EM tkuo@mednet.ucla.edu NR 30 TC 0 Z9 0 U1 1 U2 2 PU INT SOC HYPERTENSION BLACKS-ISHIB PI ATLANTA PA 100 AUBURN AVE NE STE 401, ATLANTA, GA 30303-2527 USA SN 1049-510X J9 ETHNIC DIS JI Ethn. Dis. PD WIN PY 2006 VL 16 IS 1 SU 1 BP 98 EP 106 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 010EW UT WOS:000235170700010 ER PT J AU Chiappelli, F Navarro, AM Moradi, DR Manfrini, E Prolo, P AF Chiappelli, Francesco Navarro, Audrey M. Moradi, David R. Manfrini, Ercolano Prolo, Paolo TI Evidence-based research in complementary and alternative medicine III: Treatment of patients with Alzheimer's disease SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE LA English DT Article DE Alzheimer's disease; evidence-based medicine; systematic review; treatment interventions ID RANDOMIZED CONTROLLED-TRIAL; AMYLOID PRECURSOR PROTEIN; DOUBLE-BLIND; GINKGO-BILOBA; APOLIPOPROTEIN-E; SENILE DEMENTIA; UNITED-STATES; RATING-SCALE; MODERATE; BETA AB This paper presents the novel domain of evidence-based research (EBR) in the treatment of patients with Alzheimer's disease (AD) from the perspective of traditional medicine and of complementary and alternative medicine. In earlier lectures we have described the process of evidence-based medicine as a methodological approach to clinical practice that is directed to aid clinical decision-making. Here, we present a practical example of this approach with respect to traditional pharmacological interventions and to complementary and alternative treatments for patients with AD. C1 Univ Calif Los Angeles, Sch Dent, Div Oral Biol & Med, Los Angeles, CA 90095 USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA USA. Univ Ancona, Neurol Sect Hlth Dist Urbino, Ancona, Italy. RP Chiappelli, F (reprint author), Univ Calif Los Angeles, Sch Dent, Div Oral Biol & Med, CHS 63-090, Los Angeles, CA 90095 USA. EM chiappelli@dent.ucla.edu NR 74 TC 3 Z9 3 U1 0 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1741-427X J9 EVID-BASED COMPL ALT JI Evid.-based Complement Altern. Med. PD DEC PY 2006 VL 3 IS 4 BP 411 EP 424 DI 10.1093/ecam/nel072 PG 14 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA 120GL UT WOS:000243072400003 PM 17173104 ER PT J AU Carpenter, BD Lee, M Ruckdeschel, K Van Haitsma, KS Feldman, PH AF Carpenter, Brian D. Lee, Monica Ruckdeschel, Katy Van Haitsma, Kimberly S. Feldman, Penny H. TI Adult children as informants about parent's psychosocial preferences SO FAMILY RELATIONS LA English DT Article DE adult children; family gerontology; intergenerational relations; psychosocial preferences; long-term care planning ID OLDER-ADULTS; CIRCUMPLEX MODEL; CARE; DEPRESSION; DECISIONS; SCALE AB Utilizing data from 80 adult children-older parent dyads, this study examined the degree to which adult children could predict the psychosocial preferences of their older parents. Overall, children demonstrated good knowledge about parent preferences, although there was wide variability within the sample and across preference domains. Children underestimated how important parents considered continued enrichment and personal growth. Knowledge was associated with parents' functional status and mood. Parent, but not child, perceptions of family flexibility and cohesion were related to children's knowledge. Findings suggest that family life education and intervention programs need to address contextual factors as a means to improve intergenerational knowledge and enhance the likelihood that parent preferences are considered in care planning. C1 Washington Univ, Dept Psychol, St Louis, MO 63130 USA. Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. Madlyn & Leonard Abramson Ctr Jewish Life, Polisher Res Inst, N Wales, PA 19454 USA. Visiting Nurse Serv New York, Ctr Home Care Policy & Res, New York, NY 10021 USA. RP Carpenter, BD (reprint author), Washington Univ, Dept Psychol, Campus Box 1125, St Louis, MO 63130 USA. EM bcarpenter@wustl.edu; mmlee@artsci.wustl.edu; ruckdesc@mail.med.upenn.edu; kvanhaitsma@abramsoncenter.org; Penny.Feldman@vnsny.org NR 35 TC 17 Z9 17 U1 2 U2 3 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0197-6664 J9 FAM RELAT JI Fam. Relat. PD DEC PY 2006 VL 55 IS 5 BP 552 EP 563 DI 10.1111/j.1741-3729.2006.00425.x PG 12 WC Family Studies; Social Work SC Family Studies; Social Work GA 119GC UT WOS:000242999800005 ER PT J AU Mayer, EA Naliboff, BD Craig, ADB AF Mayer, Emeran A. Naliboff, Bruce D. Craig, A. D. Bud TI Neuroimaging of the brain-gut axis: From basic understanding to treatment of functional G1 disorders SO GASTROENTEROLOGY LA English DT Review ID IRRITABLE-BOWEL-SYNDROME; LAMINA-I NEURONS; POSITRON-EMISSION-TOMOGRAPHY; 5-HT3 RECEPTOR ANTAGONIST; ANTERIOR CINGULATE CORTEX; VISCERAL STIMULI; CUTANEOUS PAIN; COGNITIVE MODULATION; CEREBRAL ACTIVATION; GENDER-DIFFERENCES AB We are enthusiastic in the introduction of a new monthly review article series, entitled "Reviews in Basic and Clinical Gastroenterology." Written by authorities in their respective fields, the objective of each review article is to provide an overview of a particular theme or topic for the broad scientific and clinical readership. Within a given topic, both basic and clinical aspects will be covered, accompanied by key figures and relevant references, The reader will also appreciate that topics will be interwoven from month to month as well. We hope you enjoy this section. C1 Univ Calif Los Angeles, Neuroimaging Program, Ctr Neurovisceral Sci & Womens Hlth, VAGLAHS,David Geffen Sch Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, CURE, Digest Dis Res Ctr, David Geffen Sch Med, Los Angeles, CA 90073 USA. Barrow Neurol Inst, Phoenix, AZ 85013 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Mayer, EA (reprint author), Univ Calif Los Angeles, Neuroimaging Program, Ctr Neurovisceral Sci & Womens Hlth, VAGLAHS,David Geffen Sch Med, Bldg 115,Room 223,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM emayer@ucla.edu FU NCCIH NIH HHS [R24 AT002681]; NIDDK NIH HHS [R01 DK48351, P50 DK64539]; NINDS NIH HHS [R01 NS40413]; NINR NIH HHS [R01 NR007768] NR 143 TC 200 Z9 205 U1 4 U2 26 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 EI 1528-0012 J9 GASTROENTEROLOGY JI Gastroenterology PD DEC PY 2006 VL 131 IS 6 BP 1925 EP 1942 DI 10.1053/j.gastro.2006.10.026 PG 18 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 119RP UT WOS:000243031100036 PM 17188960 ER PT J AU Lieberman, D AF Lieberman, David TI Organizing and designing a research study: a 12-step approach SO GASTROINTESTINAL ENDOSCOPY LA English DT Article; Proceedings Paper CT ASGE 2nd Workshop on Achieving Academic Success CY JUL 22-23, 2006 CL Washington, DC SP Amer Soc Gastrointestinal Endoscopy C1 Oregon Hlth Sci Univ, Div Gastroenterol, Portland VA Med Ctr, Portland, OR 97201 USA. RP Lieberman, D (reprint author), Oregon Hlth Sci Univ, Div Gastroenterol, Portland VA Med Ctr, P3-G1, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD DEC PY 2006 VL 64 IS 6 SU S BP S2 EP S3 DI 10.1016/j.gie.2006.10.036 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 117GP UT WOS:000242861400002 PM 17113849 ER PT J AU Vartanian, JG Carvalho, AL Yueh, B Furia, CLB Toyota, J McDowell, JA Weymuller, EA Kowalski, LP AF Vartanian, Jose Guilherme Carvalho, Andre Lopes Yueh, Bevan Furia, Cristina Lemos B. Toyota, Julia McDowell, Jennifer A. Weymuller, Ernest A., Jr. Kowalski, Luiz Paulo TI Brazilian-Portuguese validation of the University of Washington Quality of Life questionnaire for patients with head and neck cancer SO HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK LA English DT Article DE quality of life; head and neck cancer; questionnaires; validity; reliability ID CROSS-CULTURAL ADAPTATION; ORGAN PRESERVATION; HEALTH-STATUS; SCALE; CHEMOTHERAPY; RADIOTHERAPY; LARYNGECTOMY; GUIDELINES; DISABILITY; ANXIETY AB Background. The University of Washington Quality of Life (UW-QOL) questionnaire is an English-language survey instrument used worldwide to assess the quality of life of patients with head and neck cancer. To be used in other cultures, such instruments require careful translation and psychometric validation in other languages. Methods. The translation and cultural adaptation of the questionnaire were performed following accepted international guidelines. The psychometric validation was performed on a consecutive series of patients with at least 1 year of disease-free survival after treatment for squamous cell carcinoma of the upper aerodigestive tract, recruited from October 2004 to January 2005 from a tertiary cancer center hospital. Eligible subjects were invited to complete the Portuguese version of the UW-QOL questionnaire during routine clinical consultation and complete it again within 15 days. They also completed a validated Portuguese version of the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) and a questionnaire to evaluate anxiety and depression symptoms (Hospital Anxiety and Depression Scale [HADS]). Results. A Portuguese version of the questionnaire was developed in iterative fashion. In the psychometric validation process, a total of 109 patients were analyzed. Reliability was excellent, including both internal consistency (Cronleach's alpha [U] of 0.744) and test retest reliability (intraclass correlation coefficient [ICC] of 0.882). Construct validity was supported by statistically significant relationships between the SF-36 and HAD questionnaires and the translated UW-QOL questionnaire. Conclusions. The Brazilian-Portuguese version of the UW-QOL questionnaire appears to be culturally appropriate and psychometrically valid. This version is a valuable tool to evaluate accurately the quality of life of Brazilian patients with head and neck cancer. (c) 2006 Wiley Periodicals, Inc. C1 Ctr Tratamento & Pesquisa Hosp Canc AC Camargo, Dept Otorhinolaryngol Head & Neck Surg, BR-01509900 Sao Paulo, Brazil. Vet Affairs Puget Sound Healthcare Syst, Seattle, WA USA. Univ Washington, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USA. RP Kowalski, LP (reprint author), Ctr Tratamento & Pesquisa Hosp Canc AC Camargo, Dept Otorhinolaryngol Head & Neck Surg, Rua Prof Antonio Prudente,211, BR-01509900 Sao Paulo, Brazil. EM lp_kowalski@uol.com.br RI Francisco, Suely/D-9065-2014; Kowalski, Luiz/D-1701-2012; Carvalho, Andre/C-1185-2011; Vartanian, Jose/B-4470-2015; Carvalho, Andre/S-7053-2016 OI Kowalski, Luiz/0000-0001-5865-9308; Carvalho, Andre/0000-0001-7214-6402; Carvalho, Andre/0000-0001-7214-6402; Yueh, Bevan/0000-0003-1380-1053; Kowalski, Luiz Paulo/0000-0002-0481-156X NR 24 TC 21 Z9 26 U1 0 U2 2 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1043-3074 J9 HEAD NECK-J SCI SPEC JI Head Neck-J. Sci. Spec. Head Neck PD DEC PY 2006 VL 28 IS 12 BP 1115 EP 1121 DI 10.1002/hed.20464 PG 7 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 111LD UT WOS:000242452200009 PM 16823873 ER PT J AU Bruder, ED Raff, H Goodfriend, TL AF Bruder, E. D. Raff, H. Goodfriend, T. L. CA Aurora St Lukes Med Ctr TI An oxidized derivative of linoleic acid stimulates dehydroepiandrosterone production by human adrenal cells SO HORMONE AND METABOLIC RESEARCH LA English DT Article DE adrenal cortex; steroidogenesis; androgens; fatty acids ID POLYCYSTIC-OVARY-SYNDROME; ARACHIDONIC-ACID; ALDOSTERONE SECRETION; ANDROGEN PRODUCTION; FATTY-ACIDS; IN-VITRO; STEROIDOGENESIS; EXCESS; RAT; AXIS AB We previously reported that an oxidized derivative of linoleic acid stimulated steroidogenesis in rat adrenal cells. This derivative was also detected in human plasma, and was positively correlated with visceral adiposity and plasma DHEA-S. The present study sought to characterize the effects of this derivative, 12,13-epoxy-9-keto-(10-trans)-octadecenoic acid (EKODE), on steroid production by normal human adrenocortical cells obtained during clinically-indicated adrenalectomy. Cell suspensions were incubated in the presence of varying concentrations of EKODE and ACTH. EKODE (16 mu M) significantly increased DHEA production by 28% under basal conditions and by 25% in the presence of a low concentration of ACTH (0.2 ng/ml). The effect on DHEA was absent at a higher ACTH concentration (2.0 ng/ml). EKODE decreased cortisol production by 16% (low ACTH) and 25% (high ACTH), but was without effect on cortisol under basal conditions. The results suggest that EKODE affects adrenal DHEA production in the human, possibly by modulating steroidogenic enzyme activity. We postulate that excess visceral fat delivers fatty acids to the liver, where oxidized derivatives are formed that modulate adrenal steroidogenesis. This may be an important phenomenon in the genesis of changes in adrenal function associated with syndromes of obesity, especially those that include androgen excess. C1 Aurora St Lukes Med Ctr, Endocrine Res Lab, Milwaukee, WI 53215 USA. Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA. William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. Univ Wisconsin, Dept Med, Madison, WI 53706 USA. Univ Wisconsin, Dept Pharmacol, Madison, WI 53706 USA. RP Raff, H (reprint author), Aurora St Lukes Med Ctr, Endocrine Res Lab, Phys Off Bldg,2801 W KK River Pky,Suite 245, Milwaukee, WI 53215 USA. EM hraff@mcw.edu FU NHLBI NIH HHS [HL076238] NR 20 TC 6 Z9 6 U1 1 U2 2 PU GEORG THIEME VERLAG KG PI STUTTGART PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY SN 0018-5043 J9 HORM METAB RES JI Horm. Metab. Res. PD DEC PY 2006 VL 38 IS 12 BP 803 EP 806 DI 10.1055/s-2006-956182 PG 4 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 124GR UT WOS:000243356800005 PM 17163354 ER PT J AU Cooper, RA Boninger, ML Spaeth, DM Ding, D Guo, SF Koontz, AM Fitzgerald, SG Cooper, R Kelleher, A Collins, DM AF Cooper, Rory A. Boninger, Michael L. Spaeth, Donald M. Ding, Dan Guo, Songfeng Koontz, Alicia M. Fitzgerald, Shirley G. Cooper, Rosemarie Kelleher, Annmarie Collins, Diane M. TI Engineering better wheelchairs to enhance community participation SO IEEE TRANSACTIONS ON NEURAL SYSTEMS AND REHABILITATION ENGINEERING LA English DT Review DE biomechanics; controls; human-machine interfaces; rehabilitation engineering; wheelchair ID SPINAL-CORD-INJURY; POWER-ASSISTED WHEELCHAIR; BEARING UPPER EXTREMITY; LONG-TERM PARAPLEGIA; LOW-LEVEL PARAPLEGIA; PAIN INDEX WUSPI; MULTIPLE-SCLEROSIS; SHOULDER PAIN; USERS SHOULDER; ELECTROMYOGRAPHIC ANALYSIS AB With about 2.2 million Americans currently using wheeled mobility devices, wheelchairs are frequently provided to people with impaired mobility to provide accessibility to the community. Individuals with spinal cord injuries, arthritis, balance disorders, and other conditions or diseases are typical users of wheelchairs. However, secondary injuries and wheelchair-related accidents are risks introduced by wheelchairs. Research is underway to advance wheelchair design to prevent or accommodate secondary injuries related to propulsion and transfer biomechanics, while improving safe, functional performance and accessibility to the community. This paper summarizes research and development underway aimed at enhancing safety and optimizing wheelchair design. C1 Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA 15206 USA. Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA 15206 USA. Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15206 USA. Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15206 USA. RP Cooper, RA (reprint author), Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA 15206 USA. EM rcooper@pitt.edu OI Boninger, Michael/0000-0001-6966-919X FU PHS HHS [H133E990001, H133N000019] NR 192 TC 35 Z9 35 U1 4 U2 18 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855 USA SN 1534-4320 J9 IEEE T NEUR SYS REH JI IEEE Trans. Neural Syst. Rehabil. Eng. PD DEC PY 2006 VL 14 IS 4 BP 438 EP 455 DI 10.1109/TNSRE.2006.888382 PG 18 WC Engineering, Biomedical; Rehabilitation SC Engineering; Rehabilitation GA 118OJ UT WOS:000242951300005 PM 17190036 ER PT J AU Stratidis, JG Lee, SA AF Stratidis, John G. Lee, Samuel A. TI Ocular candidiasis: Update on diagnosis and management SO INFECTIONS IN MEDICINE LA English DT Article DE Candida albicans; chorioretinitis; endophthalmitis; antifungal therapy ID POLYMERASE-CHAIN-REACTION; ENDOGENOUS FUNGAL ENDOPHTHALMITIS; HOSPITAL-ACQUIRED CANDIDEMIA; ALBICANS ENDOPHTHALMITIS; ATTRIBUTABLE MORTALITY; SPECIES INFECTIONS; UNITED-STATES; EPIDEMIOLOGY; VORICONAZOLE; PENETRATION AB Ocular candidiasis has become an increasingly important complication in patients with candidemia. It presents most commonly as chorioretinitis, but endophthalmitis may also occur. Diagnosis requires a high degree of clinical suspicion, and ocular screening is advocated up to 2 weeks after negative findings on initial ophthalmologic examination. Based on available data, monotherapy with fluconazole is reasonable first-line therapy, with or without vitrectomy, Fluconazole has superior vitreal penetration and less toxicity compared with amphotericin B. Voriconazole has good ocular tissue penetration and may prove useful in treatment of ocular candidiasis requiring a broader spectrum of antifungal activity. Increasing awareness and screening for ocular candidiasis in the clinical setting and comparative data on treatment options are urgently needed to define optimal management. C1 Univ Texas, Hlth Sci Ctr, Dept Med, Div Infect Dis, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 33 TC 0 Z9 0 U1 0 U2 0 PU SCP COMMUNICATIONS INC PI NEW YORK PA 134 W 29TH ST, NEW YORK, NY 10001-5304 USA SN 0749-6524 J9 INFECT MED JI Infect. Med. PD DEC PY 2006 VL 23 IS 12 BP 579 EP + PG 5 WC Infectious Diseases SC Infectious Diseases GA 116DO UT WOS:000242782900007 ER PT J AU Chen, LX Vivino, F AF Chen, Lan X. Vivino, Frederick TI Puzzling crystals in the synovial fluid SO JCR-JOURNAL OF CLINICAL RHEUMATOLOGY LA English DT Editorial Material C1 Penn Presbyterian Med Ctr, Div Rheumatol, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Div Rheumatol, Philadelphia, PA 19104 USA. RP Chen, LX (reprint author), Penn Presbyterian Med Ctr, Div Rheumatol, Philadelphia, PA 19104 USA. EM chenxl@mail.med.upenn.edu NR 0 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-1608 J9 JCR-J CLIN RHEUMATOL JI JCR-J. Clin. Rheumatol. PD DEC PY 2006 VL 12 IS 6 BP 306 EP 306 DI 10.1097/01.rhu.0000252405.68057.eb PG 1 WC Rheumatology SC Rheumatology GA 115SH UT WOS:000242753600012 PM 17149065 ER PT J AU Hsiao, AF Wong, MD Goldstein, MS Becerra, LS Cheng, EM Wenger, NS AF Hsiao, An-Fu Wong, Mitchell D. Goldstein, Michael S. Becerra, Lida S. Cheng, Eric M. Wenger, Neil S. TI Complementary and alternative medicine use among Asian-American subgroups: Prevalence, predictors, and lack of relationship to acculturation and access to conventional health care SO JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE LA English DT Article ID ETHNIC-DIFFERENCES; BREAST-CANCER; UNITED-STATES; SERVICES; THERAPY; CHINESE; WOMEN AB Objectives: Acculturation and access to conventional health care have been found to be predictors of complementary and alternative medicine (CAM) use in the general population. We hypothesized that these factors would be predictors of CAM use in Asian-American subgroups. Because of differences in health and cultural beliefs, we also hypothesized that patterns and predictors of CAM use would vary among Asian-American subgroups. Methods: Cross-sectional survey of a sample of 9187 adults representative of the California population. Results: Nearly three quarters of Asian-Americans used at least one type of CAM in the past 12 months, which was significantly higher than the national prevalence rate. Chinese Americans had the highest prevalence of any CAM use, whereas South Asians had the lowest prevalence (86% vs. 67%, respectively). Acculturation and access to conventional medical care was unrelated to any CAM use for most Asian-American subgroups. Spirituality was the strongest predictor of any CAM use for most Asian-American subgroups. Conclusions: CAM use varies across Asian-American subgroups. Acculturation and access to conventional medical care is unrelated to any CAM use for most Asian-American subgroups. C1 Univ Calif Irvine, Ctr Hlth Policy Res, Irvine, CA 92697 USA. VA Long Beach Healthcare Syst, Long Beach, CA USA. Univ Calif Los Angeles, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Community Hlth Sci, Los Angeles, CA USA. Univ Calif Los Angeles, Ctr Hlth Policy & Res, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Hsiao, AF (reprint author), Univ Calif Irvine, Ctr Hlth Policy Res, 111 Acad,Suite 220, Irvine, CA 92697 USA. EM anfu.hsiao@va.gov OI Wong, Mitchell/0000-0002-4800-8410 FU NCCIH NIH HHS [R21 AT002248-01] NR 31 TC 27 Z9 27 U1 2 U2 7 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1075-5535 J9 J ALTERN COMPLEM MED JI J. Altern. Complement Med. PD DEC PY 2006 VL 12 IS 10 BP 1003 EP 1010 DI 10.1089/acm.2006.12.1003 PG 8 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA 123BK UT WOS:000243271100008 PM 17212572 ER PT J AU Riekse, RG Li, G Petrie, EC Leverenz, JB Vavrek, D Vuletic, S Albers, JJ Montine, TJ Lee, VMY Lee, M Seubert, P Galasko, D Schellenberg, GD Hazzard, WR Peskind, ER AF Riekse, Robert G. Li, Ge Petrie, Eric C. Leverenz, James B. Vavrek, Darcy Vuletic, Simona Albers, John J. Montine, Thomas J. Lee, Virginia M. -Y. Lee, Michael Seubert, Peter Galasko, Douglas Schellenberg, Gerard D. Hazzard, William R. Peskind, Elaine R. TI Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; statins; tau; clinical trial; CSF ID MILD COGNITIVE IMPAIRMENT; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN-E; TAU PHOSPHORYLATION; CHOLESTEROL-METABOLISM; REDUCTASE INHIBITORS; INCIDENT DEMENTIA; EPSILON-4 ALLELE; BETA PROTEIN; MAP KINASE AB Background: Treatment with HMG-CoA reductase inhibitors ("statins") has been variably associated with a reduced risk of Alzheimer's disease (AD) in epidemiologic studies and reduced amyloid-beta (A beta) deposition in animal models of AD. Putative neuroprotective effects of statins may vary in relation to their ability to penetrate into the central nervous system, (CNS). Methods: We measured levels of cerebrospinal fluid (CSF) AD biomarkers following 14 weeks of treatment with simvastatin (a CNS permeant statin; n = 10) at 40 mg/day or pravastatin (a CNS impermeant statin; a = 13) at 80 mg/day in hypercholesterolenlic subjects without dementia. Results: Simvastatin, but not pravastatin, reduced CSF levels of phospho-tau-181 (p-tau(181)) in all subjects. There were no differences in CSF levels of total tau, A beta(42), A beta(40), soluble amyloid 0 protein precuisor (sA beta PP) a or beta, or F-2-isoprostanes. Conclusions: Statins may modulate the phosphorylation of tau in humans and this effect may depend oil the CNS availability of the statin. These results suggest another mechanism by which statins may act to reduce, the risk of AD. C1 VA Puget Sound Hlth Care Syst, Geriatr & Extended Care, Seattle, WA 98108 USA. VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. Washington Univ, Sch Med, Dept Med, Div Geriatr Med, St Louis, MO 63130 USA. Washington Univ, Sch Med, Dept Psychiat & Behav Sci, St Louis, MO 63130 USA. Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63130 USA. Washington Univ, Sch Med, Dept Pathol, Div Neuropathol, St Louis, MO 63130 USA. Washington Univ, Sch Med, NW Lipid Metab & Diabet Res Labs, St Louis, MO 63130 USA. VA Puget Sound Hlth Care Syst, NW Network VISN Mental Illness Res 20, Educ & Clin Ctr, Seattle, WA USA. RP Li, G (reprint author), VA Puget Sound Hlth Care Syst, Geriatr & Extended Care, S-116 MIRECC,1660 S Columbian Way, Seattle, WA 98108 USA. EM gli@u.washington.edu FU NHLBI NIH HHS [HL30086]; NIA NIH HHS [K08 AG023670, K23 AG20020, P50 AG05136] NR 57 TC 55 Z9 58 U1 4 U2 10 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PD DEC PY 2006 VL 10 IS 4 BP 399 EP 406 PG 8 WC Neurosciences SC Neurosciences & Neurology GA 134YP UT WOS:000244120900008 PM 17183151 ER PT J AU Qin, WP Chachich, M Lane, M Roth, G Bryant, M de Cabo, R Ottinger, MA Mattison, J Ingram, D Gandy, S Pasinetti, GM AF Qin, Weiping Chachich, Mark Lane, Mark Roth, George Bryant, Mark de Cabo, Rafael Ottinger, Mary Ann Mattison, Julie Ingram, Donald Gandy, Samuel Pasinetti, Giulio Maria TI Calorie restriction attenuates Alzheimer's disease type brain amyloidosis in Squirrel monkeys (Saimiri sciureus) SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE calorie restriction; Alzheimer's disease; amyloid; Squirrel monkeys ID RHESUS-MONKEYS; FAMILY; LONGEVITY; DEACETYLASES; MECHANISM; INSULIN; SIRT1; RISK AB Recent studies from our laboratories and others suggest that calorie restriction (CR) may benefit Alzheimer's disease (AD) by preventing amyloid-beta (A beta) neuropathology in the mouse models of AD. Moreover, we found that promotion of the NAD+-dependent SIRT1 mediated deacetylase activity, a key regulator in CR extension of life span, may be a mechanism by which CR influences AD-type neuropathology. In this study we continued to explore the role of CR in AD-type brain amyloidosis in Squirrel monkeys (Saimiri sciureus). Monkeys were maintained on the normal and CR diets throughout the entire lifespan until they died of natural causes. We found that 30% CR resulted in reduced contents of A beta(1-40) and beta(1-42) peptides in the temporal cortex of Squirrel monkeys, relative to control (CON) fed monkeys. The decreased contents of cortical A beta peptide inversely correlated with SIRT1 protein concentrations in the same brain region; no detectable change in total full-lengthamyloid-beta protein precursor (AOPP) level was found. Most interestingly, we found that 30% CR resulted in a select elevation of alpha- but not beta- or gamma- secretase activity which coincided with decreased ROCK1 protein content in the same brain region, relative to CON group. Collectively, the study suggests that investigation of the role of CR in non-human primates may provide a valuable approach for further clarifying the role of CR in AD. C1 CUNY Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. CUNY Mt Sinai Sch Med, Dept Neurosci, New York, NY 10029 USA. Bronx Vet Adm Med Ctr, Geriatr Res & Clin Ctr, Bronx, NY 10468 USA. Off Res Serv, Div Vet Resources, Bethesda, MD USA. Thomas Jefferson Univ, Farber Inst Neurosci, Philadelphia, PA 19107 USA. RP Pasinetti, GM (reprint author), CUNY Mt Sinai Sch Med, Dept Psychiat, 1 Gustave L Levy Pl,Box 1668, New York, NY 10029 USA. EM giulio.pasinetti@mssm.edu RI de Cabo, Rafael/E-7996-2010; de Cabo, Rafael/J-5230-2016 OI de Cabo, Rafael/0000-0002-3354-2442; , rafael/0000-0003-2830-5693 FU NCCIH NIH HHS [AT002602]; NIA NIH HHS [AG02219, P01 AG010491, P01 AG010491-14] NR 25 TC 95 Z9 100 U1 1 U2 6 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PD DEC PY 2006 VL 10 IS 4 BP 417 EP 422 PG 6 WC Neurosciences SC Neurosciences & Neurology GA 134YP UT WOS:000244120900011 PM 17183154 ER PT J AU Kitatani, K Idkowiak-Baldys, J Bielawski, J Taha, TA Jenkins, RW Senkal, CE Ogretmen, B Obeid, LM Hannun, YA AF Kitatani, Kazuyuki Idkowiak-Baldys, Jolanta Bielawski, Jacek Taha, Tarek A. Jenkins, Russell W. Senkal, Can E. Ogretmen, Besim Obeid, Lina M. Hannun, Yusuf A. TI Protein kinase C-induced activation of a ceramide/protein phosphatase 1 pathway leading to dephosphorylation of p38 MAPK SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID NOVO SPHINGOLIPID BIOSYNTHESIS; SIGNAL-REGULATED KINASE-1/2; STRESS-INDUCED APOPTOSIS; CELL-PERMEABLE CERAMIDE; NECROSIS-FACTOR-ALPHA; SERINE PALMITOYLTRANSFERASE; SPHINGOMYELIN CYCLE; MITOCHONDRIAL POOL; PROMOTES APOPTOSIS; EPITHELIAL-CELLS AB Recently we showed that, in human breast cancer cells, activation of protein kinase C by 4 beta-phorbol 12-myristate 13-acetate (PMA) produced ceramide formed from the salvage pathway ( Becker, K. P., Kitatani, K., Idkowiak-Baldys, J., Bielawski, J., and Hannun, Y.A. (2005) J. Biol. Chem. 280, 2606-2612). In this study, we investigated intracellular signaling events mediated by this novel activated pathway of ceramide generation. PMA treatment resulted in transient activation of mitogen-activated protein kinases (ERK1/2, JNK1/2, and p38) followed by dephosphorylation/inactivation. Interestingly, fumonisin B1 (FB1), an inhibitor of the salvage pathway, attenuated loss of phosphorylation of p38, suggesting a role for ceramide in p38 dephosphorylation. This was confirmed by knock-down of longevity-assurance homologue 5, which partially suppressed the formation of C16-ceramide induced by PMA and increased the phosphorylation of p38. These results demonstrate a role for the salvage pathway in feedback inhibition of p38. To determine which protein phosphatases act in this pathway, specific knock-down of serine/threonine protein phosphatases was performed, and it was observed that knock-down of protein phosphatase 1 (PP1) catalytic subunits significantly increased p38 phosphorylation, suggesting activation of PP1 results in an inhibitory effect on p38. Moreover, PMA recruited PP1 catalytic subunits to mitochondria, and this was significantly suppressed by FB1. In addition, phospho-p38 resided in PMA-stimulated mitochondria. Upon PMA treatment, a mitochondria-enriched/purified fraction exhibited significant increases in C16-ceramide, a major ceramide specie, which was suppressed by FB1. Taken together, these data suggest that accumulation of C16-ceramide in mitochondria formed from the protein kinase C-dependent salvage pathway results at least in part from the action of longevity-assurance homologue 5, and the generated ceramide modulates the p38 cascade via PP1. C1 Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Div Gen Internal Med, Charleston, SC 29401 USA. RP Hannun, YA (reprint author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave,POB 250509, Charleston, SC 29425 USA. EM hannun@musc.edu OI Kitatani, Kazuyuki/0000-0002-8516-6135; obeid, lina/0000-0002-0734-0847 FU NCI NIH HHS [CA87584, CA88932]; NIA NIH HHS [AG16583]; NIGMS NIH HHS [GM08716] NR 71 TC 42 Z9 42 U1 1 U2 2 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD DEC 1 PY 2006 VL 281 IS 48 BP 36793 EP 36802 DI 10.1074/jbc.M608137200 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 108DP UT WOS:000242220800037 PM 17030510 ER PT J AU Kurihara, N Zhou, H Reddy, SV Palacios, VG Subler, MA Dempster, DW Windle, JJ Roodman, GD AF Kurihara, Noriyoshi Zhou, Hua Reddy, Sakamuri V. Palacios, Veronica Garcia Subler, Mark A. Dempster, David W. Windle, Jolene J. Roodman, G. David TI Experimental models of Paget's disease SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Article; Proceedings Paper CT Conference on Pagets Disease of Bone/Fibrous Dysplasia - Advances and Challenges CY JAN 12-14, 2006 CL Ft Landerdale, FL DE Paget's disease; osteoclast; TAF(II)-17; IL-6; measles virus nucleocapsid ID 1,25-DIHYDROXYVITAMIN D-3; OSTEOCLAST PRECURSORS; BONE; VIRUS; CELLS; EXPRESSION; ETIOLOGY; SEQUENCE; PROTEIN; MICE AB We targeted the MVNP gene to the OCL lineage in transgenic mice. These mice developed abnormal OCLs and bone lesions similar to those found in Paget's patients. These results show that persistent expression of MVNP in OCLs can induce pagetic-like bone lesions in vivo. C1 VA Pittsburgh Healthcare Syst, Dept Med Hematol Oncol, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Dept Med Hematol Oncol, Pittsburgh, PA USA. Helen Hayes Hosp, Reg Bone Ctr, W Haverstraw, NY USA. Childrens Res Inst, Dept Pediat, Charleston, SC USA. Virginia Commonwealth Univ, Richmond, VA USA. Columbia Univ Coll Phys & Surg, New York, NY USA. RP Roodman, GD (reprint author), VA Pittsburgh Healthcare Syst, Dept Med Hematol Oncol, R&D 151-U,Univ Dr, Pittsburgh, PA 15240 USA. EM roodmangd@upmc.edu OI Windle, Jolene/0000-0001-6690-385X FU NCATS NIH HHS [UL1 TR000005]; NCI NIH HHS [P30-CA16059]; NIAMS NIH HHS [P01-AR049363] NR 17 TC 3 Z9 3 U1 0 U2 2 PU AMER SOC BONE & MINERAL RES PI WASHINGTON PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036-3309 USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD DEC PY 2006 VL 21 SU 2 BP P55 EP P57 DI 10.1359/JBMR.06S210 PG 3 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 129ME UT WOS:000243732800011 PM 17229020 ER PT J AU Nguyen, LT Taravella, MJ Pelak, VS AF Nguyen, Ly T. Taravella, Michael J. Pelak, Victoria S. TI Determining whether delayed nonarteritic ischemic optic neuropathy associated with cataract extraction is a true entity SO JOURNAL OF CATARACT AND REFRACTIVE SURGERY LA English DT Article; Proceedings Paper CT Annual Meeting of the American-Society-of-Cataract-and-Refractive-Surgery CY MAR 22, 2006 CL San Francisco, CA SP Amer Soc Cataract & Refract Surg ID SURGERY AB PURPOSE: To evaluate cases of delayed nonarteritic anterior and posterior ischemic optic neuropathy after cataract extraction and to evaluate the need for centralized prospective reporting of nonarteritic ischemic optic neuropathy after cataract extraction. SETTING: Neuro-ophthalmology Clinics, University of Colorado Health Sciences Center and Denver Veterans Affairs Medical Center, Denver, Colorado, USA. METHODS: A retrospective review of all patients referred to the Neuro-ophthalmology Divisions, University of Colorado Health Sciences Center and Denver Veterans Affairs Medical Center, from January 2001 to October 2005 was performed. All patients with a diagnosis of nonarteritic anterior or posterior ischemic optic neuropathy were identified. Patients with ischemic optic neuropathy that occurred between 2 months and 12 months after cataract extraction were selected for evaluation. RESULTS: Six eyes with nonarteritic ischemic optic neuropathy that occurred 2 to 6 months after cataract extraction in 4 patients (2 bilateral nonarteritic ischemic optic neuropathy) and I eye with nonarteritic ischemic optic neuropathy that occurred after 6 months in 1 patient were identified. One patient had nonarteritic ischemic optic neuropathy in 1 eye 3 months after cataract extraction and 4 years later had nonarteritic ischemic optic neuropathy in the fellow eye 5 months after cataract extraction. Follow-up after the last cataract extraction was 1 to 3 years for all patients. CONCLUSIONS: Although an association between cataract extraction and delayed nonarteritic anterior and posterior ischemic optic neuropathy has been suggested, current data do not support a causal relationship. In addition, the window of postoperative susceptibility for delayed ischemic optic neuropathy after cataract extraction is unclear. C1 Univ Colorado, Hlth Sci Ctr, Denver Vet Affairs Med Ctr, Rocky Mt Lions Eye Inst,Dept Neurol, Aurora, CO 80045 USA. Univ Colorado, Hlth Sci Ctr, Denver Vet Affairs Med Ctr, Rocky Mt Lions Eye Inst,Dept Ophthalmol, Aurora, CO 80045 USA. RP Pelak, VS (reprint author), Univ Colorado, Hlth Sci Ctr, Denver Vet Affairs Med Ctr, Rocky Mt Lions Eye Inst,Dept Neurol, POB 6510,Mail Stop F727, Aurora, CO 80045 USA. EM victoria.pelak@uchsc.edu NR 17 TC 7 Z9 8 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0886-3350 J9 J CATARACT REFR SURG JI J. Cataract. Refract. Surg. PD DEC PY 2006 VL 32 IS 12 BP 2105 EP 2109 DI 10.1016/j.jcrs.2006.08.028 PG 5 WC Ophthalmology; Surgery SC Ophthalmology; Surgery GA 116RL UT WOS:000242819900032 PM 17137991 ER PT J AU Poloyac, SM Zhang, YQ Bies, RR Kochanek, PM Graham, SH AF Poloyac, Samuel M. Zhang, Yuqing Bies, Robert R. Kochanek, Patrick M. Graham, Steven H. TI Protective effect of the 20-HETE inhibitor HET0016 on brain damage after temporary focal ischemia SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM LA English DT Article DE arachidonic acid; cytochrome P450; hydroxyeicosatetraenoic acid; middle cerebral artery occlusion; N-hydroxy-N-4-butyl-2-methylphenylformamidine; stroke ID CEREBRAL-BLOOD-FLOW; ENDOTHELIAL GROWTH-FACTOR; 20-HYDROXYEICOSATETRAENOIC ACID; SUBARACHNOID HEMORRHAGE; ARACHIDONIC-ACID; ACTIVATED CHANNELS; GLOBAL-ISCHEMIA; NITRIC-OXIDE; RAT-LIVER; EXPRESSION AB Cytochrome P450 metabolism of arachidonic acid produces the potent vasoconstrictive metabolite, 20-hydroxyeicosatetraenoic acid (20-HETE). Recent studies have implicated 20-HETE as a vasoconstrictive mediator in hemorrhagic stroke. The purpose of this study was to determine the effect of the 20-HETE inhibitor, HET0016, on lesion volume and cerebral blood flow (CBF) after temporary middle cerebral artery occlusion (MCAO) in rats. Plasma pharmacokinetics and tissue concentrations of HET0016 were determined after a 10 mg/kg intraperitoneal dose. Separate rats were treated with HET0016 or vehicle before 90 mins of MCAO. Lesion volume was assessed by 2,3,5-triphenyl-tetrazolium-chloride and cerebral flow was determined using laser Doppler flow. The effect of MCAO on in vitro microsomal formation of mono-oxygenated arachidonic acid metabolites was also determined. Results show that HET0016 has a short biologic half-life, distributes into the brain, and is associated with a 79.6% reduction in 20-HETE concentration in the cortex. Lesion volume was greatly reduced in HET0016-treated (9.1%+/- 4.9%) versus vehicle-treated (57.4%+/- 9.8%; n=6; P < 0.001) rats. An attenuation of the observed decrease in CBF was observed in HET0016-treated (180 mins 89.2%+/- 6.2%; 240 mins 88.1%+/- 5.7% of baseline flow) versus vehicle control (180 mins 57.6%+/- 09.0%; 240 mins 53.8%+/- 20.0% of baseline flow; n=6; P < 0.05). Brain cortical microsomal formation rate of 20-HETE was also reduced at 24 dh in the ipsilateral hemisphere after MCAO. These data support a significant role for 20-HETE in the pathogenesis of ischemic stroke. C1 Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA. Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15261 USA. Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Crit Care Med, Pittsburgh, PA 15261 USA. VA Pittsburgh Healthcare Syst, Geriat Res Educ & Clin Ctr, Pittsburgh, PA USA. RP Poloyac, SM (reprint author), Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, 808A Salk Hall, Pittsburgh, PA 15261 USA. EM poloyac@pitt.edu RI Kochanek, Patrick/D-2371-2015 OI Kochanek, Patrick/0000-0002-2627-913X FU NIBIB NIH HHS [EB001975-06]; NINDS NIH HHS [1R01NS052315-01] NR 45 TC 36 Z9 36 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0271-678X J9 J CEREBR BLOOD F MET JI J. Cereb. Blood Flow Metab. PD DEC PY 2006 VL 26 IS 12 BP 1551 EP 1561 DI 10.1038/sj.jcbfm.9600309 PG 11 WC Endocrinology & Metabolism; Hematology; Neurosciences SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology GA 111HJ UT WOS:000242441700009 PM 16570075 ER PT J AU Utzschneider, KM Kahn, SE AF Utzschneider, Kristina M. Kahn, Steven E. TI Review: The role of insulin resistance in nonalcoholic fatty liver disease SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Review ID TYPE-2 DIABETIC-PATIENTS; ACTIVATED PROTEIN-KINASE; METABOLIC RISK-FACTORS; NECROSIS-FACTOR-ALPHA; C-REACTIVE PROTEIN; ADIPOSE-TISSUE; HEPATIC STEATOSIS; WEIGHT-LOSS; NONDIABETIC PATIENTS; GENE-EXPRESSION AB Context: Insulin resistance is an almost universal finding in nonalcoholic fatty liver disease (NAFLD). This review outlines the evidence linking insulin resistance and NAFLD, explores whether liver fat is a cause or consequence of insulin resistance, and reviews the current evidence for treatment of NAFLD. Evidence Acquisition: Evidence from epidemiological, experimental, and clinical research studies investigating NAFLD and insulin resistance was reviewed. Evidence Synthesis: Insulin resistance in NAFLD is characterized by reductions in whole-body, hepatic, and adipose tissue insulin sensitivity. The mechanisms underlying the accumulation of fat in the liver may include excess dietary fat, increased delivery of free fatty acids to the liver, inadequate fatty acid oxidation, and increased de novo lipogenesis. Insulin resistance may enhance hepatic fat accumulation by increasing free fatty acid delivery and by the effect of hyperinsulinemia to stimulate anabolic processes. The impact of weight loss, metformin, and thiazolidinediones, all treatments aimed at improving insulin sensitivity, as well as other agents such as vitamin E, have been evaluated in patients with NAFLD and have shown some benefit. However, most intervention studies have been small and uncontrolled. Conclusion: Insulin resistance is a major feature of NAFLD that, in some patients, can progress to steatohepatitis. Treatments aimed at reducing insulin resistance have had some success, but larger placebo-controlled studies are needed to fully establish the efficacy of these interventions and possibly others in reducing the deleterious effects of fat accumulation in the liver. C1 Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98108 USA. Univ Washington, Seattle, WA 98108 USA. RP Utzschneider, KM (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, 151,1660 S Columbian Way, Seattle, WA 98108 USA. EM kutzschn@u.washington.edu OI Kahn, Steven/0000-0001-7307-9002 NR 118 TC 300 Z9 320 U1 3 U2 28 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD DEC PY 2006 VL 91 IS 12 BP 4753 EP 4761 DI 10.1210/jc.2006-0587 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 113EN UT WOS:000242581300005 PM 16968800 ER PT J AU Fonseca, VA Kahn, SE AF Fonseca, Vivian A. Kahn, Steven E. TI Commentary: Of hopes and DREAMS: The quest to prevent type 2 diabetes SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Editorial Material ID RANDOMIZED CONTROLLED-TRIAL; IMPAIRED GLUCOSE-TOLERANCE; LIFE-STYLE; MELLITUS; RAMIPRIL C1 Tulane Univ, Hlth Sci Ctr, New Orleans, LA 70112 USA. Univ Washington, Seattle, WA 98108 USA. VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Fonseca, VA (reprint author), Tulane Univ, Med Ctr, Diabet Program, 1430 Tulane Ave,SL 53, New Orleans, LA 70112 USA. EM vfonseca@tulane.edu OI Kahn, Steven/0000-0001-7307-9002 NR 11 TC 1 Z9 1 U1 0 U2 2 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD DEC PY 2006 VL 91 IS 12 BP 4762 EP 4763 DI 10.1210/jc.2006-2164 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 113EN UT WOS:000242581300006 PM 17062761 ER PT J AU Eriksson, AL Lorentzon, M Mellstrom, D Vandenput, L Swanson, C Andersson, N Hammond, GL Jakobsson, J Rane, A Orwoll, ES Ljunggren, O Johnell, O Labrie, F Windahl, SH Ohlsson, C AF Eriksson, A. L. Lorentzon, M. Mellstrom, D. Vandenput, L. Swanson, C. Andersson, N. Hammond, G. L. Jakobsson, J. Rane, A. Orwoll, E. S. Ljunggren, O. Johnell, O. Labrie, F. Windahl, S. H. Ohlsson, C. TI SHBG gene promoter polymorphisms in men are associated with serum sex hormone-binding globulin, androgen and androgen metabolite levels, and hip bone mineral density SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID ELDERLY-MEN; FREE TESTOSTERONE; POSTMENOPAUSAL WOMEN; SWEDISH MEN; STEROIDS; REPEAT; STANDARDIZATION; PREDICTOR; FRACTURES; ESTRADIOL AB Context: SHBG regulates free sex steroid levels, which in turn regulate skeletal homeostasis. Twin studies have demonstrated that genetic factors largely account for interindividual variation in SHBG levels. Glucuronidated androgen metabolites have been proposed as markers of androgenic activity. Objective: Our objective was to investigate whether polymorphisms in the SHBG gene promoter [(TAAAA)(n) microsatellite and rs1799941 single-nucleotide polymorphism] are associated with serum levels of SHBG, sex steroids, or bone mineral density (BMD) in men. Design and Study Subjects: We conducted a population-based study of two cohorts of Swedish men: elderly men (MrOS Sweden; n congruent to 3000; average age, 75.4 yr) and young adult men ( GOOD study; n = 1068; average age, 18.9 yr). Main Outcome Measures: We measured serum levels of SHBG, testosterone, estradiol, dihydrotestosterone, 5 alpha-androstane-3 alpha,17 beta-diol glucuronides, androsterone glucuronide, and BMD determined by dual-energy x-ray absorptiometry. Results: In both cohorts, (TAAAA)(n) and rs1799941 genotypes were associated with serum levels of SHBG (P < 0.001), dihydrotestosterone (P < 0.05), and 5 alpha-androstane-3 alpha,17 beta- diol glucuronides (P < 0.05). In the elderly men, they were also associated with testosterone and BMD at all hip bone sites. The genotype associated with high levels of SHBG was also associated with high BMD. Interestingly, male mice overexpressing human SHBG had increased cortical bone mineral content in the femur, suggesting that elevated SHBG levels may cause increased bone mass. Conclusions: Our findings demonstrate that polymorphisms in the SHBG promoter predict serum levels of SHBG, androgens, and glucuronidated androgen metabolites, and hip BMD in men. C1 Div Endocrinol, Dept Internal Med, S-41345 Gothenburg, Sweden. Univ Gothenburg, Sahlgrenska Acad, Ctr Bone Res, SE-41345 Gothenburg, Sweden. Univ Gothenburg, Dept Internal Med, SE-41345 Gothenburg, Sweden. Univ Gothenburg, Dept Geriatr, SE-41345 Gothenburg, Sweden. Univ British Columbia, Dept Obstet & Gynaecol, Vancouver, BC V5Z 4H4, Canada. Family Res Inst, Vancouver, BC V5Z 4H4, Canada. Karolinska Univ Hosp, Karolinska Inst, Div Clin Pharmacol, SE-14186 Stockholm, Sweden. Oregon Hlth Sci Univ, Bone & Mineral Res Unit, Portland, OR 97201 USA. Portland Vet Affairs Med Ctr, Portland, OR 97207 USA. Uppsala Univ, Dept Med Sci, SE-75185 Uppsala, Sweden. Malmo Gen Hosp, Dept Orthopaed, SE-20502 Malmo, Sweden. Univ Laval Hosp, Res Ctr, Laval, PQ G1V 4G2, Canada. Univ Laval, Laval, PQ G1V 4G2, Canada. RP Ohlsson, C (reprint author), Div Endocrinol, Dept Internal Med, Grona Straket 8, S-41345 Gothenburg, Sweden. EM claes.ohlsson@medic.gu.se RI Perez , Claudio Alejandro/F-8310-2010; Schulze, Jenny/J-2909-2012 OI Perez , Claudio Alejandro/0000-0001-9688-184X; Orwoll, Eric/0000-0002-8520-7355; Vandenput, Liesbeth/0000-0002-1712-6131 NR 32 TC 54 Z9 55 U1 0 U2 4 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD DEC PY 2006 VL 91 IS 12 BP 5029 EP 5037 DI 10.1210/jc.2006-0679 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 113EN UT WOS:000242581300050 PM 16926255 ER PT J AU Ghannoum, MA Arthington-Skaggs, B Chaturvedi, V Espinel-Ingroff, A Pfaller, MA Rennie, R Rinaldi, MG Walsh, TJ AF Ghannoum, M. A. Arthington-Skaggs, B. Chaturvedi, V. Espinel-Ingroff, A. Pfaller, M. A. Rennie, R. Rinaldi, M. G. Walsh, T. J. TI Interlaboratory study of quality control isolates for a broth microdilution method (modified CLSI M38-A) for testing susceptibilities of dermatophytes to antifungals SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article AB The Clinical and Laboratory Standards Institute (CLSI; formerly National Committee for Clinical Laboratory Standards, or NCCLS) M38-A standard for the susceptibility testing of filamentous fungi does not specifically address the testing of dermatophytes. In 2003, a multicenter study investigated the reproducibility of the microdilution method developed at the Center for Medical Mycology, Cleveland, Ohio, for testing the susceptibility of dermatophytes. Data from that study supported the introduction of this method for testing dermatophytes in the future version of the CLSI M38-A standard. In order for the method to be accepted by CLSI, appropriate quality control isolates needed to be identified. To that end, an interlaboratory study, involving the original six laboratories plus two additional sites, was conducted to evaluate potential candidates for quality control isolates. These candidate strains included five Trichophyton rubrum strains known to have elevated MICs to terbinafine and five Trichophyton mentagrophytes strains. Antifungal agents tested included ciclopirox, fluconazole, griseofulvin, itraconazole, posaconazole, terbinafine, and voriconazole. Based on the data generated, two quality control isolates, one T. rubrum isolate and one T. mentagrophytes isolate, were identified and submitted to the American Type Culture Collection (ATCC) for inclusion as reference strains. Ranges encompassing 95.2 to 97.9% of all data points for all seven drugs were established. C1 Case Western Reserve Univ Hosp, Ctr Med Mycol, EMBA, Cleveland, OH 44106 USA. Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA USA. Dept Hlth, Albany, NY USA. VCU Med Ctr, Richmond, VA USA. Univ Iowa, Coll Med, Dept Pathol, Iowa City, IA 52242 USA. Univ Alberta Hosp, Natl Ctr Mycol, Edmonton, AB T6G 2B7, Canada. Univ Texas, Hlth Sci Ctr, Audie L Murphy Mem Vet Hosp, Lab Serv, San Antonio, TX USA. NCI, Pediat Oncol Branch, Bethesda, MD 20892 USA. RP Ghannoum, MA (reprint author), Case Western Reserve Univ Hosp, Ctr Med Mycol, EMBA, 11100 Euclid Ave, Cleveland, OH 44106 USA. EM mag3@case.edu NR 6 TC 22 Z9 23 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD DEC PY 2006 VL 44 IS 12 BP 4353 EP 4356 DI 10.1128/JCM.00688-06 PG 4 WC Microbiology SC Microbiology GA 117MC UT WOS:000242876300009 PM 17050812 ER PT J AU Garcia, LS Garcia, JP AF Garcia, Lynne S. Garcia, John Paul TI Detection of Giardia lamblia antigens in human fecal specimens by a solid-phase qualitative immunochromatographic assay SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID CRYPTOSPORIDIUM-PARVUM ANTIGENS; LINKED-IMMUNOSORBENT-ASSAY; ENZYME-IMMUNOASSAY; DIRECT FLUORESCENCE; MICROPLATE ASSAY; STOOL SPECIMENS AB The SIMPLE-READ Giardia rapid assay (Medical Chemical Corporation) is a solid-phase qualitative immunochromatographic assay that detects Giardia lamblia in aqueous extracts of human fecal specimens. Testing 106 Giardia-positive and 104 Giardia-negative stool specimens yielded a sensitivity of 97.2% and a speciticity of 100% for the SIMPLE-READ Giardia rapid assay. C1 LSG & Associates, Santa Monica, CA 90402 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Garcia, LS (reprint author), LSG & Associates, 512 12th St, Santa Monica, CA 90402 USA. EM Lynnegarcia12@earthlink.net NR 15 TC 9 Z9 12 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD DEC PY 2006 VL 44 IS 12 BP 4587 EP 4588 DI 10.1128/JCM.01458-06 PG 2 WC Microbiology SC Microbiology GA 117MC UT WOS:000242876300050 PM 17065273 ER PT J AU Karayiannis, NB Xiong, YH Frost, JD Wise, MS Hrachovy, RA Mizrahi, EM AF Karayiannis, Nicolaos B. Xiong, Yaohua Frost, James D., Jr. Wise, Merrill S. Hrachovy, Richard A. Mizrahi, Eli M. TI Automated detection of videotaped neonatal seizures based on motion tracking methods SO JOURNAL OF CLINICAL NEUROPHYSIOLOGY LA English DT Article DE motion tracking; motion trajectory signal; motor activity signal; neonatal seizure; neural network; seizure detection; video recording ID MOTOR-ACTIVITY SIGNALS; QUANTUM NEURAL-NETWORKS; QUANTIFYING MOTION; RECORDINGS; EEG; EXTRACTION; NEWBORN AB This study was carried out during the second phase of the project "Video Technologies for Neonatal Seizures" and aimed at the development of a seizure detection system by training neural networks, using quantitative motion information extracted by motion tracking methods from short video segments of infants monitored for seizures. The motion of the infants' body parts was quantified by temporal motion trajectory signals extracted from video recordings by robust motion trackers, based on block motion models. These motion trackers were developed to autonomously adjust to illumination and contrast changes that may occur during the video frame sequence. The computational tools and procedures developed for automated seizure detection were evaluated on short video segments selected and labeled by physicians from a set of 240 video recordings of 54 patients exhibiting myoclonic seizures (80 segments), focal clonic seizures (80 segments), and random infant movements (80 segments). This evaluation provided the basis for selecting the most effective strategy for training neural networks to detect neonatal seizures as well as the decision scheme used for interpreting the responses of the trained neural networks. The best neural networks exhibited sensitivity and specificity above 90%. The best among the motion trackers developed in this study produced quantitative features that constitute a reliable basis for detecting myoclonic and focal clonic neonatal seizures. The performance targets of the second phase of the project may be achieved by combining the quantitative features described in this paper with those obtained by analyzing motion strength signals produced by motion segmentation methods. C1 Baylor Coll Med, Peter Kellaway Sect Neurophysiol, Dept Neurol, Houston, TX 77030 USA. Baylor Coll Med, Peter Kellaway Sect Neurophysiol, Dept Pediat, Houston, TX 77030 USA. Univ Houston, Dept Elect & Comp Engn, Houston, TX USA. Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. RP Frost, JD (reprint author), Baylor Coll Med, Peter Kellaway Sect Neurophysiol, Dept Neurol, NB302,1 Baylor Plaza, Houston, TX 77030 USA. FU NIBIB NIH HHS [1 R01 EB00183]; NINDS NIH HHS [N01-NS-2316] NR 32 TC 8 Z9 8 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0736-0258 J9 J CLIN NEUROPHYSIOL JI J. Clin. Neurophysiol. PD DEC PY 2006 VL 23 IS 6 BP 521 EP 531 DI 10.1097/00004691-200612000-00004 PG 11 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 115UD UT WOS:000242758400004 PM 17143140 ER PT J AU Pettinati, HM O'Brien, CP Rabinowitz, AR Wortman, SM Oslin, DW Kampman, KM Dackis, CA AF Pettinati, Helen M. O'Brien, Charles P. Rabinowitz, Amanda R. Wortman, Shoshana M. Oslin, David W. Kampman, Kyle M. Dackis, Charles A. TI The status of naltrexone in the treatment of alcohol dependence - Specific effects on heavy drinking SO JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY LA English DT Review ID PLACEBO-CONTROLLED TRIAL; RANDOMIZED CONTROLLED-TRIAL; COGNITIVE-BEHAVIORAL THERAPY; DOUBLE-BLIND; RELAPSE PREVENTION; OPIOID DEPENDENCE; PROBLEM DRINKERS; ORAL NALMEFENE; CLINICAL-TRIAL; LOW-RISK AB Background: In almost 2 decades of naltrexone research for treating alcoholism, there have been 29 published randomized placebo-controlled trials of opioid antagonists, primarily naltrexone, for the treatment of alcohol dependence. The present review builds on prior systematic reviews while maximizing the number of included studies to date, for the purpose of resolving inconsistencies in naltrexone's reported efficacy across trials. Clinical trial results in this article are evaluated by the type of outcome measure used to determine naltrexone's treatment advantage, that is, measures related to reducing heavy drinking versus those related to increasing abstinence. Methods: We conducted a Medline search to identify double-blind studies from 1990 to the present (2006) that evaluated the use of an opiate antagonist for the treatment of alcohol dependence. There were 29 studies identified, representing 5997 alcohol-dependent patients, which met our study inclusion criteria for this review. Studies were evaluated in this review on 4 prespecified drinking outcomes-2 related to "any drinking" and 2 related to "heavy or excessive drinking." Results: In the treatment of alcohol dependence, we found that 19 (70%) of 27 clinical trials that measured reductions in "heavy or excessive drinking" demonstrated an advantage for prescribing naltrexone over placebo, whereas only 9 (36%) of 25 clinical trials that measured abstinence or "any drinking" found an advantage for medication over placebo. Conclusion: The majority of double-blind clinical trials in the literature favored prescribing naltrexone for alcohol dependence to reduce heavy drinking. This finding is consistent with our understanding of naltrexone's mechanism of action of decreasing excessive drinking by reducing the reward associated with drinking alcohol. Thus, we conclude that outcome measures related to heavy or excessive drinking are most relevant to defining naltrexone's therapeutic effects. Factors influencing naltrexone response (treatment adherence and distinct patient subgroups) are also discussed. C1 Univ Penn, Dept Psychiat, Treatment Res Ctr, Sch Med,Ctr Study Addict, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Pettinati, HM (reprint author), Univ Penn, Dept Psychiat, Treatment Res Ctr, Sch Med,Ctr Study Addict, 3900 Chestnut St, Philadelphia, PA 19104 USA. EM Pettinati_H@mail.trc.upenn.edu FU NIAAA NIH HHS [R01-AA014851, R01-AA09544]; NIDA NIH HHS [P50 DA12756]; NIMH NIH HHS [K08-MH01599-01A1] NR 103 TC 101 Z9 102 U1 3 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0271-0749 J9 J CLIN PSYCHOPHARM JI J. Clin. Psychopharmacol. PD DEC PY 2006 VL 26 IS 6 BP 610 EP 625 DI 10.1097/01.jcp.0000245566.52401.20 PG 16 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA 108RI UT WOS:000242256500010 PM 17110818 ER PT J AU Sinha, S Goldstein, M Penrod, J Hochman, T Kamran, M Tenner, C Cohen, G Schwartz, MD AF Sinha, Sanjai Goldstein, Matthew Penrod, Joan Hochman, Tsivia Kamran, Mohammad Tenner, Craig Cohen, Gabriela Schwartz, Mark D. TI beta-blocker use among veterans with systolic heart failure SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article; Proceedings Paper CT 29th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 29, 2006 CL Los Angeles, CA SP Soc Gen Internal Med DE heart failure; beta-blockers; utilization; prescription rates; guideline adherence ID MORTALITY; OUTCOMES; DISEASE; TRIAL; CARDIOLOGISTS; TOLERABILITY; CARVEDILOL; EXPERIENCE; MANAGEMENT; MORBIDITY AB beta-Blockers reduce mortality in patients with systolic chronic heart failure (CHF), yet prescription rates have remained low among primary care providers. To determine the beta-blocker prescription rate among patients with systolic CHF at primary care Veterans Affairs (VA) clinics, its change over time; and to determine factors associated with nonprescription. Retrospective chart review. Seven hundred and forty-five patients with diagnostic codes for CHF followed in primary care clinics at 3 urban VA Medical Centers. Rate of beta-blocker prescription and comparison of patient characteristics between those prescribed versus those not prescribed beta-blockers. Only 368 (49%) had documented systolic CHF. Eighty-two percent (303/368) of these patients were prescribed a beta-blocker. The prescription rate rose steadily over 3 consecutive 2-year time periods. Patients with more severely depressed ejection fractions were more likely to be on a beta-blocker than patients with less severe disease. Independent predictors of nonprescription included chronic obstructive pulmonary disease, asthma, depression, and age. Patients under 65 years old were 12 times more likely to receive beta-blockers than those over 85. Primary care providers at VA Medical Centers achieved high rates of beta-blocker prescription for CHF patients. Subgroups with relative contraindications had lower prescription rates and should be targeted for quality improvement initiatives. C1 Bronx Vet Adm Med Ctr, Dept Med, Bronx, NY USA. Mt Sinai Sch Med, Dept Med, New York, NY USA. Bronx Vet Adm Med Ctr, Bronx, NY USA. VA New York Harbor Healthcare Syst, Dept Med, New York, NY USA. NYU, Sch Med, New York, NY USA. RP Sinha, S (reprint author), 1st Floor,Suite D,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM sanjai.sinha@med.va.gov NR 21 TC 10 Z9 12 U1 1 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD DEC PY 2006 VL 21 IS 12 BP 1306 EP 1309 DI 10.1111/j.1525-1497.2006.00601.x PG 4 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 100NI UT WOS:000241675400019 PM 17105526 ER PT J AU Cha, SS Ross, JS Lurie, P Sacajiu, G AF Cha, Stephen S. Ross, Joseph S. Lurie, Peter Sacajiu, Galit TI Description of a research-based health activism curriculum for medical students SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article; Proceedings Paper CT 27th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 12-15, 2004 CL Chicago, IL SP Soc Gen Internal Med DE medical education; professionalism; health care reform; curriculum evaluation ID MANAGED CARE; PROFESSIONALISM; EDUCATION; ETHICS; SYSTEM AB Few curricula train medical students to engage in health system reform. To develop physician activists by teaching medical students the skills necessary to advocate for socially equitable health policies in the U.S. health system. Montefiore Medical Center, the University Hospital of the Albert Einstein College of Medicine, Bronx, NY. We designed a 1-month curriculum in research-based health activism to develop physician activists. The annual curriculum includes a student project and 4 course sections; health policy, research methods, advocacy, and physician activists as role models; taught by core faculty and volunteers from academic institutions, government, and nongovernmental organizations. From 2002 to 2005, 47 students from across the country have participated. Students reported improved capabilities to generate a research question, design a research proposal, and create an advocacy plan. Our curriculum demonstrates a model for training physician activists to engage in health systems reform. C1 VA Connecticut Healthcare Syst, West Haven, CT USA. Yale Univ, Dept Internal Med, New Haven, CT 06520 USA. CUNY Mt Sinai Sch Med, Brookdale Dept Geriat & Adult Dev, New York, NY 10029 USA. James J Peters Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. Publ Citizens Hlth Res Grp, Washington, DC USA. Montefiore Med Ctr, Dept Internal Med, Bronx, NY 10467 USA. RP Cha, SS (reprint author), US House Representatives, Comm Govt Reform, 511 Ford House Off Bldg, Washington, DC 20515 USA. EM stephen.cha@yale.edu NR 19 TC 11 Z9 11 U1 0 U2 5 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD DEC PY 2006 VL 21 IS 12 BP 1325 EP 1328 DI 10.1111/j.1525-1497.2006.00608.x PG 4 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 100NI UT WOS:000241675400023 PM 16961754 ER PT J AU Cotton, S Tsevat, J Szaflarski, M Kudel, I Sherman, SN Feinberg, J Leonard, AC Holmes, WC AF Cotton, Sian Tsevat, Joel Szaflarski, Magdalena Kudel, Ian Sherman, Susan N. Feinberg, Judith Leonard, Anthony C. Holmes, William C. TI Changes in religiousness and spirituality attributed to HIV/AIDS - Are there sex and race differences? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE HIV/AIDS; religion; spirituality; coping; chronic illness ID QUALITY-OF-LIFE; HIV; END; CARE; CANCER; HEALTH AB Having a serious illness such as HIV/AIDS raises existential issues, which are potentially manifested as changes in religiousness and spirituality. The objective of this study was (1) to describe changes in religiousness and spirituality of people with HIV/AIDS, and (2) to determine if these changes differed by sex and race. Three-hundred and forty-seven adults with HIV/AIDS from 4 sites were asked demographic, clinical, and religious/spiritual questions. Six religious/spiritual questions assessed personal and social domains of religiousness and spirituality. Eighty-eight participants (25%) reported being "more religious" and 142 (41%) reported being "more spiritual" since being diagnosed with HIV/AIDS. Approximately 1 in 4 participants also reported that they felt more alienated by a religious group since their HIV/AIDS diagnosis and approximately 1 in 10 reported changing their place of religious worship because of HIV/AIDS. A total of 174 participants (50%) believed that their religiousness/spirituality helped them live longer. Fewer Caucasians than African Americans reported becoming more spiritual since their HIV/AIDS diagnosis (37% vs 52%, respectively; P <.015), more Caucasians than African Americans felt alienated from religious communities (44% vs 21%, respectively; P <.001), and fewer Caucasians than African Americans believed that their religiousness/spirituality helped them live longer (41% vs 68% respectively; P <.001). There were no significantly different reported changes in religious and spiritual experiences by sex. Many participants report having become more spiritual or religious since contracting HIV/AIDS, though many have felt alienated by a religious group-some to the point of changing their place of worship. Clinicians conducting spiritual assessments should be aware that changes in religious and spiritual experiences attributed to HIV/AIDS might differ between Caucasian and African Americans. C1 Univ Cincinnati, Med Ctr, Inst Study Hlth, Cincinnati, OH 45267 USA. Univ Cincinnati, Med Ctr, Dept Family Med, Cincinnati, OH 45267 USA. Univ Penn, Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA. Univ Cincinnati, Med Ctr, Dept Internal Med, Div Gen Internal Med, Cincinnati, OH 45221 USA. Univ Cincinnati, Med Ctr, Inst Study Hlth, Cincinnati, OH 45221 USA. Vet Adm Med Ctr, Hlth Serv Res & Dev, Cincinnati, OH 45220 USA. RP Cotton, S (reprint author), Univ Cincinnati, Med Ctr, Dept Family Med, POB 670840, Cincinnati, OH 45267 USA. FU NCCIH NIH HHS [R01 AT01147, R01 AT001147, K24 AT001676]; NIAID NIH HHS [U01 AI 25897] NR 23 TC 27 Z9 27 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD DEC PY 2006 VL 21 SU 5 BP S14 EP S20 DI 10.1111/j.1525-1497.2006.00641.x PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 100TY UT WOS:000241693100004 PM 17083495 ER PT J AU Tsuang, D Simpson, K Larson, EB Peskind, E Kukull, W Bowen, JB McCormick, W Teri, L Montine, T Thompson, ML Leverenz, JB AF Tsuang, Debby Simpson, Kate Larson, Eric B. Peskind, Elaine Kukull, Walter Bowen, James B. McCormick, Wayne Teri, Linda Montine, Thomas Thompson, Mary Lou Leverenz, James B. TI Predicting Lewy body pathology in a community-based sample with clinical diagnosis of Alzheimer's disease SO JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY LA English DT Article; Proceedings Paper CT 130th Annual Meeting of the American-Neurological-Association CY SEP 25-28, 2005 CL San Diego, CA SP Amer Neurol Assoc, AstraZeneca DE clinical-neuropathological; dementia; Alzheimer's disease; Lewy bodies; prediction ID INTERNATIONAL WORKSHOP; CASE SERIES; DEMENTIA; BODIES; CRITERIA; SENSITIVITY; VALIDATION; CONSORTIUM; ACCURACY; VALIDITY AB Accurate antemortem prediction of Lewy body pathology in patients with dementia is problematic. This study generates a model that better predicts Lewy body pathology in community-based patients with clinical Alzheimer's disease. Lewy body pathology was detected in 80 of 152 participants (52.6%) with an initial diagnosis of probable Alzheimer's disease. In a stepwise logistic regression model, female gender, lower education, being married, bradykinesia, hallucinations, and absence of irritability predicted the greatest likelihood of Lewy body pathology. The predictive model correctly diagnosed Lewy body pathology with an estimated sensitivity of 75%, specificity of 68%, and accuracy of 72%; the area under the receiver operating characteristic curve was 0.75. In a community-based autopsy sample, this predictive model confirmed parkinsonism and hallucinations as important predictors of Lewy body pathology in patients with clinical Alzheimer's disease. The model also identified other demographic and clinical characteristics that might enhance the prediction of Lewy body pathology. C1 Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. Univ Washington, Dept Neurol, Seattle, WA 98195 USA. Univ Washington, Dept Internal Med, Seattle, WA 98195 USA. Univ Washington, Dept Pathol, Seattle, WA 98195 USA. Univ Washington, Dept Biostat, Seattle, WA 98195 USA. Univ Washington, Sch Nursing, Seattle, WA 98195 USA. Mental Illness Res Educ & Clin Ctr, Seattle, WA USA. VA Puget Sound Hlth Care Syst, Parkinsons Dis Res Educ & Clin Ctr, Seattle, WA USA. Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA. RP Tsuang, D (reprint author), VAPSHCS 116,1660 S Columbian Way, Seattle, WA 98108 USA. EM dwt1@u.washington.edu RI Tsuang, Debby/L-7234-2016 OI Tsuang, Debby/0000-0002-4716-1894; Kukull, Walter/0000-0001-8761-9014 FU NIA NIH HHS [AG06781, AG05136, R01-AG10845, U01AG06781] NR 35 TC 10 Z9 10 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0891-9887 J9 J GERIATR PSYCH NEUR JI J. Geriatr. Psychiatry Neurol. PD DEC PY 2006 VL 19 IS 4 BP 195 EP 201 DI 10.1177/0891988706292755 PG 7 WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry GA 107FO UT WOS:000242156300001 PM 17085757 ER PT J AU Hayashi, T Sato, KK Izumotani, KS Nishizawa, Y Okamoto, T Fujimoto, WY Boyko, EJ AF Hayashi, Tomoshige Sato, Kyoko K. Izumotani, Kyoko S. Nishizawa, Yoshiki Okamoto, Teruo Fujimoto, Wilfred Y. Boyko, Edward J. TI Optimal waist circumference cut points and the metabolic syndrome in Japanese SO JOURNAL OF HYPERTENSION LA English DT Meeting Abstract CT 21sth Scientific Meeting of the International-Society-of-Hypertension/5th Asian-Pacific Congress of Hypertension/29th Annual Scientific Meeting of the Japanese-Society-of-Hypertension CY OCT 15-19, 2006 CL Fukuoka, JAPAN SP Int Soc Hypertens, Japanese Soc Hypertens C1 Osaka City Univ, Grad Sch Med, Dept Prevent Med & Environm Hlth, Osaka 558, Japan. Osaka City Univ, Grad Sch Med, Osaka 558, Japan. Washington Univ, Dept Med, Seattle, WA USA. Epidemiol Res & Informat CTr, Vet Affairs Puget Sound Hlth care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0263-6352 J9 J HYPERTENS JI J. Hypertens. PD DEC PY 2006 VL 24 SU 6 BP 150 EP 150 PG 1 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 116AD UT WOS:000242774001040 ER PT J AU Tuck, ML Abedi, K Smutko, V Nyby, MD AF Tuck, Michael L. Abedi, Karolin Smutko, Victoria Nyby, Michael D. TI Rosiglitazone reduces hypertension in fructose-fed rats by increasing nitric oxide bioavailability SO JOURNAL OF HYPERTENSION LA English DT Meeting Abstract CT 21sth Scientific Meeting of the International-Society-of-Hypertension/5th Asian-Pacific Congress of Hypertension/29th Annual Scientific Meeting of the Japanese-Society-of-Hypertension CY OCT 15-19, 2006 CL Fukuoka, JAPAN SP Int Soc Hypertens, Japanese Soc Hypertens C1 Univ Calif Los Angeles, Va Greater Los Angeles Health Syst, Los Angeles, CA 90024 USA. EM mnyby@ucla.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0263-6352 J9 J HYPERTENS JI J. Hypertens. PD DEC PY 2006 VL 24 SU 6 BP 161 EP 161 PG 1 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 116AD UT WOS:000242774001083 ER PT J AU Tuck, ML Nyby, MD Douglas, K Abedi, K Makino, H AF Tuck, Michael L. Nyby, Michael D. Douglas, Kyle Abedi, Karolin Makino, Hirofumi TI Telmisartan and insulin affect angiotensin II type 1 and type 2 receptor expression in vascular smooth muscle and vascular endothelial cells SO JOURNAL OF HYPERTENSION LA English DT Meeting Abstract CT 21sth Scientific Meeting of the International-Society-of-Hypertension/5th Asian-Pacific Congress of Hypertension/29th Annual Scientific Meeting of the Japanese-Society-of-Hypertension CY OCT 15-19, 2006 CL Fukuoka, JAPAN SP Int Soc Hypertens, Japanese Soc Hypertens C1 Univ Calif Los Angeles, VA Greater Los Angeles Healthcare System, Los Angeles, CA 90024 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. EM mnyby@ucla.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0263-6352 J9 J HYPERTENS JI J. Hypertens. PD DEC PY 2006 VL 24 SU 6 BP 301 EP 301 PG 1 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 116AD UT WOS:000242774002090 ER PT J AU Rosendorff, C Atlas, SA Almendral, JL AF Rosendorff, Clive Atlas, Steven A. Almendral, Jesus L. TI Angiotensin receptor blockade and cardiovascular hypertrophy, results from the echocardiographic study of the effect on cardiovascular hypertrophy of olmesartan (the ECHO study) SO JOURNAL OF HYPERTENSION LA English DT Meeting Abstract CT 21sth Scientific Meeting of the International-Society-of-Hypertension/5th Asian-Pacific Congress of Hypertension/29th Annual Scientific Meeting of the Japanese-Society-of-Hypertension CY OCT 15-19, 2006 CL Fukuoka, JAPAN SP Int Soc Hypertens, Japanese Soc Hypertens C1 Mt Sinai Sch Med, James J Peters VA Med Ctr, New York, NY USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0263-6352 J9 J HYPERTENS JI J. Hypertens. PD DEC PY 2006 VL 24 SU 6 BP 373 EP 373 PG 1 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 116AD UT WOS:000242774002392 ER PT J AU Singh, I Pannu, R Singh, AK AF Singh, I. Pannu, R. Singh, A. K. TI Role of lactosylceramide in regulation of inflammatory response and astrogliosis: Implications for neuroinflammatory diseases SO JOURNAL OF NEUROCHEMISTRY LA English DT Meeting Abstract CT 2nd ISN Special Neurochemistry Conference CY DEC 01-05, 2006 CL ANTIGUA & BARBU SP ISN C1 Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Dept Pathol & Lab Med, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PD DEC PY 2006 VL 99 SU 1 MA 81 BP 27 EP 28 PG 2 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 121ZA UT WOS:000243194300083 ER PT J AU Takahashi, M Uchikado, H Caprotti, D Weidenheim, KM Dickson, DW Ksiezak-Reding, H Pasinetti, GM AF Takahashi, Makio Uchikado, Hirotake Caprotti, Domenico Weidenheim, Karen M. Dickson, Dennis W. Ksiezak-Reding, Hanna Pasinetti, Giulio M. TI Identification of G-protein coupled receptor kinase 2 in paired helical filaments and neurofibrillary tangles SO JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY LA English DT Article DE Alzheimer disease; corticobasal degeneration; Lewy body disease; Pick disease; progressive supranuclear palsy; tau ID PROGRESSIVE SUPRANUCLEAR PALSY; ALZHEIMERS-DISEASE PATHOLOGY; SPORADIC PARKINSONS-DISEASE; ALPHA-SYNUCLEIN; LEWY BODIES; PICKS-DISEASE; BETA(2)-ADRENERGIC RECEPTOR; NEURODEGENERATIVE DISEASES; PHOSPHORYLATION SITES; TAU FILAMENTS AB G-protein coupled receptor kinases (GRKs) constitute a serine/ threonine kinase family playing a major role in agonist-induced phosphorylation and desensitization of G-protein coupled receptors. Recently, GRK2 and GRX5 have been demonstrated to phosphorylate alpha-synuclein (Ser129) and other synuclein isoforms. We studied colocalization of GRK2, GRK5, alpha-synuclein, and tau in neurodegenerative disorders characterized by fibrillary tau inclusions and/or alpha-synuclein-enriched Lewy bodies. We found that Lewy bodies were negative for both GRK2 and GRK5 in Lewy body disease (LBD) and LBD mixed with Alzheimer disease (AD + LBD). Instead, GRK2 but not GRK5 colocalized with 40% to 50% of neurofibrillary tangles in AD + LBD and AD brains. In disorders with less prominent alpha-synucleinopathy, neuronal and glial fibrillary tau deposits known to contain distinct subsets of tau isoforms were also positive for GRK2. These deposits included tufted astrocytes and coiled bodies in progressive supranuclear palsy, astrocytic plaques in corticobasal degeneration, and Pick bodies in Pick disease. In addition, paired helical filaments isolated from AD and AD + LBD brains were found to immunogold-label for GRK2, suggesting that GRK2 could be a potential tau kinase associated with fibrillary tau. Our studies indicate that GRK2 is a novel component of neuronal and glial fibrillary tau deposits with no preference in tau isoform binding. GRK2 may play a role in hyperphosphory lation of tau in tauopathies. C1 James J Peters VA Med Ctr, Dept Psychiat, Neuroinflammat Res Labs, Bronx, NY 10468 USA. Mt Sinai Sch Med, Dept Psychiat, Neuroinflammat Res Labs, Bronx, NY USA. Mayo Clin, Dept Neuropathol & Neurosci, Jacksonville, FL 32224 USA. Montefiore Med Ctr, Dept Pathol, Bronx, NY 10467 USA. RP Ksiezak-Reding, H (reprint author), James J Peters VA Med Ctr, Dept Psychiat, Neuroinflammat Res Labs, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM hanna.reding@mssm.edu OI Dickson, Dennis W/0000-0001-7189-7917 NR 58 TC 11 Z9 11 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-3069 J9 J NEUROPATH EXP NEUR JI J. Neuropathol. Exp. Neurol. PD DEC PY 2006 VL 65 IS 12 BP 1157 EP 1169 DI 10.1097/01.jnen.0000248542.82681.12 PG 13 WC Clinical Neurology; Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA 126MM UT WOS:000243517000008 PM 17146290 ER PT J AU Mendez, MF Chen, AK Shapira, JS Lu, PH Miller, BL AF Mendez, MF Chen, AK Shapira, JS Lu, PH Miller, BL TI Acquired extroversion associated with bitemporal variant of frontotemporal dementia SO JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES LA English DT Article ID FRONTAL-LOBE DEGENERATION; NON-ALZHEIMER TYPE; TEMPORAL VARIANTS; SOCIAL-BEHAVIOR; WILLIAMS-SYNDROME; BLOOD-FLOW; DISEASE; EMOTION; COGNITION; NEUROBIOLOGY AB Frontotemporal dementia (FTD) is characterized by alterations in personality. The nature of the personality changes depend on the localization of the pathology. The authors present three patients with acquired extroversion who met criteria for FTD. All three patients exhibited predominant bilateral temporal involvement as determined with functional neuroimaging. Possible mechanisms for acquired extroversion in bitemporal FTD include bilateral amygdalar damage with decreased interpersonal fear or sense of threat, orbitofrontal-ventromedial damage with social disinhibition, and relative sparing of dorsolateral frontal and anterior cingulate regions with preserved interpersonal agency. FTD can be a vehicle for unraveling the basis of personality characteristics such as the introversion/extroversion dimension. C1 VA Greater Los Angeles Healthcare Syst, Neurobehav Unit 116AF, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA USA. RP Mendez, MF (reprint author), VA Greater Los Angeles Healthcare Syst, Neurobehav Unit 116AF, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM mmendez@ucla.edu FU NIA NIH HHS [AG-19724-01, P01 AG019724] NR 46 TC 12 Z9 12 U1 2 U2 4 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0895-0172 J9 J NEUROPSYCH CLIN N JI J. Neuropsychiatr. Clin. Neurosci. PD WIN PY 2006 VL 18 IS 1 BP 100 EP 107 DI 10.1176/appi.neuropsych.18.1.100 PG 8 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 014YU UT WOS:000235519900014 PM 16525077 ER PT J AU Tanvetyanon, T Choudhury, AM AF Tanvetyanon, Tawee Choudhury, Abdul M. TI Physician practice in the discontinuation of statins among patients with advanced lung cancer SO JOURNAL OF PALLIATIVE CARE LA English DT Article ID CORONARY-HEART-DISEASE; CONTROLLED-TRIAL; CHOLESTEROL; PREVENTION; CHEMOTHERAPY; PRAVASTATIN; SURVIVAL; EVENTS; DEATH AB Background. Statins are effective in reducing events from coronary heart disease and can prolong survival. However, this benefit is controversial when other concurrent serious health problems greatly limit the patient's longevity. Methods: We conducted a retrospective chart review of patients with advanced lung cancer who were receiving statins and had lived for at least one month since diagnosis. Findings: Forty-seven patients with median age of 71 years were included. Discontinuation of statins occurred in 25 patients (53.2%) before the date of death. Median survival was 370 days. Statins were discontinued at a median of 244 days after cancer diagnosis. Discontinuations were more prevalent in patients who received chemotherapy or had a history of cerebrovascular diseases. Lipid monitoring was observed in 25 patients (53.2%). Interpretation: About half of patients with advanced lung cancer who were prescribed statins did not have this drug discontinued until the time of death. Lipid monitoring was suboptimal and, when it occurred, indicated the lipid goal was rarely achieved. C1 Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. Loyola Univ, Stritch Sch Med, Maywood, IL 60153 USA. RP Tanvetyanon, T (reprint author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, 12902 Magnolia Dr, Tampa, FL 33612 USA. NR 21 TC 13 Z9 14 U1 0 U2 0 PU CENTER BIOETHICS CLIN RES INST MONTREAL PI MONTREAL PA 110 PINE AVE W, MONTREAL, QUEBEC H2W 1R7, CANADA SN 0825-8597 J9 J PALLIATIVE CARE JI J. Palliative Care PD WIN PY 2006 VL 22 IS 4 BP 281 EP 285 PG 5 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 120KK UT WOS:000243083400006 PM 17263055 ER PT J AU Thureen, P Reece, M Rodden, D Barbour, L Chappell, J Leitner, JW Jones, RO Draznin, B AF Thureen, Patti Reece, Melanie Rodden, Donna Barbour, Lynn Chappell, James Leitner, J. Wayne Jones, Richard O. Draznin, Boris TI Increased farnesylation of p21-Ras and neonatal macrosomia in women with gestational diabetes SO JOURNAL OF PEDIATRICS LA English DT Article ID GROWTH-FACTOR; INSULIN; HYPERINSULINEMIA; TISSUES AB Sit of 22 mothers with gestational diabetes mellitus had infants with macrosomia, cord blood hyperinsulinemia, and increased amounts of a key mitogenic intermediate, farnesylated p21-Ras. The ability of fetal hyperinsulinemia to increase the availability of farnesylated p21-Ras may represent one mechanism of the growth-promoting action of insulin during fetal development. C1 Univ Colorado, Hlth Sci Ctr, Dept Pediat, Res Sev,Denver Vet Affairs Med Ctr, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Obstet & Gynecol, Res Sev,Denver Vet Affairs Med Ctr, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Med, Res Sev,Denver Vet Affairs Med Ctr, Denver, CO 80262 USA. Denver Hlth & Hosp Author, Denver, CO USA. RP Thureen, P (reprint author), Univ Colorado, Hlth Sci Ctr, Dept Pediat, Res Sev,Denver Vet Affairs Med Ctr, 4200 E 9th Ave,B-195, Denver, CO 80262 USA. EM patti.thureen@uchsc.edu FU NCRR NIH HHS [M01 RR00069] NR 12 TC 6 Z9 6 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3476 EI 1097-6833 J9 J PEDIATR-US JI J. Pediatr. PD DEC PY 2006 VL 149 IS 6 BP 871 EP 873 DI 10.1016/j.jpeds.2006.08.071 PG 3 WC Pediatrics SC Pediatrics GA 122QW UT WOS:000243242500030 PM 17137910 ER PT J AU Wang, HS Oh, DS Ohning, GV Pisegna, JR AF Wang, Hank S. Oh, David S. Ohning, Gordon V. Pisegna, Joseph R. TI Cyto-reduction of neuroendocrine tumours using Sandostatin LAR (R) in combination with Infergen (R): results of a case series SO JOURNAL OF PHARMACY AND PHARMACOLOGY LA English DT Article ID ACTING SOMATOSTATIN ANALOG; MIDGUT CARCINOID-TUMORS; ENDOCRINE GASTROENTEROPANCREATIC TUMORS; INTERFERON-ALPHA; OCTREOTIDE ACETATE; CANCER CELLS; EXPRESSION; LANREOTIDE; THERAPY; GROWTH AB Historically, limited trials evaluating biotherapy in treating metastatic neuroenclocrine tumours have yielded mixed results. In this study, the efficacy of a novel combination therapy featuring longacting Sandostatin LAR (R) plus-interferon was evaluated. In a prospective case series, 12 patients with unresectable metastatic neuroendocrine tumours refractory to treatment initiated therapy with Infergen (R) and Sandostatin LAR (R). Radiological response was followed serially at 3-month intervals. A biochemical response was considered significant if marker levels decreased by >= 50% compared with baseline. Inhibition of tumour growth lasting for greater than 3 months (mean response 22.6 +/- 17.7 months) was seen in eight patients. Complete tumour regression was observed in one patient, lasting for 40 months; three patients exhibited partial tumour regression (mean response 29.3 +/- 24.0 months), and four patients maintained a stable tumour response (mean response 13.3 +/- 9.2 months). Four patients showed no response to therapy (mean response 5.0 +/- 6.0 months). All enrolled patients are alive currently. The biochemical response seen in seven patients did not correlate with the radiological response. These results suggest that the novel combination of longacting Sanclostatin LAR (R) with an a-interferon may be at least as effective as either combination therapy with short-acting octreotide or monotherapy with Sandostatin LAR (R). C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90073 USA. Vet Adm Greater Los Angeles Healthcare Syst, Dept Gastroenterol & Hepatol, Los Angeles, CA USA. RP Pisegna, JR (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, CURE Digest Dis Res Ctr, Bldg 115,Room 316,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jpisegna@ucla.edu NR 33 TC 1 Z9 1 U1 0 U2 0 PU PHARMACEUTICAL PRESS-ROYAL PHARMACEUTICAL SOC GREAT BRITIAN PI LONDON PA 1 LAMBETH HIGH ST, LONDON SE1 7JN, ENGLAND SN 0022-3573 J9 J PHARM PHARMACOL JI J. Pharm. Pharmacol. PD DEC PY 2006 VL 58 IS 12 BP 1623 EP 1628 DI 10.1211/jpp.58.12.0009 PG 6 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 126BY UT WOS:000243488400009 PM 17331326 ER PT J AU Ang-Lee, K Oreskovich, MR Saxon, AJ Jaffe, C Meredith, C Ellis, MLK Malte, CA Knox, PC AF Ang-Lee, Kathleen Oreskovich, Michael R. Saxon, Andrew J. Jaffe, Craig Meredith, Charles Ellis, Mei Ling K. Malte, Carol A. Knox, Patricia C. TI Single dose of 24 milligrams of buprenorphine for heroin detoxification: An open-label study of five inpatients SO JOURNAL OF PSYCHOACTIVE DRUGS LA English DT Article DE buprenorphine; clinical trial; detoxification; opioid dependence; opioid withdrawal ID OPIOID DETOXIFICATION; OPIATE DETOXIFICATION; WITHDRAWAL SYMPTOMS; DOUBLE-BLIND; FOLLOW-UP; ADDICTS; CLONIDINE AB Previous studies indicate that buprenorphine has efficacy in medically supervised opioid withdrawal, but the optimal dosing for maximum tolerability and case of administration remains undetermined. Five heroin-dependent individuals entered this open-label study of inpatient detoxification with a single 24mg dose of buprenorphine. The mean Clinical Opiate Withdrawal Scale (COWS) score prior to buprenorphine administration was 17.6 (SD = 3.36). COWS scores declined significantly thereafter. There was one episode of precipitated withdrawal that resolved within four hours. Use of ancillary medications was minimal. This study suggests that a single high dose of buprenorphine can be used safely and effectively for inpatient detoxification. C1 Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Washington Phys Hlth Program, Seattle, WA USA. Univ Washington, Sch Med, Mental Illness Res Educ & Clin Ctr, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Recovery Ctr King Cty, Seattle, WA USA. VA Puget Sound Healthcare Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA USA. RP Ang-Lee, K (reprint author), Univ Washington, Sch Med, Dept Psychiat & Behav Sci, 1959 NE Pacific St,Box 356560, Seattle, WA 98195 USA. EM kanglee@u.washington.edu NR 24 TC 1 Z9 1 U1 2 U2 3 PU HAIGHT-ASHBURY PUBL PI SAN FRANCISCO PA 409 CLAYTON ST, SAN FRANCISCO, CA 94117 USA SN 0279-1072 J9 J PSYCHOACTIVE DRUGS JI J. Psychoact. Drugs PD DEC PY 2006 VL 38 IS 4 BP 505 EP 512 PG 8 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 139PA UT WOS:000244443100008 PM 17373566 ER PT J AU Zivkovic, SA Lacomis, D Medsger, TA AF Zivkovic, Sasa A. Lacomis, David Medsger, Thomas A., Jr. TI Muscle cramps associated with localized scleroderma skin lesions: Focal dystonia, neuromyotonia, or nerve entrapment? SO JOURNAL OF RHEUMATOLOGY LA English DT Letter ID LINEAR SCLERODERMA; NEUROPATHY; MORPHEA C1 Univ Pittsburgh, Med Ctr, Dept Neurol, Sch Med, Pittsburgh, PA 15213 USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Univ Pittsburgh, Sch Med, Dept Pathol Neuropathol, Pittsburgh, PA 15213 USA. Univ Pittsburgh, Sch Med, Dept Med, Div Rheumatol & Clin Immunol, Pittsburgh, PA 15213 USA. RP Zivkovic, SA (reprint author), Univ Pittsburgh, Med Ctr, Dept Neurol, Sch Med, PUH F875,200 Lothrop St, Pittsburgh, PA 15213 USA. EM zivkovics@upmc.edu NR 10 TC 3 Z9 3 U1 0 U2 1 PU J RHEUMATOL PUBL CO PI TORONTO PA 920 YONGE ST, SUITE 115, TORONTO, ONTARIO M4W 3C7, CANADA SN 0315-162X J9 J RHEUMATOL JI J. Rheumatol. PD DEC PY 2006 VL 33 IS 12 BP 2549 EP 2551 PG 3 WC Rheumatology SC Rheumatology GA 123TF UT WOS:000243317900035 PM 17143993 ER PT J AU Tsao, JCI Dobalian, A Wiens, BA Gylys, JA Evans, GD AF Tsao, JCI Dobalian, A Wiens, BA Gylys, JA Evans, GD TI Posttraumatic stress disorder in rural primary care: Improving care for mental health following bioterrorism SO JOURNAL OF RURAL HEALTH LA English DT Article ID MAJOR DEPRESSION; TERRORISM; DISASTER; SEEKING AB Context. Recent bioterrorist attacks have highlighted the critical need for health care organizations to prepare for future threats. Yet, relatively little attention has been paid to the mental health needs of rural communities in the wake of such events. A critical aspect of bioterrorism is emphasis on generating fear and uncertainty, thereby contributing to increased needs for mental health care, particularly for posttraumatic stress disorder, which has been estimated to occur in 28% of terrorism survivors. Purpose: Prior experience with natural disasters suggests that first responders typically focus on immediate medical trauma or injury, leaving rural communities to struggle with the burden of unmet mental health needs both in the immediate aftermath and over the longer term. The purpose of the present article is to draw attention to the greater need to educate rural primary care providers who will be the frontline providers of mental health services following bioterrorism, given the limited availability of tertiary mental health care in. rural communities. Methods: We reviewed the literature related to bioterrorist events and mental health with an emphasis on rural communities. Findings and Conclusions: Public health agencies should work with rural primary care providers and mental health professionals to develop educational interventions focused on posttraumatic stress disorder and other mental disorders, as well as algorithms for assessment, referral, and treatment of postevent psychological disorders and somatic complaints to ensure the availability, continuity, and delivery of quality mental health care for rural residents following bioterrorism and other public health emergencies. C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Pediat Pain Program, Los Angeles, CA 90024 USA. VA Greater Los Angles Healthcare Syst, HSR&D Ctr Excellence Study Healthcare Provider Be, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA. Univ Florida, Dept Clin & Hlth Psychol, Natl Rural Behav Hlth Ctr, Gainesville, FL USA. Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL USA. N Florida S Georgia Vet Hlth Syst, Psychol Serv, Gainesville, FL USA. RP Tsao, JCI (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Pediat Pain Program, 10940 Wilshire Blvd,Suite 1450, Los Angeles, CA 90024 USA. EM jtsao@mednet.ucla.edu FU AHRQ HHS [U01HS14355-01]; PHS HHS [R04RH01310-01] NR 36 TC 9 Z9 9 U1 2 U2 5 PU NATL RURAL HEALTH ASSOC PI KANSAS CITY PA ONE WEST ARMOUR BLVD, STE 301, KANSAS CITY, MO 64111 USA SN 0890-765X J9 J RURAL HEALTH JI J. Rural Health PD WIN PY 2006 VL 22 IS 1 BP 78 EP 82 DI 10.1111/j.1748-0361.2006.00006.x PG 5 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 007HH UT WOS:000234959100011 PM 16441340 ER PT J AU Krupitsky, EM Zvartau, EE Masalov, DV Tsoy, MV Burakov, AM Egorova, VY Didenko, TY Romanova, TN Ivanova, EB Bespalov, AY Verbitskaya, EV Neznanov, NG Grinenko, AY O'Brien, CP Woody, GE AF Krupitsky, Evgeny M. Zvartau, Edwin E. Masalov, Dimitry V. Tsoy, Marina V. Burakov, Andrey M. Egorova, Valentina Y. Didenko, Tatyana Y. Romanova, Tatyana N. Ivanova, Eva B. Bespalov, Anton Y. Verbitskaya, Elena V. Neznanov, Nikolai G. Grinenko, Alexandr Y. O'Brien, Charles P. Woody, George E. TI Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia SO JOURNAL OF SUBSTANCE ABUSE TREATMENT LA English DT Article DE naltrexone; heroin addiction; HIV ID CLINICAL-EXPERIENCE; ALCOHOL DEPENDENCE; LENINGRAD REGION; EFFICACY AB This randomized placebo-controlled trial tested the efficacy of oral naltrexone with or without fluoxetine for preventing relapse to heroin addiction and for reducing HIV risk, psychiatric symptoms, and outcome. All patients received drug counseling with parental or significant-other involvement to encourage adherence. Patients totaling 414 were approached, 343 gave informed consent, and 280 were randomized (mean age, 23.6 +/- 0.4 years). At 6 months, two to three times as many naltrexone patients as naltrexone placebo patients remained in treatment and had not relapsed, odds ratio (OR) = 3.5 (1.96-6.12), p < .0001. Overall, adding fluoxetine did not improve outcomes, OR = 1.35 (0.68-2.66), p = .49; however, women receiving naltrexone and fluoxetine showed a trend toward a statistically significant advantage when compared to women receiving naltrexone and fluoxetine placebo, OR = 2.4 (0.88-6.59), p = .08. HIV risk, psychiatric symptoms, and overall adjustment were markedly improved among all patients who remained on treatment and did not relapse, regardless of group assignment. More widespread use of naltrexone could be an important addition to addiction treatment and HIV prevention in Russia. (c) 2006 Elsevier Inc. All rights reserved. C1 St Petersburg State Pavlov Med Univ, St Petersburg Sci Res Ctr Addict & Psychopharmaco, St Petersburg, Russia. Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. Univ Penn, Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. RP Woody, GE (reprint author), Treatment Res Inst, 600 Publ Ledger Bldg,150 S Independence Mall, Philadelphia, PA 19106 USA. EM woody@tresearch.org RI Verbitskaya, Elena/N-3867-2015; Bespalov, Anton/R-6506-2016 OI Verbitskaya, Elena/0000-0003-3770-993X; FU NIDA NIH HHS [K05-DA17009, P60-DA051861, U10-DA13043] NR 24 TC 50 Z9 51 U1 2 U2 6 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0740-5472 J9 J SUBST ABUSE TREAT JI J. Subst. Abus. Treat. PD DEC PY 2006 VL 31 IS 4 BP 319 EP 328 DI 10.1016/j.jsat.2006.05.005 PG 10 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 105TU UT WOS:000242056000001 PM 17084785 ER PT J AU Li, ZP Seeram, NP Carpenter, CL Thames, G Minutti, C Bowerman, S AF Li, Zhaoping Seeram, Navindra P. Carpenter, Catherine L. Thames, Gail Minutti, Chayo Bowerman, Susan TI Cranberry does not affect prothrombin time in male subjects on warfarin SO JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION LA English DT Article ID JUICE; UROPATHOGENS; CAPACITY AB There have been case reports suggesting that cranberry beverages may interact with warfarin. To date, no research study has been conducted to examine the potential interaction of cranberry and warfarin. The current study is a randomized, placebo-controlled, double-blind, crossover study to investigate the effect of cranberry juice on prothrombin time as assessed by the international normalized ratio (INR). Seven subjects with atrial fibrillation on a stable dose of warfarin for 3 months were randomized to consume 250 mL of cranberry juice for 7 days, then placebo for 7 days, or vice versa. The washout period was 7 days. The prothrombin time/INR was measured at baseline, and on days 2, 4, 7, 10, 14, 16, 18, 21, and 24. Data were analyzed by the Student t test for paired values. The baseline INR was 2.28 +/- 0.54 for the cranberry group and 2.13 +/- 0.50 for the placebo group. For all test points, the INR did not change significantly from baseline. At day 7 on cranberry juice, the INR was 2.23 +/- 0.53 for cranberry first group and 2.16 +/- 0.40 for placebo first group. The mean differences between the cranberry and placebo groups were not statistically significant. Our results suggest no significant interaction between the daily consumption of 250 mL cranberry juice and warfarin. When counseling patients on dietary changes necessary during warfarin treatment, it does not seem necessary to eliminate daily cranberry juice consumption at amounts of 250 mL, but the INR should be followed up closely. C1 Univ Calif Los Angeles, Ctr Human Nutr, Geffen Sch Med, Div Clin Nutr, Los Angeles, CA 90095 USA. VA Great Los Angeles Hlth Care Syst, Div Hospitalist, Los Angeles, CA USA. Univ Calif Los Angeles, Ctr Human Nutr, Geffen Sch Med, Analyt Phytochem Lab, Los Angeles, CA USA. RP Li, ZP (reprint author), Univ Calif Los Angeles, Ctr Human Nutr, Geffen Sch Med, Div Clin Nutr, 900 Vet Ave,Room 12-217, Los Angeles, CA 90095 USA. EM zli@mednet.ucla.edu NR 13 TC 27 Z9 28 U1 0 U2 2 PU AMER DIETETIC ASSOC PI CHICAGO PA 120 S RIVERSIDE PLZ, STE 2000, CHICAGO, IL 60606-6995 USA SN 0002-8223 J9 J AM DIET ASSOC JI J. Am. Diet. Assoc. PD DEC PY 2006 VL 106 IS 12 BP 2057 EP 2061 DI 10.1016/j.jada.2006.09.012 PG 5 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 112YH UT WOS:000242563600024 PM 17126638 ER PT J AU Kasinath, BS Mariappan, MM Sataranatarajan, K Lee, MJ Feliers, D AF Kasinath, Balakuntalam S. Mariappan, Meenalakshmi M. Sataranatarajan, Kavithalakshmi Lee, Myung Ja Feliers, Denis TI mRNA translation: Unexplored territory in renal science SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Review ID ACTIVATED PROTEIN-KINASE; TUBULAR EPITHELIAL-CELLS; INITIATION-FACTOR EIF-4E; TUMOR-SUPPRESSOR GENE; RIBOSOME ENTRY SITES; ELONGATION FACTOR-II; P70 S6 KINASE; DIABETIC-NEPHROPATHY; MAMMALIAN TARGET; ENDOPLASMIC-RETICULUM AB Ambient protein levels are under coordinated control of transcription, mRNA translation, and degradation. Whereas transcription and degradation mechanisms have been studied in depth in renal science, the role of mRNA translation, the process by which peptide synthesis occurs according to the genetic code that is present in the mRNA, has not received much attention. mRNA translation occurs in three phases: Initiation, elongation, and termination. Each phase is controlled by unique eukaryotic factors. In the initiation phase, mRNA and ribosomal subunits are brought together. During the elongation phase, amino acids are added to the nascent peptide chain in accordance with codon sequences in the mRNA. During the termination phase, the fully synthesized peptide is released from the ribosome for posttranslational processing. Signaling pathways figure prominently in regulation of mRNA translation, particularly the phosphatidylinositol 3 kinase-Akt-mammalian target of rapamycin pathway, the AMP-activated protein kinase-tuberous sclerosis complex protein 1/tuberous sclerosis complex protein 2-Rheb pathway, and the extracellular signal-regulated kinase 1/2 type mitogen-activated protein kinase signaling pathway; there is significant cross-talk among these pathways. Regulation by mRNA translation is suggested when changes in mRNA and protein levels do not correlate and in the setting of rapid protein synthesis. Ongoing work suggests an important role for mRNA translation in compensatory renal growth, hypertrophy and extracellular matrix synthesis in diabetic nephropathy, growth factor synthesis by kidney cells, and glomerulonephritis. Considering that mRNA translation plays an important role in cell growth, development, malignancy, apoptosis, and response to stress, its study should provide novel insights in renal physiology and pathology. C1 Univ Texas, Hlth Sci Ctr, Dept Med,S Texas Vet Healthcare Syst, OBrien Kidney Res Ctr,Div Nephrol, San Antonio, TX 78229 USA. RP Kasinath, BS (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med,S Texas Vet Healthcare Syst, OBrien Kidney Res Ctr,Div Nephrol, 7703 Floyd Curl Dr,MC7882, San Antonio, TX 78229 USA. EM Kasinath@uthscsa.edu NR 117 TC 43 Z9 46 U1 2 U2 4 PU AMERICAN SOCIETY NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD DEC PY 2006 VL 17 IS 12 BP 3281 EP 3292 DI 10.1681/ASN.2006050488 PG 12 WC Urology & Nephrology SC Urology & Nephrology GA 111WD UT WOS:000242485400006 PM 16959824 ER PT J AU Peralta, CA Ziv, E Katz, R Reiner, A Burchard, EG Fried, L Kwok, PY Psaty, B Shlipak, M AF Peralta, Carmen A. Ziv, Elad Katz, Ronit Reiner, Alex Burchard, Esteban Gonzalez Fried, Linda Kwok, Pui-Yan Psaty, Bruce Shlipak, Michael TI African ancestry, socioeconomic status, and kidney function in elderly African Americans: A genetic admixture analysis SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID STAGE RENAL-DISEASE; ADMIXED POPULATIONS; RACIAL-DIFFERENCES; MEXICAN-AMERICANS; PREVALENCE; HEALTH; MARKERS; RISK; ASSOCIATION; DIFFERENCE AB Kidney disease is a major public health problem in the United States that affects African Americans disproportionately. The relative contribution of environmental and genetic factors to the increased burden of kidney disease among African Americans is unknown. The associations of genetic African ancestry and socioeconomic status with kidney function were studied cross-sectionally and longitudinally among 736 community-dwelling African Americans who were aged > 65 yr and participating in the Cardiovascular Health Study. Genetic African ancestry was determined by genotyping 24 biallelic ancestry-informative markers and combining this information statistically to generate an estimate of ancestry for each individual. Kidney function was evaluated by cystatin C and estimated GFR (eGFR) using the Modification of Diet in Renal Disease equation. Longitudinal changes in serum creatinine and eGFR were estimated using baseline and follow-up values. In cross-sectional analyses, there was no association between genetic African ancestry and either measure of kidney function (P = 0.36 for cystatin C and 0.68 for eGFR). African ancestry was not associated with change in serum creatinine >= 0.05 mg/dl per yr (odds ratio [OR] 0.94; 95% confidence interval [CI] 0.83 to 1.06) or with change in eGFR >= 3 ml/min per 1.73 m(2) per yr (OR 1.02; 95% CI 0.92 to 1.13). In contrast, self reported African-American race was strongly associated with increased risk for kidney disease progression compared with white individuals for change in creatinine (OR 1.77; 95% CI 1.33 to 2.36) and for change in eGFR (OR 3.21; 95% CI 2.54 to 4.06). Among self-identified African Americans, low income (<$8000/yr) was strongly associated with prevalent kidney dysfunction by cystatin C > 1.29 g/dl (adjusted OR 2.7; 95% CI 1.0 to 7.5) or by eGFR < 60 ml/min per 1.73 m(2) (adjusted OR 3.2; 95% CI 1.1 to 9.4) compared with those with incomes >$35,000/yr. Alleles that are known to be present more frequently in the African ancestral group were not associated with kidney dysfunction or kidney disease progression. Rather, kidney dysfunction in elderly African Americans seems more attributable to differences in environmental and social factors. C1 Univ Calif San Francisco, Dept Med, San Francisco, CA USA. Univ Calif San Francisco, Div Nephrol, San Francisco, CA USA. Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Biopharmaceut Sci, San Francisco, CA 94143 USA. Univ Calif San Francisco, Ctr Human Genet, Dept Dermatol, San Francisco, CA 94143 USA. Univ Calif San Francisco, Inst Cardiovasc Res, San Francisco, CA 94143 USA. San Francisco Gen Hosp, Lung Biol Ctr, San Francisco, CA 94110 USA. Univ Washington, Collaborat Hlth Studies Coordinating Ctr, Dept Biostat, Seattle, WA 98195 USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. Univ Washington, Dept Lab Med, Seattle, WA 98195 USA. Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA. Univ Washington, Dept Epidemiol, Cardivasc Hlth Res Unit, Seattle, WA 98195 USA. Univ Washington, Dept Hlth Serv, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA. Univ Pittsburgh, Sch Med, Renal Sect, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA USA. San Francisco Vet Affairs Med Ctr, Gen Internal Med Sect, San Francisco, CA USA. RP Shlipak, M (reprint author), VA Med Ctr, Gen Intern Med Sect 111A1, Dept Med, 4150 Clement St, San Francisco, CA 94124 USA. EM shlip@itsa.ucsf.edu RI Kwok, Pui-Yan/F-7725-2014 OI Kwok, Pui-Yan/0000-0002-5087-3059 FU NHLBI NIH HHS [N01 HC-15103, N01-HC-35129, N01-HC-85079, N01-HC-85086, R01-HL-073208-01] NR 28 TC 24 Z9 26 U1 0 U2 4 PU AMERICAN SOCIETY NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD DEC PY 2006 VL 17 IS 12 BP 3491 EP 3496 DI 10.1681/ASN.2006050493 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 111WD UT WOS:000242485400026 PM 17082243 ER PT J AU Jayadev, S Michelson, S Lipe, H Bird, T AF Jayadev, Suman Michelson, Sara Lipe, Hillary Bird, Thomas TI Cambodian founder effect for spinocerebellar ataxia type 3 (Machado-Joseph disease) SO JOURNAL OF THE NEUROLOGICAL SCIENCES LA English DT Article DE ataxia; spinocerebellar ataxia; Machado-Joseph disease; neurogenetics; Cambodia; trinucleotide repeats ID DOMINANT CEREBELLAR ATAXIAS; FREQUENCY-ANALYSIS; MOLECULAR CHARACTERIZATION; TRINUCLEOTIDE REPEATS; INDIAN POPULATION; FAMILIES; EXPANSION; FEATURES; PREVALENCE; HAPLOTYPE AB Four families from the same region of Cambodia immigrated to the Pacific Northwest of the United States. All four families have been discovered to have spinocerebellar ataxia type 3 (SCA 3; Machado-Joseph disease) with a similar clinical phenotype. CAG repeat expansions in the ATAN3 gene range from 72 to 77. Mean age of onset has varied from 19 to 44 years and mean age at death of 4 individuals has been 60 years. The prevalence of the various subtypes of SCA varies worldwide from country to country. Neurologists should be alert to the possibility of SCA 3 in Cambodian patients with unexplained cerebellar ataxia. (c) 2006 Elsevier B.V. All rights reserved. C1 Univ Washington, Dept Neurol, Seattle, WA 98195 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. RP Bird, T (reprint author), VA Med Ctr, S-182-GRECC,1660 S Columbian Way, Seattle, WA 98108 USA. EM tomnroz@u.washington.edu FU NIA NIH HHS [5T32AG000258-08] NR 24 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0022-510X J9 J NEUROL SCI JI J. Neurol. Sci. PD DEC 1 PY 2006 VL 250 IS 1-2 BP 110 EP 113 DI 10.1016/j.jns.2006.08.006 PG 4 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 111RI UT WOS:000242471500018 PM 17027034 ER PT J AU Hoch, JS Smith, MW AF Hoch, Jeffrey S. Smith, Mark W. TI A guide to economic evaluation: Methods for cost-effectiveness analysis of person-level data SO JOURNAL OF TRAUMATIC STRESS LA English DT Article; Proceedings Paper CT 2nd Annual Conference on Innavations in Trauma Research Methods CY NOV 16-17, 2005 CL Toronto, CANADA ID EFFECTIVENESS ACCEPTABILITY CURVES; POSTTRAUMATIC-STRESS-DISORDER; ADMINISTERED PTSD SCALE; MEDICAL LITERATURE; CLINICAL-PRACTICE; USERS GUIDES; HEALTH-CARE; TRIAL; AUSTRALIA; FRAMEWORK AB The authors introduce economic evaluation with particular attention to cost-effectiveness analysis. They begin by establishing why health care decisions should be guided by economics. They then explore different types of economic evaluations. To illustrate how to conduct and evaluate a cost-effectiveness analysis, a hypothetical study about the treatment of posttraumatic stress disorder with psychotherapy versus pharmacotherapy is considered. The authors conclude with recommendations for increasing the strength and relevance of economic evaluations. C1 Ctr Res Inner City Hlth, Toronto, ON M5B 1W8, Canada. St Michaels Hosp, Toronto, ON M5B 1W8, Canada. Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada. US Dept Vet Affairs, Hlth Econ Resource Ctr, Menlo Pk, CA USA. Stanford Univ, Ctr Primary Care & Outcomes Res, Stanford, CA 94305 USA. RP Hoch, JS (reprint author), Ctr Res Inner City Hlth, 30 Bond St, Toronto, ON M5B 1W8, Canada. EM jeffrey.hoch@utoronto.ca RI Smith, Mark/G-1522-2012 OI Smith, Mark/0000-0002-4582-9088; Hoch, Jeffrey/0000-0002-4880-4281 NR 42 TC 16 Z9 18 U1 3 U2 6 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0894-9867 J9 J TRAUMA STRESS JI J. Trauma Stress PD DEC PY 2006 VL 19 IS 6 BP 787 EP 797 DI 10.1002/jts.20190 PG 11 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 121VD UT WOS:000243184200004 PM 17195977 ER PT J AU Fitzsimons, NJ Presti, JC Kane, CJ Terris, MK Aronson, WJ Amling, CL Freedland, SJ AF Fitzsimons, Nicholas J. Presti, Joseph C., Jr. Kane, Christopher J. Terris, Martha K. Aronson, William J. Amling, Christopher L. Freedland, Stephen J. CA Shared Equal Access Regional Canc TI Is biopsy Gleason score independently associated with biochemical progression following radical prostatectomy after adjusting for pathological Gleason score? SO JOURNAL OF UROLOGY LA English DT Article DE prostate; prostatic neoplasms; prostatectomy; biopsy; disease progression ID CANCER-SPECIFIC MORTALITY; DISEASE RECURRENCE; RADIATION-THERAPY; RISK; SPECIMENS; GRADE; NOMOGRAMS AB Purpose: Biopsy Gleason score is known to be associated with prostate specific antigen failure following radical prostatectomy. However, it is unclear whether it remains associated with outcome after surgery when the pathological Gleason score is known. Materials and Methods: We determined the association between biopsy Gleason score and biochemical progression after correcting for preoperative and postoperative characteristics, including pathological Gleason score, in 1,931 men treated with radical prostatectomy between 1988 and 2005 in the Shared Equal Access Regional Cancer Hospital Database Study Group database. Gleason score was examined as a categorical variable of 2 to 6, 3 + 4 and 4 + 3 or greater. Results: Higher biopsy Gleason scores were positively associated with extracapsular extension (p < 0.001), positive surgical margins (p < 0.001), seminal vesicle invasion (p < 0.001), positive lymph nodes (p < 0.001) and biochemical progression (log rank p < 0.001). After adjusting for only preoperative characteristics biopsy Gleason 3 + 4 and 4 + 3 or greater were associated with increased risk of biochemical progression compared to biopsy Gleason 6 or less (p = 0.001 and. < 0.001, respectively). After further adjusting for multiple pathological characteristics, including pathological Gleason score, the association between higher biopsy Gleason score and progression was little changed, in that men with biopsy Gleason 3 + 4 and 4 + 3 or greater were significantly more likely to experience progression (p = 0.001 and < 0.001, respectively). Furthermore, when stratified by pathological Gleason score, higher biopsy Gleason scores were associated with an increased risk of biochemical progression in each pathological Gleason score category (log rank p <= 0.007). Conclusions: Biopsy Gleason score remained strongly associated with progression even when the pathological Gleason score was known and controlled for. If confirmed at other centers, incorporation of biopsy Gleason score into postoperative C1 Duke Univ, Sch Med, Med Ctr, Div Urol Surg,Dept Surg, Durham, NC 27710 USA. Duke Univ, Sch Med, Med Ctr, Dept Pathol, Durham, NC 27710 USA. Duke Univ, Sch Med, Duke Prostate Ctr, Durham, NC 27710 USA. Vet Adm Med Ctr, Dept Surg, Durham, NC USA. Stanford Univ, Sch Med, Dept Urol, Palo Alto, CA 94304 USA. Vet Adm Med Ctr, Dept Surg, Urol Sect, Palo Alto, CA 94304 USA. Vet Adm Med Ctr San Francisco, Dept Surg, Urol Sect, San Francisco, CA USA. Univ Calif San Francisco, Sch Med, Dept Urol, San Francisco, CA 94143 USA. Univ Calif Los Angeles, Sch Med, Dept Urol, Los Angeles, CA 90024 USA. Vet Adm Greater Los Angeles Healthcare Syst, Dept Surg, Urol Sect, Los Angeles, CA USA. USN, Med Ctr, Dept Urol, San Diego, CA 92152 USA. Med Coll Georgia, Vet Adm Med Ctr Augusta, Dept Surg, Augusta, GA 30912 USA. Med Coll Georgia, Urol Sect, Augusta, GA 30912 USA. Univ Alabama, Dept Urol, Birmingham, AL 35233 USA. RP Fitzsimons, NJ (reprint author), Duke Univ, Sch Med, Med Ctr, Div Urol Surg,Dept Surg, Box 3707, Durham, NC 27710 USA. EM nicholas.fitzsimons@duke.edu OI Terris, Martha/0000-0002-3843-7270 FU NCI NIH HHS [R01 CA 100938, P50 CA 92131-01A1] NR 20 TC 17 Z9 17 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD DEC PY 2006 VL 176 IS 6 BP 2453 EP 2458 DI 10.1016/j.juro.2006.08.014 PN 1 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 105KM UT WOS:000242028800031 PM 17085127 ER PT J AU Gold, R Michael, YL Whitlock, EP Hubbell, FA Mason, ED Rodriguez, BL Safford, MM Sarto, GE AF Gold, Rachel Michael, Yvonne L. Whitlock, Evelyn P. Hubbell, F. Allan Mason, Ellen D. Rodriguez, Beatriz L. Safford, Monika M. Sarto, Gloria E. TI Race/ethnicity, socioeconomic status, and lifetime morbidity burden in the Women's Health Initiative: A cross-sectional analysis SO JOURNAL OF WOMENS HEALTH LA English DT Article ID CAUSE-SPECIFIC MORTALITY; AFRICAN-AMERICAN WOMEN; UNITED-STATES; RACIAL-DISCRIMINATION; BLOOD-PRESSURE; BREAST-CANCER; OLDER ADULTS; RISK-FACTORS; SOCIAL-CLASS; DISPARITIES AB Objectives: We sought to assess the extent to which race/ethnicity and socioeconomic status (SES) are independently and jointly related to lifetime morbidity burden by comparing the impact of SES on lifetime morbidity among women of different racial/ethnic groups: white, black, Hispanic, American Indian/Alaska Native (AIAN), and Asian/Pacific Islander (API). Methods: Using baseline data from the Women's Health Initiative (WHI), a national study of 162,000 postmenopausal women, we measured lifetime morbidity burden using a modified version of the Charlson Index, and measured SES with educational attainment and household income. In multivariable simple polytomous logistic regression models, we first assessed the effect of SES on lifetime morbidity burden among women of each racial/ethnic group, then assessed the combined effect of race/ethnicity and SES. Results: Five percent of all women in the study population had high lifetime morbidity burden. Women with high lifetime morbidity were more likely to be AIAN or black; poor; less educated; divorced, separated, or widowed; past or current smokers; obese; uninsured or publicly insured. Lower SES was associated with higher morbidity among most women. The extent to which morbidity was higher among lower SES compared to higher SES women was about the same among Hispanic women and white women, but was substantially greater among black and AIAN women compared with white women. Conclusions: This study demonstrates the importance of considering race/ethnicity and class together in relation to health outcomes. C1 Kaiser Permanente NW, Ctr Hlth Res, Portland, OR USA. Oregon Hlth & Sci Univ, Portland, OR USA. Univ Calif Irvine, Irvine, CA USA. Rush Univ, Chicago, IL 60612 USA. Univ Hawaii, Honolulu, HI 96822 USA. Univ Alabama, Birmingham, AL USA. Birmingham VA Med Ctr, Deep S Ctr Effectiveness, Birmingham, AL USA. Univ Wisconsin, Madison, WI USA. RP Gold, R (reprint author), Kaiser Permanente Ctr Hlth Res, 3800 N Interstate Ave, Portland, OR 97227 USA. EM rachel.gold@kpchr.org NR 54 TC 25 Z9 25 U1 2 U2 8 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD DEC PY 2006 VL 15 IS 10 BP 1161 EP 1173 DI 10.1089/jwh.2006.15.1161 PG 13 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 126GB UT WOS:000243499500008 PM 17199457 ER PT J AU Grimm, DR Schilero, GJ Spungen, AM Bauman, WA Lesser, M AF Grimm, David R. Schilero, Gregory J. Spungen, Ann M. Bauman, William A. Lesser, Marvin TI Salmeterol improves pulmonary function in persons with tetraplegia SO LUNG LA English DT Article DE spinal cord injury; spirometry bronchodilator; respiratory muscle strength; salmeterol; tetraplegia ID SPINAL-CORD-INJURY; HEALTHY NONSMOKING ADULTS; AIRWAY HYPERRESPONSIVENESS; MUSCLE STRENGTH; COMPLICATIONS; INDIVIDUALS; SALBUTAMOL; ALBUTEROL; AGONIST; COPD AB beta(2)-Adrenergic agonists are known to improve muscle strength because of anabolic properties. The purpose of this study was to determine if long-term administration of a long-acting beta(2)-adrenergic agonist to subjects with tetraplegia is associated with improvement in pulmonary function parameters and maximal static inspiratory and expiratory mouth pressures (MIP and MEP, respectively), measures of respiratory muscle strength. The study was a randomized, prospective, double-blind, placebo-controlled, crossover trial and conducted at the James J. Peters Veterans Affairs Medical Center. Thirteen subjects who had complete or incomplete tetraplegia for more than one year participated in the study. Eleven subjects completed the study. All were clinically stable outpatients without any history of asthma or use of inhaled bronchodilators. Following baseline measurements, patients were randomized to receive salmeterol or placebo from identically marked Diskus containers for 4 weeks. Following a 4-week washout period, the subjects were randomized to receive the alternate preparation for 4 weeks. Pulmonary function parameters and static mouth pressure were measured during baseline and during the fourth week of the two study periods. During the 4-week period of salmeterol administration, forced vital capacity, forced expiratory volume in 1 s, peak expiratory flow, MIP, and MEP improved significantly compared with placebo and baseline. Expiratory reserve volume increased significantly compared to baseline. Increases in MIP and MEP during salmeterol administration suggest improvement in respiratory muscle strength. However, this cannot be stated with certainty because MIP and MEP are dependent on volume parameters at which they are measured. Regardless of the mechanism, improvement in static mouth pressures indicates that salmeterol should benefit these individuals by improving cough effectiveness. C1 James J Peters Vet Affairs Med Ctr, Ctr Med Consequences Spinal Cord Injury, Bronx, NY 10468 USA. New York Chiropract Coll, Dept Basic Sci, Seneca Falls, NY 13148 USA. CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA. CUNY Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA. James J Peters Vet Affairs Med Ctr, Med Serv, Bronx, NY 10468 USA. James J Peters Vet Affairs Med Ctr, Spinal Cord Injury Serv, Bronx, NY 10468 USA. RP Schilero, GJ (reprint author), James J Peters Vet Affairs Med Ctr, Ctr Med Consequences Spinal Cord Injury, Room 1E-02,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM Greg.schilero@med.va.gov NR 28 TC 7 Z9 8 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0341-2040 J9 LUNG JI Lung PD DEC PY 2006 VL 184 IS 6 BP 335 EP 339 DI 10.1007/s00408-006-0011-6 PG 5 WC Respiratory System SC Respiratory System GA 111OU UT WOS:000242463600006 PM 17096182 ER PT J AU Duru, OK Mangione, CM Steers, NW Herman, WH Karter, AJ Kountz, D Marrero, DG Safford, MM Waitzfelder, B Gerzoff, RB Huh, S Brown, AF AF Duru, O. Kenrik Mangione, Carol M. Steers, Neil W. Herman, William H. Karter, Andrew J. Kountz, David Marrero, David G. Safford, Monika M. Waitzfelder, Beth Gerzoff, Robert B. Huh, Soonim Brown, Arleen F. CA TRIAD Study Grp TI The association between clinical care strategies and the attenuation of racial/ethnic disparities in diabetes care - The translating research into action for diabetes (TRIAD) study SO MEDICAL CARE LA English DT Article DE diabetes; quality of care; quality improvement; race and ethnicity; chronic disease ID QUALITY-OF-CARE; INFLUENZA VACCINATION RATES; MEDICARE MANAGED CARE; RACIAL DISPARITIES; UNITED-STATES; HEALTH-CARE; REDUCING DISPARITIES; ETHNIC DISPARITIES; AFRICAN-AMERICANS; DISEASE AB Objective: We sought to determine whether greater implementation of clinical care strategies in managed care is associated with attenuation of known racial/ethnic disparities in diabetes care. Research Design and Methods: Using cross-sectional data, we examined the quality of diabetes care as measured by frequencies of process delivery as well as medication management of intermediate outcomes, for 7426 black, Latinos, Asian/Pacific Islanders, and white participants enrolled in 10 managed care plans wit in provider groups. We stratified models by intensity of 3 clinical care strategies at the provider group level: physician reminders, physician feedback, or use of a diabetes registry. Results: Exposure to clinical care strategy implementation at the provider group level varied by race and ethnicity, with < 10% of black participants enrolled in provider groups in the highest-intensity quintile for physician feedback and < 10% of both black and Asian/Pacific Islander participants enrolled in groups in the highest-intensity quintile for diabetes registry use. Although disparities in care were confirmed, particularly for black relative to white subjects, we did not find a consistent pattern of disparity attenuation with increasing implementation intensity for either processes of care or medication management of intermediate outcomes. Conclusions: For the most part, high-intensity implementation of a diabetes registry, physician feedback, or physician reminders, 3 clinical care strategies similar to those used in many health care settings, are not associated with attenuation of known disparities of diabetes care in managed care. C1 Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA. Univ Michigan, Dept Internal Med, Div Endocrinol & Metab, Ann Arbor, MI 48109 USA. Kaiser Permanente, Div Res, Oakland, CA USA. UMDNJ Robert Wood Johnson Med Sch, Div Primary Care, New Brunswick, NJ USA. Indiana Univ, Dept Med, Sch Med, Indianapolis, IN USA. Univ Alabama, Birmingham, AL USA. Birmingham VA Med Ctr, Deep S Ctr Effectiveness, Birmingham, AL USA. Pacific Hlth Res Inst, Honolulu, HI USA. CDC, Ctr Dis Control & Prevent, Atlanta, GA USA. RP Duru, OK (reprint author), Univ Calif Los Angeles, Div Gen Internal Med, 911 Broxton Plaza, Los Angeles, CA 90024 USA. EM kduru@mednet.ucla.edu FU NIA NIH HHS [AG-02-004]; NIMHD NIH HHS [P20 MD000148, P20MD000148, P20MD000182]; PHS HHS [U58/CCU923530] NR 45 TC 20 Z9 20 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD DEC PY 2006 VL 44 IS 12 BP 1121 EP 1128 DI 10.1097/01.mlr.0000237423.05294.c0 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 111TI UT WOS:000242477200010 PM 17122717 ER PT J AU Matsunaga, J Werneid, K Zuerner, RL Frank, A Haake, DA AF Matsunaga, James Werneid, Kristian Zuerner, Richard L. Frank, Ami Haake, David A. TI LipL46 is a novel surface-exposed lipoprotein expressed during leptospiral dissemination in the mammalian host SO MICROBIOLOGY-SGM LA English DT Article ID OUTER-MEMBRANE PROTEIN; PATHOGENIC LEPTOSPIRA; MOLECULAR-CLONING; SEQUENCE-ANALYSIS; INTERROGANS; INFECTION; PREDICTION; BACTERIA; GROWTH; OMPL1 AB Leptospirosis is a widespread zoonosis caused by invasive spirochaetes belonging to the genus Leptospira. Pathogenic leptospires disseminate via the bloodstream to colonize the renal tubules of reservoir hosts. Little is known about leptospiral outer-membrane proteins expressed during the dissemination stage of infection. In this study, a novel surface-exposed lipoprotein is described; it has been designated LipL46 to distinguish it from a previously described 31 kDa peripheral membrane protein, P31 (LipL45), which is exported as a 45 kDa probable lipoprotein. The lipL46 gene encodes a 412 aa polypeptide with a 21 aa signal peptide. Lipid modification of cysteine at the lipoprotein signal peptidase cleavage site FSISC is supported by the finding that Leptospira interrogans intrinsically labels LipL46 during incubation in medium containing [C-14]palmitate. LipL46 appears to be exported to the leptospiral outer membrane as a 46 kDa lipoprotein, based on Triton X-114 solubilization and phase partitioning studies, which included the outer and inner membrane controls LipL32 and LipL31, respectively. Surface immunoprecipitation and whole-cell ELISA experiments indicate that LipL46 is exposed on the leptospiral surface. Immunohistochemistry studies demonstrated expression of LipL46 by leptospires found in the bloodstream of acutely infected hamsters. Leptospires expressing LipL46 were also found in the intercellular spaces of the liver, within splenic phagocytes, and invading the glomerular hilum of the kidney. Infection-associated expression is supported by the finding that LipL46 is a major antigen recognized by sera from infected hamsters. These findings indicate that LipL46 may be important in leptospiral dissemination, and that it may serve as a useful serodiagnostic antigen. C1 Vet Affairs Greater Los Angeles Healthcare Syst, Div Infect Dis, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Los Angeles, CA USA. USDA ARS, Natl Anim Dis Ctr, Ames, IA 50010 USA. RP Haake, DA (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Div Infect Dis, 111F, Los Angeles, CA 90073 USA. EM dhaake@ucla.edu FU NIAID NIH HHS [R01 AI034431, R21 AI034431, R01 AI034431-09, AI-34431, R29 AI034431] NR 38 TC 33 Z9 33 U1 0 U2 2 PU SOC GENERAL MICROBIOLOGY PI READING PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG, BERKS, ENGLAND SN 1350-0872 J9 MICROBIOL-SGM JI Microbiology-(UK) PD DEC PY 2006 VL 152 BP 3777 EP 3786 DI 10.1099/mic.0.29163-0 PN 12 PG 10 WC Microbiology SC Microbiology GA 122DL UT WOS:000243205800031 PM 17159228 ER PT J AU Zhao, R Domann, FE Zhong, WX AF Zhao, Rui Domann, Frederick E. Zhong, Weixiong TI Apoptosis induced by selenomethionine and methioninase is superoxide mediated and p53 dependent in human prostate cancer cells SO MOLECULAR CANCER THERAPEUTICS LA English DT Article ID GENE-THERAPY; SE-METHYLSELENOCYSTEINE; METHYLSELENINIC ACID; IN-VITRO; SELENIUM SUPPLEMENTATION; CARCINOSTATIC ACTIVITY; OXIDATIVE STRESS; PREVENTION; METABOLITE; EXPRESSION AB Selenomethionine (SeMet) is the chemical form or major component of selenium used for cancer chemoprevention in several clinical trials. However, evidence from experimental studies indicates that SeMet has weaker anticancer effects than most other forms of selenium. Recent studies showed that the anticancer activity of SeMet can be enhanced by methioninase (METase), indicating that SeMet metabolites are responsible for its anticancer activity. In the present study, we showed that wild-type p53-expressing LNCaP human prostate cancer cells were more sensitive to cotreatment with SeMet and METase than p53-null PC3 human prostate cancer cells. SeMet and METase cotreatment significantly increased levels of superoxide and apoptosis in LNCaP cells. Cotreatment with SeMet and METase resulted in increased levels of phosphorylated p53 (Ser15), total p53, Bax, and p21(Waf1) proteins. LNCaP cells treated with SeMet and METase also showed p53 translocation to mitochondria, decreased mitochondrial membrane potential, cytochrome c release into the cytosol, and activation of caspase-9. The effects of SeMet and METase Were suppressed by pretreatment with a synthetic superoxide dismutase mimic or by knockdown of p53 via RNA interference. Reexpression of wild-type p53 in PC3 cells resulted in increases in superoxide production, apoptosis, and caspase-9 activity and a decrease in mitochondrial membrane potential following cotreatment with SeMet and METase. Our study shows that apoptosis induced by SeMet plus METase is superoxide mediated and p53 dependent via mitochondrial pathway(s). These results suggest that superoxide and p53 may play a role in cancer chemoprevention by selenium. C1 Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol & Lab Med, Ctr Clin Sci, Madison, WI 53792 USA. William S Middleton Mem Vet Adm Med Ctr, Pathol & Lab Med Serv, Madison, WI 53705 USA. Univ Iowa, Free Rad & Radiat Biol Program, Iowa City, IA USA. RP Zhong, WX (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol & Lab Med, Ctr Clin Sci, K4-868,Box 8550,600 Highland Ave, Madison, WI 53792 USA. EM wzhong3@wisc.edu OI Domann, Frederick/0000-0002-0489-2179 FU NCI NIH HHS [R56 CA073612, CA114281, CA73612, R01 CA073612, R01 CA114281, R29 CA073612] NR 51 TC 60 Z9 64 U1 0 U2 6 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1535-7163 J9 MOL CANCER THER JI Mol. Cancer Ther. PD DEC PY 2006 VL 5 IS 12 BP 3275 EP 3284 DI 10.1158/1535-7163.MCT-06-0400 PG 10 WC Oncology SC Oncology GA 122UO UT WOS:000243252800036 PM 17172431 ER PT J AU Saeed, AI Schwartz, AP Limsukon, A AF Saeed, Ali Imran Schwartz, Andrew P. Limsukon, Atikun TI Superior vena cava syndrome (SVC syndrome): A rare cause of conjunctival suffusion SO MOUNT SINAI JOURNAL OF MEDICINE LA English DT Article DE conjunctival suffusion; SVC syndrome; suffusion; SVC obstruction; lung cancer ID PRESENTING SIGN; EYELID EDEMA AB Obstruction of blood flow in the superior vena cava results in the signs and symptoms of superior vena cava (SVC) syndrome. Venous collaterals form, to establish alternative pathways for return of venous blood to the right atrium. The rapidity of onset of symptoms and signs from SVC obstruction is directly related to the rate at which obstruction occurs and how effective the formed collaterals are. Lung cancer and lymphoma account for more than 90% of cases of SVC syndrome. Recognition of signs and symptoms allows us to make an early diagnosis. Facial swelling, distended veins over the neck, upper extremity swelling, and dyspnea are common findings. Proptosis, periorbital swelling (including eyelid), conjunctival suffusion and elevated intraocular pressure are documented ophthalmic findings in SVC syndrome. We present a rare case of conjunctival suffusion in a 72-year-old male diagnosed with superior vena cava syndrome secondary to lung cancer. C1 James J Peters VA Med Ctr, Mt Sinai Sch Med Program, Bronx, NY USA. CUNY Mt Sinai Sch Med, New York, NY 10029 USA. RP Saeed, AI (reprint author), James J Peters VA Med Ctr, Program Med, Room 7A11,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM docali@hotmail.com NR 11 TC 3 Z9 5 U1 0 U2 4 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0027-2507 J9 MT SINAI J MED JI Mt. Sinai J. Med. PD DEC PY 2006 VL 73 IS 8 BP 1082 EP 1085 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 128XF UT WOS:000243692300005 PM 17285199 ER PT J AU Shahzad, G Korsten, MA Blatt, C Motwani, P AF Shahzad, Ghulamullah Korsten, Mark A. Blatt, Charles Motwani, Pooja TI Angiotensin-converting enzyme (ACE) inhibitor-associated angioedema of the stomach and small intestine: A case report SO MOUNT SINAI JOURNAL OF MEDICINE LA English DT Article DE angioedema; angiotensin-converting enzyme inhibitors; CT scan ID VISCERAL ANGIOEDEMA; MANAGEMENT AB This is a case report on a 45-year old African-American female with newly diagnosed hypertension, who was started on a combination pill of amlodipine/benazapril 10/5 mg. The very next day, she presented at the emergency room (ER) with abdominal pain, nausea and vomiting. Physical exam, complete metabolic panel, and hemogram were in the normal range. She was discharged from the ER after a few hours of treatment with fluid and analgesics. However, she returned to the ER the next day with the same complaints. This time the physical exam was significant for a distended abdomen with dullness to percussion. CT scan of the abdomen revealed markedly thickened antrum of the stomach, duodenum and jejunum, along with fluid in the abdominal and pelvic cavity. Angiotensin-converting enzyme inhibitor (ACEI)-induced angioedema was suspected, and anti-hypertensive medications were discontinued. Her symptoms improved within the next 24 hours, and repeat CT after 72 hours revealed marked improvement in stomach and small bowel thickening and resolution of ascites. The recognition of angiotensin-converting enzyme (ACE) and angiotensin receptor blocker (ARB) intestinal angioedema constitutes a challenge to primary care physicians, internists, emergency room personal and surgeons. C1 James J Peters VA Med Ctr, Bronx, NY USA. N Cent Bronx Hosp, Jocobi Med Ctr, Bronx, NY USA. RP Shahzad, G (reprint author), 1003 Father Capdanno Blvd, Staten Isl, NY 10603 USA. EM shahzag@gmail.com NR 12 TC 14 Z9 15 U1 2 U2 3 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0027-2507 J9 MT SINAI J MED JI Mt. Sinai J. Med. PD DEC PY 2006 VL 73 IS 8 BP 1123 EP 1125 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 128XF UT WOS:000243692300015 PM 17285209 ER PT J AU Walker, RH Liu, QY Ichiba, M Muroya, S Nakamura, M Sano, A Kennedy, CA Sclar, G AF Walker, Ruth H. Liu, Qinyue Ichiba, Mio Muroya, Shinji Nakamura, Masyuki Sano, Akira Kennedy, Cheryl A. Sclar, Gary TI Self-mutilation in chorea-acanthocytosis: Manifestation of movement disorder or psychopathology? SO MOVEMENT DISORDERS LA English DT Letter ID NEUROACANTHOCYTOSIS C1 James J Peters Vet Affairs Med Ctr, Dept Neurol, Bronx, NY USA. Mt Sinai Sch Med, Dept Neurol, New York, NY USA. Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Psychiat, Newark, NJ 07103 USA. Kagoshima Univ, Dept Psychiat, Grad Sch Med & Dent Sci, Kagoshima 890, Japan. Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Psychiat, Samuel L bailey Huntingtons Dis Family Serv Ctr, Newark, NJ 07103 USA. Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Prevent Med & Community Hlth, Samuel L bailey Huntingtons Dis Family Serv Ctr, Newark, NJ 07103 USA. Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurosci, Samuel L bailey Huntingtons Dis Family Serv Ctr, Newark, NJ 07103 USA. RP Walker, RH (reprint author), James J Peters Vet Affairs Med Ctr, Dept Neurol, Bronx, NY USA. EM ruth.walker@mssm.edu NR 6 TC 14 Z9 15 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD DEC PY 2006 VL 21 IS 12 BP 2268 EP 2269 DI 10.1002/mds.21156 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 121LI UT WOS:000243158700055 PM 17044067 ER PT J AU Carroll, BJ Rubin, RT AF Carroll, Bernard J. Rubin, Robert T. TI Is mifepristone useful in psychotic depression? SO NEUROPSYCHOPHARMACOLOGY LA English DT Letter ID ANTIPSYCHOTIC-DRUGS; SCHIZOPHRENIA C1 Pacific Behav Res Fdn, Carmel Valley, CA 93922 USA. VA Greater Los Angeles Healthcare Syst, Dept Psychiat & Mental Hlth 116A, Los Angeles, CA USA. RP Carroll, BJ (reprint author), Pacific Behav Res Fdn, 100 Mesa Carmel,POB 223040, Carmel Valley, CA 93922 USA. EM bcarroll@redshift.com FU NIMH NIH HHS [MH 50604] NR 8 TC 11 Z9 11 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD DEC PY 2006 VL 31 IS 12 BP 2793 EP 2794 DI 10.1038/sj.npp.1301170 PG 2 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 105QG UT WOS:000242046800024 PM 17109015 ER PT J AU Childress, A Ehrman, R Wang, Z Li, Y Goldman, M Kampman, K Hakun, J Bernstiel, R Detre, J O'Brien, CP AF Childress, Anna Ehrman, Ronald Wang, Ze Li, Yin Goldman, Marina Kampman, Kyle Hakun, Jonathan Bernstiel, Ron Detre, John O'Brien, Charles P. TI Can the Gaba B agonist baclofen prevent limbic activation by both "seen" and "unseen" cocaine cues? SO NEUROPSYCHOPHARMACOLOGY LA English DT Meeting Abstract CT 45th Annual Meeting of the American-College-of-Neuropsychopharmacolgy CY DEC 03-07, 2006 CL Hollywood, FL SP Amer Coll Neuropsychopharmacol C1 Philadelphia VA Med Ctr, VA VISN 4 MIRECC, Philadelphia, PA USA. RI Wang, Ze/A-1043-2007 NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD DEC PY 2006 VL 31 SU 1 BP S73 EP S73 PG 1 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 108BS UT WOS:000242215900216 ER PT J AU Haroutunian, V Gibson, G Pasinetti, GM AF Haroutunian, Vahram Gibson, Gary Pasinetti, Giulio M. TI Insulin receptor deficits in schizophrenia and in cellular and animal models of insulin receptor dysfunction SO NEUROPSYCHOPHARMACOLOGY LA English DT Meeting Abstract CT 45th Annual Meeting of the American-College-of-Neuropsychopharmacolgy CY DEC 03-07, 2006 CL Hollywood, FL SP Amer Coll Neuropsychopharmacol C1 Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. Bronx Vet Affairs Med Ctr, New York, NY USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD DEC PY 2006 VL 31 SU 1 BP S17 EP S17 PG 1 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 108BS UT WOS:000242215900054 ER PT J AU Khachaturian, AS Zandi, PP Lyketsos, CG Hayden, KM Skoog, I Norton, MC Tschanz, JT Mayer, L Welsh-Bohmer, KA Breitner, JC AF Khachaturian, Ara S. Zandi, Peter P. Lyketsos, Constantine G. Hayden, Kathleen M. Skoog, Ingmar Norton, Maria C. Tschanz, JoAnn T. Mayer, Lawrence Welsh-Bohmer, Kathleen A. Breitner, John C. TI Antihypertensive medication use and incident Alzheimer disease: The cache county study SO NEUROPSYCHOPHARMACOLOGY LA English DT Meeting Abstract CT 45th Annual Meeting of the American-College-of-Neuropsychopharmacolgy CY DEC 03-07, 2006 CL Hollywood, FL SP Amer Coll Neuropsychopharmacol C1 Univ Washington, Sch Med, Div Geriatr Psychiat, VA Puget Sound Hlth Care Syst, Seattle, WA USA. RI Tschanz, JoAnn/E-5986-2010; Norton, Maria/E-6994-2013; Hayden, Kathleen/B-6442-2012 OI Hayden, Kathleen/0000-0002-7745-3513 NR 0 TC 2 Z9 2 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD DEC PY 2006 VL 31 SU 1 BP S39 EP S39 PG 1 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 108BS UT WOS:000242215900116 ER PT J AU Raskind, MA Taylor, F Peskind, ER AF Raskind, Murray A. Taylor, Fletcher Peskind, Elaine R. TI The alpha-1 adrenoreceptor antagonist prazosin improves combat veteran and civilian posttraumatic stress disorder SO NEUROPSYCHOPHARMACOLOGY LA English DT Meeting Abstract CT 45th Annual Meeting of the American-College-of-Neuropsychopharmacolgy CY DEC 03-07, 2006 CL Hollywood, FL SP Amer Coll Neuropsychopharmacol C1 VA Puget Sound HCS, Mental Hlth Serv, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD DEC PY 2006 VL 31 SU 1 BP S54 EP S54 PG 1 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 108BS UT WOS:000242215900162 ER PT J AU Tsokas, P Ma, T Blitzer, RD Landau, EM AF Tsokas, Panayiotis Ma, Tao Blitzer, Robert D. Landau, Emmanuel M. TI Tagging and capture in synaptic plasticity SO NEUROPSYCHOPHARMACOLOGY LA English DT Meeting Abstract CT 45th Annual Meeting of the American-College-of-Neuropsychopharmacolgy CY DEC 03-07, 2006 CL Hollywood, FL SP Amer Coll Neuropsychopharmacol C1 James J VAMC, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD DEC PY 2006 VL 31 SU 1 BP S188 EP S189 PG 2 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 108BS UT WOS:000242215900504 ER PT J AU Gordon, LK Goldhardt, R Holland, GN Yu, F Levinson, RD AF Gordon, Lynn K. Goldhardt, Raquel Holland, Gary N. Yu, Fei Levinson, Ralph D. TI Standardized visual field assessment for patients with birdshot chorioretinopathy SO OCULAR IMMUNOLOGY AND INFLAMMATION LA English DT Article DE birdshot chorioretinopathy; retinochoroidopathy; HLA-A29; optic disc edema; visual field; choroidal lesions ID NEURITIS TREATMENT TRIAL; OPTIC NEURITIS; FOLLOW-UP; THRESHOLD ALGORITHMS; FULL THRESHOLD; RETINOCHOROIDOPATHY; CYCLOSPORINE; THERAPY; PROFILE AB Purpose: To adapt a standardized technique for assessment of visual fields to the study of patients with birdshot chorioretinopathy and to describe visual field patterns and changes over time for affected individuals. Methods: A retrospective chart review was performed of patients with a diagnosis of birdshot chorioretinopathy who had undergone at least two automated visual field studies. A masked evaluation of each visual field was performed using standardized criteria. Subjective symptoms and visual acuity measurements were compared to visual field data from the same examination dates. Serial visual field studies were evaluated for changes in the findings over time. Results: Six patients met inclusion criteria. A total of 104 visual field studies ( ranging from 2 - 19 studies per eye) were evaluated. Visual field abnormalities occurred in all tested eyes and were observed even in eyes with a Snellen visual acuity of 20/15. Discordant patterns were observed in the two eyes of some individual patients. On serial testing, multiple patterns of visual field abnormality were observed in the same eye over time. Conclusions: A standardized protocol for systematic evaluation of visual field measurements can be used to characterize disturbances of vision in patients with birdshot chorioretinopathy. Abnormalities of visual fields may occur even when central visual acuity is preserved. C1 Univ Calif Los Angeles, Jules Stein Eye Inst, Ocular Inflammatory Dis Ctr, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA. Greater Los Angeles VA Healthcare Syst, Ophthalmol Sect, Los Angeles, CA USA. RP Gordon, LK (reprint author), Univ Calif Los Angeles, Jules Stein Eye Inst, Ocular Inflammatory Dis Ctr, 100 Stein Plaza, Los Angeles, CA 90095 USA. EM lgordon@ucla.edu NR 23 TC 15 Z9 16 U1 0 U2 3 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 0927-3948 J9 OCUL IMMUNOL INFLAMM JI Ocul. Immunol. Inflamm. PD DEC PY 2006 VL 14 IS 6 BP 325 EP 332 DI 10.1080/09273940600966400 PG 8 WC Ophthalmology SC Ophthalmology GA 115CI UT WOS:000242712000001 PM 17162602 ER PT J AU Rifai, MA AF Rifai, Muhamad Aly TI Ethical impasses in the care of patients with hepatitis C SO PSYCHOSOMATICS LA English DT Letter ID RISK-BENEFIT ASSESSMENT; PSYCHIATRIC-DISORDERS; INTERFERON; INFECTION C1 Portland Vet Affairs Med Ctr, NW Hepatitis C Resource Ctr, Portland, OR USA. RP Rifai, MA (reprint author), Portland Vet Affairs Med Ctr, NW Hepatitis C Resource Ctr, Portland, OR USA. NR 11 TC 4 Z9 4 U1 0 U2 0 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0033-3182 J9 PSYCHOSOMATICS JI Psychosomatics PD DEC PY 2006 VL 47 IS 6 BP 540 EP 541 DI 10.1176/appi.psy.47.6.540 PG 2 WC Psychiatry; Psychology SC Psychiatry; Psychology GA 107NE UT WOS:000242177500019 PM 17116963 ER PT J AU Handler, SM Castle, NG Studenski, SA Perera, S Fridsma, DB Nace, DA T Hanlon, J AF Handler, S. M. Castle, N. G. Studenski, S. A. Perera, S. Fridsma, D. B. Nace, D. A. T Hanlon, J. TI Patient safety culture assessment in the nursing home SO QUALITY & SAFETY IN HEALTH CARE LA English DT Article ID LONG-TERM-CARE; ORGANIZATIONAL CULTURE; OUTCOMES; QUALITY; CLIMATE AB Objective: To assess patient safety culture (PSC) in the nursing home setting, to determine whether nursing home professionals differ in their PSC ratings, and to compare PSC scores of nursing homes with those of hospitals. Methods: The Hospital Survey on Patient Safety Culture was modified for use in nursing homes (PSC-NH) and distributed to 151 professionals in four non-profit nursing homes. Mean scores on each PSC-NH dimension were compared across professions (doctors, pharmacists, advanced practitioners and nurses) and with published benchmark scores from 21 hospitals. Results: Response rates were 68.9% overall and 52-100% for different professions. Most respondents (76%) were women and had worked in nursing homes for an average of 9.8 years, and at their current facility for 5.4 years. Professions agreed on 11 of 12 dimensions of the survey and differed significantly (p < 0.05) only in ratings for one PSC dimension (attitudes about staffing issues), where nurses and pharmacists believed that they had enough employees to handle the workload. Nursing homes scored significantly lower (ie, worse) than hospitals (p < 0.05) in five PSC dimensions (non-punitive response to error, teamwork within units, communication openness, feedback and communication about error, and organisational learning). Conclusions: Professionals in nursing homes generally agree about safety characteristics of their facilities, and the PSC in nursing homes is significantly lower than that in hospitals. PSC assessment may be helpful in fostering comparisons across nursing home settings and professions, and identifying targets for interventions to improve patient safety. C1 Univ Pittsburgh, Div Geriatr Med, Dept Med, Pittsburgh, PA 15213 USA. Univ Pittsburgh, Sch Med, Dept Biomed Informat, Pittsburgh, PA USA. Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA 15260 USA. VA Pittsburgh, GRECC, Pittsburgh, PA USA. Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA. Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA. Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equity Res, Pittsburgh, PA USA. RP Handler, SM (reprint author), Univ Pittsburgh, Div Geriatr Med, Dept Med, 3471 5th Ave,Suite 500, Pittsburgh, PA 15213 USA. EM handlersm@upmc.edu RI Perera, Subashan/D-7603-2014 OI Handler, Steven/0000-0002-3940-3224 FU NCRR NIH HHS [K12 RR023267, 8K12 RR 023267]; NIA NIH HHS [5T32AG021885, P30 AG024827, P30-AG024827, T32 AG021885] NR 41 TC 29 Z9 31 U1 4 U2 12 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1475-3898 J9 QUAL SAF HEALTH CARE JI Qual. Saf. Health Care PD DEC PY 2006 VL 15 IS 6 BP 400 EP 404 DI 10.1136/qshc.2006.018408 PG 5 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 111UY UT WOS:000242481800006 PM 17142586 ER PT J AU Stoller, JK Niewoehner, DE Fan, VS AF Stoller, James K. Niewoehner, Dennis E. Fan, Vincent S. TI Disease management as an evolving role for respiratory therapists SO RESPIRATORY CARE LA English DT Editorial Material ID CARE C1 Cleveland Clin Fdn, Dept Pulm Allergy & Crit Care Med, Sect Resp Therapy, Cleveland, OH 44195 USA. Univ Minnesota, Minneapolis Vet Affairs Med Ctr, Pulm Sect, Minneapolis, MN USA. Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. RP Stoller, JK (reprint author), Cleveland Clin Fdn, Dept Pulm & Crit Care Med, A90,9500 Euclid Ave, Cleveland, OH 44195 USA. EM stollej@ccf.org NR 13 TC 4 Z9 4 U1 0 U2 0 PU DAEDALUS ENTERPRISES INC PI IRVING PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA SN 0020-1324 J9 RESPIR CARE JI Respir. Care PD DEC PY 2006 VL 51 IS 12 BP 1400 EP 1402 PG 3 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 119BF UT WOS:000242986500001 PM 17134519 ER PT J AU Cohen, DM AF Cohen, David M. TI Regulation of TRP channels by N-linked glycosylation SO SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY LA English DT Review DE review; transient receptor potential; ion channel ID SHAKER POTASSIUM CHANNEL; CELL-SURFACE EXPRESSION; KLOTHO GENE; SODIUM-CHANNELS; POSTMENOPAUSAL WOMEN; VANILLOID RECEPTOR-1; FUNCTIONAL VARIANT; CA2+ CHANNEL; BONE-DENSITY; PORE REGION AB A subset of TRP channel proteins undergoes regulatory N-linked glycosylation. A glycosylation site in the first extracellular loop of TRPV5 is enzymatically cleaved by a secreted glucuronidase, indirectly regulating channel function. Members of the TRPC family share a similar site, although details about a regulatory role are lacking. A second conserved TRP channel glycosylation site is found immediately adjacent to the channel pore-forming loop; both TRPV1 and TRPV4 - and perhaps other TRPV family members - are influenced by glycosylation at this site. N-linked glycosylation, and the dynamic regulation of this process, substantially impacts function and targeting of TRP channels. (c) 2006 Elsevier Ltd. All rights reserved. C1 Oregon Hlth & Sci Univ, Dept Med, Div Nephrol & Hypertens, Portland, OR 97239 USA. Portland VA Med Ctr, Portland, OR 97239 USA. RP Cohen, DM (reprint author), Oregon Hlth & Sci Univ, Dept Med, Div Nephrol & Hypertens, Mailcode PP262, Portland, OR 97239 USA. EM cohend@ohsu.edu NR 68 TC 30 Z9 30 U1 0 U2 4 PU ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 1084-9521 J9 SEMIN CELL DEV BIOL JI Semin. Cell Dev. Biol. PD DEC PY 2006 VL 17 IS 6 BP 630 EP 637 DI 10.1016/j.semcdb.2006.11.007 PG 8 WC Cell Biology; Developmental Biology SC Cell Biology; Developmental Biology GA 139HP UT WOS:000244423200004 PM 17215147 ER PT J AU Basile, JN Ventura, H AF Basile, Jan N. Ventura, Hector TI A historical look at hypertension: Celebrating 100 years with the Southern Medical Association SO SOUTHERN MEDICAL JOURNAL LA English DT Editorial Material ID UNITED-STATES C1 Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Primary Care Serv Line, Charleston, SC 29401 USA. Med Univ S Carolina, Div Gen Internal Med Geriatr, Charleston, SC 29401 USA. Tulane Univ, Sch Med, Sect Cardiomyopathy & Heart Transplant Ctr, New Orleans, LA USA. RP Basile, JN (reprint author), Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Primary Care Serv Line, 109 Bee St, Charleston, SC 29401 USA. RI Ventura, Hector/A-7691-2011 NR 20 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0038-4348 J9 SOUTH MED J JI South.Med.J. PD DEC PY 2006 VL 99 IS 12 BP 1412 EP 1413 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 172AS UT WOS:000246777100032 PM 17233212 ER PT J AU Vincent, R Treff, N Budde, M Kastenberg, Z Odorico, J AF Vincent, Robert Treff, Nathan Budde, Melisa Kastenberg, Zachary Odorico, Jon TI Generation and characterization of novel tetracycline-inducible pancreatic transcription factor-expressing murine embryonic stem cell lines SO STEM CELLS AND DEVELOPMENT LA English DT Article ID INSULIN-PRODUCING CELLS; BETA-CELLS; IN-VITRO; ISLET DIFFERENTIATION; GENE-EXPRESSION; ENDODERM; PROTEIN; PDX-1; MICE; NEUROGENIN-3 AB Pancreatic development in mammals is controlled in part by the expression and function of numerous genes encoding transcription factors. Yet, how these regulate each other and their target genes is incompletely understood. Embryonic stem (ES) cells have recently been shown to be capable of differentiating into pancreatic progenitor cells and insulin-producing cells, representing a useful in vitro model system for studying pancreatic and islet development. To generate tools to study the relationships of transcription factors in pancreatic development we have established seven unique mouse ES cell lines with tetracycline-inducible expression of either Hnf4 alpha, Hnf6, Nkx2.2, Nkx6.1, Pax4, Pdx1, and Ptf1a cDNAs. Each of the cell lines was characterized for induction of transgene expression after exposure to doxycycline (DOX) by quantitative real-time PCR and immunofluorescence microscopy. Transgene expression in the presence of DOX was at least 97-fold that seen in untreated cells. Immunofluorescent staining of DOX-treated cultures showed efficient (> 95% of cells) transgene protein expression while showing < 5% positive staining in uninduced cells. Each of the ES cell lines maintained their pluripotency as measured by teratoma formation. Furthermore, transgene expression can be efficiently achieved in vivo through DOX administration to mice. The establishment of ES cell lines with temporally controllable induction of critical pancreatic transcription factor genes provides a new set of tools that could be used to interrogate gene regulatory networks in pancreatic development and potentially generate greater numbers of ss cells from ES cells. C1 Univ Wisconsin Hosp & Clin, William S Middleton Mem Vet Adm Hosp, Madison, WI 53705 USA. Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, Madison, WI 53792 USA. WiCell Res Inst, Madison, WI 53707 USA. Reprod Med Associates New Jersey, Morristown, NJ 07960 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Vincent, R (reprint author), Univ Wisconsin Hosp & Clin, William S Middleton Mem Vet Adm Hosp, 2500 Overlook Terrace, Madison, WI 53705 USA. EM rkvincent@wisc.edu NR 42 TC 11 Z9 11 U1 0 U2 2 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1547-3287 J9 STEM CELLS DEV JI Stem Cells Dev. PD DEC PY 2006 VL 15 IS 6 BP 953 EP 962 DI 10.1089/scd.2006.15.953 PG 10 WC Cell & Tissue Engineering; Hematology; Medicine, Research & Experimental; Transplantation SC Cell Biology; Hematology; Research & Experimental Medicine; Transplantation GA 129TL UT WOS:000243752900019 PM 17253956 ER PT J AU Dobscha, SK Corson, K Pruitt, S Crutchfield, M Gerrity, MS AF Dobscha, Steven K. Corson, Kathryn Pruitt, Stephanie Crutchfield, Megan Gerrity, Martha S. TI Measuring depression and pain with home health monitors SO TELEMEDICINE JOURNAL AND E-HEALTH LA English DT Article ID SEVERITY; VETERANS; RECALL; PHQ-9 AB The objective of this pilot study was to test the feasibility of using home health monitors to administer standardized measures for depression and pain in a Veterans Affairs (VA) patient population. Five patients were recruited from a larger study of collaborative depression care, and were asked to use Viterion(TM) 100 Telehealth monitors to transmit depression (Patient Health Questionnaire-9) and pain severity (SF36-V bodily pain items) scores on a weekly basis for 24 weeks. Information was received and reviewed by a nurse care manager, who recommended treatment changes as appropriate. The care manager occasionally followed up reports of changes in symptom severity with phone calls; in one case, she called to inquire why a patient was not submitting data. Overall, four patients were able to use the monitors successfully and frequently. Patient satisfaction was high: 5 of 5 reported that they would use monitors again, and 3 of 5 preferred monitors to phone or mail for completing questionnaires. Patients expressed no concerns about privacy. The data allowed tracking of the longitudinal interrelationship between depression and pain severity. However, the monitors were limited in their ability to display questionnaire items, and the system could neither directly compute measure scores nor transfer data to patient medical records. These results suggest that with modifications, home health monitoring shows promise for monitoring symptom severity for a variety of medical and mental health conditions, for either clinical or research purposes. C1 Portland VA Med Ctr, Behav Hlth & Clin Neurosci Div, Portland, OR 97207 USA. Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR USA. Portland VA Med Ctr, Res & Dev Serv, Portland, OR 97207 USA. Portland VA Med Ctr, Div Hosp & Specialty Med, Portland, OR 97207 USA. Oregon Hlth & Sci Univ, Dept Med, Portland, OR USA. RP Dobscha, SK (reprint author), Portland VA Med Ctr, Behav Hlth & Clin Neurosci Div, POB 1034 P3MHDC, Portland, OR 97207 USA. EM steven.dobscha@med.va.gov NR 14 TC 8 Z9 8 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-5627 J9 TELEMED J E-HEALTH JI Telemed. J. e-Health PD DEC PY 2006 VL 12 IS 6 BP 702 EP 706 DI 10.1089/tmj.2006.12.702 PG 5 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 129TJ UT WOS:000243752700028 PM 17250493 ER PT J AU O'Barr, SA Oh, JS Ma, C Brent, GA Schultz, JJ AF O'Barr, Stephen A. Oh, Jin S. Ma, Chan Brent, Gregory A. Schultz, James J. TI Thyroid hormone regulates endogenous amyloid-beta precursor protein gene expression and processing in both in vitro and in vivo models SO THYROID LA English DT Article ID ALZHEIMERS-DISEASE; MESSENGER-RNA; NEUROBLASTOMA-CELLS; REGIONAL EXPRESSION; NEGATIVE REGULATION; RESPONSE ELEMENTS; RAT-BRAIN; RECEPTOR; TRIIODOTHYRONINE; DIFFERENTIATION AB Thyroid hormone negatively regulates the amyloid-beta precursor protein (APP) gene in thyroid hormone receptor (TR)-transfected neuroblastoma cells. A negative thyroid hormone response element (nTRE) that mediates this regulation has been identified in the first exon of the APP gene. We demonstrate in an in vivo system that expression of APP mRNA, APP protein, and APP secretase cleavage products in mouse brain is influenced by thyroid status. Adult female mice were made hyperthyroid or hypothyroid for 3weeks and compared to euthyroid mice. APP gene product expression was increased in hypothyroid mouse brain and reduced in hyperthyroid mouse brain, when compared to euthyroid controls. We observed similar effects of thyroid hormone on endogenous APP gene expression in human neuroblastoma cells. The incidence of hypothyroidism increases with age, and localized hypothyroidism of central nervous system has been reported in some patients with Alzheimer's disease (AD). Reduced action of thyroid hormone on the APP gene may contribute to AD pathology by increasing APP expression and the levels of processed APP products. These findings may be an underlying mechanism contributing to the association of hypothyroidism with AD in the elderly, as well as identifying a potential therapeutic target. Pharmacologic supplementation of thyroid hormone, or its analogs, may reduce APP gene expression and beta amyloid peptide accumulation. C1 Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Mol Endocrinol Lab,Dept Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Mol Endocrinol Lab,Dept Physiol, Los Angeles, CA 90073 USA. Western Univ Hlth Sci, Coll Pharm, Dept Pharmaceut Sci, Pomona, CA USA. RP Brent, GA (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Mol Endocrinol Lab,Dept Med, Bldg 114,Rm 230,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM gbrent@ucla.edu FU NIDDK NIH HHS [R01 DK67233] NR 35 TC 22 Z9 22 U1 1 U2 3 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1050-7256 J9 THYROID JI Thyroid PD DEC PY 2006 VL 16 IS 12 BP 1207 EP 1213 DI 10.1089/thy.2006.16.1207 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 123RD UT WOS:000243312200003 PM 17199430 ER PT J AU Schnickel, GT Hsieh, GR Garcia, C Shefizadeh, A Fishbein, MC Ardehali, A AF Schnickel, G. T. Hsieh, G. R. Garcia, C. Shefizadeh, A. Fishbein, M. C. Ardehali, A. TI Role of CXCR3 and CCR5 in allograft rejection SO TRANSPLANTATION PROCEEDINGS LA English DT Article; Proceedings Paper CT 1st World Transplant Congress (WTC 2006) CY JUL 23-27, 2006 CL Boston, MA SP Transplantat Soc, Amer Soc Transplantat, Amer Soc Transplan Surg ID CHEMOKINE RECEPTOR CXCR3; PROLIFERATION; RECRUITMENT; SURVIVAL; EFFECTOR AB Chemokines are known to participate in allograft rejection by mediating leukocyte trafficking. Despite redundancy in chemokine family, several chemokine-chemokine receptor interactions have proven critical in alloimmune responses. We sought to determine the effect of combined blockade of CXCR3 and CCR5, two critical chemokine receptors, in acute rejection. Methods: Heterotopic heart transplantation was performed using BALB/c to 136/129 mice deficient in CCR5. Following transplantation these mice were treated with goat anti-CXCR3 serum every other day. In the control group, BALB/c hearts were transplanted in wild type 136/129 recipients and treated with goat serum alone. No immunosuppression was given to either group. Recipient mice were then assessed daily for allograft function by abdominal palpation, and graft survival was confirmed by laparotomy. Methods: Heterotopic heart transplantation was performed using BALB/c to B6/129 mice deficient in CCR5. Following transplantation these mice were treated with goat anti-CXCR3 serum every other day. In the control group, BALB/c hearts were transplanted in wild type B6/129 recipients and treated with goat serum alone. No immunosuppression was given to either group. Recipient mice were then assessed daily for allograft function by abdominal palpation, and graft survival was confirmed by laparotomy. Results: The donor hearts in the control group were rejected at 6 +/- 1 days posttransplantation. Combined blockade of CXCR3 and CCR5 prolonged allograft survival versus control; all allografts survived to 24 days. In addition, there was a decrease in graft infiltrating CD4 and CD8 lymphocytes in the experimental group at 24 days. Conclusion: Combined CXCR3 and CCR5 blockade is effective in prolonging allograft survival in a fully MHC mismatched murine model. Combined chemokine blockade holds promise in control of acute rejection in organ transplantation. C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Div Cardiac Surg, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. Los Angeles VA Med Ctr, Los Angeles, CA USA. RP Schnickel, GT (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Div Cardiac Surg, 10833 LeConte Ave,62-186 CHS, Los Angeles, CA 90095 USA. OI Schnickel, Gabriel/0000-0003-4392-2200 NR 14 TC 11 Z9 11 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0041-1345 J9 TRANSPLANT P JI Transplant. Proc. PD DEC PY 2006 VL 38 IS 10 SI SI BP 3221 EP 3224 DI 10.1016/j.transproceed.2006.10.164 PG 4 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA 120PY UT WOS:000243098400016 PM 17175228 ER PT J AU Akoad, M Wagener, M Francis, F Ahmed, J Ulizio, D Cacciarelli, TV AF Akoad, M. Wagener, M. Francis, F. Ahmed, J. Ulizio, D. Cacciarelli, T. V. TI Outcome of imported liver allografts and impact on patient access to liver transplantation SO TRANSPLANTATION PROCEEDINGS LA English DT Article; Proceedings Paper CT 1st World Transplant Congress (WTC 2006) CY JUL 23-27, 2006 CL Boston, MA SP Transplantat Soc, Amer Soc Transplantat, Amer Soc Transplan Surg ID POSITIVE GRAFTS; DONOR AGE; EXPERIENCE; RECIPIENTS; INFECTION AB Liver allografts declined by local transplant centers are then offered regionally or nationally as imported grafts. Most of these grafts are declined because of poor donor quality. We retrospectively reviewed the medical records of patients who underwent liver transplantation between January 2004 and December 2005. There were 102 liver transplants in 98 recipients. They were divided into two groups: imported graft recipients (n = 37) and locally procured grafts recipients (n = 61). Eighty-six percent (32 of 37) of imported grafts were obtained from extended criteria donors defined as subjects treated with high doses of ionotropes with elevated liver enzymes, donor age over 70 years, macrosteatosis above 25%, positive hepatitis C or hepatitis B core antibody serology, systemic disease, history of cancer, hypernatremia, or with infection. The remaining grafts were declined due to unavailability of suitable recipients or social history. Recipient age and etiology of liver disease were similar for both groups. The mean MELD score was 22.1 +/- .9 among the imported graft recipients and 26.1 +/- 1 for the locally procured graft recipients (P < .01). There was no difference in blood loss or postoperative complications. Postoperative mean peak total bilirubin was similar in both groups. However, imported graft recipients had significantly higher mean peak AST (2436 +/- 282 vs 1380 +/- 165 U/L, P < .001) and ALT (1098 +/- 114 vs 803 +/- 87 U/L, P < .05). Primary graft nonfunction as well as 30 day and 1-year patient and graft survivals were similar for both groups. In conclusion, imported grafts can be transplanted in selected patients with outcomes comparable to locally procured grafts. C1 VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15237 USA. RP Akoad, M (reprint author), VA Pittsburgh Healthcare Syst, Univ Dr C,Suite 112F, Pittsburgh, PA 15237 USA. EM mohamed.akoad@med.va.gov NR 9 TC 3 Z9 3 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0041-1345 J9 TRANSPLANT P JI Transplant. Proc. PD DEC PY 2006 VL 38 IS 10 SI SI BP 3564 EP 3566 DI 10.1016/j.transproceed.2006.10.037 PG 3 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA 120PY UT WOS:000243098400120 PM 17175332 ER PT J AU Plassman, BL Steffens, DC Burke, JR Welsh-Bohmer, KA Newman, TN Drosdick, D Helms, MJ Potter, GG Breitner, JCS AF Plassman, Brenda L. Steffens, David C. Burke, James R. Welsh-Bohmer, Kathleen A. Newman, Tiffany N. Drosdick, Deborah Helms, Michael J. Potter, Guy G. Breitner, John C. S. TI Duke Twins Study of Memory in Aging in the NAS-NRC Twin Registry SO TWIN RESEARCH AND HUMAN GENETICS LA English DT Article ID ELDERLY MALE TWINS; ALZHEIMERS-DISEASE; INTERNATIONAL WORKSHOP; COGNITIVE STATUS; DEMENTIA QUESTIONNAIRE; DIAGNOSIS; VETERANS; RELIABILITY; VALIDITY; CRITERIA AB The Duke Twins Study of Memory in Aging is an ongoing, longitudinal study of cognitive change and dementia in the population-based National Academy of Sciences-National Research Council (NAS-NRC) Twin Registry of World War II Male Veterans. The primary goal of this study has been to estimate the overall genetic and environmental contributions to dementia with a specific focus on Alzheimer's disease. An additional goal has been to examine specific genetic and environmental antecedents of cognitive decline and dementia. Since 1989, we have completed 4 waves of data collection. Each wave included a 2-phase telephone cognitive screening protocol, followed by an in-home standardized clinical assessment for those with suspected dementia. For many participants, we have obtained postmortem neuropathological confirmation of the diagnosis of dementia. In addition to data on cognition, we have also collected information on occupational history, medical history, medications and other lifetime experiences that may influence cognitive function in late life. We provide an overview of the study's methodology and describe the focus of recent research. C1 Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27701 USA. Duke Univ, Med Ctr, Dept Neurol, Durham, NC USA. Duke Univ, Med Ctr, Joseph & Kathleen Bryan Alzheimers Dis Res Ctr, Durham, NC USA. Univ Washington, Sch Med, VA Puget Sound Hlth Care Syst, Seattle, WA USA. Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Plassman, BL (reprint author), Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, 905 W Main St,Box 41,Suite 25-D, Durham, NC 27701 USA. EM brenda.plassman@duke.edu RI Burke, James/E-4245-2016 OI Burke, James/0000-0002-3408-7787 FU NIA NIH HHS [AG 08549, R03 AG 22683-01] NR 37 TC 18 Z9 18 U1 2 U2 5 PU AUSTRALIAN ACAD PRESS PI BOWEN HILLS PA 32 JEAYS ST, BOWEN HILLS, QLD 4006, AUSTRALIA SN 1832-4274 J9 TWIN RES HUM GENET JI Twin Res. Hum. Genet. PD DEC PY 2006 VL 9 IS 6 BP 950 EP 957 DI 10.1375/183242706779462381 PG 8 WC Genetics & Heredity; Obstetrics & Gynecology SC Genetics & Heredity; Obstetrics & Gynecology GA 122HO UT WOS:000243216600042 PM 17254435 ER PT J AU Latini, DM Chan, JM Cowan, JE Arredondo, SA Kane, CJ Penson, DF DuChane, J Carroll, PR AF Latini, David M. Chan, June M. Cowan, Janet E. Arredondo, Shelley A. Kane, Christopher J. Penson, David F. DuChane, Janeen Carroll, Peter R. CA CaPSURE Investigators TI Health-related quality of life for men with prostate cancer and diabetes: A longitudinal analysis from CaPSURE SO UROLOGY LA English DT Article ID RADICAL PROSTATECTOMY; ERECTILE DYSFUNCTION; OBESITY; DISEASE; RISK; MANAGEMENT; RECURRENCE; PREDICTOR; DATABASE; EXCEED AB Objectives. To compare diabetic versus nondiabetic men with prostate cancer to understand whether diabetes mellitus (DM) imposes an additional burden on health-related quality of life (HRQOL) before and after radical prostatectomy, adjusting for obesity. Methods. Data were abstracted from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE), a disease registry of 12,005 men with localized prostate cancer. Men were included who had undergone surgical treatment from 1989 to 2003, had body mass index (BMI) information available, and had completed both a pretreatment and at least one posttreatment HRQOL questionnaire within 24 months. A repeated-measures model adjusted for baseline clinical and demographic variables was used to evaluate group differences. Results. The 1248 men were divided into two groups (117 with DM and 1131 without DM) on the basis of a history of DM or the reporting of diabetes medication use. The diabetic men were significantly more likely to be older and nonwhite, have lower education and income, and be less likely to have private insurance. They also had significantly more comorbid conditions (other than DM) and a greater BM I at baseline. Urinary function differed by diabetes status, BMI, and the DM x BMI interaction, with diabetic men who had a greater BMI reporting greater declines in urinary function over time. No other statistically significant differences in HRQOL were observed, although trends by BMI were noted in sexual function and bowel bother. Conclusions. Although previous studies of men with prostate cancer have found differences in HRQOL by obesity level, our results have indicated that the presence or absence of DM and a high BMI may have a greater impact on HRQOL than obesity alone. C1 Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA. Baylor Coll Med, Dept Urol, Houston, TX 77030 USA. Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA. Univ Calif San Francisco, Dept Urol, Program Urol Oncol, Genitourinary Canc Epidemiol & Populat Sci Progra, San Francisco, CA 94143 USA. Univ Calif San Francisco, Ctr Comprehens Canc, Sch Med, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Epidemiol & Biostat, Sch Med, San Francisco, CA 94143 USA. San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. Univ So Calif, Dept Urol & Prevent Med, Keck Sch Med, Los Angeles, CA 90089 USA. TAP Pharmaceut Prod Inc, Lake Forest, IL USA. RP Latini, DM (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, 152,2002 Holcombe Blvd, Houston, TX 77030 USA. EM latini@bcm.tmc.edu OI Latini, David/0000-0002-6161-4861 FU PHS HHS [P50 C89520] NR 22 TC 13 Z9 13 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0090-4295 J9 UROLOGY JI Urology PD DEC PY 2006 VL 68 IS 6 BP 1242 EP 1247 DI 10.1016/j.urology.2006.08.1096 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 117JR UT WOS:000242869900021 PM 17141841 ER PT J AU Sim, HG Kliot, M Lange, PH Ellis, WJ Takayama, TK Yang, CC AF Sim, Hong Gee Kliot, Michel Lange, Paul H. Ellis, William J. Takayama, Thomas K. Yang, Claire C. TI Two-year outcome of unilateral sural nerve interposition graft after radical prostatectomy SO UROLOGY LA English DT Article ID RESTORE ERECTILE FUNCTION; RETROPUBIC PROSTATECTOMY; EXTRACAPSULAR EXTENSION; INTERNATIONAL INDEX; CAVERNOUS NERVES; SEXUAL FUNCTION; CANCER; DYSFUNCTION; RATS AB Objectives. To study 41 men treated for prostate cancer with unilateral nerve-sparing radical prostatectomy and contralateral sural nerve grafting from January 2000 to September 2003. Methods. Patients were considered for sural nerve grafting if they were considered at high risk of extracapsular extension before or during surgery, were younger than 70 years of age with good preoperative erectile function, were sexually active, and had no significant risk factors for erectile dysfunction. Potency was assessed by patient-reported questionnaires, including the International Index of Erectile Function erectile domain and Rigiscan testing. Results. The mean follow-up was 27.4 +/- 14.5 months. At 24 months, 24 (63.2%) of 38 men had erections sufficient for intercourse, with or without phosphodiesterase type 5 inhibitor use. Four men had partial erections that were occasionally satisfactory (10.5%), and 10 men reported no sexual activity, no spontaneous erections, or partial erections unsatisfactory for intercourse (26.3%). In contrast, in a group of 49 men who underwent unilateral nerve-sparing prostatectomy without nerve grafting during the same period at our institution, 13 (26.5%) had rigid erections adequate for intercourse with or without phosphodiesterase type 5 inhibitor use at 24 months of follow-up. Conclusions. At 24 months of follow-up, men who had undergone unilateral nerve-sparing prostatectomy with contralateral sural nerve interposition graft repair of a cut cavernosal nerve had a greater rate of return of erectile function than men undergoing unilateral nerve-sparing prostatectomy alone. C1 Univ Washington, Sch Med, Dept Urol, Seattle, WA 98195 USA. Univ Washington, Sch Med, Dept Neurosurg, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. RP Yang, CC (reprint author), Univ Washington, Sch Med, Dept Urol, Box 356510, Seattle, WA 98195 USA. EM cyang@u.washington.edu NR 21 TC 16 Z9 18 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0090-4295 J9 UROLOGY JI Urology PD DEC PY 2006 VL 68 IS 6 BP 1290 EP 1294 DI 10.1016/j.urology.2006.08.1064 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 117JR UT WOS:000242869900030 PM 17141842 ER PT J AU Shiotani, A Haruma, K Uedo, N Iishi, H Ishihara, R Tatsuta, M Kumamoto, M Nakae, Y Ishiguro, S Graham, DY AF Shiotani, Akiko Haruma, Ken Uedo, Noriya Iishi, Hiroyasu Ishihara, Ryu Tatsuta, Masaharu Kumamoto, Mitutaka Nakae, Yukinori Ishiguro, Shingo Graham, David Y. TI Histological risk markers for non-cardia early gastric cancer - Pattern of mucin expression and gastric cancer SO VIRCHOWS ARCHIV LA English DT Article DE early gastric cancer; type III intestinal metaplasia; MUC2; MUC5AC; MUC6 ID INTESTINAL METAPLASIA; HUMAN STOMACH; CHROMOSOMAL LOCALIZATION; PHENOTYPIC-EXPRESSION; CARCINOMA; ADENOCARCINOMAS; CARCINOGENESIS; ATROPHY; GENES; CLASSIFICATION AB There are limited data regarding the prognostic value of the pattern of mucin expression in IM. To examine the role of the type of IM and pattern of mucin expression in IM as histological risk markers of gastric cancer, 80 patients with a history of endoscopic mucosal resection (EMR) for early gastric cancer and 80 sex and age-matched controls were studied. Serum levels of pepsinogen (PG) were measured by RIA, and MUC2, MUC5AC and MUC6 were evaluated immunohistochemically. There is a significant association between types of IM and atrophic scores or PG levels. The most incomplete IM (type II and III) preserving gastric mucin is the gastric and intestinal mixed (GI) type, whereas the complete type is the intestinal (I) type especially in the corpus lesser curve. Gastric cancer was most significantly associated with incomplete IM in the corpus lesser curve (OR=6.4; 95% CI, 2.0-21, p=0.002). Asynchronous multiple lesions were associated with incomplete IM in the corpus greater curve (OR=4.8; 95% CI, 1.4-16, p=0.01). Classification of IM obtained using fixed-point biopsy samples may enhance the ability of surveillance programs to detect patients at increased risk of gastric cancer. C1 Kawasaki Med Univ, Dept Internal Med, Okayama, Japan. Osaka Med Ctr Canc & Cardiovasc Dis, Dept Gastrointestinal Oncol, Osaka, Japan. Aishinkai Nakae Hosp, Dept Med, Wakayama, Japan. VA Med Ctr, Dept Med, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. RP Shiotani, A (reprint author), 577 Matsushima, Kurashiki, Okayama 7010192, Japan. EM shiotani@med.kawasaki-m.ac.jp NR 40 TC 11 Z9 11 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0945-6317 J9 VIRCHOWS ARCH JI Virchows Arch. PD DEC PY 2006 VL 449 IS 6 BP 652 EP 659 DI 10.1007/s00428-006-0300-8 PG 8 WC Pathology SC Pathology GA 109ST UT WOS:000242329600007 PM 17058096 ER PT J AU Belfort, R Harrison, SA Brown, K Darland, C Finch, J Hardies, J Balas, B Gastaldelli, A Tio, F Pulcini, J Berria, R Ma, JZ Dwivedi, S Havranek, R Fincke, C DeFronzo, R Bannayan, GA Schenker, S Cusi, K AF Belfort, Renata Harrison, Stephen A. Brown, Kenneth Darland, Celia Finch, Joan Hardies, Jean Balas, Bogdan Gastaldelli, Amalia Tio, Fermin Pulcini, Joseph Berria, Rachele Ma, Jennie Z. Dwivedi, Sunil Havranek, Russell Fincke, Chris DeFronzo, Ralph Bannayan, George A. Schenker, Steven Cusi, Kenneth TI A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID FATTY LIVER-DISEASE; HEPATIC INSULIN-RESISTANCE; ACTIVATED PROTEIN-KINASE; TYPE-2 DIABETIC-PATIENTS; WEIGHT-LOSS; PLASMA ADIPONECTIN; ADIPOSE-TISSUE; OBESE SUBJECTS; RAT-LIVER; VITAMIN-E AB BACKGROUND: No pharmacologic therapy has conclusively proved to be effective for the treatment of nonalcoholic steatohepatitis, which is characterized by insulin resistance, steatosis, and necroinflammation with or without centrilobular fibrosis. Pioglitazone is a thiazolidinedione that ameliorates insulin resistance and improves glucose and lipid metabolism in type 2 diabetes mellitus. METHODS: We randomly assigned 55 patients with impaired glucose tolerance or type 2 diabetes and liver biopsy-confirmed nonalcoholic steatohepatitis to 6 months of treatment with a hypocaloric diet (a reduction of 500 kcal per day in relation to the calculated daily intake required to maintain body weight) plus pioglitazone (45 mg daily) or a hypocaloric diet plus placebo. Before and after treatment, we assessed hepatic histologic features, hepatic fat content by means of magnetic resonance spectroscopy, and glucose turnover during an oral glucose tolerance test ([(C-14]glucose given with the oral glucose load and [H-3]glucose given by intravenous infusion). RESULTS: Diet plus pioglitazone, as compared with diet plus placebo, improved glycemic control and glucose tolerance (P<0.001), normalized liver aminotransferase levels as it decreased plasma aspartate aminotransferase levels (by 40% vs. 21%, P=0.04), decreased alanine aminotransferase levels (by 58% vs. 34%, P<0.001), decreased hepatic fat content (by 54% vs. 0%, P<0.001), and increased hepatic insulin sensitivity (by 48% vs. 14%, P=0.008). Administration of pioglitazone, as compared with placebo, was associated with improvement in histologic findings with regard to steatosis (P=0.003), ballooning necrosis (P=0.02), and inflammation (P=0.008). Subjects in the pioglitazone group had a greater reduction in necroinflammation (85% vs. 38%, P=0.001), but the reduction in fibrosis did not differ significantly from that in the placebo group (P=0.08). Fatigue and mild lower-extremity edema developed in one subject who received pioglitazone; no other adverse events were observed. CONCLUSIONS: In this proof-of-concept study, the administration of pioglitazone led to metabolic and histologic improvement in subjects with nonalcoholic steatohepatitis. Larger controlled trials of longer duration are warranted to assess the long-term clinical benefit of pioglitazone. C1 Univ Texas, Hlth Sci Ctr, Diabet Div, San Antonio, TX 78229 USA. Brooke Army Med Ctr, San Antonio, TX USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. CNR, Inst Clin Physiol, Pisa, Italy. RP Cusi, K (reprint author), Univ Texas, Hlth Sci Ctr, Diabet Div, Rm 3-3805,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM cusi@uthscsa.edu RI Gastaldelli, Amalia/H-3319-2014 OI Gastaldelli, Amalia/0000-0003-2594-1651 FU NCRR NIH HHS [M01-RR-01346] NR 38 TC 798 Z9 822 U1 1 U2 22 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD NOV 30 PY 2006 VL 355 IS 22 BP 2297 EP 2307 DI 10.1056/NEJMoa060326 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 110CG UT WOS:000242355300005 PM 17135584 ER PT J AU Grady, D AF Grady, Deborah TI Management of menopausal symptoms SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; HORMONE REPLACEMENT THERAPY; CONJUGATED EQUINE ESTROGENS; MILD COGNITIVE IMPAIRMENT; HEALTH INITIATIVE MEMORY; INDUCED HOT FLASHES; POSTMENOPAUSAL WOMEN; BREAST-CANCER; VASOMOTOR SYMPTOMS; DOUBLE-BLIND C1 Univ Calif San Francisco, Womens Hlth Clin Res Ctr, San Francisco, CA 94115 USA. San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. RP Grady, D (reprint author), Univ Calif San Francisco, Womens Hlth Clin Res Ctr, 1635 Divisadero St,Suite 600, San Francisco, CA 94115 USA. NR 61 TC 83 Z9 85 U1 1 U2 1 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD NOV 30 PY 2006 VL 355 IS 22 BP 2338 EP 2347 DI 10.1056/NEJMcp054015 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 110CG UT WOS:000242355300009 PM 17135587 ER PT J AU Harel, O Zhou, XH AF Harel, Ofer Zhou, Xiao-Hua TI Multiple imputation for correcting verification bias SO STATISTICS IN MEDICINE LA English DT Article DE missing data; multiple imputations; software; Bayesian methods; verification bias ID INTERVAL ESTIMATION; DIAGNOSTIC-TESTS; DISTRIBUTIONS; SELECTION; SAMPLES AB In the case in which all subjects are screened using a common test and only a subset of these subjects are tested using a golden standard test, it is well documented that there is a risk for bias, called verification bias. When the test has only two levels (e.g. positive and negative) and we are trying to estimate the sensitivity and specificity of the test, we are actually constructing a confidence interval for a binomial proportion. Since it is well documented that this estimation is not trivial even with complete data, we adopt multiple imputation framework for verification bias problem. We propose several imputation procedures for this problem and compare different methods of estimation. We show that our imputation methods are better than the existing methods with regard to nominal coverage and confidence interval length. Copyright (c) 2006 John Wiley & Sons, Ltd. C1 VA Puget Sound Hlth Care Syst, HSR&D Ctr Excellence, Seattle, WA 98108 USA. Univ Connecticut, Dept Stat, Storrs, CT 06269 USA. Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98195 USA. RP Zhou, XH (reprint author), VA Puget Sound Hlth Care Syst, HSR&D Ctr Excellence, 1660 S Columbian Way,1-424, Seattle, WA 98108 USA. EM oharel@stat.uconn.edu; azhou@u.washington.edu FU NIMH NIH HHS [K01 MH087219] NR 24 TC 33 Z9 33 U1 0 U2 1 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 0277-6715 J9 STAT MED JI Stat. Med. PD NOV 30 PY 2006 VL 25 IS 22 BP 3769 EP 3786 DI 10.1002/sim.2494 PG 18 WC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Medicine, Research & Experimental; Statistics & Probability SC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Research & Experimental Medicine; Mathematics GA 111CT UT WOS:000242429400001 PM 16435337 ER PT J AU Corboy, JR Gault, J Kleinschmidt-DeMasters, BK AF Corboy, John R. Gault, Judith Kleinschmidt-DeMasters, B. K. TI An adult case of leukoencephalopathy with intracranial calcifications and cysts SO NEUROLOGY LA English DT Article ID MUTATIONS AB Leukoencephalopathies are generally volume-losing processes, although several variants, such as Alexander disease and Canavan disease, may cause megalencephaly. Leukoencephalopathies that generate severe edema, are mass producing, and mimic neoplasms are rare. In 1996, a new cerebral disorder was described in three unrelated children who had onset in early infancy to adolescence of slowed cognitive performance, seizures, and extrapyramidal, cerebellar, and pyramidal signs.(1) Neuroimaging studies demonstrated a striking triad of findings: progressive calcifications in the basal ganglia, cerebellar nuclei, and deep white matter; diffuse abnormal signal on MRI in the white matter; and large, space-occupying parenchymal brain cysts generating mass effect. 1 Neuropathologic examination of surgically resected material from one patient revealed "angiomatous-like rearrangements of the microvessels..." that "suggest a constitutional, diffuse cerebral microangiopathy..."(1) Profuse numbers of Rosenthal fibers were identified around the "pseudoangiomatous" blood vessels. The disease did not fit descriptions for any previously known phakomatosis or dysgenetic syndrome. A descriptive name was given to this new syndrome, which was initially thought to be a leukodystrophy. Three more patients were subsequently reported, all of whom also had onset in childhood between the ages 9 and 14 years.(2) More extensive neuroimaging studies suggested that the white matter abnormalities were due to "increased water content rather than a demyelinating process," consistent with a leukoencephalopathy, rather than a leukodystrophy. We now present an adult patient with clinical and pathologic findings nearly identical to these six previously reported children. Because this disorder seemed somewhat similar to adult-onset Alexander disease and was associated with apparent microangiopathy, we also searched for polymorphisms in glial fibrillary acidic protein (GFAP) and cerebral cavernous malformation (CCM) genes. C1 Univ Colorado, Dept Neurol, Denver, CO 80262 USA. Univ Colorado, Dept Neurosurg, Denver, CO 80262 USA. Denver Vet Affairs Med Ctr, Dept Neurol, Denver, CO USA. RP Corboy, JR (reprint author), Univ Colorado, Dept Neurol, Box B-183,4200 E 9th Ave, Denver, CO 80262 USA. EM john.corboy@uchsc.edu NR 5 TC 20 Z9 23 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD NOV 28 PY 2006 VL 67 IS 10 BP 1890 EP 1892 DI 10.1212/01.wnl.0000244470.06748.18 PG 3 WC Clinical Neurology SC Neurosciences & Neurology GA 109WI UT WOS:000242339900039 PM 17130435 ER PT J AU Dublin, S French, B Glazer, NL Wiggins, KL Lumley, T Psaty, BM Smith, NL Heckbert, SR AF Dublin, Sascha French, Benjamin Glazer, Nicole L. Wiggins, Kerri L. Lumley, Thomas Psaty, Bruce M. Smith, Nicholas L. Heckbert, Susan R. TI Risk of new-onset atrial fibrillation in relation to body mass index SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article; Proceedings Paper CT 46th Annual Conference on Cardiovascular Disease Epidemiology and Prevention CY MAR 02-05, 2006 CL Phoenix, AZ SP Amer Heart Assoc, Natl Heart, Lung & Blood Inst ID C-REACTIVE PROTEIN; MYOCARDIAL-INFARCTION; POSTMENOPAUSAL WOMEN; INSULIN SENSITIVITY; OBESITY; ADIPONECTIN; POPULATION; ADULTS; INFLAMMATION; PREVALENCE AB Background: Obesity is associated with increased risk of atrial fibrillation (AF), but it is unknown whether the association differs by duration or persistence of AF. It is also unknown to what extent cardiovascular risk factors may mediate this association. Methods: This population-based case-control study included 425 subjects with new-onset AF and 707 controls. The AF cases were identified through International Classification of Diseases, Ninth Revision codes for inpatient and outpatient visits and verified by medical record review. Medical records provided data on height, weight, and cardiovascular risk factors. Results: On average, AF risk was 3% higher (95% confidence interval [CI], 1%-5%) per unit increment in body mass index (BMI) ( calculated as weight in kilograms divided by height in meters squared). For sustained AF ( duration >= 6 months), risk was higher by 7% (95% CI, 3%-11%) per unit BMI increment; for intermittent AF ( duration >= 8 days or recurrent), 4% ( 95% CI, 1%-6%); and for transitory AF ( duration < 8 days), 1% ( 95% CI, -1% to +4%). Compared with those with normal BMI, the odds ratios for overweight and obese subjects were as follows: overweight, 0.97 ( 95% CI, 0.68-1.38); obese class 1,1.18 ( 95% CI, 0.80-1.73); obese class 2, 1.34 ( 95% CI, 0.82-2.18); and obese class 3, 2.31 ( 95% CI, 1.36-3.91) (P = .002 for trend). When diabetes mellitus, a possible mediator, was added to the model, the odds ratio per unit increment of BMI decreased from 1.034 to 1.028. Adjustment for other cardiovascular risk factors including hyperlipidemia and blood pressure did not attenuate the BMI-AF association. Conclusions: The association with BMI was stronger for sustained AF than for transitory or intermittent AF. The obesity-AF association appears to be partially mediated by diabetes mellitus but minimally through other cardiovascular risk factors. C1 Univ Washington, Hlth Serv Res & Dev, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98101 USA. Univ Washington, Dept Biostat, Seattle, WA 98195 USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. RP Dublin, S (reprint author), Univ Washington, Hlth Serv Res & Dev, Vet Affairs Puget Sound Hlth Care Syst, Metropolitan Pk W,1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM Sascha.Dublin@va.gov FU NHLBI NIH HHS [HL 043201, HL 068639, HL 068986, HL 073410] NR 27 TC 127 Z9 131 U1 1 U2 5 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD NOV 27 PY 2006 VL 166 IS 21 BP 2322 EP 2328 DI 10.1001/archinte.166.21.2322 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 109MQ UT WOS:000242312700004 PM 17130384 ER PT J AU Vickrey, BG Mittman, BS Connor, KI Pearson, ML Della Penna, RD Ganiats, TG DeMonte, RW Chodosh, J Cui, XP Vassar, S Duan, NH Lee, M AF Vickrey, Barbara G. Mittman, Brian S. Connor, Karen I. Pearson, Marjorie L. Della Penna, Richard D. Ganiats, Theodore G. DeMonte, Robert W., Jr. Chodosh, Joshua Cui, Xinping Vassar, Stefanie Duan, Naihua Lee, Martin TI The effect of a disease management intervention on quality and outcomes of dementia care - A randomized, controlled trial SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID MANAGING ALZHEIMERS-DISEASE; LONGITUDINAL DATA-ANALYSIS; CONTROLLED CLINICAL-TRIAL; IMPROVING PRIMARY-CARE; CHRONIC ILLNESS; HEART-FAILURE; OF-CARE; DEPRESSION; GUIDELINES; HEALTH AB Background: Adherence to dementia guidelines is poor despite evidence that some guideline recommendations can improve symptoms and delay institutionalization of patients. Objective: To test the effectiveness of a dementia guideline-based disease management program on quality of care and outcomes for patients with dementia. Design: Clinic-level, cluster randomized, controlled trial. Setting: 3 health care organizations collaborating with 3 community agencies in southern California. Participants: 18 primary care clinics and 408 patients with dementia age 65 years or older paired with 408 informal caregivers. Intervention: Disease management program led by care managers and provided to 238 patient-caregiver pairs at 9 intervention clinics for more than 12 months. Measurements: Adherence to 23 guideline recommendations (primary outcome) and receipt of community resources and patient and caregiver health and quality-of-care measures (secondary outcomes). Results: The mean percentage of per-patient guideline recommendations to which care was adherent was significantly higher in the intervention group than in the usual care group (63.9% vs. 32.9%, respectively; adjusted difference, 30.1% [95% Cl, 25.2% to 34.9%]; P < 0.001). Participants who received the intervention had higher care quality on 21 of 23 guidelines (P <= 0.013 for all), and higher proportions received community agency assistance (P <= 0.03) than those who received usual care. Patient health-related quality of life, overall quality of patient care, caregiving quality, social support, and level of unmet caregiving assistance needs were better for participants in the intervention group than for those in the usual care group (P < 0.05 for all). Caregiver health-related quality of life did not differ between the 2 groups. Limitations: Participants were well-educated, were predominantly white, had a usual source of care, and were not institutionalized. Generalizability to other patients and geographic regions is unknown. Also, costs of a care management program under fee-for-service reimbursement may impede adoption. Conclusions: A dementia guideline-based disease management program led to substantial improvements in quality of care for patients with dementia. C1 Univ Calif Los Angeles, Dept Neurol, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA. RAND Corp, Santa Monica, CA USA. Kaiser Permanente Federat, San Diego, CA USA. Univ Calif San Diego, San Diego, CA 92103 USA. Univ Calif Riverside, Riverside, CA 92521 USA. Scripps Clin, La Jolla, CA USA. RP Vickrey, BG (reprint author), Univ Calif Los Angeles, Dept Neurol, VA Greater Los Angeles Healthcare Syst, C-109 RNRC,Box 951769, Los Angeles, CA 90095 USA. EM bvickrey@ucla.edu OI Penna, Maria Pietronilla/0000-0002-0982-3893 NR 63 TC 190 Z9 191 U1 2 U2 26 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD NOV 21 PY 2006 VL 145 IS 10 BP 713 EP 726 PG 14 WC Medicine, General & Internal SC General & Internal Medicine GA 110OB UT WOS:000242387100001 PM 17116916 ER PT J AU Covinsky, KE Johnston, CB AF Covinsky, Kenneth E. Johnston, C. Bree TI Envisioning better approaches for dementia care SO ANNALS OF INTERNAL MEDICINE LA English DT Editorial Material ID CAREGIVER CHARACTERISTICS; ALZHEIMERS-DISEASE; DEPRESSION; PATIENT; PROGRAM; TRIAL C1 Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94121 USA. San Francisco Vet Affairs Med Ctr, San Francisco, CA 94121 USA. RP Covinsky, KE (reprint author), Univ Calif San Francisco, Div Geriatr, 4150 Clement 181G, San Francisco, CA 94121 USA. EM ken.covinsky@ucsf.edu FU NIA NIH HHS [R0AG023626] NR 13 TC 16 Z9 16 U1 0 U2 0 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD NOV 21 PY 2006 VL 145 IS 10 BP 780 EP 781 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 110OB UT WOS:000242387100008 PM 17116923 ER PT J AU Wang, Q Tang, XN Wang, LZ Yenari, MA Ying, WH Goh, BC Lee, HS Wilder-Smith, EP Wong, PT AF Wang, Qing Tang, Xian Nan Wang, Lingzhi Yenari, Midori A. Ying, Weihai Goh, Boon-Cher Lee, How-Sung Wilder-Smith, Einar P. Wong, Peter T. TI Effects of high dose of simvastatin on levels of dopamine and its reuptake in prefrontal cortex and striatum among SD rats SO NEUROSCIENCE LETTERS LA English DT Article DE hydroxymethylglutaryl-coenzyme reductase inhibitors; simvastatin; reuptake; DA; rat striatum; prefrontal cortex ID D-2 RECEPTOR EXPRESSION; PARKINSONS-DISEASE; STATINS; STRESS; BRAIN; ATORVASTATIN; RELEASE; NEUROTRANSMITTERS; NORADRENALINE; INVOLVEMENT AB Statins are increasingly being used for the treatment of a variety of conditions beyond their original indication for cholesterol lowering. We previously reported that simvastatin increased dopamine receptors in the rat prefrontal cortex [Q. Wang, W.L. Ting, H. Yang, P.T. Wong, High doses of sirrvastatin upregulate dopamine D, and D, receptor expression in the rat prefrontal cortex: possible involvement of endothelial nitric oxide synthase, Br. J. Pharmacol. 144 (2005) 933-939] and restored its downregulation in a model of Parkinson's disease (PD) [Q. Wang, P.H. Wang, C. McLachlan, P.T. Wong, Simvastatin reverses the downregulation of dopamine D1 and D2 receptor expression in the prefrontal cortex of 6-hydroxydopamine-induced Parkinsonian rats, Brain Res. 1045 (2005) 229-233]. Here we explore the effects of simvastatin treatment on tissue dopamine content and reuptake. Sprague-Dawley rats were given simvastatin (1 and 10mgkg-1 day', p.o.) for 4 weeks. Brain tissue from prefrontal cortex and striaturn were taken out for dopamine content and its reuptake. Using high-performance liquid chromatographic-mass spectrometer (HPLC-MS), simvastatin (10 mg kg(-1) day(-1)) was found to increase dopamine content by 110% in the striaturn, but decreased by 76% in the prefrontal cortex compared with the saline treated group. Dopamine (DA) reuptake was unchanged in both brain regions. These results suaaest that chronic treatment with hiah dose of simvastatin may affect DA tissue level in prefrontal cortex and striaturn without changing on DA reuptake. This may have important clinical implications in psychiatric and striatal doparninergic disorders. (c) 2006 Elsevier Ireland Ltd. All ri-hts reserved. C1 Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pharmacol, Singapore 117597, Singapore. Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA. San Francisco Vet Affairs Med Ctr, San Francisco, CA 94121 USA. Natl Univ Singapore Hosp, Yong Loo Lin Sch Med, Div Neurol, Singapore 119074, Singapore. RP Wang, Q (reprint author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pharmacol, Singapore 117597, Singapore. EM denniswq@yahoo.com OI Wilder-Smith, Einar/0000-0003-3402-7503 NR 38 TC 14 Z9 14 U1 0 U2 2 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0304-3940 J9 NEUROSCI LETT JI Neurosci. Lett. PD NOV 20 PY 2006 VL 408 IS 3 BP 189 EP 193 DI 10.1016/j.neulet.2006.09.009 PG 5 WC Neurosciences SC Neurosciences & Neurology GA 104LB UT WOS:000241958800007 PM 16996211 ER PT J AU Martin, BK Breitner, JCS Evans, D Lyketsos, CG Meinert, CL AF Martin, Barbara K. Breitner, John C. S. Evans, Denis Lyketsos, Constantine G. Meinert, Curtis L. CA ADAPT Res Grp TI Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's disease Anti-inflammatory Prevention Trial (ADAPT) SO PLOS CLINICAL TRIALS LA English DT Article ID ACUTE MYOCARDIAL-INFARCTION; RHEUMATOID-ARTHRITIS; CYCLO-OXYGENASE-2 INHIBITORS; SELECTIVE INHIBITORS; RISK; DRUGS; CELECOXIB; CYCLOOXYGENASE-2; ROFECOXIB; NAPROXEN AB Objectives: The Alzheimer's Disease Anti-inflammatory Prevention Trial ( ADAPT) was designed to evaluate the conventional NSAID naproxen sodium and the selective COX-2 inhibitor celecoxib for primary prevention of Alzheimer's dementia ( AD). On 17 December 2004, after the Adenoma Prevention with Celecoxib (APC) trial reported increased cardiovascular risks with celecoxib, the ADAPT Steering Committee suspended treatment and enrollment. This paper reports on cardiovascular and cerebrovascular events in ADAPT. Design: ADAPT is a randomized, placebo-controlled, parallel chemoprevention trial with 1 - 46 mo of follow-up. Setting: The trial was conducted at six field sites in the United States: Baltimore, Maryland; Boston, Massachusetts; Rochester, New York; Seattle, Washington; Sun City, Arizona; and Tampa, Florida. Participants: The 2,528 participants were aged 70 y and older with a family history of AD. Interventions: Study treatments were celecoxib ( 200 mg b. i. d.), naproxen sodium ( 220 mg b. i. d.), and placebo. Outcome measures: Outcome measures were deaths, along with nonfatal myocardial infarction (MI), stroke, congestive heart failure (CHF), transient ischemic attack (TIA), and antihypertensive treatment recorded from structured interviews at scheduled intervals. Cox proportional hazards regression was used to analyze these events individually and in several composites. Results: Counts ( with 3-y incidence) of participants who experienced cardiovascular or cerebrovascular death, MI, stroke, CHF, or TIA in the celecoxib-, naproxen-, and placebo-treated groups were 28/717 (5.54%), 40/713 (8.25%), and 37/1070 (5.68%), respectively. This yielded a hazard ratio (95% confidence interval [ CI]) for celecoxib of 1.10 (0.67 - 1.79) and for naproxen of 1.63 (1.04 - 2.55). Antihypertensive treatment was initiated in 160/440 (47.43%), 147/427 (45.00%), and 164/644 (34.08%). This yielded hazard ratios (CIs) of 1.56 for celecoxib (1.26 - 1.94) and 1.40 for naproxen (1.12 - 1.75). Conclusions: For celecoxib, ADAPT data do not show the same level of risk as those of the APC trial. The data for naproxen, although not definitive, are suggestive of increased cardiovascular and cerebrovascular risk. C1 Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21218 USA. Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. Rush Univ, Med Ctr, Dept Internal Med, Chicago, IL 60612 USA. RP Martin, BK (reprint author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21218 USA. EM bmartin@jhsph.edu NR 30 TC 6 Z9 6 U1 1 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1555-5887 J9 PLOS CLIN TRIALS JI PLos Clin. Trials PD NOV 17 PY 2006 VL 1 IS 7 AR e33 DI 10.1371/journal.pctr.0010033 PG 10 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA 150ST UT WOS:000245239000001 ER PT J AU Boshkov, L Chien, G Van Winkle, D Furnary, AP Wu, YX Grunkemeier, G Morris, CD AF Boshkov, Lynn Chien, Grace Van Winkle, Donna Furnary, Antony P. Wu, Yingxing Grunkemeier, Gary Morris, Cynthia D. TI Prestorage leukoreduction of transfused red cells is associated with significant ongoing 2-12 month survival benefit in cardiac surgery patients. SO BLOOD LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-of-Hematology CY DEC 09-12, 2006 CL Orlando, FL SP Amer Soc Hematol C1 Oregon Hlth & Sci Univ, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR USA. Providence St Vincents Med Ctr, Portland, OR USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. Providence St Vincents Med Ctr, Med Data Res Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD NOV 16 PY 2006 VL 108 IS 11 BP 174A EP 174A PN 1 PG 1 WC Hematology SC Hematology GA 111GS UT WOS:000242440000579 ER PT J AU Toro, JJ Choa-Bayona, L Ahuja, SS Quinones, MP Lee, S Estrada, CA Freytes, CO AF Toro, Juan J. Choa-Bayona, Leonel Ahuja, Seema S. Quinones, Marlon P. Lee, Shuko Estrada, Carlos A. Freytes, Cesar O. TI Chemokine plasma concentration in patients with B-cell chronic lymphocytic leukemia. SO BLOOD LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-of-Hematology CY DEC 09-12, 2006 CL Orlando, FL SP Amer Soc Hematol C1 S Texas Vet Hlth Care Syst, San Antonio, TX USA. Univ Texas, Ctr Hlth Sci, San Antonio, TX 78285 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2006 VL 108 IS 11 MA 4957 BP 326B EP 327B PN 2 PG 2 WC Hematology SC Hematology GA 111GW UT WOS:000242440402076 ER PT J AU Schittenhelm, MM Yee, KW Kampa, KM Heinrich, MC AF Schittenhelm, Marcus M. Yee, Kevin W. Kampa, Kerstin M. Heinrich, Michael C. TI Tandutinib (MLN518), a potent FLT3 inhibitor, synergizes with cytarabine and/or daunorubicin in a sequence-independent manner. SO BLOOD LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-of-Hematology CY DEC 09-12, 2006 CL Orlando, FL SP Amer Soc Hematol C1 Univ Tubingen, Dept Hematol Oncol Rheumatol Immunol & Pulm, Tubingen, Germany. OHSU Canc Inst, Dept Med, Portland, OR USA. Portland VA Med Ctr, Portland, OR USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2006 VL 108 IS 11 MA 1374 BP 401A EP 401A PN 1 PG 1 WC Hematology SC Hematology GA 111GS UT WOS:000242440001633 ER PT J AU Schiller, GJ Sohn, JP Malone, R Bartone, K Habtemariam, B Paquette, R De Vos, S Territo, M AF Schiller, Gary J. Sohn, J. Phillip Malone, R. Bartone, K. Habtemariam, B. Paquette, R. De Vos, Sven Territo, M. TI Phase I/II trial of bortezomib maintenance following autolgous peripheral blood progenitor cell transplantation as treatment for intermediate- and advanced-stage multiple myeloma. SO BLOOD LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-of-Hematology CY DEC 09-12, 2006 CL Orlando, FL SP Amer Soc Hematol C1 Calif State Univ Los Angeles, David Greffen Sch Med, Dept Med, Los Angeles, CA 90032 USA. VA Greater Los Angeles Healthcare Ctr, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2006 VL 108 IS 11 MA 5433 BP 453B EP 453B PN 2 PG 1 WC Hematology SC Hematology GA 111GW UT WOS:000242440402550 ER PT J AU Heinrich, MC Morich, JR Beillard, EJ Fuller, C Galderisi, CD Druker, BJ AF Heinrich, Michael C. Morich, Jason R. Beillard, Emmanuel J. Fuller, Courtney Galderisi, Chad D. Druker, Brian J. TI A novel, high-throughput assay for detection of ABL T315I mutations. SO BLOOD LA English DT Meeting Abstract CT 48th Annual Meeting of the American-Society-of-Hematology CY DEC 09-12, 2006 CL Orlando, FL SP Amer Soc Hematol C1 Portland VA Med Ctr, OHSU Canc Inst, Dept Med, Portland, OR USA. Molecular MD, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2006 VL 108 IS 11 MA 2334 BP 661A EP 661A PN 1 PG 1 WC Hematology SC Hematology GA 111GS UT WOS:000242440003125 ER PT J AU Groeneveld, PW Matta, MA Suh, JJ Heidenreich, PA Shea, JA AF Groeneveld, Peter W. Matta, Mary Anne Suh, Janice J. Heidenreich, Paul A. Shea, Judy A. TI Costs and quality-of-life effects of implantable cardioverter-defibrillators SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Review ID SUDDEN CARDIAC DEATH; VENTRICULAR-ARRHYTHMIAS; ICD; RECIPIENTS; THERAPY; ANTIARRHYTHMICS; EXPERIENCE; ANXIETY; IMPACT; SHOCKS AB Although the clinical efficacy of implantable cardioverter-defibrillators (ICDs) has been convincingly demonstrated in clinical trials, the impact of ICDs on health care costs and recipients' quality of life (QOL) is less certain. The existing Medical research on the health care costs and QOL effects of ICDs was reviewed and summarized. Medline and the Institute for Scientific Information's.Web of Knowledge were searched for publications reporting costs of care and QOL assessments of ICD recipients. Unpublished and nonpeer-reviewed "gray" publications were excluded. Reports were included if they reported primary, original patient data that were collected after 1993, when nonthoracotomy defibrillators entered clinical practice. Two reviewers independently evaluated publications for relevance and quality, abstracted study data, and summarized the findings. Excessive heterogeneity among studies prevented formal meta-analysis, so a narrative synthesis was performed, and key themes were identified from the published research. There were limited published data on the costs of ICD care, especially for the primary prevention of sudden cardiac death. The published research on ICD QOL lacked large, multicenter, longitudinal studies. Many ICD QOL studies were performed in small numbers of patients at single centers. Initial ICD implantation costs ranged (in 2006 United States dollars) from $28,500 to $55,200, with annual follow-up costs ranging from $4,800 to $17,000. QOL was higher for ICD recipients than for patients treated with antiarrhythmic drugs, but there was a substantial prevalence of anxiety, depression, and-"loss of control" in ICD recipients, particularly in those who had received ICD shocks. In conclusion, ICD implantation remains costly but may be becoming less expensive over time, and ICD recipients' QOL is significantly affected by their devices. (c) 2006 Elsevier Inc. All rights reserved. C1 Univ Penn, Sch Med, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. Stanford Univ, Sch Med, Div Cardiol, Stanford, CA 94305 USA. RP Groeneveld, PW (reprint author), Univ Penn, Sch Med, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. EM peter.groeneveld@va.gov OI Heidenreich, Paul/0000-0001-7730-8490 NR 34 TC 25 Z9 25 U1 2 U2 3 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD NOV 15 PY 2006 VL 98 IS 10 BP 1409 EP 1415 DI 10.1016/j.amjcard.2006.06.041 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 133ZM UT WOS:000244052400024 PM 17134641 ER PT J AU Giampietro, PF Raggio, CL Reynolds, C Ghebranious, N Burmester, JK Glurich, I Rasmussen, K McPherson, E Pauli, RM Shukla, SK Merchant, S Jacobsen, FS Faciszewski, T Blank, RD AF Giampietro, Philip F. Raggio, Cathleen L. Reynolds, Cory Ghebranious, Nader Burmester, James K. Glurich, Ingrid Rasmussen, Kristen McPherson, Elizabeth Pauli, Richard M. Shukla, Sanjay K. Merchant, Sajid Jacobsen, F. Stig Faciszewski, Thomas Blank, Robert D. TI DLL3 as a candidate gene for vertebral malformations SO AMERICAN JOURNAL OF MEDICAL GENETICS PART A LA English DT Article DE congenital scoliosis; genetics; mutation; signaling pathway ID CAUSES SPONDYLOCOSTAL DYSOSTOSIS; CONGENITAL SCOLIOSIS; NATURAL-HISTORY; DELTA HOMOLOG; MUTATIONS; SOMITOGENESIS; SEGMENTATION; ANOMALIES; DEFECTS; HUMANS AB Investigations have not identified a major locus for congenital vertebral malformations. Based on observations in mice, we hypothesized that mutations in DLL3, a member of the notch-signaling pathway, might contribute to human vertebral malformations. We sequenced the DLL3 gene in 50 patients with congenital vertebral malformations. A Caucasian male patient with VACTERL manifestations including a T5-T6 block vertebrae was heterozygous for a "G" to "A" missense mutation changing glycine to arginine at codon 269. This residue is conserved in mammals, including chimpanzee, mouse, dog, and rat. Additional testing in the patient did not show evidence of chromosome abnormalities. The patient's asymptomatic mother was also heterozygous for the missense mutation. Since this mutation was not observed in a control Population and leads to an amino acid change, it may be clinically significant. The mutation was not found in a control population of 87 anonymous individuals. Several established mechanisms could explain the mutation in both the patient and his asymptomatic mother (susceptibility allele requiring additional environmental factors, somatic mosaicism, multigenic inheritance). Documenting the absence of the mutation in a larger control population or the presence of the mutation in additional affected patients, or documenting a functional difference in DLL3 would provide further evidence supporting its causal role. (c) 2006 Wiley-Liss, Inc. C1 Marshfield Clin Fdn Med Res & Educ, Dept Med Genet Serv, Marshfield, WI 54449 USA. Hosp Special Surg, Dept Pediat Orthoped, New York, NY 10021 USA. Marshfield Clin Res Fdn, Clin Res Ctr, Marshfield, WI USA. Marshfield Clin Fdn Med Res & Educ, Mol Diagnost Lab, Marshfield, WI USA. Marshfield Clin Res Fdn, Ctr Human Genet, Marshfield, WI USA. Marshfield Clin Res Fdn, Off Res Facilitat, Marshfield, WI USA. Univ Wisconsin, Clin Genet Ctr, Madison, WI USA. Marshfield Clin Fdn Med Res & Educ, Dept Orthoped Spine Surg, Marshfield, WI USA. Univ Wisconsin, Sch Med, Madison, WI USA. William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI 53705 USA. RP Giampietro, PF (reprint author), Marshfield Clin Fdn Med Res & Educ, Dept Med Genet Serv, 1000 N Oak Ave, Marshfield, WI 54449 USA. EM giampietro.philip@marshfieldclinic.org OI Blank, Robert Daniel/0000-0003-2950-1944 NR 30 TC 18 Z9 21 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1552-4825 J9 AM J MED GENET A JI Am. J. Med. Genet. A PD NOV 15 PY 2006 VL 140A IS 22 BP 2447 EP 2453 DI 10.1002/ajmg.a.31509 PG 7 WC Genetics & Heredity SC Genetics & Heredity GA 101MZ UT WOS:000241746200008 PM 17041936 ER PT J AU Tang, YL Buxbaum, SG Waldman, I Anderson, GM Zabetian, CP Kohnke, MD Cubells, JF AF Tang, YiIang Buxbaum, Sarah G. Waldman, Irwin Anderson, George M. Zabetian, Cyrus P. Koehnke, Michael D. Cubells, Joseph F. TI A single nucleotide polymorphism at DBH, possibly associated with attention-deficit/hyperactivity disorder, associates with lower plasma dopamine beta-hydroxylase activity and is in linkage disequilibrium with two putative functional single nucleotide polymorphisms SO BIOLOGICAL PSYCHIATRY LA English DT Article DE dopamine beta-hydroxylase; attention-deficit/hyperactivity disorder; linkage disequilibrium; genetic association ID DEFICIT HYPERACTIVITY DISORDER; GENE DBH; LOCUS; HAPLOTYPE; DAT1; ADHD; ALLELES; DRD5 AB Background: The DBH gene regulates plasma dopamine beta-hydroxylase activity (pD beta H). Two single nucleotide polymorphisms (SNPs), -1021C -> T (rs1611115; SNP1) and + 1603C -> T (rs6271; SNP3), independently influence pD beta H. Another SNP, commonly known as DBH Taq1A (rs2519152; SNP2) is associated with attention-deficit/hyperactivity disorder (ADHD) in some (but not all) studies. We tested whether 1) SAP2 associates with pD beta H; and 2) whether linkage disequilibrium (LD) between SNP2 and the other SNPs explains that association. Methods: Plasma dopamine beta-hydroxylase activity and genotypes at the SNPs were determined in Caucasian subjects (n = 418). Associations to pD beta H were examined using analyses of variance (ANOVAs) and LD among the SNPs using estimation maximization. Results: 1) Each polymorphism analyzed alone associated with pD beta H; 2) SNP2 was in strong LD with SNP1 and SNP3, respectively, but there was no significant LD between SNP1 and SNP3; and 3) analyzed jointly, each SNP contributed significantly and uniquely to plasma D beta H activity. Conclusions: 1) SNP2 associates with pD beta H; 2) SNP2 shows LD with SNP1 and SNP3; 3) most of the association between SNP2 and pD beta H simply reflects that LD; however, 4) SNP2 also appears to exert a small independent effect on pD beta H, suggesting that SNP2, or another variant in LD with it, uniquely influences pD beta H. C1 Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. VA Connecticut Healthcare Syst, New Haven, CT USA. Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA USA. Emory Univ, Dept Psychol, Atlanta, GA 30322 USA. Yale Univ, Sch Med, Yale Child Study Ctr, New Haven, CT USA. Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA. Univ Tubingen Hosp, Hosp Psychiat & Psychotherapy, Tubingen, Germany. RP Cubells, JF (reprint author), Emory Univ, Sch Med, Dept Human Genet, 615 Michael St,Suite 301, Atlanta, GA 30322 USA. EM jcubells@genetics.emory.edu RI Buxbaum, Sarah/E-1970-2013 OI Buxbaum, Sarah/0000-0002-4886-3564 FU NIDA NIH HHS [K02 DA 015766, R01 DA 12422]; NIMH NIH HHS [K01 MH 01818, T32 MH 2005]; NINDS NIH HHS [K08 NS 44138] NR 29 TC 27 Z9 30 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD NOV 15 PY 2006 VL 60 IS 10 BP 1034 EP 1038 DI 10.1016/j.biopsych.2006.02.017 PG 5 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 104EM UT WOS:000241939200003 PM 16616730 ER PT J AU Cooperberg, MR Freedland, SJ Pasta, DJ Elkin, EP Presti, JC Amling, CL Terris, MK Aronson, WJ Kane, CJ Carroll, PR AF Cooperberg, Matthew R. Freedland, Stephen J. Pasta, David J. Elkin, Eric P. Presti, Joseph C., Jr. Amling, Christopher L. Terris, Martha K. Aronson, William J. Kane, Christopher J. Carroll, Peter R. TI Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy SO CANCER LA English DT Article DE prostate neoplasm; prostatectomy; prognosis ID RESEARCH ENDEAVOR CAPSURE; PREOPERATIVE NOMOGRAM; DISEASE RECURRENCE; RADIATION-THERAPY; NATURAL-HISTORY; SEARCH DATABASE; OUTCOMES; PROGRESSION; MORTALITY; VELOCITY AB BACKGROUND. The University of California, San Francisco (UCSF) Cancer of the Prostate Risk Assessment (CAPRA) is a novel preoperative index which predicts the risk of biochemical recurrence after radical prostatectomy. The performance of the index is at least as good as the best available instruments based on clinical variables, and the 0 to 10 score is simple to calculate for both clinical and research purposes. This study used a large external dataset to validate CAPRA. METHODS. Data were abstracted from the Shared Equal Access Regional Cancer Hospital (SEARCH) database, a registry of men who underwent radical prostatectomy at 4 Veterans Affairs and 1 active military medical center. Of 2096 men in the database, 1346 (64%) had full data available to calculate the CAPRA score. Performance of the CAPRA score was assessed with proportional hazards regression, survival analysis, and the concordance (c) index. RESULTS. Of the studied patients, 41% were non-Caucasian, and their mean age was 62 years. Twenty-six percent suffered recurrence; median follow-up among patients who did not recur was 34 months. The hazard ratio (HR) for each 1-point increase in CAPRA was 1.39 (95% CI [confidence interval], 1.31-1.46). The 5-year recurrence-free survival rate ranged from 86% for CAPRA 0-1 patients to 21% for CAPRA 7-10 patients. Increasing CAPRA scores were significantly associated with increasing risk of adverse pathologic outcomes. The c-index for CAPRA for the validation set was 0.68, compared with 0.66 for the original development set. CONCLUSIONS. The UCSF-CAPRA accurately predicted both biochemical and pathologic outcomes after radical prostatectomy among a large, diverse, cohort of men. These results validated the effectiveness of this powerful and straightforward instrument. C1 Univ Calif San Francisco, Dept Urol, Program Urol Oncol, Urol Outcomes Res Grp,Comprehens Canc Ctr, San Francisco, CA 94143 USA. Duke Univ, Dept Surg, Div Urol, Durham, NC USA. Stanford Univ, Dept Urol, Sch Med, Stanford, CA 94305 USA. Vet Adm Med Ctr, Urol Sect, Dept Surg, Palo Alto, CA 94304 USA. San Diego Naval Med Ctr, Dept Urol, San Diego, CA USA. Vet Adm Med Ctr, Dept Surg, Urol Sect, Augusta, GA 30904 USA. Med Coll Georgia, Dept Surg, Augusta, GA 30912 USA. Vet & Adm Greater Los Angeles Healthcare Syst, Urol Sect, Dept Surg, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Urol, Sch Med, Los Angeles, CA USA. Vet Adm Med Ctr, Dept Surg, Urol Sect, San Francisco, CA USA. RP Cooperberg, MR (reprint author), Univ Calif San Francisco, Dept Urol, Program Urol Oncol, Urol Outcomes Res Grp,Comprehens Canc Ctr, Box 0738,400 Parnassus Ave,A-633, San Francisco, CA 94143 USA. EM mcooperberg@urology.ucsf.edu RI Cooperberg, Matthew/B-3867-2008; Cooperberg, Matthew/G-6249-2017 OI Cooperberg, Matthew/0000-0003-4339-6685; Terris, Martha/0000-0002-3843-7270; Pasta, David/0000-0003-2637-9293 FU NCI NIH HHS [P50 CA92131-01A1, R01 CA100938]; PHS HHS [P50 C89520] NR 28 TC 73 Z9 75 U1 0 U2 1 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0008-543X J9 CANCER JI Cancer PD NOV 15 PY 2006 VL 107 IS 10 BP 2384 EP 2391 DI 10.1002/cncr.22262 PG 8 WC Oncology SC Oncology GA 104DF UT WOS:000241935500009 PM 17039503 ER PT J AU Walter, LC Bertenthal, D Lindquist, K Konety, BR AF Walter, Louise C. Bertenthal, Daniel Lindquist, Karla Konety, Badrinath R. TI PSA screening among elderly men with limited life expectancies SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID LOCALIZED PROSTATE-CANCER; COMORBIDITY INDEX; UNITED-STATES; VIEWPOINT; VALIDATION; GUIDELINES; ACCURACY; CARE AB Context Most guidelines do not recommend prostate-specific antigen (PSA) screening in elderly men who have limited life expectancies because the known harms of screening outweigh potential benefits. However, there are no large-scale studies of actual PSA screening practices in elderly men, according to life expectancy. Objective To characterize the extent of PSA screening among elderly men, including those with limited life expectancies. Design, Setting, and Participants Cohort study of 597 642 male veterans aged 70 years and older who were seen at 104 US Department of Veterans Affairs facilities during both 2002 and 2003, without a history of prostate cancer, elevated PSA, or prostate cancer symptoms. Charlson comorbidity scores were used to stratify men into 3 groups ranging from best health ( score= 0) to worst health ( score >= 4). Main Outcome Measure Receipt of PSA testing during 2003 was based on US Department of Veterans Affairs data and Medicare claims. Results In 2003, 56% of elderly men had a PSA test performed. Although PSA screening rates decreased with advancing age, within each 5-year age group the percentage of men who underwent a PSA test did not substantially decline with worsening health. For example, among men aged 85 years and older, 34% in best health had a PSA test compared with 36% in worst health. In multivariate analyses, many nonclinical factors, such as marital status and region of the country, had a greater effect on PSA screening than health, and screening rates exceeded 60% for some subgroups of men in worst health. Conclusions Prostate-specific antigen screening rates among elderly veterans with limited life expectancies should be much lower than current practice given the known harms of screening. More attention to prognosis is needed when making screening PSA recommendations to elderly men. C1 San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA USA. Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, Res Enhancement Award Program Improve Care Older, San Francisco, CA USA. Univ Calif San Francisco, Dept Urol, San Francisco, CA 94143 USA. RP Walter, LC (reprint author), VA Med Ctr, 181G,4150 Clement St, San Francisco, CA 94121 USA. EM louise.walter@ucsf.edu NR 47 TC 161 Z9 163 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD NOV 15 PY 2006 VL 296 IS 19 BP 2336 EP 2342 DI 10.1001/jama.296.19.2336 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 104ZI UT WOS:000241998700021 PM 17105796 ER PT J AU Atkinson, C Zhu, H Qiao, F Varela, JC Yu, J Song, HB Kindy, MS Tomlinson, S AF Atkinson, Carl Zhu, Hong Qiao, Fei Varela, Juan Carlos Yu, Jin Song, Hongbin Kindy, Mark S. Tomlinson, Stephen TI Complement-dependent P-selectin expression and injury following ischemic stroke SO JOURNAL OF IMMUNOLOGY LA English DT Article ID MIDDLE CEREBRAL-ARTERY; RENAL ISCHEMIA/REPERFUSION INJURY; BRAIN-INJURY; REPERFUSION INJURY; MONOCLONAL-ANTIBODY; INHIBITORY PROTEIN; MICE DEFICIENT; MURINE STROKE; TISSUE-INJURY; C1 INHIBITOR AB The mechanisms that contribute to inflammatory damage following ischemic stroke are poorly characterized, but studies indicate a role for both complement and P-selectin. In this study, we show that compared with wild-type mice, C3-deficient mice showed significant improvement in survival, neurological deficit, and infarct size at 24 h after middle cerebral artery occlusion and reperfusion. Furthermore, P-selectin protein expression was undetectable in the cerebral microvasculature of C3-deficient mice following reperfusion, and there was reduced neutrophil influx, reduced microthrombus formation, and increased blood flow postreperfusion in C3-deficient mice. We further investigated the use of a novel complement inhibitory protein in a therapeutic paradigm. Complement receptor 2 (CR2)-Crry inhibits complement activation at the C3 stage and targets to sites of complement activation. Treatment of normal mice with CR2-Crry at 30 min postreperfusion resulted in a similar level of protection to that seen in C3-deficient mice in all of the above-measured parameters. The data demonstrate an important role for complement in cerebrovascular thrombosis, inflammation, and injury following ischemic stroke. P-selectin expression in the cerebrovasculature, which is also implicated in cerebral ischemia and reperfusion injury, was shown to be distal to and dependent on complement activation. Data also show that a CR2-targeted approach of complement inhibition provides appropriate bioavailability in cerebral injury to enable complement inhibition at a dose that does not significantly affect systemic levels of serum complement activity, a potential benefit for stroke patients where immunosuppression would be undesirable due to significantly increased susceptibility to lung infection. C1 Med Univ S Carolina, Dept Microbiol & Immunol, Childrens Res Inst, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Neurosci, Inst Neurosci, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA. RP Tomlinson, S (reprint author), Med Univ S Carolina, Dept Microbiol & Immunol, Childrens Res Inst, Charleston, SC 29425 USA. EM tomlinss@musc.edu RI Song, Hongbin/C-1963-2013 FU NHLBI NIH HHS [HL082485] NR 55 TC 48 Z9 52 U1 0 U2 3 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD NOV 15 PY 2006 VL 177 IS 10 BP 7266 EP 7274 PG 9 WC Immunology SC Immunology GA 105DN UT WOS:000242009700080 PM 17082645 ER PT J AU Sekine, H Graham, KL Zhao, SR Elliott, MK Ruiz, P Utz, PJ Gilkeson, GS AF Sekine, Hideharu Graham, Kareem L. Zhao, Shenru Elliott, Margaret K. Ruiz, Philip Utz, Paul J. Gilkeson, Gary S. TI Role of MHC-linked genes in autoantigen selection and renal disease in a murine model of systemic lupus erythematosus SO JOURNAL OF IMMUNOLOGY LA English DT Article ID MAJOR HISTOCOMPATIBILITY COMPLEX; MRL/LPR MICE; LPR MICE; ANTI-SM; RHEUMATOID-FACTOR; IGA DEFICIENCY; LPR/LPR MICE; MRL MICE; GLOMERULONEPHRITIS; AUTOANTIBODIES AB We previously described a renal protective effect of factor B deficiency in MRL/lpr mice. Factor B is in the MHC cluster; thus, the deficient mice were H2(b), the haplotype on which the knockout was derived, whereas the wild-type littermates were H2(k), the H2 of MRL/lpr mice. To determine which protective effects were due to H2 vs factor B deficiency, we derived H2(b) congenic MRL/lpr mice from the 129/Sv (H2(b)) strain. Autoantibody profiling using autoantigen microarrays revealed that serum anti-Smith and anti-small nuclear ribonucleoprotein complex autoantibodies, while present in the majority of H2(k/k) MRL/lpr mice, were absent in the H2(b/b) MRL/lpr mice. Surprisingly, 70% of MRL/lpr H2(b/b) mice were found to be serum IgG3 deficient (with few to no IgG3-producing B cells). In addition, H2(b/b) IgG3-deficient MRL/lpr mice had significantly less proteinuria, decreased glomerular immune complex deposition, and absence of glomerular subepithelial deposits compared with MRL/lpr mice of any H2 type with detectable serum IgG3. Despite these differences, total histopathologic renal scores and survival were similar among the groups. These results indicate that genes encoded within or closely linked to the MHC region regulate autoantigen selection and isotype switching to IgG3 but have minimal effect on end-organ damage or survival in MRL/lpr mice. C1 Med Univ S Carolina, Dept Med, Div Rheumatol & Immunol, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Med Res Serv, Charleston, SC 29425 USA. Stanford Univ, Sch Med, Dept Med, Div Rheumatol & Immunol, Stanford, CA 94305 USA. Univ Miami, Sch Med, Dept Pathol, Miami, FL 33125 USA. RP Sekine, H (reprint author), 96 Jonathon Lucas St,Suite 912,POB 250637, Charleston, SC 29425 USA. EM sekineh@muse.edu FU NIAID NIH HHS [AI01514, T32 AI007290, AI47469, AI10663, AI50864]; NIAMS NIH HHS [AR49328]; NIDDK NIH HHS [DK61934] NR 62 TC 20 Z9 21 U1 0 U2 1 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD NOV 15 PY 2006 VL 177 IS 10 BP 7423 EP 7434 PG 12 WC Immunology SC Immunology GA 105DN UT WOS:000242009700097 PM 17082662 ER PT J AU Ma, ZJ Chen, FQ Madaio, MP Cohen, PL Eisenberg, RA AF Ma, Zhongjie Chen, Fangqi Madaio, Michael P. Cohen, Philip L. Eisenberg, Robert A. TI Modulation of autoimmunity by TLR9 in the chronic graft-vs-host model of systemic lupus erythematosus SO JOURNAL OF IMMUNOLOGY LA English DT Article ID TOLL-LIKE RECEPTORS; B-CELLS; INNATE IMMUNITY; MURINE LUPUS; VERSUS-HOST; DNA; AUTOANTIBODIES; SLE; DISEASE; MICE AB Chronic graft-vs-host (cGVH) disease is induced in nonautoimmune mice by the transfer of alloreactive T cells that recognize foreign MHC class II. It closely resembles. systemic lupus erythematosus, with antinuclear Abs and immune-mediated nephritis. Recent work has implicated TLRs, particularly TLR9, in the recognition of certain autoantigens in vitro and in vivo. To explore further the role of TLR9 in systemic autoimmunity, we induced cGVH disease in C57BL/6 (1116) mice lacking TLR9, including B6 mice expressing the anti-DNA-encoding IgH transgenes; 3119 or 56R (B6.3H9.TLR9(-/-), B6.56R.TLR9(-/-)). We found that cGVH disease caused breakdown of B cell tolerance to chromatin and DNA in TLR9(-/-) recipients of alloreactive cells, yet that nephritis was less severe and that some autoantibody titers were lower compared with B6-cGVH controls. Spleen lymphocyte analysis showed that cGVH disease strikingly depleted marginal zone B cells in B6 mice, but did not influence T cell subsets in either B6 or B6-TLR9(-/-) hosts. B6.56R.TLR9(-/-) mice had less spontaneous production of autoantibodies than B6.56R mice, but there were no significant differences between B6.56R and B6.56R.TLR9(-/-) postinduction of cGVH disease. Taken together, these results suggested that TLR9 may worsen some aspects of systemic autoimmunity while alleviating others. C1 Univ Penn, Div Rheumatol, Philadelphia, PA 19104 USA. Univ Penn, Div Renal Electrolyte & Hypertens, Dept Med, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. RP Eisenberg, RA (reprint author), Univ Penn, Div Rheumatol, 756 BRB2 3,421 Curie Blvd, Philadelphia, PA 19104 USA. EM raemd@mail.med.upenn.edu FU NIAID NIH HHS [U19-AI-46358, R01-AI063626-22]; NIAMS NIH HHS [R01-AR-34156]; NIDDK NIH HHS [R01-DK53088] NR 25 TC 11 Z9 14 U1 0 U2 1 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD NOV 15 PY 2006 VL 177 IS 10 BP 7444 EP 7450 PG 7 WC Immunology SC Immunology GA 105DN UT WOS:000242009700099 PM 17082664 ER PT J AU Xie, AL Skatrud, JB Morgan, B Chenuel, B Khayat, R Reichmuth, K Lin, J Dempsey, JA AF Xie, Ailiang Skatrud, James B. Morgan, Barbara Chenuel, Bruno Khayat, Rami Reichmuth, Kevin Lin, Jenny Dempsey, Jerome A. TI Influence of cerebrovascular function on the hypercapnic ventilatory response in healthy humans SO JOURNAL OF PHYSIOLOGY-LONDON LA English DT Article ID CEREBRAL-BLOOD-FLOW; CONGESTIVE-HEART-FAILURE; CAROTID-BODY DENERVATION; CENTRAL SLEEP-APNEA; CARBON-DIOXIDE; NEWBORN PIGLETS; ASPHYXIATED PIGLETS; QUANTITATIVE EEG; GRADED REDUCTION; CO2 REACTIVITY AB An important determinant of [H+] in the environment of the central chemoreceptors is cerebral blood flow. Accordingly we hypothesized that a reduction of brain perfusion or a reduced cerebrovascular reactivity to CO2 would lead to hyperventilation and an increased ventilatory responsiveness to CO2. We used oral indomethacin to reduce the cerebrovascular reactivity to CO2 and tested the steady-state hypercapnic ventilatory response to CO2 in nine normal awake human subjects under normoxia and hyperoxia (50% O-2). Ninety minutes after indomethacin ingestion, cerebral blood flow velocity (CBFV) in the middle cerebral artery decreased to 77 +/- 5% of the initial value and the average slope of CBFV response to hypercapnia was reduced to 31% of control in normoxia (1.92 versus 0.59 cm(-1) s(-1) mmHg(-1), P < 0.05) and 37% of control in hyperoxia (1.58 versus 0.59 cm(-1) s(-1) mmHg(-1), P < 0.05). Concomitantly, indomethacin administration also caused 40-60% increases in the slope of the mean ventilatory response to CO2 in both normoxia (1.27 +/- 0.31 versus 1.76 +/- 0.37 l min(-1) mmHg(-1), P < 0.05) and hyperoxia (1.08 +/- 0.22 versus 1.79 +/- 0.37 l min(-1) mmHg(-1), P < 0.05). These correlative findings are consistent with the conclusion that cerebrovascular responsiveness to CO2 is an important determinant of eupnoeic ventilation and of hypercapnic ventilatory responsiveness in humans, primarily via its effects at the level of the central chemoreceptors. C1 William S Middleton Mem Vet Adm Med Ctr, Pulm Physiol Lab, Madison, WI 53705 USA. Univ Wisconsin, Dept Med, Madison, WI 53706 USA. Univ Wisconsin, Dept Populat Hlth Sci, Madison, WI 53706 USA. Univ Wisconsin, Dept Orthopeid & Rehabil, Madison, WI 53706 USA. RP Xie, AL (reprint author), William S Middleton Mem Vet Adm Med Ctr, Pulm Physiol Lab, 2500 Overlook Terrace, Madison, WI 53705 USA. EM axie@facstaff.wisc.edu RI Khayat, Rami/E-3380-2011 NR 68 TC 73 Z9 73 U1 0 U2 2 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0022-3751 J9 J PHYSIOL-LONDON JI J. Physiol.-London PD NOV 15 PY 2006 VL 577 IS 1 BP 319 EP 329 DI 10.1113/jphysiol.2006.110627 PG 11 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA 108LC UT WOS:000242240300025 PM 16931556 ER PT J AU McGory, ML Shekelle, PG Ko, CY AF McGory, Marcia L. Shekelle, Paul G. Ko, Clifford Y. TI Development of quality indicators for patients undergoing colorectal cancer surgery SO JOURNAL OF THE NATIONAL CANCER INSTITUTE LA English DT Article ID CORONARY REVASCULARIZATION; PRACTICE PARAMETERS; VULNERABLE ELDERS; ASSESSING CARE; COLON-CANCER; OF-CARE; APPROPRIATENESS; UNDERUSE; PROGRAM; RATINGS AB Background. Colorectal cancer is the second most common cancer type among new cancer diagnoses in the United States. Attention to the quality of surgical care for colorectal cancer is of particular importance given the increasing numbers of colorectal cancer resections performed in the aging population. A National Cancer Institute-sponsored consensus panel produced guidelines for colorectal cancer surgery in 2000. We have updated and extended that work by using a formal process to identify and rate quality indicators as valid for care during the preoperative, intraoperative, and postoperative periods. Methods: Using a modification of the RAND/UCLA Appropriateness Methodology, we carried out structured interviews with leaders in the field of colorectal cancer surgery and systematic reviews of the literature to identify candidate quality indicators addressing perioperative care for patients undergoing surgery for colorectal cancer. A panel of 14 colorectal surgeons, general surgeons, and surgical oncologists then evaluated and formally rated the indicators using the modified Delphi method to identify valid indicators. Results: A total of 142 candidate indicators were identified in six broad domains: privileging (which addresses surgical credentials), preoperative evaluation, patient-provider discussions, medication use, intraoperative care, and postoperative management. The expert panel rated 92 indicators as valid. These indicators address all domains of perioperative care for patients undergoing surgery for colorectal cancer. Conclusions: The RAND/UCLA Appropriateness Methodology can be used to identify and rate indicators of high-quality perioperative care for patients undergoing surgery for colorectal cancer. The indicators can be used as quality performance measures and for quality-improvement programs. C1 Univ Calif Los Angeles, Dept Surg, David Geffen Sch Med, Ctr Hlth Sci,Ctr Surg Outcomes & Qual, Los Angeles, CA 90095 USA. VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA. RP McGory, ML (reprint author), Univ Calif Los Angeles, Dept Surg, David Geffen Sch Med, Ctr Hlth Sci,Ctr Surg Outcomes & Qual, 10833 Conte Ave,72-215,Box 956904, Los Angeles, CA 90095 USA. EM mmcgory@mednet.ucla.edu NR 28 TC 77 Z9 79 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0027-8874 J9 J NATL CANCER I JI J. Natl. Cancer Inst. PD NOV 15 PY 2006 VL 98 IS 22 BP 1623 EP 1633 DI 10.1093/jnci/djj438 PG 11 WC Oncology SC Oncology GA 110LF UT WOS:000242379700009 PM 17105985 ER PT J AU Barzilay, JI Davis, BR Cutler, JA Pressel, SL Whelton, PK Basile, J Margolis, KL Ong, ST Sadler, LS Summerson, J AF Barzilay, Joshua I. Davis, Barry R. Cutler, Jeffrey A. Pressel, Sara L. Whelton, Paul K. Basile, Jan Margolis, Karen L. Ong, Stephen T. Sadler, Laurie S. Summerson, John CA ALLHAT Collaborative Res Grp TI Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment - A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID ISOLATED SYSTOLIC HYPERTENSION; CARDIOVASCULAR EVENTS; THIAZIDE DIURETICS; THERAPY; RISK; OUTCOMES; INTOLERANCE; POTASSIUM; REDUCTION; INHIBITOR AB Background: Elevated blood glucose levels are reported with thiazide-type diuretic treatment of hypertension. The significance of this finding is uncertain. Our objectives were to compare the effect of first-step antihypertensive drug therapy with thiazide-type diuretic, calcium-channel blocker, or angiotensin-converting enzyme inhibitor on fasting glucose (FG) levels and to determine cardiovascular and renal disease risks associated with elevated FG levels and incident diabetes mellitus (DM) in 3 treatment groups. Methods: We performed post hoc subgroup analyses from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) among nondiabetic participants who were randomized to receive treatment with chlorthalidone (n= 8419), amlodipine (n= 4958), or lisinopril ( n= 5034) and observed for a mean of 4.9 years. Results: Mean FG levels increased during follow-up in all treatment groups. At year 2, those randomized to the chlorthalidone group had the greatest increase ( + 8.5 mg/dL [0.47 mmol/L] vs + 5.5 mg/dL [0.31 mmol/L] for amlodipine and + 3.5 mg/dL [0.19 mmol/L] for lisinopril). The odds ratios for developing DM with lisinopril (0.55 [95% confidence interval, 0.43-0.70]) or amlodipine (0.73 [ 95% confidence interval, 0.58-0.91]) vs chlorthalidone at 2 years were significantly lower than 1.0 (P <. 01). There was no significant association of FG level change at 2 years with subsequent coronary heart disease, stroke, cardiovascular disease, total mortality, or endstage renal disease. There was no significant association of incident DM at 2 years with clinical outcomes, except for coronary heart disease ( risk ratio, 1.64; P=. 006), but the risk ratio was lower and nonsignificant in the chlorthalidone group ( risk ratio, 1.46; P=. 14). Conclusions: Fasting glucose levels increase in older adults with hypertension regardless of treatment type. For those taking chlorthalidone vs other medications, the risk of developing FG levels higher than 125 mg/dL (6.9 mmol/L) is modestly greater, but there is no conclusive or consistent evidence that this diuretic-associated increase in DM risk increases the risk of clinical events. C1 Univ Texas, Sch Publ Hlth, Coordinating Ctr Clin Trials, Houston, TX 77030 USA. Emory Univ, Sch Med, Kaiser Permanente, Atlanta, GA 30322 USA. Emory Univ, Sch Med, Div Endocrinol, Atlanta, GA 30322 USA. NHLBI, Div Epidemiol & Clin Applicat, Bethesda, MD 20892 USA. Tulane Univ, Hlth Sci Ctr, New Orleans, LA 70118 USA. Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA. Hennepin Cty Med Ctr, Div Clin Epidemiol, Minneapolis, MN 55415 USA. Ong Med Ctr, Oxon Hill, MD USA. St Vincent Char Hosp & Hlth Ctr, Lipid Res Ctr, Cleveland, OH USA. Wake Forest Univ, Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27109 USA. RP Davis, BR (reprint author), Univ Texas, Sch Publ Hlth, Coordinating Ctr Clin Trials, 1200 Herman Pressler St,Suite E801, Houston, TX 77030 USA. EM barry.r.davis@uth.tmc.edu FU NHLBI NIH HHS [N01-HC-35130] NR 30 TC 147 Z9 153 U1 1 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD NOV 13 PY 2006 VL 166 IS 20 BP 2191 EP 2201 DI 10.1001/archinte.166.20.2191 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 104VF UT WOS:000241987500005 PM 17101936 ER PT J AU Taha, TA El-Alwani, M Hannun, YA Obeid, LM AF Taha, Tarek A. El-Alwani, Mazen Hannun, Yusuf A. Obeid, Lina M. TI Sphingosine kinase-1 is cleaved by cathepsin B in vitro: Identification of the initial cleavage sites for the protease SO FEBS LETTERS LA English DT Article DE sphingosine kinase; cathepsin B; proteases ID LYSOSOMAL CYSTEINE PROTEASES; PLASMA-MEMBRANE; CYTOCHROME-C; CELL-DEATH; APOPTOSIS; RELEASE; EXPRESSION; SPHINGOSINE-1-PHOSPHATE; PROGRESSION; ACTIVATION AB Previous work has identified sphingosine kinase-1 (SKI) as a substrate for the cysteine protease cathepsin B in vitro. In this study, the mechanism of SKI cleavage by cathepsin B was investigated. We identified two initial cleavage sites for the protease, the first at histidine 122 and the second at arginine 199. Mutation analysis showed that replacement of histidine 122 with a tyrosine maintained the activity of SKI while significantly reducing cleavage by cathepsin B at the initial cleavage site. The efficacy of cleavage of SKI at arginine 199, however, was not affected. These studies demonstrate that SKI is cleaved by cathepsin B in a sequential manner after basic amino acids, and that the initial cleavages at the two identified sites occur independently of each other. (c) 2006 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved. C1 Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. Ralph H Johnson Vet Adm Hosp, Div Gen Internal Med, Charleston, SC 29401 USA. Med Univ S Carolina, Charleston, SC 29425 USA. RP Obeid, LM (reprint author), Med Univ S Carolina, Dept Med, 114 Doughty St,POB 250779, Charleston, SC 29425 USA. EM obeidl@musc.edu OI obeid, lina/0000-0002-0734-0847 FU NCI NIH HHS [P01 CA097132] NR 26 TC 17 Z9 17 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0014-5793 J9 FEBS LETT JI FEBS Lett. PD NOV 13 PY 2006 VL 580 IS 26 BP 6047 EP 6054 DI 10.1016/j.febslet.2006.09.070 PG 8 WC Biochemistry & Molecular Biology; Biophysics; Cell Biology SC Biochemistry & Molecular Biology; Biophysics; Cell Biology GA 108II UT WOS:000242233100004 PM 17064696 ER PT J AU Hyams, KC AF Hyams, Kenneth Craig TI Mental health screening before troop deployment SO BRITISH MEDICAL JOURNAL LA English DT Editorial Material ID GULF-WAR; MORTALITY; VETERANS; MILITARY C1 US Dept Vet Affairs, Off Publ Hlth & Environm Hazards, Washington, DC 20420 USA. RP Hyams, KC (reprint author), US Dept Vet Affairs, Off Publ Hlth & Environm Hazards, Washington, DC 20420 USA. EM Kenneth.Hyams@va.gov NR 8 TC 7 Z9 8 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0959-8146 J9 BRIT MED J JI Br. Med. J. PD NOV 11 PY 2006 VL 333 IS 7576 BP 979 EP 980 DI 10.1136/bmj.39023.648970.80 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 108GX UT WOS:000242229400001 PM 17095759 ER PT J AU Cao, Q Mak, KM Lieber, CS AF Cao, Qi Mak, Ki M. Lieber, Charles S. TI DLPC and SAMe prevent alpha 1(I) collagen mRNA up-regulation in human hepatic stellate cells, whether caused by leptin or menadione SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article DE dilinoleoylphosphatidylcholine; S-adenosylmethionine; leptin; menadione; hepatic stellate cells; alpha 1(I) collagen mRNA; H2O2; reduced glutathione; ERK1/2; p38 ID HYDROGEN-PEROXIDE; OXIDATIVE STRESS; RAT HEPATOCYTES; INHIBITOR; GLUTATHIONE; METABOLISM; EXPRESSION; FIBROSIS; ROLES; MAPK AB We previously reported that the combination of dilinoleoylphosphatidylcholine (DLPC) and S-adenosylmethionine (SAMe), which have antioxidant properties and antifibrogenic actions, prevented leptin-stimulated tissue inhibitor of metalloproteinase (TIMP)-1 production in hepatic stellate cells (HSCs) by inhibiting H2O2-mediated signal transduction. We now show that DLPC and SAMe inhibit alpha 1(I) collagen mRNA expression induced by leptin or menadione in LX-2 human HSCs. We found that DLPC and SAMe prevent H2O2 generation and restore reduced glutathione (GSH) depletion whether caused by leptin or menadione. Blocking H2O2 signaling through ERK1/2 and p38 pathways resulted in a complete inhibition of leptin or menadione-induced alpha 1(I) collagen mRNA. The inhibition of collagen mRNA by DLPC and SAMe combined is at least two times more effective than that by DLPC or SAMe alone. In conjunction with the prevention of TIMP-1 production, the ability of DLPC and SAMe to inhibit alpha 1(I) collagen mRNA expression provides a mechanistic basis for these innocuous compounds in the prevention of hepatic fibrosis, because enhanced TIMP-1 and collagen productions are associated with hepatic fibrogenesis and their attenuation may diminish fibrosis. (c) 2006 Elsevier Inc. All rights reserved. C1 Mt Sinai Sch Med, James J Peters Vet Affairs Med Ctr, Ctr Alcohol Res & Treatment, Bronx, NY 10468 USA. RP Lieber, CS (reprint author), Mt Sinai Sch Med, James J Peters Vet Affairs Med Ctr, Ctr Alcohol Res & Treatment, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM LIEBERCS@AOL.COM FU NCCIH NIH HHS [AT001583, R01 AT001583] NR 21 TC 7 Z9 7 U1 0 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD NOV 10 PY 2006 VL 350 IS 1 BP 50 EP 55 DI 10.1016/j.bbrc.2006.08.174 PG 6 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 094AZ UT WOS:000241212700007 PM 16996477 ER PT J AU Spassieva, S Seo, JG Jiang, JC Bielawski, J Alvarez-Vasquez, F Jazwinski, SM Hannun, YA Obeid, LM AF Spassieva, Stefka Seo, Jae-Gu Jiang, James C. Bielawski, Jacek Alvarez-Vasquez, Fernando Jazwinski, S. Michal Hannun, Yusuf A. Obeid, Lina M. TI Necessary role for the Lag1p motif in (dihydro)ceramide synthase activity SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID LONGEVITY-ASSURANCE GENE; CERAMIDE SYNTHASE; FAMILY-MEMBERS; YEAST; COA; HOMOLOG; PROTEIN; CLONING; GROWTH; TRANSLOCATION AB Lag1 (longevity assurance gene 1) homologues, a family of transmembrane proteins found in all eukaryotes, have been shown to be necessary for (dihydro) ceramide synthesis. All Lag1 homologues contain a highly conserved stretch of 52 amino acids known as the Lag1p motif. However, the functional significance of the conserved Lag1p motif for (dihydro) ceramide synthesis is currently unknown. In this work, we have investigated the function of the motif by introducing eight point mutations in the Lag1p motif of the mouse LASS1 (longevity assurance homologue 1 of yeast Lag1). The (dihydro) ceramide synthase activity of the mutants was tested using microsomes in HeLa cells and in vitro. Six of the mutations resulted in loss of activity in cells and in vitro. In addition, our results showed that C18:0 fatty acid CoA (but not cis-C18:1 fatty acid CoAs) are substrates for LASS1 and that LASS1 in HeLa cells is sensitive to fumonisin B-1, an in vitro inhibitor of ( dihydro)ceramide synthase. Moreover, we mutated the Lag1p motif of another Lag homologue, human LASS5. The amino acid substitutions in the human LASS5 were the same as in mouse LASS1, and had the same effect on the in vitro activity of LASS5, suggesting the Lag1p motif appears to be essential for the enzyme activity of all Lag1 homologues. C1 Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Hosp, Div Gen Internal Med, Charleston, SC 29401 USA. Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA. RP Obeid, LM (reprint author), Med Univ S Carolina, Dept Med, 114 Doughty St,POB 250779, Charleston, SC 29425 USA. EM obeidl@musc.edu OI obeid, lina/0000-0002-0734-0847; Alvarez-Vasquez, Fernando/0000-0003-4008-9858 FU NCI NIH HHS [P01 CA97132]; NIA NIH HHS [AG006168, AG016583] NR 30 TC 64 Z9 67 U1 0 U2 1 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD NOV 10 PY 2006 VL 281 IS 45 BP 33931 EP 33938 DI 10.1074/jbc.M608092200 PG 8 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 101UZ UT WOS:000241767600014 PM 16951403 ER PT J AU Rubin, RT Rhodes, ME Miller, TH Jakab, RL Czambel, RK AF Rubin, Robert T. Rhodes, Michael E. Miller, Thomas H. Jakab, Robert L. Czambel, R. Kenneth TI Sequence of pituitary-adrenal cortical hormone responses to low-dose physostigmine administration in young adult women and men SO LIFE SCIENCES LA English DT Article DE cholinergic; physostigmine; ACTH; cortisol; sex difference ID PRIMARY ENDOGENOUS-DEPRESSION; FUNCTIONAL SEX-DIFFERENCES; VASOPRESSIN MESSENGER-RNA; CHOLINERGIC STIMULATION; HUMAN HYPOTHALAMUS; EXTRAHYPOTHALAMIC VASOPRESSIN; NEUROTRANSMITTER REGULATION; DEXAMETHASONE SUPPRESSION; PARAVENTRICULAR NUCLEUS; NEUROENDOCRINE ASPECTS AB We previously demonstrated greater HPA axis activation in adult men compared to adult women following low-dose administration of the anticholinesterase inhibitor, physostigmine (PHYSO). Because blood sampling was done infrequently following PHYSO, the rise times of AVP, ACTH(1-39), and cortisol could not be determined. In the present study, we determined the sequence of hormone increases by frequent blood sampling following PHYSO. Twelve adult women and 12 adult men underwent three test sessions 5-7 days apart: PHYSO, saline control, and repeat PHYSO. As in the earlier study, PHYSO produced no side effects in half the subjects and mild side effects in the other half, with no significant female-male differences. None of the hormone responses was significantly correlated with the presence or absence of side effects. In both women and men, the AVP increase preceded the ACTH(1-39) increase, which in turn preceded the cortisol increase. The AVP and ACTH AUCs were significantly positively correlated in both women and men, supporting AVP as an acute stimulus to ACTH secretion. Also as in the earlier study, the AVP response to PHYSO was more than twice as great in men as in women, but the difference was not statistically significant. We therefore analyzed the results of both studies combined (N=26 women and 26 men). The men had a significantly greater AVP response and a trend toward a greater ACTH (1-39) response compared to the women. These findings further support the concept of sexual diergism (functional sex difference) in the influence of CNS cholinergic systems on HPA hormone secretion. (c) 2006 Elsevier Inc. All rights reserved. C1 VA Greater LA Healthcare Syst, Dept Psychiat & Mental Hlth 116A, Los Angeles, CA 90073 USA. St Vincent Coll, Dept Biol, Latrobe, PA 15650 USA. Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15260 USA. Drexel Univ, Coll Med, Neurosci Res Ctr, Pittsburgh, PA 15212 USA. Drexel Univ, Coll Med, Allegheny Gen Hosp, Neurosci Res Ctr, Pittsburgh, PA 15212 USA. RP Rubin, RT (reprint author), VA Greater LA Healthcare Syst, Dept Psychiat & Mental Hlth 116A, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM robert.rubin@va.gov FU NIMH NIH HHS [MH 028380] NR 58 TC 7 Z9 7 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0024-3205 J9 LIFE SCI JI Life Sci. PD NOV 10 PY 2006 VL 79 IS 24 BP 2260 EP 2268 DI 10.1016/j.lfs.2006.07.023 PG 9 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA 108HG UT WOS:000242230300003 PM 16935309 ER PT J AU Darouiche, RO AF Darouiche, Rabih O. TI Current concepts: Spinal epidural abscess SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Review ID PROGNOSTIC FACTORS; CLINICAL PRESENTATION; MEDICAL-MANAGEMENT; INFECTIONS; ASPIRATION; INJECTION; ANALGESIA; PATHOLOGY C1 Baylor Coll Med, Ctr Protheses Infect, Houston, TX 77030 USA. Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Infect Dis Sect, Houston, TX 77030 USA. RP Darouiche, RO (reprint author), Baylor Coll Med, Ctr Protheses Infect, 1333 Moursund Ave,Suite A221, Houston, TX 77030 USA. EM rdarouiche@aol.com NR 45 TC 184 Z9 189 U1 1 U2 8 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD NOV 9 PY 2006 VL 355 IS 19 BP 2012 EP 2020 DI 10.1056/NEJMra055111 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 102SG UT WOS:000241833000009 PM 17093252 ER PT J AU Boockvar, KS Meier, DE AF Boockvar, Kenneth S. Meier, Diane E. TI Palliative care for frail older adults - "There are things I can't do anymore that I wish I could ..." SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID OF-LIFE CARE; CONTROLLED-TRIAL; ELDERLY PEOPLE; INSTRUMENTAL ACTIVITIES; GERIATRIC DEPRESSION; FUNCTIONAL DECLINE; PHYSICAL FRAILTY; PAIN MANAGEMENT; WOMENS HEALTH; DOUBLE-BLIND AB Frailty in older adults is increasingly a recognized syndrome of decline, sometimes subtle, in function and health that may be amenable to available approaches to care. Frailty manifests the following core clinical features: loss of strength, weight loss, low levels of activity, poor endurance or fatigue, and slowed performance. The presence of 3 or more of these features is associated with adverse outcomes including falls, new or worsened function impairment, hospitalization, and death. In this article, we use the case of Mrs K to describe the challenges of recognizing frailty in clinical practice, common problems and symptoms that frail older adults experience, and approaches to these issues that clinicians may incorporate into their practices. We discuss the importance of advance care planning, provider-patient communication, and appropriate palliative care and hospice referral for frail older adults. Frailty is associated with symptomatic long-term disease, decline in function, and abbreviated survival. Therefore, when frailty is severe, delivery of palliative care focused on relief of discomfort and enhancement of quality of life is highly appropriate. The application of multidisciplinary, team-based palliative approaches and of up-to-date geriatrics knowledge is beneficial for treating these patients because of the complexity of their coexisting social, psychological, and medical needs. C1 James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA. CUNY Mt Sinai Sch Med, New York, NY 10029 USA. Jewish Home & Hosp, New York, NY USA. RP Boockvar, KS (reprint author), James J Peters Vet Affairs Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM kenneth.boockvar@mssm.edu OI Boockvar, Kenneth/0000-0003-1165-5558 NR 77 TC 40 Z9 41 U1 3 U2 10 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD NOV 8 PY 2006 VL 296 IS 18 BP 2245 EP 2253 DI 10.1001/jama.296.18.2245 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 102QM UT WOS:000241827700025 PM 17090771 ER PT J AU Li, JD Hu, WP Boehmer, L Cheng, MY Lee, AG Jilek, A Siegel, JM Zhou, QY AF Li, Jia-Da Hu, Wang-Ping Boehmer, Lisa Cheng, Michelle Y. Lee, Alex G. Jilek, Alexander Siegel, Jerome M. Zhou, Qun-Yong TI Attenuated circadian rhythms in mice lacking the prokineticin 2 gene SO JOURNAL OF NEUROSCIENCE LA English DT Article DE circadian rhythm; prokineticin 2; knock-out; suprachiasmatic nucleus; sleep; locomotor ID SUPRACHIASMATIC NUCLEUS; LOCOMOTOR-ACTIVITY; EFFERENT PROJECTIONS; OLFACTORY BULBECTOMY; PERIPHERAL-TISSUES; BODY-TEMPERATURE; CLOCK; SLEEP; RAT; VASOPRESSIN AB Circadian clocks drive daily rhythms in virtually all organisms. In mammals, the suprachiasmatic nucleus (SCN) is recognized as the master clock that synchronizes central and peripheral oscillators to evoke circadian rhythms of diverse physiology and behavior. How the timing information is transmitted from the SCN clock to generate overt circadian rhythms is essentially unknown. Prokineticin 2 (PK2), a clock-controlled gene that encodes a secreted protein, has been indicated as a candidate SCN clock output signal that regulates circadian locomotor rhythm. Here we report the generation and analysis of PK2-null mice. The reduction of locomotor rhythms in PK2-null mice was apparent in both hybrid and inbred genetic backgrounds. PK2-null mice also displayed significantly reduced rhythmicity for a variety of other physiological and behavioral parameters, including sleep-wake cycle, body temperature, circulating glucocorticoid and glucose levels, as well as the expression of peripheral clock genes. In addition, PK2-null mice showed accelerated acquisition of food anticipatory activity during a daytime food restriction. We conclude that PK2, acting as a SCN output factor, is important for the maintenance of robust circadian rhythms. C1 Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92697 USA. Univ Calif Los Angeles, Sch Med, Dept Psychiat, Vet Adm Greater Los Angeles Healthcare Syst Sepul, North Hills, CA 91343 USA. Univ Calif Los Angeles, Sch Med, Brain Res Inst, North Hills, CA 91343 USA. Johannes Kepler Univ Linz, Inst Organ Chem, A-4040 Linz, Austria. RP Zhou, QY (reprint author), Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92697 USA. EM qzhou@uci.edu FU NIMH NIH HHS [MH067753, R01 MH067753-05] NR 55 TC 90 Z9 92 U1 2 U2 7 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD NOV 8 PY 2006 VL 26 IS 45 BP 11615 EP 11623 DI 10.1523/JNEUROSCI.3679-06.2006 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 103NE UT WOS:000241892700013 PM 17093083 ER PT J AU Casarett, D AF Casarett, David TI The median is not the (only) message SO ANNALS OF INTERNAL MEDICINE LA English DT Editorial Material ID BREAST-CARCINOMA TREATMENT; LUNG-CANCER; OLDER WOMEN; PATIENT C1 Univ Penn, Ctr Hlth Equ Res & Promot, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. RP Casarett, D (reprint author), Univ Penn, Ctr Hlth Equ Res & Promot, Philadelphia Vet Affairs Med Ctr, 3615 Chestnut St, Philadelphia, PA 19104 USA. EM casarett@mail.med.upenn.edu NR 15 TC 5 Z9 5 U1 0 U2 0 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD NOV 7 PY 2006 VL 145 IS 9 BP 700 EP 701 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 100ZD UT WOS:000241707800010 PM 17088585 ER PT J AU Coyle, TR Kochunov, P Patel, RD Nery, FG Lancaster, JL Mangin, JF Riviere, D Pillow, DR Davis, GJ Nicoletti, MA Monkul, ES Fox, PT Soares, JC AF Coyle, Thomas R. Kochunov, Peter Patel, Rupal D. Nery, Fabiano G. Lancaster, Jack L. Mangin, Jean-Francois Riviere, Denis Pillow, David R. Davis, Gregory J. Nicoletti, Mark A. Monkul, E. Serap Fox, Peter T. Soares, Jair C. TI Cortical sulci and bipolar disorder SO NEUROREPORT LA English DT Article DE bipolar disorder; brain; cortical sulci; diagnostic imaging; magnetic resonance imaging; sulcal width ID MOOD DISORDERS; BRAIN; SCHIZOPHRENIA; MORPHOMETRY; VOLUMES; CORTEX; MATTER AB The width of cortical sulci in bipolar patients (n = 19) and healthy controls (n = 35) was examined using a novel automated technique involving magnetic resonance imaging. All sulci were wider for bipolar patients than for healthy controls. Bipolar-control differences were largest for the superior and intermediate frontal sulci, smallest for the occipital and cingulate sulci, and intermediate in magnitude for the other sulci (intraparietal, inferior frontal, and central sulci). The results were interpreted in terms of neurodegenerative-illness-related processes, which could produce cortical atrophy and result in wider sulci. C1 Univ Texas, Dept Psychol, San Antonio, TX 78249 USA. Univ Texas, Hlth Sci Ctr, Res Imaging Ctr, San Antonio, TX 78249 USA. Univ Texas, Hlth Sci Ctr, MOOD CNS Program, Dept Psychiat,Div Mood & Anxiety Disorders, San Antonio, TX 78249 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. Univ Sao Paulo, Sch Med, Dept Psychiat, BR-05508 Sao Paulo, Brazil. Commissariat Energie Atom, Serv Hosp Frederic Joliot, Orsay, France. Dokuz Eylul Univ, Sch Med, Dept Psychiat, Izmir, Turkey. RP Coyle, TR (reprint author), Univ Texas, Dept Psychol, 1 UTSA Circle, San Antonio, TX 78249 USA. EM Thomas.Coyle@utsa.edu RI Lancaster, Jack/F-2994-2010; Kochunov, Peter/E-4711-2010; Fox, Peter/B-4725-2010 OI Fox, Peter/0000-0002-0465-2028 FU NCRR NIH HHS [M01-RR-01346, RR 20571]; NIDA NIH HHS [P20 MH/DA52176]; NIMH NIH HHS [MH 68766, MH 68662, MH 69774] NR 21 TC 11 Z9 11 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0959-4965 J9 NEUROREPORT JI Neuroreport PD NOV 6 PY 2006 VL 17 IS 16 BP 1739 EP 1742 DI 10.1097/01.wnr.0000239957.53072.f0 PG 4 WC Neurosciences SC Neurosciences & Neurology GA 104MG UT WOS:000241961900016 PM 17047464 ER PT J AU Gilbert, S Zheng, B Leader, JK Luketich, JD Fuhrman, CR Landreneau, RJ Gur, D Sciurba, FC AF Gilbert, Sebastien Zheng, Bin Leader, Joseph K. Luketich, James D. Fuhrman, Carl R. Landreneau, Rodney J. Gur, David Sciurba, Frank C. TI Computerized estimation of the lung volume removed during lung volume reduction surgery SO ACADEMIC RADIOLOGY LA English DT Article DE lung volume reduction surgery; computed tomography; emphysema; CT densitomtery ID SEVERE EMPHYSEMA; PULMONARY-FUNCTION; DIFFUSE EMPHYSEMA; QUANTITATIVE CT; CLINICAL-TRIAL; RABBIT MODEL; DISEASE; IMPROVEMENT; TOMOGRAPHY AB Rationale and Objectives. This study was designed to develop an automated method for estimating lung volume removed during lung volume reduction surgery (LVRS) using computed tomography (CT). Materials and Methods. The CT examinations of six patients who underwent bilateral LVRS were analyzed in this study. The resected lung tissue (right and left) was weighed during pathologic examination. An automated computer scheme was developed to estimate the lung volume removed using the CT voxel values and lung specimen weight. The computed fraction of lung volume removed was evaluated across a range of simulated surgical planes (ie, other than parallel to the CT image plane) and CT reconstruction kernels, and it was compared with the surgeons' postsurgical estimates. Results. The computed fraction of the lung volume removed during LVRS was linearly correlated with the resected lung tissue weight (Pearson correlation = 0.697, P =.012). The computed fraction of lung volume removed ranged from 12.9% to 51.7% of the total lung volume. The surgeons' postsurgical estimates of lung volume removed ranged from 30% to 33%. The percent difference between the surgeons' estimates and the computed lung volume removed as a percentage of the surgeons' estimates ranged from -72.3% to 57.0% with mean absolute difference of 29.7% (+/- 20.7). Conclusion. The preliminary findings of this study suggest that the proposed quantitative model should provide an objective measure of lung volume removed during LVRS that may be used to investigate the relationship between lung volume removed and outcome. C1 Univ Pittsburgh, Imaging Res Div, Dept Radiol, Pittsburgh, PA 15213 USA. Univ Pittsburgh, Imaging Res Div, Dept Surg, Pittsburgh, PA 15213 USA. Univ Pittsburgh, Imaging Res Div, Dept Med, Pittsburgh, PA 15213 USA. Vet Affairs Pittsburgh Hlth Syst, Pittsburgh, PA 15240 USA. RP Leader, JK (reprint author), Univ Pittsburgh, Imaging Res Div, Dept Radiol, 300 Halket St,Suite 4200, Pittsburgh, PA 15213 USA. EM leaderjk@upmc.edu OI Gilbert, Sebastien/0000-0003-4357-9553; Zheng, Bin/0000-0002-7682-6648 NR 33 TC 1 Z9 2 U1 0 U2 1 PU ASSOC UNIV RADIOLOGISTS PI OAK BROOK PA 820 JORIE BLVD, OAK BROOK, IL 60523-2251 USA SN 1076-6332 J9 ACAD RADIOL JI Acad. Radiol. PD NOV PY 2006 VL 13 IS 11 BP 1379 EP 1386 DI 10.1016/j.acra.2006.08.013 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 106PY UT WOS:000242114400009 PM 17070456 ER PT J AU Kleinschmidt-DeMasters, BK Filley, CM Rojiani, AM AF Kleinschmidt-DeMasters, B. K. Filley, Christopher M. Rojiani, Amyn M. TI Overlapping features of extrapontine myelinolysis and acquired chronic (non-Wilsonian) hepatocerebral degeneration SO ACTA NEUROPATHOLOGICA LA English DT Article DE central pontine myelinolysis; osmotic demyelination; hyponatremia; chronic alcoholism; lateral pontine myelinolysis; extrapontine myelinolysis; pathogenesis; liver failure; U-fibers; arcuate fibers ID CENTRAL PONTINE MYELINOLYSIS; ELECTROLYTE-INDUCED DEMYELINATION; RAPID CORRECTION; HYPONATREMIA; RATS AB Central pontine myelinolysis (CPM, osmotic demyelination syndrome) and acquired chronic hepatocerebral degeneration (ACHD) both occur in patients with liver failure, but are not thought to be caused by similar etiopathogenic mechanisms despite the fact that occasional patients exhibit both disorders. In our autopsy practice we have recently encountered three patients with the pontine lesions of acute or subacute osmotic demyelination syndrome, coupled with superimposed non-Wilsonian ACHD. All three patients had well-documented rapid elevations in serum sodium proximate to their demise, as well as terminal liver failure. A close intermingling and juxtaposition of lesions with severe demyelination and macrophage breakdown [thought to represent extrapontine myelinolysis (EPM)] to those with vacuolization of myelin but no cellular reaction or myelin loss (ACHD) was noted within some of the same anatomic areas. Particular overlap was seen in lesions at the cerebral cortical gray-white junction and in pencil fibers of the striatum. In these areas it was difficult to be certain whether the lesions were due to EPM or ACHD. We concluded that there was a synergism between the two disorders and raise the possibility that there may be factors common to both disorders that lead to similar anatomic sites for involvement. C1 Univ Colorado Denver & Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA. Univ Colorado Denver & Hlth Sci Ctr, Dept Neurol, Denver, CO 80262 USA. Univ Colorado Denver & Hlth Sci Ctr, Dept Psychiat, Denver, CO 80262 USA. Univ Colorado Denver & Hlth Sci Ctr, Dept Neurosurg, Denver, CO 80262 USA. Denver Vet Affairs Med Ctr, Denver, CO USA. Univ S Florida, Dept Interdisciplinary Oncol & Pathol Neuropathol, Tampa, FL USA. RP Kleinschmidt-DeMasters, BK (reprint author), Univ Colorado Denver & Hlth Sci Ctr, Dept Pathol, 4200 E 9th Ave,B-216, Denver, CO 80262 USA. EM BK.DeMasters@uchsc.edu NR 24 TC 8 Z9 10 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0001-6322 J9 ACTA NEUROPATHOL JI Acta Neuropathol. PD NOV PY 2006 VL 112 IS 5 BP 605 EP 616 DI 10.1007/s00401-006-0112-6 PG 12 WC Clinical Neurology; Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA 094RR UT WOS:000241257200009 PM 16871403 ER PT J AU Oursler, KK Goulet, JL Leaf, DA Akingicil, A Katzel, LI Justice, A Crystal, S AF Oursler, Krisann K. Goulet, Joseph L. Leaf, David A. Akingicil, Ayse Katzel, Leslie I. Justice, Amy Crystal, Stephen TI Association of comorbidity with physical disability in older HIV-infected adults SO AIDS PATIENT CARE AND STDS LA English DT Article ID QUALITY-OF-LIFE; HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; HEPATITIS-C VIRUS; FUNCTIONAL STATUS; HEALTH; VETERANS; DISEASE; COHORT; HAART AB Comorbidity, aging, and their impact on physical functioning will play an increasingly greater role in HIV medical care as the number of infected adults over 50 years of age grows. The study objective was to investigate the relationship of comorbidity and age with physical functioning in HIV-infected and HIV-negative patients. Eight hundred eighty-nine HIV-infected veterans and 647 HIV-negative veterans from the Veterans Aging Cohort Study conducted between September 2001 and June 2002 were included in the study. Physical functioning was measured by self-reported difficulty with various physical activities. Regression analyses were performed to examine demographic and clinical factors associated with physical functioning. Separate models were used for HIV-infected and HIV negative subjects since these groups differed in demographic makeup. In both patient groups, chronic lung disease, coronary artery disease, hypertension, smoking, and major depression were independently associated with reduced physical functioning in age and race adjusted regression models. Increased age was associated with reduced physical functioning in both HIV-infected and HIV-negative patients. However, when comorbid conditions were entered into the models for both HIV-infected and HIV-negative patients, age coefficients were reduced and were no longer statistically significant. Among the HIV-infected patients, results remained unchanged after controlling for the impact of antiretroviral therapy and HIV disease stage. Our findings demonstrate the important role of general medical comorbidity in physical functioning in both HIV-infected and HIV-negative patients. This suggests the importance of effectively treating comorbid conditions in persons with HIV, in order to reduce the overall impact of disease on physical functioning. C1 Baltimore VA Med Ctr, Baltimore, MD 21201 USA. Univ Maryland, Sch Med, Baltimore, MD 21201 USA. Yale Univ, Sch Med, New Haven, CT USA. W Haven VA Med Ctr, New Haven, CT USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. Greater Los Angeles VA Healthcare Syst Los Angele, Los Angeles, CA USA. Rutgers State Univ, Sch Social Work, New Brunswick, NJ 08903 USA. Rutgers State Univ, Inst Hlth Hlth Care Policy & Aging Res, New Brunswick, NJ 08903 USA. RP Oursler, KK (reprint author), Baltimore VA Med Ctr, BT 111,10 N Greene St, Baltimore, MD 21201 USA. EM Oursler@umbi.umd.edu OI Goulet, Joseph/0000-0002-0842-804X FU AHRQ HHS [418-HS016097]; NCRR NIH HHS [M01 RR016500]; NIA NIH HHS [5 P60 AG12583-09, K23 AG00826]; NIAAA NIH HHS [3U01 AA 13566]; NIMH NIH HHS [2R01-MH058984] NR 41 TC 38 Z9 38 U1 1 U2 1 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1087-2914 J9 AIDS PATIENT CARE ST JI Aids Patient Care STDS PD NOV PY 2006 VL 20 IS 11 BP 782 EP 791 DI 10.1089/apc.2006.20.782 PG 10 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 114FJ UT WOS:000242651800006 PM 17134352 ER PT J AU Beresford, TP Arciniegas, DB Alfers, J Clapp, L Martin, B Liu, YPDDF Shen, DG Davatzikos, C AF Beresford, Thomas P. Arciniegas, David B. Alfers, Julie Clapp, Lori Martin, Brandon Liu, Yiping Du Dengfeng Shen, Dinggang Davatzikos, Christos TI Hippocampus volume loss due to chronic heavy drinking SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE hippocampus; alcohol drinking; volume loss; MRI scan ID STRUCTURED CLINICAL INTERVIEW; ALCOHOL DEPENDENCE; ELASTIC REGISTRATION; SEX-DIFFERENCES; BRAIN; RELIABILITY; DISORDERS; DEFICITS; GENDER; HAMMER AB Objective: No clear consensus exists regarding the effect of sustained, heavy drinking on hippocampal volume. Our prior work hypothesized significantly lowered total hippocampus volumes in heavy chronically drinking alcohol-dependent (AD) subjects compared with light-drinking nondependent control subjects matched for age and gender. Method: Using a series of applicable exclusion criteria culled from previous published studies, we measured hippocampal volumes from MRI scan data acquired on a 3T scanner and subjected those data to automated volume analysis blind to the drinking history. Results: Comparison with AD test (n=8) and non-AD control (n=8) subjects found significant lessening in total (p=0.020) and left (p=0.010) hippocampal volumes with a near-significant difference on the right (p=0.051). Linear regression demonstrated that neither total brain volume nor intracranial volume affected the hippocampus measures. Conclusions: These data support the view that heavy drinking exerts a unique and selectively injurious effect on the hippocampus. Further study in larger samples must verify this in a search for possible mechanisms of injury. C1 Univ Colorado, Sch Med, Mental Hlth Serv, Dept Vet Affairs Med Ctr, Denver, CO USA. Univ Colorado, Sch Med, Dept Psychiat, Denver, CO 80262 USA. Univ Colorado, Sch Med, Dept Neurol, Denver, CO USA. Univ Colorado, Sch Med, Dept Radiol, Denver, CO USA. Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA. RP Beresford, TP (reprint author), Denver VA Med Ctr, 116,1055 Clermont St, Denver, CO 80220 USA. EM thomas.beresford@uchsc.edu RI Arciniegas, David/A-3792-2009 FU NIAAA NIH HHS [R21 AA 14010] NR 25 TC 70 Z9 71 U1 1 U2 8 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD NOV PY 2006 VL 30 IS 11 BP 1866 EP 1870 DI 10.1111/j.1530-0277.2006.00223.x PG 5 WC Substance Abuse SC Substance Abuse GA 098HA UT WOS:000241510400007 PM 17067350 ER PT J AU Amin, AA Jones, AMH Nugent, K Rumsfeld, JS Spertus, JA AF Amin, Alpesh A. Jones, Angela M. H. Nugent, Karen Rumsfeld, John S. Spertus, John A. TI The prevalence of unrecognized depression in patients with acute coronary syndrome SO AMERICAN HEART JOURNAL LA English DT Article ID QUALITY-OF-LIFE; MYOCARDIAL-INFARCTION; HEALTH QUESTIONNAIRE; MORTALITY RISK; PRIMARY-CARE; SYMPTOMS; VALIDITY; DISORDERS; SEVERITY; DISEASE AB Background Depression in patients with acute coronary syndrome (ACS) is common and independently prognostic of a higher mortality and worse health status. Despite great attention to its prevalence and prognostic import, little is known about how often hospitalized patients with ACS who have significant depressive symptoms are recognized while receiving routine cardiovascular care. Methods We performed a cross-sectional study of 1181 consecutive patients with confirmed ACS. Detailed reviews of hospital records were performed for the documentation that depressive symptoms were recognized. Multivariable regression analysis was used to identify factors associated with unrecognized depressive symptoms. Results The prevalence of moderate/severe depressive symptoms was 17.6%. Only 24.5% had documentation that their depressive symptoms were recognized. In multivariable regression analysis, characteristics associated with unrecognized depressive symptoms were race (minorities vs whites; odds ratio [OR]=6.73, 95% confidence interval [CI] 2.62-19.33), ejection fraction (EF < 0.40 vs EF >= 0.40; OR=3.45, 95% CI 1.06-11.23), and education level (no college vs some college; OR=2.77, 95% Cl 1.38-5.69). Conclusions Despite its prognostic importance and prevalence, moderate to severe depressive symptoms are poorly recognized in hospitalized patients with ACS. Better interventions are warranted to increase the recognition and improve the management of depressive symptoms in patients with ACS. C1 St Lukes Hosp, Mid Amer Heart Inst, Kansas City, MO 64111 USA. Univ Missouri, Kansas City, MO 64110 USA. Univ Colorado, Denver, CO 80202 USA. Denver VA Med Ctr, Denver, CO USA. Univ Missouri, Truman Med Ctr, Kansas City, MO 64108 USA. RP Amin, AA (reprint author), 4401 Wornall Rd, Kansas City, MO 64111 USA. EM aamin@saint-lukes.org FU AHRQ HHS [R-01 HS11282-01] NR 30 TC 34 Z9 34 U1 2 U2 6 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0002-8703 J9 AM HEART J JI Am. Heart J. PD NOV PY 2006 VL 152 IS 5 BP 928 EP 934 DI 10.1016/j.ahj.2006.05.006 PG 13 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 101MV UT WOS:000241745800026 PM 17070162 ER PT J AU Ruo, B Bertenthal, D Sen, S Bittner, V Ireland, CC Hlatky, MA AF Ruo, Bernice Bertenthal, Daniel Sen, Saunak Bittner, Vera Ireland, Christine C. Hlatky, Mark A. TI Self-rated health among women with coronary disease: Depression is as important as recent cardiovascular events SO AMERICAN HEART JOURNAL LA English DT Article ID INFLAMMATORY RISK MARKERS; DWELLING OLDER ADULTS; ARTERY-DISEASE; HEART-DISEASE; MYOCARDIAL-INFARCTION; CARDIAC MORTALITY; CES-D; SYMPTOMS; COMMUNITY; ASSOCIATION AB Background Prior studies have shown an association between depression and self-rated health among patients with coronary disease. However, the magnitude of the effect of depression on self-rated health compared with that of major clinical events is unknown. Our main objective was to clarify the association between depression and self-rated health using longitudinal data. Methods We performed a prospective cohort study of 2675 postmenopausal women with coronary disease. The primary predictor variable was a 4-state categorical depression variable based on the Burnam depression screen assessed at sequential visits. The outcome variable was self-rated overall health (excellent, very good, or good vs fair or poor). Results After adjustment for age, comorbidities, prior self-rated health, and interim events, women with depression at both current and prior annual visits had a > 5-fold increased odds of fair/poor self-rated health (odds ratio [OR] 5.1, 95% Cl 3.8-6.8). New depression was associated with a > 2-fold increased odds of fair/poor self-rated health (OR 2.6, 95% Cl 2.0-3.4). Having a history of depression at the preceding annual visit but not at the current visit was associated with a slight increased odds of fair/poor self-rated health (OR 1.3, 95% Cl 1.0-1.7). The magnitude of the impact of persistent or new depression was comparable to that of recent angina, myocardial infarction, angioplasty, heart failure, or bypass surgery. Conclusions Women with persistent or new depression are more likely to report fair/poor self-rated health. The magnitude of the impact of persistent or new depression is comparable to that of major cardiac events. C1 Northwestern Univ, Div Gen Internal Med, Feinberg Sch Med, Dept Internal Med, Chicago, IL 60611 USA. San Francisco Vet Affairs Med Ctr, Hlth Serv Res Enhancement Award Program, San Francisco, CA USA. Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. Univ Alabama, Div Cardiovasc Dis, Birmingham, AL 35294 USA. Stanford Univ, Sch Med, Stanford, CA 94305 USA. RP Ruo, B (reprint author), Northwestern Univ, Div Gen Internal Med, Feinberg Sch Med, Dept Internal Med, 676 N St Clair St,Suite 200, Chicago, IL 60611 USA. EM bruo@nmff.org OI Bittner, Vera/0000-0001-9456-850X NR 37 TC 6 Z9 6 U1 1 U2 1 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0002-8703 J9 AM HEART J JI Am. Heart J. PD NOV PY 2006 VL 152 IS 5 AR 921.e1 DI 10.1016/j.ahj.2006.01.012 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 101MV UT WOS:000241745800024 ER PT J AU Lau, M Le, A El-Serag, HB AF Lau, Melvin Le, Anne El-Serag, Hashem B. TI Noncardia gastric adenocarcinoma remains an important and deadly cancer in the United States: Secular trends in incidence and survival SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID CARCINOMA; STOMACH; STATISTICS; PATTERNS; CARDIA; USA AB BACKGROUND: Noncardia gastric adenocarcinoma is not frequently mentioned in the United States. However, it is unclear if the previously reported decline in noncardia gastric adenocarcinoma has continued, and if detection and management has affected overall survival outside the setting of clinical trials. METHODS: We used the Surveillance, Epidemiology, and End Results registry (SEER) to identify all cases of noncardia gastric adenocarcinoma diagnosed between 1973 and 2002. The yearly age-adjusted incidence rates and the relative survival rates were calculated. Cox proportional hazards (PH) models were used to examine temporal trends from 1983 to 2003. RESULTS: Between 1973 and 2002, there were 24,103 cases of noncardia gastric adenocarcinoma. The age-adjusted yearly incidence rate declined by 23% between 1973 and 2002 from 4.3 to 3.3 per 100,000 person-years. However, the incidence of localized noncardia gastric adenocarcinoma (invasive neoplasm confined to the organ of origin) remained without change between 0.9 and 1.0 per 100,000 person-years, and increased with age, especially in the 85+ yr age group (a 47% increase between 1973 and 2002). The incidence rates in men were double those in women, and 1.6-fold and 2.6-fold higher in blacks and other races (mostly Asians), respectively, compared with whites. Patients with radiation and chemotherapy after gastrectomy had a 22% better mortality risk compared with those treated with gastrectomy alone. The Cox PH analysis shows no significant change in mortality risk related to year of diagnosis between 1983 and 2002, both in unadjusted as well as adjusted analyses. However, there were significant independent regional and racial variations in survival. Asians had a 17% lower mortality risk compared with whites. CONCLUSIONS: Despite the overall decline in noncardia gastric adenocarcinoma, the incidence of local stage disease has remained stable in most ages and even increased in old ages. Unfortunately, there has been no significant improvement in survival during the past 20 yr. Moreover, there remain considerable regional as well as racial variations in mortality. C1 Baylor Coll Med, Dept Med, Houston, TX 77030 USA. Baylor Coll Med, Dept Surg, Houston, TX 77030 USA. Houston Dept Vet Affairs Med Ctr, Gastroenterol Sect, Houston, TX USA. Houston Dept Vet Affairs Med Ctr, Sect Hlth Serv Res, Houston, TX USA. RP El-Serag, HB (reprint author), Houston Vet Affairs Med Ctr, 152,2002 Holcombe Blvd, Houston, TX 77030 USA. NR 20 TC 46 Z9 48 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD NOV PY 2006 VL 101 IS 11 BP 2485 EP 2492 DI 10.1111/j.1572-0241.2006.00778.x PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 101GH UT WOS:000241728300008 PM 17029617 ER PT J AU Khalid, A Nodit, L Zahid, M Bauer, K Brody, D Finkelstein, SD McGrath, KM AF Khalid, Asif Nodit, Laurentia Zahid, Maliha Bauer, Kathy Brody, Debra Finkelstein, Sydney D. McGrath, Kevin M. TI Endoscopic ultrasound fine needle aspirate DNA analysis to differentiate malignant and benign pancreatic masses SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID AUTOIMMUNE-RELATED PANCREATITIS; TUMOR-SUPPRESSOR GENE; K-RAS; INTRAEPITHELIAL NEOPLASIA; SCLEROSING PANCREATITIS; CLINICAL UTILITY; DIAGNOSIS; ADENOCARCINOMA; P53; MUTATIONS AB OBJECTIVES: Accurate diagnosis of malignant and benign pancreatic masses can be challenging, potentially delaying treatment for cancer and subjecting patients with benign disease to unnecessary surgery. Endoscopic ultrasound fine needle aspirate (EUS-FNA) of pancreatic masses remains inconclusive in a subset of patients. The role of EUS-FNA molecular analysis in this context is studied. METHODS: Patients with benign pancreatic masses (6 cases, 4 autoimmune pancreatitis, 2 focal chronic pancreatitis) and malignant pancreatic masses (15) with inconclusive cytology (5 cases) and positive cytology (10 controls) were selected. All cases had definitive pathology. Representative cells were microdissected from each EUS-FNA sample and subjected to PCR for analysis of 16 microsatellite allele loss markers situated at 1p, 3p, 5q, 9p, 9q, 10q, 17p, 17q, 21q, and 22q. Loss of heterozygosity analysis used fluorescent capillary electrophoresis for quantitative determination of allelic imbalance. k-ras-2 point mutation analysis was also performed. Mean fractional mutation rate (FMR) was calculated and compared for each group. RESULTS: All malignant cases carried multiple mutations (FMR 0.50), regardless of positive cytology (FMR 0.52) or suspicious cytology (FMR 0.47) (p = NS). Five of the 6 benign cases carried no mutations whereas 1 case of autoimmune pancreatitis and coexisting PanIN lesions exhibited a k-ras mutation (FMR 0.01). The mean FMR for the malignant and benign samples was significantly different (p < 0.0001). CONCLUSIONS: Broad panel microsatellite loss and k-ras point mutation analysis can be reliably performed on EUS-FNA samples from pancreatic masses and improves the diagnostic accuracy. Furthermore, it accurately differentiates between malignant and benign pancreatic masses. C1 Univ Pittsburgh, Med Ctr, Dept Med,VA Pittsburgh Hlth Care Syst, Div Gastroenterol Hepatol & Nutr,PUH, Pittsburgh, PA 15213 USA. VA Pittsburgh Hlth Care, Pittsburgh, PA USA. Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA. RedPath Integrated Pathol Inc, Pittsburgh, PA USA. RP Khalid, A (reprint author), Univ Pittsburgh, Med Ctr, Dept Med,VA Pittsburgh Hlth Care Syst, Div Gastroenterol Hepatol & Nutr,PUH, M2,C Wing,200 Lothrop St, Pittsburgh, PA 15213 USA. NR 41 TC 60 Z9 63 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD NOV PY 2006 VL 101 IS 11 BP 2493 EP 2500 DI 10.1111/j.1572-0241.2006.00740.x PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 101GH UT WOS:000241728300009 PM 17029619 ER PT J AU Darouiche, RO Goetz, L Kaldis, T Cerra-Stewart, C AlSharif, A Priebe, M AF Darouiche, Rabih O. Goetz, Lance Kaldis, Teresa Cerra-Stewart, Colleen AlSharif, Atef Priebe, Michael TI Impact of StatLock securing device on symptomatic catheter-related urinary tract infection: A prospective, randomized, multicenter clinical trial SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article; Proceedings Paper CT 15th Annual Meeting of the Society-for-Healthcare-Epidemiology-of-America CY APR 09-12, 2005 CL Los Angeles, CA SP Soc Healthcare Epidemiol Amer ID CENTRAL VENOUS CATHETERS; SPINAL-CORD INJURY; BLOOD-STREAM INFECTION; DOUBLE-BLIND; TRIMETHOPRIM-SULFAMETHOXAZOLE; BACTERIAL INTERFERENCE; HOSPITALIZED-PATIENTS; PILOT TRIAL; MEATAL CARE; PREVENTION AB Background: The objective of this study was to assess the impact of using the StatLock securing device on symptomatic catheter-related urinary tract infection (UTI). Methods: In this prospective, randomized, multicenter clinical trial, adult patients with spinal cord injury or dysfunction because of multiple sclerosis were randomized to have their indwelling bladder catheters secured in place by using the StatLock device (experimental group) versus preexisting methods (control group that included tape, Velcro strap, CathSecure, or none). Patients were monitored for the development of symptomatic UTI within the subsequent period of 8 weeks. Results: Of a total of 127 enrolled patients, 118 (60 in the experimental group and 58 in the control group) were evaluable. The 2 groups of evaluable patients were comparable in terms of clinical characteristics and risk factors for infection. Symptomatic UTI was diagnosed in 8 of 60 (13.3%) patients in the experimental group versus 14 of 58 (24.1%) patients in the control group (P = .16; RR = 0.55, 95% confidence interval: 0.25-1.22). Conclusion: Although the trial size precluded the demonstration of statistically significant differences, the finding of a 45% reduction in the rate of symptomatic UTI in patients who received the StatLock securing device is clinically relevant and prompts further investigations. C1 Baylor Coll Med, Ctr Prostheses Infect, Houston, TX 77030 USA. Michael E Debakey Vet Affairs Med Ctr, Houston, TX USA. Vet Affairs N Texas Healthcare Syst, Dallas, TX USA. Univ Texas, SW Med Ctr, Dallas, TX 75230 USA. Inst Rehabil & Res, Houston, TX USA. Hines Vet Affairs Med Ctr, Hines, IL USA. RP Darouiche, RO (reprint author), Baylor Coll Med, Ctr Prostheses Infect, 1333 Moursund Ave,Suite A221, Houston, TX 77030 USA. EM rdarouiche@aol.com NR 36 TC 22 Z9 22 U1 1 U2 3 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0196-6553 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD NOV PY 2006 VL 34 IS 9 BP 555 EP 560 DI 10.1016/j.ajic.2006.03.010 PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 105MX UT WOS:000242035400003 PM 17097449 ER PT J AU Bryson, CL Ross, HJ Boyko, EJ Young, BA AF Bryson, Chris L. Ross, Heather J. Boyko, Edward J. Young, Bessie A. TI Racial and ethnic variations in albuminuria in the US Third National Health and Nutrition Examination Survey (NHANES III) population: Associations with diabetes and level of CKD SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE race; ethnicity; microalbuminuria; macroalbuminuria; proteinuria; diabetes; chronic kidney disease; cohort study ID BLOOD-PRESSURE; YOUNG-ADULTS; MICROALBUMINURIA AB Background: Racial and ethnic differences in prevalence of albuminuria in a nationally representative population with and without diabetes were assessed. Methods: We analyzed cross-sectional data collected for the 20,050 participants of the Third National Health and Nutrition Examination Survey (NHANES 111) to determine factors that contributed to racial/ethnic differences in microalbuminuria and macroalbuminuria prevalence. Results: For the 15,522 NHANES III participants for whom relevant data were available, racial/ethnic minorities tended to be younger, be less well educated, have lower income, and be less likely to have insurance than non-Hispanic whites, findings that were similar for those with and without diabetes. After adjusting for baseline covariates and medication use, racial and ethnic minorities with and without diabetes had greater odds of alburninuria compared with whites without diabetes (blacks with diabetes, adjusted odds ratio [aOR], 2.77; 95% confidence interval [CI], 1.46 to 2.72), Mexican Americans with diabetes (aOR, 2.43; 95% Cl, 1.07 to 2.11), and those of other ethnicity with diabetes (aOR, 2.93; 95% Cl, 1.28 to 6.75). Of those without diabetes, blacks had 2.18-fold (95% Cl, 1.44 to 3.30) and Mexican Americans had 1.81-fold (95% Cl, 1.08 to 3.02) greater odds of microalbuminuria or macroalbuminuria than whites after adjustment for potential confounding factors. Stratifying by estimated glomerular filtration rate (eGFR) less than 60 mL/min/1.73 m(2) (<1.00 mUs) showed similar results for racial/ethnic minorities and those with diabetes, whereas results were significant only for blacks with and without diabetes for those with an eGFR of 60 mL/min/1.73 m(2) or greater. Level of metabolic control (hemoglobin A(1c) level), systolic blood pressure, income, diuretic use, and hypertensive treatment status remained independent factors associated with alburninuria. Conclusion: Racial and ethnic minorities have greater odds of albuminuria than whites with and without diabetes, which persists primarily for those with an eGFR less than 60 mL/min/1.73m(2). C1 Epidemiol Res & Informat Ctr, VA Puget Sound Hlth Care Syst, Seattle, WA 98101 USA. NW Ctr Excellence,Hlth Serv Res & Dev, VA Puget Sound Hlth Care Syst, Seattle, WA 98101 USA. Univ Washington, Dept Med, Div Gen Internal Med, Seattle, WA USA. NW Kidney Ctr, Seattle, WA USA. RP Young, BA (reprint author), Epidemiol Res & Informat Ctr, VA Puget Sound Hlth Care Syst, 1100 Olive Way,Ste 1400, Seattle, WA 98101 USA. EM youngb@u.washington.edu OI Boyko, Edward/0000-0002-3695-192X NR 20 TC 63 Z9 63 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD NOV PY 2006 VL 48 IS 5 BP 720 EP 726 DI 10.1053/j.ajkd.2006.07.023 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 197FV UT WOS:000248540900004 PM 17059991 ER PT J AU Szabo, CA Lancaster, JL Lee, S Xiong, JH Cook, C Mayes, BN Fox, PT AF Szabo, C. A. Lancaster, J. L. Lee, S. Xiong, J. -H. Cook, C. Mayes, B. N. Fox, P. T. TI MR imaging volumetry of subcortical structures and cerebellar hemispheres in temporal lobe epilepsy SO AMERICAN JOURNAL OF NEURORADIOLOGY LA English DT Article ID VOXEL-BASED MORPHOMETRY; QUANTITATIVE MRI; HIPPOCAMPAL ATROPHY; PARTIAL SEIZURES; THALAMUS; BRAIN; DURATION; AMYGDALA; ORIGIN; MATTER AB BACKGROUND AND PURPOSE: There is mounting evidence of extratemporal volume changes associated with medically refractory temporal lobe epilepsy (TLE). This MR imaging study aimed to characterize volume changes in subcortical structures and cerebellar hemispheres with respect to lateralization of the seizure focus, onset and duration of epilepsy, and frequency of generalized tonic-clonic seizures (GTCS). METHODS: Amygdalar, hippocampal, thalamic, caudate head, and cerebellar volume measurements were obtained in the preoperative MR images of 40 patients with TLE (20 right, 20 left), who underwent temporal lobe resection with good outcome, and in 20 right-handed control participants. All 3D MR images were spatially aligned and normalized before measurements were obtained. Standardized volumes and right-to-left volume ratios (VRs) were compared between control participants and right and left TLE groups. Multiple regression analyses were performed to study the effects of epilepsy onset and duration and GTCS frequency on ipsilateral-to-contra lateral VRs with respect to the resected seizure focus. RESULTS: Thalamic volumes were smaller bilaterally in patients with TLE. Hippocampal volumes were smaller ipsilateral to the seizure focus, but there was no significant volume loss involving the amygdala, caudate, or cerebellum. Hippocampal and annygdalar right-to-left VRs differed significantly between right and left TLE groups and controls, whereas thalamic right-to-left VRs differed only between the TLE groups. Thalamic ipsilateral-to-contralateral VRs were correlated positively with epilepsy onset and negatively with epilepsy duration. Caudate ipsilateral-to-contra lateral VRs were positively, whereas annygdalar and cerebellar VRs were negatively, correlated with GTCS frequency. CONCLUSIONS: Unilateral annygdalar and bilateral thalamic volume loss, in the absence of caudate head atrophy, is likely to reflect seizure-induced injury due to TLE. Correlations of VRs affecting the amygdala, caudate, and cerebellum with GTCS frequency may also reflect injury or a prediposition for secondary generalization. Potential effects of complex partial seizures, febrile seizures, or antiepileptic medications on subcortical structures need to be evaluated in future studies. C1 Univ Texas, Hlth Sci Ctr, Dept Med Neurol, S Texas Comprehens Epilepsy Ctr, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Res Imaging Ctr, San Antonio, TX 78229 USA. Audie L Murphy Mem Vet Adm Med Ctr, Res & Dev Serv, San Antonio, TX 78284 USA. Univ Iowa, Dept Radiol, Iowa City, IA 52242 USA. RP Szabo, CA (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med Neurol, S Texas Comprehens Epilepsy Ctr, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM Charles.Szabo@uhs-sa.com RI Lancaster, Jack/F-2994-2010; Fox, Peter/B-4725-2010 OI Fox, Peter/0000-0002-0465-2028 FU NIDA NIH HHS [P20 DA52176] NR 27 TC 33 Z9 35 U1 1 U2 9 PU AMER SOC NEURORADIOLOGY PI OAK BROOK PA 2210 MIDWEST RD, OAK BROOK, IL 60521 USA SN 0195-6108 J9 AM J NEURORADIOL JI Am. J. Neuroradiol. PD NOV-DEC PY 2006 VL 27 IS 10 BP 2155 EP 2160 PG 6 WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 109CE UT WOS:000242284700032 PM 17110687 ER PT J AU Huang, AJ Thom, DH Kanaya, AM Wassel-Fyr, CL Van Den Eeden, SK Ragins, AI Subak, LL Brown, JS AF Huang, A. J. Thom, D. H. Kanaya, A. M. Wassel-Fyr, C. L. Van Den Eeden, S. K. Ragins, A. I. Subak, L. L. Brown, J. S. TI Urinary incontinence and pelvic floor dysfunction in Asian-American women SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Article DE urinary incontinence; anal incontinence; fecal incontinence; pelvic organ prolapse; pelvic floor dysfunction; Asian-American; Asian; race; ethnicity ID TAIWANESE WOMEN; PREVALENCE; IMPACT; POPULATION; SYMPTOMS; DISTRESS; SEEKING; HEALTH; AGE AB Objective: The objective of the study was to describe the prevalence, risk factors, and impact of urinary incontinence and other pelvic floor disorders among Asian-American women. Study design: This was a population-based cohort study of older women randomly selected from age and race strata. Results: Weekly urinary incontinence was reported by 65 of 345 Asian women (18%), with stress and urge incontinence being approximately equally common. In multivariate analysis, higher body mass index (greater than 25 kg/m(2)) was associated with both stress incontinence (odds ratio 4.90, 95% confidence interval 1.76 to 13.68) and urge incontinence (odds ratio 2.49, 95% confidence interval 1.01 to 6.16) in Asians. Hysterectomy was a significant risk factor for stress incontinence (odds ratio 2.79, 95% confidence interval 1.03 to 7.54). Only 34% of Asian women with weekly urinary incontinence reported ever having sought treatment. Pelvic floor exercises were the most common form of treatment, being used by 29% of Asian women with weekly incontinence. Asians were-less likely then white women to report anal incontinence (21% versus 29%, P = .007), although this difference became nonsignificant after adjusting for differences in risk factors. Conclusion: Asian women share some risk factors for stress and urge urinary incontinence with white women. Urinary incontinence is associated with anal incontinence among Asian women. (c) 2006 Mosby, Inc. All rights reserved. C1 San Francisco Vet Affairs Med Ctr, Div Gen Med, San Francisco, CA 94121 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. Kaiser Permanente, Div Res, Oakland, CA USA. RP Huang, AJ (reprint author), San Francisco Vet Affairs Med Ctr, Div Gen Med, 4150 Clement St,VAMC 111A1, San Francisco, CA 94121 USA. EM ajhuan@yahoo.com FU NIDDK NIH HHS [P50 DK064538, R01 DK053335, P50 DK044538, R01-DK53335] NR 23 TC 16 Z9 17 U1 0 U2 1 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0002-9378 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD NOV PY 2006 VL 195 IS 5 BP 1331 EP 1337 DI 10.1016/j.ajog.2006.03.052 PG 7 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 105MZ UT WOS:000242035700022 PM 16643821 ER PT J AU Perell, KL Manzano, MLP Weaver, R Fiuzat, M Voss-McCarthy, M Opava-Rutter, D Castle, SC AF Perell, Karen L. Manzano, Maria Lyn P. Weaver, Robert Fiuzat, Mona Voss-McCarthy, Michelle Opava-Rutter, Dorene Castle, Steven C. TI Outcomes of a consult fall prevention screening clinic SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION LA English DT Article DE geriatrics; fall prevention; aged; patient satisfaction; pharmacology ID RANDOMIZED CONTROLLED-TRIAL; COMMUNITY; INTERVENTION; HOME; RISK; GO AB Objective: To report patient satisfaction and quality outcomes from a standardized, multicenter fall prevention screening clinic. Design: Referrals were made to the fall prevention screening clinic, which was staffed by a physician, pharmacist, therapist, nurse, and the site coordinator. The fall prevention screening clinic staff utilized a team-meeting format with clearly delineated management options to determine the appropriate interventions based on various screening examinations. Results: Primary care providers acknowledged pharmacy recommendations and > 80% of the recommendations were followed. There was a reduction in reported falls (initial visit = 297 falls, follow-up visit = 141 falls, P = 0.0002) and in the number of recurrent fallers. There was a small (average difference = 1.8 secs) but significant (P = 0.025) decrease in the 8-foot Up-and-Go time, representing a functional improvement in walking speed. There was no significant change in the Fall Efficacy Scale, however. At least > 80% of the patients reported that they were completely satisfied with their care. Conclusions: Patients who attended the fall prevention screening clinic demonstrated improved confidence during activities of daily living and reduced falls. They reported high satisfaction with the clinic format. C1 Calif State Univ Fullerton, Dept Kinesiol, Fullerton, CA 92834 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. San Francisco VA Med Ctr, San Francisco, CA USA. RP Perell, KL (reprint author), Calif State Univ Fullerton, Dept Kinesiol, Fullerton, CA 92834 USA. NR 18 TC 6 Z9 6 U1 6 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0894-9115 J9 AM J PHYS MED REHAB JI Am. J. Phys. Med. Rehabil. PD NOV PY 2006 VL 85 IS 11 BP 882 EP 888 DI 10.1097/01.phm.0000233209.49518.46 PG 7 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 098OL UT WOS:000241532400004 PM 17079960 ER PT J AU Mukherjee, R Mingoia, JT Bruce, JA Austin, JS Stroud, RE Escobar, GP McClister, DM Allen, CM Alfonso-Jaume, MA Fini, ME Lovett, DH Spinale, FG AF Mukherjee, Rupak Mingoia, Joseph T. Bruce, James A. Austin, Jeffrey S. Stroud, Robert E. Escobar, G. Patricia McClister, David M., Jr. Allen, Claire M. Alfonso-Jaume, Maria A. Fini, M. Elizabeth Lovett, David H. Spinale, Francis G. TI Selective spatiotemporal induction of matrix metalloproteinase-2 and matrix metalloproteinase-9 transcription after myocardial infarction SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Article DE structure; remodeling; matrix metalloproteinases ID LEFT-VENTRICULAR ENLARGEMENT; PREVENTS CARDIAC RUPTURE; TARGETED DELETION; HEART-FAILURE; TISSUE INHIBITOR; RAT MYOCARDIUM; MICE; EXPRESSION; MMP-2; CELLS AB Myocardial remodeling after myocardial infarction (MI) is associated with increased levels of the matrix metalloproteinases (MMPs). Levels of two MMP species, MMP-2 and MMP-9, are increased after MI, and transgenic deletion of these MMPs attenuates post-MI left ventricular (LV) remodeling. This study characterized the spatiotemporal patterns of gene promoter induction for MMP-2 and MMP-9 after MI. MI was induced in transgenic mice in which the MMP-2 or MMP-9 promoter sequence was fused to the beta-galactosidase reporter, and reporter level was assayed up to 28 days after MI. Myocardial localization with respect to cellular sources of MMP-2 and MMP-9 promoter induction was examined. After MI, LV diameter increased by 70% (P < 0.05), consistent with LV remodeling. beta-Galactosidase staining in MMP-2 reporter mice was increased by 1 day after MI and increased further to 64 +/- 6% of LV epicardial area by 7 days after MI (P < 0.05). MMP-2 promoter activation occurred in fibroblasts and myofibroblasts in the MI region. In MMP-9 reporter mice, promoter induction was detected after 3 days and peaked at 7 days after MI (53 +/- 6%, P < 0.05) and was colocalized with inflammatory cells at the peri-infarct region. Although MMP-2 promoter activation was similarly distributed in the MI and border regions, activation of the MMP-9 promoter was highest at the border between the MI and remote regions. These unique findings visually demonstrated that activation of the MMP-2 and MMP-9 gene promoters occurs in a distinct spatial relation with reference to the MI region and changes in a characteristic time-dependent manner after MI. C1 Med Univ S Carolina, Div Cardiovasc Surg, Charleston, SC 29425 USA. Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, McKnight Vis Res Ctr, Miami, FL 33152 USA. Univ Calif San Francisco, Vet Affairs Med Ctr, Dept Med, San Francisco, CA 94143 USA. RP Mukherjee, R (reprint author), Med Univ S Carolina, Div Cardiovasc Surg, Strom thurmond Res Bldg,770 MUSC Complex,Ste 625, Charleston, SC 29425 USA. EM mukherr@musc.edu FU NEI NIH HHS [EY-14801, EY-12651]; NHLBI NIH HHS [HL-66029, P01-HL-48788, HL-45024, HL-97012, P01-HL-68738]; NIDDK NIH HHS [DK-29776] NR 45 TC 51 Z9 52 U1 0 U2 3 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD NOV PY 2006 VL 291 IS 5 BP H2216 EP H2228 DI 10.1152/ajpheart.01343.2005 PG 13 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA 092NB UT WOS:000241102700027 PM 16766634 ER PT J AU Stewart, L Grifiss, JM Jarvis, GA Way, LW AF Stewart, Lygia Grifiss, J. McLeod Jarvis, Gary A. Way, Lawrence W. TI Biliary bacterial factors determine the path of gallstone formation SO AMERICAN JOURNAL OF SURGERY LA English DT Article; Proceedings Paper CT 30th Annual Surgical Symposium of the Association-of-VA-Surgeons CY MAY 07-09, 2006 CL Cincinnati, OH DE gallstone formation; biofilm; slime; pigment stones; bacteria; beta-glucuronidase ID BROWN PIGMENT STONES; CHOLESTEROL GALLSTONES; BETA-GLUCURONIDASE; PATHOGENESIS; BILE; GLYCOCALYX; BIOFILMS; DISEASE; DNA AB Background: Bacteria cause pigment gallstones and can act as a nidus for cholesterol gallstone formation. Bacterial factors that facilitate gallstone formation include beta-glucuronidase (bG), phospholipase (PhL), and slime. The current study sought to determine whether bacterial factors influence the path of gallstone formation. Methods: A total of 382 gallstones were cultured and/or examined using scanning electron microscopy (SEM). Bacteria were tested for bG and slime production. Gallstone composition was determined using infrared spectrography. Ca-palmitate presence documented bacterial PhL production. Groups were identified based upon bacterial factors present: slime and bGPhL (slime/bGPhL), bGPhL only, and slime only. Influence of bacterial stone-forming factors on gallstone composition and morphology was analyzed. Results: Bacteria were present in 75% of pigment, 76% of mixed, and 20% of cholesterol stones. Gallstones with. bGPhL producing bacteria contained more pigment (71% vs. 26%, P < .0001). The slime/bGPhL group was associated (79%) with pigment stones, bGPhL was associated (56%) with mixed stones, while slime (or none) only was associated (67%) with cholesterol stones (P < .031, all comparisons). Conclusions: Bacterial properties determined the path of gallstone formation. Bacteria that produced all stone-forming factors promoted pigment stone formation, while those that produced only bGPhL promoted mixed stone formation. Bacteria that only produced slime lacked the ability to generate pigment solids, and consequently were more common in the centers of cholesterol stones. This shows how bacterial characteristics may govern the process of gallstone formation. (c) 2006 Excerpta Medica Inc. All rights reserved. C1 Univ Calif San Francisco, Vet Adm Med Ctr, Dept Surg, San Francisco, CA 94121 USA. San Francisco Vet Affairs Med Ctr, Surg Serv, San Francisco, CA USA. San Francisco Vet Affairs Med Ctr, Ctr Immunochem, San Francisco, CA USA. Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA. RP Stewart, L (reprint author), Univ Calif San Francisco, Vet Adm Med Ctr, Dept Surg, 4150 Clement St, San Francisco, CA 94121 USA. EM lygia.stewart@med.va.gov NR 30 TC 16 Z9 17 U1 1 U2 3 PU EXCERPTA MEDICA INC PI BRIDGEWATER PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA SN 0002-9610 J9 AM J SURG JI Am. J. Surg. PD NOV PY 2006 VL 192 IS 5 BP 598 EP 603 DI 10.1016/j.amjsurg.2006.08.001 PG 6 WC Surgery SC Surgery GA 102NW UT WOS:000241820000008 PM 17071191 ER PT J AU Riscoe, M Winter, R Kelly, J Smilkstein, M Dodean, R Hinrichs, D AF Riscoe, Michael Winter, Rolf Kelly, Jane Smilkstein, Martin Dodean, Rosie Hinrichs, Dave TI Evaluation and lead optimization of antimalarial aromatic ketones SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Meeting Abstract C1 Portland VA Med Ctr, Portland, OR USA. NR 0 TC 3 Z9 3 U1 1 U2 2 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD NOV PY 2006 VL 75 IS 5 SU S MA 336 BP 97 EP 98 PG 2 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 109XW UT WOS:000242343900337 ER PT J AU Smilkstein, M Kelly, J Dodean, R Hinrichs, D Winter, R Riscoe, M AF Smilkstein, Martin Kelly, Jane Dodean, Rosie Hinrichs, David Winter, Rolf Riscoe, Michael TI Novel antimalarial acridone derivatives with both intrinsic potency and synergy with selected quinolines: In vitro and in vivo studies SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Meeting Abstract C1 Portland VA Med Ctr, Portland, OR USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD NOV PY 2006 VL 75 IS 5 SU S MA 337 BP 98 EP 98 PG 1 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 109XW UT WOS:000242343900338 ER PT J AU Peniche, AG Osorio, Y Melby, PC Travi, BL AF Peniche, Alex G. Osorio, Yaneth Melby, Peter C. Travi, Bruno L. TI Neutrophil infiltration is associated with initial parasite control but subsequently contributes to tissue damage in hamsters infected with leishmania (viannia) panamensis SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Meeting Abstract C1 Ctr Int Entrenamiento Invest Med, Cali, Colombia. S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD NOV PY 2006 VL 75 IS 5 SU S MA 506 BP 148 EP 148 PG 1 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 109XW UT WOS:000242343900507 ER PT J AU Burgess, S Andrews, S Liebman, K Kelly, J Peyton, D AF Burgess, Steven Andrews, Simeon Liebman, Katherine Kelly, Jane Peyton, David TI Syntheses and evaluations of reversed chloroquines SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Meeting Abstract C1 Portland State Univ, Portland, OR 97207 USA. Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD NOV PY 2006 VL 75 IS 5 SU S MA 540 BP 157 EP 157 PG 1 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 109XW UT WOS:000242343900541 ER PT J AU Peyton, DH Burgess, S Liebman, K Kelly, J Andrews, S AF Peyton, David H. Burgess, Steven Liebman, Katherine Kelly, Jane Andrews, Simeon TI Reversed chloroquines: An update on molecules designed to subvert chloroquine resistance in P-falciparum SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Meeting Abstract C1 Portland State Univ, Portland, OR 97207 USA. Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD NOV PY 2006 VL 75 IS 5 SU S MA 539 BP 157 EP 157 PG 1 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 109XW UT WOS:000242343900540 ER PT J AU Osorio, Y Zhao, WG Travi, BL Hawel, L Saldarriaga, OA Espitia, C Melby, PC AF Osorio, Yaneth Zhao, Weiguo Travi, Bruno L. Hawel, Leo Saldarriaga, Omar A. Espitia, Claudia Melby, Peter C. TI Arginine metabolism in macrophages determines the outcome in experimental visceral leishmaniasis SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Meeting Abstract C1 Univ Texas, Hlth Sci Ctr, S Texas Vet Hlth Care Syst, San Antonio, TX 78285 USA. Univ Calif Riverside, Riverside, CA 92521 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD NOV PY 2006 VL 75 IS 5 SU S MA 650 BP 187 EP 188 PG 2 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 109XW UT WOS:000242343901085 ER PT J AU Anstead, GM Zhang, Q Melby, PC AF Anstead, Gregory M. Zhang, Qiong Melby, Peter C. TI Nutrikine dysregulation: A new paradigm for the immunodeficiency of malnutrition SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Meeting Abstract C1 S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD NOV PY 2006 VL 75 IS 5 SU S MA 786 BP 227 EP 227 PG 1 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 109XW UT WOS:000242343901221 ER PT J AU Kelly, JX Smilkstein, M Winter, R Doclean, R Hinrichs, D Riscoe, M AF Kelly, Jane X. Smilkstein, Martin Winter, Rolf Doclean, Rosie Hinrichs, Dave Riscoe, Mike TI Orally active acridones as novel and potent antimalarial chemotypes SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Meeting Abstract C1 Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD NOV PY 2006 VL 75 IS 5 SU S MA 870 BP 250 EP 251 PG 2 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 109XW UT WOS:000242343901305 ER PT J AU Kelly, JX Smilkstein, M Winter, R Dodean, R Riscoe, M AF Kelly, Jane X. Smilkstein, Martin Winter, Rolf Dodean, Rosie Riscoe, Mike TI Structure-activity relationships of orally active antimalarial acridones: Synthesis, optimization, and biological activity SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Meeting Abstract C1 Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD NOV PY 2006 VL 75 IS 5 SU S MA 872 BP 251 EP 251 PG 1 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 109XW UT WOS:000242343901307 ER PT J AU Bosso, JA Mauldin, PD Steed, LL AF Bosso, John A. Mauldin, Patrick D. Steed, Lisa L. TI Consequences of combining cystic fibrosis- and non-cystic fibrosis-derived Pseudomonas aeruginosa antibiotic susceptibility results in hospital antibiograms SO ANNALS OF PHARMACOTHERAPY LA English DT Article; Proceedings Paper CT Annual Meeting of the American-College-of-Clinical-Pharmacy CY OCT 23-26, 2005 CL San Francisco, CA SP Amer Coll Clin Pharm DE antibiogram; Pseudomonas aeruginosa; resistance; susceptibility ID RESISTANCE; LUNG AB BACKGROUND: In preparing hospital antibiograms for individual organisms and antibiotics, laboratories often combine susceptibility data for isolates from a variety of sources and patient types. If results from patients with known resistance patterns that vary from normal are included, the overall susceptibility value for the institution could be misleadingly skewed. OBJECTIVE: To assess the degree of bias introduced into a hospital antibiogram by combining cystic fibrosis (CF) and non-CIF isolates of Pseudomonas aeruginosa to produce one hospital-wide percent susceptible figure for each tested antibiotic. METHODS: A retrospective analysis was conducted of an academic, tertiary care medical center's microbiology database. We examined quarterly and annual susceptibility data from 2004, comparing non-CF data with combined susceptibility data for 10 antibiotics within each quarter, as well as those reported in the annual antibiogram. Differences were assessed for statistical significance using chi(2) testing with Bonferroni correction. RESULTS: Large differences were observed between non-CIF and combined percent susceptible data in the 4 quarters (aminoglycosides 3% vs 20%, fluoroquinolones 2% vs 18%, respectively) and when comparing annual non-CF (n = 191) with annual combined (n = 266) data. With the annual figures, these differences were frequently statistically significant (70% vs 58%, 91% vs 83%, 85% vs 70%, and 72% vs 60% for gentamicin, tobramycin, amikacin, and gatifloxacin/levofloxacin, respectively; all p <= 0.01). CONCLUSIONS: Combining CIF and non-CIF P aeruginosa susceptibility into one percent susceptibility value for all isolates may produce figures that underestimate the activity of some antibiotic classes against non-CIF isolates. Clinicians may make less than optimal empiric antibiotic selection choices based on such data. C1 S Carolina Coll Pharm, Dept Pharm & Clin Sci, Charleston, SC 29425 USA. Med Univ S Carolina, Coll Med, Div Infect Dis, Columbia, SC 29208 USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. Med Univ S Carolina, Dept Pathol & Lab Med, Columbia, SC 29208 USA. RP Bosso, JA (reprint author), S Carolina Coll Pharm, Dept Pharm & Clin Sci, MUSC Campus,280 Calhoun St,Rm QF213C, Charleston, SC 29425 USA. EM bossoja@musc.edu NR 8 TC 9 Z9 10 U1 1 U2 1 PU HARVEY WHITNEY BOOKS CO PI CINCINNATI PA PO BOX 42696, CINCINNATI, OH 45242 USA SN 1060-0280 J9 ANN PHARMACOTHER JI Ann. Pharmacother. PD NOV PY 2006 VL 40 IS 11 BP 1946 EP 1949 DI 10.1345/aph.1H377 PG 4 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 104OF UT WOS:000241967000005 PM 17018687 ER PT J AU O'Rourke, RW Seltman, AK Chang, EY Reavis, KM Diggs, BS Hunter, JG Jobe, BA AF O'Rourke, Robert W. Seltman, Ann K. Chang, Eugene Y. Reavis, Kevin M. Diggs, Brian S. Hunter, John G. Jobe, Blair A. TI A model for gastric banding in the treatment of morbid obesity - The effect of chronic partial gastric outlet obstruction on esophageal physiology SO ANNALS OF SURGERY LA English DT Article ID GASTROESOPHAGEAL-REFLUX DISEASE; HYPERTROPHIC SMOOTH-MUSCLE; OPOSSUM ESOPHAGUS; MANOMETRIC ABNORMALITIES; MOTILITY DISORDERS; BARIATRIC SURGERY; BODY-MASS; FOLLOW-UP; ACHALASIA; SYMPTOMS AB Objective: This work establishes an animal model for nonadjustable gastric banding and characterizes the effect of gastric banding on esophageal physiology. Summary Background Data: Obstruction at the esophagogastric junction (EGJ) results in esophageal dilation and aperistalsis. Although laparoscopic gastric banding as a primary treatment of morbid obesity has been widely accepted, the effects of this therapy on esophageal function remain unknown. Methods: Twenty-five opossums were randomly divided into sham (n = 5), EGJ band (n = 5), and gastric band (n = 15) groups. Gastric and EGJ bands were surgically placed, and esophageal manometry was performed prebanding, at 2-week intervals during the banding period (up to 14 weeks), and 2 and 4 weeks after band removal. Results: Manometric measures were equivalent prior to banding in all groups. There were no changes in LES or esophageal pressures during the study period in the sham group. During banding, there was a 36% decrease in baseline mean resting lower esophageal sphincter pressure in the gastric band group (P = 0.003). Mean distal esophageal peristaltic pressure decreased from baseline by 36% in gastric band animals (P < 0.001). The incidence of esophageal motility disorder during the study period for sham, EGJ band, and gastric band groups, was 2.9%, 42.1%, and 31.3%, respectively (P = 0.001, P = 0.381, pairwise comparisons of gastric band vs. sham and gastric band versus EGJ groups, respectively). Immediately prior to band removal, the probability of an abnormal peristaltic sequence with each swallow was 1%, 38%, and 16% for sham, EGJ, and gastric band groups, respectively (P < 0.005, pairwise comparisons of band groups with sham). Conclusions: Nonadjustable gastric banding results in impaired esophageal body motility, a reduction in esophageal peristaltic pressure, and a reduction in resting lower esophageal sphincter pressure. These findings suggest that gastric banding causes esophageal outlet obstruction and subsequent decompensation of peristaltic function as well as a compromise of the native antireflux mechanism. C1 Portland VA Med Ctr, Surg Serv, Dept Surg, Portland, OR 97207 USA. Oregon Hlth & Sci Univ, Dept Surg, Portland, OR USA. RP Jobe, BA (reprint author), Portland VA Med Ctr, Surg Serv, Dept Surg, P3Surg,POB 1034, Portland, OR 97207 USA. EM jobeb@ohsu.edu OI Diggs, Brian/0000-0003-3586-3757 NR 42 TC 20 Z9 20 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-4932 J9 ANN SURG JI Ann. Surg. PD NOV PY 2006 VL 244 IS 5 BP 723 EP 733 DI 10.1097/01.sla.0000218082.12999.9a PG 11 WC Surgery SC Surgery GA 108ZS UT WOS:000242278300017 PM 17060765 ER PT J AU Yaghoubian, A de Virgilio, C AF Yaghoubian, Arezou de Virgilio, Christian TI Noniatrogenic aneurysm of the distal radial artery: A case report SO ANNALS OF VASCULAR SURGERY LA English DT Article AB Radial artery aneurysms are extremely rare. The majority are traumatic in origin and are iatrogenic pseudoaneurysms following arterial cannulation. We present an unusual case of an idiopathic isolated aneurysm of the most distal portion of the radial artery. Interestingly, upon performance of the Allen test, it was determined that the majority of blood flow to the hand was derived from the aneurysmal artery. Arteriography showed an occluded ulnar artery, a tortuous superficial palmar arch and absent deep palmar arch, and multiple small vessels that arose from the aneurysm that supplied the thumb. Given these findings, it was determined that there would be a significant risk of digital ischemia and gangrene if operative repair was attempted. A course of nonoperative management with observation was recommended. C1 Harbor UCLA Med Ctr, Dept Surg, Div Vasc Surg, Los Angeles, CA USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. RP de Virgilio, C (reprint author), 1000 W Carson St,Bldg 1-E,Box 25 Torrance, Torrance, CA 90509 USA. EM cdevirgilio@labiomed.org NR 7 TC 8 Z9 11 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0890-5096 J9 ANN VASC SURG JI Ann. Vasc. Surg. PD NOV PY 2006 VL 20 IS 6 BP 784 EP 786 DI 10.1007/s10016-006-9121-0 PG 3 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA 117CM UT WOS:000242850300014 PM 17103134 ER PT J AU Dick, SE Werth, VP AF Dick, Sarah E. Werth, Victoria P. TI Pemphigus: A treatment update SO AUTOIMMUNITY LA English DT Article DE pemphigus; bullous disease; systemic corticosteroid; medication ID CYCLOPHOSPHAMIDE PULSE THERAPY; NECROSIS-FACTOR-ALPHA; TERM FOLLOW-UP; ANTI-CD20 MONOCLONAL-ANTIBODY; GLUCOCORTICOID-SPARING AGENT; MYCOPHENOLATE-MOFETIL; ENDEMIC PEMPHIGUS; ADJUVANT THERAPY; CHOLINERGIC-RECEPTORS; INITIAL TREATMENT AB Pemphigus is a group of rare autoimmune mucocutaneous bullous diseases with potential significant morbidity and mortality. The two main subtypes are pemphigus vulgaris (PV) and pemphigus foliaceus (PF). Systemic corticosteroid use and other advances in management have dramatically decreased the mortality rate for pemphigus. At present, the primary cause of morbidity and mortality is complications from treatment. Thus, the goal of pemphigus management is to induce and maintain remission with the lowest possible doses of medication and with the fewest side effects. Although our controlled studies to evaluate the true effectiveness of the available therapies. Here we review the available treatment options and novel therapies for pemphigus and the supporting data. C1 Univ Penn, Philadelphia VA Med Ctr, Dept Dermatol, Philadelphia, PA 19104 USA. RP Werth, VP (reprint author), Univ Penn, Philadelphia VA Med Ctr, Dept Dermatol, 2 Rhoads Pavil,36th & Spruce, Philadelphia, PA 19104 USA. EM werth@mail.med.upenn.edu FU NIAMS NIH HHS [K24-AR 02207] NR 96 TC 14 Z9 18 U1 0 U2 1 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0891-6934 J9 AUTOIMMUNITY JI Autoimmunity PD NOV PY 2006 VL 39 IS 7 BP 591 EP 599 DI 10.1080/08916930600972008 PG 9 WC Immunology SC Immunology GA 106MG UT WOS:000242104100008 PM 17101503 ER PT J AU Belogrudov, GI Schirf, V Demeler, B AF Belogrudov, Grogory I. Schirf, Virgil Demeler, Borries TI Reversible self-association of recombinant bovine factor B SO BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS LA English DT Article DE factor B; energy coupling; proton leak; cross-link; dimer; trimer; self-association; analytical ultracentrifugation; sedimentation equilibrium; sedimentation velocity; ultrascan ID MITOCHONDRIAL ATP SYNTHASE; CONSERVED GXXXG MOTIF; OXIDATIVE-PHOSPHORYLATION; SUBUNIT-G; F1F0-ATP SYNTHASE; PROTEIN; INHIBITOR; COMPLEX; CRISTAE; IDENTIFICATION AB The recombinant bovine factor B, obtained by a newly developed bacterial expression system, was found to exhibit features characteristic of a reversible self-associating system. Using size-sieving chromatography, distribution of the factor B species ranged from a monomer to a trimer, but not oligomers of higher molecular weights. At high protein concentrations, factor B migrated as a single band in a native gel. Cross-linking with the amino-reactive cross-linking reagent bis (sulfosuccinimidyl) suberate (BS), at a low cross-linker to protein ratio yielded cross-linked products identified as factor B dimer and trimer. The cross-linking pattern was shown to be a function of the protein and cross-linker concentrations. The range of sedimentation coefficients in a sedimentation velocity experiment suggested that the largest particle present in the distribution was more than twice as large as the smallest. The data obtained under multiple conditions in the sedimentation equilibrium experiments are best fit to a model describing a reversible self-association of a monomer-trimer of factor B species, with a dissociation constant Kd(1,3)=2.48 X 10(0-10) M-2. (c) 2006 Elsevier B.V. All rights reserved. C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90073 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA. RP Belogrudov, GI (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90073 USA. EM gbelo@ucla.edu; demeler@biochem.uthscsa.edu FU NIGMS NIH HHS [R01 GM066085] NR 38 TC 7 Z9 7 U1 1 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1570-9639 J9 BBA-PROTEINS PROTEOM JI BBA-Proteins Proteomics PD NOV PY 2006 VL 1764 IS 11 BP 1741 EP 1749 DI 10.1016/j.bbapap.2006.09.005 PG 9 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 112UZ UT WOS:000242554300009 PM 17049939 ER PT J AU Szulc, ZM Bielawski, J Gracz, H Gustilo, M Mayroo, N Hannun, YA Obeid, LM Bielawska, A AF Szulc, Zdzislaw M. Bielawski, Jacek Gracz, Hanna Gustilo, Marietta Mayroo, Nalini Hannun, Yusuf A. Obeid, Lina M. Bielawska, Alicja TI Tailoring structure-function and targeting properties of ceramides by site-specific cationization SO BIOORGANIC & MEDICINAL CHEMISTRY LA English DT Article DE ceramide; cationic ceramides; ceramidoids; ceramide conjugates with pyridinium salts; CCPS-analogs; synthesis; LC-MS; NMR; cytotoxicity ID SHORT-CHAIN CERAMIDE; TANDEM MASS-SPECTROMETRY; ADENOCARCINOMA CELL-LINE; D-ERYTHRO-SPHINGOSINE; BREAST-CANCER CELLS; D-THREO-SPHINGOSINE; CARCINOMA-CELLS; TUMOR-GROWTH; LONG-CHAIN; ANTITUMOR-ACTIVITY AB In the course of our studies on compartment-specific lipid-mediated cell regulation, we identified an intimate connection between ceramides (Cers) and the mitochondria-dependent death-signaling pathways. Here, we report on a new class of cationic Cer mimics, dubbed ceramidoids, designed to act as organelle-targeted sphingolipids (SPLs), based on conjugates of Cer and dihydroceramide (dhCer) with pyridinium salts (CCPS and dhCCPS, respectively). Ceramidoids having the pyridinium salt unit (PSU) placed internally (alpha and gamma-CCPS) or as a tether (omega-CCPS) in the N-acyl moiety were prepared by N-acylation of sphingoid bases with different omega-bromo acids or pyridine carboxylic acid chlorides following capping with respective pyridines or alkyl bromides. Consistent with their design, these analogs, showed a significantly improved solubility in water, well-resolved NMR spectra in D2O, broadly modified hydrophobicity, fast cellular uptake, and higher anticancer activities in cells in comparison to uncharged counterparts. Structure-activity relationship (SAR) studies in MCF-7 breast carcinoma cells revealed that the location of the PSU and its overall chain length affected markedly the cytotoxic effects of these ceramidoids. All omega-CCPSs were more potent (IC50/48 h: 0.6-8.0 mu M) than their alpha/gamma-CCPS (IC50/48 h: 8-20 mu M) or D-erythro-C6-Cer (IC50/48 h: 15 mu M) analogs. omega-DhCCPSs were also moderately potent (IC(50/)48 h: 2.5-12.5 mu M). Long-chain omega-dhCCPSs were rapidly and efficiently oxidized in cells to the corresponding omega-CCPSs, as established by LC-MS analysis. CCPS analogs also induced acute changes in the levels and composition of endogenous Cers (upregulation of C16-, C14-, and C18-Cers, and downregulation of C24:0- and C24:1-Cers). These novel ceramidoids illustrate the feasibility of compartment-targeted lipids, and they should be useful in cell-based studies as well as potential novel therapeutics. (c) 2006 Elsevier Ltd. All rights reserved. C1 Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. N Carolina State Univ, Dept Mol & Struct Biochem, Raleigh, NC 27695 USA. Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. Med Univ S Carolina, Ralph H Johnson Vet Adm Med Ctr, Charleston, SC 29425 USA. RP Bielawska, A (reprint author), Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. EM bielawsk@musc.edu OI Szulc, Zdzislaw M./0000-0003-1756-9028; obeid, lina/0000-0002-0734-0847 FU NCI NIH HHS [IP01CA097132]; NCRR NIH HHS [RR17677, C06RR018823]; NIA NIH HHS [AG16583] NR 94 TC 32 Z9 33 U1 0 U2 4 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0968-0896 J9 BIOORGAN MED CHEM JI Bioorg. Med. Chem. PD NOV 1 PY 2006 VL 14 IS 21 BP 7083 EP 7104 DI 10.1016/j.bmc.2006.07.016 PG 22 WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry, Organic SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry GA 095YP UT WOS:000241344500002 PM 16919460 ER PT J AU Chak, A Faulx, A Eng, C Grady, W Kinnard, M Ochs-Balcom, H Falk, G AF Chak, Amitabh Faulx, Ashley Eng, Charis Grady, William Kinnard, Margaret Ochs-Balcom, Heather Falk, Gary TI Gastroesophageal reflux symptoms in patients with adenocarcinoma of the esophagus or cardia SO CANCER LA English DT Article DE esophageal adenocarcinoma; Barrett esophagus; gastroesophageal reflux disease; cardia ID BARRETTS-ESOPHAGUS; GASTRIC CARDIA; ESOPHAGOGASTRIC JUNCTION; ENDOSCOPIC SURVEILLANCE; INTESTINAL METAPLASIA; ACID EXPOSURE; RISK-FACTOR; PREVALENCE; CANCER; DISEASE AB BACKGROUND. The efficacy of endoscopic screening for chronic gastroesophageal reflux symptoms of heartburn and regurgitation in adult subjects depends on the sensitivity of this strategy for detecting Barrett esophagus in subjects before the development of adenocarcinoma of the esophagus or cardia. The aim of the current study was to determine what proportion of patients with cancer of the esophagus or cardia would have been candidates for a screening endoscopy before their cancer diagnosis based on the presence and duration of preceding reflux symptoms. METHODS. All patients with adenocarcinoma of the esophagus, adenocarcinoma of the cardia, or long-segment Barrett esophagus presenting for endoscopy at 4 tertiary care and 2 Veterans Affairs (VA) hospitals were given a previously validated questionnaire to determine their recall of common gastroesophageal reflux symptoms. RESULTS. The study population of 375 subjects consisted primarily of 294 (78%) white men. Only 67 of 110 patients (61%) with adenocarcinoma of the esophagus and 8 of 21 patients (38%) with adenocarcinoma of the cardia recalled symptoms of heartburn or regurgitation being present for > 5 years before their diagnosis of cancer. Only 40 of 110 patients (36%) with adenocarcinoma. of the esophagus and 5 of 21 patients (24%) with adenocarcinoma of the cardia recalled weekly symptoms being present for > 5 years before their cancer diagnosis. Of the 244 patients with Barrett esophagus, 170 (70%) recalled heartburn or regurgitation for > 5 years and 89 patients (37%) recalled weekly symptoms for > 5 years. CONCLUSIONS. Current practice, which uses a screening strategy of performing endoscopy in patients with > 5 years of heartburn or regurgitation, can detect Barrett epithelium in only a limited proportion of those patients at risk for developing adenocarcinoma of the esophagus or adenocarcinoma of the cardia. C1 Univ Hosp Cleveland, Case Sch Med, Div Gastroenterol, Cleveland, OH 44106 USA. Case Western Reserve Univ, Ireland Canc Ctr, Cleveland, OH 44106 USA. Case Western Reserve Univ, Sch Med, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA. Case Western Reserve Univ, Sch Med, Div Gastroenterol, Wade Pk Vet Affairs Med Ctr, Cleveland, OH 44106 USA. Ohio State Univ, Sch Med, Div Human Genet, Dept Med, Columbus, OH 43210 USA. Cleveland Clin Fdn, Genom Med Inst, Cleveland, OH 44195 USA. Vanderbilt Univ, Dept Med, Nashville, TN USA. Vanderbilt Univ, Dept Canc Biol, Nashville, TN USA. Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, R&D Serv, Seattle, WA USA. Case Western Reserve Univ, Sch Med, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA. Cleveland Clin Fdn, Ctr Swallowing & Esophageal Disorders, Dept Gastroenterol & Hepatol, Cleveland, OH 44195 USA. RP Chak, A (reprint author), Univ Hosp Cleveland, Case Sch Med, Div Gastroenterol, 11100 Euclid Ave, Cleveland, OH 44106 USA. EM Amitabh.chak@case.edu RI Ochs-Balcom, Heather/F-3500-2012 OI Falk, Gary/0000-0002-7143-1436; Eng, Charis/0000-0002-3693-5145 FU NIDDK NIH HHS [DK002800, DK061426, DK070863] NR 40 TC 36 Z9 38 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X EI 1097-0142 J9 CANCER-AM CANCER SOC JI Cancer PD NOV 1 PY 2006 VL 107 IS 9 BP 2160 EP 2166 DI 10.1002/cncr.22245 PG 7 WC Oncology SC Oncology GA 101YK UT WOS:000241777300008 PM 17019737 ER PT J AU Agoulnik, IU Vaid, A Nakka, M Alvarado, M Bingman, WE Erdem, H Frolov, A Smith, CL Ayala, GE Ittmann, MM Weigel, NL AF Agoulnik, Irina U. Vaid, Ajula Nakka, Manjula Alvarado, Misty Bingman, William E., III Erdem, Halime Frolov, Anna Smith, Carolyn L. Ayala, Gustavo E. Ittmann, Michael M. Weigel, Nancy L. TI Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer SO CANCER RESEARCH LA English DT Article ID CELL-PROLIFERATION; THERAPY; KINASE; GENE; INACTIVATION; RESISTANCE; MECHANISM; CARCINOMA; SURVIVAL; DOMAINS AB Prostate cancer is an androgen-dependent disease; metastatic prostate cancer is typically treated by androgen receptor (AR) blockade. Recurrence after androgen ablation and evidence that AR continues to play a role in many prostate cancers has led to an examination of other factors that potentiate AR activity. AR is a ligand-activated transcription factor whose activity is regulated not only by hormone but also by the levels of coactivators recruited by AR to facilitate transcription. We sought to assess the consequences of reducing expression of the transcription intermediary factor 2 (TIF2) coactivator on prostate cancer cell growth and AR action in cell lines to examine TIF2 expression in prostate cancer and to correlate expression with clinical outcome. Depletion of TIF2 reduced expression of AR-induced target genes and slowed proliferation of AR-dependent and AR-independent prostate cancer cells. Remarkably, we found that TIF2 expression is directly repressed by high levels of androgens in multiple AR-expressing cell lines. Expression of a reporter containing 5'-flanking region of the TIF2 was repressed both by androgens and by the antagonist, Casodex. Expression of TIF2 correlates with biochemical (prostate-specific antigen) recurrence (P = 0.0136). In agreement with our in vitro findings, the highest expression of TIF2 was found in patients whose cancer relapsed after androgen ablation therapy, supporting the idea that AR blockade might activate pathways that lead to stimulation of AR-dependent and AR-independent proliferation of prostate epithelium. The elevated expression of TIF2 at low hormone levels likely aids in inducing AR activity under these conditions; treatment with Casodex has the potential to counteract this induction. C1 Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA. Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA. Baylor Coll Med, Dept Urol, Houston, TX 77030 USA. Michael E DeBakey Dept Vet Affairs Med Ctr, Houston, TX USA. RP Weigel, NL (reprint author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA. EM nweigel@bcm.edu OI Agoulnik, Irina/0000-0003-4889-0324 FU NCI NIH HHS [CA58204]; NIDDK NIH HHS [DK65252, T32-DK07763] NR 29 TC 106 Z9 106 U1 0 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD NOV 1 PY 2006 VL 66 IS 21 BP 10594 EP 10602 DI 10.1158/0008-5472.CAN-06-1023 PG 9 WC Oncology SC Oncology GA 101ZY UT WOS:000241781600050 PM 17079484 ER PT J AU McNicholas-Bevensee, CM DeAndrade, KB Bradley, WE Dell'Italia, LJ Lucchesi, PA Bevensee, MO AF McNicholas-Bevensee, Carmel M. DeAndrade, Kevin B. Bradley, Wayne E. Dell'Italia, Louis J. Lucchesi, Pamela A. Bevensee, Mark O. TI Activation of gadolinium-sensitive ion channels in cardiomyocytes in early adaptive stages of volume overload-induced heart failure SO CARDIOVASCULAR RESEARCH LA English DT Article DE calcium (cellular); heart failure; ion channels; stretch; membrane currents ID VENTRICULAR MYOCYTES; CARDIAC-HYPERTROPHY; CATION CURRENT; RAT; MECHANISMS; CURRENTS; CELLS AB Objective: The objective of this study was to investigate whether gadolinium, (Gd3+)-sensitive stretch-activated ion channels (SAC) are basally active in left ventricular (LV) myocytes in early stages of heart failure (HF) induced by volume overload. Methods: The aortocaval fistula (ACF) model was employed to induce HF due to volume overload in rat. At specific time-points, LV myocytes were acutely isolated using a modified Langendorff apparatus. Whole-cell currents were measured using the patch-clamp technique and intracellular Ca2+(Ca-i(2+)) was examined using fluorescence imaging and the Ca2+ -sensitive dye Fura-2. Results: Current-voltage data were obtained from sham and ACF myocytes at 5-d and 2-, 6-, 8- and 10-wk post surgery. Compared to data from matching sham rats, a 10 mu M Gd3+-sensitive current at -100 mV comprised a larger fraction of total cur-rent in myocytes from 5-d, 2wk, and 6-wk ACF rats. In general, the Gd3+-sensitive current contributed to inward currents at mV <=-80 and outward currents at >+20 mV The enhanced Gd3+-sensitive current was absent in myocytes from 8- and 10-wk ACF rats. 10 or 100 mu M Gd3+ had no appreciable effect on resting Ca-i(2+) of myocytes from 5-d ACF or corresponding sham rats. The Gd3+-sensitive current in 5-d ACF myocytes was i) sensitive to the cation-selective SAC inhibitor, GsMTx-4, ii) non-selective for Na+/K+, and iii) impermeable to Ca2+ Conclusion: A basally-active, Gd3+- and GsMTx-4-sensitive SAC current that is non-selective for Na+ and K+, but impermeable to Ca2+ under resting conditions is transiently elevated in LV myocytes from rats in early stages of volume overload-induced HF. (c) 2006 European Society of Cardiology. Published by Elsevier B.V. All rights reserved. C1 Univ Alabama, Dept Physiol & Biophys, Birmingham, AL 35294 USA. Univ Alabama, Div Cardiovasc Dis, Dept Med, Birmingham, AL 35294 USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP McNicholas-Bevensee, CM (reprint author), Univ Alabama, Dept Physiol & Biophys, 868 McCallum Basic Hlth Sci Bldg,1918 Univ Blvd, Birmingham, AL 35294 USA. EM carmel@physiology.uab.edu RI Lucchesi, Pamela/E-3558-2011 FU NHLBI NIH HHS [T35 HL74371] NR 27 TC 4 Z9 4 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0008-6363 J9 CARDIOVASC RES JI Cardiovasc. Res. PD NOV 1 PY 2006 VL 72 IS 2 BP 262 EP 270 DI 10.1016/j.cardiores.2006.08.001 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 101AR UT WOS:000241711800009 PM 16959228 ER PT J AU Doebis, C Schu, S Ladhoff, J Busch, A Beyer, F Reiser, J Nicosia, RF Broesel, S Volk, HD Seifert, M AF Doebis, Cornelia Schu, Sabine Ladhoff, Juliane Busch, Annette Beyer, Florian Reiser, Jakob Nicosia, Roberto F. Broesel, Sabine Volk, Hans-Dieter Seifert, Martina TI An anti-major histocompatibility complex class I intrabody protects endothelial cells from an attack by immune mediators SO CARDIOVASCULAR RESEARCH LA English DT Article DE endothelial cell; gene therapy; intrabody; tissue engineering ID GROWTH-FACTOR RECEPTOR-2; ALLOGRAFT-REJECTION; GENE-TRANSFER; VITRO ENDOTHELIALIZATION; BYPASS GRAFTS; CLINICAL-EXPERIENCE; NONDIVIDING CELLS; RNA INTERFERENCE; LANGERHANS CELL; MHC AB Objective: In vitro endothelialization has significantly improved the overall outcome of artificial prostheses in cardiovascular bypass surgery. A drawback of this tissue-engineering method remains the limited availability of suitable autologous endothelial cells (EC), especially in aged patients. Allogeneic EC with high proliferative capacity represent a potentially valuable alternative to a patient-specific vascular transplant. However, such cells carry the risk of being rejected due to Major Histocompatibility Complex (MHC) mismatches. Methods: We investigated the effects of a very potent, intracellularly expressed antibody directed against MHC class I molecules, referred to as alpha-rat MHC I single chain variable fragment (sFv) intrabody. The intrabody was stably expressed in rat aortic EC (RAEC) following lentiviral vector-mediated gene transfer. The functional consequence of the MHC I down-regulation was tested in an allogeneic setting in two different in vitro assays. Results: Stable expression of the a-rat MHC I sFv intrabody resulted in a highly efficient depletion of surface MHC I. Thereby those RAEC which displayed low MHC I levels over extended periods of time were protected against killing by allo-specific, cytotoxic T cells (CTL) and by allo-antibody/complement-mediated lysis. Conclusions: These results demonstrate that intrabody-mediated down-regulation of MHC I reduces the immunogenicity of RAEC which may provide a suitable alternative supply for the lining of vascular prostheses. (c) 2006 European Society of Cardiology. Published by Elsevier B.V. All rights reserved. C1 Charite Univ Med Berlin, Inst Med Immunol, D-10117 Berlin, Germany. Louisiana State Univ, Hlth Sci Ctr, Gene Therapy Program, New Orleans, LA 70112 USA. Vet Affairs Puget Sound Hlth Care Syst, Div Pathol & Lab Med, Seattle, WA 98108 USA. RP Seifert, M (reprint author), Charite Univ Med Berlin, Inst Med Immunol, Monbijoustr 2A, D-10117 Berlin, Germany. EM martina.seifert@charite.de FU NHLBI NIH HHS [HL52585]; NINDS NIH HHS [NS044832] NR 37 TC 6 Z9 7 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0008-6363 J9 CARDIOVASC RES JI Cardiovasc. Res. PD NOV 1 PY 2006 VL 72 IS 2 BP 331 EP 338 DI 10.1016/j.cardiores.2006.08.005 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 101AR UT WOS:000241711800016 PM 16963004 ER PT J AU Choudhury, GG Mahimainathan, L Das, F Venkatesan, B Ghosh-Choudhury, N AF Choudhury, Goutam Ghosh Mahimainathan, Lenin Das, Falguni Venkatesan, Balachandar Ghosh-Choudhury, Nandini TI C-Src couples PI 3 kinase/Akt and MAPK signaling to PDGF-induced DNA synthesis in mesangial cells SO CELLULAR SIGNALLING LA English DT Article DE PDGF; DNA synthesis; c-fos; pRb; CDK2 ID ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR-BETA; CYCLIN-DEPENDENT KINASES; FAMILY TYROSINE KINASES; FACTOR-ALPHA RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; RETINOBLASTOMA PROTEIN; CDK INHIBITOR; PROLIFERATIVE GLOMERULONEPHRITIS; PHOSPHORYLATION SITE AB Platelet-derived growth factor BB (PDGF) and PDGF receptor-beta (PDGFR) play critical roles in mesangial cell proliferation during embryonic development and in mesangioproliferative glomerulonephritis. We have shown previously that phosphatidylinositol (PI) 3 kinase/Akt and Erk1/2 mitogen-activated protein kinase (MAPK) contribute to PDGF-dependent proliferation of mesangial cells, but the mechanism by which these two enzyme cascades are activated by PDGFR signaling is not precisely known. We examined the role of c-Src tyrosine kinase in this process. PDGF increased phosphorylation of c-Src in a time-dependent manner indicating its activation. A pharmacologic inhibitor of c-Src, PP1, blocked PDGF-induced DNA synthesis with concomitant inhibition of c-Src phosphorylation. Inummecomplex kinase assays of c-Src and PDGFR demonstrated inhibition of c-Src tyrosine kinase activity by PP1, without an effect on PDGFR tyrosine phosphorylation. Both PPI and expression of dominant negative c-Src inhibited PDGF-induced PI 3 kinase, resulting in attenuation of Akt kinase activity. Expression of constitutively active c-Src increased Akt activity to the same extent as with PDGF. Constitutively active c-Src augmented PDGF-induced Akt activity, thus contributing to Akt signaling. Inhibition of c-Src tyrosine kinase blocked PDGF-stimulated MAPK activity and resulted in attenuation of c-fos gene transcription with concomitant prevention of Elk-1 transactivation. Furthermore, inhibition of c-Src increased p27(Kip1) cyclin kinase inhibitor, and attenuated PDGF-induced pRb phosphorylation and CDK2 activity. These data provide the first evidence in mesangial cells that PDGF-activated c-Src tyrosine kinase relays signals to PI 3 kinase/Akt and MAPK. Furthermore our results demonstrate that c-Src integrates signals into the nucleus to activate CDK2, which is required for DNA synthesis. (c) 2006 Elsevier Inc. All rights reserved. C1 Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA. Ctr Geriatr Res Educ & Clin, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Choudhury, GG (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM choudhuryg@uthscsa.edu OI /0000-0001-5077-3552 FU NIAMS NIH HHS [R01 AR 5242]; NIDDK NIH HHS [R01 DK 50190, R01 DK 55815] NR 79 TC 40 Z9 41 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0898-6568 J9 CELL SIGNAL JI Cell. Signal. PD NOV PY 2006 VL 18 IS 11 BP 1854 EP 1864 DI 10.1016/j.cellsig.2006.02.003 PG 11 WC Cell Biology SC Cell Biology GA 101DA UT WOS:000241717900004 PM 16530387 ER PT J AU Crothers, K Butt, AA Gibert, CL Rodriguez-Barradas, MC Crystal, S Justice, AC AF Crothers, Kristina Butt, Adeel A. Gibert, Cynthia L. Rodriguez-Barradas, Maria C. Crystal, Stephen Justice, Amy C. CA Veterans Aging Cohort 5 TI Increased COPD among HIV-positive compared to HIV-negative veterans SO CHEST LA English DT Article DE AIDS; HIV infection; obstructive lung diseases; smoking ID OBSTRUCTIVE PULMONARY-DISEASE; QUALITY-OF-LIFE; UNITED-STATES; LUNG-DISEASE; PNEUMOCYSTIS COLONIZATION; ALCOHOL-CONSUMPTION; ADMINISTRATIVE DATA; AIRWAY-OBSTRUCTION; SMOKING-CESSATION; CIGARETTE-SMOKING AB Background: Limited data prior to highly active antiretroviral therapy (HAART) suggested the possibility of an increased risk of COPD among those persons with HIV infection. We sought to determine whether HIV infection is associated with increased prevalence of COPD in the era of HAART. Methods: Prospective observational study of 1,014 HIV-positive and 713 HIV-negative men who were enrolled in the Veterans Aging Cohort 5 Site Study. COPD was determined by patient self-report and International Classification of Diseases, ninth revision (ICD-9), diagnostic codes. Cigarette smoking and injection drug use (IDU) were determined by self-report, and alcohol abuse was determined by ICD-9 diagnostic codes. Laboratory and pharmacy data were obtained from electronic medical records. Results: The prevalence of COPD as determined by ICD-9 codes was 10% in HIV-positive subjects and 9% in HIV-negative subjects (p = 0.4), and as determined by patient self-report was 15% and 12%, respectively (p = 0.04). After adjusting for age, race/ethnicity, pack-years of smoking, IDU, and alcohol abuse, HIV infection was an independent risk factor for COPD. HIV-infected subjects were approximately 50 to 60% more likely to have COPD than HIV-negative subjects (by ICD-9 codes: odds ratio [OR], 1.47; 95% confidence interval [CI], 1.01 to 2.13; p = 0.04; by patient self-report: OR, 1.58; 95% CI, 1.14 to 2.18; p = 0.005). Conclusions: HIV infection was an independent risk factor for COPD, when determined either by ICD-9 codes or patient self-report. Health-care providers should be aware of the increased likelihood of COPD among their HIV-positive patients. The possibility that HIV infection increases susceptibility to and/or accelerates COPD deserves further investigation and has implications regarding the pathogenesis of COPD. C1 VA Connecticut Healthcare Syst, Dept Internal Med, West Haven, CT 06516 USA. Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA. Univ Pittsburgh, Sch Med, Dept Internal Med, Pittsburgh, PA USA. George Washington Univ, Dept Med, Washington, DC USA. Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. Rutgers State Univ, Ctr Pharmacotherapy Chron Dis Management & Outcom, New Brunswick, NJ 08903 USA. RP Justice, AC (reprint author), VA Connecticut Healthcare Syst, Dept Internal Med, 950 Campbell Ave,Mailstop 11-ACSLG, West Haven, CT 06516 USA. EM amy.justice2@va.gov OI Crothers, Kristina/0000-0001-9702-0371 FU NCRR NIH HHS [K12 RR0117594-01]; NIA NIH HHS [K23 AG00826]; NIAAA NIH HHS [3U01 AA 13566] NR 47 TC 148 Z9 151 U1 2 U2 6 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD NOV PY 2006 VL 130 IS 5 BP 1326 EP 1333 DI 10.1378/chest.130.5.1326 PG 8 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 106OH UT WOS:000242109800010 PM 17099007 ER PT J AU Weisbord, SD Bernardini, J Mor, MK Hartwig, KC Nicoletta, PJ Palevsky, PM Piraino, B AF Weisbord, Steven D. Bernardini, Judith Mor, Maria K. Hartwig, Kathryn C. Nicoletta, Patricia J. Palevsky, Paul M. Piraino, Beth TI The effect of coronary angiography on residual renal function in patients on peritoneal dialysis SO CLINICAL CARDIOLOGY LA English DT Article DE coronary angiography; residual renal function; peritoneal dialysis ID MORTALITY; DECLINE; CLEARANCES; RATES; CAPD AB Background: The risk of intravascular radiocontrast to residual renal function (RRF) in patients on peritoneal dialysis (PD) remains largely unknown. Hypothesis: This study sought to estimate the effect of coronary angiography on RRF in patients on PD. Methods: All patients at the VA Pittsburgh Healthcare System and University of Pittsburgh who underwent coronary angiography between 1993 and 2005 while on PD and who had RRF measured prior to angiography were identified retrospectively. For patients without a postprocedure RRF recorded, medical records were reviewed to determine whether anuria had developed. The longer-term rate of loss of RRF among cases was compared with a composite rate of decline in RRF among cases before angiography and matched controls. Results: Twenty-nine patients with a mean preprocedure RRF of 4.4 +/- 3.2 ml/min/1.73m(2) were evaluated. Of these patients, 23 (79%) had postangiography RRF assessments (mean clearance 3.4 +/- 3.0 ml/min/1.73m(2)). One of the remaining six patients definitely became permanently anuric following angiography, one was lost to follow-up, and there was no postprocedure RRF assessment in four others. The rate of decline in RRF in the cases was similar to the composite rate (0.07 ml/min/1.73m(2)/month vs. 0.09 ml/min/1.73m(2)/Month, p = 0.53) Conclusion: The risk for permanent anuria in patients on PD undergoing coronary angiography appears to be quite small. Patients who do not develop anuria following coronary angiography have the same gradual rate of loss of RRF as other patients on PD. Providers should be vigilant in protecting RRF in patients on PD undergoing coronary angiography. C1 VA Pittsburgh Healthcare Syst, Renal Sect, Med Special Serv Line, Pittsburgh, PA 15240 USA. VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Dept Med, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA. RP Weisbord, SD (reprint author), VA Pittsburgh Healthcare Syst, Renal Sect, Med Special Serv Line, Mailstop 111F-U,7E rm120, Pittsburgh, PA 15240 USA. EM weisbordsd@upmc.edu OI Piraino, Beth/0000-0001-5061-0841; Palevsky, Paul/0000-0002-7334-5400 NR 15 TC 13 Z9 13 U1 0 U2 0 PU CLINICAL CARDIOLOGY PUBL CO PI MAHWAH PA PO BOX 832, MAHWAH, NJ 07430-0832 USA SN 0160-9289 J9 CLIN CARDIOL JI Clin. Cardiol. PD NOV PY 2006 VL 29 IS 11 BP 494 EP 497 DI 10.1002/clc.4960291105 PG 4 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 100AF UT WOS:000241638700004 PM 17133846 ER PT J AU Gupta, S Vittinghoff, E Bertenthal, D Corley, D Shen, H Walter, LC McQuaid, K AF Gupta, Samir Vittinghoff, Eric Bertenthal, Daniel Corley, Douglas Shen, Hui Walter, Louise C. McQuaid, Kenneth TI New-onset diabetes and pancreatic cancer SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article ID UNITED-STATES ADULTS; GLUCOSE-METABOLISM; SUBTOTAL PANCREATECTOMY; MELLITUS; RISK; COHORT; MORTALITY; CARCINOMA; METAANALYSIS; PROBABILITY AB Background & Aims: Although many individuals with pancreatic cancer have diabetes, the association between new-onset diabetes mellitus and the subsequent incidence of pancreatic cancer is unclear. Methods: We conducted a retrospective cohort study to estimate the incidence of pancreatic cancer subsequent to a new diabetes diagnosis and to evaluate factors associated with a subsequent pancreatic cancer diagnosis. We used the Veterans Health Administration National Patient Care Database to assemble a cohort of 1,421,794 US veterans without prior diabetes or pancreatic cancer diagnoses. We recorded coding for new diabetes diagnoses (>= 2 International Classification of Diseases-9 codes for diabetes within a 12-month period), pancreatic cancer, age, sex, race, and common gastrointestinal symptoms. Results: A total of 36,631 (2.6%) of the 1,421,794 veterans were diagnosed with new-onset diabetes in 1999, 149 subsequently received a diagnosis of pancreatic cancer. Pancreatic cancer incidence in patients with new-onset diabetes (83.8/100,000 person-years) was 2.2-fold higher (95% confidence interval, 1.84-2.56) than in nondiabetics, and was highest during the first 2 years after diabetes diagnosis. One additional pancreatic cancer was diagnosed for every 332 new diabetics over 6 years. A subsequent pancreatic cancer diagnosis (among new-onset diabetics) was associated independently with younger age groups, changes in bowel habits, constipation, epigastric pain, and malnutrition. Conclusions: New-onset diabetes was associated with a significantly increased rate of pancreatic cancer diagnosis, particularly in the first 2 years after diabetes diagnosis. Factors associated with pancreatic cancer diagnosis included younger age groups and the presence of gastrointestinal symptoms. The absolute incidence of pancreatic cancer was low. C1 Vet Affairs Med Ctr, GI Sect, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA USA. Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. San Francisco Vet Affairs Med Ctr, Dept Vet Affairs,Res Enhancement Award Program, Hlth Serv Res & Dev Serv, Interdisciplinary Res Program Improve Care Older, San Francisco, CA USA. Kaiser Permanente Div Res, Oakland, CA USA. RP McQuaid, K (reprint author), Vet Affairs Med Ctr, GI Sect, 111-B-1,4150 Clement St, San Francisco, CA 94121 USA. EM kenneth.mcquaid@med.va.gov NR 42 TC 40 Z9 46 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD NOV PY 2006 VL 4 IS 11 BP 1366 EP 1372 DI 10.1016/j.cgh.2006.06.024 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 108UD UT WOS:000242263800015 PM 16945591 ER PT J AU Aslam, N Bernardini, J Fried, L Burr, R Piraino, B AF Aslam, Nabeel Bernardini, Judith Fried, Linda Burr, Renee Piraino, Beth TI Comparison of infectious complications between incident hemodialysis and peritoneal dialysis patients SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article; Proceedings Paper CT 38th Annual Meeting of the American-Society-of-Nephrology CY NOV 08-13, 2005 CL Philadelphia, PA SP Amer Soc Nephrol ID VASCULAR ACCESS; UNITED-STATES; RISK-FACTORS; SEPTICEMIA; MORTALITY; MULTICENTER; POPULATION; PREVENTION; BACTEREMIA; OUTCOMES AB The impact of dialysis modality on infection, especially early in the course of dialysis, has not been well studied. This study compared infection between hemodialysis (HD) and peritoneal dialysis (PD) from the start of dialysis and evaluated factors that have an impact on infection risk. In this observational cohort study, all incident dialysis patients (n = 181; HD 119 and PD 62) at a single center from 1999 to 2005 had data collected prospectively beginning day 1 of dialysis. Excluded were those with any previous ESRD therapy. Infection rates were evaluated using multivariate Poisson regression. Overall infection rates were similar (HD 0.77 versus PD 0.86/yr; P = 0.24). Only HD patients had bacteremia (0.16/yr), and only PD patients had peritonitis (0.24/yr). Bacteremia that occurred :590 d after start of HD was 0.44/yr, increased compared with overall rate of 0.16/yr (P < 0.004). HD catheters, used in 67% of patients who started HD, were associated with a strikingly increased rate of bacteremia. Peritonitis <= 90 d was 0.22/yr, no different from the overall rate. Modality was not an independent predictor of overall infections (PD versus HD: relative risk 1.30; 95% confidence interval 0.93 to 1.8; P = 0.12) using multivariate analysis. PD and HD patients had similar infection rates overall, but type of infection and risk over time varied. HD patients had an especially high risk for bacteremia in the first 90 d, whereas the risk for peritonitis for the PD cohort was not different over time. These results support the placement of permanent accesses (fistula or PD catheter) before the start of dialysis to avoid use of HD catheters. C1 Univ Pittsburgh, Sch Med, Dept Med, Div Renal & Electrolyte, Pittsburgh, PA 15260 USA. VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. RP Piraino, B (reprint author), 3504 5th Ave,Suite 200, Pittsburgh, PA 15213 USA. EM piraino@pitt.edu OI Piraino, Beth/0000-0001-5061-0841 NR 24 TC 66 Z9 68 U1 0 U2 3 PU AMERICAN SOCIETY NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD NOV PY 2006 VL 1 IS 6 BP 1226 EP 1233 DI 10.2215/CJN.01230406 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 107CK UT WOS:000242148100017 PM 17699352 ER PT J AU Dong, MH Kaunitz, JD AF Dong, Mamie H. Kaunitz, Jonathan D. TI Gastroduodenal mucosal defense SO CURRENT OPINION IN GASTROENTEROLOGY LA English DT Article DE annexin-1; antioxidants; esophagus; ghrelin; Helicobacter pylori; reactive oxygen species ID HELICOBACTER-PYLORI INFECTION; REACTIVE OXYGEN METABOLITES; GASTRIC EPITHELIAL-CELLS; RAT DUODENAL MUCOSA; ACID-INDUCED INJURY; FUNCTIONAL DYSPEPSIA; CARBONIC-ANHYDRASES; GHRELIN LEVELS; BLOOD-FLOW; IN-VIVO AB Purpose of review The duodenum absorbs nearly all secreted gastric acid. Carbonic anhydrases facilitate transmucosal acid movement. The upper gastrointestinal tract must resist a variety of injuries, including those caused by ingested noxious substances, acid, ischemia/reperfusion, and infections such as Helicobacter pylori. The results are similar, however, regardless of insult: inflammation, ulceration, or metaplasia/dysplasia. In the past year, there have been prominent findings suggesting that oxidative stress and the formation of reactive oxygen species may play a pivotal role in all forms of injury, and that antioxidants may be the key to injury prevention and healing. Recent findings Oxidative injury may be a common mechanism by which the upper gastrointestinal mucosa responds to noxious insults. Endogenous antioxidants, such as ghrelin, L-carnitine, and annexin-1 attenuate the oxidative-stress response. Similarly, exogenous antioxidants have also been shown to decrease inflammation, upregulate free radical scavengers, and prevent the formation of reactive oxygen species. Summary Many studies published in the past year have linked oxidative stress to a variety of upper gastrointestinal insults. Exogenous and endogenous antioxidant compounds prevent the oxidative stress response. The future holds great promise for the development of pharmaceuticals with antioxidant properties that are safe, efficacious, and inexpensive. C1 W Los Angeles Vet Affairs Med Ctr, Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Med Ctr, Dept Internal Med, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Med, Dept Med, CURE Digest Dis Res Ctr, Los Angeles, CA 90024 USA. Brentwood Biomed Res Inst, Los Angeles, CA USA. RP Kaunitz, JD (reprint author), W Los Angeles Vet Affairs Med Ctr, Greater Los Angeles Vet Affairs Healthcare Syst, Bldg 114,Suite 217, Los Angeles, CA 90073 USA. EM jake@ucla.edu FU NIDDK NIH HHS [P30 DK0413, R01 DK54221] NR 66 TC 18 Z9 21 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0267-1379 J9 CURR OPIN GASTROEN JI Curr. Opin. Gastroenterol. PD NOV PY 2006 VL 22 IS 6 BP 599 EP 606 DI 10.1097/01.mog.0000245540.87784.75 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 106WI UT WOS:000242132300003 PM 17053436 ER PT J AU Boyko, EJ Ahroni, JH Nelson, KM AF Boyko, Edward J. Ahroni, Jessie H. Nelson, Karin M. TI Prediction of diabetic foot ulcer occurrence using commonly available clinical information - Response to Leese and Morris SO DIABETES CARE LA English DT Letter ID RISK C1 VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA. Seattle Univ, Dept Med, Seattle, WA 98122 USA. RP Boyko, EJ (reprint author), VA Epidemiol Res & Informat Ctr, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM eboyko@u.washington.edu NR 5 TC 0 Z9 0 U1 0 U2 0 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD NOV PY 2006 VL 29 IS 11 BP 2563 EP 2563 DI 10.2337/dc06-1661 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 105LA UT WOS:000242030200047 ER PT J AU Reger, MA Craft, S AF Reger, Mark A. Craft, Suzanne TI Intranasal insulin administration: A method for dissociating central and peripheral effects of insulin SO DRUGS OF TODAY LA English DT Article ID CENTRAL-NERVOUS-SYSTEM; APOLIPOPROTEIN-E GENOTYPE; OBESE ZUCKER RATS; GROWTH-FACTOR-I; CEREBRAL GLUCOSE-UTILIZATION; RECEPTOR SUBSTRATE-1 IRS-1; AMYLOID PRECURSOR PROTEIN; FOOD-INTAKE; CEREBROSPINAL-FLUID; ALZHEIMERS-DISEASE AB Animal studies have demonstrated the effects of insulin on central nervous system (CNS) functions such as cognition and control of adiposity, but human studies of insulin's CNS effects are more difficult to interpret. Peripheral insulin administration, which increases CNS insulin levels, is associated with increased insulin-stimulated glucose disposal and the release of counter-regulatory hormones - events that can confound CNS results. However, intranasal insulin administration results in direct insulin transport from the nasal cavity to the CNS via intraneuronal and extraneuronal pathways. Recent studies from independent groups of investigators have demonstrated functional, cognitive and adiposity changes following acute and chronic intranasal administration in humans. Available evidence suggests that intranasal insulin administration is safe in humans. Thus, this approach may provide the opportunity to dissociate the central and peripheral effects of insulin. Furthermore, intranasal insulin administration may offer a novel treatment strategy for disorders associated with central insulin abnormalities, such as diabetes and neurodegenerative diseases. (c) 2006 Prous Science. All rights reserved. C1 Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Craft, S (reprint author), 1660 S Columbian Way,GRECC S182, Seattle, WA 98108 USA. EM scraft@u.washington.edu NR 98 TC 27 Z9 27 U1 3 U2 9 PU PROUS SCIENCE, SA PI BARCELONA PA PO BOX 540, PROVENZA 388, 08025 BARCELONA, SPAIN SN 1699-3993 J9 DRUGS TODAY JI Drugs Today PD NOV PY 2006 VL 42 IS 11 BP 729 EP 739 DI 10.1358/dot.2006.42.11.1007675 PG 11 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 122IO UT WOS:000243219600005 PM 17171192 ER PT J AU Wang, J Ho, L Zhao, Z Seror, I Humala, N Dickstein, DL Thiyagarajan, M Percival, SS Talcott, ST Pasinetti, GM AF Wang, Jun Ho, Lap Zhao, Zhong Seror, Ilana Humala, Nelson Dickstein, Dara L. Thiyagarajan, Meenakshisundaram Percival, Susan S. Talcott, Stephen T. Pasinetti, Giulio Maria TI Moderate consumption of Cabernet Sauvignon attenuates A beta neuropathology in a mouse model of Alzheimer's disease SO FASEB JOURNAL LA English DT Article DE APP; nonamyloidogenic; polyphenols; AD dementia ID AMYLOID PRECURSOR PROTEIN; COGNITIVE IMPAIRMENT; TRANSGENIC MICE; SENILE PLAQUES; DEMENTIA; WINE; ALCOHOL; ASSOCIATION; DEPOSITION; CLEAVAGE AB Recent studies suggest that moderate red wine consumption reduces the incidence of Alzheimer's disease (AD) clinical dementia. Using Tg2576 mice, which model AD-type amyloid beta-protein (A beta) neuropathology, we tested whether moderate consumption of the red wine Cabernet Sauvignon modulates AD-type neuropathology and cognitive deterioration. The wine used in the study was generated using Cabernet Sauvignon grapes from Fresno, California, and was delivered to Tg2576 in a final concentration of similar to 6% ethanol. We found that Cabernet Sauvignon significantly attenuated AD-type deterioration of spatial memory function and A beta neuropathology in Tg2576 mice relative to control Tg2576 mice that were treated with either a comparable amount of ethanol or water alone. Chemical analysis showed the Cabernet Sauvignon used in this study contains a very low content of resveratrol (0.2 mg/L), 10-fold lower than the minimal effective concentration shown to promote A beta clearance in vitro. Our studies suggest Cabernet Sauvignon exerts a beneficial effect by promoting nonamyloidogenic processing of amyloid precursor protein, which ultimately prevents the generation of A beta peptides. This study supports epidemiological evidence indicating that moderate wine consumption, within the range recommended by the FDA dietary guidelines of one drink per day for women and two for men, may help reduce the relative risk for AD clinical dementia. C1 CUNY Mt Sinai Sch Med, Dept Neurosci, New York, NY 10029 USA. CUNY Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. James J Peters VA Med Ctr, Geriatr Res & Clin Ctr, Bronx, NY USA. Univ Florida, Dept Food Sci & Human Nutr, Gainesville, FL USA. RP Pasinetti, GM (reprint author), CUNY Mt Sinai Sch Med, Dept Neurosci, 1 Gustave L Levy Pl, New York, NY 10029 USA. EM giulio.pasinetti@mssm.edu RI Dickstein, Dara/F-3036-2013 NR 34 TC 154 Z9 160 U1 0 U2 13 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD NOV PY 2006 VL 20 IS 13 BP 2313 EP 2320 DI 10.1096/fj.06-6281com PG 8 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 100XD UT WOS:000241702600016 PM 17077308 ER PT J AU El-Serag, HB Gilger, MA Shud, MD Rechardson, P Bancroft, J AF El-Serag, Hashem B. Gilger, Mark A. Shud, Mitchell D. Rechardson, Peter Bancroft, John TI The prevalence of suspected Barrett's esophagus in children and adolescents: a multicenter endoscopic study SO GASTROINTESTINAL ENDOSCOPY LA English DT Article ID GASTROESOPHAGEAL-REFLUX DISEASE AB Background: The prevalence of Barrett's esophagus (BE) in young individuals is unclear. Objective: To estimate the prevalence of suspected BE in children and adolescent patients undergoing endoscopy. Design: A retrospective cross-sectional study Setting: Prospectively collected data in the Pediatric Clinical Outcomes Research Initiative (PEDS-CORI) Patients: We identified patients younger than 20 years of age with suspected BE in the PEDS-CORI between 1999 and 2002; the corresponding histopathologic records were examined. Main Outcome Measurements: We analyzed the distribution of demographic and endoscopic risk factors for BE between cases and non-cases with and without suspected BE in bivariate and multivariable analyses. Results: We identified a total of 6731 patients who underwent upper endoscopy in 12 pediatric facilities. Only 17 patients had suspected BE (prevalence, 2.5 per 1000). Intestinal metaplasia was reported in only 9 of these patients (53%). Patients with suspected BE were older than patients without BE (median 14.7 vs 10.1 years; P =.011). Hiatus hernia was more commonly recorded in patients with suspected BE (11.8% vs 2.2%; P =.008). In a logistic regression model, both older age (odds ratio [OR] 1.13, 95% confidence interval [CI] 1.02-1.35) and hiatus hernia (OR 4.62, 95% CI 1.03-20.66) were independently associated with suspected BE. Conclusions: Endoscopically suspected BE is rare (< 0.25%) in children and adolescents. Older age and the presence of hiatus hernia are possible risk factors for BE in this group. Limitations: Lack of standardization for identifying and recording endoscopic landmarks. C1 Michael E DeBakey Vet Affairs Med Ctr 152, Dept Gastroenterol & Hlth Serv Res, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA. Barbara Bush Childrens Hosp, Portland, ME USA. Phoenix Childrens Hosp, Phoenix, AZ USA. RP El-Serag, HB (reprint author), Michael E DeBakey Vet Affairs Med Ctr 152, Dept Gastroenterol & Hlth Serv Res, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM hasheme@bcm.tmc.edu FU NIDDK NIH HHS [R03 DK068148-01, R01-DK30144-21/23] NR 16 TC 20 Z9 21 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 EI 1097-6779 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD NOV PY 2006 VL 64 IS 5 BP 671 EP 675 DI 10.1016/j.gie.2006.03.010 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 099YR UT WOS:000241634300001 PM 17055854 ER PT J AU Graham, DY Shiotani, A El-Zimaity, HMT AF Graham, David Y. Shiotani, Akiko El-Zimaity, Hala M. T. TI Chromoendoscopy points the way to understanding recovery of gastric function after Helicobacter pylori eradication SO GASTROINTESTINAL ENDOSCOPY LA English DT Editorial Material ID ATROPHIC BODY GASTRITIS; CONGO RED TEST; DUODENAL-ULCER SUBJECTS; ACID-SECRETION; INTESTINAL METAPLASIA; FOLLOW-UP; FUNDAL GASTRITIS; MUCOSAL ATROPHY; SYDNEY SYSTEM; INFECTION C1 Baylor Coll Med, Dept Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA. Baylor Coll Med, Dept Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Mol Virol, Houston, TX 77030 USA. Baylor Coll Med, Dept Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Microbiol, Houston, TX 77030 USA. Wakayama Univ, Hlth Adm Ctr, Wakayama, Japan. Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA. RP Graham, DY (reprint author), Baylor Coll Med, Dept Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA. FU NIDDK NIH HHS [DK56338] NR 58 TC 9 Z9 9 U1 0 U2 0 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD NOV PY 2006 VL 64 IS 5 BP 686 EP 690 DI 10.1016/j.gie.2006.03.013 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 099YR UT WOS:000241634300004 PM 17055857 ER PT J AU Jensen, DM Machicado, GA Hirabayashi, K AF Jensen, Dennis M. Machicado, Gustavo A. Hirabayashi, Ken TI Randomized controlled study of 3 different types of hemoclips for hemostasis of bleeding canine acute gastric ulcers SO GASTROINTESTINAL ENDOSCOPY LA English DT Article ID ENDOSCOPIC HEMOCLIP; PEPTIC-ULCER; ETHANOL INJECTION; TRIAL; THERAPY; HEMORRHAGE; CLIP AB Background: Mechanical closure of bleeding vessels is clinically appealing, and several types of hemoclips are now marketed for endoscopic hemostasis of nonvariceal lesions. No comparative data have been reported on ease of clip placement, hemostasis efficacy, or clip retention rates on bleeding ulcers. Objective: To compare 3 different types of hemoclips for hemostasis of bleeding ulcers. Design: Randomized controlled study Subjects: Seven adult dogs with prehepatic portal hypertension were heparinized, and acute gastric ulcers were made with jumbo biopsy forceps. Animals had oral proton pump inhibitors daily and weekly endoscopies to quantitate clip retention and ulcer healing. Interventions: Bleeding ulcers were randomized in pairs (2 for each treatment/dog) to endoscopic hemoclip treatment or control. Main Outcome Measurements: Initial times and success of deployment, hemostasis efficacy, clip retention rates, and ulcer healing during endoscopic follow-ups. Results: There was no difference in initial hemostasis rates of hemoclips, and no major complications occurred. Ulcer healing times were faster (Resolution Clip [RC] or TriClip [TC]) or similar (QuickClip2 [QC]) to controls. Clip retention at I week was significantly less with TC and, at 3 to 7 weeks, was significantly higher with RC. Conclusions: (1) For the 3 hemoclip devices, initial hemostasis rates were 100%, but all devices required similar learning time to place clips successfully (2) Short-term retention rates of TC were significantly less than QC or RC. (3) Long-term clip retention was significantly higher with RC. (4) All 3 hemoclips were safe, and none interfered with ulcer healing. C1 Univ Calif Los Angeles, CURE Digest Dis Res Ctr, David Geffen Sch Med, CURE Hemostasis Res Grp, Los Angeles, CA 90073 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Jensen, DM (reprint author), Univ Calif Los Angeles, CURE Digest Dis Res Ctr, David Geffen Sch Med, CURE Hemostasis Res Grp, Bldg 115,Rm 318,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. FU NIDDK NIH HHS [K24 DK02650] NR 20 TC 37 Z9 37 U1 0 U2 1 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD NOV PY 2006 VL 64 IS 5 BP 768 EP 773 DI 10.1016/j.gie.2006.06.031 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 099YR UT WOS:000241634300019 PM 17055872 ER PT J AU Peters, MG Andersen, J Lynch, P Liu, T Alston-Smith, B Brosgart, CL Jacobson, JM Johnson, VA Poflard, RB Rooney, JF Sherman, KE Swindells, S Polsky, B AF Peters, Marion G. Andersen, Janet Lynch, Patrick Liu, Tun Alston-Smith, Beverly Brosgart, Carol L. Jacobson, Jeffrey M. Johnson, Victoria A. Poflard, Richard B. Rooney, James F. Sherman, Kenneth E. Swindells, Susan Polsky, Bruce CA ACTG Protocol A5127 Team TI Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127 SO HEPATOLOGY LA English DT Article ID HUMAN-IMMUNODEFICIENCY; DISOPROXIL FUMARATE; IN-VITRO; LAMIVUDINE; DIPIVOXIL; ANTIGEN; RECOMMENDATIONS; INDIVIDUALS; COMBINATION; PREVALENCE AB Chronic hepatitis B virus (HBV) infection is an important cause of morbidity and mortality in subjects coinfected with HIV. Tenofovir disoproxil fumarate (TDF) and adefovir dipivoxil (ADV) are licensed for the treatment of HIV-1 and HBV infection, respectively, but both have in vivo and in vitro activity against HBV. This study evaluated the anti-HBV activity of TDF compared to ADV in HIV/HBV-coinfected subjects. ACTG A5127 was a prospective randomized, double-blind, placebo-controlled trial of daily 10 mg of ADV versus 300 mg of TDF in subjects with HBV and HIV coinfection on stable ART, with serum HBV DNA >= 100,000 copies/mL, and plasma HIV-1 RNA:5 10,000 copies/mL. This study closed early based on results of a prespecified interim review, as the primary noninferiority end point had been met without safety issues. Fifty-two subjects were randomized. At baseline, 73% of subjects had a plasma HIV-1 RNA < 50 copies/mL, 86% were HBeAg positive, 94% were 3TC resistant, median serum ALT was 52 IU/L, and 98% had compensated liver disease. The mean time-weighted average change in serum HBV DNA from baseline to week 48 (DAVG(48)) was -4.44 log(10) copies/mL for TDF and -3.21 log(10) copies/mL for ADV. There was no difference in toxicity between the 2 treatment arms, with 11 subjects (5 ADV and 6 TDF) experiencing elevations of serum ALT on treatment. In conclusion, over 48 weeks, treatment with either ADV or TDF resulted in clinically important suppression of serum HBV DNA. Both drugs arc safe and efficacious for patients coinfected with HBV and HIV. C1 Univ Calif San Francisco, Div Gastroenterol, San Francisco, CA 94143 USA. Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. Northwestern Univ, Sch Med, Chicago, IL USA. NIAID, NIH, AIDS Clin Trials Grp, Bethesda, MD USA. Gilead Sci Inc, Foster City, CA USA. Beth Israel Med Ctr, New York, NY 10003 USA. Albert Einstein Coll Med, New York, NY USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. Univ Alabama, Birmingham Sch Med, Birmingham, AL USA. Univ Calif Davis, Med Ctr, Sacramento, CA 95817 USA. Univ Cincinnati, Coll Med, Cincinnati, OH USA. Univ Nebraska, Ctr Med, Omaha, NE 68198 USA. St Lukes Roosevelt Hosp, Div Infect Dis, New York, NY USA. Columbia Univ, Coll Phys & Surg, New York, NY USA. RP Peters, MG (reprint author), Univ Calif San Francisco, Div Gastroenterol, 513 Parnassus Ave,Room S-357, San Francisco, CA 94143 USA. EM marion.perers@ucsf.edu FU NCRR NIH HHS [M01-RR00096, RR00047, RR00046, RR-00052, RR00051]; NIAID NIH HHS [AI46370, AI38855, AI32782, AI32770, AI50410, U01 AI069502, P30 AI27767, AI-27668, AI25915, U01 AI038858, AI46386, 3U01AI38858-09S1, U01 AI038855, U01AI38858, P30 AI027767, AI25868]; NIDDK NIH HHS [P30 DK 26743, P30 DK026743]; PHS HHS [5 UO1 A1027665-18] NR 25 TC 111 Z9 123 U1 0 U2 2 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD NOV PY 2006 VL 44 IS 5 BP 1110 EP 1116 DI 10.1002/hep.21388 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 099IH UT WOS:000241586400006 PM 17058225 ER PT J AU Fujitani, S Ricardo-Dukelow, M Kamiya, T Sullivan, L Low, L AF Fujitani, Shigeki Ricardo-Dukelow, M. Kamiya, Toru Sullivan, Loretta Low, Lewis TI Ethnicity and other possible risk factors for candidemia at 3 tertiary care university hospitals in Hawaii SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID BLOOD-STREAM INFECTIONS; EPIDEMIOLOGY; SURVEILLANCE; TROPICALIS; FUNGEMIA; CANDIDIASIS; ALBICANS; PROGRAM; CANCER; ADULT AB A total of 108 cases of candidemia detected in 3 tertiary care university hospitals in Hawaii between January 2001 and December 2002 were retrospectively reviewed. Candida albicans, Candida glabrata, and Candida tropicalis accounted for 28% of the cases. Mortality among Filipino patients was significantly higher than that among other ethnic groups ( 71% vs 48%; P < .05). C1 VA Greater Los Angeles Healthcare Syst, Infect Dis Sect 111F, Dept Med, Los Angeles, CA 90073 USA. Univ Hawaii, Dept Med, Honolulu, HI 96822 USA. Legacy Hlth Syst, Dept Med, Portland, OR USA. RP Fujitani, S (reprint author), VA Greater Los Angeles Healthcare Syst, Infect Dis Sect 111F, Dept Med, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM shigekifujitani@hotmail.com NR 19 TC 5 Z9 5 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD NOV PY 2006 VL 27 IS 11 BP 1261 EP 1263 DI 10.1086/508831 PG 3 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 205AG UT WOS:000249084500022 PM 17080389 ER PT J AU Miller, G Randolph, S Patterson, JE AF Miller, George Randolph, Stephen Patterson, Jan E. TI Responding to bioterrorist smallpox in San Antonio SO INTERFACES LA English DT Article DE health care : epidemiology; simulation : applications ID VACCINATION; LOGISTICS; OUTBREAKS; NETWORKS; MODEL AB We used discrete-event simulation to help the San Antonio public health and acute medical care communities to plan their response to a bioterrorist attack. The analysis, based on a scenario positing an attack with aerosolized smallpox, indicated the resources and strategies needed for an effective response. We found that a mixture of public-health measures designed to stop the spread of the disease would form a more robust and effective response than any single measure. However, unless the attack is very small, the public-health system is unlikely to be able to prevent a surge in demand for acute care that will require community-wide coordination of resources, a definitive patient-triage policy, and temporary treatment practices. The San Antonio communities are integrating our recommendations into their plans. C1 Altarum Inst, Ann Arbor, MI 48113 USA. Altarum Inst, San Antonio, TX 78209 USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Miller, G (reprint author), Altarum Inst, POB 134001, Ann Arbor, MI 48113 USA. EM george.miller@altarum.org; steve.randolph@altarum.org; pattersonj@uthscsa.edu NR 18 TC 17 Z9 19 U1 0 U2 2 PU INST OPERATIONS RESEARCH MANAGEMENT SCIENCES PI LINTHICUM HTS PA 901 ELKRIDGE LANDING RD, STE 400, LINTHICUM HTS, MD 21090-2909 USA SN 0092-2102 J9 INTERFACES JI Interfaces PD NOV-DEC PY 2006 VL 36 IS 6 BP 580 EP 590 DI 10.1287/inte.1060.0228 PG 11 WC Management; Operations Research & Management Science SC Business & Economics; Operations Research & Management Science GA 117JA UT WOS:000242868100010 ER PT J AU Garrow, D Egede, LE AF Garrow, Donald Egede, Leonard E. TI National patterns and correlates of complementary and alternative medicine use in adults with diabetes SO JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE LA English DT Article ID UNITED-STATES; PREVALENCE; RELIABILITY; ASSOCIATION; THERAPIES; MELLITUS; SERVICES; COSTS AB Objective: The aim of this study was to determine national patterns and correlates of complementary and alternative medicine (CAM) use among adults with diabetes. Methods: The authors compared CAM use in 2474 adults with and 28,625 adults without diabetes who participated in the most comprehensive national survey on CAM use (2002 National Health Interview Survey). Eight CAM use categories were created, including dietary, herbal, chiropractic, yoga, relaxation, vitamin, prayer, and other (acupuncture, Ayurveda, biofeedback, chelation, energy healing or Reiki therapy, hypnosis, massage, naturopathy, and homeopathy). An overall CAM use category also was created that excluded vitamins and prayer. Patterns of use were compared with chi-square and independent correlates of CAM use with multiple logistic regression controlling for relevant covariates. STATA was used for analysis to account for the complex survey design. Results: Prevalence of overall use of CAM did not differ significantly by diabetes status (47.6 versus 47.9%, p = 0.81). Diabetes was not an independent predictor of overall use of CAM (OR 0.93, 95% confidence interval [CI] 0.83, 1.05). However, persons with diabetes were more likely to use prayer (OR 1.19, 95% Cl 1.05, 1.36), but less likely to use herbs (OR 0.86, 95% Cl 0.75, 0.99), yoga (OR 0.56, 95% Cl 0.43, 0.72), or vitamins (OR 0.82, 95% Cl 0.72, 0.93) than people without diabetes after controlling for relevant covariates. Independent correlates of overall use of CAM differed by age, income, employment, comorbidity, and health status between people with and without diabetes. Conclusions: This study found that there has been a dramatic increase in overall use of CAM in adults with diabetes; diabetes was not an independent predictor of overall use of CAM; and people with diabetes were more likely to use prayer, but less likely to use herbs, yoga, or vitamins compared to persons without diabetes. C1 Med Univ S Carolina, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Med, Div Gen Internal Med, Charleston, SC 29425 USA. Ralph H Johnson Vet Adm Med Ctr, Charleston VA TREP, Charleston, SC USA. RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280H, Charleston, SC 29425 USA. EM egedel@musc.edu NR 29 TC 36 Z9 36 U1 4 U2 15 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1075-5535 J9 J ALTERN COMPLEM MED JI J. Altern. Complement Med. PD NOV PY 2006 VL 12 IS 9 BP 895 EP 902 DI 10.1089/acm.2006.12.895 PG 8 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA 104MW UT WOS:000241963500010 PM 17109581 ER PT J AU Shelburne, SA Montes, M Hamill, R AF Shelburne, S. A. Montes, M. Hamill, R. TI Immune reconstitution inflammatory syndrome: more answers, more questions - authors' response SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY LA English DT Letter DE immune reconstitution inflammatory syndrome ID ANTIRETROVIRAL THERAPY C1 Baylor Coll Med, Dept Med, Infect Dis Sect, Houston, TX 77030 USA. Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Infect Dis Sect 111G, Houston, TX 77030 USA. RP Hamill, R (reprint author), Baylor Coll Med, Dept Med, Infect Dis Sect, 1 Baylor Pl, Houston, TX 77030 USA. EM richard.hamill@med.va.gov NR 4 TC 2 Z9 2 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-7453 J9 J ANTIMICROB CHEMOTH JI J. Antimicrob. Chemother. PD NOV PY 2006 VL 58 IS 5 BP 1094 EP 1095 DI 10.1093/jac/dkl390 PG 2 WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy GA 109XM UT WOS:000242342900032 ER PT J AU Levine, S Nguyen, T Friscia, M Zhu, JL Szeto, W Kucharczuk, JC Tikunov, BA Rubinstein, NA Kaiser, LR Shrager, JB AF Levine, Sanford Nguyen, Taitan Friscia, Michael Zhu, Jianliang Szeto, Wilson Kucharczuk, John C. Tikunov, Boris A. Rubinstein, Neal A. Kaiser, Larry R. Shrager, Joseph B. TI Parasternal intercostal muscle remodeling in severe chronic obstructive pulmonary disease SO JOURNAL OF APPLIED PHYSIOLOGY LA English DT Article DE muscle fiber types; myosin heavy chain isoform expression; diaphragm ID RAT SKELETAL-MUSCLE; HUMAN DIAPHRAGM; GENE-EXPRESSION; SEVERE COPD; FIBER SIZE; MYOSIN; ACTIVATION; VOLUME; DRIVE; STIMULATION AB Studies in experimental animals indicate that chronic increases in neural drive to limb muscles elicit a fast-to-slow transformation of fiber-type proportions and myofibrillar proteins. Since neural drive to the parasternal intercostal muscles (parasternals) is chronically increased in patients with severe chronic obstructive pulmonary diseases (COPDs), we carried out the present study to test the hypothesis that the parasternals of COPD patients exhibit an increase in the proportions of both slow fibers and slow myosin heavy chains (MHCs). Accordingly, we obtained full thickness parasternal muscle biopsies from the third interspace of seven COPD patients (mean +/- SE age: 59 +/- 4 yr) and seven age-matched controls (AMCs). Fiber typing was done by immunohistochemistry, and MHC proportions were determined by SDS-PAGE followed by densitometry. COPD patients exhibited higher proportions of slow fibers than AMCs (73 +/- 4 vs. 51 +/- 3%; P < 0.01). Additionally, COPD patients exhibited higher proportions of slow MHC than AMCs (56 +/- 4 vs. 46 +/- 4%, P < 0.04). We conclude that the parasternal muscles of patients with severe COPD exhibit a fast-to-slow transformation in both fiber-type and MHC proportions. Previous workers have demonstrated that remodeling of the external intercostals, another rib cage inspiratory muscle, elicited by severe COPD is characterized by a slow-to-fast transformation in both fiber types and MHC isoform proportions. The physiological significance of this difference in remodeling between these two inspiratory rib cage muscles remains to be elucidated. C1 Univ Penn, Sch Med, Dept Surg, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Surg & Res Serv, Philadelphia, PA USA. Univ Penn, Dept Biol, Philadelphia, PA 19104 USA. RP Levine, S (reprint author), Hosp Univ Penn, Div Thorac Surg, 6 Silverstein Pavil,3400 Spruce St, Philadelphia, PA 19104 USA. EM sdlevine@mail.med.upenn.edu NR 36 TC 18 Z9 20 U1 2 U2 3 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 8750-7587 J9 J APPL PHYSIOL JI J. Appl. Physiol. PD NOV PY 2006 VL 101 IS 5 BP 1297 EP 1302 DI 10.1152/japplphysiol.01607.2005 PG 6 WC Physiology; Sport Sciences SC Physiology; Sport Sciences GA 107GS UT WOS:000242159300007 PM 16777998 ER PT J AU He, L Game, BA Nareika, A Garvey, WT Huang, Y AF He, Lin Game, Bryan A. Nareika, Alena Garvey, W. Timothy Huang, Yan TI Administration of pioglitazone in low-density lipoprotein receptor-deficient mice inhibits lesion progression and matrix metalloproteinase expression in advanced atherosclerotic plaques SO JOURNAL OF CARDIOVASCULAR PHARMACOLOGY LA English DT Article DE matrix metalloproteinase; atherosclerosis; diabetes; gene expression ID MUSCLE-CELL-MIGRATION; COLLAGENASE-1 GENE-TRANSCRIPTION; RAT CAROTID-ARTERY; ACTIVATOR PROTEIN-1; BALLOON INJURY; OVEREXPRESSION; ASSOCIATION; MEMBRANE; INSULIN; DISEASE AB Recent clinical trials have provided evidence that pioglitazone reduces cardiovascular events in patients with type 2 diabetes. However, the underlying mechanisms are not well understood. Because it has been well established that disruption of atherosclerotic plaques is a key event involved in acute myocardial infarction, we hypothesized that pioglitazone reduces cardiovascular events by stabilizing atherosclerotic lesions. In this study, we used an animal model to test our hypothesis. Low-density lipoprotein receptor-deficient (LDLR-/-) male mice were first fed a high-fat diet for 4 months to induce the formation of aortic atherosclerotic plaques and then treated with pioglitazone for the next 3 months. Analysis of atherosclerotic plaques at the end of the study showed that treatment with pioglitazone at 20 mg/kg/day reduced the progression of atherosclerotic plaques as compared to untreated mice. Furthermore, gene array analysis, quantitative real-time polymerase chain reaction, and immunohistochemical analysis showed that pioglitazone inhibited high-fat diet-induced upregulation of matrix metalloprotemase (MMP) expression. Finally, Sirius red staining showed that atherosclerotic lesions in mice receiving pioglitazone had higher collagen contents than those in untreated mice. This study demonstrated for the first time that administration of pioglitazone in LDLR-/- mice inhibited lesion progression and MMP expression in established atherosclerotic plaques and thus delineated a potential mechanism by which pioglitazone reduces cardiovascular events in patients with type 2 diabetes. C1 Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29403 USA. Med Univ S Carolina, Div Endocrinol Diabet & Med Genet, Charleston, SC 29403 USA. Univ Alabama, Dept Nutr Sci, Birmingham, AL 35294 USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. Med Univ S Carolina, Dept Med, Charleston, SC 29403 USA. RP Huang, Y (reprint author), Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, 114 Doughty St,Room 531, Charleston, SC 29403 USA. EM huangyan@musc.edu NR 36 TC 13 Z9 15 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0160-2446 J9 J CARDIOVASC PHARM JI J. Cardiovasc. Pharmacol. PD NOV PY 2006 VL 48 IS 5 BP 212 EP 222 DI 10.1097/01.fjc.0000248831.21973.c4 PG 11 WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy GA 110DP UT WOS:000242358800004 PM 17110803 ER PT J AU Elango, N Li, Y Shivshankar, P Katz, MS AF Elango, Narayanasamy Li, Ye Shivshankar, Pooja Katz, Michael S. TI Expression of RUNX2 isoforms: Involvement of cap-dependent and cap-independent mechanisms of translation SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Article DE type-I RUNX2; type-II RUNX2; internal ribosomal entry site; cap-dependent translation; 4E-BP1; RNA Aptamer-1 ID RIBOSOME ENTRY SITES; BONE MORPHOGENETIC PROTEIN-2; OSTEOBLAST DIFFERENTIATION; CLEIDOCRANIAL DYSPLASIA; TRANSCRIPTION FACTOR; GENE-EXPRESSION; CHONDROCYTE MATURATION; DOMAIN PROTEINS; RNA; CBFA1 AB RUNX2, a major regulator of skeletogenesis, is expressed as type-I and type-II isoforms. Whereas most eukaryotic mRNAs are translated by the cap-dependent scanning mechanism, translation of many mRNAs including type-I and type-II RUNX2 mRNAs has been reported to be initiated by a cap independent internal ribosomal entry site (IRES). Since the dicistronic plasmid assay used to demonstrate IRES has been questioned, we investigated the presence of IRES in RUNX2 mRNAs using dicistronic plasmid and mRNA assays. Our results show that the dicistronic plasmid assay cannot be used to demonstrate IRES in RUNX2 mRNAs because the intercistronic region of dicistronic plasmids containing the 5'-UTRs of both RUNX2 mRNAs operates as a cryptic promoter. In dicistronic mRNA transfection studies the 5'-UTRs of both RUNX2 mRNAs exhibited no IRES activity. When transfected into osteoblastic cells, monocistronic reporter mRNA preceded by the 5'-UTR of type-II RUNX2 (Type-II-FLuc-A100) was translated to a high degree only in the presence of a functional cap (m(7) GpppG); in contrast, luciferase mRNA preceded by the 5'-UTR of type-I-RUNX2 mRNA (Type-1-FLuc-A100) was translated poorly in the presence of either m(7) GpppG or a nonfunctional cap (ApppG). Notably, in transfected cells inhibitors of cap-dependent translation suppressed the translation of m(7) GpppG-capped Type-II-FLuc-A100, but not ApppG-capped reporter mRNA preceded by the IRES-containing hepatitis C virus (HCV) 5'-UTR. Our study demonstrates that type-II RUNX2 mRNA is translated by the cap-dependent mechanism. Although efficient translation of type-I RUNX2 mRNA appears to require a process other than cap-dependent, the mechanism of type-I RUNX2 mRNA translation remains to be resolved. C1 S Texas Vet Hlth Care Syst, Geriatr Res,Educ & Clin Ctr, Audie L Murphy Div, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, Dept Med, Div Geriatr & Gerontol, San Antonio, TX 78284 USA. RP Elango, N (reprint author), VA Med Ctr, GRECC 182, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM elangon@uthscsa.edu NR 52 TC 11 Z9 11 U1 0 U2 4 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PD NOV 1 PY 2006 VL 99 IS 4 BP 1108 EP 1121 DI 10.1002/jcb.20909 PG 14 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 100SO UT WOS:000241689200011 PM 16767703 ER PT J AU Page, ST Amory, JK Anawalt, BD Irwig, MS Brockenbrough, AT Matsumoto, AM Bremner, WJ AF Page, Stephanie T. Amory, John K. Anawalt, Bradley D. Irwig, Michael S. Brockenbrough, Andrew T. Matsumoto, Alvin M. Bremner, William J. TI Testosterone gel combined with depomedroxyprogesterone acetate is an effective male hormonal contraceptive regimen and is not enhanced by the addition of a GnRH antagonist SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID INSULIN-LIKE FACTOR-3; NORMALIZES ANDROGEN LEVELS; NORMAL YOUNG MEN; MEDROXYPROGESTERONE ACETATE; TRANSDERMAL TESTOSTERONE; HYPOGONADAL MEN; CLINICAL-TRIAL; LEVONORGESTREL IMPLANTS; INJECTABLE TESTOSTERONE; ORAL LEVONORGESTREL AB Introduction: Exogenous androgens plus progestins can be used to suppress spermatogenesis, resulting in effective male hormonal contraception; however, induction of azoospermia can require 3-6 months, and these methods require injectable or implantable androgens. We hypothesized that testosterone (T) transdermal gel (T gel) could be combined with a depot formulation of the progestin, depomedroxyprogesterone acetate (DMPA), with or without the potent GnRH antagonist, acyline, to suppress spermatogenesis conveniently, rapidly, and reversibly. Objectives: The objectives of the study were: 1) to determine the rate of severe oligospermia (<= 1 million sperm/ml) using T gel + DMPA; and 2) to determine whether the addition of acyline to T gel + DMPA during the first 12 wk of the regimen would accelerate and improve suppression of spermatogenesis. Methods: Forty-four healthy men, ages 18-55 yr, were randomized to T gel (100 mg daily) + DMPA (300 mg/3 months) or acyline (300 mu g/kg center dot 2 wk x 12 wk) + T gel + DMPA. Thirty-eight men completed the 24-wk treatment protocol. Results: All men had dramatic suppression of spermatogenesis; 90% of the subjects became severely oligospermic, a rate comparable to implantable and injectable T + progestin combinations. The addition of acyline did not significantly accelerate spermatogenic suppression or improve rates of severe oligospermia. There were no serious adverse events, and there were minimal changes in weight, serum lipids, and prostate-specific antigen. Conclusions: The combination of T gel + DMPA is a promising new regimen in male contraception. The addition of the GnRH antagonist acyline, as part of an induction phase in a male contraception regimen, has limited clinical utility. Additional studies using T gel for male contraception are warranted. C1 Univ Washington, Dept Med, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Seattle, WA 98108 USA. RP Page, ST (reprint author), POB 357138,1959 NE Pacific, Seattle, WA 98195 USA. EM page@u.washington.edu OI Irwig, Michael/0000-0003-1231-1941 FU NIA NIH HHS [K23 AG027238, K23 AG027238-02]; NICHD NIH HHS [U54 HD-42454, U54-HD-12629] NR 38 TC 38 Z9 38 U1 0 U2 8 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD NOV PY 2006 VL 91 IS 11 BP 4374 EP 4380 DI 10.1210/jc.2006-1411 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 102MO UT WOS:000241816300028 PM 16940442 ER PT J AU McGinnis, KA Fultz, SL Skanderson, M Conigliaro, J Bryant, K Justice, AC AF McGinnis, Kathleen A. Fultz, Shawn L. Skanderson, Melissa Conigliaro, Joseph Bryant, Kendall Justice, Amy C. TI Hepatocellular carcinoma and non-Hodgkin's lymphoma: The roles of HIV, hepatitis C infection, and alcohol abuse SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article; Proceedings Paper CT 15th International AIDS Conference CY JUL 11-17, 2004 CL Bangkok, THAILAND ID VIRUS-INFECTION; UNITED-STATES; CONNECTICUT WOMEN; AIDS; COHORT; VETERANS; RISK; PREVALENCE; SCHIZOPHRENIA; ASSOCIATION AB Purpose To explore the relationship of HIV, hepatitis C (HCV), and alcohol abuse/dependence to risk for hepatocellular carcinoma and non-Hodgkin's lymphoma (NHL). Patients and Methods Male veterans ( n = 14,018) with a first HIV diagnosis in the Veterans Affairs Healthcare System from October 1997 to September 2004; and 28,036 age-, race-, sex-, and location-matched HIV-negative veterans were identified. We examined the incidence of hepatocellular carcinoma and NHL and presence of HCV and alcohol abuse/dependence using International Classification of Diseases, ninth revision (ICD-9-CM) codes. HIV-positive to HIV-negative incident rate ratios (IRRs) and 95% CIs for the occurrence of hepatocellular carcinoma and NHL were calculated using Poisson regression models. Results HIV-positive veterans were at greater risk for hepatocellular carcinoma than HIV-negative veterans (IRR = 1.68; 95% CI, 1.02 to 2.77). After adjusting for HCV infection and alcohol abuse/ dependence, HIV status was not independently associated with hepatocellular cancer ( IRR = 0.96; 95% CI, 0.56 to 1.63). HIV-positive veterans had 9.71 times ( 95% CI, 6.99 to 13.49) greater risk of NHL than HIV-negative veterans. After adjusting for HCV and alcohol abuse/ dependence, the IRR for NHL comparing HIV-positive with HIV-negative veterans is similar ( IRR = 10.03, 95% CI, 7.19 to 13.97). Conclusion HIV-positive veterans have a higher relative incidence of hepatocellular carcinoma and NHL than HIV-negative veterans. For hepatocellular carcinoma, this association appears to be largely explained by the higher prevalence of HCV and alcohol abuse/ dependence. Efforts to decrease hepatocellular carcinoma among persons with HIV should focus primarily on detecting and treating HCV and reducing heavy alcohol use. C1 Yale Univ, Sch Med, Dept Med, West Haven, CT 06516 USA. Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. Univ Pittsburgh, Univ Ctr Social & Urban Res, Pittsburgh, PA USA. VA Connecticut Healthcare Syst, West Haven, CT USA. Univ Kentucky, Lexington, KY USA. NIAAA, NIH, Bethesda, MD USA. RP Justice, AC (reprint author), Yale Univ, Sch Med, Dept Med, 950 Campbell Ave, West Haven, CT 06516 USA. EM amy.justice2@va.gov FU PHS HHS [U01-13566] NR 31 TC 41 Z9 41 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 330 JOHN CARLYLE ST, STE 300, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD NOV 1 PY 2006 VL 24 IS 31 BP 5005 EP 5009 DI 10.1200/JCO.2006.05.7984 PG 5 WC Oncology SC Oncology GA 102PX UT WOS:000241825900011 PM 17075119 ER PT J AU Tapp, AM Kennedy, A Peskind, ER Raskind, MA AF Tapp, Andre M. Kennedy, Annette Peskind, Elaine R. Raskind, Murray A. TI Beneficial effects of prazosin for visual hallucinations associated with chronic cocaine abuse SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Letter ID DOPAMINE NEURONS; D-AMPHETAMINE; RECEPTORS C1 VA Puget Sound Hlth Care Syst, Seattle, WA USA. VA Puget Sound Hlth Care Syst, Tacoma, WA USA. RP Tapp, AM (reprint author), VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 5 TC 0 Z9 0 U1 0 U2 2 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD NOV PY 2006 VL 67 IS 11 BP 1819 EP 1820 PG 2 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 111DT UT WOS:000242432300024 PM 17196067 ER PT J AU Tan, G Alvarez, JA Jensen, MP AF Tan, Gabriel Alvarez, Julie A. Jensen, Mark P. TI Complementary and alternative medicine approaches to pain management SO JOURNAL OF CLINICAL PSYCHOLOGY LA English DT Article DE pain management; complementary and alternative medicine (CAM); hypnosis; cranial electrotherapy stimulation ID CRANIAL ELECTROTHERAPY STIMULATION; METAANALYSIS; ANALGESIA; HYPNOSIS AB This article argues for and illustrates incorporating complementary and alternative medicine (CAM) interventions into pain treatment plans. Two CAM treatments, cranial electrotherapy stimulation (CES) and self-hypnosis training, are offered in a multidisciplinary pain treatment program. Because these interventions focus on pain relief, they may be of particular interest to patients who have chronic pain who begin treatment with a primary interest in pain reduction. Two cases that illustrate the clinical application of CES and self-hypnosis are presented. When effective, these interventions can help patients have greater confidence in treatments offered by psychologists for pain management and may help make them more open to participating in other psychological interventions that have established efficacy for pain management (e.g., cognitive-behavioral therapy). Because of their brevity, these treatments also can be offered alone to patients who may not have the resources or time to participate in more time-intensive treatment. (c) 2006 Wiley Periodicals, Inc. C1 Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. Univ Washington, Sch Med, Seattle, WA 98195 USA. RP Tan, G (reprint author), Michael E DeBakey Vet Affairs Med Ctr, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM TAN.GABRIEL@med.va.gov NR 25 TC 5 Z9 7 U1 3 U2 6 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0021-9762 J9 J CLIN PSYCHOL JI J. Clin. Psychol. PD NOV PY 2006 VL 62 IS 11 BP 1419 EP 1431 DI 10.1002/jclp.20321 PG 13 WC Psychology, Clinical SC Psychology GA 098OY UT WOS:000241533900010 PM 16937354 ER PT J AU Franco, GEL Huang, A Camacho, NP Stone, DS Blank, RD AF Franco, G. E. Lopez Huang, A. Camacho, N. Pleshko Stone, D. S. Blank, R. D. TI Increased Young's modulus and hardness of Col1a2(oim) dentin SO JOURNAL OF DENTAL RESEARCH LA English DT Article; Proceedings Paper CT 27th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research CY SEP 23-27, 2005 CL Nashville, TN SP Amer Soc Bone & Mineral Res DE collagen type I; dentinogenesis imperfecta; osteogenesis imperfecta; biomechanics; tooth calcification ID COLLAGEN MUTATION DATABASE; OIM MICE EXHIBIT; OSTEOGENESIS IMPERFECTA; DENTINOGENESIS IMPERFECTA; MECHANICAL-PROPERTIES; ELECTRON-MICROSCOPY; BONE; MODEL; DSPP AB Mice harboring the Col1a2(oim) mutation (oim) express dentinogenesis imperfecta. To determine the effect of Col1a2 genotype on tissue mechanical properties, we compared Young's modulus and hardness of dentin in the 3 Col1a2 genotypes. Upper incisors were tested by nanoindentation. Genotype had a significant effect on Young's modulus, but there was not a simple mutant allele dosage relationship. The effect of genotype on hardness did not reach significance. Hardness and Young's modulus were greater near the dento-enamel junction than near the pulp chamber. Greater hardness and Young's modulus values near the dento-enamel junction reflected continued mineralization of the dentin following its initial synthesis. Analysis showed the mechanical data to be consistent with Fourier transform infrared and backscattered electron microscopy studies that revealed increased mineralization in oim bone. Analysis of the data suggests that clinical fragility of teeth in oim mice is not due to deficiencies of hardness or Young's modulus, but may be due to defects in post-yield behavior or resistance to fatigue damage. C1 William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI 53705 USA. Univ Wisconsin, Dept Med, Endocrinol Sect, Madison, WI 53792 USA. Hosp Special Surg, Div Res, New York, NY 10021 USA. Univ Wisconsin, Dept Mat Sci & Engn, Madison, WI 53706 USA. Osteoporosis Res & Clin Ctr, Madison, WI 53705 USA. RP Blank, RD (reprint author), William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, 2500 Overlook Terrace, Madison, WI 53705 USA. EM rdb@medicine.wisc.edu RI Stone, Donald/A-7496-2016; Huang, Alice/L-2256-2015 OI Huang, Alice/0000-0002-5037-6829 NR 28 TC 6 Z9 7 U1 0 U2 1 PU INT AMER ASSOC DENTAL RESEARCHI A D R/A A D R PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314-3406 USA SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PD NOV PY 2006 VL 85 IS 11 BP 1032 EP 1036 PG 5 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 098KY UT WOS:000241520600011 ER PT J AU Volpp, KGM Epstein, AJ Williams, SV AF Volpp, Kevin G. M. Epstein, Andrew J. Williams, Sankey V. TI The effect of market reform on racial differences in hospital mortality SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article; Proceedings Paper CT 26th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 30-MAY 03, 2003 CL VANCOUVER, CANADA SP Soc Gen Internal Med DE quality of health care; economics; medical; financing; organized ID PRICE-COMPETITION; NEW-JERSEY; CARE AB OBJECTIVE: To determine whether racial differences in hospital mortality worsened after implementation of a New Jersey law in 1993 that reduced subsidies for uninsured hospital care and changed hospital payment from rate regulation to price competition. DATA SOURCES/STUDY SETTING: State discharge data for New Jersey and New York from 1990 to 1996. STUDY DESIGN: We used an interrupted time series design to compare risk-adjusted in-hospital mortality rates between states over time. Adjusting for patient characteristics, baseline interstate differences, and common intertemporal trends, we compared the effect sizes for whites and blacks in the following 4 groups: overall, uninsured, insured under age 65, and Medicare patients. DATA COLLECTION/EXTRACTION METHODS: The study sample included 1,357,394 patients admitted to New Jersey or New York hospitals between 1990 to 1996 with stroke, hip fracture, pneumonia, pulmonary embolism, congestive heart failure, or acute myocardial infarction (AMI). PRINCIPAL FINDINGS: The increase in mortality in New Jersey versus New York was significantly larger among blacks than among whites for AMI (2.4% points vs 0.1% points, P-value for difference .026) but not for the other 6 conditions. In groupings of conditions for which hospital admission is non-discretionary and conditions in which admission is discretionary, we found qualitatively larger increases in mortality for blacks but no statistically significant racial differences among patients overall, uninsured patients, insured patients under age 65, or Medicare patients. CONCLUSIONS: Market-based reform and reductions in subsidies for hospital care for the uninsured in New Jersey were associated with worsening racial disparities in in-hospital mortality for AMI but not for 6 other common conditions. C1 Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Philadelphia, PA 19104 USA. Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA. Yale Univ, Sch Publ Hlth, New Haven, CT USA. RP Volpp, KGM (reprint author), Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equity Res & Promot, 9th Floor,Univ & Woodland Ave, Philadelphia, PA 19104 USA. EM volpp70@mail.med.upenn.edu NR 26 TC 3 Z9 3 U1 1 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD NOV PY 2006 VL 21 IS 11 BP 1198 EP 1202 DI 10.1111/j.1525-1497.2006.00484.x PG 5 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 089ZQ UT WOS:000240920800018 PM 17026731 ER PT J AU Saha, S AF Saha, Somnath TI The inherent inequities of market-based health care reform SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material ID ACUTE MYOCARDIAL-INFARCTION; RACIAL-DIFFERENCES; MORTALITY; RACE; SEX C1 Portland VA Med Ctr, Gen Internal Med Sect, Portland, OR 97239 USA. RP Saha, S (reprint author), Portland VA Med Ctr, Gen Internal Med Sect, Portland, OR 97239 USA. EM sahas@ohsu.edu NR 18 TC 1 Z9 1 U1 1 U2 4 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD NOV PY 2006 VL 21 IS 11 BP 1211 EP 1212 DI 10.1111/j.1525-1497.2006.00618.x PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 089ZQ UT WOS:000240920800022 PM 17026737 ER PT J AU Leykum, L AF Leykum, Luci TI Unfractionated- versus low-molecular-weight-heparin-associated HIT in hospitalized medical patients - Author reply SO JOURNAL OF HOSPITAL MEDICINE LA English DT Letter ID INDUCED THROMBOCYTOPENIA C1 Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Leykum, L (reprint author), Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1553-5592 J9 J HOSP MED JI J. Hosp. Med. PD NOV-DEC PY 2006 VL 1 IS 6 BP 381 EP 382 DI 10.1002/jhm.130 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 291PX UT WOS:000255210400011 ER PT J AU Simon, JH Zhang, S Laidlaw, DH Miller, DE Brown, M Corboy, J Bennett, J AF Simon, Jack H. Zhang, Song Laidlaw, David H. Miller, David E. Brown, Mark Corboy, John Bennett, Jeffrey TI Identification of fibers at risk for degeneration by diffusion tractography in patients at high risk for MS after a clinically isolated syndrome SO JOURNAL OF MAGNETIC RESONANCE IMAGING LA English DT Article DE multiple sclerosis; diffusion; tractography; neuronal degeneration; MRI; inflammation; Wallerian degeneration ID APPEARING WHITE-MATTER; REMITTING MULTIPLE-SCLEROSIS; CORPUS-CALLOSUM; WALLERIAN DEGENERATION; AXONAL LOSS; ATROPHY; LESIONS; DAMAGE; TRACT; MRI AB Purpose: Focal inflammatory/demyelinating lesions are thought to be the source of Wallerian degeneration or other injury to local, transiting fiber tracts in the brain or spinal cord in multiple sclerosis (MS). A methodology is established to isolate connections between focal demyelinating lesions and intersecting fibers to permit explicit analyses of the pathology of secondary fiber injury distant from the focal lesion. Materials and Methods: A strategy is described and feasibility demonstrated in three patients with a clinically isolated syndrome and positive MRI (at high risk for MS). The strategy utilizes streamtube diffusion tractography to identify neuronal fibers that intersect a focal lesion and pass through a region of interest, in this case the corpus callosum, where distal (to focal lesion) interrogation can be accomplished. Results: A sizeable fraction of the normal appearing white matter (NAWM) in the early stages of disease can be defined in the corpus callosum, which is distinctive in that this tissue connects to distant demyelinating lesions. Conclusion: The new class of tissue called fibers-at-risk for degeneration (FAR) can be identified and interrogated by a variety of quantitative MRI methodologies to better understand neuronal degeneration in MS. C1 Univ Colorado, Hlth Sci Ctr, Dept Radiol, Denver, CO 80262 USA. Brown Univ, Dept Comp Sci, Providence, RI 02912 USA. Univ Colorado, Dept Neurol, Denver, CO 80262 USA. Univ Colorado, Dept Ophthalmol, Denver, CO 80262 USA. Denver Vet Affairs Med Ctr, Dept Neurol, Denver, CO USA. RP Simon, JH (reprint author), Univ Colorado, Hlth Sci Ctr, Dept Radiol, Box A-034,4200 E 9th Ave, Denver, CO 80262 USA. EM jack.simon@uchsc.edu NR 23 TC 15 Z9 15 U1 0 U2 1 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1053-1807 J9 J MAGN RESON IMAGING JI J. Magn. Reson. Imaging PD NOV PY 2006 VL 24 IS 5 BP 983 EP 988 DI 10.1002/jmri.20719 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 100DS UT WOS:000241648400004 PM 17024655 ER PT J AU Jacobs, JV Horak, FB Tran, VK Nutt, JG AF Jacobs, Jesse V. Horak, Fay B. Tran, Van K. Nutt, John G. TI An alternative clinical postural stability test for patients with Parkinson's disease SO JOURNAL OF NEUROLOGY LA English DT Article DE Parkinson's disease; posture; balance; UPDRS; push and release test ID CONFIDENCE ABC SCALE; BALANCE CONFIDENCE; FALLS; INSTABILITY; FEAR AB We compared the sensitivity and consistency of a new Push and Release Test versus the Pull Test (item 30 of the Unified Parkinson's Disease Rating Scale; UPDRS) as clinical measures of postural stability. Subjects with Parkinson's disease and age-matched control subjects participated in 3 protocols investigating: (1) the sensitivity and specificity of the two tests related to the subjects' balance confidence, as measured by the Activities-specific Balance Confidence (ABC) scale, (2) the inter-rater reliability of the two tests, and (3) the consistency of the perturbation forces applied to the subjects by each balance test. As a test for concurrent validity, the balance tests were also compared with the subjects' retrospective reports of fall frequency. Compared with the Pull Test, the Push and Release Test was more sensitive to subjects with low balance confidence, but less specific for subjects with high balance confidence. The inter-rater correlations were higher with the Push and Release Test. Examiners applied more consistent perturbation forces to the subjects with the Push and Release Test than with the Pull Test. The Push and Release Test correlated better with self-reported falls. Therefore, the Push and Release Test provided a more sensitive and consistent test of postural stability than the Pull Test. C1 Oregon Hlth & Sci Univ, Inst Neurol Sci, Beaverton, OR 97006 USA. Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Beaverton, OR 97006 USA. Portland VA Med Ctr, Parkinson Dis Res Educ & Clin Ctr, Beaverton, OR 97006 USA. RP Horak, FB (reprint author), Oregon Hlth & Sci Univ, Inst Neurol Sci, 505 NEW 185th Ave, Beaverton, OR 97006 USA. EM HorakF@ohsu.edu FU NIA NIH HHS [AG06457] NR 14 TC 39 Z9 39 U1 0 U2 11 PU DR DIETRICH STEINKOPFF VERLAG PI HEIDELBERG PA TIERGARTENSTRASSE 17, 69121 HEIDELBERG, GERMANY SN 0340-5354 J9 J NEUROL JI J. Neurol. PD NOV PY 2006 VL 253 IS 11 BP 1404 EP 1413 DI 10.1007/s00415-006-0224-x PG 10 WC Clinical Neurology SC Neurosciences & Neurology GA 122LD UT WOS:000243227600003 PM 16788773 ER PT J AU Zhang, XP Alber, S Watkins, SC Kochanek, PM Marion, DW Graham, SH Clark, RSB AF Zhang, Xiaopeng Alber, Sean Watkins, Simon C. Kochanek, Patrick M. Marion, Donald W. Graham, Steven H. Clark, Robert S. B. TI Proteolysis consistent with activation of caspase-7 after severe traumatic brain injury in humans SO JOURNAL OF NEUROTRAUMA LA English DT Article DE apoptosis; cysteine protease; head injury; inflammation; programmed cell death ID NEURONAL APOPTOSIS; EXPRESSION; DEATH; RATS; RECRUITMENT; SUBSTRATE; PATHWAYS; ISCHEMIA; CLEAVAGE; EPILEPSY AB The expression and proteolysis of caspase family proteins are involved in the initiation and execution of apoptosis, which has been reported to occur in human and experimental traumatic brain injury (TBI). Caspase-3, -6, and -7 belong to the group of executioner caspases, which are cleaved and activated at the late, irreversible stage of apoptosis. Our previous studies demonstrated roles for caspase-1, -3, and -8 in humans after severe TBI. Here we report expression of caspase-7 mRNA and protein in humans after TBI (n = 16) and control brain-bank tissue (n = 6). Semiquantitative reverse transcription polymerase chain reaction showed no differences between caspase-7 mRNA in TBI patients versus controls (73 +/- 24 vs. 85 +/- 56 relative optical density [ROD], respectively). In contrast, Western blot analysis showed increased pro-caspase-7 in TBI patients versus controls (214 +/- 30 vs. 1 +/- 1 ROD, respectively), as well as an increase in the similar-to-20 kD proteolytic fragment in TBI patients versus controls (86 +/- 13 vs. 22 +/- 12 ROD, respectively), consistent with activation of caspase-7 after TBI in humans. Immunohistochemical analysis showed that cells expressing caspase-7 included astrocytes and neurons and possibly other glial cell types and infiltrated inflammatory cells. These data show that caspase-7 and its cleavage product are increased in human brain after TBI in many central nervous system, as well as noncentral nervous system, cell types. Thus, caspase-7 may play a role in the glial and inflammatory responses, and possibly neuronal death, after TBI in humans. C1 Safar Ctr Resuscitat Res, Dept Crit Care Med, Pittsburgh, PA 15260 USA. Safar Ctr Resuscitat Res, Dept Cell Biol & Physiol, Pittsburgh, PA USA. Safar Ctr Resuscitat Res, Dept Neurol Surg, Pittsburgh, PA USA. Safar Ctr Resuscitat Res, Dept Neurol, Pittsburgh, PA USA. Univ Pittsburgh, Brain Tumor Res Ctr, Pittsburgh, PA USA. VA Pittsburgh Hlth Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA. RP Clark, RSB (reprint author), Safar Ctr Resuscitat Res, Dept Crit Care Med, 3434 5th Ave, Pittsburgh, PA 15260 USA. EM clarkrs@ccm.upmc.edu RI Kochanek, Patrick/D-2371-2015 OI Kochanek, Patrick/0000-0002-2627-913X FU NINDS NIH HHS [P50 NS 30318, R01 NS 38620] NR 27 TC 8 Z9 10 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 J9 J NEUROTRAUM JI J. Neurotrauma PD NOV PY 2006 VL 23 IS 11 BP 1583 EP 1590 DI 10.1089/neu.2006.23.1583 PG 8 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA 106RK UT WOS:000242118200001 PM 17115905 ER PT J AU Jones, D Edes, T Shreve, S Casarett, DJ AF Jones, Diane Edes, Thomas Shreve, Scott Casarett, David J. TI You won't know if you're improving unless you measure: Recommendations for evaluating hospice-veteran partnerships SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE hospice; veterans; end-of-life care; palliative care ID OF-LIFE CARE; NURSING-HOME; END; PAIN; PREFERENCES; MANAGEMENT; VALIDITY; SERVICES; CRITERIA; CANCER AB Growing evidence indicates that there are abundant opportunities to improve the care that patients receive near the end of life. Hospice care has been associated with improvements in these and other outcomes, but hospice is underused by most patient Populations. Therefore, the Department of Veterans Affairs (VA) has made hospice access a priority in its plan to improve end-of-life care for all veterans. In addition to committing funding for hospice care, the VA has also established a national network of Hospice-Veteran Partnerships (HVPs) whose goal is to improve access to hospice for veterans. This article describes the results Of a nationwide consensus project to develop measures of the success of HVPs and recommends key measures that should be used to track improvements and to identify opportunities for highly successful collaborative strategies. C1 US Dept Vet Affairs, Off Geriatr & Extended Care, Washington, DC USA. Ethos Consulting Grp, Moorestown, NJ USA. Univ Penn, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Casarett, DJ (reprint author), 3615 Chestnut St, Philadelphia, PA 19104 USA. EM casarett@mail.med.upenn.edu NR 21 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD NOV PY 2006 VL 32 IS 5 BP 488 EP 496 DI 10.1016/j.jpainsymman.2006.08.001 PG 9 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 107XS UT WOS:000242204900016 PM 17085275 ER PT J AU Valdiserri, RO AF Valdiserri, Ronald O. TI The continued spread of HIV in the United States: Prevention failure or systems defect? SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Editorial Material ID HEALTH; PROGRAMS; FUTURE; TIME; CARE C1 Natl Ctr HIV STD & TB Prevent, Atlanta, GA USA. RP Valdiserri, RO (reprint author), US Dept Vet Affairs, Publ Hlth Strateg Hlth Care Grp, 810 Vermont Ave NW, Washington, DC 20420 USA. EM R.Valdiserri@va.gov NR 35 TC 1 Z9 1 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1078-4659 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD NOV-DEC PY 2006 VL 12 IS 6 BP 586 EP 589 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 099KN UT WOS:000241593400013 PM 17041308 ER PT J AU Hubbard, SL Fitzgerald, SG Reker, DM Boninger, ML Cooper, RA Kazis, LE AF Hubbard, Sandra L. Fitzgerald, Shirley G. Reker, Dean M. Boninger, Michael L. Cooper, Rory A. Kazis, Lewis E. TI Demographic characteristics of veterans who received wheelchairs and scooters from Veterans Health Administration SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE age; assistive technology; equity; ethnicity; power wheelchair; race; rehabilitation; sex; standard manual wheelchair; wheeled mobility equipment ID SPINAL-CORD-INJURY; PUSHRIM BIOMECHANICS; ANSI/RESNA STANDARDS; JOINT KINETICS; PROPULSION; SHOULDER; PERFORMANCE; DISABILITY; MOBILITY; FORCES AB Little is known about the reasoning process clinicians use when prescribing wheeled mobility equipment (WAM) or about the outcomes of this process, i.e., how many devices are prescribed, to whom, how often, and at what cost. This study characterized veterans who received WME from the Veterans Health Administration. We analyzed variance in wheelchair provision based on sex, race/ethnicity, diagnosis, and age. Three years of data from the National Prosthetics Patient Database and the National Patient Care Database were merged, yielding more than 77,000 observations per fiscal year. Logistic regression analysis revealed associations between WME provision and age, sex, and race/ethnicity, when analysis was controlled for diagnosis and number of comorbidities. Hispanics (odds ratio [OR] = 1.864), African Americans (OR = 1.360), and American Indians/Asians (OR = 1.585) were more likely than Caucasians to receive standard wheelchairs. Hispanics (OR = 0.4), African Americans (OR = 0.7), and American Indians/Asians (OR = 0.4) were less likely than Caucasians to receive scooters. C1 N Florida S Georgia Vet Hlth Syst, Dept Vet Affairs, Rehabil Outcomes Res Ctr Excellence, Gainesville, FL USA. Univ Florida, Dept Occupat Therapy, Gainesville, FL USA. Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA 15206 USA. Kansas City VA Med Ctr, Kansas City, MO USA. Univ Kansas, Med Ctr, Dept Hlth Policy & Management, Kansas City, MO USA. Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA. Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02215 USA. VA Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA. RP Fitzgerald, SG (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, 151R-1,7180 Highland Dr, Pittsburgh, PA 15206 USA. EM sgf9@pitt.edu OI Kazis, Lewis/0000-0003-1800-5849; Boninger, Michael/0000-0001-6966-919X NR 47 TC 21 Z9 22 U1 1 U2 5 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PD NOV-DEC PY 2006 VL 43 IS 7 BP 831 EP 844 DI 10.1682/JRRD.2005.11.0174 PG 14 WC Rehabilitation SC Rehabilitation GA 156FO UT WOS:000245633700006 PM 17436170 ER PT J AU Segal, AD Orendurff, MS Mute, GK McDowell, ML Pecoraro, JA Shofer, J Czerniecki, JM AF Segal, Ava D. Orendurff, Michael S. Mute, Glenn K. McDowell, Martin L. Pecoraro, Janice A. Shofer, Jane Czerniecki, Joseph M. TI Kinematic and kinetic comparisons of transfemoral amputee gait using C-Leg (R) and Mauch SNS (R) prosthetic knees SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE amputee; biomechanics; C-Leg (R); gait; kinematics; kinetics; knee; microprocessor; rehabilitation; transfernoral ID PHASE-CONTROL; COMPONENTS; JOINT; REHABILITATION; OSTEOARTHRITIS; DEGENERATION; BIOMECHANICS; AMBULATION; DENSITY; SPEED AB The C-Leg (R) (Otto Bock, Duderstadt, Germany) is a microprocessor-controlled prosthetic knee that may enhance amputee gait. This intrasubject randomized study compared the gait biomechanics of transfemoral amputees wearing the C-Lege with those wearing a common noncomputerized prosthesis, the Mauch SNS (R) (Ossur, Reykjavik, Iceland). After subjects had a 3-month acclimation period with each prosthetic knee, typical gait biomechanical data were collected in a gait laboratory. At a controlled walking speed (CWS), peak swing phase knee-flexion angle decreased for the C-Lege group compared with the Mauch SNS (R) group (55.2 degrees +/- 6.5 degrees vs 64.41 degrees +/- 5.8 degrees, respectively; p = 0.005); the C-Leg (R) group was similar to control subjects' peak swing knee-flexion angle (56.0 degrees +/- 3.4 degrees). Stance knee-flexion moment increased for the C-Legs group compared with the Mauch SNS (R) group (0.142 +/- 0.05 vs 0.067 +/- 0.07 N(.)m, respectively; p = 0.01), but remained significantly reduced compared with control subjects (0.477 +/- 0.1 N(.)m). Prosthetic limb step length at CWS was less for the C-Leg (R) group compared with the Mauch SNS (R) group (0.66 +/- 0.04 vs 0.70 +/- 0.06 in, respectively; p = 0.005), which resulted in increased symmetry between limbs for the C-Leg (R) group. Subjects also walked faster with the C-Leg (R) versus the Mauch SNS (R) (1.30 +/- 0.1 vs 1.21 +/- 0.1 m/s, respectively; p = 0.004). The C-Lee prosthetic limb vertical ground reaction force decreased compared with the Mauch SNS (R) (96.3 +/- 4.7 vs 100.3 +/- 7.5 % body weight, respectively; p = 0.0092). C1 VA Puget Sound Hlth Care Syst, Ctr Excellence Limb Loss Prevent & Prosthet Engn, Dept Vet Affairs Rehabil Res & Dev, Seattle, WA 98108 USA. Univ Washington, Dept Engn Mech, Seattle, WA 98195 USA. Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. Univ Washington, Dept Elect Engn, Seattle, WA 98195 USA. RP Segal, AD (reprint author), VA Puget Sound Hlth Care Syst, Ctr Excellence Limb Loss Prevent & Prosthet Engn, Dept Vet Affairs Rehabil Res & Dev, 1660 S Columbian Way,Mail Stop 151, Seattle, WA 98108 USA. EM avasegal@gmail.com NR 30 TC 85 Z9 89 U1 6 U2 26 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 EI 1938-1352 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PD NOV-DEC PY 2006 VL 43 IS 7 BP 857 EP 869 DI 10.1682/JRRD.2005.09.0147 PG 13 WC Rehabilitation SC Rehabilitation GA 156FO UT WOS:000245633700008 PM 17436172 ER PT J AU Latini, DM Penson, DF Wallace, KL Lubeck, DP Lue, TF AF Latini, David M. Penson, David F. Wallace, Katrine L. Lubeck, Deborah P. Lue, Tom F. TI Clinical and psychosocial characteristics of men with erectile dysfunction: Baseline data from ExCEED (TM) SO JOURNAL OF SEXUAL MEDICINE LA English DT Article DE erectile dysfunction; psychosocial characteristics ID QUALITY-OF-LIFE; SELF-ESTEEM; RELATIONSHIP QUESTIONNAIRE; INTERNATIONAL INDEX; DEPRESSIVE SYMPTOMS; VALIDATION; SILDENAFIL; IMPOTENCE; IMPACT AB Introduction. Erectile dysfunction (ED) is associated with psychological impairment, and further research is required to understand their relationship. Aim. We present descriptive baseline results from a longitudinal observational study of North American men seeking treatment for ED. Methods. Patients completed clinical and health-related quality-of-life information at baseline and three follow-up points over 12 months; 162 patients had usable baseline data, including clinical history and current status, sociodemographic information, and standard paper-and-pencil scales of psychosocial characteristics. Scores on the International Index of Erectile Functioning erectile functioning subscale were collapsed into mild (N = 27), moderate (N = 41), or severe (N = 94) categories. Using chi-square, ANOVA, and logistic regression, we identified baseline characteristics associated with ED severity. Main Outcome Measure. The main outcome measure was the degree of psychosocial impairment associated with mild, moderate, and severe ED. Results. Severe ED was significantly associated with not having a regular sex partner; a history of prostate cancer; and worse scores on measures of positive affect, belonging/loneliness, sexual self-efficacy-strength, psychological adjustment, marital happiness, anxiety at last intercourse, and depression. In a multivariate logistic regression model, poorer sexual self-efficacy was most closely associated with severe ED. The model rescaled R-2 was 0.63 (area-under-the-curve, 0.91). Conclusions. Severe ED is related to impairment across a broad range of psychosocial domains, and clinicians should consider offering patients assistance in dealing with its psychosocial impact. C1 Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utlizat Studies, Houston, TX 77030 USA. Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA. Univ So Calif, Keck Sch Med, Dept Urol, Los Angeles, CA USA. Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA USA. Univ Illinois, Sch Publ Hlth, Chicago, IL USA. Genentech Inc, San Francisco, CA 94080 USA. Univ Calif San Francisco, Dept Urol, San Francisco, CA 94143 USA. RP Latini, DM (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utlizat Studies, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM latini@bcm.tmc.edu OI Latini, David/0000-0002-6161-4861 NR 29 TC 44 Z9 45 U1 1 U2 7 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1743-6095 J9 J SEX MED JI J. Sex. Med. PD NOV PY 2006 VL 3 IS 6 BP 1059 EP 1067 DI 10.1111/j.1743-6109.2006.00331.x PG 9 WC Urology & Nephrology SC Urology & Nephrology GA 098ZL UT WOS:000241562200016 PM 17100939 ER PT J AU Latini, DM Penson, DF Wallace, KL Lubeck, DP Lue, TF AF Latini, David M. Penson, David F. Wallace, Katrine L. Lubeck, Deborah P. Lue, Tom F. TI Longitudinal differences in psychological outcomes for men with erectile dysfunction: Results from ExCEED (TM) SO JOURNAL OF SEXUAL MEDICINE LA English DT Article DE erectile dysfunction; health-related quality of life; psychosocial characteristics; longitudinal analysis ID QUALITY-OF-LIFE; INTERPERSONAL RELATIONSHIP SCALES; DEPRESSIVE SYMPTOMS; SELF-ESTEEM; SILDENAFIL/; VALIDATION; DISEASE AB Introduction. The direction of the relationship between psychological adjustment and erectile dysfunction (ED) is unclear and may differ for different men, and few studies have examined psychological outcomes for men receiving ED treatment. Aim. This study assessed the impact of ED therapy at baseline and 12-month follow-up, using standard psychological measures. Methods. Using an observational ED registry, we collected clinical and psychosocial data at baseline and 3, 6, and 12 months. Participants had (i) a patient-reported outcomes questionnaire at baseline and at least one follow-up; and (ii) data about ED treatments received during the study. Treated men were classified as responders based on improvements in International Index of Erectile Function scores from baseline to 12 months. Main Outcome Measures. The main outcome measures were changes in psychological outcomes in relation to treatment status and baseline ED severity. Results. Of 153 patients, 40 responded to treatment, 49 did not respond to treatment, and 64 did not receive treatment. Treatment responders reported significant improvements in 12-month sexual self-efficacy but only small improvements or no change across five other psychological domains, whereas nonresponders reported small decrements. There was a trend for differences in sexual self-efficacy to vary by baseline ED severity, as well as by treatment response. Conclusions. Diagnosing and successfully treating ED significantly affects patient psychological adjustment, so providers should actively diagnose and treat ED. C1 Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA. Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA. Univ So Calif, Keck Sch Med, Dept Urol, Los Angeles, CA USA. Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA USA. Univ Illinois, Sch Publ Hlth, Chicago, IL USA. Genentech Inc, San Francisco, CA 94080 USA. Univ Calif San Francisco, Dept Urol, San Francisco, CA 94143 USA. RP Latini, DM (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM latini@bcm.tmc.edu OI Latini, David/0000-0002-6161-4861 NR 26 TC 17 Z9 17 U1 2 U2 3 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1743-6095 J9 J SEX MED JI J. Sex. Med. PD NOV PY 2006 VL 3 IS 6 BP 1068 EP 1076 DI 10.1111/j.1743-6109.2006.00332.x PG 9 WC Urology & Nephrology SC Urology & Nephrology GA 098ZL UT WOS:000241562200017 PM 17100940 ER PT J AU Friedlander, AH Vagiela, JA Paterno, VI Mahler, ME AF Friedlander, Arthur H. Vagiela, John A. Paterno, Victoria I. Mahler, Michael E. TI The neuropathology, medical management and dental implications of autism SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION LA English DT Review DE autism; neurodevelopmental disorders; Asperger's syndrome; pervasive developmental disorder; adverse effects; dental treatment ID ADVERSE DRUG-INTERACTIONS; DEVELOPMENTAL DISORDERS; SPECTRUM DISORDERS; SLEEP PROBLEMS; CHILDREN; FAMILIES; DIAGNOSIS; PREVALENCE; SYMPTOMS; PATTERNS AB Background. A paucity of information exists in the dental literature about autism and its dental implications. Types of Studies Reviewed. The authors conducted a MEDLINE search for the period 2000 through 2006, using the term "autism," with the aim of defining the condition's clinical manifestations, dental and medical treatment and dental implications. Results. Autism is a severe developmental. brain disorder that appears in infancy, persists throughout life, and is characterized by impaired social interaction, abnormalities in communication (both verbal and nonverbal and restricted interests. Often accompanying the disorder are behavioral disturbances-such as self-mutilation, aggression, psychiatric symptoms and seizures-that necessitate the administration of multiple medications to help the affected person participate effectively in the educational and rehabilitative process. Clinical Implications. Dentists caring for people with autism must be familiar with the manifestations of the, disease and its associated features so that they can garner the maximum level of patient cooperation. They also must be familiar with the medications used to treat the associated features of the disorder because many of them cause untoward orofacial and systemic reactions and may precipitate adverse interactions with dental therapeutic agents. C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Friedlander, AH (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM arthur.friedlander@med.va.gov NR 102 TC 36 Z9 37 U1 3 U2 9 PU AMER DENTAL ASSN PI CHICAGO PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA SN 0002-8177 J9 J AM DENT ASSOC JI J. Am. Dent. Assoc. PD NOV PY 2006 VL 137 IS 11 BP 1517 EP 1527 PG 11 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 108MY UT WOS:000242245100020 PM 17082277 ER PT J AU Williams, BA Lindquist, K Moody-Ayers, SY Walter, LC Covinsky, KE AF Williams, Brie A. Lindquist, Karla Moody-Ayers, Sandra Y. Walter, Louise C. Covinsky, Kenneth E. TI Functional impairment, race, and family expectations of death SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE functional impairment; palliative care; geriatric ID OF-LIFE CARE; SERIOUSLY ILL PATIENTS; NURSING-HOME RESIDENTS; ADVANCE DIRECTIVES; END; OLDER; PREFERENCES; COMMUNICATION; ETHNICITY; CANCER AB To assess the effect of functional impairment on family expectations of death and to examine how this association varies by race. Cross-sectional. Community based. Two thousand two hundred thirty-seven family members of decedents from the Health and Retirement Survey (HRS), a national study of persons aged 50 and older. Families were interviewed within 2 years of the HRS participant's death. The primary outcome was whether death was expected. The primary predictors were the decedent's functional status (impairment in any activity of daily living (ADL; eating, dressing, transferring, toileting, or bathing) during the last 3 months of life and the decedent's race. Overall, 58% of families reported that their family member's death was expected. Expecting death was strongly associated with functional impairment; 71% of families of decedents with ADL disability expected death, compared with 24% of those without ADL disability (P <.01). Death was expected more often in families of white decedents (60%) than African Americans (49%) (P <.01), although the effect of ADL disability was similar in both groups. After adjustment for potentially confounding factors, there were still significant associations between expecting death and functional impairment (odds ratio (OR) = 3.58, 95% confidence interval (CI) 2.73-4.70), and families of African Americans expected death less often than families of white decedents (OR = 0.63, 95% CI = 0.46-0.86). Family members of older adults expected death only 58% of the time. Families of functionally impaired older people were more likely to expect death when it occurred than were families of older people who were not functionally impaired, and the expectation of death was lower for families of African Americans than for whites. C1 Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, San Francisco, CA USA. RP Williams, BA (reprint author), 4150 Clement St Box 181-G, San Francisco, CA 94121 USA. EM brie.williams@ucsf.edu FU NIA NIH HHS [T32-AG00212, 5 R01 AG023626-02] NR 43 TC 6 Z9 6 U1 0 U2 2 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD NOV PY 2006 VL 54 IS 11 BP 1682 EP 1687 DI 10.1111/j.1532-5415.2006.00941.x PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 100NS UT WOS:000241676400008 PM 17087694 ER PT J AU Vig, EK Taylor, JS Starks, H Hopley, EK Fryer-Edwards, K AF Vig, Elizabeth K. Taylor, Janelle S. Starks, Helene Hopley, Elizabeth K. Fryer-Edwards, Kelly TI Beyond substituted judgment: How surrogates navigate end-of-life decision-making SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article; Proceedings Paper CT Annual Meeting of the American-Society-for-Bioethics-and-Humanities CY OCT 28-31, 2004 CL Philadelphia, PA SP Amer Soc Bioethics & Humanities DE surrogate decision-making; advance care planning; substituted judgment; qualitative research ID ADVANCE DIRECTIVES; CARE; FAMILY; INTERESTS; PHYSICIAN; SUPPORT; ENOUGH; PROXY; WANT AB To characterize how surrogates plan to make medical decisions for others. Descriptive study using semistructured qualitative interviews. Surrogates were interviewed by telephone from their homes. Fifty experienced surrogate decision-makers identified to make decisions for older, chronically ill veterans. Surrogates were asked to describe advance care planning conversations with loved ones and how they planned to make future medical decisions. Thematic content analysis was used to identify bases for decision-making. Surrogates described the motivators and the content of advance care planning conversations with loved ones. Surrogates described five bases for decision-making: (1) conversations (making decisions based on their knowledge of their loved ones' preferences), (2) relying on documents (referring to their loved ones' advance care directives), (3) shared experience (believing an "inner sense" would guide decisions because of shared lived experience with loved ones), (4) surrogates' own values and preferences about life, and (5) surrogates' network (enlisting the help of others). Although ethicists and clinicians expect surrogates to use substituted judgment or patients' best interests when making decisions, these data indicate that many surrogates rely on other factors such as their own best interests or mutual interests of themselves and the patient or intend to base substituted judgments on documents with which they have little familiarity. C1 VA Puget Sound Hlth Care Syst, Geriatr & Extended Care, Seattle, WA 98108 USA. Univ Washington, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. Univ Washington, Dept Anthropol, Seattle, WA 98195 USA. Univ Washington, Dept Med Hist & Eth, Seattle, WA 98195 USA. Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. RP Vig, EK (reprint author), VA Puget Sound Hlth Care Syst, Geriatr & Extended Care, 1660 S Columbian Way S-182 Eth, Seattle, WA 98108 USA. EM vigster@u.washington.edu FU NIA NIH HHS [K23 AG19635] NR 31 TC 75 Z9 75 U1 2 U2 11 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD NOV PY 2006 VL 54 IS 11 BP 1688 EP 1693 DI 10.1111/j.1532-5415.2006.00911.x PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 100NS UT WOS:000241676400009 PM 17087695 ER PT J AU Hutt, E Ruscin, JM Corbett, K Radcliff, TA Kramer, AM Williams, EM Liebrecht, D Klenke, W Hartmann, S AF Hutt, Evelyn Ruscin, J. Mark Corbett, Kitty Radcliff, Tiffany A. Kramer, Andrew M. Williams, Elizabeth M. Liebrecht, Debra Klenke, William Hartmann, Sheryl TI A multifaceted intervention to implement guidelines improved treatment of nursing home-acquired pneumonia in a state veterans home SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE nursing homes; pneumonia; veterans ID LONG-TERM-CARE; RANDOMIZED CONTROLLED-TRIAL; MINIMUM DATA SET; RESIDENTS; MORTALITY; FACILITIES; INFLUENZA; REDUCE; HOSPITALIZATION; VACCINATION AB To assess the feasibility of a multifaceted strategy to translate evidence-based guidelines for treating nursing home-acquired pneumonia (NHAP) into practice using a small intervention trial. Pre-posttest with untreated control group. Two Colorado State Veterans Homes (SVHs) during two influenza seasons. Eighty-six residents with two or more signs of lower respiratory tract infection. Multifaceted, including a formative phase to modify the intervention, institutional-level change emphasizing immunization, and availability of appropriate antibiotics; interactive educational sessions for nurses; and academic detailing. Subjects' SVH medical records were reviewed for guideline compliance retrospectively for the influenza season before the intervention and prospectively during the intervention. Bivariate comparisons-of-care processes between the intervention and control facility before and after the intervention were made using the Fischer exact test. At the intervention facility, compliance with five of the guidelines improved: influenza vaccination, timely physician response to illness onset, x-ray for patients not being hospitalized, use of appropriate antibiotics, and timely antibiotic initiation for unstable patients. Chest x-ray and appropriate and timely antibiotics were significantly better at the intervention than at the control facility during the intervention year but not during the control year. Multifaceted, evidence-based, NHAP guideline implementation improved care processes in a SVH. Guideline implementation should be studied in a national sample of nursing homes to determine whether it improves quality of life and functional outcomes of this debilitating illness for long-term care residents. C1 Denver VA Med Ctr, Dept Med, Denver, CO 80220 USA. Denver VA Med Ctr, Nursing Serv, Denver, CO 80220 USA. Denver VA Med Ctr, Res Serv, Denver, CO 80220 USA. Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80202 USA. Univ Colorado, Hlth Sci Ctr, Sch Pharm, Denver, CO 80202 USA. Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC V5A 1S6, Canada. RP Hutt, E (reprint author), Denver VA Med Ctr, Dept Med, 151,1055 Clermont St, Denver, CO 80220 USA. EM Evelyn.Hutt@uchsc.edu NR 35 TC 24 Z9 24 U1 0 U2 2 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD NOV PY 2006 VL 54 IS 11 BP 1694 EP 1700 DI 10.1111/j.1532-5415.2006.00937.x PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 100NS UT WOS:000241676400010 PM 17087696 ER PT J AU Casarett, DJ Teno, J Higginson, I AF Casarett, David J. Teno, Joan Higginson, Irene TI How should nations measure the quality of end-of-life care for older adults? Recommendations for an international minimum data set SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article ID AFTER-DEATH INTERVIEWS; SUB-SAHARAN AFRICA; PALLIATIVE CARE; FAMILY-MEMBERS; DEVELOPING-COUNTRIES; TELEPHONE SURVEY; CANCER-PATIENTS; PUBLIC-HEALTH; HOSPICE CARE; ILL PATIENTS AB Nations face numerous challenges in providing high-quality end-of-life care for their citizens, and an aging population that has a prolonged trajectory of decline and substantial needs for care magnifies these challenges. As nations begin to address these challenges, it will be essential to determine whether their responses are effective, but current national data collection efforts are sporadic, and data are often collected only for patients who receive care through certain funding programs or provider organizations or in selected sites of care. Therefore, governments do not know whether their citizens are receiving adequate care, whether current programs are improving care, or how their outcomes compare with those of other countries. This article describes the importance of developing national minimum data sets that can be used to assess the quality of end-of-life care that older adults receive and recommends key variables that these data sets should include. C1 Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA. Univ Penn, Div Geriatr, Philadelphia, PA 19104 USA. Brown Univ, Sch Med, Dept Med, Providence, RI 02912 USA. Brown Univ, Sch Med, Dept Community Hlth, Providence, RI 02912 USA. Kings Coll London, Sch Med & Dent, Dept Palliat Care & Policy, Rayne Inst, London WC2R 2LS, England. RP Casarett, DJ (reprint author), 3615 Chestnut St, Philadelphia, PA 19104 USA. EM Casarett@mail.med.upenn.edu NR 53 TC 31 Z9 31 U1 1 U2 7 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD NOV PY 2006 VL 54 IS 11 BP 1765 EP 1771 DI 10.1111/j.1532-5415.2006.00925.x PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 100NS UT WOS:000241676400020 PM 17087706 ER PT J AU Pickens, S Naik, AD Dyer, CB AF Pickens, Sabrina Naik, Aanand D. Dyer, Carmel Bitondo TI Self-neglect in older adults is a geriatric syndrome SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Letter ID ABUSE C1 Baylor Coll Med, Houston, TX 77030 USA. Quentin Mease Community Hosp, Houston, TX USA. Michael DeBakey Vet Affairs Med Ctr, Houston, TX USA. RP Pickens, S (reprint author), Baylor Coll Med, Houston, TX 77030 USA. FU NCRR NIH HHS [P20 RR020626, P20RR20626] NR 7 TC 6 Z9 6 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD NOV PY 2006 VL 54 IS 11 BP 1796 EP 1797 DI 10.1111/j.1532-5415.2006.00930.x PG 3 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 100NS UT WOS:000241676400030 PM 17087715 ER PT J AU Schnelle, JF Ouslander, JG Simmons, SF AF Schnelle, John F. Ouslander, Joseph G. Simmons, Sandra F. TI Direct observations of nursing home care quality: Does care change when observed? SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION LA English DT Article ID ENVIRONMENTAL INTERVENTION; REFLECT DIFFERENCES; FEEDING ASSISTANCE; WEIGHT-LOSS; RESIDENTS; INDICATOR; ACCURACY; DELIVERY; SLEEP AB Objectives: Recent research demonstrates that care recorded by nursing home (NH) staff is often inaccurate. Direct observations of care may therefore be of critical importance in assessing and improving care in this setting. Unfortunately, despite their apparent use in several types of quality assurance activities, there is little written information about the reliability or accuracy of observational procedures in NHs. This paper provides information about one important measurement issue (reactivity) that is often cited as a limitation of observational procedures in measuring usual care practices accurately. Design: Descriptive. Setting: Seven nursing homes. Participants: Staff and residents. Measurements: Direct observational time in bed; repositioning and feeding assistance. Results: Observational measures of care quality were stable over multiple observation periods and consistently detected quality problems even on the first and last days of observation. Conclusion: Direct observations of care provided to residents do not appear to change provider behavior. C1 Los Angeles Jewish Home Aging, Borun Ctr Gerontol Res, Reseda, CA 91335 USA. VA Greater Los Angeles Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Med, Div Geriatr, Los Angeles, CA 90024 USA. Emory Univ, Sch Med, Dept Med, Div Geriatr Med & Gerontol, Atlanta, GA USA. Emory Univ, Sch Med, Ctr Hlth Aging, Atlanta, GA USA. Atlanta VA Rehabil Res & Dev Ctr, Atlanta, GA USA. Birmingham Atlanta VA GRECC, Atlanta, GA USA. RP Schnelle, JF (reprint author), Los Angeles Jewish Home Aging, Borun Ctr Gerontol Res, 7150 Tampa Ave, Reseda, CA 91335 USA. EM JSchnell@ucla.edu FU NIA NIH HHS [AG10415] NR 16 TC 29 Z9 30 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-8610 J9 J AM MED DIR ASSOC JI J. Am. Med. Dir. Assoc. PD NOV PY 2006 VL 7 IS 9 BP 541 EP 544 DI 10.1016/j.jamda.2006.03.009 PG 4 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 108VU UT WOS:000242268100001 PM 17095417 ER PT J AU Chun, J Chodosh, J AF Chun, Jeremy Chodosh, Joshua TI Controversy in heart failure management: Digoxin use in the elderly SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION LA English DT Article ID NURSING-HOME PATIENTS; INVESTIGATION GROUP TRIAL; DIGITALIS WITHDRAWAL; EJECTION FRACTION; MORTALITY; MORBIDITY; ASSOCIATION; OUTCOMES; WOMEN C1 VA Greater Los Angeles Healthcare Syst, Ctr Geriatr Res Educ & Clin, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Multicampus Program Geriatr & Gerontol, Los Angeles, CA USA. RP Chodosh, J (reprint author), VA Greater Los Angeles Healthcare Syst, Ctr Geriatr Res Educ & Clin, 11G,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jchodosh@mednet.ucla.edu OI Chodosh, Joshua/0000-0001-7784-4306 NR 35 TC 5 Z9 5 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-8610 J9 J AM MED DIR ASSOC JI J. Am. Med. Dir. Assoc. PD NOV PY 2006 VL 7 IS 9 BP 581 EP 586 DI 10.1016/j.jamda.2006.08.010 PG 6 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 108VU UT WOS:000242268100007 PM 17095423 ER PT J AU Dekay, ML Hershey, JC Spranca, MD Ubel, PA Asch, DA AF DeKay, Michael L. Hershey, John C. Spranca, Mark D. Ubel, Peter A. Asch, David A. TI Are medical treatments for individuals and groups like single-play and multiple-play gambles? SO JUDGMENT AND DECISION MAKING JOURNAL LA English DT Article DE aggregation; fungibility; individuals versus groups; medical treatment decisions; multiple-play; repeated-play AB People are often more likely to accept risky monetary gambles with positive expected values when the gambles will be played more than once. We investigated whether this distinction between single-play and multiple-play gambles extends to medical treatments for individual patients and groups of patients. Resident physicians and medical students (n = 69) and undergraduates (n = 99) ranked 9 different flu shots and a no-flu-shot option in 1 of 4 combinations of perspective (individual patient vs. group of 1000 patients) and uncertainty frame (probability vs. frequency). The rank of the no-flu- shot option (a measure of preference for treatment vs. no treatment) was not significantly related to perspective or participant population. The main effect of uncertainty frame and the interaction between perspective and uncertainty frame approached significance (0.1 > p > 0.05), with the no-flu-shot option faring particularly poorly (treatment faring particularly well) when decisions about many patients were based on frequency information. Undergraduate participants believed that the no-flu-shot option would be less attractive (treatment would be more attractive) in decisions about many patients, but these intuitions were inconsistent with the actual ranks. These results and those of other studies suggest that medical treatments for individuals and groups are not analogous to single-play and multiple-play monetary gambles, perhaps because many people are unwilling to aggregate treatment outcomes over patients in the same way that they would compute net gains or losses over monetary gambles. C1 [DeKay, Michael L.] Carnegie Mellon Univ, Dept Engn & Publ Policy, Pittsburgh, PA 15213 USA. [Hershey, John C.] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA. [Hershey, John C.; Asch, David A.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Spranca, Mark D.] ABT Associates Inc, Cambridge, MA 02138 USA. [Ubel, Peter A.] VA Ann Arbor Healthcare Syst, VA Hlth Serv Res & Dev Ctr Excellence, Ann Arbor, MI USA. [Ubel, Peter A.] Univ Michigan, Div Gen Internal Med, Ann Arbor, MI 48109 USA. [Ubel, Peter A.] Ctr Behav & Decis Sci Med, Ann Arbor, MI USA. [Ubel, Peter A.] Univ Michigan, Dept Psychol, Ann Arbor, MI 48109 USA. [Asch, David A.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Dekay, ML (reprint author), Carnegie Mellon Univ, Dept Engn & Publ Policy, Pittsburgh, PA 15213 USA. EM dekay@andrew.cmu.edu NR 57 TC 5 Z9 6 U1 1 U2 4 PU SOC JUDGMENT & DECISION MAKING PI TALLAHASSEE PA FLORIDA STATE UNIV, TALLAHASSEE, FL 32306-1110 USA SN 1930-2975 J9 JUDGM DECIS MAK JI Judgm. Decis. Mak. PD NOV PY 2006 VL 1 IS 2 BP 134 EP 145 PG 12 WC Psychology, Multidisciplinary SC Psychology GA V54MB UT WOS:000203681700005 ER PT J AU Weaver, FM Stern, MB Follett, K AF Weaver, Frances M. Stern, Matthew B. Follett, Kenneth TI Deep-brain stimulation in Parkinson's disease SO LANCET NEUROLOGY LA English DT Editorial Material C1 Hines VA Med Ctr, Mid W Ctr Hlth Serv & Policy Res, Hines, IL USA. Northwestern Univ, Chicago, IL 60611 USA. Univ Penn Hlth Syst, Philadelphia, PA USA. Philadelphia VA Med Ctr, Philadelphia, PA USA. Univ Nebraska Med Ctr, Omaha, NE 68198 USA. RP Weaver, FM (reprint author), Hines VA Med Ctr, Mid W Ctr Hlth Serv & Policy Res, Hines, IL USA. EM frances.weaver@va.gov NR 5 TC 4 Z9 4 U1 0 U2 2 PU LANCET LTD PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 1474-4422 J9 LANCET NEUROL JI Lancet Neurol. PD NOV PY 2006 VL 5 IS 11 BP 900 EP 901 DI 10.1016/S1474-4422(06)70586-5 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 099JY UT WOS:000241591600005 PM 17052655 ER PT J AU Elbaz, A Nelson, LM Payami, H Ioannidis, JPA Fiske, BK Annesi, G Belin, AC Factor, SA Ferrarese, C Hadjigeorgiou, GM Higgins, DS Kawakami, H Kruger, R Marder, KS Mayeux, RP Mellick, GD Nutt, JG Ritz, B Samii, A Tanner, CM Van Broeckhoven, C Van Den Eeden, SK Wirdefeldt, K Zabetian, CP Dehem, M Montimurro, JS Southwick, A Myers, RM Trikalinos, TA AF Elbaz, Alexis Nelson, Lorene M. Payami, Haydeh Ioannidis, John P. A. Fiske, Brian K. Annesi, Grazia Belin, Andrea Carmine Factor, Stewart A. Ferrarese, Carlo Hadjigeorgiou, Georgios M. Higgins, Donald S. Kawakami, Hideshi Krueger, Rejko Marder, Karen S. Mayeux, Richard P. Mellick, George D. Nutt, John G. Ritz, Beate Samii, Ali Tanner, Caroline M. Van Broeckhoven, Christine Van Den Eeden, Stephen K. Wirdefeldt, Karin Zabetian, Cyrus P. Dehem, Marie Montimurro, Jennifer S. Southwick, Audrey Myers, Richard M. Trikalinos, Thomas A. TI Lack of replication of thirteen single-nucleotide polymorphisms implicated in Parkinson's disease: a large-scale international study SO LANCET NEUROLOGY LA English DT Article ID GENOME-WIDE ASSOCIATION; COMMON GENETIC VARIANT; RISK; SEMA5A AB Background A genome-wide association study identified 13 single-nucleotide polymorphisms (SNPs) significantly associated with Parkinson's disease. Small-scale replication studies were largely non-confirmatory, but a meta-analysis that included data from the original study could not exclude all SNP associations, leaving relevance of several markers uncertain. Methods Investigators from three Michael J Fox Foundation for Parkinson's Research-funded genetics consortia-comprising 14 teams-contributed DNA samples from 5526 patients with Parkinson's disease and 6682 controls, which were genotyped for the 13 SNPs. Most (88%) participants were of white, non-Hispanic descent. We assessed log-additive genetic effects using fixed and random effects models stratified by team and ethnic origin, and tested for heterogeneity across strata. A meta-analysis was undertaken that incorporated data from the original genome-wide study as well as subsequent replication studies. Findings In fixed and random-effects models no associations with any of the 13 SNPs were identified (odds ratios 0(.)89 to 1(.)09). Heterogeneity between studies and between ethnic groups was low for all SNPs. Subgroup analyses by age at study entry, ethnic origin, sex, and family history did not show any consistent associations. In our meta-analysis, no SNP showed significant association (summary odds ratios 0(.)95 to 1.08); there was little heterogeneity except for SNP rs7520966. Interpretation Our results do not lend support to the finding that the 13 SNPs reported in the original genome-wide association study are genetic susceptibility factors for Parkinson's disease. C1 J Fox Fdn Parkinsons Res, New York, NY 10163 USA. INSERM, Unit 708, F-75654 Paris 13, France. Stanford Univ, Med Ctr, Sch Med, Dept Hlth Res & Policy,Div Epidemiol, Stanford, CA 94305 USA. New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12237 USA. Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, Clin & Mol Epidemiol Unit, GR-45110 Ioannina, Greece. CNR, Inst Neurol Sci, Mangone, Italy. Karolinska Inst, Dept Neurosci, S-10401 Stockholm, Sweden. Albany Med Ctr, Parkinsons Dis & Movement Disorder Clin, Albany, NY USA. Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA. Univ Milan, Osped San Gerardo, Dept Neurosci, Neurol Sect, I-20122 Milan, Italy. Univ Thessaly, Sch Med, Larisa, Greece. Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Epidemiol, Hiroshima 730, Japan. Univ Tubingen, Ctr Neurol, D-72074 Tubingen, Germany. Univ Tubingen, Hertie Inst Clin Brain Res, D-72074 Tubingen, Germany. Columbia Univ, Gertrude H Sergievsky Ctr, New York, NY 10027 USA. Griffith Univ, Eskitis Inst Cell & Mol Therapies, Nathan, Qld 4111, Australia. Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90024 USA. VA Puget Sound Healthcare Syst, Parkinson Dis Res Educ & Clin Ctr, Seattle, WA USA. Parkinsons Inst, Sunnyvale, CA USA. Univ Antwerp VIB, Dept Mol Genet, Neurodegenerat Brain Dis Grp, B-2610 Antwerp, Belgium. Kaiser Fdn, Res Inst, Div Res, Oakland, CA USA. Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden. VA Puget Sound Hlth Care Syst, Res Educ & Clin Ctr, Seattle, WA USA. Univ Washington, Dept Neurol, Seattle, WA 98195 USA. Genoscreen, Lille, France. Stanford Univ, Med Ctr, Sch Med, Dept Genet, Stanford, CA 94305 USA. RP Fiske, BK (reprint author), J Fox Fdn Parkinsons Res, Grand Cent Stn,POB 4777, New York, NY 10163 USA. EM bfiske@michaeljfox.org RI Trikalinos, Thomas/A-1217-2009; Kawakami, Hideshi/A-2086-2009; Nelson, Lorene/D-1305-2011; Ioannidis, John/G-9836-2011; Nuytemans, Karen/F-4797-2012; Morino, Hiroyuki/H-9583-2013; Mellick, George/A-7650-2010; Ritz, Beate/E-3043-2015; Elbaz, Alexis/F-8952-2017 OI Kawakami, Hideshi/0000-0002-1405-0901; Morino, Hiroyuki/0000-0002-5190-3547; Mellick, George/0000-0002-7211-4651; Elbaz, Alexis/0000-0001-9724-5490; Zabetian, Cyrus/0000-0002-7739-4306; Goldwurm, Stefano/0000-0002-1651-567X FU NIA NIH HHS [P30 AG008017, U24 AG021886, AG 08017]; NIEHS NIH HHS [ES10758, P01 ES016732, R01 ES010544, R01 ES010758]; NINDS NIH HHS [K08 NS044138, K08-NS044138, NS R01-31964, NS R01-36960] NR 25 TC 68 Z9 70 U1 0 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1474-4422 J9 LANCET NEUROL JI Lancet Neurol. PD NOV PY 2006 VL 5 IS 11 BP 917 EP 923 DI 10.1016/S1474-4422(06)70579-8 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA 099JY UT WOS:000241591600014 PM 17052658 ER PT J AU Francis, DO Kaufman, R Yueh, B Mock, C Nathens, AB AF Francis, David O. Kaufman, Robert Yueh, Bevan Mock, Charlie Nathens, Avery B. TI Air bag-induced orbital blow-out fractures SO LARYNGOSCOPE LA English DT Article DE orbital; blow-out fracture; air bags; motor vehicle crashes; out-of-position; facial trauma; CIREN ID FRONTAL AUTOMOBILE CRASHES; MOTOR-VEHICLE COLLISIONS; EYE INJURIES; FLOOR FRACTURES; MECHANISM; PATTERNS; AIRBAGS AB Rationale. Although air bags have decreased the risk of serious injury from motor vehicle crashes, their deployment is not innocuous and can result in injury. The force of the deploying air bag can cause orbital blow-out fractures. We investigated the circumstances that predispose a crash occupant to this particular injury. Study Design: The authors conducted a case series. Methods: A total of 150 orbital fractures occurred among 2,739 occupants in crashes included in the Crash Injury Research and Engineering Network (CIREN) database from January 1997 to July 2005. Ten orbital blow-out fractures attributed solely to air bag deployment were extracted and four reported in depth. Occupant, vehicle, and crash char acteristics were reviewed for predisposing similarities and to investigate the mechanism of injury. Results: All crashes had air bag deployment and a frontal or near-frontal principle direction of force. Nine of 10 injured occupants were positioned within the air bag's deployment zone at the time of impact as a result of a forward seat track position, falling asleep at the wheel, being unestrained, or having decelerated before impact. Six of 10 occupants experiencing orbital blow-out fractures were of shorter than average height. Based on rigorous crash reconstructions, the orbital blow-out injuries were felt to be causally related to air bag deployment. Conclusion: Air bag deployment may result in orbital blow-out fractures. Occupants positioned in close proximity to the air bag during its deployment phase appear to be at increased risk for orbital blow-out fractures. C1 Univ Washington, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USA. Univ Washington, Dept Surg, Seattle, WA 98195 USA. Harborview Injury Prevent & Res Ctr, Seattle, WA USA. VA Puget Sound Hlth Care Syst, Surg & Perioperat Care Serv, Hlth Serv Res & Dev Serv, Seattle, WA USA. RP Nathens, AB (reprint author), 325 9th Ave,Box 359796, Seattle, WA 98104 USA. EM anathens@u.washington.edu OI Mock, Charles/0000-0002-0564-568X; Yueh, Bevan/0000-0003-1380-1053 NR 40 TC 7 Z9 7 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PD NOV PY 2006 VL 116 IS 11 BP 1966 EP 1972 DI 10.1097/01.mlg.0000236080.63733.eb PG 7 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA 102JG UT WOS:000241806300006 PM 17075425 ER PT J AU Schittenhelm, MM Yee, KWH Tyner, JW McGreevey, L Haley, AD Town, A Griffith, DJ Bainbridge, T Braziel, RM O'Farrell, AM Cherrington, JM Heinrich, MC AF Schittenhelm, M. M. Yee, K. W. H. Tyner, J. W. McGreevey, L. Haley, A. D. Town, A. Griffith, D. J. Bainbridge, T. Braziel, R. M. O'Farrell, A. -M. Cherrington, J. M. Heinrich, M. C. TI FLT3 K663Q is a novel AML-associated oncogenic kinase: determination of biochemical properties and sensitivity to Sunitinib (SU11248) SO LEUKEMIA LA English DT Article DE AML; FLT3; mutations; tyrosine kinase; growth factor receptor ID ACUTE MYELOID-LEUKEMIA; GASTROINTESTINAL STROMAL TUMORS; INTERNAL TANDEM DUPLICATION; RECEPTOR TYROSINE KINASE; WILD-TYPE; C-KIT; CONSTITUTIVE ACTIVATION; NORMAL CYTOGENETICS; POOR-PROGNOSIS; 32D CELLS AB Somatic mutations of FLT3 resulting in constitutive kinase activation are the most common acquired genomic abnormality found in acute myeloid leukemia (AML). The majority of these mutations are internal tandem duplications (ITD) of the juxtamembrane region (JM). In addition, a minority of cases of AML are associated with mutation of the FLT3 activation loop (AL), typically involving codons D835 and/or I836. We hypothesized that other novel mutations of FLT3 could also contribute to leukemogenesis. We genotyped 109 cases of AML and identified two novel gain-of-function mutations. The first mutation, N841H, is similar to previously described mutations involving amino-acid substitutions of codon 841. The other novel mutation, FLT3 K663Q, is the first AML-associated gain-of-function mutation located outside the JM and AL domains. Of note, this mutation was potently inhibited by Sunitinib (SU11248), a previously described FLT3 kinase inhibitor. Sunitinib reduced the proliferation and induced apoptosis of transformed Ba/F3 cells expressing FLT3 K663Q. The potency of Sunitinib against FLT3 K663Q was similar to its potency against FLT3 ITD mutations. We conclude that FLT3 mutations in AML can involve novel regions of the TK1. Future studies are needed to define the incidence and prognostic significance of FLT3 mutations outside the well-established JM and AL regions. C1 Oregon Hlth Sci Univ, Dept Pathol & Med, Inst Canc, Portland, OR 97201 USA. Portland Vet Affairs Med Ctr, Portland, OR USA. Univ Tubingen, Med Ctr, Dept Hematol Oncol Rheumatol Immunol & Pneumol, Tubingen, Germany. SUGEN Inc, Dept Preclin Res & Exploratory Med, San Francisco, CA USA. RP Heinrich, MC (reprint author), Oregon Hlth Sci Univ, Inst Canc, Div Hematol & Med Oncol, Dept Med, 3710 SW US Vet Hosp Rd,R&D-19, Portland, OR 97239 USA. EM heinrich@ohsu.edu OI Tyner, Jeffrey/0000-0002-2133-0960 FU NCI NIH HHS [5-T32-CA101690-03, P30 CA69533] NR 41 TC 25 Z9 25 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0887-6924 J9 LEUKEMIA JI Leukemia PD NOV PY 2006 VL 20 IS 11 BP 2008 EP 2014 DI 10.1038/sj.leu.2404374 PG 7 WC Oncology; Hematology SC Oncology; Hematology GA 098XJ UT WOS:000241556100014 PM 16990784 ER PT J AU Ioannou, GN AF Ioannou, George N. TI Development and validation of a model predicting graft survival after liver transplantation SO LIVER TRANSPLANTATION LA English DT Article ID BODY-MASS INDEX; DONOR LIVER; PRIMARY NONFUNCTION; UNITED-STATES; RISK-FACTORS; RECIPIENTS; MORTALITY; HEPATITIS; IMPACT; ALLOGRAFTS AB This study aimed to develop and validate a comprehensive model that predicts survival after liver transplantation based on pretransplant donor and recipient characteristics. Complete data were available from the United Network for Organ Sharing for 20,301 persons who underwent liver transplantation in the United States between 1994 and 2003. Proportional-hazards regression was used to identify the donor and recipient characteristics that best predicted survival and incorporate these characteristics in a multivariate model. A data-splitting approach was used to compare survival predicted by the model to the observed survival in samples not used in the derivation of the model. A model was derived using 4 donor characteristics (age, cold ischemia time, gender, and race/ethnicity) and 9 recipient characteristics (age, body mass index, model for end-stage liver disease score, United Network for Organ Sharing priority status, gender, race/ethnicity, diabetes mellitus, cause of liver disease, and serum albumin) that adequately predicted survival after liver transplantation in patients without hepatitis C virus, and a slightly different model was used for patients with hepatitis C virus. The models illustrate that variations in both pretransplant donor and recipient characteristics have a large effect on posttransplant survival. In conclusion, the models presented here can be used to derive scores that are proportional to the excess risk of graft loss after liver transplantation for potential donors, recipients, or donor/recipient combinations. The models may be used to inform liver transplant candidates and their doctors what posttransplant survival would be expected when a given donor is offered and may be particularly helpful for marginal or high-risk donors. C1 Vet Affairs Puget Sound Hlth Care Syst, Res Enhancement Award Program, Seattle, WA 98108 USA. Hlth Serv Res & Dev, Div Gastroenterol, Dept Med, Hepatitis C Resource Ctr, Seattle, WA USA. Univ Washington, Div Gastroenterol, Dept Med, Seattle, WA USA. RP Ioannou, GN (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Res Enhancement Award Program, S-111 Gastro,1660 S Columbian Way, Seattle, WA 98108 USA. EM georgei@medicine.washington.edu FU PHS HHS [231-00-0115] NR 33 TC 72 Z9 73 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1527-6465 J9 LIVER TRANSPLANT JI Liver Transplant. PD NOV PY 2006 VL 12 IS 11 BP 1594 EP 1606 DI 10.1002/lt.20764 PG 13 WC Gastroenterology & Hepatology; Surgery; Transplantation SC Gastroenterology & Hepatology; Surgery; Transplantation GA 099JS UT WOS:000241590700006 PM 16952176 ER PT J AU Carvalho, FD Medina-Flores, R Sartori, AL Wiley, CA AF Carvalho, F. D. Medina-Flores, R. Sartori, A. L. Wiley, C. A. TI YKL-40, a potential inhibitor of axonal growth and pathfinding SO MATRIX BIOLOGY LA English DT Meeting Abstract CT Biennial Meeting of the American-Society-for-Matrix-Biology CY NOV 01-04, 2006 CL Nashville, TN SP Amer Soc Matrix Biol C1 VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Sch Med, Div Neuropathol, Pittsburgh, PA 15213 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0945-053X J9 MATRIX BIOL JI Matrix Biol. PD NOV PY 2006 VL 25 SU S BP S93 EP S93 DI 10.1016/j.matbio.2006.08.256 PG 1 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 103CP UT WOS:000241863600255 ER PT J AU Chaudhuri, AR de Waal, EM Pierce, A Van Remmen, H Ward, WE Richardson, A AF Chaudhuri, Asish R. de Waal, Eric M. Pierce, Anson Van Remmen, Holly Ward, Walter E. Richardson, Arlan TI Detection of protein carbonyls in aging liver tissue: A fluorescence-based proteornic approach SO MECHANISMS OF AGEING AND DEVELOPMENT LA English DT Article DE protein oxidation; protein carbonyls; fluorescence; proteomics; aging ID 2-DIMENSIONAL GEL-ELECTROPHORESIS; OXIDATIVELY MODIFIED PROTEINS; METAL-CATALYZED OXIDATION; AMINO-ACID-RESIDUES; OXIDIZED PROTEINS; IMMUNOCHEMICAL DETECTION; SUPEROXIDE-DISMUTASE; POLYACRYLAMIDE GELS; ALZHEIMERS-DISEASE; PROTEOMIC ANALYSIS AB Protein carbonyls are commonly used as a marker of protein oxidation in cells and tissues. Currently, 2,4-dinitrophenyl hydrazine (DNPH) is widely used (spectrophotometrically or immunologically) to quantify the global carbonyl levels in proteins and identify the specific proteins that are carbonylated. We have adapted a fluorescence-based approach using fluorescein-5-thiosemicarbazide (FTC), to quantify the global protein carbonyls as well as the carbonyl levels on individual proteins in the proteome. Protein carbonyls generated in vitro were quantified by labeling the oxidized proteins with FTC followed by separating the FTC-labeled protein from free probe by gel electrophoresis. The reaction of FTC with protein carbonyls was found to be specific for carbonyl groups. We measured protein carbonyl levels in the livers of young and old mice, and found a significant increase (two-fold) in the global protein carbonyl levels with age. Using 2-D gel electrophoresis, we used this assay to directly measure the chances in protein carbonyl levels in specific proteins. We identified 12 proteins showing a greater than two-fold increase in carbonyl content (pmoles of carbonyls/mu g of protein) with age. Most of the 12 proteins contained transition metal binding sites, with Cu/Zn superoxide dismutase containing the highest molar ratio of carbonyls in old mice. Thus, the fluorescence-based assay gives investigators the ability to identify potential target proteins that become oxidized under different pathological and physiological conditions. (c) 2006 Elsevier Ireland Ltd. All rights reserved. C1 Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78284 USA. RP Richardson, A (reprint author), Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM richardsona@uthscsa.edu RI Pierce, Anson/D-1079-2012 OI Pierce, Anson/0000-0002-1383-0180 FU NIA NIH HHS [P01 AG020591, P01 AG19316, R01 AG025362] NR 71 TC 91 Z9 93 U1 3 U2 24 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0047-6374 J9 MECH AGEING DEV JI Mech. Ageing Dev. PD NOV PY 2006 VL 127 IS 11 BP 849 EP 861 DI 10.1016/j.mad.2006.08.006 PG 13 WC Cell Biology; Geriatrics & Gerontology SC Cell Biology; Geriatrics & Gerontology GA 105RF UT WOS:000242049300005 PM 17002888 ER PT J AU Wilkins, EG Lowery, JC Copeland, LA Goldfarb, SL Wren, PA Janz, NK AF Wilkins, Edwin G. Lowery, Julie C. Copeland, Laurel A. Goldfarb, Sherry L. Wren, Patricia A. Janz, Nancy K. TI Impact of an educational video on patient decision making in early breast cancer treatment SO MEDICAL DECISION MAKING LA English DT Article DE decision making; patient preferences; breast cancer ID BENIGN PROSTATIC HYPERPLASIA; ISCHEMIC-HEART-DISEASE; CONTROLLED-TRIAL; MEDICAL-CARE; INVOLVEMENT; SCALE; ATTITUDES; OUTCOMES; ILLNESS; PROGRAM AB Previous research suggests that patient education programs promoting shared decision making (SDM) may improve patient satisfaction and outcomes, yet controlled clinical trials are lacking. The authors evaluate the impact of an early breast cancer treatment educational video on patients' decisional preferences and behavior. Newly diagnosed stage I/stage II breast cancer patients were assigned to SDM video program or control groups in alternating months. Surveys were administered prior to the provider visit and 1 week following the treatment decision. Variables assessed included autonomy preferences, perceived involvement in care, satisfaction, and treatment choice. There were no significant intervention effects on informationol/decisional preferences, anxiety, knowledge, or satisfaction. Although 25% of SDM patients chose mastectomy compared to 14% of controls, this difference was not statistically significant. Eventhough enthusiasm for SDM programs remains high among some patients and providers, this study found only modest benefits. C1 Univ Michigan, Sect Plast Surg, Sch Med, Ann Arbor, MI 48109 USA. Vet Affairs Ann Arbor Healthcare Syst, HSR&D Ctr Excellence, Ann Arbor, MI USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, Dept Psychiat, San Antonio, TX 78285 USA. Univ Michigan, Sch Med, Dept Emergency Med, Ann Arbor, MI 48109 USA. Univ Michigan, Sch Publ Hlth, Dept Hlth Behav & Hlth Educ, Ann Arbor, MI 48109 USA. RP Wilkins, EG (reprint author), Univ Michigan, Sect Plast Surg, Sch Med, 2130 Taubman Ctr,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA. EM ewilkins@umich.edu OI Copeland, Laurel/0000-0002-9478-0209 NR 26 TC 9 Z9 9 U1 0 U2 2 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0272-989X J9 MED DECIS MAKING JI Med. Decis. Mak. PD NOV-DEC PY 2006 VL 26 IS 6 BP 589 EP 598 DI 10.1177/0272989X06295355 PG 10 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA 107LD UT WOS:000242172200004 PM 17099197 ER PT J AU Riggio, S Sano, M AF Riggio, Silvana Sano, Mary TI Neuropsychiatry - Introduction SO MOUNT SINAI JOURNAL OF MEDICINE LA English DT Editorial Material C1 CUNY Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. James J Peters VA Med Ctr, Consultat Liaison Serv, Bronx, NY USA. RP Riggio, S (reprint author), CUNY Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOUNT SINAI HOSPITAL PI NEW YORK PA BOX 1094 ONE GUSTAVE L LEVY PLACE ATTN: CIRCULATION ASST, NEW YORK, NY 10029-6574 USA SN 0027-2507 J9 MT SINAI J MED JI Mt. Sinai J. Med. PD NOV PY 2006 VL 73 IS 7 BP 930 EP 930 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 116BB UT WOS:000242776400001 ER PT J AU Elder, GA De Gasperi, R Sosa, MAG AF Elder, Gregory A. De Gasperi, Rita Sosa, Miguel A. Gama TI Research update: Neurogenesis in adult brain and neuropsychiatric disorders SO MOUNT SINAI JOURNAL OF MEDICINE LA English DT Article DE Alzheimer's disease; bromodeoxyuridine; depression; hippocampus; major affective disordeis; neural progenitors; neural stem cells; neurodegenerative diseases; neurogenesis; stem cell therapy ID NEURAL PROGENITOR CELLS; CORD STEM-CELLS; DENTATE GYRUS; HIPPOCAMPAL NEUROGENESIS; ALZHEIMERS-DISEASE; SUBVENTRICULAR ZONE; RAT HIPPOCAMPUS; IN-VITRO; ANTIDEPRESSANT TREATMENT; CEREBRAL METABOLITES AB Until recently neurogenesis in mammals was considered to occur only during the embryonic and early post-natal periods and to have no significant role in the adult nervous system. However, it is now accepted that neurogenesis occurs in two brain regions in adult mammals, namely, the hippocampus and olfactory bulb. In both regions new neurons arise from a resident population of neural progenitor cells that are maintained throughout adult life. Hippocampal neurogenesis is required for some types of hippocampal-dependent learning. Many factors enhance hippocampal neurogenesis including hormones, growth factors, drugs, neurotransmitters, and physical exercise as well as learning a hippocampal-dependent task. Other factors suppress hippocampal neurogenesis; these include aging, stress, glucocorticoids and stimuli that activate the pituitary/adrenal axis. Recently much attention has focused on the relevance of hippocampal neurogenesis to the pathophysiology and treatment of mood disorders. Indeed all major pharmacological and non-pharmacological treatments for depression enhance hippocampal neurogenesis and suppressing hippocampal neurogenesis in mice blocks behavioral responses in some antidepressant-sensitive tests. Altered hippocampal neurogenesis may also play a pathophysiological role in neurodegenerative disorders such as Alzheimer's disease. How much neurogenesis occurs normally in other brain regions is unclear. Neural progenitors are found throughout the neuraxis including both neurogenic and non-neurogenic regions. When cultured in vitro or isolated and transplanted back into neurogenic brain regions, these cells can differentiate into neurons, although in their in situ location they seem to behave as lineage-restricted glial progenitors. The environmental cues that limit the potential of progenitor cells in non-neurogenic brain regions are unknown. However, an emerging view is that astrocytes, a subset of which also functions as neural progenitor cells, are critical in regulating the local environment. After transplantation into adult brain, neural stem cells are capable of surviving and differentiating into both neurons and glial cells, offering hope that stem cell therapy may be utilized to treat a variety of neurological and perhaps psychiatric disorders. The widespread existence of endogenous neural progenitors even in non-neurogenic brain regions also offers hope that the potential of these cells may be harnessed to repair cellular injuries caused by injuries such as stroke, trauma or neurodegenerative diseases. While obstacles remain to both approaches, stem-cell-based therapies remain an area of intense research interest. Key Words: Alzheimer's disease, bromodeoxyuridine, depression, hippocampus, major affective disorders, neural progenitors, neural stem cells, neurodegenerative diseases, neurogenesis, stem cell therapy. C1 James J Peters Dept Vet Affairs Med Ctr, Psychiat Serv, Bronx, NY 10468 USA. CUNY Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. RP Elder, GA (reprint author), James J Peters Dept Vet Affairs Med Ctr, Psychiat Serv, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM gregory.elder@mssm.edu FU NIA NIH HHS [AG020139, AG023599]; NIMH NIH HHS [MH070603] NR 66 TC 57 Z9 64 U1 0 U2 18 PU MOUNT SINAI HOSPITAL PI NEW YORK PA BOX 1094 ONE GUSTAVE L LEVY PLACE ATTN: CIRCULATION ASST, NEW YORK, NY 10029-6574 USA SN 0027-2507 J9 MT SINAI J MED JI Mt. Sinai J. Med. PD NOV PY 2006 VL 73 IS 7 BP 931 EP 940 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 116BB UT WOS:000242776400002 PM 17195878 ER PT J AU Riggio, S AF Riggio, Silvana TI Psychiatric manifestations of nonconvulsive status epilepticus SO MOUNT SINAI JOURNAL OF MEDICINE LA English DT Article DE nonconvulsive status epilepticus; absence status; complex partial status ID COMPLEX PARTIAL STATUS; CONVULSIVE STATUS EPILEPTICUS; ABSENCE-STATUS; CLINICAL-FEATURES; FRONTAL ORIGIN; LATER LIFE; ADULTS; POPULATION; MORBIDITY; MORTALITY AB Nonconvulsive status epilepticus (NCSE) is clinically characterized by altered mental status and the diagnosis is confirmed by electroencephalography. Absence status (AS) and complex partial status (CPS) are the two primary types of NCSE. Patients in NCSE may exhibit a wide range of clinical presentations including subtle memory deficits, bizarre behavior, psychosis, or coma. While prognosis is dependent on the underlying etiology and possibly related to duration of the event, there is limited research in this area. Treatment focuses on correcting underlying pathologic abnormalities such as hyponatremia or drug toxicity, and initiating pharmacologic therapy. The benzodiazepines are considered the first line treatment for both AS and CPS. C1 CUNY Mt Sinai Sch Med, New York, NY 10029 USA. James J Peters VA Med Ctr, Consultat Liaison Serv, Bronx, NY USA. RP Riggio, S (reprint author), Mt Sinai Med Ctr, Dept Psychiat, Box 1230,1 Gustave L Levy Pl, New York, NY 10029 USA. EM silvana.rig-gio@mssm.edu NR 47 TC 13 Z9 14 U1 0 U2 1 PU MOUNT SINAI HOSPITAL PI NEW YORK PA BOX 1094 ONE GUSTAVE L LEVY PLACE ATTN: CIRCULATION ASST, NEW YORK, NY 10029-6574 USA SN 0027-2507 J9 MT SINAI J MED JI Mt. Sinai J. Med. PD NOV PY 2006 VL 73 IS 7 BP 960 EP 966 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 116BB UT WOS:000242776400005 PM 17195881 ER PT J AU Aloysi, A Van Dyk, K Sano, M AF Aloysi, Amy Van Dyk, Kathleen Sano, Mary TI Women's cognitive and affective health and neuropsychiatry SO MOUNT SINAI JOURNAL OF MEDICINE LA English DT Article DE women's health; cognition; affect; estrogen ID RANDOMIZED CONTROLLED-TRIAL; ESTROGEN REPLACEMENT THERAPY; SURGICALLY MENOPAUSAL WOMEN; PLACEBO-CONTROLLED TRIAL; POSTMENOPAUSAL WOMEN; DOUBLE-BLIND; PERIMENOPAUSAL WOMEN; VASOMOTOR SYMPTOMS; INITIATIVE MEMORY; MENSTRUAL-CYCLE AB Recent interest in women's health has focused on the cognitive consequences of aging and hormonal changes. Based on hypotheses about estrogenic effects in the central nervous system (CNS), large-scale clinical trials were designed to address the efficacy of hormone replacement on protection against dementia and cognitive decline. Surprisingly, an absence of risk reduction for dementia and cognitive loss was found and much reanalysis of these findings has focused on timing of hormone replacement. Here we take a broad perspective to address a fuller range of psychological health. Gender differences in other psychiatric conditions including depression and anxiety have been attributed to hormones, and the neurotransmitter systems that are implicated in affective disorders may have an impact on cognitive impairment as well. Hormonal influences on neurotrophic mechanisms, as well as neurotransmitter effects, may be responsible for a breadth of neuropsychiatric conditions, particularly in aging. This review will focus on cognition, mood and anxiety issues among women, with an emphasis on changes associated with aging. We will review data on the epidemiology of these entities and examine the biological mechanisms that may be involved, with an emphasis on those mechanisms that may contribute to the multiple aspects of neuropsychiatry and women's health. C1 James J Peters VA Med Ctr, Bronx, NY 10468 USA. CUNY Mt Sinai Sch Med, Alzheimer Dis Res Ctr, New York, NY 10029 USA. RP Sano, M (reprint author), James J Peters VA Med Ctr, 130 Kingsbridge Rd,Room 1F01, Bronx, NY 10468 USA. OI Van Dyk, Kathleen/0000-0003-1500-930X FU NIA NIH HHS [AG10483, AG05138, AG15922] NR 56 TC 12 Z9 12 U1 6 U2 9 PU MOUNT SINAI HOSPITAL PI NEW YORK PA BOX 1094 ONE GUSTAVE L LEVY PLACE ATTN: CIRCULATION ASST, NEW YORK, NY 10029-6574 USA SN 0027-2507 J9 MT SINAI J MED JI Mt. Sinai J. Med. PD NOV PY 2006 VL 73 IS 7 BP 967 EP 975 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 116BB UT WOS:000242776400006 PM 17195882 ER PT J AU Grossman, H Bergmann, C Parker, S AF Grossman, Hillel Bergmann, Christine Parker, Susan TI Dementia: A brief review SO MOUNT SINAI JOURNAL OF MEDICINE LA English DT Review DE aging; dementia; diagnosis; treatment; pathology; Alzheimer's disease; vascular dementia; Lewy Body disease; frontotemporal dementia ID APOLIPOPROTEIN-E EPSILON-4; FRONTOTEMPORAL LOBAR DEGENERATION; ISCHEMIC VASCULAR-DISEASE; ALZHEIMERS-DISEASE; LEWY BODIES; INTERNATIONAL WORKSHOP; ALPHA-SYNUCLEIN; DOUBLE-BLIND; TAU; RISK AB Dementia is an increasingly common diagnosis in our aging population, and the numbers are expected to rise exponentially in coming years. Alzheimer's disease alone now affects 4.5 million people in the US, while millions more are currently affected by vascular dementia, Lewy Body disease and frontotemporal dementia. Each of these is a distinct entity, though overlapping symptoms and comorbidities occur frequently. Within the past two decades research has progressed rapidly on multiple fronts, including epidemiology, etiology, pathology, diagnosis and treatment. It is important for clinicians to recognize early signs and symptoms of dementia, and to note critical differences among them. Dementia research has moved beyond description of symptoms and clinicopathological correlation to the elucidation of risk factors, the pathobiology of the disease process, and most important, to the first generation of dementia treatments. Our purpose here is to review the current state of knowledge and directions of research for the four major dementias noted above. We are entering an era of dementia care that will be based upon the identification of potentially modifiable risk factors and early disease markers, and the application of new disease-specific diagnostic tools and treatment modalities. C1 Mt Sinai Med Ctr, Dept Psychiat, Alzheimers Dis Res Ctr, New York, NY 10029 USA. James J Peters VA Med Ctr, Bronx, NY USA. RP Grossman, H (reprint author), Mt Sinai Med Ctr, Dept Psychiat, Alzheimers Dis Res Ctr, Box 1230, New York, NY 10029 USA. EM hillel.grossman@mssm.edu FU NIA NIH HHS [P60-AG005138] NR 61 TC 35 Z9 40 U1 4 U2 9 PU MOUNT SINAI HOSPITAL PI NEW YORK PA BOX 1094 ONE GUSTAVE L LEVY PLACE ATTN: CIRCULATION ASST, NEW YORK, NY 10029-6574 USA SN 0027-2507 J9 MT SINAI J MED JI Mt. Sinai J. Med. PD NOV PY 2006 VL 73 IS 7 BP 985 EP 992 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 116BB UT WOS:000242776400008 PM 17195884 ER PT J AU Chemerinski, E Levine, SR AF Chemerinski, Eran Levine, Steven R. TI Neuropsychiatric disorders following vascular brain injury SO MOUNT SINAI JOURNAL OF MEDICINE LA English DT Article DE stroke; neuropsychiatric disorders; review ID POST-STROKE DEPRESSION; DOUBLE-BLIND TREATMENT; POSTSTROKE DEPRESSION; CEREBROVASCULAR LESIONS; MOOD DISORDERS; COGNITIVE IMPAIRMENT; GENERALIZED ANXIETY; SECONDARY MANIA; LEFT-HEMISPHERE; INTELLECTUAL IMPAIRMENT AB Several neuropsychiatric disorders such as mood, anxiety and psychotic disorders occur following cerebrovascular lesions. Post-stroke depression is the most common of these disorders and, along with post-stroke anxiety, has been shown to inhibit physical and cognitive recovery. Antidepressants have been shown to effectively treat post-stroke depression and to have a positive impact on rehabilitation efforts in patients suffering from this disorder. Much less is known about the potential impact of psychiatric conditions on recovery after stroke. Controlled trials will be able to adequately determine the effectiveness of treatment for these disorders. C1 Bronx Vet Adm Med Ctr, OOMH, Bronx, NY 10468 USA. CUNY Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. CUNY Mt Sinai Sch Med, Dept Neurol, Mt Sinai Stroke Ctr, New York, NY 10029 USA. RP Chemerinski, E (reprint author), Bronx Vet Adm Med Ctr, OOMH, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM eran.chemerinski@mssm.edu FU NINDS NIH HHS [1R01NS052417, K24NS43992, P01NS23393, R01NS30896] NR 94 TC 33 Z9 42 U1 7 U2 14 PU MOUNT SINAI HOSPITAL PI NEW YORK PA BOX 1094 ONE GUSTAVE L LEVY PLACE ATTN: CIRCULATION ASST, NEW YORK, NY 10029-6574 USA SN 0027-2507 J9 MT SINAI J MED JI Mt. Sinai J. Med. PD NOV PY 2006 VL 73 IS 7 BP 1006 EP 1014 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 116BB UT WOS:000242776400011 PM 17195887 ER PT J AU Limsukon, A Saeed, AI Ramasamy, V Nalamati, J Dhuper, S AF Limsukon, Atikun Saeed, Ali Imran Ramasamy, Vimala Nalamati, Jhansi Dhuper, Sunil TI HIV-related pulmonary hypertension SO MOUNT SINAI JOURNAL OF MEDICINE LA English DT Article DE HIV-related pulmonary hypertension; AIDS-related pulmonary disease; pulmonary hypertension; epoprostenol; highly active antiretroviral therapy ID HUMAN-IMMUNODEFICIENCY-VIRUS; ARTERIAL-HYPERTENSION; ANTIRETROVIRAL THERAPY; INFECTION; SURVIVAL; ARTERIOPATHY; PROSTACYCLIN; HEMOPHILIA; SILDENAFIL; BOSENTAN AB With the availability of better treatment and prophylactic regimens for the infectious complications of human immunodeficiency virus (HIV), the non-infectious complications are gaining greater attention. HIV-related pulmonary arterial hypertension (HIV-PAH) is one of these. The incidence of HIV-PAH is estimated at 0.5% of HIV-infected individuals. The pathogenesis remains unclear. Patients present with symptoms as diverse as progressive shortness of breath, pedal edema, dry cough, fatigue, syncope, as well as chest pain. Chest X-ray always shows cardiomegaly and prominent pulmonary artery, and evidence of tight ventricular hypertrophy can be seen from the electrocardiogram. The pulmonary arterial systolic pressure, diastolic pressure and pulmonary vascular resistance from right heart catheterization are increased. There are a few small studies showing the benefit of prostacyclin analog (epoprostenol and iloprost) and bosentan. The role of antiretrovirals remains controversial, as do those of other agents such as calcium channel blockers and anticoagulants. The prognosis of HIV-PAH is grave. Two thirds of HIV-PAH related mortality is usually secondary to consequences of pulmonary hypertension, with the worst survival noted in New York Heart Association (NYHA) functional class III-IV. The probability of survival in one series was 73%, 60% and 47% at one, two and three years, respectively. C1 Bronx Vet Affairs Med Ctr, Dept Internal Med, Bronx, NY USA. CUNY Mt Sinai Sch Med, New York, NY 10029 USA. N Cent Bronx Hosp, Dept Internal Med, Bronx, NY USA. N Cent Bronx Hosp, Dept Pulm & Crit Care Med, Bronx, NY USA. N Cent Bronx Hosp, Dept Med, Bronx, NY USA. Albert Einstein Coll Med, Bronx, NY 10467 USA. RP Limsukon, A (reprint author), 130 S Flores St,Apt 310, Los Angeles, CA 90048 USA. EM atikhun@hotmail.com NR 35 TC 16 Z9 16 U1 0 U2 4 PU MOUNT SINAI HOSPITAL PI NEW YORK PA BOX 1094 ONE GUSTAVE L LEVY PLACE ATTN: CIRCULATION ASST, NEW YORK, NY 10029-6574 USA SN 0027-2507 J9 MT SINAI J MED JI Mt. Sinai J. Med. PD NOV PY 2006 VL 73 IS 7 BP 1037 EP 1044 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 116BB UT WOS:000242776400019 PM 17195895 ER PT J AU Heinrich, MC Corless, CL AF Heinrich, Michael C. Corless, Christopher L. TI Does tumor mutational status correlate with clinical response to imatinib? SO NATURE CLINICAL PRACTICE ONCOLOGY LA English DT Editorial Material DE gastrointestinal stromal tumor; genotype analysis; imatinib; KIT; PDGFRA ID GASTROINTESTINAL STROMAL TUMORS C1 Oregon Hlth Sci Univ, Dept Med, Portland, OR 97239 USA. Portland VA Med Ctr, Portland, OR USA. RP Heinrich, MC (reprint author), Oregon Hlth Sci Univ, Dept Med, R&D-19,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM heinrich@ohsu.edu NR 5 TC 3 Z9 3 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 1743-4254 J9 NAT CLIN PRACT ONCOL JI Nat. Clin. Pract. Oncol. PD NOV PY 2006 VL 3 IS 11 BP 600 EP 601 DI 10.1038/ncponc0639 PG 2 WC Oncology SC Oncology GA 102VZ UT WOS:000241842700008 PM 17080176 ER PT J AU Li, G Cherrier, MM Tsuang, DW Petrie, EC Colasurdo, EA Craft, S Schellenberg, GD Peskind, ER Raskind, MA Wilkinson, CW AF Li, Ge Cherrier, Monique M. Tsuang, Debby W. Petrie, Eric C. Colasurdo, Elizabeth A. Craft, Suzanne Schellenberg, Gerard D. Peskind, Elaine R. Raskind, Murray A. Wilkinson, Charles W. TI Salivary cortisol and memory function in human aging SO NEUROBIOLOGY OF AGING LA English DT Article DE cortisol; hypothalamic-pituitary-adrenal; memory; cognitive function; longitudinal study; aging ID MEDIAL PREFRONTAL CORTEX; HEALTHY ELDERLY SUBJECTS; AGE-RELATED-CHANGES; MINI-MENTAL-STATE; ALZHEIMERS-DISEASE; FEEDBACK INHIBITION; PYRAMIDAL NEURONS; SENILE-DEMENTIA; DENDRITIC REORGANIZATION; CIRCADIAN RHYTHMICITY AB Objective: To examine the association of salivary cortisol with cognitive changes in a 3 year longitudinal study. Previous studies have suggested that elevated glucocorticoid concentrations alter hippocampal neuronal morphology, inhibit neurogenesis, and impair cognition. Methods: Salivary cortisol samples were collected at home by 79 cognitively intact older persons (mean age 78 +/- 7 years) at 08:00, 15:00 and 23:00 h, and collections were repeated annually for 3 years. Cognitive function was also assessed annually. Results: The mean cortisol level of samples taken at three times of day and the cortisol concentration at 23:00 h were significantly associated with poorer performance on tasks of declarative memory and executive function. Of 46 subjects who completed the entire 3 year study, higher initial cortisol concentration at 23:00 h predicted a decline in performance of delayed paragraph recall. Conclusion: These results partially confirm previous findings that high cortisol is associated with impaired declarative memory function in non-demented older persons. In addition, our data show that high salivary cortisol concentrations predict a decline in memory function over the next 3 years. (c) 2005 Elsevier Inc. All rights reserved. C1 Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA 98108 USA. VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. RP Li, G (reprint author), Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. EM gli@u.washington.edu RI Tsuang, Debby/L-7234-2016 OI Tsuang, Debby/0000-0002-4716-1894 FU NIA NIH HHS [R35 AG010917, P50 AG05136, R01 AG08419] NR 79 TC 69 Z9 70 U1 1 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PD NOV PY 2006 VL 27 IS 11 BP 1705 EP 1714 DI 10.1016/j.neurobiolaging.2005.09.031 PG 10 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 090RU UT WOS:000240969500016 PM 16274857 ER PT J AU Samuelson, KW Neylan, TC Metzler, TJ Lenoci, M Rothlind, J Henn-Haase, C Choucroun, G Weiner, MW Marmar, CR AF Samuelson, Kristin W. Neylan, Thomas C. Metzler, Thomas J. Lenoci, Maryanne Rothlind, Johannes Henn-Haase, Clare Choucroun, Gerard Weiner, Michael W. Marmar, Charles R. TI Neuropsychological functioning in posttraumatic stress disorder and alcohol abuse SO NEUROPSYCHOLOGY LA English DT Article DE PTSD; veterans; memory; attention; alcohol abuse ID REDUCED HIPPOCAMPAL VOLUME; CHILDHOOD SEXUAL-ABUSE; EXPLICIT MEMORY; COMBAT VETERANS; PTSD; ATTENTION; DEFICITS; DYSFUNCTION; RECOVERY; VICTIMS AB Studies have shown differences in neuropsychological functioning between groups with posttraumatic stress disorder (PTSD) and control participants. Because individuals with PTSD often have a history of comorbid alcohol abuse, the extent to which an alcohol confound is responsible for these differences remains a concern. The current study compares neuropsychological testing scores in 4 groups of veterans with and without PTSD (PTSD+ and PTSD-, respectively) and with and without a history of alcohol abuse (ETOH+ and ETOH-, respectively): n for PTSD+/ETOH+ = 30, n for PTSD+/ETOH- = 37, n for PTSD-/ETOH+ = 30, and n for PTSD-/ETOH- = 31. Results showed that PTSD, when alcohol. educational level, vocabulary, and depression are controlled for, was associated with decreased verbal memory, attention, and processing speed performance. Alcohol abuse history was associated with decreased visual memory performance. By controlling for alcohol and depression, the authors can more conclusively demonstrate that verbal memory and attention differences are associated with PTSD. C1 San Francisco Vet Affairs Med Ctr, Mental Hlth Serv, San Francisco, CA USA. Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. San Franciscos Vet Affairs Med Ctr, Dept Radiol, San Francisco, CA USA. RP Samuelson, KW (reprint author), Alliant Int Univ, Calif Sch Profess Psychol, 1 Beach St,Suite 100, San Francisco, CA USA. EM ksamuelson@alliant.edu FU NIA NIH HHS [P01 AG019724, P01 AG019724-050002] NR 55 TC 62 Z9 63 U1 4 U2 11 PU AMER PSYCHOLOGICAL ASSOC/EDUCATIONAL PUBLISHING FOUNDATION PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0894-4105 J9 NEUROPSYCHOLOGY JI Neuropsychology PD NOV PY 2006 VL 20 IS 6 BP 716 EP 726 DI 10.1037/0894-4105.20.6.716 PG 11 WC Psychology, Clinical; Neurosciences; Psychology SC Psychology; Neurosciences & Neurology GA 101SO UT WOS:000241761000010 PM 17100516 ER PT J AU Swan, BA Conway-Phillips, R Griffin, KF AF Swan, Beth Ann Conway-Phillips, Regina Griffin, Karen F. TI Demonstrating the value of the RN in ambulatory care SO NURSING ECONOMICS LA English DT Editorial Material ID STAFF NURSE ROLE; PATIENT SATISFACTION; DIABETES CARE; DIMENSIONS; TELEPHONE; COMMUNITY; OUTCOMES; MANAGEMENT; CENTERS; LESSONS AB center dot During 2003, an estimated 906 million visits were made to physician offices in the United States (Hing, Cherry, & Woodwell, 2005). center dot Overall, 42% of visits to outpatient settings were attended by a registered nurse (Middleton & Hing, 2005). center dot Despite ambulatory care being the fastest growing site for care, it is the least studied. center dot The purpose of this article is to provide an overview of the role of the RN in ambulatory care and describe the direct and indirect economic value of RNs in ambulatory care settings. C1 Thomas Jefferson Univ, Grad Program, Jefferson Sch Nursing, Jefferson Coll Hlth Profess, Philadelphia, PA 19107 USA. Humana Inc, Delegat Compliance, Louisville, KY USA. S Texas Vet Hlth Care Syst, Grand Prairie, TX USA. RP Swan, BA (reprint author), Thomas Jefferson Univ, Grad Program, Jefferson Sch Nursing, Jefferson Coll Hlth Profess, Philadelphia, PA 19107 USA. NR 58 TC 13 Z9 13 U1 0 U2 2 PU JANNETTI PUBLICATIONS, INC PI PITMAN PA EAST HOLLY AVENUE, BOX 56, PITMAN, NJ 08071-0056 USA SN 0746-1739 J9 NURS ECON JI Nurs. Econ. PD NOV-DEC PY 2006 VL 24 IS 6 BP 315 EP 322 PG 8 WC Nursing SC Nursing GA 121SH UT WOS:000243176800006 PM 17266008 ER PT J AU Gallagher, RM AF Gallagher, Rollin M. TI Pain intensity, emotional state, and personality trait: Which comes first? SO PAIN MEDICINE LA English DT Editorial Material ID WADDELL SIGNS C1 Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. RP Gallagher, RM (reprint author), Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. NR 9 TC 0 Z9 0 U1 0 U2 2 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1526-2375 J9 PAIN MED JI Pain Med. PD NOV-DEC PY 2006 VL 7 IS 6 BP 471 EP 472 DI 10.1111/j.1526-4637.2006.00245.x PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 118JU UT WOS:000242939400001 PM 17112358 ER PT J AU Mareninova, OA Lugea, A Odinokova, IV Tsukamoto, H Gukovsky, I Pandol, SJ Gukovskaya, AS AF Mareninova, O. A. Lugea, A. Odinokova, I. V. Tsukamoto, H. Gukovsky, I. Pandol, S. J. Gukovskaya, A. S. TI Akt activation in alcoholic pancreatitis: Role of PTEN SO PANCREAS LA English DT Meeting Abstract C1 Univ Calif Los Angeles, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Res Ctr Alcohol Liver & Pancreat Dis, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-3177 J9 PANCREAS JI Pancreas PD NOV PY 2006 VL 33 IS 4 BP 481 EP 481 DI 10.1097/00006676-200611000-00150 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 101BS UT WOS:000241714500150 ER PT J AU Hudson, LA Bernard, TJ Tseng, BS Miller, BR Corboy, JR AF Hudson, Lynsee A. Bernard, Timothy J. Tseng, Brian S. Miller, Bradford R. Corboy, John R. TI Neuromyelitis optica immunoglobulin G in a child SO PEDIATRIC NEUROLOGY LA English DT Article DE - ID MULTIPLE-SCLEROSIS; MARKER AB Neuromyelitis optica or Devic's syndrome is an uncommon demyelinating disorder that preferentially attacks the spinal cord and optic nerves. Although it is well described in adults, childhood neuromyelitis optica has rarely been reported in the literature and is frequently misdiagnosed as severe multiple sclerosis. Recently, a serum immunoglobulin G test for neuromyelitis optica has become available which may clarify and accelerate the diagnosis. This report describes a child with recurrent myelitis and an elongated spinal cord lesion who was found to have positive neuromyelitis optica autoantibody. We believe that neuromyelitis optica autoantibody testing should be performed in cases of pediatric transverse myelitis with multiple vertical segments or recurrence. (c) 2006 by Elsevier Inc. All rights reserved. C1 Univ Colorado & Hlth Sci Ctr, Dept Neurol, Denver, CO 80262 USA. Childrens Hosp, Dept Neurol, Denver, CO 80218 USA. Childrens Hosp, Dept Pediat, Denver, CO 80218 USA. Childrens Hosp, Dept Cell & Dev Biol, Denver, CO 80218 USA. Denver Vet Affairs Med Ctr, Denver, CO USA. RP Corboy, JR (reprint author), Univ Colorado & Hlth Sci Ctr, Dept Neurol, 4200 E 9th Ave B183, Denver, CO 80262 USA. EM john.corboy@uchsc.edu FU NIAMS NIH HHS [K08 AR052308-04] NR 11 TC 4 Z9 4 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0887-8994 J9 PEDIATR NEUROL JI Pediatr. Neurol. PD NOV PY 2006 VL 35 IS 5 BP 370 EP 372 DI 10.1016/j.pediatrneurol.2006.06.008 PG 3 WC Clinical Neurology; Pediatrics SC Neurosciences & Neurology; Pediatrics GA 105ND UT WOS:000242036100015 PM 17074612 ER PT J AU Gourcerol, G Million, M Adelson, DW Wang, Y Wang, L Rivier, J St-Pierre, DH Tache, Y AF Gourcerol, G. Million, M. Adelson, D. W. Wang, Y. Wang, L. Rivier, J. St-Pierre, D. H. Tache, Y. TI Lack of interaction between peripheral injection of CCK and obestatin in the regulation of gastric satiety signaling in rodents SO PEPTIDES LA English DT Article DE CCK; obestatin; food intake; gastric emptying; gastric relaxation; gastric vagal afferent ID FOOD-INTAKE; SYNERGISTIC INTERACTION; OBESE MICE; LEAN MICE; CHOLECYSTOKININ; GHRELIN; LEPTIN; RATS; SENSITIVITY; RECEPTORS AB Obestatin is a new peptide for which anorexigenic effects were recently reported in mice. We investigate whether peripheral injection of obestatin or co-injection with cholecystokinin (CCK) can modulate food intake, gastric motor function (intragastric pressure and emptying) and gastric vagal afferent activity in rodents. Obestatin (30, 100 and 300 mu g/kg, i.p.) did not influence cumulative food intake for the 2 h post-injection in rats or mice nor gastric emptying in rats. In rats, obestatin (300 mu g/kg) did not modify CCK (1 mu g/kg, i.p.)induced significant decrease in food intake (36.6%) and gastric emptying (31.0%). Furthermore, while rats injected with CCK (0.3 mu g/kg, i.v.) displayed gastric relaxation, no change in gastric intraluminal pressure was elicited by obestatin (300 mu g/kg, i.v.) pre- or post-CCK administration. In in vitro rat gastric vagal afferent preparations, 20 units that had nonsignificant changes in basal activity after obestatin at 30 mu g responded to CCK at 10 ng by a 182% increase. These data show that obestatin neither influences cumulative food intake, gastric motility or vagal afferent activity nor CCK-induced satiety signaling (c) 2006 Elsevier Inc. All rights reserved. C1 Univ Calif Los Angeles, Ctr Neurovisceral Sci & Womens Hlth, VA Greater Los Angeles Healthcare Syst, Dept Med,Div Digest Dis, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, CURE Digest Dis Res Ctr, VA Greater Los Angeles Healthcare Syst, Dept Med,Div Digest Dis, Los Angeles, CA 90073 USA. Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, La Jolla, CA 92037 USA. Univ Montreal, Fac Med, Dept Nutr, Montreal, PQ H3C 3J7, Canada. RP Tache, Y (reprint author), Univ Calif Los Angeles, Ctr Neurovisceral Sci & Womens Hlth, VA Greater Los Angeles Healthcare Syst, Dept Med,Div Digest Dis, CURE Bldg 115,Room 203,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM ytache@mednet.ucla.edu OI Adelson, David/0000-0002-4623-6030 FU NIDDK NIH HHS [DK-41301, DK-26741, R01 DK-33061] NR 36 TC 93 Z9 97 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-9781 J9 PEPTIDES JI Peptides PD NOV PY 2006 VL 27 IS 11 BP 2811 EP 2819 DI 10.1016/j.peptides.2006.07.012 PG 9 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy GA 109OW UT WOS:000242318900035 PM 16934368 ER PT J AU Pekary, AE Stevens, SA Sattin, A AF Pekary, A. E. Stevens, S. A. Sattin, A. TI Valproate and copper accelerate TRH-like peptide synthesis in male rat pancreas and reproductive tissues SO PEPTIDES LA English DT Article DE prostate; epididymis; testis; RIA; HPLC ID THYROTROPIN-RELEASING-HORMONE; MALE WISTAR RATS; BETA-CELL LINES; ANTIEPILEPTIC DRUGS; IN-VITRO; HISTONE DEACETYLASE; EPILEPTIC PATIENTS; MOOD STABILIZER; SERUM-INSULIN; FOLLICULAR CELLS AB Treatment with valproate (Valp) facilitates the synthesis of TRH-like peptides (pGlu-X-Pro-NH2) in rat brain where "X" can be any amino acid residue. Because high levels of TRH-like peptides occur in the pancreas and pGlu-Glu-Pro-NH2 (Glu-TRH) has been shown to be a fertilization promoting peptide, we hypothesized that these peptides mediate some of the metabolic and reproductive side effects of Valp. Male WKY rats were treated with Valp acutely (AC), chronically (CHR) or chronically followed by a 2 day withdrawal (WD). AC, CHR and WD treatments significantly altered TRH and/or TRH-like peptide levels in pancreas and reproductive tissues. Glu-TRH was the predominant TRH-like peptide in epididymis, consistent with its fertilization promoting activity. Glu-TRH levels in the epididymis increased 3-fold with AC Valp. Phe-TRH, the most abundant TRH-like peptide in the pancreas, increased 4-fold with AC Valp. Phe-TRH inhibits both basal and TRH-stimulated insulin release. Large dense core vesicles (LDCV's) contain a copper-dependent enzyme responsible for the post-translational processing of precursors of TRH and TRH-like peptides. Copper (500 mu M) increased the in vitro C-terminal amidation of TRH-like peptides by 8- and 4-fold during 24 degrees C incubation of homogenates of pancreas and testis, respectively. Valp (7 mu M) accelerated 3-fold the processing of TRH and TRH-like peptide precursors in pancreatic LDCV's incubated at 24 degrees C. We conclude that copper, an essential cofactor for TRH and TRH-like peptide biosynthesis that is chelated by Valp, mediates some of the metabolic and reproductive effects of Valp treatment via acceleration of intravesicular synthesis and altered release of these peptides. (c) 2006 Published by Elsevier Inc. C1 Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Psychiat Serv, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Ctr Ulcer Res & Educ, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Brain Res Inst, Dept Biobehav Sci, Los Angeles, CA 90073 USA. RP Pekary, AE (reprint author), Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Res Serv, Bldg 114,Rm 229,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM Eugene.Pekary@med.va.gov NR 67 TC 13 Z9 13 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-9781 J9 PEPTIDES JI Peptides PD NOV PY 2006 VL 27 IS 11 BP 2901 EP 2911 DI 10.1016/j.peptides.2006.07.014 PG 11 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy GA 109OW UT WOS:000242318900045 PM 16945452 ER PT J AU Motsinger, AA Ritchie, MD Shafer, RW Robbins, GK Morse, GD Labbe, L Wilkinson, GR Clifford, DB D'Aquila, RT Johnson, VA Pollard, RB Merigan, TC Hirsch, MS Donahue, JP Kim, RB Haas, DW AF Motsinger, Alison A. Ritchie, Marylyn D. Shafer, Robert W. Robbins, Gregory K. Morse, Gene D. Labbe, Line Wilkinson, Grant R. Clifford, David B. D'Aquila, Richard T. Johnson, Victoria A. Pollard, Richard B. Merigan, Thomas C. Hirsch, Martin S. Donahue, John P. Kim, Richard B. Haas, David W. TI Multilocus genetic interactions and response to efavirenz-containing regimens: an Adult AIDS Clinical Trials Group study SO PHARMACOGENETICS AND GENOMICS LA English DT Article; Proceedings Paper CT 13th Conference on Retroviruses and Opportunistic Infections CY FEB 05-09, 2006 CL Denver, CO DE HIV therapy-efavirenz; multifactor dimensionality reduction; pharmacogenomics ID MULTIFACTOR-DIMENSIONALITY REDUCTION; SEQUENTIAL 3-DRUG REGIMENS; P-GLYCOPROTEIN EXPRESSION; HIV-INFECTED INDIVIDUALS; MDR1 GENE; CYTOCHROME P4502B6; DIGOXIN PHARMACOKINETICS; REGRESSION-ANALYSIS; ALLELIC VARIANTS; INITIAL THERAPY AB Objective For the HIV-1 reverse transcriptase inhibitor efavirenz, variant drug transporter gene ABCB1 may predict virologic response but not plasma efavirenz exposure. Conversely, variant drug metabolizing enzyme gene CYP2B6 predicts greater plasma efavirenz exposure but not virologic response. We examined whether long-term responses to efavirenz, and/or plasma efavirenz exposure, are better predicted by multilocus genetic interactions than by individual polymorphisms. Materials and methods We studied anti retroviral-naive study participants randomized to receive efavirenz (with or without nelfinavir) plus two nucleoside analogues in study ACTG 384, and who had DNA available for analysis. Participants were followed up for up to 3 years. Nine single nucleotide polymorphisms in ABCB1, CYP2B6, CYP3A4, CYP3A5 and CYP2C19 were identified. Gene-gene interactions were identified using multifactor dimensionality reduction. Results Among 340 efavirenz recipients, higher efavirenz AUC(24h) values were associated with a single locus model involving CYP2B6 516G > T (73% accuracy; P < 0.001). This was also the best model among blacks (69% accuracy; P < 0.001), whereas among whites the best model involved a gene-gene interaction between CYP2B6516G > T and ABCB1 2677G > T (82% accuracy, P < 0.001). Among 155 participants who received efavirenz without nelfinavir, virologic failure was associated with a two-locus interaction between ABCB1 2677G > T and CYP2B6 516G > T (65% accuracy, P < 0.001). Toxicity failure was best predicted by an interaction between ABCB1 2677G > T and ABCB1 3435C > T (71% accuracy, P < 0.001). Conclusions Multilocus genetic interactions between variant drug metabolism and transporter genes may predict efavirenz pharmacokinetics and treatment responses. This finding may have implications for better individualizing antiretroviral therapy. C1 Vanderbilt Univ, Ctr Human Genet Res, Div Infect Dis, Sch Med, Nashville, TN 37203 USA. Stanford Univ, Stanford, CA 94305 USA. Univ Calif Davis, Davis, CA 95616 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. SUNY Buffalo, Buffalo, NY 14260 USA. Washington Univ, St Louis, MO USA. Birmingham VA Med Ctr, Birmingham, AL USA. Univ Alabama, Med Sch Birmingham, Birmingham, AL USA. Univ Montreal, Montreal, PQ, Canada. RP Haas, DW (reprint author), Vanderbilt Univ, Ctr Human Genet Res, Div Infect Dis, Sch Med, 345 24th Ave N,Suite 105, Nashville, TN 37203 USA. EM david.w.haas@vanderbilt.edu RI Robbins, Gregory/F-7988-2011; Ritchie, Marylyn/C-1114-2012 FU NCRR NIH HHS [RR000095]; NHLBI NIH HHS [HL65962]; NIAID NIH HHS [AI38855, AI54999, AI29193, AI27658, AI25903, AI46339, AI27666, AI27659, AI38858]; NIGMS NIH HHS [GM31304]; NINDS NIH HHS [NS32228] NR 52 TC 39 Z9 41 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1744-6872 J9 PHARMACOGENET GENOM JI Pharmacogenet. Genomics PD NOV PY 2006 VL 16 IS 11 BP 837 EP 845 PG 9 WC Biotechnology & Applied Microbiology; Genetics & Heredity; Pharmacology & Pharmacy SC Biotechnology & Applied Microbiology; Genetics & Heredity; Pharmacology & Pharmacy GA 104PU UT WOS:000241971500009 PM 17047492 ER PT J AU Wang, JH Cai, Y Penland, R Chauhan, S Miesfeld, RL Ittmann, M AF Wang, Jianghua Cai, Yi Penland, Rebecca Chauhan, Sanjay Miesfeld, Roger L. Ittmann, Michael TI Increased expression of the metastasis-associated gene Ehm2 in prostate cancer SO PROSTATE LA English DT Article DE Ehm2; prostate cancer; recurrence; cell adhesion; metastasis ID GROWTH-FACTOR RECEPTOR-4; FERM DOMAIN; INTEGRIN ACTIVATION; MURINE MELANOMA; ARG(388) ALLELE; CELL-ADHESION; PROGRESSION; PROGNOSIS; MEMBRANE; PROTEINS AB BACKGROUND. Alterations of fibroblast growth factors and their receptors contribute to prostate cancer progression by enhancing cell survival, motility, and proliferation. The expression of the FGFR-4 Arg 388 variant is correlated with the occurrence of pelvic lymph node metastasis and biochemical (PSA) recurrence in men undergoing radical prostatectomy. Ehm2 is an androgen-regulated gene that has been associated with metastasis in other systems, so we sought to determine if it is expressed in prostate cancer and if the FGFR-4 Arg 388 variant can increase its expression. METHODS. Expression of Ehm2 was examined by quantitative RT-PCR and Western blotting in prostate cell lines and by quantitative RT-PCR, in situ hybridization, and immunohistochemistry in prostate tissues. The effect of Ehm2 expression on collagen IV adhesion was tested by transient overexpression and RNA interference. RESULTS. Ehm2 expression is upregulated in prostate cancer cell lines and prostate cancer tissues. Expression of the FGFR-4 Arg(388) variant results in increased expression of Ehm2. Increased expression of Ehm2 leads to decreased adhesion to collagen IV, which has been associated with metastasis in cancers. Analysis of tissue microarrays revealed that increased Ehm2 expression is associated with biochemical recurrence after radical prostatectomy, which is indicative of more aggressive disease. CONCLUSIONS. Ehm2 is overexpressed in prostate cancer and may enhance disease progression and metastasis. C1 Michael E DeBakey Dept Vet Affairs Med Ctr, Houston, TX USA. Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA. Univ Arizona, Dept Biochem & Mol Biophys, Tucson, AZ USA. RP Ittmann, M (reprint author), Michael E DeBakey VAMC, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM mittmann@bcm.tmc.edu FU NCI NIH HHS [P50CA058204] NR 37 TC 19 Z9 19 U1 1 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-4137 J9 PROSTATE JI Prostate PD NOV 1 PY 2006 VL 66 IS 15 BP 1641 EP 1652 DI 10.1002/pros.20474 PG 12 WC Endocrinology & Metabolism; Urology & Nephrology SC Endocrinology & Metabolism; Urology & Nephrology GA 099QE UT WOS:000241609600007 PM 16927306 ER PT J AU Dowben, JS AF Dowben, Jonathan S. TI Current occupational aspects of army psychiatry SO PSYCHIATRIC ANNALS LA English DT Article C1 Birmingham VAMC, Outpatient Menta Hlth Clin, Birmingham, AL 35233 USA. RP Dowben, JS (reprint author), Birmingham VAMC, Outpatient Menta Hlth Clin, 700 19th St S, Birmingham, AL 35233 USA. EM jonathan.dowben@va.gov NR 5 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 0048-5713 J9 PSYCHIAT ANN JI Psychiatr. Ann. PD NOV PY 2006 VL 36 IS 11 BP 764 EP + PG 16 WC Psychiatry SC Psychiatry GA 107SK UT WOS:000242191100007 ER PT J AU Golier, JA Schmeidler, J Legge, J Yehuda, R AF Golier, Julia A. Schmeidler, James Legge, Juliana Yehuda, Rachel TI Enhanced cortisol suppression to dexamethasone associated with Gulf War deployment SO PSYCHONEUROENDOCRINOLOGY LA English DT Article DE Gulf War illness; medically unexplained illnesses; cortisol; PTSD ID POSTTRAUMATIC-STRESS-DISORDER; REPORTED PHYSICAL HEALTH; CHRONIC-FATIGUE-SYNDROME; PITUITARY-ADRENAL AXIS; COMBAT VETERANS; PYRIDOSTIGMINE BROMIDE; CIRCADIAN VARIATION; PLASMA-CORTISOL; SYMPTOMS; RESPONSES AB Objective: To examine whether PTSD or post-deployment health symptoms in veterans of the first Gulf War (Operation Desert Shield/Storm) are associated with enhanced suppression of the pituitary-adrenal axis to low-dose dexamethasone (DEX). Method: Plasma cortisol and lymphocyte glucocorticoid receptor (GR) number were measured at 08:00h on two consecutive days, before and after administration of 0.5 mg of DEX at 23:00h in 42 male Gulf War veterans (14 without psychiatric illness, 16 with PTSD only, and 12 with both PTSD and MDD) and 12 healthy mate veterans not deployed to the Gulf War or another war zone. Results: In the absence of group differences in basal cortisol levels or GR number, Gulf War veterans without psychiatric illness and Gulf War veterans with PTSD only had significantly greater cortisol suppression to DEX than non-deployed veterans and Gulf War veterans with both PTSD and MDD. Gulf War deployment was associated with significantly greater cortisol suppression to DEX controlling for weight, smoking status, PTSD, and MDD; PTSD was not associated with response to DEX. Among Gulf War veterans musculoskeletal symptoms were significantly associated with cortisol suppression and those who reported taking anti-nerve gas pills (i.e., pyridostigmine bromide) during the war had significantly greater DEX-induced cortisol suppression than those who did not. Conclusions: The data demonstrate that alterations in neuroendocrine function are associated with deployment to the Gulf War and post-deployment musculosketetal symptoms, but not PTSD. Additional studies are needed to examine the relationship of enhanced glucocorticoid responsivity to deployment exposures and chronic unexplained medical symptoms in Gulf War veterans. (c) 2006 Elsevier Ltd. All. rights reserved. C1 James J Peters VA Med Ctr, Dept Psychiat, Bronx, NY 10468 USA. Mt Sinai Sch Med, New York, NY USA. RP Golier, JA (reprint author), James J Peters VA Med Ctr, Dept Psychiat, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM julia.golier@med.va.gov FU NCRR NIH HHS [5M01 RR 00071] NR 52 TC 24 Z9 24 U1 4 U2 7 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4530 J9 PSYCHONEUROENDOCRINO JI Psychoneuroendocrinology PD NOV PY 2006 VL 31 IS 10 BP 1181 EP 1189 DI 10.1016/j.psyneuen.2006.08.005 PG 9 WC Endocrinology & Metabolism; Neurosciences; Psychiatry SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry GA 120OZ UT WOS:000243095800005 PM 17049422 ER PT J AU Pajer, K Tabbah, R Gardner, W Rubin, RT Czambel, RK Wang, Y AF Pajer, Kathleen Tabbah, Rhonda Gardner, William Rubin, Robert T. Czambel, R. Kenneth Wang, Yun TI Adrenal androgen and gonadal hormone levels in adolescent girls with conduct disorder SO PSYCHONEUROENDOCRINOLOGY LA English DT Article DE female antisocial behavior; female conduct disorder; adrenal androgens; gonadal hormones; DHEA-s; testosterone; free testosterone index ID OPPOSITIONAL-DEFIANT DISORDER; AGGRESSIVE-BEHAVIOR; DEHYDROEPIANDROSTERONE-SULFATE; SALIVARY TESTOSTERONE; BINDING GLOBULIN; DEPENDENT AGGRESSION; PLASMA TESTOSTERONE; SOCIAL-DOMINANCE; COMMUNITY SAMPLE; FOLLOW-UP AB There are few data on the biological correlates of female antisocial behavior. This study compared adrenal androgen and gonadal hormone levels in adolescent girls with conduct disorder (CID) to girls without any psychiatric disorder (NC). We studied 87 girls, (47 CID; 36 NC), ages 15-17 years, obtaining three blood samples, drawn 20 min apart between 8 and 9 AM in the first 72 h of the onset of menstrual flow. Plasma was assayed for testosterone, estradiol, androstenedione, dehydroepiandrosterone (DHEA), dehydroepiandrosterone-sulfate (DHEA-S), sex hormone binding globulin (SHBG), and cortisol; area under the curve (AUC) for each of the three samples was used in the data analysis. We also calculated the Free Testosterone Index, Free Estrogen Index, Index of Hyperandrogenism and cortisol to DHEA ratio. In addition to receiving a full psychiatric interview, each girt completed a self-report questionnaire on general aggression. Main hormone analyses controlled for potentially confounding variables such as psychiatric comorbidity and race. Girls with CID had significantly lower cortisol to DHEA ratios, but did not differ from NC girls on any other hormone variable. Girls with symptoms of aggressive CD had significantly higher mean free testosterone indexes, lower SHBG Levels, and Lower cortisol. to DHEA ratios than girls with non-aggressive CD. Girls with CD scored higher on the aggression questionnaire, but there was no association between general aggression and any hormone variable for the sample. Our data suggest that girls with CD, particularly aggressive CID, have lower cortisol to DHEA ratios, higher levels of free testosterone, and lower levels of SHBG. Clinical and research implications of these findings are discussed. (c) 2006 Elsevier Ltd. ALL rights reserved. C1 Ohio State Univ, Dept Pediat, Columbus Childrens Res Inst, Coll Med & Publ Hlth, Columbus, OH 43210 USA. VA Greater Los Angeles Healthcare Syst, Dept Psychiat & Mental Hlth, Los Angeles, CA USA. Allegheny Gen Hosp, Allegheny Singer Res Inst, Pittsburgh, PA 15212 USA. RP Pajer, K (reprint author), Ohio State Univ, Dept Pediat, Columbus Childrens Res Inst, Coll Med & Publ Hlth, Columbus, OH 43210 USA. EM pajerk@pediatrics.ohio-state.edu RI Perez , Claudio Alejandro/F-8310-2010 OI Perez , Claudio Alejandro/0000-0001-9688-184X FU NIMH NIH HHS [MH 01285-04] NR 86 TC 53 Z9 57 U1 3 U2 13 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4530 J9 PSYCHONEUROENDOCRINO JI Psychoneuroendocrinology PD NOV PY 2006 VL 31 IS 10 BP 1245 EP 1256 DI 10.1016/j.psyneuen.2006.09.005 PG 12 WC Endocrinology & Metabolism; Neurosciences; Psychiatry SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry GA 120OZ UT WOS:000243095800011 PM 17126492 ER PT J AU Loftis, JM Wall, JM Pagel, RL Hauser, P AF Loftis, Jennifer M. Wall, Jennifer M. Pagel, Rebecca L. Hauser, Peter TI Administration of pegylated interferon-alpha-2a or -2b does not induce sickness behavior in Lewis rats SO PSYCHONEUROENDOCRINOLOGY LA English DT Article DE pegylated interferon; depression; sickness behavior; forced swim test; serotonin ID FORCED SWIMMING TEST; ALPHA-INTERFERON; HEPATITIS-C; GAMMA; ASSOCIATION; IMMOBILITY; DEPRESSION; INJECTION; SYMPTOMS; THERAPY AB Repeated administration of interferon-a (IFN-alpha) or pegylated IFN-alpha to patients with chronic hepatitis C viral infection induces a flu-like syndrome as well as neuropsychiatric side effects, which are well recognized, but poorly understood. Although pegylation appears to have improved viral response rates in patients with hepatitis C, there are still neurotoxicities associated with pegylated IFN-alpha therapy, in particular, depression, which can compromise and sometime prevent successful completion of antiviral treatment. This study assessed the effects of two forms of pegylated IFN-alpha [peginterferon-alfa-2a (PEG-2a) and peginterferon-alfa-2b (PEG-2b)] in rats in order to develop an animal model of IFN-induced "depression" (often described as sickness behavior) that can be used to more comprehensively investigate the neurochemical mechanisms of IFN-induced depression. Sixty mate and female Lewis rats were randomly assigned to one of six treatment groups: (1) saline (SAL)+SAL (2) SAL+PEG-2a; (3) SAL+PEG-2b; (4) selective serotonin reuptake inhibitor (SSRI)+SAL, (5) SSRI+PEG-2a; (6) SSRI+PEG-2b. Rats were pretreated with intraperitoneal (i.p.) saline (0.9%) or 7.5 mg/kg/day fluoxetine for 1 week, followed by 3 weeks of concurrent i.p. administration of 650 mu g/wk of PEG-2a or PEG-2b.Using locomotor activity, the forced swim test, and weight gain as behavioral measures of sickness behavior, our data showed that Lewis rats did not develop an IFN-induced "depressive syndrome." Western blot analyses of brain and liver tissue indicated that signal transducer and activator of transcripton (STAT1) was not phosphorylated following IFN-alpha administration, suggesting that the pegylated compounds may not have bound type I IFN receptors in the rat. Collectively, our data suggest that Lewis rats are likely not a useful model to study IFN-induced depression. (c) 2006 Elsevier Ltd. All rights reserved. C1 Oregon Hlth & Sci Univ, Dept Psychiat, Portland VA Med Ctr, Behav Hlth & Clin Neurosci Div, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland VA Med Ctr, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Dept Internal Med, Portland VA Med Ctr, Portland, OR 97239 USA. Portland VA Med Ctr, JENS Lab, Portland, OR 97239 USA. Portland VA Med Ctr, NW Hepatitis C Resource Ctr, Portland, OR 97239 USA. RP Loftis, JM (reprint author), Oregon Hlth & Sci Univ, Dept Psychiat, Portland VA Med Ctr, Behav Hlth & Clin Neurosci Div, Mail Code P3MHAdm,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM loftisj@ohsu.edu NR 25 TC 20 Z9 23 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4530 J9 PSYCHONEUROENDOCRINO JI Psychoneuroendocrinology PD NOV PY 2006 VL 31 IS 10 BP 1289 EP 1294 DI 10.1016/j.psyneuen.2006.07.006 PG 6 WC Endocrinology & Metabolism; Neurosciences; Psychiatry SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry GA 120OZ UT WOS:000243095800015 PM 17049181 ER PT J AU Inslicht, SS Marmar, CR Neylan, TC Metzler, TJ Hart, SL Otte, C McCaslin, SE Larkin, GL Hyman, KB Baum, A AF Inslicht, Sabra S. Marmar, Charles R. Neylan, Thomas C. Metzler, Thomas J. Hart, Stacey L. Otte, Christian McCaslin, Shannon E. Larkin, G. Luke Hyman, Kelly B. Baum, Andrew TI Increased cortisol in women with intimate partner violence-related posttraumatic stress disorder (vol 37, pg 825, 2006) SO PSYCHONEUROENDOCRINOLOGY LA English DT Correction C1 Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Med Ctr, Dept Psychiat, Univ Pittsburgh Canc Inst, Pittsburgh, PA 15213 USA. Dept Vet Affairs Med Ctr, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. Univ Hamburg, Hosp Eppendorf, Dept Psychiat & Psychotherapy, D-20246 Hamburg, Germany. Univ Texas, Div Emergency Med, Dept Surg, SW Med Ctr,Parkland Mem Hosp, Dallas, TX 75390 USA. Ctr Hlth Equ Res & Promot, VA Pittsburgh Hlth Care Syst, Pittsburgh, PA 15240 USA. RP Inslicht, SS (reprint author), Univ Pittsburgh, Dept Psychol, Sennott Sq,3rd Floor,210 S Bouquet St, Pittsburgh, PA 15260 USA. EM sabra@itsa.ucsf.edu RI Hart, Stacey/E-4819-2011 NR 1 TC 1 Z9 1 U1 0 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4530 J9 PSYCHONEUROENDOCRINO JI Psychoneuroendocrinology PD NOV PY 2006 VL 31 IS 10 BP 1295 EP 1296 DI 10.1016/j.psyneuen.2006.08.002 PG 2 WC Endocrinology & Metabolism; Neurosciences; Psychiatry SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry GA 120OZ UT WOS:000243095800016 ER PT J AU Kerwin, WS O'Brien, KD Ferguson, MS Polissar, N Hatsukami, TS Yuan, C AF Kerwin, William S. O'Brien, Kevin D. Ferguson, Marina S. Polissar, Nayak Hatsukami, Thomas S. Yuan, Chun TI Inflammation in carotid atherosclerotic plaque: A dynamic contrast-enhanced MR imaging study SO RADIOLOGY LA English DT Article ID CELL-ADHESION MOLECULE-1; HISTOLOGICAL CLASSIFICATION; DENSITY-LIPOPROTEIN; HIGH-RESOLUTION; LESIONS; PROGRESSION; ASSOCIATION; EXPRESSION; ATHEROMA; SERUM AB Purpose: To prospectively evaluate if there is an association between plaque enhancement at magnetic resonance (MR) imaging and proinflammatory cardiovascular risk factors and plaque content. Materials and Methods: This study was performed with informed consent, HIPAA compliance, and institutional review board approval. Contrast agent dynamics within carotid plaques were measured in 30 patients (29 men, one woman; mean age, 67.7 years +/- 10.7 [standard deviation]) who were scheduled to undergo carotid endarterectomy. Measurements were based on kinetic modeling of images obtained at 15-second intervals during which a gadolinium-based contrast agent was injected. The time-varying signal intensities within the plaques were used to estimate the fractional plasma volume (v(p)) and transfer constant (K-trans) of contrast material into the extracellular space. Pearson correlation coefficients were computed between blinded MR measurements and histologic measurements of plaque composition, including macrophages, neovasculature, necrotic core, calcification, loose matrix, and dense fibrous tissue. Correlation coefficients or mean differences were computed regarding clinical markers of cardiovascular risk. Results: Analyzable MR images and histologic results were obtained in 27 patients. Measurements of Ktrans correlated with macrophage (r = 0.75, P < .001), neovasculature (r = 0.71, P < .001), and loose matrix (r = 0.50, P = .01) content. Measurements of vp correlated with macrophage (r = 0.54, P = .004), neovasculature (r = 0.68, P < .001), and loose matrix (r = 0.42, P = .03) content. For clinical parameters, significant associations were correlated with Ktrans only, with decreased high-density lipoprotein levels (r = -0.66, P < .001) and elevated K-trans measurements in smokers compared with nonsmokers (mean, 0.134 min(-1) vs 0.074 min(-1), respectively; P = .01). Conclusion: The correlations between Ktrans and histologic markers of inflammation suggest that Ktrans is a quantitative and non=invasive marker of plaque inflammation, which is further supported by the correlation of Ktrans with proinflammatory cardiovascular risk factors, decreased high-density lipoprotein levels, and smoking. C1 Univ Washington, Dept Radiol, Seattle, WA 98109 USA. Univ Washington, Div Cardiol, Seattle, WA 98109 USA. Univ Washington, Dept Surg, Seattle, WA 98109 USA. Mt Whisper Light Stat Consulting, Seattle, WA USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Kerwin, WS (reprint author), Univ Washington, Dept Radiol, 815 Mercer St, Seattle, WA 98109 USA. EM bkerwin@u.washington.edu FU NHLBI NIH HHS [P01 HL072262, R01 HL073401, R01-HL56874]; NIBIB NIH HHS [EB-01975]; PHS HHS [P01-072262] NR 37 TC 141 Z9 160 U1 0 U2 6 PU RADIOLOGICAL SOC NORTH AMERICA PI OAK BROOK PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA SN 0033-8419 J9 RADIOLOGY JI Radiology PD NOV PY 2006 VL 241 IS 2 BP 459 EP 468 DI 10.1148/radiol.2412051336 PG 10 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 098KM UT WOS:000241519400017 PM 16966482 ER PT J AU Adams, SG Anzueto, A Pugh, JA Lee, S Hazuda, HP AF Adams, Sandra G. Anzueto, Antonio Pugh, Jacqueline A. Lee, Shuko Hazuda, Helen P. TI Mexican American elders have similar severities of COPD despite less tobacco exposure than European American elders SO RESPIRATORY MEDICINE LA English DT Article DE chronic obstructive pulmonary disease; tobacco; exposure; Mexican Americans; European Americans; ethnicity; severity ID SAN-ANTONIO; ETHNIC-DIFFERENCES; PULMONARY-DISEASE; RISK-FACTORS; MORTALITY; WOMEN; DIFFERENCE; HISPANICS; HEALTH; ASTHMA AB Introduction: Hispanics are the fastest growing ethnicity of the US population and the largest subset includes those of Mexican origin. Hispanics, including Mexican Americans (MAs), consistently report less tobacco exposure than European Americans (EAs), but limited data are available regarding differences in the clinical characteristics, severity of airflow obstruction, and functional status between MAs and EAs with chronic obstructive pulmonary disease (COPD). Methods: Participants in a community-based study of aging and frailty among MAs and EAs, San Antonio Longitudinal Study of Aging, underwent spirometry. Participants with spirometry values consistent with COPD by Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria are described here. Results: Thirty-four percent (248/721) of the participants who underwent spirometry had evidence of GOLD Stages 1-4 COPD. Significantly more MAs with COPD reported being never smokers compared to EAs with COPD. Among those with COPD who also smoked, MAs reported significantly less tobacco exposure than EAs (115.7 vs. 32.4 pack-years, respectively), but both groups had surprisingly similar seventies of airflow obstruction. Additionally, MAs had worse functional status and perceived health than did EAs. Conclusions: Despite significantly less exposure to tobacco smoke, MAs with COPD had a similar degree of obstruction to airflow compared with EAs with COPD. Healthcare providers should have a high index of suspicion for COPD in MAs who are exposed to even small amounts of cigarette smoke. (c) 2006 Elsevier Ltd. All rights reserved. C1 Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Div Pulm Dis Crit Care Med, San Antonio, TX 78285 USA. S Texas Vet Hlth Care Syst, Vet Evidence Based Res Disseminat & Implementat C, VERDICT, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, Div Epidemiol, San Antonio, TX 78285 USA. RP Adams, SG (reprint author), Audie L Murphy Mem Vet Adm Med Ctr, Pulm Dis Sect 111E, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM adamssg@uthscsa.edu OI Pugh, Jacqueline/0000-0003-4933-141X FU NCRR NIH HHS [M01-RR-01346]; NIA NIH HHS [R01-AG16518, R01-AG10444] NR 28 TC 5 Z9 5 U1 0 U2 0 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 0954-6111 J9 RESP MED JI Respir. Med. PD NOV PY 2006 VL 100 IS 11 BP 1966 EP 1972 DI 10.1016/j.rmed.2006.02.023 PG 7 WC Cardiac & Cardiovascular Systems; Respiratory System SC Cardiovascular System & Cardiology; Respiratory System GA 100ZY UT WOS:000241709900013 PM 16626949 ER PT J AU Rehman, SU Hutchison, FN AF Rehman, Shakaib U. Hutchison, Florence N. TI Hypertensive men living in a southern city: Is it a recipe for disaster? SO SOUTHERN MEDICAL JOURNAL LA English DT Editorial Material ID BLOOD-PRESSURE CONTROL C1 Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. Med Univ S Carolina, Charleston, SC 29425 USA. RP Rehman, SU (reprint author), Ralph H Johnson Vet Affairs Med Ctr, 109 Bee St 11C, Charleston, SC 29401 USA. EM shakaib.rehman@va.gov NR 7 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0038-4348 J9 SOUTH MED J JI South.Med.J. PD NOV PY 2006 VL 99 IS 11 BP 1200 EP 1200 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 134HA UT WOS:000244072900003 PM 17195408 ER PT J AU Treff, NR Vincent, RK Budde, ML Browning, VL Magliocca, JF Kapur, V Odorico, JS AF Treff, Nathan R. Vincent, Robert K. Budde, Melisa L. Browning, Victoria L. Magliocca, Joseph F. Kapur, Vivek Odorico, Jon S. TI Differentiation of embryonic stem cells conditionally expressing neurogenin 3 SO STEM CELLS LA English DT Article DE microarray; notch; quantitative reverse transcription; polymerase chain reaction; tanscriptional regulation; embryonic stem cells; pancreatic differentiation ID ISLET DIFFERENTIATION; IN-VITRO; ENDOCRINE; PANCREAS; NOTCH; PROGENITORS; LINEAGES; GENES AB Expression of the proendocrine gene neurogenin 3 (Ngn3) is required for the development of pancreatic islets. To better characterize the molecular events regulated by Ngn3 during development, we have determined the expression profiles of murine embryonic stem cells (mESCs) uniformly induced to overexpress Ngn3. An mESC line was created in order to induce Ngn3 by adding doxycycline to the culture medium. Genome-wide microarray analysis was performed to identify genes regulated by Ngn3 in a variety of contexts, including undifferentiated ESCs and differentiating embryoid bodies (EBs). Genes regulated by Ngn3 in a context-independent manner were identified and analyzed using systematic gene ontology tools. This analysis revealed Notch signaling as the most significantly regulated signaling pathway (p = .009). This result is consistent with the hypothesis that Ngn3 expression makes the cell competent for Notch signaling to be activated and, conversely, more sensitive to Notch signaling inhibition. Indeed, EBs induced to express Ngn3 were significantly more sensitive to gamma-secretase inhibitormediated Notch signaling inhibition (p <.0001) when compared with uninduced EBs. Moreover, we find that Ngn3 induction in differentiating ESCs results in significant increases in insulin, glucagon, and somatostatin expression. C1 Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, Madison, WI 53706 USA. William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. Univ Minnesota, Dept Vet Sci, St Paul, MN 55108 USA. Univ Minnesota, Dept Biomed Sci, St Paul, MN 55108 USA. Univ Minnesota, Dept Microbiol, St Paul, MN 55108 USA. WiCell Res Inst, Madison, WI USA. RP Odorico, JS (reprint author), Univ Wisconsin Hosp, N4-756 CSC,600 Highland Ave, Madison, WI 53792 USA. EM jon@surgery.wisc.edu RI Kapur, Vivek/F-7610-2013 OI Kapur, Vivek/0000-0002-9648-0138 FU NIAID NIH HHS [T32 AI52037]; NIDDK NIH HHS [U19-DK061244] NR 27 TC 36 Z9 38 U1 0 U2 2 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 1066-5099 J9 STEM CELLS JI Stem Cells PD NOV PY 2006 VL 24 IS 11 BP 2529 EP 2537 DI 10.1634/stemcells.2006-0082 PG 9 WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology GA 103NM UT WOS:000241893600023 PM 16809427 ER PT J AU Drenser, K Sarraf, D Jain, A Small, KW AF Drenser, Kimberly Sarraf, David Jain, Atul Small, Kent W. TI Crystalline retinopathies SO SURVEY OF OPHTHALMOLOGY LA English DT Review DE crystalline maculopathy; crystalline retinopathy; refractile retinal deposits; retinal crystals ID SJOGREN-LARSSON-SYNDROME; JUXTAFOVEOLAR RETINAL TELANGIECTASIS; FATTY ALDEHYDE DEHYDROGENASE; EXPERIMENTAL CAROTENOID RETINOPATHY; HYPEROXALURIA TYPE-I; TALC RETINOPATHY; NEPHROPATHIC CYSTINOSIS; ISCHEMIC RETINOPATHY; MACULAR DEGENERATION; KJELLINS-SYNDROME AB Man), types of crystalline retinopathies have been described, associated with a myriad of medical conditions ranging from chronic retinal conditions to inherited systemic diseases. This comprehensive review summarizes the different types of crystalline retinopathics, including their clinical presentations, diagnostic criteria, pathology, and treatment options. C1 Univ Calif Los Angeles, Jules Stein Eye Inst, Sch Med, Los Angeles, CA 90095 USA. Associated Retinal Consultants, Royal Oak, MI USA. Greater Los Angeles Vet Adm Healthcare Ctr, Los Angeles, CA USA. King Drew Med Ctr, Los Angeles, CA USA. Stanford Univ, Dept Ophthalmol, Stanford, CA 94305 USA. Cedars Sinai Med Towers, Macula & Retina Ctr, Mol Insight LLC, Los Angeles, CA USA. RP Sarraf, D (reprint author), Univ Calif Los Angeles, Jules Stein Eye Inst, Sch Med, 100 Stein Plaza, Los Angeles, CA 90095 USA. NR 108 TC 19 Z9 19 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0039-6257 J9 SURV OPHTHALMOL JI Surv. Ophthalmol. PD NOV-DEC PY 2006 VL 51 IS 6 BP 535 EP 549 DI 10.1016/j.survophthal.2006.08.006 PG 15 WC Ophthalmology SC Ophthalmology GA 104SS UT WOS:000241980000001 PM 17134644 ER PT J AU Habib, MJ Lawson, K Summers, KK Eakin, RT Barner, J Brown, C Shepherd, MD AF Habib, M. J. Lawson, K. Summers, K. K. Eakin, R. T. Barner, J. Brown, C. Shepherd, M. D. TI Relationship between adherence to antiretroviral therapy and the cost-effectiveness of antiretroviral therapy SO VALUE IN HEALTH LA English DT Meeting Abstract C1 i3 Innovus, Burlington, ON, Canada. Univ Texas, Austin, TX 78712 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1098-3015 J9 VALUE HEALTH JI Value Health PD NOV-DEC PY 2006 VL 9 IS 6 BP A206 EP A206 DI 10.1016/S1098-3015(10)63213-5 PG 1 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 090AC UT WOS:000240922000066 ER PT J AU Oikawa, M Yuan, C Underhill, H Chu, B Yu, W Ferguson, MS Hatsukami, TS AF Oikawa, Minako Yuan, Chun Underhill, Hunter Chu, Baocheng Yu, Wei Ferguson, Marina S. Hatsukami, Thomas S. TI The association of carotid artery plaque calcification and fibrous cap status: A high-resolution magnetic resonance imaging study SO CIRCULATION LA English DT Meeting Abstract CT 79th Annual Scientific Session of the American-Heart-Association CY NOV 12-15, 2006 CL Chicago, IL SP Amer Heart Assoc C1 Univ Washington, Dept Radiol, Seattle, WA 98195 USA. VA Puget Sound HCS, Dept Surg, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 31 PY 2006 VL 114 IS 18 SU S BP 40 EP 40 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 102EC UT WOS:000241792800204 ER PT J AU Colston, JT Chandrasekar, B de la Rosa, SD Freeman, GL Murphy, AL AF Colston, James T. Chandrasekar, Bysani de la Rosa, Sam D. Freeman, Gregory L. Murphy, Audie L. TI Wnt-induced secreted protein-1 is a pro-hypertrophic and pro-fibrotic growth factor SO CIRCULATION LA English DT Meeting Abstract CT 79th Annual Scientific Session of the American-Heart-Association CY NOV 12-15, 2006 CL Chicago, IL SP Amer Heart Assoc C1 Univ Texas, HSC, San Antonio, TX 78285 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 31 PY 2006 VL 114 IS 18 SU S BP 86 EP 86 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 102EC UT WOS:000241792800416 ER PT J AU Rosendorff, C AF Rosendorff, Clive TI Certain anti-hypertensive agents reduce beta-amyloid neuropathology and improve cognition in a mouse model of Alzheimer's disease. SO CIRCULATION LA English DT Meeting Abstract CT 79th Annual Scientific Session of the American-Heart-Association CY NOV 12-15, 2006 CL Chicago, IL SP Amer Heart Assoc C1 Mt Sinai Sch Med, Dept Med, New York, NY USA. VA Med Ctr, New York, NY USA. Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. Mt Sinai Sch Med, Dept Neurosci, New York, NY USA. James J Peters VA Med Ctr, New York, NY USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 31 PY 2006 VL 114 IS 18 SU S BP 129 EP 129 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 102EC UT WOS:000241792800614 ER PT J AU Van Winkle, DM Cao, Z Liu, LJ Packwood, WH Hum, PD AF Van Winkle, Donna M. Cao, Zhiping Liu, Lijuan Packwood, William H. Hum, Patricia D. TI Gender dependence in PI3K/Akt signaling in Met(5)-enkephalin-induced cardioprotection SO CIRCULATION LA English DT Meeting Abstract CT 79th Annual Scientific Session of the American-Heart-Association CY NOV 12-15, 2006 CL Chicago, IL SP Amer Heart Assoc C1 Portland VA Med Ctr, Portland, OR USA. Oregon Hlth & Sci Univ, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 31 PY 2006 VL 114 IS 18 SU S BP 313 EP 313 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 102EC UT WOS:000241792802114 ER PT J AU Turakhia, M Ali, S Schiller, NB Whooley, MA AF Turakhia, Mintu Ali, Sadia Schiller, Nelson B. Whooley, Mary A. TI Left ventricular mass predicts death and sudden death in patients with CAD regardless of ejection fraction: Data from the heart & soul study SO CIRCULATION LA English DT Meeting Abstract CT 79th Annual Scientific Session of the American-Heart-Association CY NOV 12-15, 2006 CL Chicago, IL SP Amer Heart Assoc C1 Univ Calif San Francisco, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 31 PY 2006 VL 114 IS 18 SU S BP 404 EP 404 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 102EC UT WOS:000241792802498 ER PT J AU Oikawa, M Yuan, C Underhill, H Chu, B Yu, W Ferguson, MS Hatsukami, TS AF Oikawa, Minako Yuan, Chun Underhill, Hunter Chu, Baocheng Yu, Wei Ferguson, Marina S. Hatsukami, Thomas S. TI Calcification within the advanced human carotid atherosclerotic plaque is associated with intraplaque hemorrhage: A magnetic resonance imaging and histology investigation SO CIRCULATION LA English DT Meeting Abstract CT 79th Annual Scientific Session of the American-Heart-Association CY NOV 12-15, 2006 CL Chicago, IL SP Amer Heart Assoc C1 Univ Washington, Dept Radiol, Seattle, WA 98195 USA. VA Puget Sound HCS, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 31 PY 2006 VL 114 IS 18 SU S BP 497 EP 498 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 102EC UT WOS:000241792803262 ER PT J AU Peterson, PN Ho, PM Rumsfeld, JS Lyons, EE Ross, C Smith, S Magid, DJ Permanente, K Masoudi, FA AF Peterson, Pam N. Ho, P. Michael Rumsfeld, John S. Lyons, Ella E. Ross, Colleen Smith, Scott Magid, David J. Permanente, Kaiser Masoudi, Frederick A. TI Exercise capacity on exercise treadmill test predicts future cardiac events SO CIRCULATION LA English DT Meeting Abstract CT 79th Annual Scientific Session of the American-Heart-Association CY NOV 12-15, 2006 CL Chicago, IL SP Amer Heart Assoc C1 Denver Hlth Med Ctr, Denver, CO USA. Denver VA Med Ctr, Denver, CO USA. Kaiser Permanente, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 31 PY 2006 VL 114 IS 18 BP 538 EP 538 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 102EC UT WOS:000241792803437 ER PT J AU Feit, F Manoukian, SV Ebrahimi, R Pollack, CV Ohman, EM Attubato, MJ Mehran, R Stone, GW AF Feit, Frederick Manoukian, Steven V. Ebrahimi, Ramin Pollack, Charles V., Jr. Ohman, E. M. Attubato, Michael J. Mehran, Roxana Stone, Gregg W. TI Bivalinudin monotherapy improves 30 day clinical outcomes in diabetics with acute coronary syndrome (ACS). Report from the ACUITY trial SO CIRCULATION LA English DT Meeting Abstract CT 79th Annual Scientific Session of the American-Heart-Association CY NOV 12-15, 2006 CL Chicago, IL SP Amer Heart Assoc C1 NYU, Sch Med, New York, NY 19107 USA. Emory Univ, Sch Med, Atlanta, GA USA. Univ Calif Los Angeles, Los Angeles, CA 10016 USA. Greater Los Angeles VA Med Ctr, Los Angeles, CA USA. Penn Hosp, Philadelphia, PA USA. Duke Univ, Med Ctr, Durham, NC USA. NYU Med Ctr, New York, NY USA. Columbia Univ, Med Ctr, New York, NY USA. Cardiovasc Rsch Fdn, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 31 PY 2006 VL 114 IS 18 BP 551 EP 551 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 102EC UT WOS:000241792803485 ER PT J AU Singh, M Rihal, C Lennon, R Spertus, J Rumsfeld, J Holmes, D AF Singh, Mandeep Rihal, Charanjit Lennon, Ryan Spertus, John Rumsfeld, John Holmes, David TI Bedside estimation of risk from percutaneous coronary interventions: The new Mayo Clinic risk scores? SO CIRCULATION LA English DT Meeting Abstract CT 79th Annual Scientific Session of the American-Heart-Association CY NOV 12-15, 2006 CL Chicago, IL SP Amer Heart Assoc C1 Mayo Clin, Rochester, MN USA. Mid Amer Heart Inst, Kansas City, MO USA. Denver VA Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 31 PY 2006 VL 114 IS 18 BP 733 EP 733 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 102EC UT WOS:000241792804617 ER PT J AU Saam, T Hatsukami, TS Underhill, H Chu, B Takaya, N Cai, J Yuan, C AF Saam, Tobias Hatsukami, Thomas S. Underhill, Hunter Chu, Baocheng Takaya, Norhide Cai, Jianming Yuan, Chun TI Prevalence of AHA type VI carotid lesions identified by MRI across different categories of stenosis measured by duplex ultrasound SO CIRCULATION LA English DT Meeting Abstract CT 79th Annual Scientific Session of the American-Heart-Association CY NOV 12-15, 2006 CL Chicago, IL SP Amer Heart Assoc C1 Univ Munich, Dept Clin Radiol, Munich, Germany. VA Puget Sound Hlth Care Syst, Seattle, WA USA. Univ Washington, Dept Surg, Seattle, WA 98195 USA. Univ Washington, Dept Radiol, Seattle, WA 98195 USA. Juntendo Univ, Sch Med, Dept Cardiol, Tokyo 113, Japan. Peoples Liberat Army Gen Hosp, Dept Radiol, Beijing, Peoples R China. NR 0 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 31 PY 2006 VL 114 IS 18 BP 776 EP 776 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 102EC UT WOS:000241792805115 ER PT J AU Zoghbi, GJ Goyal, MK Hage, FG Brott, BC Misra, VK Myers, PR Hillegass, WB AF Zoghbi, Gilbert J. Goyal, Munish K. Hage, Fadi G. Brott, Brigitta C. Misra, Vijay K. Myers, Paul R. Hillegass, William B. TI Prophylactic sodium nitroprusside administration in saphenous vein graft intervention reduces post-procedural cardiac marker elevation SO CIRCULATION LA English DT Meeting Abstract CT 79th Annual Scientific Session of the American-Heart-Association CY NOV 12-15, 2006 CL Chicago, IL SP Amer Heart Assoc C1 Univ Alabama, Birmingham, AL USA. Birmingham VA Med Ctr, Birmingham, AL USA. St Thomas Med Ctr, Nashville, TN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 31 PY 2006 VL 114 IS 18 SU S BP 786 EP 786 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 102EC UT WOS:000241792805160 ER PT J AU Dada, M O'Rourke, RA Teo, KK Hartigan, PM Knudtson, M Kostuk, W Maron, DJ Casperson, P Weintraub, WS Boden, WE AF Dada, Marcin O'Rourke, Robert A. Teo, Koon K. Hartigan, Pamela M. Knudtson, Merril Kostuk, William Maron, David J. Casperson, Paul Weintraub, William S. Boden, William E. TI Long-term adherence to the ACC/AHA class I post-discharge medications and recommendations using optimal medical therapy in 2,287 patients with established coronary heart disease: Interim data from the clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial SO CIRCULATION LA English DT Meeting Abstract CT 79th Annual Scientific Session of the American-Heart-Association CY NOV 12-15, 2006 CL Chicago, IL SP Amer Heart Assoc C1 Hartford Hosp, Hartford, CT 06115 USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. McMaster Univ, Hlth Sci Ctr, Hamilton, ON, Canada. Vet Affairs Cooperat Studies Program Coordinating, VA Connecticut Healthcare Syst, West Haven, CT USA. Foothills Prov Gen Hosp, Calgary, AB T2N 2T9, Canada. Hlth Sci Ctr, London, ON, Canada. Vanderbilt Univ, Med Ctr, Nashville, TN USA. Christiana Care Hlth Syst, Newark, DE USA. Ctr Outcomes Rech, Newark, DE USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 31 PY 2006 VL 114 IS 18 SU S BP 798 EP 798 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 102EC UT WOS:000241792805212 ER PT J AU Glickman, SW Mulgund, J Lytle, BL Rumsfeld, JS Roe, MT Gibler, WB Ohman, EM Fintel, D Schulman, KA Peterson, ED AF Glickman, Seth W. Mulgund, Jyotsna Lytle, Barbara L. Rumsfeld, John S. Roe, Matthew T. Gibler, W. Brian Ohman, E. Magnus Fintel, Dan Schulman, Kevin A. Peterson, Eric D. TI The impact of pay for performance (P4P) on quality of care in acute coronary syndromes: Initial external evaluation of the center for medicare and medicaid services P4P pilot SO CIRCULATION LA English DT Meeting Abstract CT 79th Annual Scientific Session of the American-Heart-Association CY NOV 12-15, 2006 CL Chicago, IL SP Amer Heart Assoc C1 Duke Clin Res Inst, Durham, NC USA. Denver VA Med Ctr, Denver, CO USA. Univ Cincinnati, Sch Med, Cincinnati, OH 45221 USA. Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 31 PY 2006 VL 114 IS 18 SU S BP 835 EP 835 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 102EC UT WOS:000241792805371 ER PT J AU Rumsfeld, JS Masoudi, FA Jones, PG Havranek, E Peterson, ED Krumholz, HM Spertus, JA AF Rumsfeld, John S. Masoudi, Frederick A. Jones, Philip G. Havranek, Edward Peterson, Eric D. Krumholz, Harlan M. Spertus, John A. TI Predictors of 1-year quality of life after acute myocardial infarction SO CIRCULATION LA English DT Meeting Abstract CT 79th Annual Scientific Session of the American-Heart-Association CY NOV 12-15, 2006 CL Chicago, IL SP Amer Heart Assoc C1 Denver VA Med Ctr, Denver, CO USA. Denver Hlth Med Ctr, Denver, CO USA. St Lukes Hosp, Mid Amer Heart Inst, UMKC, Kansas City, MO 64111 USA. Duke Univ, Med Ctr, Durham, NC USA. Yale Univ, Med Ctr, New Haven, CT USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 31 PY 2006 VL 114 IS 18 SU S BP 842 EP 842 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 102EC UT WOS:000241792805392 ER PT J AU Deo, R Fyr, CLW Fried, LF Newman, AB Harris, TB Angleman, S Green, C Kritchevsky, SB Chertow, G Cummings, SR Shlipak, MG AF Deo, Rajat Fyr, Christina L. Wassel Fried, Linda F. Newman, Anne B. Harris, Tamara B. Angleman, Sara Green, Christie Kritchevsky, Stephen B. Chertow, Glenn Cummings, Steven R. Shlipak, Michael G. TI Cystatin C and cardiovascular events in the elderly: The health, aging, and body composition (Health ABC) study SO CIRCULATION LA English DT Meeting Abstract CT 79th Annual Scientific Session of the American-Heart-Association CY NOV 12-15, 2006 CL Chicago, IL SP Amer Heart Assoc C1 Univ Calif San Francisco, San Francisco, CA 94143 USA. Univ Pittsburgh, Pittsburgh, PA 15260 USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NIA, Bethesda, MD 20892 USA. Univ Tennessee, Memphis, TN 38163 USA. Wake Forest Sch Med, Winston Salem, NC USA. Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA. RI Newman, Anne/C-6408-2013 OI Newman, Anne/0000-0002-0106-1150 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 31 PY 2006 VL 114 IS 18 SU S BP 875 EP 875 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 102EC UT WOS:000241792805533 ER PT J AU Qin, GS Hsu, YS Zhou, XH AF Qin, Gengsheng Hsu, Yu-Sheng Zhou, Xiao-Hua TI New confidence intervals for the difference between two sensitivities at a fixed level of specificity SO STATISTICS IN MEDICINE LA English DT Article DE specificity; sensitivity; diagnostic tests; bootstrap; confidence intervals ID BINOMIAL PROPORTIONS AB For two continuous-scale diagnostic tests, it is of interest to compare their sensitivities at a predetermined level of specificity. In this paper, we propose three new intervals for the difference between two sensitivities at a fixed level of specificity. These intervals are easy to compute. We also conduct simulation studies to compare the relative performance of the new intervals with the existing normal-approximation-based interval proposed by Wieand et al. Our simulation results show that the newly proposed intervals perform better than the existing normal-approximation-based interval in terms of coverage accuracy and interval length. Copyright (c) 2005 John Wiley & Sons, Ltd. C1 Univ Washington, Dept Biostat, Seattle, WA 98195 USA. Georgia State Univ, Dept Math & Stat, Atlanta, GA 30303 USA. NW HSR&D Ctr Excellence, VA Puget Sound Healthcare Syst, Biostat Unit, Seattle, WA 98101 USA. RP Zhou, XH (reprint author), Univ Washington, Dept Biostat, 1705 NE Pacific St,Box 357232, Seattle, WA 98195 USA. EM azhou@u.washington.edu FU NIBIB NIH HHS [R01EB005829] NR 9 TC 10 Z9 10 U1 0 U2 3 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 0277-6715 J9 STAT MED JI Stat. Med. PD OCT 30 PY 2006 VL 25 IS 20 BP 3487 EP 3502 DI 10.1002/sim.2459 PG 16 WC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Medicine, Research & Experimental; Statistics & Probability SC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Research & Experimental Medicine; Mathematics GA 093UT UT WOS:000241196500007 PM 16345124 ER PT J AU Hamilton, L Green, L AF Hamilton, Lesley Green, Linda TI Low serum alpha fetoprotein in hepatocellular carcinoma in the US: A continued need for liver fine needle aspiration SO CANCER CYTOPATHOLOGY LA English DT Meeting Abstract C1 Baylor Coll Med, Houston, TX 77030 USA. Houston VAMC, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0008-543X J9 CANCER CYTOPATHOL JI Cancer Cytopathol. PD OCT 25 PY 2006 VL 108 IS 5 SU S BP 403 EP 403 PG 1 WC Oncology; Pathology SC Oncology; Pathology GA 098MC UT WOS:000241523700130 ER PT J AU Velasco, V Galan, K Gattuso, P Green, L AF Velasco, Veronica Galan, Kristin Gattuso, Paolo Green, Linda TI A review of 68 metastatic malignancies of inguinal lymph nodes diagnosed by superficial FNA: Where, oh, where may the primary tumor be? SO CANCER CYTOPATHOLOGY LA English DT Meeting Abstract C1 Baylor Coll Med, Houston, TX 77030 USA. ME Debakey Vet Affairs Med Ctr, Houston, TX USA. Rush Univ, Med Ctr, Chicago, IL USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0008-543X J9 CANCER CYTOPATHOL JI Cancer Cytopathol. PD OCT 25 PY 2006 VL 108 IS 5 SU S BP 415 EP 415 PG 1 WC Oncology; Pathology SC Oncology; Pathology GA 098MC UT WOS:000241523700154 ER PT J AU Liu, JH Zingmond, DS McGory, ML SooHoo, NF Ettner, SL Brook, RH Ko, CY AF Liu, Jerome H. Zingmond, David S. McGory, Marcia L. SooHoo, Nelson F. Ettner, Susan L. Brook, Robert H. Ko, Clifford Y. TI Disparities in the utilization of high-volume hospitals for complex surgery SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID TRANSLUMINAL CORONARY ANGIOPLASTY; UNITED-STATES; OPERATIVE MORTALITY; SURGICAL MORTALITY; UNINSURED ADULTS; OUTCOMES; ASSOCIATION; HEALTH; RISK; RACE AB Context Referral to high-volume hospitals has been recommended for operations with a demonstrated volume-outcome relationship. The characteristics of patients who receive care at low-volume hospitals may be different from those of patients who receive care at high-volume hospitals. These differences may limit their ability to access or receive care at a high-volume hospital. Objective To identify patient characteristics associated with the use of high-volume hospitals, using California's Office of Statewide Health Planning and Development patient discharge database. Design, Setting, and Participants Retrospective study of Californians receiving the following inpatient operations from 2000 through 2004: elective abdominal aortic aneurysm repair, coronary artery bypass grafting, carotid endarterectomy, esophageal cancer resection, hip fracture repair, lung cancer resection, cardiac valve replacement, coronary angioplasty, pancreatic cancer resection, and total knee replacement. Main Outcome Measures Patient race/ethnicity and insurance status in high-volume ( highest 20% of patients by mean annual volume) and in low-volume ( lowest 20%) hospitals. Results A total of 719 608 patients received 1 of the 10 operations. Overall, non-whites, Medicaid patients, and uninsured patients were less likely to receive care at high-volume hospitals and more likely to receive care at low-volume hospitals when controlling for other patient-level characteristics. Blacks were significantly ( P <. 05) less likely than whites to receive care at high-volume hospitals for 6 of the 10 operations ( relative risk [RR] range, 0.40-0.72), while Asians and Hispanics were significantly less likely to receive care at high-volume hospitals for 5 ( RR range, 0.60-0.91) and 9 ( RR range, 0.46-0.88), respectively. Medicaid patients were significantly less likely than Medicare patients to receive care at high-volume hospitals for 7 of the operations ( RR range, 0.22-0.66), while uninsured patients were less likely to be treated at high-volume hospitals for 9 ( RR range, 0.20-0.81). Conclusions There are substantial disparities in the characteristics of patients receiving care at high-volume hospitals. The interest in selective referral to high-volume hospitals should include explicit efforts to identify the patient and system factors required to reduce current inequities regarding their use. C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Ctr Surg Outcomes & Qual, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Orthopaed Surg, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA. RAND Corp, Santa Monica, CA USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. RP Ko, CY (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Ctr Surg Outcomes & Qual, 10833 Le Conte Ave,72-215 CHS,Box 956904, Los Angeles, CA 90095 USA. EM cko@mednet.ucla.edu FU NIA NIH HHS [1K08AG023024] NR 33 TC 238 Z9 238 U1 2 U2 7 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD OCT 25 PY 2006 VL 296 IS 16 BP 1973 EP 1980 DI 10.1001/jama.296.16.1973 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 098BL UT WOS:000241495300019 PM 17062860 ER PT J AU Duda, JE AF Duda, J. E. TI Striatal pathology in the Lewy body disorders SO JOURNAL OF THE NEUROLOGICAL SCIENCES LA English DT Meeting Abstract CT International Symposium on Dementia in Parkinson's Disease CY OCT 24-27, 2004 CL Salzburg, AUSTRIA C1 Philadelphia VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0022-510X J9 J NEUROL SCI JI J. Neurol. Sci. PD OCT 25 PY 2006 VL 248 IS 1-2 MA 199 BP 323 EP 323 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 109JX UT WOS:000242305200244 ER PT J AU El-Shewy, HM Johnson, KR Lee, MH Jaffa, AA Obeid, LM Luttrell, LM AF El-Shewy, Hesham M. Johnson, Korey R. Lee, Mi-Hye Jaffa, Ayad A. Obeid, Lina M. Luttrell, Louis M. TI Insulin-like growth factors mediate heterotrimeric G protein-dependent ERK1/2 activation by transactivating sphingosine 1-phosphate receptors SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID FACTOR-I RECEPTOR; BC3H-1 MURINE MYOCYTES; MANNOSE 6-PHOSPHATE; SPHINGOSINE 1-PHOSPHATE; KINASE-C; FACTOR-II/MANNOSE-6-PHOSPHATE RECEPTOR; G(BETA-GAMMA) SUBUNITS; BETA-ARRESTIN; EGF RECEPTOR; CELLS AB Although several studies have shown that a subset of insulin-like growth factor (IGF) signals require the activation of heterotrimeric G proteins, the molecular mechanisms underlying IGF-stimulated G protein signaling remain poorly understood. Here, we have studied the mechanism by which endogenous IGF receptors activate the ERK1/2 mitogen-activated protein kinase cascade in HEK293 cells. In these cells, treatment with pertussis toxin and expression of a G alpha(q/11)-305-359) peptide that inhibits G(q/11) signaling additively inhibited IGF-stimulated ERK1/2 activation, indicating that the signal was almost completely G protein-dependent. Treatment with IGF-1 or IGF-2 promoted translocation of green fluorescent protein (GFP)-tagged sphingosine kinase (SK) 1 from the cytosol to the plasma membrane, increased endogenous SK activity within 30 s of stimulation, and caused a statistically significant increase in intracellular and extracellular sphingosine 1-phosphate (S1P) concentration. Using a GFP-tagged S1P(1) receptor as a biological sensor for the generation of physiologically relevant S1P levels, we found that IGF-1 and IGF-2 induced GFP-S1P receptor internalization and that the effect was blocked by pretreatment with the SK inhibitor, dimethylsphingosine. Treating cells with dimethylsphingosine, silencing SK1 expression by RNA interference, and blocking endogenous S1P receptors with the competitive antagonist VPC23019 all significantly inhibited IGF-stimulated ERK1/2 activation, suggesting that IGFs elicit G protein-dependent ERK1/2 activation by stimulating SK1-dependent transactivation of S1P receptors. Given the ubiquity of SK and S1P receptor expression, S1P receptor transactivation may represent a general mechanism for G protein-dependent signaling by non-G protein-coupled receptors. C1 Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC 29401 USA. RP Luttrell, LM (reprint author), Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, 96 Jonathan Lucas St,816 CSB,POB 250624, Charleston, SC 29425 USA. EM luttrell@musc.edu OI obeid, lina/0000-0002-0734-0847 FU NIDDK NIH HHS [DK58283]; NIGMS NIH HHS [GM62887] NR 58 TC 53 Z9 54 U1 0 U2 4 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD OCT 20 PY 2006 VL 281 IS 42 BP 31399 EP 31407 DI 10.1074/jbc.M605339200 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 094JI UT WOS:000241235300024 PM 16926156 ER PT J AU Lorenz, KA Lynn, J Dy, S Wilkinson, A Mularski, RA Shugarman, LR Hughes, R Asch, SM Rolon, C Rastegar, A Shekelle, PG AF Lorenz, Karl A. Lynn, Joanne Dy, Sydney Wilkinson, Anne Mularski, Richard A. Shugarman, Lisa R. Hughes, Rhonda Asch, Steven M. Rolon, Cony Rastegar, Afshin Shekelle, Paul G. TI Quality measures for symptoms and advance care planning in cancer: A systematic review SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article; Proceedings Paper CT Annual Meeting of the American-Academy-of-Hospice-and-Palliative-Medicine CY FEB 08-11, 2006 CL Nashville, TN SP Amer Acad Hospice & Palliat Med ID HEALTH-ORGANIZATION GUIDELINES; PAIN MANAGEMENT; OF-LIFE; PALLIATIVE CARE; HOSPICE CARE; VALIDATION; RELIEF; END; IMPLEMENTATION; IMPROVEMENT AB Purpose Measuring quality of care for symptom management and ascertaining patient goals offers an important step toward improving palliative cancer management. This study was designed to identify systematically the quality measures and the evidence to support their use in pain, dyspnea, depression, and advance care planning (ACP), and to identify research gaps. Methods English-language documents were selected from MEDLINE, Cumulative Index to Nursing and Allied Health, PsycINFO ( 1995 to 2005); Internet-based searches; and contact with measure developers. We used terms for each domain to select studies throughout the cancer care continuum. We included measures that expressed a normative relationship to quality, specified the target population, and specified the indicated care. Dual data review and abstraction was performed by palliative care researchers describing populations, testing, and attributes for each measure. Results A total of 4,599 of 5,182 titles were excluded at abstract review. Of 537 remaining articles, 19 contained measures for ACP, six contained measures for depression, five contained measures for dyspnea, and 20 contained measures for pain. We identified 10 relevant measure sets that included 36 fully specified or fielded measures and 14 additional measures ( 16 for pain, five for dyspnea, four for depression, and 25 for ACP). Most measures were unpublished, and few had been tested in a cancer population. We were unable to describe the specifications of all measures fully and did not search for measures for pain and depression that were not cancer specific. Conclusion Measures are available for assessing quality and guiding improvement in palliative cancer care. Existing measures are weighted toward ACP, and more nonpain symptom measures are needed. Additional testing is needed before the measures are used for accountability, and basic research is required to address measurement when self-report is impaired. C1 VA Greater Los Angeles Healthcare Syst, Div Gen Internal Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Geffen Sch Med, Los Angeles, CA USA. RAND, So Calif Evidence Based Practice Ctr, Santa Monica, CA USA. Agcy Healthcare Res & Qual, Rockville, MD USA. Johns Hopkins Univ, Sch Publ Hlth, Baltimore, MD USA. RP Lorenz, KA (reprint author), VA Greater Los Angeles Healthcare Syst, Div Gen Internal Med, 11301 Wilshire Blvd,Code 111-G, Los Angeles, CA 90073 USA. EM karl.lorenz@med.va.gov NR 45 TC 50 Z9 51 U1 0 U2 4 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 330 JOHN CARLYLE ST, STE 300, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD OCT 20 PY 2006 VL 24 IS 30 BP 4933 EP 4938 DI 10.1200/JCO.2006.06.8650 PG 6 WC Oncology SC Oncology GA 098CF UT WOS:000241497900023 PM 17050878 ER PT J AU Ho, PM Rumsfeld, JS AF Ho, P. Michael Rumsfeld, John S. TI Beyond inpatient and outpatient care: alternative model for hypertension management SO BMC PUBLIC HEALTH LA English DT Editorial Material ID BLOOD-PRESSURE AB Hypertension is a major contributor to worldwide cardiovascular mortality, however, only one-third of patients with hypertension have their blood pressure treated to guideline recommended levels. To improve hypertension control, there may need to be a fundamental shift in care delivery, one that is population-based and simultaneously addresses patient, provider and system barriers. One potential approach is home-based disease management, based on the triad of home monitoring, team care, and patient self-care. Although there may be challenges to achieving the vision of home-based disease management, there are tremendous potential benefits of such an approach for reducing the global burden of cardiovascular disease. C1 Denver VA Med Ctr, Cardiol Sect, Denver, CO 80220 USA. RP Ho, PM (reprint author), Denver VA Med Ctr, Cardiol Sect, 1055 Clermont St 111B, Denver, CO 80220 USA. EM Michael.Ho@UCHSC.edu; John.Rumsfeld@va.gov NR 7 TC 11 Z9 12 U1 0 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND SN 1471-2458 J9 BMC PUBLIC HEALTH JI BMC Public Health PD OCT 19 PY 2006 VL 6 AR 257 DI 10.1186/1471-2458-6-257 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 098JQ UT WOS:000241517200001 PM 17052330 ER PT J AU Ioannou, GN Liou, IW Weiss, NS AF Ioannou, G. N. Liou, I. W. Weiss, N. S. TI Serum bilirubin and risk of colorectal cancer: authors' reply SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Letter ID POPULATION C1 Univ Washington, NW Hepatitis C Resource Ctr, Seattle, WA 98195 USA. Univ Washington, Res Enhancement Award Program, Seattle, WA 98195 USA. Univ Washington, Div Gastroenterol, Dept Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. Univ Washington, Div Gastroenterol, Dept Med, Seattle, WA 98195 USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. RP Ioannou, GN (reprint author), Univ Washington, NW Hepatitis C Resource Ctr, Seattle, WA 98195 USA. EM georgei@medicine.washington.edu NR 2 TC 0 Z9 0 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0269-2813 J9 ALIMENT PHARM THERAP JI Aliment. Pharmacol. Ther. PD OCT 15 PY 2006 VL 24 IS 8 BP 1259 EP 1261 DI 10.1111/j.1365-2036.2006.03101.x PG 4 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA 086FZ UT WOS:000240660500014 ER PT J AU Taylor, SE Lehman, BJ Kiefe, CI Seeman, TE AF Taylor, Shelley E. Lehman, Barbara J. Kiefe, Catarina I. Seeman, Teresa E. TI Relationship of early life stress and psychological functioning to adult C-reactive protein in the coronary artery risk development in young adults study SO BIOLOGICAL PSYCHIATRY LA English DT Article DE stress; family; health; SES; comorbidities; HPA ID SOCIOECONOMIC-STATUS; CARDIOVASCULAR-DISEASE; INFLAMMATORY MARKERS; FAMILY ENVIRONMENT; LINKING DEPRESSION; PHYSICAL HEALTH; ASSOCIATION; METAANALYSIS; EXPRESSION; MEDIATORS AB Background: Low socioeconomic status (SES) and a harsh family environment in childhood have been linked to mental and physical health disorders in adulthood. The objective of the present investigation was to evaluate a developmental model of pathways that may help explain these links and to relate them to C-reactive protein (CRP) in the Coronary Artery Risk Development in Young Adults (CARDIA) dataset. Methods: Participants (n = 3248) in the CARDLA study, age 32 to 47 years, completed measures of childhood SES(CSES), early family environment (risky families [RF]), adult psychosocial functioning (PsyF, a latent factor measured by depression, mastery, and positive and negative social contacts), body mass index (BMI), and C-reactive protein. Results: Structural equation modeling indicated that CSES and RF are associated with C-reactive protein via their association with PsyF (standardized path coefficients: CSES to RF, RF to PsyF, PsyF to CRP, CSES to CRI all p < .05), with good overall modelfit. The association between PsyF and CRP was partially mediated by BMI (PsyF to BMI, BMI to CRP, both p < .05). Conclusions: Low childhood SES and a harsh early family environment appear to be related to elevated C-reactive protein in adulthood through pathways involving psychosocial dysfunction and high body mass index. C1 Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Dept Geriatr, Los Angeles, CA 90095 USA. Univ Alabama, Div Prevent Med, Birmingham, AL USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Taylor, SE (reprint author), Univ Calif Los Angeles, Dept Psychol, 1282A Franz Hall,405 Hilgard Ave, Los Angeles, CA 90095 USA. EM taylors@psych.ucla.edu FU NHLBI NIH HHS [N01-HC-48047, N01-HC-05187, N01-HC-45134, N01-HC-48048, N01-HC-48049, N01-HC-48050, N01-HC-95095]; NIMH NIH HHS [MH15750, R01-MH56880-05] NR 39 TC 137 Z9 139 U1 1 U2 13 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD OCT 15 PY 2006 VL 60 IS 8 BP 819 EP 824 DI 10.1016/j.biopsych.2006.03.016 PG 6 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 094UH UT WOS:000241264100007 PM 16712805 ER PT J AU Roodman, GD AF Roodman, G. David TI New potential targets for treating myeloma bone disease SO CLINICAL CANCER RESEARCH LA English DT Article; Proceedings Paper CT Conference on Advances in Treating Metastatic Bone Cancer CY OCT 28-29, 2005 CL Cambridge, MA ID INFLAMMATORY PROTEIN-1 ALPHA; MULTIPLE-MYELOMA; OSTEOLYTIC LESIONS; CELLS; EXPRESSION; DIFFERENTIATION; DESTRUCTION; INHIBITION; 1-ALPHA; MODEL AB Purpose: Myeloma bone disease results, in severe pain and pathologic fractures in >80% of patients. Myeloma bone disease is characterized, by both increased osteoclast activity and suppressed new bone formation. The basis for both, the increased bone destruction and decreased bone formation has been a topic of extensive investigation during the last several years. Experimental Design: Marrow samples for patients with myeloma were screened by both molecular biological and gene expression profiling techniques to identify factors that may be responsible for the enhanced bone destruction and suppressed bone formation in patients with the disease. Results: Several novel factors have been identified that directly stimulate osteoclastic bone destruction in myeloma. These include receptor activation NF-kappa B ligand, macrophage inflammatory peptide 1 alpha and interleukin (IL)-3. All of these factors are increased in most patients with myeloma. Furthermore osteoprotegerin levels are markedly suppressed, further driving osteoclast formation. In addition, four novel inhibitors of osteoblast differentiation or activity have been identified. These include two inhibitors of the Wnt signaling pathway. DKK1 and soluble frizzled protein 2. The Wnt signaling pathway is critical for osteoblast differentiation. Two cytokines IL-3 and IL-7, have also been reported that directly or indirectly inhibit osteoblast differentiation in patients with myeloma. Interestingly, increased macrophage inflammatory peptide 1 alpha, IL-3 and IL-7 result from abnormal transcriptional regulation of these genes by increased levels of acute myelogenous leukemia-1 to acute myelogenous leukemia-1B transcription factors. Conclusions: The recent identification of novel stimulators of osteoclast activity and inhibitors of osteoblast differentiation provide new therapeutic targets for treating this devastating bone disease in patients with myeloma. C1 VA Pittsburgh Healthcare Syst, R&D, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Dept Med Hematol Oncol, Pittsburgh, PA USA. RP Roodman, GD (reprint author), VA Pittsburgh Healthcare Syst, R&D, 151-U,Room 2E-113,Univ Dr C, Pittsburgh, PA 15240 USA. EM roodmangd@upmc.edu NR 25 TC 14 Z9 17 U1 0 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 J9 CLIN CANCER RES JI Clin. Cancer Res. PD OCT 15 PY 2006 VL 12 IS 20 SU S BP 6270S EP 6273S DI 10.1158/1078-0432.CCR-06-0845 PN 2 PG 4 WC Oncology SC Oncology GA 099AC UT WOS:000241563900011 PM 17062712 ER PT J AU Musher, DM Rueda-Jaimes, AM Graviss, EA Rodriguez-Barradas, MC AF Musher, Daniel M. Rueda-Jaimes, Adriana M. Graviss, Edward A. Rodriguez-Barradas, Maria C. TI Effect of pneumococcal vaccination: A comparison of vaccination rates in patients with bacteremic and nonbacteremic pneumococcal pneumonia SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID POLYSACCHARIDE VACCINE; STREPTOCOCCUS-PNEUMONIAE; EFFICACY; DISEASE; ADULTS AB Background. Despite the widespread acceptance of the 23-valent pneumococcal capsular polysaccharide vaccine (PPV), its protective effect continues to be disputed. We describe a novel approach to examine the protective effect of this vaccine. Methods. We recorded the vaccination status of every patient for whom a culture yielded Streptococcus pneumoniae during a 4.5-year period, comparing rates of prior PPV administration in patients with ( 1) bacteremic pneumococcal pneumonia, ( 2) all-invasive pneumococcal disease, ( 3) nonbacteremic pneumococcal pneumonia, ( 4) acute exacerbation of chronic bronchitis (AECB) due to S. pneumoniae, and ( 5) pneumococcal colonization. The principal comparisons were with patients who had bacteremic pneumonia or any invasive pneumococcal disease and those with nonbacteremic pneumococcal pneumonia. We also compared vaccination rates in patients who had nonbacteremic pneumonia with vaccination rates in patients with AECB or pneumococcal colonization. Results. The rate of prior PPV vaccination was lower among patients with bacteremic pneumococcal pneumonia (39.7%) or any invasive pneumococcal disease (38.0%) than among patients with nonbacteremic pneumonia (57.6%), AECB (60.0%), or pneumococcal colonization (57.8%). PPV conferred a 54% protection rate against bacteremic versus nonbacteremic pneumococcal pneumonia. There was no apparent protection against nonbacteremic pneumonia compared, for example, with colonized persons or with those who had AECB. Conclusions. PPV provides moderate protection against invasive pneumococcal disease but does not protect against nonbacteremic pneumococcal pneumonia. These findings suggest the importance of a continued search for a better pneumococcal vaccine. C1 Michael E DeBakey Vet Affairs Med Ctr, Infect Dis Sect, Med Serv, Houston, TX 77030 USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA. Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA. RP Musher, DM (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Infect Dis Sect, Med Serv, Rm 4B-370,2002 Holcombe Blvd, Houston, TX 77030 USA. EM daniel.musher@med.va.gov NR 19 TC 33 Z9 33 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 15 PY 2006 VL 43 IS 8 BP 1004 EP 1008 DI 10.1086/507699 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 086IE UT WOS:000240666200009 PM 16983612 ER PT J AU Hamill, RJ AF Hamill, Richard J. TI Free fluconazole for cryptococcal meningitis: Too little of a good thing? SO CLINICAL INFECTIOUS DISEASES LA English DT Editorial Material ID ACQUIRED-IMMUNODEFICIENCY-SYNDROME; AMPHOTERICIN-B; ANTIRETROVIRAL THERAPY; AIDS; NEOFORMANS; DISEASE C1 Michael E DeBakey Vet Affairs Med Ctr, Infect Dis Sect, Houston, TX 77030 USA. Baylor Coll Med, Dept Med, Cardiol Sect, Houston, TX 77030 USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA. RP Hamill, RJ (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Infect Dis Sect, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM rhamill@bcm.tmc.edu NR 16 TC 11 Z9 14 U1 1 U2 3 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 15 PY 2006 VL 43 IS 8 BP 1074 EP 1076 DI 10.1086/507900 PG 3 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 086IE UT WOS:000240666200020 PM 16983623 ER PT J AU Im, JS Tapinos, N Chae, GT Illarionov, PA Besra, GS DeVries, GH Modlin, RL Sieling, PA Rambukkana, A Porcelli, SA AF Im, Jin S. Tapinos, Nikos Chae, Gue-Tae Illarionov, Petr A. Besra, Gurdyal S. DeVries, George H. Modlin, Robert. L. Sieling, Peter A. Rambukkana, Anura Porcelli, Steven A. TI Expression of CD1d molecules by human Schwann cells and potential interactions with immunoregulatory invariant NK T cells SO JOURNAL OF IMMUNOLOGY LA English DT Article ID CHEMOKINE RECEPTOR EXPRESSION; C VIRUS-INFECTION; MYCOBACTERIUM-LEPRAE; GLYCOLIPID ANTIGENS; MULTIPLE-SCLEROSIS; PERIPHERAL-NERVE; IN-VITRO; RECOGNITION; LEPROSY; ACTIVATION AB CD1d-restricted NKT cells expressing invariant TCR alpha-chains (iNKT cells) produce both proinflammatory and anti-inflammatory cytokines rapidly upon activation, and are believed to play an important role in both host defense and immunoregulation. To address the potential implications of iNKT cell responses for infectious or inflammatory diseases of the nervous system, we investigated the expression of CD1d in human peripheral nerve. We found that CD1d was expressed on the surface of Schwann cells in situ and on primary or immortalized Schwann cell lines in culture. Schwann cells activated iNKT cells in a CD1d-dependent manner in the presence of a-galactosylceramide. Surprisingly, the cytokine production of iNKT cells stimulated by a-galactosylceramide presented by CD1d(+) Schwann cells showed a predominance of Th2-associated cytokines such as IL-5 and IL-13 with a marked deficiency of proinflammatory Th1 cytokines such as IFN-gamma or TNF-alpha. Our findings suggest a mechanism by which iNKT cells may restrain inflammatory responses in peripheral nerves, and raise the possibility that the expression of CD1d by Schwann cells could be relevant in the pathogenesis of infectious and inflammatory diseases of the peripheral nervous system. C1 Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA. Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA. Rockefeller Univ, Lab Bacterial Pathogenesis & Immunol, New York, NY 10021 USA. Catholic Univ, Inst Hansens Dis, Seoul, South Korea. Univ Birmingham, Sch Biosci, Birmingham, W Midlands, England. US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. Univ Calif Los Angeles, David Geffen Sch Med, Div Dermatol, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA. RP Porcelli, SA (reprint author), Albert Einstein Coll Med, Dept Microbiol & Immunol, 1300 Morris Pk Ave, Bronx, NY 10461 USA. OI Modlin, Robert/0000-0003-4720-031X; Besra, Gurdyal/0000-0002-5605-0395 FU Medical Research Council [G0400421]; NCI NIH HHS [CA 133330]; NIAID NIH HHS [AI 051519, AI 064424, AI 45816, AI 45889, AI 51391]; NIAMS NIH HHS [AR 40312]; NINDS NIH HHS [NS 45187]; Wellcome Trust [072021/Z/03/Z] NR 60 TC 21 Z9 21 U1 0 U2 6 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD OCT 15 PY 2006 VL 177 IS 8 BP 5226 EP 5235 PG 10 WC Immunology SC Immunology GA 092JP UT WOS:000241093100035 PM 17015708 ER PT J AU Lu, GW Maeda, H Reddy, SV Kurihara, N Leach, R Anderson, JL Roodman, GD AF Lu, Ganwei Maeda, Hidefumi Reddy, Sakamuri V. Kurihara, Noriyoshi Leach, Robin Anderson, Judith L. Roodman, G. David TI Cloning and characterization of the annexin II receptor on human marrow stromal cells SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID OSTEOCLAST-STIMULATING FACTOR; HUMAN-BONE MARROW; A2 HETEROTETRAMER; GENE FAMILY; MEMBRANE; CULTURES; IDENTIFICATION; RESORPTION; DIFFERENTIATION; PRECURSORS AB Annexin II is a heterotetramer, consisting of two 11-kDa (p11) and two 36-kDa (p36) subunits, that is produced by osteoclasts and stimulates osteoclast formation. However, its receptor is unknown. We showed that annexin II binds to normal primary human marrow stromal cells and the Paget's marrow-derived PSV10 stromal cell line to induce osteoclast formation. I-125-Labeled annexin II binding assays with PSV10 cells demonstrated that there was a single class of annexin II receptors with a K-d of 5.79 nM and B-max of 2.13 x 10(5) receptors/cell. Annexin III or annexin V did not bind this receptor. Using I-125-labeled annexin II binding to screen NIH3T3 transfected with a human marrow cDNA expression library, we identified a putative annexin II receptor clone, which encoded a novel 26-kDa type I membrane receptor protein when expressed in HEK 293 cells. HEK 293 cells transformed with the cloned annexin II receptor cDNA showed a similar binding affinity to annexin II as that observed in PSV10 cells. Chemical cross-linking experiments with biotinylated annexin II and intact PSV10 cells identified a 55-kDa band on Western blot analysis that reacted with both an anti-p11 antibody and streptavidin but not anti-p36 antibody. A rabbit polyclonal antibody raised against the putative recombinant annexin II receptor also recognized the same 26-kDa protein band detected in PSV10 cells. Importantly, the annexin II receptor antibody dose-dependently blocked the stimulatory effects of annexin II on human osteoclast formation, demonstrating that the receptor mediates the effects of annexin II on osteoclast formation. C1 VA Pittsburgh Healthcare Syst, Med Hematol Oncol 151U, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Pittsburgh, PA 15240 USA. Kyushu Univ Hosp, Fukuoka 8128581, Japan. Med Univ S Carolina, Childrens Res Inst, Dept Pediat, Charleston, SC 29425 USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX 78229 USA. RP Roodman, GD (reprint author), VA Pittsburgh Healthcare Syst, Med Hematol Oncol 151U, Univ Dr C, Pittsburgh, PA 15240 USA. EM roodmangd@upmc.edu FU NIA NIH HHS [AG13625]; NIAMS NIH HHS [AR41336, AR44603] NR 37 TC 16 Z9 18 U1 0 U2 2 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD OCT 13 PY 2006 VL 281 IS 41 BP 30542 EP 30550 DI 10.1074/jbc.M607072200 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 092CZ UT WOS:000241075900030 PM 16895901 ER PT J AU Schneider, LS Tariot, PN Dagerman, KS Davis, SM Hsiao, JK Ismail, MS Lebowitz, BD Lyketsos, CG Ryan, JM Stroup, TS Sultzer, DL Weintraub, D Lieberman, JA AF Schneider, Lon S. Tariot, Pierre N. Dagerman, Karen S. Davis, Sonia M. Hsiao, John K. Ismail, M. Saleem Lebowitz, Barry D. Lyketsos, Constantine G. Ryan, J. Michael Stroup, T. Scott Sultzer, David L. Weintraub, Daniel Lieberman, Jeffrey A. CA CATIE-AD Study Grp TI Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID PLACEBO-CONTROLLED TRIALS; DIAGNOSTIC-CRITERIA; INTERNATIONAL WORKSHOP; CEREBROVASCULAR EVENTS; NEUROLEPTIC TREATMENT; DEMENTIA TRIALS; METAANALYSIS; DEPRESSION; PSYCHOSIS; RISK AB BACKGROUND Second-generation (atypical) antipsychotic drugs are widely used to treat psychosis, aggression, and agitation in patients with Alzheimer's disease, but their benefits are uncertain and concerns about safety have emerged. We assessed the effectiveness of atypical antipsychotic drugs in outpatients with Alzheimer's disease. METHODS In this 42-site, double-blind, placebo-controlled trial, 421 outpatients with Alzheimer's disease and psychosis, aggression, or agitation were randomly assigned to receive olanzapine (mean dose, 5.5 mg per day), quetiapine (mean dose, 56.5 mg per day), risperidone (mean dose, 1.0 mg per day), or placebo. Doses were adjusted as needed, and patients were followed for up to 36 weeks. The main outcomes were the time from initial treatment to the discontinuation of treatment for any reason and the number of patients with at least minimal improvement on the Clinical Global Impression of Change (CGIC) scale at 12 weeks. RESULTS There were no significant differences among treatments with regard to the time to the discontinuation of treatment for any reason: olanzapine (median, 8.1 weeks), quetiapine (median, 5.3 weeks), risperidone (median, 7.4 weeks), and placebo (median, 8.0 weeks) (P=0.52). The median time to the discontinuation of treatment due to a lack of efficacy favored olanzapine (22.1 weeks) and risperidone (26.7 weeks) as compared with quetiapine (9.1 weeks) and placebo (9.0 weeks) (P=0.002). The time to the discontinuation of treatment due to adverse events or intolerability favored placebo. Overall, 24% of patients who received olanzapine, 16% of patients who received quetiapine, 18% of patients who received risperidone, and 5% of patients who received placebo discontinued their assigned treatment owing to intolerability (P=0.009). No significant differences were noted among the groups with regard to improvement on the CGIC scale. Improvement was observed in 32% of patients assigned to olanzapine, 26% of patients assigned to quetiapine, 29% of patients assigned to risperidone, and 21% of patients assigned to placebo (P=0.22). CONCLUSIONS Adverse effects offset advantages in the efficacy of atypical antipsychotic drugs for the treatment of psychosis, aggression, or agitation in patients with Alzheimer's disease. C1 Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. Banner Alzheimers Inst, Phoenix, AZ USA. Quintiles, Res Triangle Pk, NC USA. NIMH, NIH, Bethesda, MD 20892 USA. Univ Rochester, Med Ctr, Rochester, NY 14642 USA. Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA. Johns Hopkins Univ, Johns Hopkins Bayview, Dept Psychiat, Baltimore, MD USA. Univ N Carolina, Sch Med, Chapel Hill, NC USA. Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Penn, Sch Med, Philadelphia, PA 19104 USA. Coll Phys & Surg, New York, NY USA. RP Schneider, LS (reprint author), Univ So Calif, Keck Sch Med, 1510 San Pablo St,HCC 600, Los Angeles, CA 90033 USA. EM lschneid@usc.edu RI ; Stroup, Thomas/F-9188-2014 OI Adler, Lawrence/0000-0002-6619-2493; Stroup, Thomas/0000-0002-3123-0672 NR 33 TC 558 Z9 564 U1 3 U2 30 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD OCT 12 PY 2006 VL 355 IS 15 BP 1525 EP 1538 DI 10.1056/NEJMoa061240 PG 14 WC Medicine, General & Internal SC General & Internal Medicine GA 093HW UT WOS:000241160400004 PM 17035647 ER PT J AU Marderosian, M Sharma, AP Funk, AP Vartanian, R Masri, J Jo, OD Gera, JF AF Marderosian, M. Sharma, A. P. Funk, A. P. Vartanian, R. Masri, J. Jo, O. D. Gera, J. F. TI Tristetraprolin regulates Cyclin D1 and c-myc mRNA stability in response to rapamycin in an Akt-dependent manner via p38 MAPK signaling SO ONCOGENE LA English DT Article DE akt; mTOR; rapamycin; cyclin D1; c-myc; tristetraprolin; mRNA stability ID ACTIVATED PROTEIN-KINASE; AU-RICH ELEMENTS; ENHANCED SENSITIVITY; MAMMALIAN-CELLS; BINDING PROTEIN; DOWN-REGULATION; TURNOVER; EXPRESSION; CANCER; TRANSLATION AB The differential expression of the critical cell cycle control proteins cyclin D1 and c-myc has been shown to result in Akt-dependent hypersensitivity of tumor cells to mTOR inhibitors. We have previously demonstrated that the differential utilization of internal ribosome entry sites within the mRNAs of these transcripts allows maintenance of protein synthesis in the face of rapamycin ( rapa) exposure in an Akt-dependent manner. Here, we demonstrate that in addition to this mechanism, cyclin D1 and c-myc mRNA stability is also coordinately regulated following rapa treatment depending on Akt activity status. We identify A/U-rich response elements within the 3' untranslated regions ( UTRs) of these transcripts, which confer the observed differential stabilities and show that the RNA-binding protein, tristetraprolin (TTP), interacts with these elements. We also present evidence that TTP accumulates in response to rapa exposure, binds to the cis-acting elements within the cyclin D1 and c-myc 3' UTRs and is differentially serine phosphorylated in an Akt-dependent manner. Furthermore, the differential phosphorylation status of TTP results in its sequestration by 14-3-3 proteins in quiescent Akt-containing cells. Finally, siRNA-mediated knockdown of TTP expression or inhibiting a known regulator of TTP phosphorylation, p38 MAP kinase, abolishes the effects on cyclin D1 and c-myc mRNA stability. We assume that the differential control of cyclin D1 and c-myc mRNA stability and translational efficiency constitutes a coordinate response to rapa contributing to the maintenance of expression of these determinants in rapa-resistant quiescent Akt-containing cells following exposure. C1 Greater Los Angeles VA Healthcare Syst, Dept Res & Dev, Sepulveda, CA 91343 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA USA. RP Gera, JF (reprint author), Greater Los Angeles VA Healthcare Syst, Dept Res & Dev, Bldg 1,Rm C111A, Sepulveda, CA 91343 USA. EM gera@ucla.edu FU NCI NIH HHS [R01-CA-109312] NR 52 TC 81 Z9 84 U1 2 U2 7 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0950-9232 J9 ONCOGENE JI Oncogene PD OCT 12 PY 2006 VL 25 IS 47 BP 6277 EP 6290 DI 10.1038/sj.onc.1209645 PG 14 WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity GA 094CY UT WOS:000241218200005 PM 16702957 ER PT J AU Nelson, JE Tandon, N Mercado, AF Camhi, SL Ely, W Morrison, S AF Nelson, Judith E. Tandon, Nidhi Mercado, Alice F. Camhi, Sharon L. Ely, Wesley Morrison, Sean TI Brain dysfunction - Another burden for the chronically critically ill SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID INTENSIVE-CARE-UNIT; MECHANICALLY VENTILATED PATIENTS; CONFUSION ASSESSMENT METHOD; CHRONIC CRITICAL ILLNESS; DELIRIUM; VALIDATION; STAY; ICU; RELIABILITY; IMPAIRMENT AB Background: Chronic critical illness is a devastating syndrome of prolonged respiratory failure and other derangements. To our knowledge, no previous research has addressed brain dysfunction in the chronically critically ill, although this topic is important for medical decision making. Methods: We studied a prospective cohort of 203 consecutive, chronically critically ill adults transferred to our hospital's respiratory care unit (RCU) after tracheotomy for failure to wean. We measured prevalence and duration of coma and delirium during RCU treatment using the Confusion Assessment Method for the Intensive Care Unit with the Richmond Agitation-Sedation Scale. To assess survivors (at 3 and 6 months after RCU discharge), we used a validated telephone Confusion Assessment Method. Results: Before hospitalization, most (153 [75.4%]) of the 203 patients in the study were at home, completely independent (115 [56.7%]), and cognitively intact (116 [82.0%]). In the RCU, 61 (30.0%) were comatose throughout the stay. Approximately half of patients (66 of 142) who were not in coma were delirious. Patients spent an average of 17.9 days (range, 1-153 days) in coma or delirium (average RCU stay, 25.6 days). Half of survivors (79 of 160) had one of these disturbances at RCU discharge. At 6 months, three fourths (151) of the study patients were dead or institutionalized; of 85 survivors, 58 (68.2%) were too profoundly impaired to respond to telephone cognitive assessment, and 53 (62.4%) were dependent in all activities of daily living. Conclusions: Severe, prolonged, and permanent brain dysfunction is a prominent feature of chronic critical illness. These data, together with previous reports of symptom distress and rates of mortality and institutionalization, describe burdens for chronically critically ill patients receiving continued life-prolonging treatment and for their families. C1 CUNY Mt Sinai Sch Med, Div Pulm & Crit Care, Dept Med, New York, NY 10029 USA. CUNY Mt Sinai Sch Med, Hertzberg Palliat Care Inst, Brookdale Dept Geriatr & Adult Dev, New York, NY 10029 USA. Vet Adm Tennessee Valley Geriatr Res, Educ & Clin Ctr, Nashville, TN USA. Vanderbilt Univ, Sch Med, Ctr Hlth Serv Res, Nashville, TN USA. Vanderbilt Univ, Sch Med, Dept Med, Div Allergy Pulmonary Crit Care Med, Nashville, TN USA. Bronx Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, New York, NY USA. RP Nelson, JE (reprint author), CUNY Mt Sinai Sch Med, Div Pulm & Crit Care, Dept Med, Box 1232,1 Gustave L Levy Pl, New York, NY 10029 USA. EM judith.nelson@mountsinai.org FU NIA NIH HHS [K02 AG024476, K23 AG01023, K24 AG022345, R01 AG21172] NR 40 TC 59 Z9 62 U1 4 U2 6 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD OCT 9 PY 2006 VL 166 IS 18 BP 1993 EP 1999 DI 10.1001/archinte.166.18.1993 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 091VV UT WOS:000241057300009 PM 17030833 ER PT J AU Parashar, S Rumsfeld, JS Spertus, JA Reid, KJ Wenger, NK Krumholz, HM Amin, A Weintraub, WS Lichtman, J Dawood, N Vaccarino, V AF Parashar, Susmita Rumsfeld, John S. Spertus, John A. Reid, Kimberly J. Wenger, Nanette K. Krumholz, Harlan M. Amin, Alpesh Weintraub, William S. Lichtman, Judith Dawood, Nazeera Vaccarino, Viola CA PREMIER Registry Investigators TI Time course of depression and outcome of myocardial infarction SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID CORONARY-HEART-DISEASE; QUALITY-OF-LIFE; MAJOR DEPRESSION; ENHANCING RECOVERY; RISK SCORE; MORTALITY; EVENTS; SYMPTOMS; ANGINA; SEVERITY AB Background: Depression predicts worse outcomes after myocardial infarction (MI), but whether its time course in the month following MI has prognostic importance is unknown. Our objective was to evaluate the prognostic importance of transient, new, or persistent depression on outcomes at 6 months after MI. Methods: In a prospective registry of acute MI ( Prospective Registry Evaluating outcomes after Myocardial Infarction: Events and Recovery [PREMIER]), depressive symptoms were measured in 1873 patients with the Patient Health Questionnaire (PHQ) during hospitalization and 1 month after discharge and were classified as transient (only at baseline), new (only at 1 month), or persistent (at both times). Outcomes at 6 months included (1) all-cause rehospitalization or mortality and (2) health status (angina, physical limitation, and quality of life using the Seattle Angina Questionnaire). Results: Compared with nondepressed patients, all categories of depression were associated with higher rehospitalization or mortality rates, more frequent angina, more physical limitations, and worse quality of life. The adjusted hazard ratios for rehospitalization or mortality were 1.34, 1.71, and 1.42 for transient, new, and persistent depression, respectively (all P < .05). Corresponding odds ratios were 1.62, 2.73, and 2.64 (all P < .01) for angina and 1.69, 2.25, and 3.27 (all P < .05) for physical limitation. Depressive symptoms showed a stronger association with health status compared with traditional measures of disease severity. Conclusion: Depressive symptoms after MI, irrespective of whether they persist, subside, or newly develop in the first month after hospitalization, are associated with worse outcomes after MI. C1 Emory Univ, Sch Med, Dept Med, Div Gen Med, Atlanta, GA 30303 USA. Emory Univ, Sch Med, Dept Med, Div Cardiol, Atlanta, GA 30303 USA. Denver VA Med Ctr, Denver, CO USA. St Lukes Hosp, Mid Amer Heart Inst, Kansas City, MO 64111 USA. Yale Univ, Sch Med, Sect Cardiovasc Med, Dept Med, New Haven, CT USA. Yale Univ, Sch Med, Sect Cardiovasc Med, Dept Epidemiol & Publ Hlth, New Haven, CT USA. Christiana Hosp, Ctr Heart & Vasc Hlth, Wilmington, DE USA. RP Parashar, S (reprint author), Emory Univ, Sch Med, Dept Med, Div Gen Med, Fac Off Bldg,49 Jesse Hill Jr Dr, Atlanta, GA 30303 USA. EM smallik@emory.edu FU NCCDPHP CDC HHS [K01-DP000085-01]; NCRR NIH HHS [K12-RR17643, K23-RR023171, MO1-RR00039]; NHLBI NIH HHS [K24-HL077506, R01-HL68630]; NIA NIH HHS [R01-AG026255] NR 26 TC 95 Z9 98 U1 0 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD OCT 9 PY 2006 VL 166 IS 18 BP 2035 EP 2043 DI 10.1001/archinte.166.18.2035 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 091VV UT WOS:000241057300016 PM 17030839 ER PT J AU Pan, S Wang, Y Quinn, JF Peskind, ER Waichunas, D Wimberger, JT Jin, JH Li, JG Zhu, D Pan, C Zhang, J AF Pan, Sheng Wang, Yan Quinn, Joseph F. Peskind, Elaine R. Waichunas, Dana Wimberger, Jake T. Jin, Jinghua Li, Jane G. Zhu, David Pan, Catherine Zhang, Jing TI Identification of glycoproteins in human cerebrospinal fluid with a complementary proteomic approach SO JOURNAL OF PROTEOME RESEARCH LA English DT Article DE mass spectrometry; proteomics; cerebrospinal fluid; glycoprotein; hydrazide chemistry; lectin affinity column ID TANDEM MASS-SPECTROMETRY; N-LINKED GLYCOPROTEINS; NEURODEGENERATIVE DISEASES; PROTEIN GLYCOSYLATION; BIOMARKER DISCOVERY; HYDRAZIDE CHEMISTRY; ALZHEIMERS-DISEASE; STATISTICAL-MODEL; HUMAN SERUM; DIAGNOSIS AB Biomarkers are pressingly needed to assist with the clinical diagnosis of neurodegenerative diseases and/or the monitoring of disease progression. Glycoproteins are enriched in bodily fluids such as human cerebrospinal fluid (CSF), an ideal source for discovering biomarkers due to its proximity to the central nervous system (CNS), and consequently can serve as diagnostic and/or therapeutic markers for CNS diseases. We report here an in-depth identification of glycoproteins in human CSF using a complementary proteomic approach which integrated hydrazide chemistry and lectin affinity column for glycoprotein enrichment, followed by multidimensional chromatography separation and tandem mass spectrometric analysis. Using stringent criteria, a total of 216 glycoproteins, including many low-abundance proteins, was identified with high confidence. Approximately one-third of these proteins was already known to be relevant to the CNS structurally or functionally. This investigation, for the first time, not only categorized many glycoproteins in human CSF but also expanded the existing overall CSF protein database. C1 Univ Washington, Sch Med, Div Neuropathol, Harborview Med Ctr,Dept Pathol, Seattle, WA 98104 USA. Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Inst Syst Biol, Seattle, WA 98103 USA. Oregon Hlth & Sci Univ, Portland, OR 97239 USA. Portland VA Med Ctr, Portland, OR 97239 USA. VA NW Network Mental Illness Res Educ & Clin Ctr, Va Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Zhang, J (reprint author), Univ Washington, Sch Med, Div Neuropathol, Harborview Med Ctr,Dept Pathol, Box 359635, Seattle, WA 98104 USA. EM zhangj@u.washington.edu RI Jin, Jinghua/G-6385-2010 FU NIA NIH HHS [AG05136, AG08017, AG08419, AG025327]; NIEHS NIH HHS [ES012703] NR 38 TC 68 Z9 70 U1 2 U2 6 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1535-3893 J9 J PROTEOME RES JI J. Proteome Res. PD OCT 6 PY 2006 VL 5 IS 10 BP 2769 EP 2779 DI 10.1021/pr060251s PG 11 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA 091UF UT WOS:000241053100029 PM 17022648 ER PT J AU Dobscha, SK Corson, K Hickam, DH Perrin, NA Kraemer, DF Gerrity, MS AF Dobscha, Steven K. Corson, Kathryn Hickam, David H. Perrin, Nancy A. Kraemer, Dale F. Gerrity, Martha S. TI Depression decision support in primary care - A cluster randomized trial SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID COMORBID MEDICAL ILLNESS; IMPROVING PRIMARY-CARE; MANAGED PRIMARY-CARE; COLLABORATIVE CARE; MAJOR DEPRESSION; TREATMENT GUIDELINES; OUTCOMES; DISORDERS; EDUCATION; IMPACT AB Background: Intensive collaborative interventions improve depression outcomes, but the benefit of less intensive interventions is not clear. Objective: To determine whether decision support improves outcomes for patients with depression. Design: Clinician-level, cluster randomized, controlled trial. Setting: 5 primary care clinics of 1 Veterans Affairs medical center. Participants: 41 primary care clinicians, and 375 patients with depression (Patient Health Questionnaire [PHQ-9] depression scores of 10 to 25 or Hopkins Symptom Checklist-20 [SCL-20] scores >= 1.0). Measurements: The primary outcome was change in depression score (SCL-20) at 6 and 12 months. Secondary outcomes were health-related quality-of-life (36-item Short Form for Veterans [SF-36V] score), patient satisfaction, antidepressant use, and health care utilization. Intervention: Clinicians received depression education and were randomly assigned to depression decision support or usual care. The depression decision support team, which consisted of a psychiatrist and nurse, provided 1 early patient educational contact and depression monitoring with feedback to clinicians over 12 months. Results: Although SCL-20 depression scores improved in both groups, the intervention had no effect compared with usual care. The difference in slopes comparing intervention and control over 12 months was 0.20 (95% Cl, -0.37 to 0.78; P = 0.49), which was neither clinically nor statistically significant. Changes in SF-36V scores also did not differ between groups. At 12 months, intervention patients reported greater satisfaction (P = 0.002) and were more likely to have had at least 1 mental health specialty appointment (41.1 % vs. 27.2%; P = 0.025), to have received any antidepressant (79.3% vs. 69.3%; P = 0.041), and to have received antidepressants for 90 days or more (76.2% vs. 61.6%; P 0.008). Limitations: Usual care clinicians received depression education and had on-site mental health support, which may have mitigated intervention effectiveness. Conclusions: Decision support improved processes of care but not depression outcomes. More intensive care management or specialty treatment may be needed to improve depression outcomes. C1 Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Portland, OR 97207 USA. Oregon State Univ, Portland, OR USA. RP Dobscha, SK (reprint author), Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, POB 1034 P3MHDC, Portland, OR 97207 USA. EM steven.dobscha@va.gov NR 64 TC 48 Z9 49 U1 4 U2 10 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD OCT 3 PY 2006 VL 145 IS 7 BP 477 EP 487 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 092JX UT WOS:000241093900001 PM 17015865 ER PT J AU Rubenstein, LV AF Rubenstein, Lisa V. TI Improving care for depression: There's no free lunch SO ANNALS OF INTERNAL MEDICINE LA English DT Editorial Material ID RANDOMIZED CONTROLLED-TRIAL; LATE-LIFE DEPRESSION; COST-EFFECTIVENESS; COLLABORATIVE CARE; MANAGEMENT; QUALITY; BENEFIT; IMPACT C1 VA Greater Los Angeles, Healthcare Syst, North Hills, CA 91343 USA. RAND Corp, Hlth Program, Santa Monica, CA 90406 USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 91343 USA. RP Rubenstein, LV (reprint author), VA Greater Los Angeles, Healthcare Syst, 16111 Plummer St 152, North Hills, CA 91343 USA. NR 21 TC 10 Z9 12 U1 4 U2 4 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD OCT 3 PY 2006 VL 145 IS 7 BP 544 EP 546 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 092JX UT WOS:000241093900009 PM 17015873 ER PT J AU Aplin, AC Gelati, M Fogel, E Carnevale, E Nicosia, RF AF Aplin, Alfred C. Gelati, Maurizio Fogel, Eric Carnevale, Edvige Nicosia, Roberto F. TI Angiopoietin-1 and vascular endothelial growth factor induce expression of inflammatory cytokines before angiogenesis SO PHYSIOLOGICAL GENOMICS LA English DT Article DE aorta; oligonucleotide microarray; gene profiling ID SMOOTH-MUSCLE-CELLS; TOLL-LIKE RECEPTORS; IN-VITRO; GENE-EXPRESSION; RAT AORTA; VESSEL FORMATION; INNATE IMMUNITY; TIE2 RECEPTOR; VEGF; MIGRATION AB The purpose of this study was to identify novel transcriptional events occurring in the aortic wall before angiogenesis. We used a defined tissue culture system that takes advantage of the capacity of rat aortic rings to generate neovessels ex vivo in response to angiogenic factor stimulation. Total RNA isolated from aortic rings 18 h posttreatment with angiopoietin (Ang)-1 or vascular endothelial growth factor (VEGF) was used to probe oligonucleotide microarrays. Many genes were up- or downregulated by either Ang-1 or VEGF, with a subset being affected by treatment with both growth factors. Grouping of genes by biological function revealed that Ang-1 and VEGF both upregulated a host of immune-related genes including many inflammatory cytokines. A mixture of the Ang-1- and VEGF-induced cytokines stimulated the spontaneous angiogenic response of aortic rings and was synergistic with a low dose of recombinant VEGF. This effect was associated with enhanced recruitment of adventitial macrophages and dendritic cells in the angiogenic outgrowths. Thus Ang-1 and VEGF activate the innate immune system of the vessel wall, stimulating the production of proangiogenic inflammatory cytokines before the emergence of neovessels. This hitherto unreported feature of the angiogenic response might represent an important early component of the cellular and molecular cascade responsible for the angiogenic response of the aortic wall. C1 VA Puget Sound Hlth Care Syst, Div Pathol & Lab Med, Lab S113, Seattle, WA 98108 USA. Carlo Besta Inst, Lab Neurobiol & Neuroregenerat Med, Milan, Italy. Univ Washington, Dept Pathol, Seattle, WA 98195 USA. RP Nicosia, RF (reprint author), VA Puget Sound Hlth Care Syst, Div Pathol & Lab Med, Lab S113, 1660 S Columbian Way, Seattle, WA 98108 USA. EM roberto.nicosia@va.gov RI Gelati, Maurizio/H-2110-2016 OI Gelati, Maurizio/0000-0002-4828-9849 FU NHLBI NIH HHS [HL-52585, HL-072370] NR 59 TC 40 Z9 43 U1 0 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1094-8341 J9 PHYSIOL GENOMICS JI Physiol. Genomics PD OCT 3 PY 2006 VL 27 IS 1 BP 20 EP 28 DI 10.1152/physiolgenomics.00048.2006 PG 9 WC Cell Biology; Genetics & Heredity; Physiology SC Cell Biology; Genetics & Heredity; Physiology GA 090XJ UT WOS:000240987500003 PM 17018690 ER PT J AU Duarte, A Hayasaka, S Du, AT Schuff, N Jahng, GH Kramer, J Miller, B Weiner, M AF Duarte, Audrey Hayasaka, Satoru Du, Antao Schuff, Norbert Jahng, Geon-Ho Kramer, Joel Miller, Bruce Weiner, Michael TI Volumetric correlates of memory and executive function in normal elderly, mild cognitive impairment and Alzheimer's disease SO NEUROSCIENCE LETTERS LA English DT Article DE mild cognitive impairment; Alzheimer's; correlation; volumetry; memory; executive ID VOXEL-BASED MORPHOMETRY; GRAY-MATTER LOSS; HIPPOCAMPAL VOLUME; STRUCTURAL MRI; TEMPORAL-LOBE; OLDER-ADULTS; ATROPHY; AD; RECOLLECTION; FAMILIARITY AB In Alzheimer's disease (AD), atrophy negatively impacts cognition while in healthy adults, inverse relationships between brain volume and cognition may occur. We investigated correlations between gray matter volume and cognition in elderly controls, AD and mild cognitive impairment (MCI) patients with memory and executive deficits. AD demonstrated substantial loss in temporal, parietal and frontal regions while MCI exhibited moderate volume loss in temporal and frontal regions. In controls, memory and executive function were negatively correlated with frontal regions, while in AD, memory was positively correlated with temporal and frontal gyri, and executive function with frontal regions. The combination of the two patterns may explain the lack of correlations in MCI. Developmental versus pathological contributions to these relationships are discussed. (c) 2006 Elsevier Ireland Ltd. All rights reserved. C1 San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA USA. Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA. Univ Calif San Francisco, Memory & Aging Ctr, San Francisco, CA 94143 USA. RP Duarte, A (reprint author), MRC, Cognit & Brain Sci Unit, 15 Chaucer Rd, Cambridge CB2 2EF, England. EM audrey.duarte@mrc-cbu.cam.ac.uk FU NIA NIH HHS [2R01AG10897-18, P01 AG012435, R01 AG010897] NR 27 TC 42 Z9 46 U1 0 U2 5 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0304-3940 J9 NEUROSCI LETT JI Neurosci. Lett. PD OCT 2 PY 2006 VL 406 IS 1-2 BP 60 EP 65 DI 10.1016/j.neulet.2006.07.029 PG 6 WC Neurosciences SC Neurosciences & Neurology GA 087XH UT WOS:000240775600012 PM 16904823 ER PT J AU Watnick, S AF Watnick, Suzanne TI Obesity: A problem of Darwinian proportions? SO ADVANCES IN CHRONIC KIDNEY DISEASE LA English DT Article DE obesity; chronic kidney disease; dialysis; kidney transplantation; bioethics ID BODY-MASS INDEX; STAGE RENAL-DISEASE; CHRONIC KIDNEY-DISEASE; CARDIOVASCULAR-DISEASE; HEMODIALYSIS-PATIENTS; METABOLIC SYNDROME; FOLLOW-UP; MORTALITY; DIALYSIS; SURVIVAL AB Obesity has been described as an abnormality arising from the evolution of man, who becomes fat during the time of perpetual plenty. From the perspective of "Darwinian Medicine," if famine is avoided, obesity will prevail. Problems regarding obesity arise within many disciplines, including socioeconomic environments, the educational system, science, law, and government. This article will discuss various ethical aspects of several disciplines regarding obesity, with a focus on scientific inquiry. We will discuss this within the categories: (1) chronic kidney disease predialysis, (2) dialysis, and (3) renal transplantation. This article aims to help nephrologists and their patients navigate through the ethical aspects of obesity and chronic kidney disease. (c) 2006 by the National Kidney Foundation, Inc. C1 Portland VA Med Ctr, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Div Nephrol & Hypertens, Dept Med, Portland, OR 97201 USA. RP Watnick, S (reprint author), Portland VA Med Ctr, 3710 SW US Vet Hosp Dr,P3NEPH, Portland, OR 97239 USA. EM watnicks@ohsu.edu NR 37 TC 7 Z9 7 U1 0 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1548-5595 J9 ADV CHRONIC KIDNEY D JI Adv. Chronic Kidney Dis. PD OCT PY 2006 VL 13 IS 4 BP 428 EP 432 DI 10.1053/j.ackd.2006.07.005 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 096SH UT WOS:000241396600013 PM 17045229 ER PT J AU Fernandez, E Koek, W Ran, QT Gerhardt, GA France, CP Strong, R AF Fernandez, Elizabeth Koek, Wouter Ran, Qitao Gerhardt, Greg A. France, Charles P. Strong, Randy TI Monoamine metabolism and behavioral responses to ethanol in mitochondrial aldehyde dehydrogenase knockout mice SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE mitochondrial aldehyde dehydrogenase; ALDH2; monoamines; ethanol ID RETINOIC ACID SYNTHESIS; RAT-LIVER; ALCOHOL SENSITIVITY; DOPAMINE METABOLISM; BIOGENIC ALDEHYDES; PREFERENCE; MOUSE; ACETALDEHYDE; OXIDATION; DAIDZIN AB Background: It is widely accepted that, in addition to removing acetaldehyde produced during the metabolism of ethanol, mitochondrial aldehyde dehydrogenase (ALDH2) functions in the pathway by which aldehyde metabolites of the monoamines dopamine (DA) and serotonin (5-HT) are converted to their acidic metabolites. Moreover, studies of ALDH2 inhibitors used for treating alcoholism suggest that their antidipsotropic effects may be related to inhibition of monoamine metabolism. Therefore, we examined the hypothesis that altered brain monoamine metabolism is related to the influence of ALDH2 on behavioral responses to ethanol. Methods: Mice were generated with a gene-trap mutation of the ALDH2 gene. ALDH2 mRNA was absent in ALDH2-/- mice. Western blot analysis of liver mitochondria confirmed the absence of ALDH2 protein in the ALDH2-/- mice. Wild-type and ALDH2-deficient mice were tested for the effects of different doses of ethanol on locomotor activity, ataxia, and a 2-bottle ethanol-water preference test. Results: Wild-type and ALDH2+/- mice preferred ethanol to water. However, ALDH2-/- mice drank significantly less ethanol than wild-type or ALDH2+/- mice. Locomotor activity and ataxia were significantly more affected by ethanol in ALDH2-/- mice than in wild-type or ALDH2+/- mice. There was no effect of genotype on levels of 5-HT, DA, or their precursors or metabolites in several brain regions, as measured by HPLCec. Conclusions: The results indicate that: (1) the effect of the mutant genotype on behavioral responses to ethanol is unrelated to altered brain monoamine metabolism and (2) ALDH2 is not required for the metabolism of brain monoamines in vivo. C1 Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78245 USA. Univ Texas, Hlth Sci Ctr, Dept Psychiat & Cellular & Struct Biol, San Antonio, TX 78245 USA. S Texas Vet Hlth Care Syst, Res Serv & Geriatr Res Educ & Clin Ctr, San Antonio, TX USA. Univ Kentucky, Albert B Chandler Med Ctr, Dept Anat & Neurobiol, Lexington, KY 40536 USA. Univ Kentucky, Albert B Chandler Med Ctr, Dept Neurol & Psychiat, Lexington, KY 40536 USA. RP Strong, R (reprint author), Univ Texas, Hlth Sci Ctr, Dept Pharmacol, 1355 Lambda Dr,MSC 7755, San Antonio, TX 78245 USA. EM strong@uthscsa.edu FU NIA NIH HHS [AG022307, AG022014]; NIDA NIH HHS [K05 DA017918, DA17198]; NINDS NIH HHS [NS039787] NR 37 TC 10 Z9 10 U1 1 U2 3 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD OCT PY 2006 VL 30 IS 10 BP 1650 EP 1658 DI 10.1111/j.1530-0277.2006.00200.x PG 9 WC Substance Abuse SC Substance Abuse GA 088NO UT WOS:000240818600009 PM 17010132 ER PT J AU Chapko, MK Dominitz, JA AF Chapko, M. K. Dominitz, J. A. TI Cost-effectiveness of growth factors during hepatitis C anti-viral therapy SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article ID ALPHA-2B PLUS RIBAVIRIN; HCV-INFECTED PATIENTS; RED-CELL APLASIA; RIBAVIRIN/INTERFERON-INDUCED ANEMIA; QUALITY-OF-LIFE; EPOETIN-ALPHA; PEGINTERFERON ALPHA-2B; COMBINATION THERAPY; INITIAL TREATMENT; INTERFERON-ALPHA AB Background Although the current standard of care for controlling anaemia and neutropenia during anti-viral therapy for hepatitis C is to use dose reduction of ribavirin and pegylated interferon, respectively, erythropoietin and granulocyte colony-stimulating factor are now being advocated as alternatives to dose reduction. Aim To determine the cost-effectiveness of erythropoietin and granulocyte colony-stimulating factor as an alternative to anti-viral dose reduction during antihepatitis C therapy. Methods Decision analysis was used to assess cost-effectiveness by estimating the cost of using a growth factor per quality-adjusted life-year gained. Results Under baseline assumptions, the cost per quality-adjusted life-year of using growth factors ranged from $16 247 for genotype 1 with neutropenia to $145 468 for genotype 2/3 patients with anaemia. These findings are sensitive to the relationship between dose reduction and sustained virological response. Conclusions Based upon our findings and the varying strength of the evidence for a relationship between dose reduction and sustained virological response: granulocyte colony-stimulating factor may be cost-effective for genotype 1 patients; erythropoietin is probably not cost-effective for genotype 2/3 patients; no conclusion can be reached regarding the cost-effectiveness of erythropoietin for genotype 1 patients or granulocyte colony-stimulating factor for genotype 2/3 patients. Randomized trials are needed to firmly establish the relationship between dose reduction and sustained virological response. C1 VA Puget Sound Hlth Care Syst, NW Hepatitis C Resource Ctr, Seattle, WA 98108 USA. VA Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA 98108 USA. VA Puget Sound Hlth Care Syst, NW Hlth Serv Res & Dev Ctr Excellence, Seattle, WA 98108 USA. Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. Univ Washington, Div Gastroenterol, Dept Med, Seattle, WA 98195 USA. RP Chapko, MK (reprint author), VA Puget Sound Hlth Care Syst, NW Hepatitis C Resource Ctr, 152,1660 S Columbian Way, Seattle, WA 98108 USA. EM chapko@u.washington.edu OI Dominitz, Jason/0000-0002-8070-7086 NR 53 TC 11 Z9 11 U1 0 U2 2 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0269-2813 J9 ALIMENT PHARM THERAP JI Aliment. Pharmacol. Ther. PD OCT 1 PY 2006 VL 24 IS 7 BP 1067 EP 1077 DI 10.1111/j.1365-2036.2006.03089.x PG 11 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA 083FH UT WOS:000240441300009 PM 16984501 ER PT J AU Sano, M Egelko, S Jin, S Cummings, J Clark, CM Pawluczyk, S Thomas, RJ Schittini, M Thal, LJ AF Sano, Mary Egelko, Susan Jin, Shelia Cummings, Jeffrey Clark, Christopher M. Pawluczyk, Sonia Thomas, Ronald J. Schittini, Mario Thal, Leon J. CA Alzheimers Dis Cooperative St TI Spanish instrument protocol: New treatment efficacy instruments for Spanish-speaking patients in Alzheimer disease clinical trials SO ALZHEIMER DISEASE & ASSOCIATED DISORDERS LA English DT Article DE Alzheimer disease; Spanish language assessment; outcome measures; clinical trials ID BEHAVIOR RATING-SCALE; MULTICENTER EVALUATION; DEMENTIA; VALIDITY AB Objective: To evaluate the feasibility of longitudinal assessment and the psychometric properties of both established and new outcome measures used in clinical trials of patients with dementia in a cohort of Spanish-speaking elders in the United States. Methods: This is a prospectively collected multicenter study comparing patients with Alzheimer disease (AD) (N = 77) and elderly controls (N = 17) who are primary Spanish speakers. Spanish-speaking individuals with AD (SSI AD) were selected to represent predefined categories of impairment as determined by a Mini-Mental State Examination score. Controls were selected to approximately match by age and education (SSI C). Subjects were administered a series of Spanish translations of established outcome measures (Mini-Mental State Examination., Clinical Dementia Rating, Geriatric Dementia Scale), and Functional Assessment Staging (FAST)] and new outcome measures developed for United States in clinical trials to assess cognition, function, behavioral disturbance, and clinical global change. Half of the subjects were assessed at 1 and 2 months to evaluate reliability; all subjects were assessed at 6 and 12 months. Comparisons were made between patients and controls and between the Spanish-speaking cohort and a similar English-speaking cohort. Results: The 12-month completion rate was 77%, with a trend toward greater impairment in those with full retention. Both established and new measures demonstrated good internal consistency and test-retest reliability in this cohort. All but one measure of cognition demonstrated excellent discriminability between AD subjects and controls. The SSI AD cohort declined significantly on measures of cognition, function, and clinical global change over the 12-month assessment period. The SSI AD and English AD (ESI AD) cohorts declined equivalently on the most common outcomes in clinical trials of AD (delayed recall, clinical global change). Likewise, the most common behavioral changes were also similar in the ESI and SSI groups. However, the annual change was lower in SSI AD than in the ESI AD on several other measures of cognition and function. Conclusions: These results support the recruitment of Spanish-speaking patients and the use of Spanish language translations for use in the clinical trials for AD. C1 Bronx Vet Adm Med Ctr, Bronx, NY 10468 USA. Mt Sinai Sch Med, Bronx, NY USA. Psychol Consulting Practice, New York, NY USA. UCSD, Alzheimers Dis Cooperat Study, La Jolla, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. Univ So Calif, Keck Sch Med, Los Angeles, CA USA. Univ Penn, Alzheimers Dis Ctr, Dept Neurol, Philadelphia, PA 19104 USA. Univ Penn, Inst Aging, Philadelphia, PA 19104 USA. RP Sano, M (reprint author), Bronx Vet Adm Med Ctr, 139 W Kingsbridge Rd,Code 151 Rm 1F01, Bronx, NY 10468 USA. EM Mary.Sano@mssm.edu FU NIA NIH HHS [AG05138, P50 AG005138, P50 AG005138-20, U01 AG010483, U01 AG010483-18, U01 AG10483, U19 AG010483] NR 21 TC 7 Z9 7 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0893-0341 J9 ALZ DIS ASSOC DIS JI Alzheimer Dis. Assoc. Dis. PD OCT-DEC PY 2006 VL 20 IS 4 BP 232 EP 241 DI 10.1097/01.wad.0000213862.20108.f5 PG 10 WC Clinical Neurology; Pathology SC Neurosciences & Neurology; Pathology GA 117OX UT WOS:000242883700009 PM 17132967 ER PT J AU Craft, S AF Craft, Suzanne TI Insulin resistance syndrome and Alzheimer disease: pathophysiologic mechanisms and therapeutic implications SO ALZHEIMER DISEASE & ASSOCIATED DISORDERS LA English DT Review DE insulin; Alzheimer disease; diabetes; amyloid ID HYPOGLYCEMIC AGENT CS-045; COGNITIVE IMPAIRMENT; OLDER-ADULTS; MEMORY; BETA; ROSIGLITAZONE; INCREASES; TRANSPORT; GENOTYPE; GLUCOSE AB Insulin plays a key role in cognition and other aspects of normal brain function. Insulin resistance induces chronic peripheral insulin elevations, reduces insulin activity, and reduces brain insulin levels. The insulin resistance syndrome and associated conditions such as type 2 diabetes mellitus and hypertension, are associated with age-related memory impairment and Alzheimer disease. Our work has focused on potential mechanisms through which this association is forged, including the effects of peripheral hyperinsulinemia on memory, inflammation, and regulation of the beta-amyloid peptide. We have shown that raising plasma insulin to levels that characterize patients with insulin resistance invokes synchronous increases in levels of beta-amyloid and inflammatory agents. These convergent effects may impair memory and induce AD pathology. Therapeutic strategies focused on preventing or correcting insulin abnormalities may thus benefit adults with age-related memory impairment and AD. C1 Univ Washington, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr,Dept Psychiat & Behav, Seattle, WA 98195 USA. RP Craft, S (reprint author), VAPSHCS, GRECC S182, 1660 S Columbian Way, Seattle, WA 98108 USA. EM scraft@u.washington.edu FU NIA NIH HHS [R01 AG-10880] NR 22 TC 100 Z9 105 U1 0 U2 12 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0893-0341 J9 ALZ DIS ASSOC DIS JI Alzheimer Dis. Assoc. Dis. PD OCT-DEC PY 2006 VL 20 IS 4 BP 298 EP 301 DI 10.1097/01.wad.0000213866.86934.7e PG 4 WC Clinical Neurology; Pathology SC Neurosciences & Neurology; Pathology GA 117OX UT WOS:000242883700019 PM 17132977 ER PT J AU Sano, M Zhu, CW Whitehouse, PJ Edland, S Jin, SL Ernstrom, K Thomas, RG Thal, LJ Ferris, SH AF Sano, Mary Zhu, Carolyn W. Whitehouse, Peter J. Edland, Steven Jin, Shelia Ernstrom, Karin Thomas, Ronald G. Thal, Leon J. Ferris, Steven H. CA Alzheimer Dis Cooperative St TI ADCS Prevention Instrument Project: Pharmacoeconomics: Assessing health-related resource use among healthy elderly SO ALZHEIMER DISEASE & ASSOCIATED DISORDERS LA English DT Article DE Alzheimer disease; primary prevention; assessment measure; resource use; health care utilization; clinical trials ID SEVERE ALZHEIMERS-DISEASE; CAREGIVER TIME; DONEPEZIL TREATMENT; DOUBLE-BLIND; MODERATE; TRIAL; CARE; GALANTAMINE; DEMENTIA; COSTS AB Background: The Prevention Instrument project of the Alzheimer's Disease Cooperative Study (ADCS) seeks to develop instruments to assess treatment efficacy including potential economic benefit. The Resource Use Inventory (RUI) is an instrument that has been used to capture resource utilization and costs in populations with Alzheimer disease (AD). However, resource utilization and costs for healthy, cognitively intact elderly as they begin to demonstrate cognitive deterioration are not well understood. In addition, the loss that relates to the subjects' own time as they transition through cognitive impairment is not well documented. Objectives: To evaluate the utility of the RUI in a sample of cognitively intact elderly individuals living in the community and enrolled in AD prevention trials. Methods: The RUI was administered to 644 subjects and their study partners either at home or in the clinic. For half of each sample, 3-month retesting was carried out. The RUI consisted of 9 questions. The first part of the RUI captured subjects' use of direct medical care (eg, hospitalizations) and nonmedical care (eg, home health aides). The second part of the RUI captured the time caregivers spend providing care to the subjects. The third part of the RUI captured subjects' participation in volunteer work and employment. The assessment interval for each question was the past 3 months. Results: The percentage of RUI forms returned incomplete or inaccurate for both in-clinic and at-home groups was extremely low. There were no differences in utilization rates between in-clinic and at-home group for all items in the RUI. Except for use of outpatient procedures, tests, or treatments, there were no differences in utilization rates between subjects who filled out the RUI with the help of their study partners or by themselves. Items in the RUI were sensitive to subjects' cognitive and functional status and demographic characteristics. Conclusions: Home-based completion of the RUI by participants in an AD prevention study is feasible, and seems to provide data that are reliable and valid. The instrument will be useful for tracking resource and time use through transition from healthy to cognitive impairment. C1 Mt Sinai Sch Med, Bronx, NY 10468 USA. James J Peters VAMC, Bronx, NY 10468 USA. Case Western Reserve Univ, Cleveland, OH 44106 USA. Univ Calif San Diego, San Diego, CA 92103 USA. NYU, Sch Med, Alzheimers Dis Ctr, Silberstein Inst Aging & Dementia, New York, NY USA. RP Sano, M (reprint author), Mt Sinai Sch Med, 130 Kingsbridge Rd,Rm1F01, Bronx, NY 10468 USA. EM mary.sano@mssm.edu FU NIA NIH HHS [U19 AG010483, P50 AG005138, P50 AG005138-19, U01 AG 10483, U01 AG010483] NR 19 TC 17 Z9 17 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0893-0341 J9 ALZ DIS ASSOC DIS JI Alzheimer Dis. Assoc. Dis. PD OCT-DEC PY 2006 VL 20 IS 4 SU 3 BP S191 EP S202 PG 12 WC Clinical Neurology; Pathology SC Neurosciences & Neurology; Pathology GA 119JD UT WOS:000243007700009 PM 17135812 ER PT J AU Slone, S Janckila, A Martin, A Lear, S Yam, L AF Slone, Stephen Janckila, Anthony Martin, Alvin Lear, Sheron Yam, Lung TI Immunohistochemical demonstration of human tartrate-resistant acid phosphatase as a specific biomarker for inflammatory macrophages SO AMERICAN JOURNAL OF CLINICAL PATHOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-for-Clinical-Pathology CY OCT 19-22, 2006 CL Los Angeles, NV SP Amer Soc Clin Pathol C1 Univ Louisville, Dept Pathol & Lab Med, Louisville, KY 40292 USA. Univ Louisville, Sch Med, Dept Microbiol & Immunol, Louisville, KY 40292 USA. Univ Louisville, Sch Med, Dept Med, Louisville, KY 40292 USA. US Dept Vet Affairs, Med Ctr, Special Hematol Lab, Louisville, KY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL PATHOLOGY PI CHICAGO PA 2100 W HARRISON ST, CHICAGO, IL 60612 USA SN 0002-9173 J9 AM J CLIN PATHOL JI Am. J. Clin. Pathol. PD OCT PY 2006 VL 126 IS 4 BP 648 EP 648 PG 1 WC Pathology SC Pathology GA 085XY UT WOS:000240638900085 ER PT J AU Hunt, SC Jakupcak, M McFall, M Orsborn, M Felker, B Larson, S Klevens, M AF Hunt, Stephen C. Jakupcak, Mathew McFall, Miles Orsborn, Mack Felker, Bradford Larson, Stephanie Klevens, Michele TI Re: "Chronic multisymptom illness complex in Gulf War I Veterans 10 years later" SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Letter ID POSTTRAUMATIC-STRESS-DISORDER; SYMPTOMS C1 Univ Washington, Deployment Hlth Clin, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Hunt, SC (reprint author), Univ Washington, Deployment Hlth Clin, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. EM stephen.hunt@med.va.gov NR 11 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD OCT 1 PY 2006 VL 164 IS 7 DI 10.1093/aje/kwj297 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 086UH UT WOS:000240698000018 ER PT J AU Lee, E Winter, ME Boro, MS AF Lee, Elena Winter, Michael E. Boro, Maureen S. TI Comparing two predictive methods for determining serum vancomycin concentrations at a Veterans Affairs medical center SO AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY LA English DT Article DE antibiotics; blood levels; dosage; drugs, body distribution; equations; methodology; vancomycin; weight ID CREATININE CLEARANCE; RENAL-FUNCTION; THERAPY; PHARMACOKINETICS; PREVALENCE; OBESITY AB Purpose. Two predictive methods for determining serum vancomycin concentrations (SVCs) at a Veterans Affairs medical center were compared. Methods. The data for inpatients at the San Francisco Veterans Affairs Medical Center who received i.v. vancomycin and had vancomycin concentrations recorded in 2003 were included in this retrospective study. Creatinine clearance was estimated by the Cockcroft and Gault equation. Volume of distribution and creatinine clearance were calculated for each patient, using the Leonard and Boro method and the Rushing and Ambrose method. The Sheiner and Beal method for determining precision and bias was used to evaluate whether the two methods significantly differed in their ability to predict SVCs. Results. Of the 223 patients identified, 122 patients were included, and 212 SVCs were analyzed. The population was mostly male and had a mean age of 64.1 years. There were no significant differences in 95% confidence intervals for relative precision and relative bias between the two methods. In patients whose weight was within 120% of their ideal body weight (IBW), the Leonard and Boro, method was significantly more precise and less biased in predicting SVCs. In patients whose weight exceeded 120% of their IBW, the Rushing and Ambrose method was less biased and tended to be more precise, although the difference in precision was not significant. Conclusion. Both methods yielded similar predictability for SVCs in a veterans population. The Leonard and Boro method better predicted SVCs in patients weighing within 120% of their IBW, while the Rushing and Ambrose method appeared to be more appropriate for calculating vancomycin dosages in patients whose weight exceeded 120% of their IBW. C1 San Francisco Vet Affairs Med Ctr, Pharm Serv 119, San Francisco, CA 94121 USA. Kaiser Fdn Hosp, Richmond Med Ctr, Richmond, CA USA. Univ Calif San Francisco, Sch Pharm, San Francisco, CA 94143 USA. Univ Pacific, Sch Pharm & Hlth Sci, San Francisco, CA USA. RP Boro, MS (reprint author), San Francisco Vet Affairs Med Ctr, Pharm Serv 119, 4150 Clement St, San Francisco, CA 94121 USA. EM maureenboro@va.gov NR 13 TC 5 Z9 6 U1 2 U2 2 PU AMER SOC HEALTH-SYSTEM PHARMACISTS PI BETHESDA PA 7272 WISCONSIN AVE, BETHESDA, MD 20814 USA SN 1079-2082 J9 AM J HEALTH-SYST PH JI Am. J. Health-Syst. Pharm. PD OCT 1 PY 2006 VL 63 IS 19 BP 1872 EP 1875 DI 10.2146/ajhp060138 PG 4 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 091TR UT WOS:000241051700017 PM 16990634 ER PT J AU Zabetian, CP Hutter, CM Yearout, D Lopez, AN Factor, SA Griffith, A Leis, BC Bird, TD Nutt, JG Higgins, DS Roberts, JW Kay, DM Edwards, KL Samii, A Payami, H AF Zabetian, Cyrus P. Hutter, Carolyn M. Yearout, Dora Lopez, Alexis N. Factor, Stewart A. Griffith, Alida Leis, Berta C. Bird, Thomas D. Nutt, John G. Higgins, Donald S. Roberts, John W. Kay, Denise M. Edwards, Karen L. Samii, Ali Payami, Haydeh TI LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: Evidence of two distinct founding events beginning two millennia ago SO AMERICAN JOURNAL OF HUMAN GENETICS LA English DT Article ID AUTOSOMAL-DOMINANT PARKINSONISM; COMMON FOUNDER; ASHKENAZI JEWS; GENETIC DRIFT; MUTATION; POPULATIONS; FREQUENT AB The leucine-rich repeat kinase 2 (LRRK2) G2019S mutation is the most common genetic determinant of Parkinson disease (PD) identified to date. It accounts for 1%-7% of PD in patients of European origin and 20%-40% in Ashkenazi Jews and North African Arabs with PD. Previous studies concluded that patients from these populations all shared a common Middle Eastern founder who lived in the 13th century. We tested this hypothesis by genotyping 25 microsatellite and single-nucleotide-polymorphism markers in 22 families with G2019S and observed two distinct haplotypes. Haplotype 1 was present in 19 families of Ashkenazi Jewish and European ancestry, whereas haplotype 2 occurred in three European American families. Using a maximum-likelihood method, we estimated that the families with haplotype 1 shared a common ancestor 2,250 (95% confidence interval 1,650 - 3,120) years ago, whereas those with haplotype 2 appeared to share a more recent founder. Our data suggest two separate founding events for G2019S in these populations, beginning at a time that coincides with the Jewish Diasporas. C1 Univ Washington, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin,Dept Neurol, Seattle, WA 98108 USA. Univ Washington, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Dept Neurol,Parkinsons Dis Res Educ & Clin Ctr, Seattle, WA 98108 USA. Univ Washington, Sch Publ Hlth & Community Med, Dept Epidemiol, Seattle, WA 98195 USA. Virginia Mason Med Ctr, Seattle, WA 98101 USA. Albany Med Ctr, Parkinsons Dis & Movement Disorder Clin, Albany, NY USA. New York State Dept Hlth, Wadsworth Ctr, Genom Inst, Albany, NY USA. Evergreen Hosp, Med Ctr, Booth Gardner Parkinsons Care Ctr, Kirkland, WA USA. Oregon Hlth Sci Univ, Dept Neurol, Portland, OR 97201 USA. RP Zabetian, CP (reprint author), Univ Washington, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin,Dept Neurol, S-182,1660 S Columbian Way, Seattle, WA 98108 USA. EM zabetian@u.washington.edu OI Zabetian, Cyrus/0000-0002-7739-4306; Kay, Denise/0000-0002-9928-2698 FU NIA NIH HHS [P30 AG008017]; NINDS NIH HHS [K08 NS044138-04, K08 NS044138, R01 NS036960] NR 30 TC 74 Z9 75 U1 1 U2 4 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0002-9297 J9 AM J HUM GENET JI Am. J. Hum. Genet. PD OCT PY 2006 VL 79 IS 4 BP 752 EP 758 DI 10.1086/508025 PG 7 WC Genetics & Heredity SC Genetics & Heredity GA 089BV UT WOS:000240855900018 PM 16960813 ER PT J AU Bradley, KA Williams, EC Achtmeyer, CE Volpp, B Collins, BJ Kivlahan, DR AF Bradley, Katharine A. Williams, Emily C. Achtmeyer, Carol E. Volpp, Bryan Collins, Bonny J. Kivlahan, Daniel R. TI Implementation of evidence-based alcohol screening in the veterans health administration SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID PRIMARY-CARE PATIENTS; AT-RISK DRINKING; BEHAVIORAL-COUNSELING INTERVENTIONS; RANDOMIZED CONTROLLED TRIAL; BRIEF PHYSICIAN ADVICE; GENERAL-PRACTITIONERS; PREVENTIVE-SERVICES; PUBLIC-HEALTH; USE DISORDERS; DRINKERS AB Background: Despite evidence-based guidelines, brief alcohol screening and counseling have not been routinely integrated into most primary care practices in the United States. Objective: To describe the results of the implementation of evidence-based alcohol screening by the Veterans Health Administration (VA) in 2004, as the first step toward implementation of brief alcohol counseling. Study Design: This observational study of outpatients from all 21 VA networks relied on the following 2 data sources from the VA Office of Quality and Performance: (1) Medical record reviews, designed to compare VA networks quarterly, evaluated whether established VA patients had documented screening for alcohol misuse and documented follow-up assessment for alcohol use disorders among those who screened positive for alcohol misuse (January-March 2005); and (2) Mailed patient satisfaction surveys from 2004, which oversampled patients new to the VA (response rate, > 70%), included the Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) questions and asked about past-year advice "to drink less or not to drink alcohol" from a VA provider. Results: Based on 10 115 medical record reviews, 93% (range, 89%-96% across networks) of outpatients were screened for alcohol misuse, and 25% (range, 11%-36%) screened positive. Among screen-positive patients, 42% (range, 5%-84%) had documented follow-up assessment, but absolute numbers of screen-positive patients evaluated were small (27-80 patients per network). Based on 235 481 patient surveys, the prevalence of alcohol misuse was 22% (range, 15%-27% across networks), and 28% (range, 20%-36%) of screen-positive patients reported receiving alcohol-related advice. Alcohol-related advice increased as AUDIT-C scores increased. Conclusion: The VA successfully implemented evidence-based alcohol screening, but the rate of follow-up among screen-positive patients remained low. C1 VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev 152, Seattle, WA 98101 USA. VA Puget Sound Hlth Care Syst, Primary & Specialty Med Care, Seattle, WA USA. Univ Washington, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA 98195 USA. Univ Washington, Dept Med, Seattle, WA USA. Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. VA No Calif Healthcare Syst, Martinez, CA USA. VA Off Qual & Performance, Washington, DC USA. RP Bradley, KA (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev 152, 1100 Olive Way,Ste 1400, Seattle, WA 98101 USA. EM willi@u.washington.edu FU NIAAA NIH HHS [K23AA00313] NR 57 TC 108 Z9 108 U1 4 U2 5 PU AMER MED PUBLISHING, M W C COMPANY PI JAMESBURG PA 241 FORSGATE DR, STE 102, JAMESBURG, NJ 08831 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD OCT PY 2006 VL 12 IS 10 BP 597 EP 606 PG 10 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 099TE UT WOS:000241618000004 PM 17026414 ER PT J AU Federman, AD Halm, EA Zhu, C Hochman, T Siu, AL AF Federman, Alex D. Halm, Ethan A. Zhu, Carolyn Hochman, Tsivia Siu, Albert L. TI Association of income and prescription drug coverage with generic medication use among older adults with hypertension SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID POTENTIAL SAVINGS; CHRONIC ILLNESSES; BENEFIT PLANS; COSTS; PHYSICIAN; CARE; UNDERUSE; SUBSTITUTION; OUTCOMES; COMMUNICATION AB Objective: To determine whether low-income seniors and those without prescription drug coverage are more likely to use generic cardiovascular drugs than more affluent and better insured adults. Study Design: Cross-sectional analysis. Methods: We used data from the 2001 Medicare Current Beneficiary Survey. Analyses included noninstitutionalized survey respondents over age 65 years with hypertension who used >= 1 multisource cardiovascular drugs (N = 1710). We examined the association of income and prescription coverage with use of generic versions of multisource drugs from 5 classes: angiotensin-converting enzyme (ACE) inhibitors, beta-adrenergic receptor antagonists (beta-blockers), calcium channel blockers, alpha-adrenergic receptor antagonists (alpha-blockers), and thiazide diuretics. Results: Rates of generic medication use were 88.5% (beta-blockers); 92.8% (thiazides); 58.7% (calcium channel blockers); 60.7% (ACE inhibitors); and 52.6% (alpha-blockers). In multivariate anaysis of generic medication use aggregated across the 5 drug classes, individuals with incomes below 200% of the federal poverty level were modestly more likely to use generic medications compared with seniors with incomes above 300% the poverty level. Seniors who lacked prescription coverage were more likely to use generics than those who had employer-sponsored coverage, although the association was of marginal statistical significance (relative risk = 1.29, 95% confidence interval = 1.00, 1.60). Conclusion: Seniors with low incomes or no prescription coverage were only somewhat more likely to use generic cardiovascular drugs than more affluent and insured seniors. These findings suggest that physicians and policy makers may be missing opportunities to reduce costs for Medicare and its economically disadvantaged beneficiaries. C1 Mt Sinai Sch Med, Div Gen Internal Med, New York, NY 10029 USA. Mt Sinai Sch Med, Brookdale Dept Geriatr & Adult Dev, New York, NY USA. Bronx Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Bronx, NY USA. RP Federman, AD (reprint author), Mt Sinai Sch Med, Div Gen Internal Med, 1470 Madison Ave,Box 1087, New York, NY 10029 USA. EM alex.federman@mssm.edu FU NIA NIH HHS [K24 AG000918] NR 42 TC 19 Z9 19 U1 1 U2 1 PU AMER MED PUBLISHING, M W C COMPANY PI JAMESBURG PA 241 FORSGATE DR, STE 102, JAMESBURG, NJ 08831 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD OCT PY 2006 VL 12 IS 10 BP 611 EP 618 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 099TE UT WOS:000241618000005 PM 17026415 ER PT J AU Mortensen, EM Restrepo, MI Anzueto, A Pugh, JA AF Mortensen, Eric M. Restrepo, Marcos I. Anzueto, Antonio Pugh, Jacqueline A. TI Antibiotic therapy and 48-hour mortality for patients with pneumonia SO AMERICAN JOURNAL OF MEDICINE LA English DT Article DE antibacterial agents; community-acquired infections; pneumonia ID COMMUNITY-ACQUIRED PNEUMONIA; BACTEREMIC PNEUMOCOCCAL PNEUMONIA; INITIAL ANTIMICROBIAL THERAPY; PROPENSITY SCORE; ELDERLY-PATIENTS; GUIDELINES; MANAGEMENT; OUTCOMES; ADULTS; INPATIENTS AB PURPOSE: Although numerous articles have demonstrated that recommended empiric antimicrobial regimens are associated with decreased mortality at 30 days, there is controversy over whether appropriate antibiotic selection has a beneficial impact on mortality within the first 48 to 96 hours after admission. Our aim was to determine whether the use of guideline-concordant antibiotic therapy is associated with decreased mortality within the first 48 hours after admission for patients with pneumonia. METHODS: A retrospective cohort study was conducted at two tertiary teaching hospitals in San Antonio, Texas. A propensity score was used to balance the covariates associated with the use of guideline-concordant antimicrobial therapy. A multivariable logistic regression model was used to assess the association between mortality within 48 hours and the use of guideline-concordant antibiotic therapy, after adjusting for potential confounders including the propensity score. RESULTS: Information was obtained on 787 patients with community-acquired pneumonia. The median age was 60 years, 79% were male, and 20% were initially admitted to the intensive care unit. At presentation 52% of subjects were low risk, 34% were moderate risk, and 14% were high risk. Within the first 48 hours, 20 patients died. After adjustment for potential confounders, the use of guideline-concordant antimicrobial therapy (odds ratio 0.37, 95% confidence interval, 0.14-0.95) was significantly associated with decreased mortality at 48 hours after admission. CONCLUSION: Using initial empiric guideline-concordant antimicrobial therapy is associated with decreased mortality at 48 hours. Further research needs to investigate methods to ensure that patients with community-acquired pneumonia are treated with appropriate antimicrobial therapies. (c) 2006 Elsevier Inc. All rights reserved. C1 S Texas Vet Hlth Care Syst, Vet Evidence Based Res Disseminat & Implementat C, San Antonio, TX USA. S Texas Vet Hlth Care Syst, Div Gen Internal Med, San Antonio, TX USA. S Texas Vet Hlth Care Syst, Div Pulm Crit Care Med, San Antonio, TX USA. RP Mortensen, EM (reprint author), UTHSCSA, VERDICT, ALMD, 7400 Merton Minter Blvd, San Antonio, TX 78284 USA. EM mortensene@uthscsa.edu OI Pugh, Jacqueline/0000-0003-4933-141X; Mortensen, Eric/0000-0002-3880-5563 NR 27 TC 31 Z9 33 U1 0 U2 1 PU EXCERPTA MEDICA INC PI BRIDGEWATER PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD OCT PY 2006 VL 119 IS 10 BP 859 EP 864 DI 10.1016/j.amjmed.2006.04.017 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 086UX UT WOS:000240699600012 PM 17000217 ER PT J AU Frei, CR Restrepo, MI Mortensen, EM Burgess, DS AF Frei, Christopher R. Restrepo, Marcos I. Mortensen, Eric M. Burgess, David S. TI Impact of guideline-concordant empiric antibiotic therapy in community-acquired pneumonia SO AMERICAN JOURNAL OF MEDICINE LA English DT Article DE community-acquired pneumonia; antibiotics; in-hospital mortality; hospital length of stay; time-to-clinical stability; time-to-switch therapy ID INITIAL ANTIMICROBIAL THERAPY; HOSPITALIZED-PATIENTS; ATYPICAL COVERAGE; MANAGEMENT; ADULTS; DIAGNOSIS; SEVERITY; OUTCOMES; INPATIENTS; MORTALITY AB PURPOSE: We evaluated the impact of guideline-concordant empiric antibiotic therapy on time to clinical stability, time to switch therapy, length of hospital stay, and mortality among patients with community-acquired pneumonia. METHODS: This is a retrospective cohort study of all adult community-acquired pneumonia patients managed at 5 community hospitals from November 1, 1999 to April 30, 2000. Patients were stratified into guideline-concordant and discordant groups as defined by the 2001 American Thoracic Society and the 2003 Infectious Diseases Society of America guidelines. Time to clinical stability, time to switch therapy, length of hospital stay, and in-hospital mortality were evaluated in per-protocol and intention-to-treat stepwise regression models that included the outcome as the dependent variable, guideline-concordant antibiotic therapy as the independent variable, and Pneumonia Severity Index score as a covariate. RESULTS: Of the 631 evaluable patients, 357 (57%) received guideline-concordant empiric antibiotic therapy. Groups were similar with respect to age, sex, comorbidities, severity of illness, and processes of care. Guideline-concordant antibiotic therapy was associated with a significant decrease in time to switch therapy (P <=. 01), length of hospital stay (P <=. 01), and in-hospital mortality (P =. 04) for both per-protocol and intention-to-treat analyses. In addition, guideline-concordant antibiotic therapy was associated with a significant decrease in time to clinical stability for intention-to-treat analysis only (P =. 03). CONCLUSIONS: Among hospitalized community-acquired patients, guideline- concordant antibiotic therapy is associated with improved in-hospital survival and shorter time to clinical stability, time to switch therapy, and length of hospital stay. (c) 2006 Elsevier Inc. All rights reserved. C1 Univ Texas, Hlth Sci Ctr, Clin Pharm Programs, San Antonio, TX 78229 USA. Univ Texas, Coll Pharm, Austin, TX 78712 USA. Vet Evidence Based Res Disseminat & Implementat C, San Antonio, TX USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Burgess, DS (reprint author), Univ Texas, Hlth Sci Ctr, Clin Pharm Programs, MSC 6220,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM burgessd@uthscsa.edu OI Mortensen, Eric/0000-0002-3880-5563 NR 30 TC 80 Z9 81 U1 0 U2 3 PU EXCERPTA MEDICA INC PI BRIDGEWATER PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD OCT PY 2006 VL 119 IS 10 BP 865 EP 871 DI 10.1016/j.amjmed.2006.02.014 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 086UX UT WOS:000240699600013 PM 17000218 ER PT J AU Anzueto, A AF Anzueto, Antonio TI Clinical course of chronic obstructive pulmonary disease: Review of therapeutic interventions SO AMERICAN JOURNAL OF MEDICINE LA English DT Article DE chronic obstructive pulmonary disease; salmeterol; tiotropium ID FLUTICASONE PROPIONATE; MAINTENANCE THERAPY; COPD PATIENTS; TIOTROPIUM; SALMETEROL; EFFICACY; HEALTH; REHABILITATION; COMBINATION; FORMOTEROL AB Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease in which patients experience a progressive decline in lung function. Based on clinical evidence, the management of COPD should focus on (1) earlier diagnosis; (2) risk reduction through smoking cessation, decreased exposure to inhaled irritants, and immunization against respiratory pathogens; (3) symptom reduction with pharmacotherapy and pulmonary rehabilitation; (4) decreasing complications by reducing exacerbations and improving pulmonary function; and (5) improving health-related quality of life (HRQOL). Smoking cessation has been shown to slow lung function decline and to reduce mortality-including deaths due to lung cancer, other respiratory disease (including COPD), and cardiovascular disease. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) and the American Thoracic Society and European Respiratory Society (ATS/ERS) guidelines advocate interventions according to the severity of COPD and recommend initiation of maintenance long-acting bronchodilator therapy in patients with moderate disease. However, recent evidence from a post hoc analysis of randomized controlled trials of tiotropium suggests that initiation of long-acting bronchodilator therapy at earlier stages of disease may also provide improvements in lung function and HRQOL. The results of ongoing long-term studies may soon provide evidence that in addition to relieving symptoms and improving patient HRQOL, specific pharmacologic therapies may also alter the clinical course of COPD. (c) 2006 Elsevier Inc. All rights reserved. C1 Audie L Murphy Mem Vet Adm Med Ctr, Pulm Dis Sect, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78285 USA. RP Anzueto, A (reprint author), Audie L Murphy Mem Vet Adm Med Ctr, Pulm Dis Sect, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM anzueto@uthscsa.edu NR 25 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9343 EI 1555-7162 J9 AM J MED JI Am. J. Med. PD OCT PY 2006 VL 119 IS 10 SU 1 BP S46 EP S53 DI 10.1016/j.amjmed.2006.08.007 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 086SH UT WOS:000240692800007 PM 16996899 ER PT J AU Berfield, AK Hansen, KM Abrass, CK AF Berfield, Anne K. Hansen, Kim M. Abrass, Christine K. TI Rat glomerular mesangial cells require laminin-9 to migrate in response to insulin-like growth factor binding protein-5 SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY LA English DT Article DE migration; integrins; extracellular matrix ID ALPHA-4 CHAIN; BASEMENT-MEMBRANE; IN-VITRO; G-DOMAIN; ENDOTHELIAL-CELLS; INTEGRIN; DYSTROGLYCAN; EXPRESSION; RECEPTOR; ADHESION AB Temporal and spatial differences in extracellular matrix play critical roles in cell proliferation, differentiation and migration. Different migratory stimuli use different substrates and receptors to achieve cell migration. To understand the mechanism of insulin-like growth factor binding protein-5 (IGFBP5)-induced migration in mesangial cells, the roles of integrins and substrates were examined. IGFBP-5 induced an increase in mRNA expression for laminin (LN) chains lama4, lamb2, and lamc1, suggesting that LN-9 might be required for migration. Antibodies to the LN alpha(4) and LN beta(2) chains, but not LN beta(1), blocked IGFBP-5-induced migration. Anti-sense morpholino oligonucleotide inhibition of expression of LN alpha(4) substantially reduced expression of LN-8/9 (alpha(4)beta(1)gamma(1)/alpha(4)beta(2)gamma(1), 411/421) and prevented IGFBP-5-induced migration. Anti-sense inhibition of lamb2 reduced expression of LN-9. Absence of LN-9 prevented IGFBP-5-induced migration, which was not preserved by continued expression of LN-8. The requirement for LN-9 was further supported by studies of T98G cells, which express predominantly LN-8. IGFBP-5 had little effect on migration in these cells, but increased migration when T98G cells were plated on LN-8/9. IGFBP-5-mediated mesangial cell migration was inhibited by antibodies that block attachment to alpha(6)beta(1)-integrins but was unaffected by antibodies and disintegrins that block binding to other integrins. Furthermore, in cells with anti-sense inhibited expression of LN-9, integrin alpha(6)beta(1) was no longer detected on the cell surface. These studies suggest the specificity of mechanisms of migration induced by specific stimuli and for the first time demonstrate a unique function for LN-9 in mediating IGFBP-5-induced migration. C1 Univ Washington, Dept Med, Sch Med, Seattle, WA 98109 USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. RP Abrass, CK (reprint author), Univ Washington, Dept Med, Sch Med, S Lake Union,815 Mercer St, Seattle, WA 98109 USA. EM cabrass@u.washington.edu FU NIDDK NIH HHS [R01-DK49971-08] NR 66 TC 6 Z9 7 U1 0 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6143 J9 AM J PHYSIOL-CELL PH JI Am. J. Physiol.-Cell Physiol. PD OCT PY 2006 VL 291 IS 4 BP C589 EP C599 DI 10.1152/ajpcell.00623.2005 PG 11 WC Cell Biology; Physiology SC Cell Biology; Physiology GA 084CM UT WOS:000240509400003 PM 16672690 ER PT J AU Krudys, KM Kahn, SE Vicini, P AF Krudys, Kevin M. Kahn, Steven E. Vicini, Paolo TI Population approaches to estimate minimal model indexes of insulin sensitivity and glucose effectiveness using full and reduced sampling schedules SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM LA English DT Article DE two-stage; parameter estimation; minimal model; insulin sensitivity ID RESISTANCE; TOLERANCE; KINETICS; NIDDM AB The intravenous glucose tolerance test (IVGTT) interpreted with the minimal model provides individual indexes of insulin sensitivity (S-I) and glucose effectiveness (S-G). In population studies, the traditional approach, the standard two-stage (STS) method, fails to account for uncertainty in individual estimates, resulting in an overestimation of between-subject variability. Furthermore, in the presence of reduced sampling and/or insulin resistance, individual estimates may be unobtainable, biasing population information. Therefore, we investigated the use of two population approaches, the iterative two-stage (ITS) method and nonlinear mixed-effects modeling (NM), in a population (n = 235) of insulin-sensitive and insulin-resistant subjects under full (FSS, 33 samples) and reduced [RSS(240-min), 13 samples and RSS(180-min), 12 samples] IVGTT sampling schedules. All three population methods gave similar results with the FSS. Using RSS( 240), the three methods gave similar results for S-I, but S-G population means were overestimated. With RSS( 180), S-I and S-G population means were higher for all three methods compared with their FSS counterparts. NM estimated similar between-subject variability (19% S-G, 53% S-I) with RSS(180), whereas ITS showed regression to the mean for S-G (0.01% S-G, 56% S-I) and STS provided larger population variability in S-I (29% S-G, 91% S-I). NM provided individual estimates for all subjects, whereas the two-stage methods failed in 16-18% of the subjects using RSS(180) and 6-14% using RSS(240). We conclude that population approaches, specifically NM, are useful in studies with a sparsely sampled IVGTT (similar to 12 samples) of short duration (similar to 3h) and when individual parameter estimates in all subjects are desired. C1 Univ Washington, Dept Bioengn, Resource Facil Populat Kinet, Seattle, WA 98195 USA. Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. RP Vicini, P (reprint author), Univ Washington, Dept Bioengn, Resource Facil Populat Kinet, Box 352255, Seattle, WA 98195 USA. EM vicini@u.washington.edu OI Kahn, Steven/0000-0001-7307-9002 FU NIBIB NIH HHS [P41 EB-001975]; NIDCR NIH HHS [T32 DE-07023]; NIDDK NIH HHS [DK-17047, DK-35816] NR 18 TC 12 Z9 13 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1849 J9 AM J PHYSIOL-ENDOC M JI Am. J. Physiol.-Endocrinol. Metab. PD OCT PY 2006 VL 291 IS 4 BP E716 EP E723 DI 10.1152/ajpendo.00346.2005 PG 8 WC Endocrinology & Metabolism; Physiology SC Endocrinology & Metabolism; Physiology GA 086DQ UT WOS:000240654100005 PM 16954338 ER PT J AU Wang, LX Basa, NR Shaikh, A Luckey, A Heber, D St-Pierre, DH Tache, Y AF Wang, Lixin Basa, Nicole R. Shaikh, Almaas Luckey, Andrew Heber, David St-Pierre, David H. Tache, Yvette TI LPS inhibits fasted plasma ghrelin levels in rats: role of IL-1 and PGs and functional implications SO AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY LA English DT Article DE insulin; food intake; gastric emptying; urocortin 1; prostaglandins; interleukin-1; lipopolysaccharide ID CORTICOTROPIN-RELEASING-FACTOR; INSULIN-INDUCED HYPOGLYCEMIA; GROWTH-HORMONE-SECRETION; PITUITARY-ADRENAL AXIS; STIMULATES FOOD-INTAKE; HELICOBACTER-PYLORI; BACTERIAL LIPOPOLYSACCHARIDE; STOMACH GHRELIN; GASTRIC-MUCOSA; IN-VIVO AB LPS injected intraperitoneally decreases fasted plasma levels of ghrelin at 3 h postinjection in rats. We characterized the inhibitory action of LPS on plasma ghrelin and whether exogenous ghrelin restores LPS-induced suppression of food intake and gastric emptying in fasted rats. Plasma ghrelin and insulin and blood glucose were measured after intraperitoneal injection of LPS, intravenous injection of IL-1 beta and urocortin 1, and in response to LPS under conditions of blockade of IL-1 or CRF receptors by subcutaneous injection of IL-1 receptor antagonist (IL-1Ra) or astressin B, respectively, and prostaglandin (PG) synthesis by intraperitoneal indomethacin. Food intake and gastric emptying were measured after intravenous injection of ghrelin at 5 h postintraperitoneal LPS injection. LPS inhibited the elevated fasted plasma ghrelin levels by 47.6 +/- 4.9%, 58.9 +/- 3.3%, 74.4 +/- 2.7%, and 48.9 +/- 8.7% at 2, 3, 5, and 7 h postinjection, respectively, and values returned to preinjection levels at 24 h. Insulin levels were negatively correlated to those of ghrelin, whereas there was no significant correlation between glucose and ghrelin. IL-1Ra and indomethacin prevented the first 3-h decline in ghrelin levels induced by LPS, whereas astressin B did not. IL-1 beta inhibited plasma ghrelin levels, whereas urocortin 1 had no influence. Ghrelin injected intravenously prevented an LPS-induced 87% reduction of gastric emptying and 61% reduction of food intake. These data showed that IL-1 and PG pathways are part of the early mechanisms by which LPS suppresses fasted plasma ghrelin and that exogenous ghrelin can normalize LPS-induced-altered digestive functions. C1 Univ Calif Los Angeles, David Geffen Sch Med, Ctr Ulcer Res & Educ, Digest Dis Res Ctr,Dept Med,Div Digest Dis, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, David Geffen Sch Med, Ctr Human Nutr, Dept Med, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurovisceral Sci & Womens Hlth, Dept Med, Los Angeles, CA 90024 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Montreal, Dept Nutr, Montreal, PQ H3C 3J7, Canada. RP Wang, LX (reprint author), CURE Bldg 115,Rm 117B,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. FU NIDDK NIH HHS [DK-41301, R37-DK-33061-17S1, R01-DK-33061, P50-DK-64539] NR 63 TC 57 Z9 58 U1 0 U2 3 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1857 J9 AM J PHYSIOL-GASTR L JI Am. J. Physiol.-Gastroint. Liver Physiol. PD OCT PY 2006 VL 291 IS 4 BP G611 EP G620 DI 10.1152/ajpgi.00533.2005 PG 10 WC Gastroenterology & Hepatology; Physiology SC Gastroenterology & Hepatology; Physiology GA 082CN UT WOS:000240364400009 PM 16959954 ER PT J AU Alfonso-Jaume, MA Bergman, MR Mahimkar, R Cheng, S Jin, ZQ Karliner, JS Lovett, DH AF Alfonso-Jaume, Maria Alejandra Bergman, Marina R. Mahimkar, Rajeev Cheng, Sunfa Jin, Zhu Q. Karliner, Joel S. Lovett, David H. TI Cardiac ischemia-reperfusion injury induces matrix metalloproteinase-2 expression through the AP-1 components FosB and JunB SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Article DE reperfusion injury; transcription factor; activator protein-1 ID GLOMERULAR MESANGIAL CELLS; NF-KAPPA-B; GELATINASE-A; GENE-EXPRESSION; TRANSCRIPTION FACTORS; NITRIC-OXIDE; MYOCARDIAL-ISCHEMIA; C-FOS; ACTIVATION; HEART AB Matrix metalloproteinase-2 (MMP-2) is a central component of the response to injury in the heart. During ischemia, MMP-2 influences ventricular performance and is a determinant of postinfarction remodeling. Elevation of MMP-2 during reperfusion after ischemia suggests that new protein is synthesized, but the molecular regulation of MMP-2 generation during ischemia-reperfusion (I/R) injury has not been studied. Using the MMP-2 promoter linked to a beta-galactosidase reporter in transgenic mice, we investigated the transcriptional regulation and cellular sources of MMP-2 in isolated, perfused mouse hearts subjected to acute global I/R injury. I/R injury induced a rapid activation of MMP-2 promoter activity with the appearance of beta-galactosidase antigen in cardiomyocytes, fibroblasts, and endothelial cells. Activation of intrinsic MMP-2 transcription and translation was confirmed by real-time PCR and quantitative Western blot analyses. MMP-2 transcription and translation were inhibited by perfusion with 1.0 mM hydroxyl radical scavenger N-(-2-mercaptopropionyl)-glycine. Nuclear extracts demonstrated increased abundance of two activator proteins-1 (AP-1) components JunB and FosB following I/ R injury. Immunohistochemical staining localized JunB and FosB proteins to the nuclei of all three cardiac cell types following I/ R injury, consistent with enhanced nuclear transport of these transcription factors. Chromatin immunoprecipitation (ChIP) of the AP-1 binding site in the intrinsic murine MMP-2 promoter yielded only JunB under control conditions, whereas ChIP following I/ R injury recovered both JunB and FosB, consistent with a change in occupancy from JunB homodimers in controls to JunB/FosB heterodimers following I/ R injury. We conclude that enhanced MMP-2 transcription and translation following I/R injury are mediated by induction, via oxidant stress, of discrete AP-1 transcription factor components. C1 Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Med, San Francisco, CA 94121 USA. Univ Wisconsin, Sch Med, Dept Med, William S Middleton Vet Affairs Med Ctr, Madison, WI USA. Univ Calif San Francisco, Inst Cardiovasc Res, San Francisco, CA 94143 USA. RP Lovett, DH (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Med, 111J,4150 Clement St, San Francisco, CA 94121 USA. EM david.lovett@med.va.gov FU NHLBI NIH HHS [P01-HL-68738] NR 44 TC 49 Z9 50 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD OCT PY 2006 VL 291 IS 4 BP H1838 EP H1846 DI 10.1152/ajpheart.00026.2006 PG 9 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA 084CP UT WOS:000240509700042 PM 16699069 ER PT J AU Kobelt, P Goebel, M Stengel, A Schmidtmann, M van der Voort, IR Tebbe, JJ Veh, RW Klapp, BF Wiedenmann, B Wang, L Tache, Y Monnikes, H AF Kobelt, Peter Goebel, Miriam Stengel, Andreas Schmidtmann, Marco van der Voort, Ivo R. Tebbe, Johannes J. Veh, Ruediger W. Klapp, Burghard F. Wiedenmann, Bertram Wang, Lixin Tache, Yvette Moennikes, Hubert TI Bombesin, but not amylin, blocks the orexigenic effect of peripheral ghrelin SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY LA English DT Article DE c-fos; food intake ID CORTICOTROPIN-RELEASING-FACTOR; HYPOTHALAMIC ARCUATE NUCLEUS; GROWTH-HORMONE-SECRETION; AREA POSTREMA NUCLEUS; REDUCES FOOD-INTAKE; NEUROPEPTIDE-Y; RAT-BRAIN; SOLITARY TRACT; C-FOS; INTRAPERITONEAL INJECTION AB The interaction between ghrelin and bombesin or amylin administered intraperitoneally on food intake and brain neuronal activity was assessed by Fos-like immunoreactivity (FLI) in nonfasted rats. Ghrelin (13 mu g/kg ip) increased food intake compared with the vehicle group when measured at 30 min (g/kg: 3.66 +/- 0.80 vs. 1.68 +/- 0.42, P < 0.0087). Bombesin (8 mu g/kg) injected intraperitoneally with ghrelin (13 mu g/kg) blocked the orexigenic effect of ghrelin (1.18 +/- 0.41 g/kg, P < 0.0002). Bombesin alone (4 and 8 mu g/kg ip) exerted a dose-related nonsignificant reduction of food intake (g/kg: 1.08 +/- 0.44, P > 0.45 and 0.55 +/- 0.34, P > 0.16, respectively). By contrast, ghrelin-induced stimulation of food intake (g/kg: 3.96 +/- 0.56 g/kg vs. vehicle 0.82 +/- 0.59, P < 0.004) was not altered by amylin (1 and 5 mu g/kg ip) (g/kg: 4.37 +/- 1.12, P > 0.69, and 3.01 +/- 0.78, respectively, P > 0.37). Ghrelin increased the number of FLI-positive neurons/ section in the arcuate nucleus (ARC) compared with vehicle (median: 42 vs. 19, P < 0.008). Bombesin alone (4 and 8 mu g/kg ip) did not induce FLI neurons in the paraventricular nucleus of the hypothalamus (PVN) and coadministered with ghrelin did not alter ghrelin-induced FLI in the ARC. However, bombesin (8 mu g/kg) with ghrelin significantly increased neuronal activity in the PVN approximately threefold compared with vehicle and similar to 1.5-fold compared with the ghrelin group. Bombesin (8 mu g/kg) with ghrelin injected intraperitoneally induced Fos expression in 22.4 +/- 0.8% of CRF-immunoreactive neurons in the PVN. These results suggest that peripheral bombesin, unlike amylin, inhibits peripheral ghrelin induced food intake and enhances activation of CRF neurons in the PVN. C1 Free Univ Berlin, Dept Med, Div Hepatol Gastroenterol & Endocrinol, Charite,Fac Med, D-13353 Berlin, Germany. Free Univ Berlin, Dept Med, Div Psychosomat Med & Psychotherapy, Charite, D-13353 Berlin, Germany. Free Univ Berlin, Inst Anat, Sect Electron Microscopy & Neuroanat, Charite, D-13353 Berlin, Germany. Univ Marburg, Dept Med, Div Gastroenterol & Endocrinol, Marburg, Germany. Univ Calif Los Angeles, Dept Med, Ctr Ulcer Res, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Med, Educ Digest Dis Res Ctr, Ctr Neurol Sci,Digest Dis Div, Los Angeles, CA 90024 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Monnikes, H (reprint author), Free Univ Berlin, Dept Med, Div Hepatol Gastroenterol & Endocrinol, Charite,Fac Med, Campus Virchow Klinikum,Augustenburger Pl 1, D-13353 Berlin, Germany. EM moennikes@web.de FU PHS HHS [R01 33061] NR 75 TC 14 Z9 14 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6119 J9 AM J PHYSIOL-REG I JI Am. J. Physiol.-Regul. Integr. Comp. Physiol. PD OCT PY 2006 VL 291 IS 4 BP R903 EP R913 DI 10.1152/ajpregu.00681.2005 PG 11 WC Physiology SC Physiology GA 083LO UT WOS:000240457600007 PM 16644908 ER PT J AU Janech, MG Fitzgibbon, WR Ploth, DW Lacy, ER Miller, DH AF Janech, Michael G. Fitzgibbon, Wayne R. Ploth, David W. Lacy, Eric R. Miller, Donald H. TI Effect of low environmental salinity on plasma composition and renal function of the Atlantic stingray, a euryhaline elasmobranch SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article DE free water clearance; glomerular filtration rate; tubular urea reabsorption ID ACID-BASE-BALANCE; ST JOHNS RIVER; FRESH-WATER; SCYLIORHINUS-CANICULA; SQUALUS-ACANTHIAS; DASYATIS-SABINA; RAJA-ERINACEA; CARCHARHINUS-LEUCAS; UREA REABSORPTION; EXTERNAL MEDIUM AB Marine elasmobranchs maintain internal osmolality higher than their external environment, resulting in an osmotic gradient for branchial water uptake. This gradient is markedly increased in low-salinity habitats. The subsequent increase in water uptake presents a challenge to volume homeostasis. The Atlantic stingray is a marine elasmobranch that inhabits a remarkable range of environmental salinities. We hypothesized that the ability of these stingrays to regulate fluid volume in low-salinity environments is due primarily to a renal glomerular and tubular functional reserve. We tested this hypothesis by measuring renal excretory function after a rapid and sustained 50% reduction in the osmolality of the external medium. Atlantic stingrays were maintained in harbor water [control salinity (CS) similar to 850 mosmol/kgH(2)O] for 1 wk. Rays were then either transferred to diluted harbor water [low salinity (LS) similar to 440 mosmol/kgH(2)O] or maintained in CS for a further 24 h. Renal excretory function was markedly higher in the rays subjected to low salinity. Glomerular filtration rate was threefold higher and urine flow rate ninefold higher in the LS group. The clearance of solute-free water was greater, and solute-free water comprised a significantly larger proportion of the urine output for the stingrays transferred to dilute harbor water. We conclude that 1) the kidneys of Atlantic stingrays have a remarkable glomerular and tubular functional reserve, and 2) the marked increase in renal function attenuates the increase in fluid volume when these fish move into low-salinity habitats. C1 Med Univ S Carolina, Coll Charleston, Dept Med, Div Nephrol,Grice Marine Lab, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Fitzgibbon, WR (reprint author), Med Univ S Carolina, Coll Charleston, Dept Med, Div Nephrol,Grice Marine Lab, Charleston, SC 29425 USA. EM fitzgiwr@musc.edu OI Janech, Michael/0000-0002-3202-4811 NR 57 TC 9 Z9 10 U1 0 U2 8 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X EI 1522-1466 J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD OCT PY 2006 VL 291 IS 4 BP F770 EP F780 DI 10.1152/ajprenal.00026.2006 PG 11 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA 081JD UT WOS:000240313000008 PM 16609153 ER PT J AU Haroutunian, V Katsel, P Dracheva, S Davis, KL AF Haroutunian, Vahram Katsel, Pavel Dracheva, Stella Davis, Kenneth L. TI The human homolog of the QKI gene affected in the severe dysmyelination "quaking" mouse phenotype: Downregulated in multiple brain regions in schizophrenia SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Article ID BINDING PROTEINS; MESSENGER-RNA; MUTANT MICE; EXPRESSION; MYELIN; DYSFUNCTION AB Objective: The authors sought to understand the origins of oligodendrocyte/ myelin gene expression abnormalities in the brains of persons with schizophrenia. Method: Twelve cortical regions ( Brodmann's areas 8, 10, 44, 46, 23/31, 24/32, 20, 21, 22, 36/28, 7, and 17) and three non-cortical regions ( caudate, hippocampus, and putamen) of 16 elderly schizophrenia patients and 14 matched comparison subjects were examined using 450 separate microarrays. The mRNA levels of QKI and its isoforms were then measured in a larger cohort by using quantitative real-time polymerase chain reaction (qPCR) in the cingulate cortex of schizophrenia subjects and matched comparison subjects. Results: Expression of QKI mRNA was decreased in seven cortical regions and the hippocampus in the schizophrenia subjects. QKI gene expression deficits detected by microarray were validated by qPCR in the cingulate cortex, where the expression of isoforms QKI-5, QKI-6, and QKI-7 were profoundly perturbed in schizophrenia. Conclusions: Since QKI plays a fundamental role in oligodendrocyte differentiation and in myelination, its underexpression may be pivotal to, and upstream of, other myelin-associated gene expression abnormalities in schizophrenia. Given the role of QKI in determination of oligodendrocyte fate, these results not only confirm oligodendrocyte-related gene expression abnormalities in schizophrenia but suggest that the physiology of glial progenitor cells may be altered in schizophrenia. C1 Bronx Vet Adm Med Ctr, Dept Psychiat, Bronx, NY 10468 USA. Mt Sinai Sch Med, Dept Psychiat, Bronx, NY USA. RP Haroutunian, V (reprint author), Bronx Vet Adm Med Ctr, Dept Psychiat, Rm 4F-33A,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM vahram.haroutunian@mssm.edu FU NCRR NIH HHS [M01-RR-00071]; NIMH NIH HHS [MH-064673, MH-45212] NR 12 TC 62 Z9 62 U1 0 U2 3 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X J9 AM J PSYCHIAT JI Am. J. Psychiat. PD OCT PY 2006 VL 163 IS 10 BP 1834 EP 1837 DI 10.1176/appi.ajp.163.10.1834 PG 4 WC Psychiatry SC Psychiatry GA 089UN UT WOS:000240906800032 PM 17012699 ER PT J AU Almyroudis, NG Sutton, DA Linden, P Rinaldi, MG Fung, J Kusne, S AF Almyroudis, N. G. Sutton, D. A. Linden, P. Rinaldi, M. G. Fung, J. Kusne, S. TI Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Review DE mould; mucorales; solid organ transplantation; zygomycosis ID INVASIVE GASTROINTESTINAL ZYGOMYCOSIS; CARDIAC ALLOGRAFT RECIPIENT; CARE CANCER CENTER; PULMONARY MUCORMYCOSIS; FUNGAL-INFECTIONS; RENAL-TRANSPLANTATION; RHINOCEREBRAL MUCORMYCOSIS; LIVER-TRANSPLANTATION; AMPHOTERICIN-B; CUNNINGHAMELLA-BERTHOLLETIAE AB Zygomycetes are ubiquitous fungi that can cause invasive disease associated with high mortality. We report 10 solid organ transplant recipients with zygomycosis (incidence 2 per 1000) and reviewed 106 cases in the English-language literature. These included renal (n = 73), heart (n = 16), lung (n = 4), heart/lung (n = 2), liver (n = 19) and kidney/pancreas (n = 2) transplant recipients. All patients were receiving immunosuppression and the vast majority steroids. The clinical presentation included rhino-sino-orbital (n = 20), rhinocerebral (n = 16), pulmonary (n = 28), gastrointestinal (n = 13), cutaneous (n = 18), renal (n = 6) and disseminated disease (n = 15). Most frequently isolated genera were Rhizopus (73%) followed by Mucor (13%). The overall mortality was 49%. While rhino-sino-orbital disease had the best prognosis, rhinocerebral disease had high mortality (93%) comparable to disseminated disease. A favorable outcome was associated with limited, surgically accessible disease and early surgical intervention along with amphotericin B administration. C1 Univ Pittsburgh, Med Ctr, Thomas E Starzl Transplantat Inst, Dept Crit Care, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Med Ctr, Thomas E Starzl Transplantat Inst, Dept Med, Pittsburgh, PA USA. Univ Pittsburgh, Med Ctr, Thomas E Starzl Transplantat Inst, Dept Surg, Pittsburgh, PA USA. Mayo Clin Scottsdale, Scottsdale, AZ USA. Univ Texas, Hlth Sci Ctr, Dept Pathol, Fungus Testing Lab, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Linden, P (reprint author), Univ Pittsburgh, Med Ctr, Thomas E Starzl Transplantat Inst, Dept Crit Care, Pittsburgh, PA 15260 USA. EM lindenpk@ccm.upmc.edu; Kusne.shimon@mayo.edu RI Fung, John/A-2679-2012 NR 104 TC 111 Z9 115 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD OCT PY 2006 VL 6 IS 10 BP 2365 EP 2374 DI 10.1111/j.1600-6143.2006.01496.x PG 10 WC Surgery; Transplantation SC Surgery; Transplantation GA 082DD UT WOS:000240366000018 PM 16925570 ER PT J AU Kezirian, EJ Weaver, EM Yueh, B Khuri, SF Daley, J Henderson, WG AF Kezirian, Eric J. Weaver, Edward M. Yueh, Bevan Khuri, Shukri F. Daley, Jennifer Henderson, William G. TI Risk factors for serious complication after uvulopalatopharyngoplasty SO ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY LA English DT Article; Proceedings Paper CT 17th Annual Meeting of the Associated-Professional-Sleep-Societies CY JUN 03-08, 2003 CL CHICAGO, IL SP Assoc Prof Sleep Soc ID OBSTRUCTIVE SLEEP-APNEA; PERIOPERATIVE COMPLICATIONS; CARDIOVASCULAR-DISEASE; MORTALITY; CARE; HYPERTENSION; ASSOCIATION; SURGERY; QUALITY AB Objective: To test the hypothesis that comorbidity, performance of concurrent sleep apnea procedures in addition to uvulopalatopharyngoplasty, body mass index, apnea-hypopnea index, and lowest oxygen saturation are risk factors for serious perioperative complications after uvulopalatopharyngoplasty. Design: Prospective cohort and nested case-control studies. Setting: United States Veterans Affairs medical centers. Patients: A prospective cohort of 3130 consecutive adult inpatients who underwent uvulopalatopharyngoplasty from 1991 to 2001 was retrospectively analyzed from the Veterans Affairs National Surgical Quality Improvement Program database to determine the relationship between perioperative complications and both concurrent procedures and medical comorbidity. A nested case-control analysis was conducted on 43 cases with complications and 212 controls without complications from the cohort. Controls were matched on age, sex, year of operation, and concurrent surgery; this case-control analysis enabled the study of body mass index, apnea-hypopnea index, and lowest oxygen saturation, which were not available in the cohort database. Multivariate logistic regression measured associations between risk factors and complications, adjusting or controlling for age, sex, race, smoking status, year of uvulopalatopharyngoplasty, and presence of any concurrent procedure. Main Outcome Measure: Sixteen specific serious perioperative complications, including 30-day mortality. Results: The cohort included 3130 veterans (97% were men aged 50 +/- 11 [ mean +/- SD] years). In the cohort study, comorbidity was associated with serious complication: the adjusted risk ratio was 1.96 (95% confidence interval, 1.16-3.18) for each increase in American Society of Anesthesiologists class. Concurrent nonnasal procedures increased the risk of complication compared with no concurrent procedures ( adjusted risk ratio, 4.94; 95% confidence interval, 2.34-10.4). In the case-control analyses, the apnea-hypopnea index, body mass index, and medical comorbidity were each associated with serious complication after adjustment for confounding variables, but this study had insufficient power to determine if these risk factors were independent of each other. Concurrent retrolingual procedures demonstrated an independent association with complication after adjustment for confounders. The lowest oxygen saturation was not associated with serious complication. Conclusions: Apnea-hypopnea index, body mass index, and medical comorbidity were each associated with serious complication; however, the low complication rate precluded demonstration of associations independent of each other. Concurrent retrolingual procedures were also associated with serious complication, but the cumulative risk of separate retrolingual procedures is unknown. C1 Univ Calif San Francisco, Sch Med, Dept Otolaryngol Head & Neck Surg, San Francisco, CA USA. Vet Affairs Puget Sound Hlth Care Syst, Dept Otolaryngol Head & Neck Surg, Seattle, WA USA. Univ Washington, Sch Med, Dept Otolaryngol Head & Neck Surg, Seattle, WA USA. Brockton W Roxbury Vet Affairs Med Ctr, Dept Surg, W Roxbury, MA USA. Harvard Univ, Sch Med, Boston, MA USA. Tenet HealthCare, Dallas, TX USA. Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Community & Family Med, Hanover, NH 03756 USA. Univ Washington, Sch Publ Hlth & Community Med, Dept Hlth Serv, Seattle, WA 98195 USA. Univ Colorado, Hlth Sci Ctr, Colorado Hlth Outcomes Program, Denver, CO USA. Univ Colorado, Hlth Sci Ctr, Dept Prevent Med & Biometr, Denver, CO 80262 USA. RP Weaver, EM (reprint author), Mail Stop 112-OTO,1660 S Columbian Way, Seattle, WA 98108 USA. EM eweaver@u.washington.edu OI Yueh, Bevan/0000-0003-1380-1053 FU NHLBI NIH HHS [HL068849, K23 HL068849, K23 HL068849-04]; NIDCD NIH HHS [T32 DC000018] NR 23 TC 17 Z9 24 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0886-4470 J9 ARCH OTOLARYNGOL JI Arch. Otolaryngol. Head Neck Surg. PD OCT PY 2006 VL 132 IS 10 BP 1091 EP 1098 DI 10.1001/archotol.132.10.1091 PG 8 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 095DD UT WOS:000241287500011 PM 17043257 ER PT J AU Zmitrewicz, RJ Neptune, RR Walden, JG Rogers, WE Bosker, GW AF Zmitrewicz, Robert J. Neptune, Richard R. Walden, Judith G. Rogers, William E. Bosker, Gordon W. TI The effect of foot and ankle prosthetic components on braking and propulsive impulses during transtibial amputee gait SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE amputees; rehabilitation; walking ID BELOW-KNEE AMPUTEES; SOUND LIMB; FLEX-FOOT; SACH FOOT; FEET; INDIVIDUALS; AMPUTATION; AMBULATION; SEATTLE AB Objective: To assess the influence of energy storage and return (ESAR) prosthetic feet and multi-axis ankles on ground reaction forces and loading asymmetry between lower limbs in transtibial amputees. Design: Subjects wore 2 different prosthetic feet with and without a multi-axis ankle and were analyzed using a blind repeated-measures multivariate analysis-of-variance design. Setting: Gait analysis laboratory. Participants: Fifteen healthy unilateral transtibial amputees (>55 y) who had an amputation at least 1 year before testing because of vascular disorders. Interventions: Not applicable. Main Outcome Measures: The anteroposterior ground reaction force impulse, peak ground reaction forces, and braking and propulsion impulse duration were analyzed as subjects walked at a self-selected speed while wearing each of the 4 foot-ankle prosthesis combinations. Statistical analyses were used to determine if there was a significant foot, ankle, or foot-ankle interaction effect on the outcome measures for each foot (P<.05). Results: Amputees generated a significantly greater propulsive impulse with the residual leg when wearing a multi-axis ankle with the ESAR and non-ESAR foot, which improved the propulsive symmetry between the residual and intact legs. There was no prosthetic foot effect on these measures. There were no significant differences in the peak residual-leg braking or propulsive ground reaction forces or the impulse durations due to the prosthetic foot, ankle, or foot-ankle interactions, although an increase in the propulsive impulse duration approached significance (P=.062) with a multi-axis ankle. Conclusions: These results suggest that amputee gait may improve with the prescription of multi-axis ankles that allow for greater propulsive impulses by the residual leg, which improve the loading symmetry between legs. C1 Univ Texas, Dept Mech Engn, Austin, TX 78712 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, Dept Rehabil Med, San Antonio, TX USA. RP Neptune, RR (reprint author), Univ Texas, Dept Mech Engn, 1 Univ Stn C2200, Austin, TX 78712 USA. EM rneptune@mail.utexas.edu RI Rogers, Bill/F-7689-2010 NR 21 TC 45 Z9 46 U1 1 U2 11 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD OCT PY 2006 VL 87 IS 10 BP 1334 EP 1339 DI 10.1016/j.apmr.2006.06.013 PG 6 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 095OA UT WOS:000241316000007 PM 17023242 ER PT J AU Yehuda, R Tischler, L Golier, JA Grossman, R Brand, SR Kaufman, S Harvey, PD AF Yehuda, Rachel Tischler, Lisa Golier, Julia A. Grossman, Robert Brand, Sarah R. Kaufman, Shira Harvey, Philip D. TI Longitudinal assessment of cognitive performance in Holocaust survivors with and without PTSD SO BIOLOGICAL PSYCHIATRY LA English DT Article DE aging; California Verbal Learning Test; memory; paired associate learning; PTSD ID POSTTRAUMATIC-STRESS-DISORDER; VIVO HIPPOCAMPAL VOLUMETRICS; MEMORY PERFORMANCE; COMBAT VETERANS; CORTISOL-LEVELS; FOLLOW-UP; DYSFUNCTION; PRISONERS; DEFICITS; ATROPHY AB Background: There are currently no longitudinal studies of cognitive performance in older patients with Posttraumatic Stress Disorder (PTSD). It is therefore unclear whether relationships between memory and symptoms differ over time among older persons with and without PTSD. Methods: Twenty-eight Holocaust survivors and nineteen comparison subjects were evaluated 5 years after they had received a memory assessment including paired-associates learning and the California Verbal Learning Test (CVLT). Results: While Holocaust survivors with PTSD showed a diminution in symptom severity (t = 2.99, df = 12, p = .011), they still manifested a decline in paired associates learning, suggesting an acceleration in age-related memory impairment (related word pairs: t = 2.87. df = 13, p = .013; unrelated word pairs: t = 2.06 df = 13, p = .060). The survivors with PTSD showed improvements on several CVLT measures over time. These improvements correlated with symptom improvements, such that group differences at the follow-up were no longer detected. Conclusions: The discrepancy in the pattern of performance on these two tests of memory following symptom improvement suggests possible differentiation between of aspects of memory functions associated with aging and trauma exposure and those associated with the severity of PTSD symptoms. Performance on the CVLT appeared related to clinical symptom severity while paired associate learning worsened over time in Holocaust survivors with PTSD, consistent with earlier cross-sectional findings. C1 Bronx Vet Affairs, Mt Sinai Sch Med, Traumat Stress Studies Program, Dept Psychiat, New York, NY USA. Mt Sinai Sch Med, Div Psychol, Dept Psychiat, New York, NY USA. James J Peters VA Med Ctr, VISN 3, Mental Illness Res Educ & Clin Ctr, Bronx, NY USA. RP Yehuda, R (reprint author), Bronx VA OOMH, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM Rachel.Yehuda@med.va.gov FU PHS HHS [NIMH R01-0-64675, NIMH R01-2-49555] NR 37 TC 44 Z9 44 U1 4 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD OCT 1 PY 2006 VL 60 IS 7 BP 714 EP 721 DI 10.1016/j.biopsych.2006.03.069 PG 8 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 090TB UT WOS:000240973300008 PM 17008144 ER PT J AU Rowe, PSN Matsumoto, N Jo, OD Shih, RNJ Oconnor, J Roudier, MP Bain, S Liu, SG Harrison, J Yanagawa, N AF Rowe, Peter S. N. Matsumoto, Naoko Jo, Oak D. Shih, Remi N. J. Oconnor, Jeannine Roudier, Martine P. Bain, Steve Liu, Shiguang Harrison, Jody Yanagawa, Norimoto TI Correction of the mineralization defect in hyp mice treated with protease inhibitors CA074 and pepstatin SO BONE LA English DT Article DE MEPE; rickets; osteomalacia; PHEX; mineralization; FGF23 ID LINKED HYPOPHOSPHATEMIC RICKETS; MOUSE BONE-CELLS; MATRIX EXTRACELLULAR PHOSPHOGLYCOPROTEIN; TUMOR-INDUCED OSTEOMALACIA; RENAL PHOSPHATE-TRANSPORT; ABNORMAL PHEX EXPRESSION; HUMAN OSTEOBLAST CELLS; VITAMIN-D METABOLISM; IN-VIVO; SKELETAL ABNORMALITIES AB Increased expression of several osteoblastic proteases and MEPE (a bone matrix protein) occurs in X-linked hypophosphatemic rickets (hyp). This is associated with an increased release of a protease-resistant MEPE peptide (ASARM peptide), a potent inhibitor of mineralization. Cathepsin B cleaves MEPE releasing ASARM peptide and hyp osteoblast/osteocyte cells hypersecrete cathepsin D, an activator of cathepsin B. Our aims were to determine whether cathepsin inhibitors correct the mineralization defect in vivo and whether hyp-bone ASARM peptide levels are reduced after protease treatment. Normal littermates and hyp mice (n = 6) were injected intraperitoneally once a day for 4 weeks with pepstatin, CAO74 or vehicle. Animals were then sacrificed and bones plus serum removed for comprehensive analysis. All hyp mice groups (treated and untreated) remained hypophosphatemic with serum 1,25 vitamin D3 inappropriately normal. Serum PTH was significantly elevated in all hyp mice groups relative to normal mice (P = 0.0017). Untreated hyp mice had six-fold elevated levels of serum alkaline-phosphatase and two-fold elevated levels of ASARM peptides relative to normal mice (P < 0.001). In contrast, serum alkaline phosphatase and serum ASARM peptides were significantly reduced (normalized) in hyp mice treated with CA074 or pepstatin. Serum FGF23 levels remained high in all hyp animal groups (P < 0.0001). Hyp mice treated with protease inhibitors showed dramatic reductions in unmineralized osteoid (femurs) compared to control hyp mice (Goldner staining). Also, hyp animals treated with protease inhibitors showed marked and significant improvements in growth plate width (42%), osteoid thickness (40%) and cortical area (40%) (P < 0.002). The mineralization apposition rate, bone formation rate and mineralization surface were normalized by protease-treatment. High-resolution pQCT mineral histomorphometry measurements and uCT also confirmed a marked mineralization improvement. Finally, the growth plate and cortical bone of hyp femurs contained a massive accumulation of osteoblast-derived ASARM peptide(s) that was reduced in hyp animals treated with CA074 or pepstatin. This study confirms in vivo administration of cathepsin inhibitors improves bone mineralization in hyp mice. This may be due to a protease inhibitor mediated decrease in proteolytic degradation of the extracellular matrix and a reduced release of ASARM peptides (potent mineralization inhibitors). (c) 2006 Elsevier Inc. All rights reserved. C1 Univ Kansas, Med Ctr, Dept Internal Med, Kidney Inst, Kansas City, KS 66160 USA. Univ Kansas, Med Ctr, Div Nephrol, Kansas City, KS 66160 USA. Greater Los Angeles Vet Affairs Healthcare Syst, Med & Res Serv, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. Univ Texas, Hlth Sci Ctr, Dept Periodont, San Antonio, TX 78229 USA. SkeleTech Inc, Bothell, WA 98021 USA. RP Rowe, PSN (reprint author), Univ Kansas, Med Ctr, Dept Internal Med, Kidney Inst, 3901 Rainbow Blvd,6020B Wahl Hall E, Kansas City, KS 66160 USA. EM prowe@kumc.edu FU NCRR NIH HHS [5P20RR017708-03, M01 RR000865, P20 RR017708, MO1-RR00865]; NIAMS NIH HHS [R01 AR051598, P30 AR058886, 2 RO1-AR045955-07, R0-1 DK-AR58886, R01 AR045955, R0-1 AR51598-01]; NIDCR NIH HHS [R03 DE015900, 1R03DE015900-01] NR 88 TC 37 Z9 39 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 8756-3282 J9 BONE JI Bone PD OCT PY 2006 VL 39 IS 4 BP 773 EP 786 DI 10.1016/j.bone.2006.04.012 PG 14 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 088DW UT WOS:000240792700011 PM 16762607 ER PT J AU Lycette, JL Luoh, SW Beer, TM Deloughery, TG AF Lycette, Jennifer L. Luoh, Shiuh-Wen Beer, Tomasz M. Deloughery, Thomas G. TI Acute bilateral pulmonary emboli occurring while on adjuvant aromatase inhibitor therapy with anastrozole: case report and review of the literature SO BREAST CANCER RESEARCH AND TREATMENT LA English DT Review DE anastrozole; aromatase inhibitors; breast cancer; pulmonary embolus; venous thromboembolism ID EARLY BREAST-CANCER; HORMONE REPLACEMENT THERAPY; DEEP-VEIN THROMBOSIS; POSTMENOPAUSAL WOMEN; TAMOXIFEN THERAPY; RANDOMIZED-TRIAL; VENOUS THROMBOEMBOLISM; RISK-FACTORS; HEALTHY WOMEN; LETROZOLE AB Hormonal therapy is the mainstay of adjuvant treatment for women with early-stage estrogen receptor-positive breast cancer. Recently, the aromatase inhibitors have moved to the forefront of adjuvant hormonal therapy,. however, the adverse effects of these agents are not yet fully understood. It is generally accepted that tamoxifen, but not the aromatase inhibitors, is associated with an increased risk of thrombosis in women with breast cancer. Studies comparing aromatase inhibitors to tamoxifen in the adjuvant setting have reported a lower rate of venous thromboembolism with the aromatase inhibitors, yet the incidence of venous thromboembolism with these new agents is higher than that expected in the general population. Here we report a case of acute bilateral pulmonary emboli occurring while on adjuvant aromatase inhibitor therapy with anastrozole, and review the literature on the incidence of venous thromboembolism during the use of aromatase, inhibitors in the adjuvant setting. C1 Oregon Hlth Sci Univ, Div Hematol & Med Oncol, Portland, OR 97239 USA. Portland VA Med Ctr, Portland, OR 97239 USA. RP Lycette, JL (reprint author), Oregon Hlth Sci Univ, Div Hematol & Med Oncol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM lycettej@ohsu.edu NR 41 TC 14 Z9 14 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0167-6806 J9 BREAST CANCER RES TR JI Breast Cancer Res. Treat. PD OCT PY 2006 VL 99 IS 3 BP 249 EP 255 DI 10.1007/s10549-006-9212-1 PG 7 WC Oncology SC Oncology GA 093UD UT WOS:000241194900002 PM 16752073 ER PT J AU Panek, J Karcz, D Pieton, R Zasada, J Tusinski, M Dolecki, M Winiarski, M AF Panek, Jozefa Karcz, Danuta Pieton, Richard Zasada, Jakub Tusinski, Marcin Dolecki, Miroslaw Winiarski, Marek TI Blood serum levels of proinflammatory cytokines in patients with different degrees of biliary pancreatitis SO CANADIAN JOURNAL OF GASTROENTEROLOGY LA English DT Article DE acute biliary pancreatitis; interleukins ID CLASSIFICATION-SYSTEM; ORGAN DYSFUNCTION; INTERLEUKIN-6; SEVERITY AB BACKGROUND: Proinflammatory cytokines play a fundamental role in the local and systemic inflammatory responses in the initial stages of acute biliary pancreatitis (ABP) and in the development of severe forms of the disease. OBJECTIVES: The aim of the present study was to assess the systemic release of proinflammatory cytokines and to characterize differences between patients with mild ABP (MABP) and severe ABP (SABP) PATIENTS AND METHODS: In the current study, 54 patients with MABP were compared with 14 patients with SABP. Serum levels of turnout necrosis)actor-alpha, interleukin (IL)-1 beta, IL-6, IL-8 and IL-12p40 were measured every second day after admission for one week. RESULTS: The turnout necrosis factor-alpha level was similar in all days of analysis in patients with MABP but was lower compared with SABP patients. The level of IL-1 beta was higher at admission in patients with MABP. The level of IL-6 peaked on admission day in both groups, but in patients with SABP, the obtained values were higher. The level of IL-8 on admission day was slightly higher in patients with MABP and systematically decreased when measured on the following days (the third, fifth and seventh days of the study). An increased level of IL-8 during the third, fifth and seventh days of the investigation was seen in SABP patients. The level of IL-12p40 was slightly higher in patients with MABP on the day of admission. CONCLUSIONS: The levels of some proinflammatory cytokines are higher in patients with SABP than in patients with MABP. The most consistent difference between the two groups was that the levels of IL-6 were significantly higher in patients with SABP throughout the study. Serum concentration of IL-6 may be helpful as a marker of severity and outcome of ABP. C1 Jagiellonian Univ, Coll Med, Dept Surg 2, PL-31501 Krakow, Poland. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. RP Panek, J (reprint author), Jagiellonian Univ, Coll Med, Dept Surg 2, Ul Kopernika 21, PL-31501 Krakow, Poland. EM mspanek@cyf-kr.edu.pl NR 23 TC 10 Z9 14 U1 0 U2 0 PU PULSUS GROUP INC PI OAKVILLE PA 2902 S SHERIDAN WAY, OAKVILLE, ONTARIO L6J 7L6, CANADA SN 0835-7900 J9 CAN J GASTROENTEROL JI Can. J. Gastroenterol. PD OCT PY 2006 VL 20 IS 10 BP 645 EP 648 PG 4 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 097IP UT WOS:000241441000006 PM 17066155 ER PT J AU Mantena, SK Sharma, SD Katiyar, SK AF Mantena, Sudheer K. Sharma, Som D. Katiyar, Santosh K. TI Berberine inhibits growth, induces G(1) arrest and apoptosis in human epidermoid carcinoma A431 cells by regulating Cdki-Cdk-cyclin cascade, disruption of mitochondrial membrane potential and cleavage of caspase 3 and PARP SO CARCINOGENESIS LA English DT Article ID DEPENDENT KINASE INHIBITORS; CYTOCHROME-C; BCL-2 FAMILY; CANCER; DEATH; INDUCTION; PROTEIN; NEOPLASIA; HEALTH; DRUGS AB Chemotherapeutic approach using non-toxic botanicals may be one of the strategies for the management of the skin cancers. Here we report that in vitro treatment of human epidermoid carcinoma A431 cells with berberine, a naturally occurring isoquinoline alkaloid, decreased cell viability (3-77%, P < 0.05-0.001) and induced cell death (3-51%, P < 0.01-0.001) in a dose (5-75 mu M)- and time (12-72 h)-dependent manner, which was associated with an increase in G(1) arrest. G(0)/G(1) phase of the cell cycle is known to be controlled by cyclin dependent kinases (Cdk), cyclin kinase inhibitors (Cdki) and cyclins. Our western blot analysis showed that berberine-induced G(1) cell cycle arrest was mediated through the increased expression of Cdki proteins (Cip1/p21 and Kip1/p27), a simultaneous decrease in Cdk2, Cdk4, Cdk6 and cyclins D1, D2 and E and enhanced binding of Cdki-Cdk. In additional studies, treatment of A431 cells with berberine (15-75 mu M) for 72 h resulted in a significant dose-dependent increase in apoptosis (31-60%, P < 0.05-0.001) than non-berberine-treated control (11.7%), which was associated with an increased expression of pro-apoptotic protein Bax, decreased expression of anti-apoptotic proteins Bcl-2 and Bcl-xl, disruption of mitochondrial membrane potential, and activation of caspases 9, 3 and poly (ADP-ribose) polymerase. Pretreatment of A431 cells with the pan-caspase inhibitor (z-VAD-fmk) significantly blocked the berberine-induced apoptosis in A431 cells confirmed that berberine-induced apoptosis is mediated through activation of caspase 3-dependent pathway. Together, this study for the first time identified berberine as a chemotherapeutic agent against human epidermoid carcinoma A431 cells in vitro, further in vivo studies are required to determine whether berberine could be an effective chemotherapeutic agent for the management of non-melanoma skin cancers. C1 Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA. Univ Alabama, Skin Dis Res Ctr, Birmingham, AL 35294 USA. Birmingham VA Med Ctr, Birmingham, AL 35294 USA. RP Katiyar, SK (reprint author), Univ Alabama, Dept Dermatol, 1670,Univ Blvd,Volker Hall 557,POB 202, Birmingham, AL 35294 USA. EM skatiyar@uab.edu FU NIAMS NIH HHS [AR050948-01] NR 42 TC 127 Z9 136 U1 2 U2 11 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0143-3334 J9 CARCINOGENESIS JI Carcinogenesis PD OCT PY 2006 VL 27 IS 10 BP 2018 EP 2027 DI 10.1093/carcin/bgl043 PG 10 WC Oncology SC Oncology GA 090CF UT WOS:000240927500010 PM 16621886 ER PT J AU Mortensen, E Restrepo, M Copeland, L Anzueto, A Pugh, J Pugh, MJ AF Mortensen, Eric Restrepo, Marcos Copeland, Laurel Anzueto, Antonio Pugh, Jacqueline Pugh, Mary Jo TI Impact of statin and angiotensin II receptor blocker use on mortality for patients hospitalized with sepsis SO CHEST LA English DT Meeting Abstract CT CHEST 2006 Conference CY OCT 21-26, 2006 CL Salt Lake City, UT C1 S Texas Vet Healthcare Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD OCT PY 2006 VL 130 IS 4 SU S BP 135S EP 135S PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 095DI UT WOS:000241288000182 ER PT J AU Adams, SG Simpson, T Allan, PF Lee, S Vipraio, G Smith, PK Anzueto, A Pugh, JA Kearney, L AF Adams, Sandra G. Simpson, Tamara Allan, Patrick F. Lee, Shuko Vipraio, Gilbert Smith, Paulla K. Anzueto, Antonio Pugh, Jacqueline A. Kearney, Lisa TI Cognitive behavioral group therapy improves quality of life more than general health education for anxiety in severe chronic obstructive pulmonary disease SO CHEST LA English DT Meeting Abstract CT CHEST 2006 Conference CY OCT 21-26, 2006 CL Salt Lake City, UT C1 UTHSCSA, San Antonio, TX USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 1 Z9 1 U1 1 U2 7 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD OCT PY 2006 VL 130 IS 4 SU S BP 180S EP 180S PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 095DI UT WOS:000241288000338 ER PT J AU Gorse, GJ O'Connor, TZ Young, SL Habib, MP Wittes, J Neuzil, KM Nichol, KL AF Gorse, Geoffrey J. O'Connor, Theresa Z. Young, Stephen L. Habib, Michael P. Wittes, Janet Neuzil, Kathleen M. Nichol, Kristin L. TI Impact of a winter respiratory virus season on patients with COPD and association with influenza vaccination SO CHEST LA English DT Article DE COPD; health-related quality of life; influenza virus; pulmonary function; vaccine ID OBSTRUCTIVE PULMONARY-DISEASE; CHRONIC LUNG-DISEASE; VIRAL-INFECTIONS; ELDERLY PERSONS; UNDERLYING CONDITIONS; ACUTE EXACERBATIONS; CHRONIC-BRONCHITIS; SYNCYTIAL VIRUS; A INFECTIONS; MORTALITY AB Background: We assessed the effects of an influenza season on patients with COPD. Data from 2,215 veterans in a multicenter, randomized, double-blind influenza vaccine efficacy study were analyzed for changes in spirometric and functional status, comparing patients with laboratory-documented influenza (LDI)-caused illness, non-LDI-caused respiratory illness, or no illness, and for association with influenza vaccination. Methods: Patients received either IM trivalent inactivated influenza virus vaccine (TIV) plus intranasal trivalent, live attenuated, cold-adapted influenza virus vaccine (TC) or TIV plus intranasal placebo (TP). We performed spirometry, measured the chronic lung disease severity index (CLDSI) score to assess functional status and well-being, and tested for influenza virus infection. Results: Worsening in FEV1, percentage of predicted FEV, and CLDSI score (p < 0.001) was associated with acute respiratory illness in 585 illnesses including 94 LDI-caused illnesses. LDI-caused illness was more likely to be associated with worsening in FEV, and CLDSI score acutely than non-LDI-caused illness (p < 0.01). Logistic regression showed acute respiratory illness (odds ratio [OR], 1.78; 95% confidence limit [CL], 1.40 to 2.26) to be associated with worsening in CLDSI score, and receipt of TC (OR, 1.39; 95% CL, 1.10 to 1.74) and no illness (OR, 0.70; 95% CL, 0.53 to 0.91 for acute respiratory illness) to be associated with better CLDSI score at the end of the study. Hospitalization was more frequent in patients with acute respiratory illness (p < 0.0001). Conclusions: Acute respiratory illness was associated with increased health-care utilization and obstruction to airflow, and worse functional status and well-being. At the end of the study, receipt of TC was associated with improvement and acute respiratory illness was associated with worsening in functional status and well-being. C1 St Louis Univ, Hlth Sci Ctr, Div Infect Dis & Immunol, St Louis, MO 63110 USA. Dept Vet Affairs Med Ctr, St Louis, MO USA. Cooperat Studies Program, Coordinating Ctr, Dept Vet Affairs, West Haven, CT USA. Dept Vet Affairs Med Ctr, Durham, NC USA. Dept Vet Affairs Med Ctr, Tucson, AZ USA. Stat Collaborat, Washington, DC USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. Univ Washington, Seattle, WA 98195 USA. Univ Minnesota, Minneapolis, MN USA. Dept Vet Affairs Med Ctr, Minneapolis, MN USA. RP Gorse, GJ (reprint author), St Louis Univ, Hlth Sci Ctr, Div Infect Dis & Immunol, 3635 Vista Ave FDT-8N, St Louis, MO 63110 USA. EM gorsegj@slu.edu NR 45 TC 21 Z9 24 U1 0 U2 6 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD OCT PY 2006 VL 130 IS 4 BP 1109 EP 1116 DI 10.1378/chest.130.4.1109 PG 8 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 094UX UT WOS:000241265700029 PM 17035445 ER PT J AU Mercer, JL Boninger, M KoontZ, A Ren, DX Dyson-Hudson, T Cooper, R AF Mercer, Jennifer L. Boninger, Michael KoontZ, Alicia Ren, Dianxu Dyson-Hudson, Trevor Cooper, Rory TI Shoulder joint kinetics and pathology in manual wheelchair users SO CLINICAL BIOMECHANICS LA English DT Article DE shoulder; joint kinetics; spinal cord injury; biomechanics; pathology; inverse dynamics ID SPINAL-CORD-INJURY; REPETITIVE WORK; ROTATOR CUFF; IMAGING ABNORMALITIES; PUSHRIM BIOMECHANICS; NECK/SHOULDER PAIN; UPPER EXTREMITY; RISK-FACTORS; PROPULSION; WEIGHT AB Background. Manual wheelchair users rely heavily on their upper limbs for independent mobility which likely leads to a high prevalence of shoulder pain and injury. The goal of this study was to examine the relationship between shoulder forces and moments experienced during wheelchair propulsion and shoulder pathology. Methods. Kinetic and kinematic data was recorded from 33 subjects with paraplegia as they propelled their wheelchairs at two speeds (0.9 and 1.8 m/s). Shoulder joint forces and moments were calculated using inverse dynamic methods and shoulder pathology was evaluated using a physical exam and magnetic resonance imaging scan. Findings. Subjects who experienced higher posterior force (Odds Ratio (OR) = 1.29, P = 0.03), lateral force (OR = 1.35, P = 0.047), or extension moment (OR = 1.35, P = 0.09) during propulsion were more likely to exhibit coracoacromial ligament edema. Individuals who displayed larger lateral forces (OR = 4.35, P = 0.045) or abduction moments (OR = 1.58, P = 0.06) were more likely to have coracoacromial ligament thickening. Higher superior forces (OR = 1.05, P = 0.09) and internal rotation moments (OR = 1.61 P = 0.02) at the shoulder were associated with increased signs of shoulder pathology during the physical exam. Interpretation. Specific joint forces and moments were related to measures of shoulder pathology. This may indicate a need to reduce the overall force required to propel a wheelchair in order to preserve upper limb integrity. Potential interventions include changes to wheelchair setup, propulsion training, or alternative means of mobility. (c) 2006 Elsevier Ltd. All rights reserved. C1 VA Pittsburgh Healthcare Syst, Human Engn Res Labs, VA Rehabil Res & Dev Ctr, Pittsburgh, PA 15206 USA. Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA 15260 USA. Spinal Cord Injury Rehabil Res, Kessler Med Rehabil Res & Educ Corp, W Orange, NJ USA. Univ Med & Dent New Jersey, Dept Phys Med & Rehabil, Newark, NJ 07103 USA. RP Boninger, M (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, VA Rehabil Res & Dev Ctr, 7180 Highland Dr,151R1-H, Pittsburgh, PA 15206 USA. EM boninger@pitt.edu OI Boninger, Michael/0000-0001-6966-919X FU PHS HHS [H133A011107] NR 40 TC 106 Z9 108 U1 2 U2 21 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0268-0033 J9 CLIN BIOMECH JI Clin. Biomech. PD OCT PY 2006 VL 21 IS 8 BP 781 EP 789 DI 10.1016/j.clinbiomech.2006.04.010 PG 9 WC Engineering, Biomedical; Orthopedics; Sport Sciences SC Engineering; Orthopedics; Sport Sciences GA 082LE UT WOS:000240387500003 PM 16808992 ER PT J AU Cusack, KJ Grubaugh, AL Knapp, RG Frueh, BC AF Cusack, Karen J. Grubaugh, Anouk L. Knapp, Rebecca G. Frueh, B. Christopher TI Unrecognized trauma and PTSD among public mental health consumers with chronic and severe mental illness SO COMMUNITY MENTAL HEALTH JOURNAL LA English DT Article DE community mental health; severe mental illness; traumatic events; posttraumatic stress disorder ID POSTTRAUMATIC-STRESS-DISORDER; PSYCHOMETRIC PROPERTIES; CIVILIAN VERSION; WOMEN; PREVALENCE; CHECKLIST; COMMUNITY; COMORBIDITY; SERVICES; HISTORY AB Lifetime prevalence of traumatic events and current PTSD was assessed among 142 mental health consumers with serious mental illness served by a psychosocial. rehabilitation day program. Lifetime exposure to trauma was high (87%). The rate of PTSD based on the PTSD Checklist (PCL) was also high (19-30% depending on different scoring criteria). Overall, the PCL had strong internal reliability for this sample. Documentation of trauma and PTSD was exceptionally low in medical records. Results suggest that trauma and PTSD are significantly overlooked in the public mental health system. Improved recognition of trauma and PTSD are needed in order to provide meaningful services to this highly vulnerable population. C1 Univ N Carolina, Cecil G Sheps Ctr Hlth Serv Res, Chapel Hill, NC 27515 USA. Med Univ S Carolina, Charleston, SC 29425 USA. Ralph Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Cusack, KJ (reprint author), Univ N Carolina, Cecil G Sheps Ctr Hlth Serv Res, 725 Martin Luther King, Chapel Hill, NC 27515 USA. EM kcusack@schsr.unc.edu NR 42 TC 35 Z9 35 U1 6 U2 10 PU KLUWER ACADEMIC-HUMAN SCIENCES PRESS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA SN 0010-3853 J9 COMMUNITY MENT HLT J JI Community Ment. Health J. PD OCT PY 2006 VL 42 IS 5 BP 487 EP 500 DI 10.1007/s10597-006-9049-4 PG 14 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 101CO UT WOS:000241716700005 PM 16868841 ER PT J AU Behnam, K Murray, SS Brochmann, EJ AF Behnam, Keyvan Murray, Samuel S. Brochmann, Elsa J. TI BMP stimulation of alkaline phosphatase activity in pluripotent mouse C2C12 cells is inhibited by dermatopontin, one of the most abundant low molecular weight proteins in demineralized bone matrix SO CONNECTIVE TISSUE RESEARCH LA English DT Article DE bone morphogenetic protein; demineralized bone matrix; dermatopontin; proteomics; TGF-beta ID GROWTH-FACTOR-BETA; OSTEOBLAST-LIKE CELLS; EXTRACELLULAR-MATRIX; MORPHOGENETIC PROTEINS; TARGETED DISRUPTION; BOVINE BONE; IN-VITRO; EXPRESSION; COLLAGEN; IDENTIFICATION AB Demineralized bone matrix (DBM) is a complex mixture of osteoinductive bone morphogenetic proteins (BMPs), as well as BMP-binding proteins that regulate BMP bioactivity and localization. Our aim was to use modern proteomic methods to identify additional BMP-binding proteins in DBM, with initial emphasis on the most abundant. Relatively large, water-soluble noncollagenous proteins (NCPs) were preferentially extracted from DBM with alkalinized urea. The insoluble residue, which contained the BMP activity, was extracted with GuHCl/CaCl2, dialyzed versus citrate, defatted, resuspended in GuHCl, dialyzed sequentially against Triton X-100 and water, pelleted, and lyophilized. The proteins in this pellet were fractionated by hydroxyapatite affinity chromatography. Proteins that copurified with BMP bioactivity were separated by SDS-PAGE. Distinct bands were excised, and the proteins in them were reduced and alkylated, digested with trypsin, eluted, and subjected to MALDI/ToF MS (matrix-assisted laser-desorption ionization time-of-flight mass spectrometry). Computer-assisted peptide fingerprint analysis of the MS profiles was used to identify C-terminal lysine-6-oxidase; dermatopontin (DPT); histones H2A2, H2A3, and H2B; and trace amounts of gamma-actin. DPT is a 22-kDa, tyrosine-rich acidic matrix protein not previously recognized to be among the most abundant small proteins to copurify with BMP bioactivity in DBM. We tested the effects of DPT on BMP-2 stimulation of alkaline phosphatase (ALP) activity in C2C12 cells. BMP-2 stimulated ALP activity in C2C12 cells by 6.2-fold above basal levels. DPT alone had no effect on ALP activity in C2C12 cells. When added with BMP-2, DPT blocked 40% of the stimulatory effect of BMP-2 on ALP activity in C2C12 cells. DPT is an abundant protein in DBM, and it can inhibit the stimulatory effects of BMP-2 on ALP activity in C2C12 cells. C1 VA Great Los Angeles Healthcare Syst, GRECC, Sepulveda, CA USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. RP Murray, SS (reprint author), VA Med Ctr, GRECC, 11-E,16111 Plummer St, Sepulveda, CA 91343 USA. EM Samuel.Murray@med.va.gov NR 26 TC 10 Z9 10 U1 0 U2 4 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0300-8207 J9 CONNECT TISSUE RES JI Connect. Tissue Res. PD OCT-DEC PY 2006 VL 47 IS 5 BP 271 EP 277 DI 10.1080/03008200600995908 PG 7 WC Cell Biology; Orthopedics SC Cell Biology; Orthopedics GA 107ZQ UT WOS:000242209900004 PM 17118749 ER PT J AU John, JF AF John, Joseph F., Jr. TI Drug evaluation: Tefibazumab - a monoclonal antibody against staphylococcal infection SO CURRENT OPINION IN MOLECULAR THERAPEUTICS LA English DT Article ID CLUMPING FACTOR-A; AUREUS BACTEREMIA; EVOLUTION; SAFETY AB Inhibitex Inc is investigating tefibazumab, a humanized monoclonal antibody specific for the fibrin-binding surface epitope clumping factor A protein ( expressed on the surface of most Staphylococcus aureus strains), for the potential intravenous prevention and/or treatment of S aureus infections. In June 2006, Inhibitex was seeking to outlicense certain development rights to the drug. Pending the outcome of partnering discussions, Inhibitex suspended the initiation of any additional clinical trials of tefibazumab. Preclinical in vivo studies were ongoing at that time. C1 Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC 29401 USA. Med Univ S Carolina, Charleston, SC 29401 USA. RP John, JF (reprint author), Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC 29401 USA. EM joseph.john2@med.va.gov NR 24 TC 7 Z9 7 U1 0 U2 1 PU CURRENT DRUGS LTD PI LONDON PA MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1P 6LB, ENGLAND SN 1464-8431 J9 CURR OPIN MOL THER JI Curr. Opin. Mol. Ther. PD OCT PY 2006 VL 8 IS 5 BP 455 EP 460 PG 6 WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Research & Experimental Medicine GA 088NC UT WOS:000240817400011 PM 17078388 ER PT J AU Ramasubbu, K Bozkurt, B Mann, DL AF Ramasubbu, Kumudha Bozkurt, Biykem Mann, Douglas L. TI Mechanisms of idiopathic dilated cardiomyopathies SO CURRENT OPINION IN ORGAN TRANSPLANTATION LA English DT Review DE dilated cardiomyopathy; familial dilated cardiomyopathy; pathomechanisms; viral cardiomyopathy ID LEFT-VENTRICULAR DYSFUNCTION; CONGESTIVE-HEART-FAILURE; BLACK-WHITE DIFFERENCES; ENDOMYOCARDIAL BIOPSY; MUSCULAR-DYSTROPHY; CLINICAL-FEATURES; RANDOMIZED-TRIAL; NATURAL-HISTORY; SKELETAL-MUSCLE; CARDIAC-MUSCLE AB Purpose of review Dilated cardiomyopathy is a disease of the heart muscle, characterized by ventricular dilation and depressed myocardial contractility in the absence of abnormal loading conditions or ischemic heart disease. Dilated cardiomyopathy may be viewed as a progressive disorder that is initiated after an 'index event' damages the heart muscle, thereby preventing the heart from contracting normally. This review will discuss the mechanisms of dilated cardiomyopathy, with special focus on familial dilated cardiomyopathy and virus-induced dilated cardiomyopathy. Recent findings In the past few years, discoveries in molecular genetics and virology have offered insights into the pathomechanisms of dilated cardiomyopathy. Summary The increasing knowledge of a potential causal link between genetic mutations and viral infections and the development of dilated cardiomyopathy may lead to a breakthrough in the treatment of the disease. In particular, the development of gene therapy to treat familial cardiomyopathy and the development of antiviral agents to treat persistent viral infections in virus-induced cardiomyopathy could greatly enhance the treatment of dilated cardiomyopathy. C1 Baylor Coll Med, Dept Cardiol, Houston, TX 77030 USA. Michael E DeBakey Vet Affairs Med Ctr, Cardiol Sect, Houston, TX USA. St Lukes Episcopal Hosp, Houston, TX 77030 USA. Texas Heart Inst, Winters Ctr Heart Failure Res, Houston, TX 77025 USA. RP Mann, DL (reprint author), St Lukes Episcopal Hosp, Baylor Coll Med, Dept Cardiol, 1709 Dryden,Suite 900, Houston, TX 77030 USA. EM dmann@bcm.tmc.edu OI Mann, Douglas /0000-0002-2516-0145 NR 81 TC 0 Z9 0 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1087-2418 J9 CURR OPIN ORGAN TRAN JI Curr. Opin. Organ Transpl. PD OCT PY 2006 VL 11 IS 5 BP 553 EP 559 DI 10.1097/01.mot.0000244643.62599.9e PG 7 WC Transplantation SC Transplantation GA 097LC UT WOS:000241448000014 ER PT J AU Gritman, K Van Winkle, DM Lorentz, CU Pennica, D Habecker, BA AF Gritman, Kurt Van Winkle, Donna M. Lorentz, Christina U. Pennica, Diane Habecker, Beth A. TI The lack of cardiotrophin-1 alters expression of interleukin-6 and leukemia inhibitory factor mRNA but does not impair cardiac injury response SO CYTOKINE LA English DT Article DE gp130; cardiac protection; leukemia inhibitory factor; cardiotrophin-1; interleukin-6 ID EXPERIMENTAL MYOCARDIAL-INFARCTION; SYMPATHETIC-NERVE ACTIVITY; FACTOR-RECEPTOR; TARGETED DISRUPTION; MYOCYTE HYPERTROPHY; CELL HYPERTROPHY; GP130; CYTOKINE; SURVIVAL; HEART AB Cardiotrophin-1 (CT-1) was identified as a growth factor for cardiac myocytes and CT-1 protects myocytes from cell death. Adult CT-1(-/-) mice exhibit neural deficits including the loss of preganglionic sympathetic neurons, but their autonomic and cardiac parameters have not been examined. We used these mice to determine if the absence of CT-1 or loss of preganglionic sympathetic input altered heart rate, left ventricular pressure, cardiac contractility (dP/dt), or cell death following ischemia-reperfusion. Basal heart rate was increased in CT-1(-/-) mice, and this difference was abolished by ganglionic block. Left ventricular pressure and dP/dt were unchanged. Dobutamine stimulated similar increases in heart rate and dP/dt in both genotypes, but ventricular pressure was significantly lower in CT-1 nulls. Cardiac expression of interleukin-6 (IL-6) mRNA was increased significantly in CT-1 null mice, while leukemia inhibitory factor (LIF) mRNA was unchanged. Infarct size normalized to area at risk was no different in CT-1(-/-) mice (33.8 +/- 1.0% vs. 37.7 +/- 3.2% WT) 24 h after ischemia-reperfusion. Induction of IL-6 mRNA after infarct was significantly abrogated in CT-1 null mice compared to wild-type mice, but LIF mRNA-induction remained significant in CT-1 null mice and might contribute to cardiac protection in the absence of CT-1. (c) 2006 Elsevier Ltd. All rights reserved. C1 Oregon Hlth Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Dept Anesthesiol, Portland, OR 97239 USA. Portland VA Med Ctr, Anesthesiol Serv, Portland, OR 97239 USA. Genentech Inc, Dept Mol Biol, San Francisco, CA 94080 USA. RP Habecker, BA (reprint author), Oregon Hlth Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97239 USA. EM habecker@ohsu.edu OI Habecker, Beth/0000-0002-4658-8730 FU NHLBI NIH HHS [HL68231, R01 HL068231] NR 46 TC 16 Z9 19 U1 0 U2 0 PU ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 1043-4666 J9 CYTOKINE JI Cytokine PD OCT PY 2006 VL 36 IS 1-2 BP 9 EP 16 DI 10.1016/j.cyto.2006.10.004 PG 8 WC Biochemistry & Molecular Biology; Cell Biology; Immunology SC Biochemistry & Molecular Biology; Cell Biology; Immunology GA 130PA UT WOS:000243810300002 PM 17150369 ER PT J AU Yao-Borengasser, A Rasouli, N Varma, V Miles, LM Phanavanh, B Starks, TN Phan, J Spencer, HJ McGehee, RE Reue, K Kern, PA AF Yao-Borengasser, Aiwei Rasouli, Neda Varma, Vijayalakshmi Miles, Leslie M. Phanavanh, Bounleut Starks, Tasha N. Phan, Jack Spencer, Horace J., III McGehee, Robert E., Jr. Reue, Karen Kern, Philip A. TI Lipin expression is attenuated in adipose tissue of insulin-resistant human subjects and increases with peroxisome proliferator-activated receptor gamma activation SO DIABETES LA English DT Article ID TREATMENT PANEL-III; NONDIABETIC SUBJECTS; WEIGHT-LOSS; IN-VIVO; SENSITIVITY; GLUCOSE; OBESITY; FAT; LIPODYSTROPHY; REDUCTION AB Lipin-alpha and -beta are the alternatively spliced gene products of the Lpin1 gene, whose product lipin is required for adipocyte differentiation. Lipin deficiency causes lipodystrophy, fatty liver, and insulin resistance in mice, whereas adipose tissue lipin overexpression results in increased adiposity but improved insulin sensitivity. To assess lipin expression and its relation to insulin resistance in humans, we examined lipin-alpha and -beta mRNA levels in subjects with normal or impaired glucose tolerance. We found higher expression levels of both lipin isoforms in lean, insulin-sensitive subjects. When compared with normal glucose-tolerant subjects, individuals with impaired glucose tolerance were more insulin resistant, demonstrated higher levels of intramyocellular lipids (IMCLs), and expressed similar to 50% lower levels of lipin-alpha and -beta. In addition, there was a strong inverse correlation between adipose tissue lipin expression and muscle IMCLs but no evidence for an increase in muscle lipid oxidation. After treatment of the impaired glucose-tolerant subjects with insulin sensitizers for 10 weeks, pioglitazone (but not metformin) resulted in a 60% increase in the insulin sensitivity index (Si) and a 32% decrease in IMCLs (both P < 0.01), along with an increase in lipin-beta (but not lipin-alpha) expression by 200% (P < 0.005). Lipin expression in skeletal muscle, however, was not related to obesity or insulin resistance. Hence, high adipose tissue lipin expression is found in insulin-sensitive subjects, and lipin-beta expression increases following treatment with pioglitazone. These results suggest that increased adipogenesis and/or lipogenesis in subcutaneous fat, mediated by the LPIN1 gene, may prevent lipotoxicity in muscle, leading to improved insulin sensitivity. C1 Univ Arkansas Med Sci, Dept Med, Div Endocrinol, Cent Arkansas Vet Healthcare Syst, Little Rock, AR 72205 USA. Univ Calif Los Angeles, Dept Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Human Genet, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Arkansas Med Sci, Dept Biostat, Little Rock, AR 72205 USA. Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA. RP Kern, PA (reprint author), Univ Arkansas Med Sci, Dept Med, Div Endocrinol, Cent Arkansas Vet Healthcare Syst, 598-151 LR,4300 W 7th St, Little Rock, AR 72205 USA. EM kernphilipa@uams.edu FU NCRR NIH HHS [M01RR14288]; NHLBI NIH HHS [HL 24841]; NIDDK NIH HHS [DK 71277, DK 39176, DK 71346] NR 36 TC 71 Z9 75 U1 0 U2 4 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 J9 DIABETES JI Diabetes PD OCT PY 2006 VL 55 IS 10 BP 2811 EP 2818 DI 10.2337/db05-1688 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 089VU UT WOS:000240910400018 PM 17003347 ER PT J AU Gross, RD Horne, RS Atwood, CW AF Gross, Roxann D. Horne, R. S. Atwood, C. W. TI Novel computer program that quantifies pharyngeal residue SO DYSPHAGIA LA English DT Meeting Abstract C1 Univ Pittsburgh, Pittsburgh, PA USA. Visualizat Software LLC, Stanford, CA USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0179-051X J9 DYSPHAGIA JI Dysphagia PD OCT PY 2006 VL 21 IS 4 BP 292 EP 292 PG 1 WC Otorhinolaryngology SC Otorhinolaryngology GA 128IJ UT WOS:000243651100022 ER PT J AU Kammer, R Baillies, A Gill, G Hind, J Hewitt, A Robbins, J AF Kammer, Rachael Baillies, A. Gill, G. Hind, J. Hewitt, A. Robbins, J. TI Comparison of commercial thickeners for achieving diagnostic and treatment congruence SO DYSPHAGIA LA English DT Meeting Abstract C1 Univ Wisconsin Hosp & Clin, Madison, WI 53792 USA. Univ Wisconsin, Sch Med, Madison, WI USA. William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0179-051X J9 DYSPHAGIA JI Dysphagia PD OCT PY 2006 VL 21 IS 4 BP 328 EP 328 PG 1 WC Otorhinolaryngology SC Otorhinolaryngology GA 128IJ UT WOS:000243651100091 ER PT J AU Baskin, DG AF Baskin, Denis G. TI Single-minded view of melanocortin signaling in energy homeostasis SO ENDOCRINOLOGY LA English DT Editorial Material ID CAUDAL BRAIN-STEM; CENTRAL-NERVOUS-SYSTEM; FOOD-INTAKE; SIM1 GENE; PARAVENTRICULAR NUCLEUS; RECEPTOR STIMULATION; EXPRESSION PATTERNS; OBESITY; NEURONS; PROTEIN C1 Univ Washington, Sch Med, Div Endocrinol Metab, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. Univ Washington, Sch Med, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98108 USA. RP Baskin, DG (reprint author), Univ Washington, Sch Med, Div Endocrinol Metab, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. NR 32 TC 7 Z9 7 U1 1 U2 3 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0013-7227 J9 ENDOCRINOLOGY JI Endocrinology PD OCT PY 2006 VL 147 IS 10 BP 4539 EP 4541 DI 10.1210/en.2006-0807 PG 3 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 087IW UT WOS:000240737100001 PM 16980439 ER PT J AU Bird, TD AF Bird, Thomas D. TI Invited comments on the Shostak and Ottman review SO EPILEPSIA LA English DT Editorial Material ID HUNTINGTON-DISEASE; ALZHEIMERS-DISEASE; SUICIDE; IMPACT; RISK C1 Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Bird, TD (reprint author), Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA USA. EM tomnroz@u.washington.edu NR 7 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PD OCT PY 2006 VL 47 IS 10 BP 1748 EP 1749 DI 10.1111/j.1528-1167.2006.00885_3.x PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 093TB UT WOS:000241191100024 PM 17054702 ER PT J AU Cavusoglu, E Ruwende, C Chopra, V Yanamadala, S Eng, C Clark, LT Pinsky, DJ Marmur, JD AF Cavusoglu, Erdal Ruwende, Cyril Chopra, Vineet Yanamadala, Sunitha Eng, Calvin Clark, Luther T. Pinsky, David J. Marmur, Jonathan D. TI Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain SO EUROPEAN HEART JOURNAL LA English DT Article DE inflammation; adiponectin; prognosis; body mass index; TIMP-1; biomarker; IL-10 ID CHRONIC HEART-FAILURE; ADIPOSE-SPECIFIC PROTEIN; TISSUE INHIBITOR; PLASMA ADIPONECTIN; CARDIOVASCULAR-DISEASE; FAT DISTRIBUTION; RAT MODEL; EXPRESSION; OBESITY; RISK AB Aims To determine the prognostic value of baseline plasma adiponectin levels in patients with known or suspected coronary artery disease referred for coronary angiography. Methods and results Adiponectin was measured in 325 male patients with stable angina, troponin-negative unstable angina, and non-ST-segment elevation myocardial infarction (MI) undergoing coronary angiography at a Veterans Administration Medical Center. The patients were then followed prospectively for the occurrence of all-cause mortality, cardiac mortality, and MI. Follow-up data at 24 months were available for 97% of the patients. Adiponectin was the only biomarker to independently predict the individual endpoints of all-cause mortality, cardiac mortality, and MI. The 24-month survival rates for patients in the lower (<= 4.431 mg/L), middle (> 4.431 and <= 8.008 mg/L), and upper (> 8.008 mg/L) tertiles of plasma adiponectin values were 95.0, 90.4, and 83.5%, respectively (P=0.0232 by log-rank test). Furthermore, when patients with chest pain were risk-stratified into those with and without a non-ST-segment elevation acute coronary syndrome (NSTEACS), adiponectin remained an independent predictor of both all-cause mortality and cardiac mortality in the NSTEACS subgroup. Conclusion In a cohort of male patients undergoing coronary angiography, a single baseline determination of plasma adiponectin is independently predictive of the subsequent risk of death and MI. C1 Suny Downstate Med Ctr, Dept Med, Div Cardiol, Brooklyn, NY 11203 USA. Bronx Vet Affairs Med Ctr, Dept Med, Div Cardiol, Bronx, NY USA. Univ Michigan, Dept Med, Div Cardiovasc Med, Ann Arbor, MI 48109 USA. RP Marmur, JD (reprint author), Suny Downstate Med Ctr, Dept Med, Div Cardiol, 450 Clarkson Ave,Box 1257, Brooklyn, NY 11203 USA. EM jonathan@marmur.com NR 31 TC 137 Z9 145 U1 0 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X J9 EUR HEART J JI Eur. Heart J. PD OCT PY 2006 VL 27 IS 19 BP 2300 EP 2309 DI 10.1093/eurheartj/ehl153 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 086TZ UT WOS:000240697200010 PM 16864609 ER PT J AU Aggarwal, R Ghobrial, IA Roodman, GD AF Aggarwal, Rohit Ghobrial, Irene A. Roodman, G. David TI Chemokines in multiple myeloma SO EXPERIMENTAL HEMATOLOGY LA English DT Review ID MACROPHAGE-INFLAMMATORY PROTEIN-1-ALPHA; CELL-DERIVED FACTOR-1-ALPHA; MARROW STROMAL CELLS; BONE-MARROW; PERIPHERAL-BLOOD; RECEPTOR CXCR3; LYMPHOCYTE CHEMOATTRACTANT; PROTEIN (MIP)-1-ALPHA; CHEMOTACTIC CYTOKINES; ENDOTHELIAL-CELLS AB Objective. In this article we focus on the role that chemokines and chemokine receptors play in the pathogenesis of multiple myeloma and the associated bone destructive process, and consider their utility as novel therapeutic targets for treating this devastating disease. Methods. Current research on the role that chemokine and chemokine receptors play in the pathogenesis of myeloma is reviewed. Results. The chemokines, MIP-1 alpha, MCP-1, IL-8, and SDF-1, and their receptors play important roles in homing of MM cells, tumor growth, and bone destruction in myeloma. They are attractive therapeutic targets for treating myeloma patients. Conclusion. Addition of chemokine antagonists to current treatment regimens for myeloma should result in better therapeutic responses because of the loss of both the protective effect of the marrow microenvironment on the MM cells and the induction of osteoclast activity. (c) 2006 International Society for Experimental Hematology. Published by Elsevier Inc. C1 Univ Pittsburgh, Dept Internal Med, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Div Hematol, Pittsburgh, PA 15260 USA. RP Roodman, GD (reprint author), VA Pittsburgh Healthcare Syst, Res & Dev 151U, Univ Dr C, Pittsburgh, PA 15240 USA. EM roodmangd@upmc.edu FU NCI NIH HHS [R01 CA133799, R01 CA133799-01A1] NR 76 TC 70 Z9 73 U1 0 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0301-472X J9 EXP HEMATOL JI Exp. Hematol. PD OCT PY 2006 VL 34 IS 10 BP 1289 EP 1295 DI 10.1016/j.exphem.2006.06.017 PG 7 WC Hematology; Medicine, Research & Experimental SC Hematology; Research & Experimental Medicine GA 092YV UT WOS:000241134700001 PM 16982321 ER PT J AU Gordon, LK AF Gordon, L. K. TI Orbital inflammatory disease: a diagnostic and therapeutic challenge SO EYE LA English DT Review DE inflammation; orbit; myositis; pseudotumour ID TOLOSA-HUNT-SYNDROME; ERDHEIM-CHESTER-DISEASE; IDIOPATHIC SCLEROSING INFLAMMATION; SUPERIOR OBLIQUE MUSCLE; CHURG-STRAUSS-SYNDROME; GIANT-CELL ARTERITIS; RHEUMATOID-ARTHRITIS; WEGENERS-GRANULOMATOSIS; EYE DISEASE; MYCOPHENOLATE-MOFETIL AB The spectrum of orbital inflammatory disease (OID) ranges broadly from specific disease diagnoses, for example, Wegener's granulomatosis or sarcoidosis, to nonspecific inflammation which may involve one or multiple structures of the orbit. Mimics of idiopathic OID must be considered in a comprehensive differential diagnosis and include malignancies, congenital mass lesions, infectious diseases, and occult or distant trauma. Idiopathic OID may be secondary to an underlying systemic inflammatory disease, which must be diagnosed in order to develop a comprehensive therapeutic plan, or may represent localized pathologic processes without systemic involvement. Evaluation of the patient with suspected OID must include a careful history, physical examination, directed laboratory, and radiologic studies, and may sometimes require tissue for diagnostic studies. Therapeutic options for inflammatory diseases are expanding as biologically targeted agents become available that act on specific segments of the inflammatory cascades. The purpose of this paper is to provide a framework for the evaluation and management of patients with the spectrum of diseases known as OID and to discuss some of the new advances in immunologic monitoring and targeted immune therapies that will likely play an increasingly important role in the care of these patients. C1 Univ Calif Los Angeles, Jules Stein Eye Inst, Los Angeles, CA 90024 USA. Greater Los Angeles Vet Affairs Healthcare, Los Angeles, CA USA. RP Gordon, LK (reprint author), Univ Calif Los Angeles, Jules Stein Eye Inst, Los Angeles, CA 90024 USA. EM lgordon@ucla.edu NR 123 TC 68 Z9 70 U1 2 U2 6 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0950-222X J9 EYE JI Eye PD OCT PY 2006 VL 20 IS 10 BP 1196 EP 1206 DI 10.1038/sj.eye.6702383 PG 11 WC Ophthalmology SC Ophthalmology GA 092EG UT WOS:000241079200010 PM 17019419 ER PT J AU Probst, JC Laditka, SB Moore, CG Harun, N Powell, MP Baxley, EG AF Probst, Janice C. Laditka, Sarah B. Moore, Charity G. Harun, Nusrat Powell, M. Paige Baxley, Elizabeth G. TI Rural-urban differences in depression prevalence: Implications for family medicine SO FAMILY MEDICINE LA English DT Article ID NATIONAL-COMORBIDITY-SURVEY; MENTAL-HEALTH-SERVICES; MAJOR DEPRESSION; UNITED-STATES; SURVEY REPLICATION; RACIAL/ETHNIC DIFFERENCES; OLDER-ADULTS; DISORDERS; CARE; POLICY AB Background and Objectives: Rural populations experience more adverse living circumstances than urban populations, but the evidence regarding the prevalence of mental health disorders in rural areas is contradictory. We examined the prevalence of depression in rural versus urban areas. Methods: We performed a cross-sectional study using the 1999 National Health Interview Survey (NHIS). In face-to-face interviews, the NHIS administered the Composite International Diagnostic Interview Short Form (CIDI-SF) depression scale to a nationally representative sample of 30,801 adults, ages 18 and suffer from depression. The unadjusted prevalence over. Results: An estimated 2.6 million rural adults suffer from depression. was significantly higher among rural than urban populations (6.1% versus 5.2%). After adjusting for rural/urban population characteristics, however, the odds of depression did not differ by residence. Depression risk was higher among persons likely to be encountered in a primary care setting: those with fair or poor se self-reported health, hypertension, with limitations in daily activities, or whose health status changed during the previous year. Conclusions: The prevalence of depression is slightly but significantly higher in residents of rural areas compared to urban areas, possibly due to differing population characteristics. C1 Univ S Carolina, S Carolina Rural Hlth Res Ctr, Columbia, SC 29210 USA. Univ S Carolina, Dept Family & Prevent Med, Columbia, SC 29210 USA. Univ N Carolina, Sheps Ctr Hlth Serv Res, Chapel Hill, NC 27515 USA. Univ Alabama, Dept Hlth Serv Adm, Birmingham, AL USA. Birmingham VA Med Ctr, Deep S Ctr Effectiveness, Birmingham, AL USA. RP Probst, JC (reprint author), Univ S Carolina, S Carolina Rural Hlth Res Ctr, 220 Stoneridge Dr,Suite 204, Columbia, SC 29210 USA. EM jprobst@gwm.se.edu NR 37 TC 65 Z9 65 U1 9 U2 16 PU SOC TEACHERS FAMILY MEDICINE PI LEAWOOD PA 11400 TOMAHAWK CREEK PARKWAY, STE 540, LEAWOOD, KS 66207 USA SN 0742-3225 J9 FAM MED JI Fam. Med. PD OCT PY 2006 VL 38 IS 9 BP 653 EP 660 PG 8 WC Primary Health Care; Medicine, General & Internal SC General & Internal Medicine GA 186SQ UT WOS:000247798900010 PM 17009190 ER PT J AU Spruill, LS McDermott, PJ AF Spruill, Laura S. McDermott, Paul J. TI Regulation of c-jun mRNA expression in adult cardiocytes by MAP kinase interacting kinase-1 (MNK1) SO FASEB JOURNAL LA English DT Article DE cardiac hypertrophy; translation; eIF4E; protein synthesis; mRNA stability ID INITIATION-FACTOR 4E; ACTIVATED PROTEIN-KINASES; MYOCYTE ENHANCER FACTOR-2; TRANSLATION INITIATION; CARDIAC-HYPERTROPHY; GENE-EXPRESSION; SYNTHESIS RATES; OVERLOAD HYPERTROPHY; FELINE CARDIOCYTES; FACTOR EIF-4E AB Hypertrophic growth of adult myocardium is associated with increased expression of the early response gene c-jun. The purpose of this study was to determine whether eukaryotic initiation factor (elF) 4E (eIF4E) regulates translational efficiency of c-jun mRNA as measured by flux into polysomes. Adult feline cardiomyocytes in primary culture were treated with 0.2 mu M 12-O-tetradecanoylphorbol 13-acetate (TPA), and c-jun mRNA was quantified in total, monosome, and polysome fractions by real-time polymerase chain reaction. After 1 h, TPA increased total c-jun mRNA by 10.5-fold. The corresponding flux into polysomes was significantly lower (5-fold). Adenoviral-mediated overexpression of either eIF4E or a nonphosphorylatable mutant (S209/A) did not affect total c-jun mRNA or its flux between monosomes and polysomes. Similar results were obtained following overexpression of the eIF4E kinase Mnk1. Thus, translational efficiency of c-jun mRNA was not affected by changes in activity or amount of eIF4E. In contrast, a kinase-deficient Mnk1 mutant significantly reduced total c-jun mRNA from 9.8-fold to 6.0-fold while flux between monosomes and polysomes remained constant. The decrease in total c-jun mRNA resulted from increased decay of c-jun mRNA incorporated into the polysomes. We conclude that Mnk1 activity stabilizes c-jun mRNA in polysomes independent of eIF4E phosphorylation. C1 Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Charleston, SC 29403 USA. Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. RP McDermott, PJ (reprint author), Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Strom Thurmond Biomed Res Bldg,Rm 303,114 Dohty, Charleston, SC 29403 USA. EM mcdermp@musc.edu FU NHLBI NIH HHS [P01 HL-48788] NR 48 TC 7 Z9 7 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD OCT PY 2006 VL 20 IS 12 BP 2133 EP + DI 10.1096/fj.06-6245fje PG 11 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 093GS UT WOS:000241156900033 PM 16940435 ER PT J AU Goodwin, SC AF Goodwin, Scott C. TI Follow-up after uterine artery embolization versus myomectomy - Reply SO FERTILITY AND STERILITY LA English DT Letter C1 Greater Los Angeles Vet Adm Hlth Care Syst, Los Angeles, CA USA. RP Goodwin, SC (reprint author), Greater Los Angeles Vet Adm Hlth Care Syst, Los Angeles, CA USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 J9 FERTIL STERIL JI Fertil. Steril. PD OCT PY 2006 VL 86 IS 4 BP 1029 EP 1029 DI 10.1016/j.fertnstert.2006.06.003 PG 1 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA 093JU UT WOS:000241165400041 ER PT J AU Lin, OS Kozarek, RA Schembre, DB Ayub, K Gluck, M Cantone, N Soon, MS Dominitz, JA AF Lin, Otto S. Kozarek, Richard A. Schembre, Drew B. Ayub, Kamran Gluck, Michael Cantone, Nico Soon, Maw-Soan Dominitz, Jason A. TI Risk stratification for colon neoplasia: Screening strategies using colonoscopy and computerized tomographic colonography SO GASTROENTEROLOGY LA English DT Article ID COLORECTAL-CANCER; CT COLONOGRAPHY; AVERAGE-RISK; VIRTUAL COLONOSCOPY; ASYMPTOMATIC ADULTS; CONVENTIONAL COLONOSCOPY; ENDOSCOPIC CAPACITY; ADENOMATOUS POLYPS; PROXIMAL NEOPLASIA; FAMILY-HISTORY AB Background & Aims: We developed a risk index to identify low-risk patients who may be screened for colorectal cancer with computerized tomographic colonography (CTC) instead of colonoscopy. Methods: Asymptomatic persons aged 50 years or older who had undergone screening colonoscopy were randomized retrospectively to derivation (n = 1512) and validation (n = 1493) subgroups. We developed a risk index (based on age, sex, and family history) from the derivation group. The expected results of 3 screening strategies-universal colonoscopy, universal CTC, and a stratified strategy of colonoscopy for high-risk and CTC for low-risk patients-were then compared. outcomes for the 3 strategies were extrapolated from the known colonic findings in each patient, using sensitivity/specificity values for CTC from the medical literature. Results were validated in the validation subgroup. Results: In the derivation subgroup, universal colonoscopy detected 94% of advanced neoplasia and universal CTC detected only 70% and resulted in the largest total number of procedures and number of patients undergoing both procedures. The stratified strategy detected 92% of advanced neoplasia, requiring colonoscopy in 68% and CTC in 36% of patients, with only 4% having to undergo both procedures. In the validation subgroup, universal colonoscopy detected 94% and universal CTC detected 71% of advanced neoplasia, whereas the stratified strategy detected 89%, requiring colonoscopy in 64% and CTC in 40%. Unlike universal CTC, the stratified strategy was independent of assumptions for CTC sensitivity, specificity, and threshold for colonoscopy. Conclusions: The stratified strategy based on our risk index may optimize the yield of colonoscopic resources and reduce the number of patients undergoing colonoscopy. C1 Virginia Mason Med Ctr, Gastroenterol Sect, Seattle, WA 98101 USA. ChangHua Christian Med Ctr, Div Gastroenterol, Changhua, Taiwan. VA Puget Sound Hlth Care Syst, Div Gastroenterol, Seattle, WA USA. Univ Washington, Seattle, WA 98195 USA. RP Lin, OS (reprint author), Virginia Mason Med Ctr, Gastroenterol Sect, 1100 9th Ave, Seattle, WA 98101 USA. EM Otto.Lin@vmmc.org OI Dominitz, Jason/0000-0002-8070-7086 NR 39 TC 32 Z9 34 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD OCT PY 2006 VL 131 IS 4 BP 1011 EP 1019 DI 10.1053/j.gastro.2006.08.015 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 094NS UT WOS:000241246800011 PM 17030171 ER PT J AU Lieberman, D AF Lieberman, David TI Home repair and colonoscopy: quality counts SO GASTROINTESTINAL ENDOSCOPY LA English DT Editorial Material ID COMPUTED TOMOGRAPHIC COLONOGRAPHY C1 Oregon Hlth Sci Univ, Div Gastroenterol, Portland VA Med Ctr, Portland, OR 97201 USA. RP Lieberman, D (reprint author), Oregon Hlth Sci Univ, Div Gastroenterol, Portland VA Med Ctr, Portland, OR 97201 USA. NR 7 TC 3 Z9 3 U1 0 U2 0 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD OCT PY 2006 VL 64 IS 4 BP 563 EP 564 DI 10.1016/j.gie.2006.04.024 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 092ZE UT WOS:000241135800017 PM 16996350 ER PT J AU Davis, GE Bryson, CL Yueh, B McDonell, MB Micek, MA Fihn, SD AF Davis, Greg E. Bryson, Chris L. Yueh, Bevan McDonell, Mary B. Micek, Mark A. Fihn, Stephan D. TI Treatment delay associated with alternative medicine use among veterans with head and neck cancer SO HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK LA English DT Article DE complementary medicine; alternative medicine; head and neck cancer; delay of treatment; veterans ID UNITED-STATES; COMPLEMENTARY/ALTERNATIVE MEDICINE; PREVALENCE; HEALTH; DISTRESS; BREAST; COSTS AB Background. Use of complementary and alternative medicine (CAM) is increasing in the United States. This study investigates whether the use of alternative medicine is associated with a delay of treatment in head and neck cancer. Methods. This study used the records obtained from a large trial involving ambulatory care US veterans. Subjects completed a CAM utilization questionnaire. The primary outcome variable was the time duration from cancer diagnosis to the time of cancer treatment. Results. Of veterans with head and neck cancer, 51% reported using some form of CAM, whereas 23% reported using a therapy classified as alternative medicine. Patients who used alternative medicine significantly delayed cancer treatment by 22 days compared with those who did not use alternative medicine (p = .05, 95% confidence interval [CI] = 0-44 days). Conclusions. CAM use is common in veterans with head and neck cancer. Use of alternative medicine was associated with a significant delay in cancer treatment. (c) 2006 Wiley Periodicals, Inc. C1 VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA USA. Univ Washington, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USA. Univ Washington, Dept Med, Seattle, WA USA. Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. RP Davis, GE (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA USA. EM gedavis@u.washington.edu OI Yueh, Bevan/0000-0003-1380-1053 FU NIDCD NIH HHS [DC 00018] NR 17 TC 15 Z9 15 U1 2 U2 7 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1043-3074 J9 HEAD NECK-J SCI SPEC JI Head Neck-J. Sci. Spec. Head Neck PD OCT PY 2006 VL 28 IS 10 BP 926 EP 931 DI 10.1002/hed.20420 PG 6 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 088ZL UT WOS:000240849500009 PM 16755583 ER PT J AU Currie, S Tracy, D Ryan, J Belaye, T Kim, M Monto, A AF Currie, Sue Tracy, Daniel Ryan, James Belaye, Tigist Kim, Michael Monto, Alexander TI Injection drug users who resolve the HCV virus appear to be protected from reinfection SO HEPATOLOGY LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY OCT 27-31, 2006 CL Boston, MA SP Amer Assoc Study Liver Dis C1 Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Med, Div GI, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2006 VL 44 IS 4 SU 1 MA 167 BP 251A EP 251A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 096FF UT WOS:000241362300168 ER PT J AU Matthews, AM Huckans, MS Blackwell, AD Hauser, P AF Matthews, Annette M. Huckans, Marilyn S. Blackwell, Aaron D. Hauser, Peter TI Hepatitis C testing, infection, and treatment rates in bipolar patients with and without comorbid substance use disorders SO HEPATOLOGY LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY OCT 27-31, 2006 CL Boston, MA SP Amer Assoc Study Liver Dis C1 Portland VA Med Ctr, NW Hepatitis C Resource Ctr, Portland, OR USA. Oregon Hlth Sci Univ, Portland, OR 97201 USA. Portland VA Med Ctr, JENS Lab, Portland, OR USA. Univ Oregon, Eugene, OR 97403 USA. RI Blackwell, Aaron/B-5258-2008 OI Blackwell, Aaron/0000-0002-5871-9865 NR 0 TC 0 Z9 0 U1 0 U2 1 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2006 VL 44 IS 4 SU 1 MA 241 BP 280A EP 280A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 096FF UT WOS:000241362300242 ER PT J AU Nakamoto, N Ebinuma, H Li, Y Kwok, WW Price, D Levine, B Chang, KM AF Nakamoto, Nobuhiro Ebinuma, Hirotoshi Li, Yun Kwok, William W. Price, David Levine, Bruce Chang, Kyong-Mi TI In-vitro expansion of HCV-specific FoxP3+CD4+CD25+Treg cells SO HEPATOLOGY LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY OCT 27-31, 2006 CL Boston, MA SP Amer Assoc Study Liver Dis C1 Univ Penn, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Philadelphia, PA USA. Benaroya Res Inst, Seattle, WA USA. NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA. RI Levine, Bruce/D-1688-2009; Price, David/C-7876-2013 OI Price, David/0000-0001-9416-2737 NR 0 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2006 VL 44 IS 4 SU 1 MA 299 BP 301A EP 301A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 096FF UT WOS:000241362300300 ER PT J AU Barakat, F Carlson, MD Oliver, DL Edwards, K Karlen, N Hilsabeck, R Perry, W Hassanein, TI AF Barakat, Fatma Carlson, Meghan D. Oliver, Deanna L. Edwards, Kimberly Karlen, Naomi Hilsabeck, Robin Perry, William Hassanein, Tarek I. TI Fatigue in patients with hepatitis C and nonviral chronic liver disease SO HEPATOLOGY LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY OCT 27-31, 2006 CL Boston, MA SP Amer Assoc Study Liver Dis C1 Univ Calif San Diego, San Diego, CA 92103 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2006 VL 44 IS 4 SU 1 MA 347 BP 319A EP 320A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 096FF UT WOS:000241362300348 ER PT J AU Morasco, BJ Rifai, MA Loftis, JM Indest, DW Kizer, EE Moles, JK Hauser, P AF Morasco, Benjamin J. Rifai, Muhamad A. Loftis, Jennifer M. Indest, David W. Kizer, Emily E. Moles, James K. Hauser, Peter TI A randomized double-blind placebo-controlled trial of paroxetine to prevent interferon-ainduced depression in patients with hepatitis C SO HEPATOLOGY LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY OCT 27-31, 2006 CL Boston, MA SP Amer Assoc Study Liver Dis C1 Portland VA Med Ctr, Behav Hlth & Clin Neurosci Div, Portland, OR USA. Salem VA Med Ctr, Salem, VA USA. NW Hepatitis C Resource Ctr, Portland, OR USA. Univ Virginia, Sch Med, Roanoke Salem, VA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2006 VL 44 IS 4 SU 1 MA 379 BP 332A EP 332A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 096FF UT WOS:000241362300380 ER PT J AU Kanwal, F Spiegel, BM Bolus, R Hays, RD Kim, SJ Gralnek, IM AF Kanwal, Fasiha Spiegel, Brennan M. Bolus, Roger Hays, Ron D. Kim, Sun J. Gralnek, Ian M. TI Validation of the short form of liver disease quality of life (LDQOL) instrument SO HEPATOLOGY LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY OCT 27-31, 2006 CL Boston, MA SP Amer Assoc Study Liver Dis C1 St Louis VA Med Ctr, St Louis, MO USA. St Louis Univ, St Louis, MO 63103 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. Univ San Diego, San Diego, CA 92110 USA. Rambam Med Ctr, Haifa, Israel. RI Hays, Ronald/D-5629-2013 NR 0 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2006 VL 44 IS 4 SU 1 MA 689 BP 445A EP 445A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 096FF UT WOS:000241362301230 ER PT J AU Lieber, CS Cao, Q DeCarli, L Leo, MA Mak, KM Ponomarenko, A Ren, C Wang, XL AF Lieber, Charles S. Cao, Qi DeCarli, Leonore Leo, Maria A. Mak, Ki M. Ponomarenko, Anatoly Ren, Chaoling Wang, Xiaolei TI Role of medium-chain triglycerides (MCT) in the alcohol-mediated CYP2E1 induction of mitochondria SO HEPATOLOGY LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY OCT 27-31, 2006 CL Boston, MA SP Amer Assoc Study Liver Dis C1 Mt Sinai Sch Med, James J Peters VA Med Ctr, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2006 VL 44 IS 4 SU 1 MA 895 BP 521A EP 521A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 096FF UT WOS:000241362301436 ER PT J AU Kanwal, F Hoang, T Spiegel, BM Goetz, M Gralnek, IM Dominitz, JA Di Bisceglie, A Asch, S AF Kanwal, Fasiha Hoang, Tuyen Spiegel, Brennan M. Goetz, Mathew Gralnek, Ian M. Dominitz, Jason A. Di Bisceglie, Adrian Asch, Steve TI Quality of care in chronic hepatitis C virus (HCV) infection SO HEPATOLOGY LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY OCT 27-31, 2006 CL Boston, MA SP Amer Assoc Study Liver Dis C1 VA Med Ctr, St Louis, MO USA. St Louis Univ, St Louis, MO 63103 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Portland VA Med Ctr, Portland, OR USA. Rambam Med Ctr, Haifa, Israel. NR 0 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2006 VL 44 IS 4 SU 1 MA 1296 BP 672A EP 673A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 096FF UT WOS:000241362302390 ER PT J AU Yee, HS Currie, SL Chapko, MK Monto, A AF Yee, Helen S. Currie, Sue L. Chapko, Michael K. Monto, Alexander TI Is hepatitis A and B screening and vaccination in chronic hepatitis C patients effective? SO HEPATOLOGY LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY OCT 27-31, 2006 CL Boston, MA SP Amer Assoc Study Liver Dis C1 Vet Affairs Med Ctr, San Francisco, CA 94121 USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2006 VL 44 IS 4 SU 1 MA 1307 BP 676A EP 677A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 096FF UT WOS:000241362302401 ER PT J AU Nyby, MD Douglas, K Albedi, K Makino, H Tuck, ML AF Nyby, Michael D. Douglas, Kyle Albedi, Karolin Makino, Hirofumi Tuck, Michael L. TI Telmisartan and insulin affect angiotensin II type 1 and type 2 receptor expression in vascular smooth muscle and vascular endothelial cells SO HYPERTENSION LA English DT Meeting Abstract CT 11th Annual Meeting of the European-Council- for Cardiovascular Reseach CY SEP 29-OCT 01, 2006 CL Nice, FRANCE SP European Council Cardiovasc Res C1 VA Greater Los Angeles Healtcare Syst, Sepulveda, CA USA. Univ Calif Los Angeles, VA Greater Los Angeles Healtcare Syst, Sepulveda, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0194-911X J9 HYPERTENSION JI Hypertension PD OCT PY 2006 VL 48 IS 4 BP E89 EP E89 PG 1 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 127FR UT WOS:000243571200512 ER PT J AU Lo, M Bulach, DM Powell, DR Haake, DA Matsunaga, J Paustian, ML Zuerner, RL Adler, B AF Lo, Miranda Bulach, Dieter M. Powell, David R. Haake, David A. Matsunaga, James Paustian, Michael L. Zuerner, Richard L. Adler, Ben TI Effects of temperature on gene expression patterns in Leptospira interrogans serovar Lai as assessed by whole-genome microarrays SO INFECTION AND IMMUNITY LA English DT Article ID BORRELIA-BURGDORFERI; ESCHERICHIA-COLI; OUTER-MEMBRANE; SIGMA-FACTOR; MOLECULAR CHARACTERIZATION; GLOBAL ANALYSIS; PROTEINS; GROWTH; COPENHAGENI; SURVIVAL AB Leptospirosis is an important zoonosis of worldwide distribution. Humans become infected via exposure to pathogenic Leptospira spp. from infected animals or contaminated water or soil. The availability of genome sequences for Leptospira interrogans, serovars Lai and Copenhageni, has opened up opportunities to examine global transcription profiles using microarray technology. Temperature is a key environmental factor known to affect leptospiral protein expression. Leptospira spp. can grow in artificial media at a range of temperatures reflecting conditions found in the environment and the mammalian host. Therefore, transcriptional changes were compared between cultures grown at 20 degrees C, 30 degrees C, 37 degrees C, and 39 degrees C to represent ambient temperatures in the environment, growth under laboratory conditions, and temperatures in healthy and febrile hosts. Data from direct pairwise comparisons of the four temperatures were consolidated to examine transcriptional changes at two generalized biological conditions representing mammalian physiological temperatures (37 degrees C and 39 degrees C) versus environmental temperatures (20 degrees C and 30 degrees C). Additionally, cultures grown at 30 degrees C then shifted overnight to 37 degrees C were compared with those grown long-term at 30 degrees C and 37 degrees C to identify genes potentially expressed in the early stages of infection. Comparison of data sets from physiological versus environmental experiments with upshift experiments provided novel insights into possible transcriptional changes at different stages of infection. Changes included differential expression of chemotaxis and motility genes, signal transduction systems, and genes encoding proteins involved in alteration of the outer membrane. These findings indicate that temperature is an important factor regulating expression of proteins that facilitate invasion and establishment of disease. C1 Monash Univ, Dept Microbiol, Victorian Bioinformat Consortium, Clayton, Vic 3800, Australia. Monash Univ, Australian Bacterial Pathogenesis Program, Clayton, Vic 3800, Australia. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Div Infect Dis, Los Angeles, CA 90073 USA. USDA ARS, Bacterial Dis Livestock Res Unit, Natl Anim Dis Ctr, Ames, IA 50010 USA. Monash Univ, Australian Res Council, Ctr Excellence Struct & Funct Microbial Genom, Clayton, Vic 3800, Australia. RP Adler, B (reprint author), Monash Univ, Dept Microbiol, Victorian Bioinformat Consortium, Clayton, Vic 3800, Australia. EM Ben.Adler@med.monash.edu.au RI Bulach, Dieter/D-5793-2011 OI Bulach, Dieter/0000-0001-9823-6078 FU NIAID NIH HHS [AI-34431, R01 AI034431, R01 AI034431-09, R21 AI034431, R29 AI034431] NR 47 TC 66 Z9 67 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0019-9567 J9 INFECT IMMUN JI Infect. Immun. PD OCT PY 2006 VL 74 IS 10 BP 5848 EP 5859 DI 10.1128/IAI.00755-06 PG 12 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 090RF UT WOS:000240967900048 PM 16988264 ER PT J AU Gonzalez, BE Rueda, AM Shelburne, SA Musher, DM Hamill, RJ Hulten, KG AF Gonzalez, Blanca E. Rueda, Adriana M. Shelburne, Samuel A., III Musher, Daniel M. Hamill, Richard J. Hulten, Kristina G. TI Community-associated strains of methicillin-resistant Staphylococccus aureus as the cause of healthcare-associated infection SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID PANTON-VALENTINE LEUKOCIDIN; FIELD GEL-ELECTROPHORESIS; UNITED-STATES; EMERGENCE; CHILDREN; CLONE; DEFINITIONS; CASSETTE; SEPSIS; GENOME AB OBJECTIVE. Methicillin-resistant Staphylococcus aureus ( MRSA) isolates from patients with community-associated infection have been described as strains genetically distinct from the strains isolated from patients with healthcare-associated infection. This study examines the hypothesis that community-associated MRSA ( CA-MRSA) strains now cause serious infections in hospitalized patients. METHODS. Thirty-seven clinical MRSA isolates were randomly selected from blood isolates obtained from July 2003 through June 2004. Strains were tested for staphylococcal chromosomal cassette mec ( SCCmec) type, pulsed-field gel electrophoresis ( PFGE) type, and presence of Panton-Valentine leukocidin ( PVL) genes. Medical records review and epidemiologic classification was performed by an investigator blinded to the results of the bacterial strain analysis. Episodes of bloodstream infection were independently classified as either community-associated or healthcare-associated infections, and bacterial isolates were independently classified as either CA-MRSA strains or healthcare-associated MRSA ( HA-MRSA) strains, according to established definitions. SETTING. A tertiary care Veterans Affairs Medical Center. RESULTS. Twenty-four ( 65%) of 37 MRSA isolates were SCCmec type IV, a genetic type characteristic of CA-MRSA strains; 22 of these 24 isolates belonged to the CA-MRSA clone USA300 and carried PVL genes. Thirteen ( 35%) of the 37 strains were SCCmec type II, of which 12 were USA100-ST5 and 12 lacked PVL genes. Thirty patients ( 81%) had healthcare-associated infections; 18 ( 60%) of these 30 were infected with isolates carrying markers of CA-MRSA strains. Of 7 patients with CA- MRSA infections, 6 were infected with isolates belonging to the USA300 clone. Patients with healthcare-associated bloodstream infections were as likely to be infected with a CA-MRSA strain as patients with a community-associated infection (P=.38). CONCLUSIONS. MRSA strains with molecular characteristics of CA- MRSA strains have emerged as an important cause of serious healthcare-associated infection in our hospital. C1 Baylor Coll Med, Infect Dis Sect, Dept Pediat, Houston, TX 77030 USA. Baylor Coll Med, Infect Dis Sect, Dept Med, Houston, TX 77030 USA. Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. RP Hulten, KG (reprint author), Texas Childrens Hosp, Mail Code 3-2371,6621 Fannin St, Houston, TX 77030 USA. EM khulten@bcm.tmc.edu OI Hulten, Kristina/0000-0001-7446-157X FU NCRR NIH HHS [K12 RR 17665-04] NR 34 TC 112 Z9 115 U1 0 U2 7 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD OCT PY 2006 VL 27 IS 10 BP 1051 EP 1056 DI 10.1086/507923 PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 205AF UT WOS:000249084400008 PM 17006811 ER PT J AU Sonnenberg, A Collins, JF AF Sonnenberg, Amnon Collins, Judith F. TI Vicious circles in inflammatory bowel disease SO INFLAMMATORY BOWEL DISEASES LA English DT Article DE complications of IBD; Crohn's disease; decision analysis; health service research; influence diagram; simulation; surgery of IBD ID ULCERATIVE-COLITIS; CROHNS-DISEASE; HEPARIN AB Background: Inflammatory bowel disease can present with a bewildering array of disease manifestations whose overall impact on patient health is difficult to disentangle. The multitude of disease complications and therapeutic side effects result in conflicting ideas on how to best manage a patient. The aim of the study is to test the usefulness of influence diagrams in resolving conflicts centered on managing complex disease processes. Methods: The influences of a disease process and the ensuing medical interventions on the health of a patient with inflammatory bowel disease are modeled by an influence diagram. Patient health is the focal point of multiple influences affecting its overall strength. Any downstream influence represents the focal point of other preceding upstream influences. The mathematics underlying the influence diagram is similar to that of a decision tree. Its formalism allows one to consider additive and inhibitory influences and include in the same analysis qualitatively different types of parameters, such as diagnoses, complications, side effects, and therapeutic outcomes. Results: Three exemplary cases are presented to illustrate the potential use of influence diagrams. In all three case scenarios, Crohn's disease resulted in disease manifestations that seemingly interfered with its own therapy. The presence of negative feedback loops rendered the management of each case particularly challenging. The analyses by influence diagrams revealed subtle interactions among the multiple influences and their joint contributions to the patient's overall health that would have been difficult to appreciate by verbal reasoning alone. Conclusion: influence diagrams represent a decision too] that is particularly suited to improve decision-making in inflammatory bowel disease. They highlight key factors of a complex disease process and help to assess their quantitative interactions. C1 Portland VA Med Ctr, Portland, OR USA. Oregon Hlth & Sci Univ, Portland, OR USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr P3G1, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 18 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1078-0998 J9 INFLAMM BOWEL DIS JI Inflamm. Bowel Dis. PD OCT PY 2006 VL 12 IS 10 BP 944 EP 949 DI 10.1097/01.mib.0000231577.19301.95 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 092WP UT WOS:000241128300004 PM 17012965 ER PT J AU Luck, J Peabody, JW Lewis, BL AF Luck, J. Peabody, J. W. Lewis, B. L. TI An automated scoring algorithm for computerized clinical vignettes: Evaluating physician performance against explicit quality criteria SO INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS LA English DT Article DE quality measurement; quality improvement; vignettes; informatics; primary care ID INFORMATION-TECHNOLOGY; STANDARDIZED PATIENTS; CHART ABSTRACTION; CARE; TERMINOLOGY; VALIDATION; DEPRESSION AB Objective: To evaluate the accuracy of an automated algorithm for scoring physicians' responses to open-ended clinical vignettes against explicit, evidence-based quality criteria. Methods: One hundred sixteen physicians completed a total of 915 computerized clinical vignettes at 4 sites. Each vignette simulated an outpatient primary care visit for one of 8 different clinical cases. The automated algorithm scored disease-specific quality criterion as done or not done by recognizing the presence or absence of predefined patterns in the physician's text response to the vignette. Scores generated by the automated algorithm for each criterion were compared to scores generated by trained human abstractors. Vignette responses were divided into development and test sets. Percentage agreement between automated and manual scores was computed separately for the development and test sets. Sensitivity and specificity were calculated. Costs of automated and manual scoring were compared. Results: Accuracy of the algorithm exceeds 90% for both the development and test sets, and is high for care items that were deemed either necessary or unnecessary, across diverse clinical cases, and for all domains of the outpatient clinical encounter. The sensitivity of the automated scoring algorithm is 89.0%, and specificity is 93.5%. Automated scoring is approximately 84% less expensive than manual scoring. Conclusion: Automated scoring of computerized vignettes appears feasible and accurate. Computerized vignettes incorporating accurate automated scoring offer the promise of a highly standardized but relatively inexpensive measurement tool for a wide range of quality assessments within and across health systems. Published by Elsevier Ireland Ltd. C1 Vet Affairs Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90095 USA. Univ Calif San Francisco, Dept Epidemiol & Biostat, Inst Global Hlth, San Francisco, CA 94143 USA. San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. RAND, Santa Monica, CA USA. Analyt Solut, Spokane, WA USA. RP Luck, J (reprint author), Vet Affairs Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. EM jluck@ucla.edu NR 28 TC 6 Z9 6 U1 4 U2 5 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 1386-5056 J9 INT J MED INFORM JI Int. J. Med. Inform. PD OCT-NOV PY 2006 VL 75 IS 10-11 BP 701 EP 707 DI 10.1016/j.ijmedinf.2005.10.005 PG 7 WC Computer Science, Information Systems; Health Care Sciences & Services; Medical Informatics SC Computer Science; Health Care Sciences & Services; Medical Informatics GA 100EE UT WOS:000241649800002 PM 16324882 ER PT J AU Horner, MD Bedwell, JS Duong, A AF Horner, Michael David Bedwell, Jeffrey S. Duong, Anna TI Abbreviated form of the Test of Memory Malingering SO INTERNATIONAL JOURNAL OF NEUROSCIENCE LA English DT Article; Proceedings Paper CT 32nd Annual Meeting of the International-Neuropsychological-Society CY FEB 04-07, 2004 CL Baltimore, MD SP Int Neuropsychol Soc DE assessment; effort; malingering; measurement; memory; neuro-psychology ID TOMM AB The Test of Memory Malingering (TOMM) is a neuropsychological effort test in which scores below 45 on Trial 2 or Retention Trial indicate insufficient effort on testing, but Trial 1 score is not used. This study attempted to identify Trial 1 cut points above and below which further trials need not be administered. Data were analyzed from 114 patients referred for clinical neuropsychological evaluation. Sensitivity, specificity, and positive and negative predictive value for identifying failure on TOMM were calculated. Trial 1 scores >= 36 indicated 99% likelihood that TOMM would be passed; Trial 1 scores <= 27 indicated 100% likelihood of failure. C1 Ralph H Johnson VA Med Ctr, Mental Hlth Serv, Charleston, SC 29401 USA. Med Univ S Carolina, Charleston, SC 29425 USA. RP Horner, MD (reprint author), Ralph H Johnson VA Med Ctr, Mental Hlth Serv, 116,109 Bee St, Charleston, SC 29401 USA. EM hornermd@musc.edu NR 6 TC 14 Z9 14 U1 1 U2 1 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0020-7454 J9 INT J NEUROSCI JI Int. J. Neurosci. PD OCT PY 2006 VL 116 IS 10 BP 1181 EP 1186 DI 10.1080/00207450500514029 PG 6 WC Neurosciences SC Neurosciences & Neurology GA 075YG UT WOS:000239922900005 PM 16923686 ER PT J AU Primack, BA Gold, MA Land, SR Fine, MJ AF Primack, Brian A. Gold, Melanie A. Land, Stephanie R. Fine, Michael J. TI Association of cigarette smoking and media literacy about smoking among adolescents SO JOURNAL OF ADOLESCENT HEALTH LA English DT Article DE smoking; tobacco; media; advertising; television; media messages; movies; media literacy; media education; adolescence; aubstance abuse; education; school-based ID TOBACCO USE; PROMOTION; CHILDREN; SUSCEPTIBILITY; VALIDATION; PREVENTION; INDUSTRY; ALCOHOL; PROGRAM; TRIAL AB Purpose: To determine whether media literacy concerning tobacco use is independently associated with two clinically relevant outcome measures in adolescents: current smoking and susceptibility to smoking. Methods: We asked high school students aged 14-18 years to complete a survey that included a validated 18-item smoking media literacy (SML) scale, items assessing current smoking and susceptibility to future smoking, and covariates shown to be related to smoking. We used logistic regression to assess independent associations between the two outcome measures and SML. Results: Of the 1211 students who completed the survey, 19% reported current smoking. Controlling for all potential confounders of smoking, we found that an increase of one point (out of 10) in SML was independently associated with an odds ratio for smoking of.84 (95% confidence interval [CI].71-99). Compared with students below the median score on the SML scale, students above the median had an odds ratio for smoking of.57 (95% CI.37-87). Of the students who were nonsmokers, 40% were classified as susceptible to future smoking. Controlling for all potential confounders of smoking, we found that an increase of one point (out of 10) was independently associated with and an odds ratio for smoking susceptibility of .68 (95% CI.58-79). Compared with students below the median SML, students above the median SML had an odds ratio for smoking susceptibility of .49 (95% CI .35-68). Conclusions: In this sample of high school students, higher SML is independently associated with reduced current smoking and reduced susceptibility to future smoking. (c) 2006 Society for Adolescent Medicine. All rights reserved. C1 Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Sch Med, Dept Pediat, Div Adolescent Med, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Grad Sch Publ Hlth, Dept Behav & Community Hlth Sci, Pittsburgh, PA 15260 USA. VA Pittsburgh Hlth Care Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. RP Primack, BA (reprint author), Ctr Res Hlth Care, 230 McKee Pl,Suite 600, Pittsburgh, PA 15213 USA. EM bprimack@pitt.edu FU NCI NIH HHS [K07 CA114315, K07 CA114315-01A1]; NIAID NIH HHS [5K24 AI01769, K24 AI001769] NR 40 TC 33 Z9 35 U1 4 U2 20 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD OCT PY 2006 VL 39 IS 4 BP 465 EP 472 DI 10.1016/j.jadohealth.2006.05.011 PG 8 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 090QR UT WOS:000240966400003 PM 16982379 ER PT J AU Dienes, KA Hammen, C Henry, RM Cohen, AN Daley, SE AF Dienes, Kimberly A. Hammen, Constance Henry, Risha M. Cohen, Amy N. Daley, Shannon E. TI The stress sensitization hypothesis: Understanding the course of bipolar disorder SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE bipolar disorder; stress; kindling; behavioral sensitization; stress sensitization ID LIFE EVENTS; KINDLING HYPOTHESIS; DEPRESSION; NEUROBIOLOGY; RECURRENCE; REACTIVITY; WOMEN; ABUSE AB Background: The influence of psychosocial stress on the course of bipolar disorder has been increasingly recognized. The authors tested hypotheses about both stress and early adversity "sensitization" on the course of bipolar disorder over a one-year period. Methods: The participants were 58 adults (29 male and 29 female) with a diagnosis of bipolar I disorder. They were evaluated every three months for one year. Stressful life events and the presence of early adversity were assessed by structured interview. Results: There was no significant interaction between stress and episode number in the prediction of bipolar recurrence. The interaction of early adversity severity and stressful life events significantly predicted recurrence in a manner consistent with the sensitization hypothesis. Participants with early adversity reported lower levels of stress prior to recurrence than those without early adversity. Individuals with early adversity also had a significantly younger age of bipolar onset. Limitations: The sample size was small and the number of past episodes was determined retrospectively, mainly through self-report. Conclusions: Severe early adversity may result in a greater effect of stress on bipolar recurrence and earlier onset of bipolar disorder, suggesting the need for further studies of stress mechanisms in bipolar disorder and of treatments designed to intervene early among those at risk. (c) 2006 Elsevier B.V. All rights reserved. C1 Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. W Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. MIRECC, Los Angeles, CA USA. Univ So Calif, Dept Psychol, Los Angeles, CA 90089 USA. RP Dienes, KA (reprint author), Univ Calif Los Angeles, Dept Psychol, 1285 Franz Hall,POB 951563,405 Hilgard Ave, Los Angeles, CA 90095 USA. EM kdienes@ucla.edu OI Dienes, Kimberly/0000-0002-6119-7025 FU NIMH NIH HHS [MH-14584, MH52239] NR 19 TC 60 Z9 62 U1 5 U2 10 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD OCT PY 2006 VL 95 IS 1-3 BP 43 EP 49 DI 10.1016/j.jad.2006.04.009 PG 7 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 097VQ UT WOS:000241477700006 PM 16837055 ER PT J AU Rodriguez, KL Young, AJ AF Rodriguez, Keri L. Young, Amanda J. TI Elderly veterans' beliefs concerning life-sustaining treatment and the control of their end-of-life health and health care SO JOURNAL OF AGING AND HEALTH LA English DT Article DE veterans; advance care planning; geriatrics; health locus of control; qualitative research ID PERCEIVED CONTROL; EXTERNAL CONTROL; MHLC SCALES; LOCUS; DEPRESSION; DISEASES AB Objective: This study used qualitative methods to explore patients' beliefs about control of their end-of-life health and health care. Method: The authors recruited 30 elderly patients from a large, urban Veterans Administration medical center in the United States and engaged them in semistructured interviews about end-of-life care concepts. Using grounded theory methods, they coded, categorized, and compared responses. Results: The authors discovered that patients' decisions about using life-sustaining treatment were interconnected with their beliefs about their degree of control over circumstances and the role of external factors, including a higher power; institutions and individuals; medical interventions; medical conditions; and luck, chance, or fate. Discussion: The results shed light on why patients do or do not take active roles in advance decisions concerning the use of life-sustaining treatment. C1 Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15260 USA. Univ Memphis, Memphis, TN 38152 USA. RP Rodriguez, KL (reprint author), Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15260 USA. NR 52 TC 6 Z9 6 U1 1 U2 5 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0898-2643 J9 J AGING HEALTH JI J. Aging Health PD OCT PY 2006 VL 18 IS 5 BP 686 EP 706 DI 10.1177/08982643063293258 PG 21 WC Gerontology; Health Policy & Services SC Geriatrics & Gerontology; Health Care Sciences & Services GA 088TC UT WOS:000240833000003 PM 16980635 ER PT J AU Green, DM Noble, PC Bocell, JR Ahuero, JS Poteet, BA Birdsall, HH AF Green, D. M. Noble, P. C. Bocell, J. R., Jr. Ahuero, J. S. Poteet, B. A. Birdsall, H. H. TI Effect of early full weight-bearing after joint injury on inflammation and cartilage degradation SO JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME LA English DT Article ID TUMOR-NECROSIS-FACTOR; DETECTED BONE BRUISES; ARTICULAR-CARTILAGE; CHONDROCYTE DEATH; FACTOR-ALPHA; IMPACT LOAD; TNF-ALPHA; EXPRESSION; MATRIX; INTERLEUKIN-10 AB Background: Early full weight-bearing after an acute osteochondral injury avoids problems associated with immobility but may also be harmful by amplifying the inflammatory response. To investigate these effects, we developed an in vivo model of subchondral trauma. Methods: After an impact injury to the femoral condyle, fourteen dogs were randomized to immediate full weight-bearing or to four weeks of minimal weight-bearing before full weight-bearing. Synovial fluid was sampled by aspiration at one, two, four, eight, twelve, sixteen, twenty, and twenty-four weeks. Neutrophils, monocytes, and lymphocytes were enumerated, and the concentrations of tumor necrosis factor-alpha, interleukin-10, nitric oxide, matrix metalloproteinases, and glycosaminoglycans were measured. Results: Compared with the findings for uninjured joints, the synovial fluid from the impacted joints of full-weight-bearing dogs had significantly higher peak concentrations of neutrophils (p = 0.0006 at one week), mononuclear leukocytes (p = 0.001 at four weeks), tumor necrosis factor-alpha (p = 0.001 at one week), nitric oxide (p = 0.001 at one week), matrix metalloproteinases (p = 0.008 at one week), and glycosaminoglycans (p = 0.002 at four weeks and p = 0.001 at six months). The size of the bone bruise correlated with the peak concentrations of tumor necrosis factor-alpha (r(2) = 0.89, p = 0.007; Spearman rank test), matrix metalloproteinases (r(2) = 0.96, p = 0.0004), and glycosaminoglycans (r(2) = 0.96, p = 0.0004). However, restriction to minimal weight-bearing for four weeks after the injury led to a significant reduction in the synovial fluid concentrations of neutrophils (p = 0.007 at one week and p = 0.01 at two weeks), tumor necrosis factor-alpha (p = 0.0006 to 0.02 during the first four weeks), nitric oxide (p = 0.001 to 0.04 during the first four weeks), and matrix metalloproteinases (p = 0.007 to 0.01 from the second week to the eighth week). In contrast, interleukin-10 concentrations were significantly higher (p = 0.002 at one week) and glycosaminoglycan levels remained at normal levels in animals that were restricted from immediate full weight-bearing after the injury. Conclusions: The magnitude of the inflammatory response is proportional to the size of the bone bruise. Restriction to minimal weight-bearing for four weeks reduces the magnitude of the inflammatory response and the cartilage degradation following articular cartilage impact injury. Clinical Relevance: Strategies to minimize mechanical stress during the early postinjury period may help to preserve cartilage integrity and forestall the development of osteoarthritis. C1 Michael E DeBakey Vet Affairs Med Ctr, Res Off, Houston, TX 77030 USA. Baylor Coll Med, Dept Orthoped Surg, Houston, TX 77030 USA. RP Green, DM (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Res Off, MS 151,2002 Holcombe Blvd, Houston, TX 77030 USA. EM dgreen@bcm.tmc.edu NR 40 TC 19 Z9 24 U1 0 U2 0 PU JOURNAL BONE JOINT SURGERY INC PI NEEDHAM PA 20 PICKERING ST, NEEDHAM, MA 02192 USA SN 0021-9355 J9 J BONE JOINT SURG AM JI J. Bone Joint Surg.-Am. Vol. PD OCT PY 2006 VL 88A IS 10 BP 2201 EP 2209 DI 10.2106/JBJS.E.00812 PG 9 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 096YI UT WOS:000241412400012 PM 17015597 ER PT J AU Rao, HW Lu, GW Kajiya, H Garcia-Palacios, V Kurihara, N Anderson, J Patrene, K Sheppard, D Blair, HC Windle, JJ Choi, SJ Roodman, GD AF Rao, Honowei Lu, Ganwei Kajiya, Hiroshi Garcia-Palacios, Veronica Kurihara, Noriyoshi Anderson, Judy Patrene, Ken Sheppard, Dean Blair, Harry C. Windle, Jolene J. Choi, Sun Jin Roodman, G. David TI alpha(9)beta(1): A novel osteoclast integrin that regulates osteoclast formation and function SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Article DE alpha(9)beta(1) integrin; osteoclast; ADAM8; alpha(9) knockout mice ID STIMULATING FACTOR; MICE LACKING; CELL; BONE; EXPRESSION; IDENTIFICATION; OSTEOPONTIN; MIGRATION; ADHESION; FAMILY AB We identified a previously unknown integrin, alpha(9)beta(1), on OCLs and their precursors. Antibody to alpha(9) inhibited OCL formation in human marrow cultures, and OCLs from alpha(9) knockout mice had a defect in actin ring reorganization and an impaired bone resorption capacity. C1 VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Pittsburgh, PA USA. Fukuoka Dent Coll, Sawara Ku, Fukuoka, Japan. Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA. Virginia Commonwealth Univ, Dept Human Genet, Richmond, VA USA. Natl Inst Dent & Craniofacial Res, Bethesda, MD USA. RP Roodman, GD (reprint author), VA Pittsburgh Healthcare Syst, R&D 151C-U,Room 2E-113,Univ Dr, Pittsburgh, PA 15240 USA. EM roodmangd@upmc.edu OI Windle, Jolene/0000-0001-6690-385X FU NIA NIH HHS [R01 AG012951, R01 AG012951-07, AG12951]; NIAMS NIH HHS [R01 AR041336-15, R01 AR041336, R01 AR047700-05, R01 AR047700, R01-AR41336, AR47700] NR 28 TC 49 Z9 53 U1 0 U2 1 PU AMER SOC BONE & MINERAL RES PI WASHINGTON PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036-3309 USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD OCT PY 2006 VL 21 IS 10 BP 1657 EP 1665 DI 10.1359/JBMR.060718 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 088KG UT WOS:000240810000018 PM 16995821 ER PT J AU Wu, JD Haugk, K Woodke, L Nelson, P Coleman, I Plymate, SR AF Wu, Jennifer D. Haugk, Kathy Woodke, Libby Nelson, Peter Coleman, Ilsa Plymate, Stephen R. TI Interaction of IGF signaling and the androgen receptor in prostate cancer progression SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Article DE insulin-like growth factor type I receptor (IGF-IR); androgen receptor (AR); androgen-independent (AI); prostate cancer; AR co-regulators ID GROWTH-FACTOR-I; INSULIN-DEGRADING ENZYME; MALIGNANT PHENOTYPE; EPITHELIAL-CELLS; TUMOR-CELLS; EXPRESSION; APOPTOSIS; PROTEIN; INDEPENDENCE; ACTIVATION AB The insulin-like growth factor type I receptor (IGF-IR) has been suggested to play an important role in prostate cancer progression and possibly in the progression to androgen-independent (AI) disease. The term AI may not be entirely correct, in that recent data suggest that expression of androgen receptor (AR) and androgen-regulated genes is the primary association with prostate cancer progression after hormone ablation. Therefore, signaling through other growth factors has been thought to play a role in AR-mediated prostate cancer progression to AI disease in the absence of androgen ligand. However, existing data on how IGF-IR signaling interacts with AR activation in prostate cancer are conflicting. In this Prospect article, we review some of the published data on the mechanisms of IGF-IR/AR interaction and present new evidence that IGF-IR signaling may modulate AR compartmentation and thus alter AR activity in prostate cancer cells. Inhibition of IGF-IR signaling can result in cytoplasmic AR retention and a significant change in androgen-regulated gene expression. Translocation of AR from the cytoplasm to the nucleus may be associated with IGF-induced dephosphorylation. Since fully humanized antibodies targeting the IGF-IR are now in clinical trials, the current review is intended to reveal the mechanisms of potential therapeutic effects of these antibodies on AI prostate cancers. C1 Univ Washington, Dept Med, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA. Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. RP Plymate, SR (reprint author), 325 9th Ave,Box 359625, Seattle, WA 98104 USA. EM splymate@u.washington.edu FU NCI NIH HHS [1K01CA116002-01, P01-CA85859] NR 45 TC 100 Z9 105 U1 1 U2 5 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PD OCT 1 PY 2006 VL 99 IS 2 BP 392 EP 401 DI 10.1002/jcb.20929 PG 10 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 087RA UT WOS:000240758600007 PM 16639715 ER PT J AU Page, ST Lin, DW Mostaghel, EA Hess, DL True, LD Amory, JK Nelson, PS Matsumoto, AM Bremner, WJ AF Page, Stephanie T. Lin, Daniel W. Mostaghel, Elahe A. Hess, David L. True, Lawrence D. Amory, John K. Nelson, Peter S. Matsumoto, Alvin M. Bremner, William J. TI Persistent intraprostatic androgen concentrations after medical castration in healthy men SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID BENIGN PROSTATIC HYPERPLASIA; DUAL 5-ALPHA-REDUCTASE INHIBITOR; DEPRIVATION THERAPY; HORMONE ANTAGONIST; 3-MONTH TREATMENT; TISSUE; CANCER; DIHYDROTESTOSTERONE; TESTOSTERONE; EXPRESSION AB Context: The impact of serum androgen manipulation on prostate tissue hormone levels in normal men is unknown. Studies of men with prostate cancer have suggested that prostatic androgens are preserved in the setting of castration. Tissue androgens might stimulate prostate growth, producing adverse clinical consequences. Objective: The objective of the study was to determine the effect of serum androgen manipulation on intraprostatic androgens in normal men. Design: Thirteen male volunteers ages 35-55 yr (prostate-specific antigen < 2.0 ng/ml; normal transrectal ultrasound) were randomly assigned to: 1) a long-acting GnRH-antagonist, acyline, every 2 wk; 2) acyline plus testosterone ( T) gel ( 10 mg/d); or 3) placebo for 28 d. Serum hormones were assessed weekly. Prostate biopsies were obtained on d 28. Extracted androgens were measured by RIA, and immunohistochemistry for androgen-regulated proteins was performed. Results: The mean decrease in serum T was 94%, whereas prostatic T and dihydrotestosterone levels were 70 and 80% lower, respectively, in subjects receiving acyline alone compared with controls ( P < 0.05). Despite this decrease in prostate androgens, there were no detectable differences in prostate epithelial proliferation, apoptosis, prostate-specific antigen, and androgen receptor expression. Conclusion: In this small study of healthy subjects, despite a 94% decrease in serum T with medical castration, intraprostatic T and dihydrotestosterone levels remained 20-30% of control values, and prostate cell proliferation, apoptosis, and androgen-regulated protein expression were unaffected. Our data highlight the importance of assessing tissue hormone levels. The source of persistent prostate androgens associated with medical castration and their potential role in supporting prostate metabolism deserves further study. C1 Univ Washington, Sch Med, Med Ctr, Dept Med,Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. Univ Washington, Sch Med, Dept Urol, Seattle, WA 98195 USA. Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. Ctr Geriatr Res Educ & Clin, Seattle, WA 98108 USA. Oregon Hlth Sci Univ, Oregon Reg Primate Res Ctr, Beaverton, OR 97006 USA. Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA. Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA. RP Page, ST (reprint author), Univ Washington, Sch Med, Med Ctr, Dept Med,Div Metab Endocrinol & Nutr, Box 357138,1959 NE Pacific, Seattle, WA 98195 USA. EM page@u.washington.edu FU NCI NIH HHS [CA 97186]; NCRR NIH HHS [RR 00163]; NIA NIH HHS [K23 AG027238, K23 AG027238-03]; NICHD NIH HHS [U54 HD 12629, U54 HD 42454]; NIDDK NIH HHS [DK 65204, DK 65083] NR 41 TC 122 Z9 123 U1 2 U2 3 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD OCT PY 2006 VL 91 IS 10 BP 3850 EP 3856 DI 10.1210/jc.2006-0968 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 092ML UT WOS:000241100900024 PM 16882745 ER PT J AU Robert, S Hamner, MB Ulmer, HG Lorberbaum, JP Durkalski, VL AF Robert, Sophie Hamner, Mark B. Ulmer, Helen G. Lorberbaum, Jeffrey P. Durkalski, Valerie L. TI Open-label trial of escitalopram in the treatment of posttraumatic stress disorder SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT 45th Annual Meeting of the New-Clinical-Drug-Evaluation-Unit CY JUN 06-09, 2005 CL Boca Raton, FL SP NIMH, New Clin Drug Evaluat Unit ID SLEEP QUALITY INDEX; RATING SCALE; DOUBLE-BLIND; CITALOPRAM; PLACEBO; MULTICENTER; PAROXETINE; VETERANS; PTSD AB Background: Posttraumatic stress disorder (PTSD) is a highly prevalent, disabling illness. Selective serotonin reuptake inhibitors (SSRIs) are considered first-line medication treatment, with sertraline, paroxetine, and fluoxetine being the most studied. More limited but favorable data suggest that citalopram, an SSRI, may also have a role in the treatment of PTSD. Its S-enantiomer escitalopram, which may have faster onset and greater magnitude of effect than citalopram in other conditions, has not yet been investigated in PTSD. Objective: To assess the efficacy, safety, and tolerability of escitalopram in the treatment of PTSD. Method: A 12-week, prospective, open-label trial of escitalopram was conducted from January 2003 through August 2004 in military veterans with PTSD. Escitalopram was initiated at 10 mg daily for 4 weeks, then increased to 20 mg daily for the remainder of the study. Concomitant psychiatric medications were discontinued at least 2 weeks prior to enrollment. The primary outcome variable was the change from baseline to endpoint in global Clinician-Administered PTSD Scale-Symptom version (CAPS-SX) score. Secondary efficacy measures included the Clinical Global Impressions-Severity of Illness (CGI-S) and -Improvement (CGI-I) scales, the Hamilton Rating Scale for Depression (HAM-D), and the Davidson Trauma Scale (DTS). Posttraumatic stress disorder and comorbid diagnoses were established using the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Results: Twenty-four of 25 patients were evaluated for efficacy. The mean global CAPS-SX score decreased from 79.4 (SD = 15.7) at baseline to 61.2 (SD = 24.7) at the end of the study (p = .0002). The CAPS-C avoidance/numbing and CAPS-D hyper-arousal subscale scores decreased significantly from baseline to endpoint (CAPS-C, p = .0171; CAPS-D, p = .0001), with trend-level reductions observed in CAPS-B reexperiencing subscale scores (p = .0593). Forty-five percent of patients (9/20) were much or very much improved at the end of the study (CGI-I of I or 2). The HAM-D and DTS also significantly improved (p = .0063 and p = .0004, respectively). Mild to moderate gastrointestinal disturbances were the most common side effects. Only 4 patients discontinued early because of adverse effects. Conclusions: This preliminary open-label study suggests that escitalopram is both efficacious and well tolerated in PTSD patients. However, randomized controlled studies are needed to confirm these results and to further define its potential role in the treatment of PTSD. C1 Ralph H Johnson VA Med Ctr, Mental Hlth Serv, Charleston, SC 29401 USA. Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA. Penn State Univ, Milton S Hershey Med Ctr, Dept Psychiat, Hershey, PA 17033 USA. RP Robert, S (reprint author), Ralph H Johnson VA Med Ctr, Mental Hlth Serv, 109 Bee St 116, Charleston, SC 29401 USA. EM robertso@musc.edu NR 29 TC 25 Z9 25 U1 6 U2 6 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD OCT PY 2006 VL 67 IS 10 BP 1522 EP 1526 PG 5 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 104NE UT WOS:000241964300005 PM 17107242 ER PT J AU Altshuler, LL Post, RM Black, DO Keck, PE Nolen, WA Frye, MA Suppes, T Grunze, H Kupka, RW Leverich, GS McElroy, SL Walden, J Mintz, J AF Altshuler, Lori L. Post, Robert M. Black, David O. Keck, Paul E., Jr. Nolen, Willem A. Frye, Mark A. Suppes, Trisha Grunze, Heinz Kupka, Ralph W. Leverich, Gabriele S. McElroy, Susan L. Walden, Joerg Mintz, Jim TI Subsyndromal depressive symptoms are associated with functional impairment in patients with bipolar disorder: Results of a large, multisite study SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID QUALITY-OF-LIFE; PROSPECTIVE FOLLOW-UP; SOCIAL-ADJUSTMENT; MAJOR DEPRESSION; SUBCLINICAL SYMPTOMS; GENERAL-POPULATION; SYMPTOMATOLOGY IDS; MEDICAL OUTCOMES; NATURAL-HISTORY; MOOD DISORDERS AB Objective: Studies of patients with unipolar depression have demonstrated a relationship between subthreshold depressive symptoms and impairment in role functioning. Research examining this relationship in persons with bipolar disorder is rare. This study sought to evaluate the association between subsyndromal depressive symptoms and role functioning in subjects with bipolar disorder. Method: 759 adult outpatients with a DSM-IV diagnosis of bipolar disorder were entered into this study at 7 different sites in the Stanley Foundation Bipolar Network (SFBN) beginning in March 1996 and ending in November 2002 and were followed longitudinally for assessment of their course of illness. Subsyndromal depression was operationalized using cutoff scores on the Inventory for Depressive Symptomatology-Clinician Rated (IDS-C), and patients were divided into 3 groups: not depressed (IDS-C score < 13), subsyndromally depressed (IDS-C score 13 to 27), and syndromally depressed (IDS-C score >= 28). Groups were compared using a series Of chi(2) analyses on degree of role function impairment across 4 role domains (work, home duties, family life, and friendships) from the Life Functioning Questionnaire. Logistic regression was used to estimate the probability of any impairment in life functioning based on severity of depressive symptoms. Results: Subsyndromally depressed patients were significantly more likely than those not depressed to report impairment in their work and home functioning roles, as well as impairment in relations with family and friends (p < .001). Across all domains of role function, the proportion of patients impaired in the subsyndromally depressed group was more similar to the syndromally depressed group than to the not depressed group. Conclusions: These findings clearly demonstrate the public health significance of subsyndromal depression in the bipolar population. The most appropriate interventions for subsyndromal depressive symptoms in patients with bipolar disorder remain to be determined. C1 Univ Calif Los Angeles, Dept Psychiat, VA Greater Los Angeles Heathcare Syst, W Los Angeles Healthcare, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA USA. NIMH, Biol Psychiat Branch, NIH, Bethesda, MD 20892 USA. Univ Cincinnati, Coll Med, Dept Psychiat, Psychopharmacol Res Program, Cincinnati, OH USA. Vet Affairs Med Ctr, Mental Hlth Care Line & Gen Clin Res Ctr, Cincinnati, OH 45267 USA. Univ Groningen, Med Ctr, Dept Psychiat, Groningen, Netherlands. Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX 75230 USA. Ludwig Maximilians Univ Munchen, Dept Psychiat, Munich, Germany. Altrecht Inst Mental Hlth Care, Utrecht, Netherlands. Univ Freiburg, Dept Psychiat, Freiburg, Germany. Univ Munster, Dept Psychiat, Munster, Germany. RP Altshuler, LL (reprint author), 300 UCLA Med Plaza,Suite 1544,Box 957057, Los Angeles, CA 90095 USA. EM laltshuler@mednet.ucla.edu RI Nolen, Willem/E-9006-2014 NR 67 TC 114 Z9 119 U1 2 U2 5 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 EI 1555-2101 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD OCT PY 2006 VL 67 IS 10 BP 1551 EP 1560 PG 12 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 104NE UT WOS:000241964300009 PM 17107246 ER PT J AU Gukovskaya, AS Mareninova, OA Odinokova, IV Sung, KF Lugea, A Fischer, L Wang, YL Gukovsky, I Pandol, SJ AF Gukovskaya, Anna S. Mareninova, Olga A. Odinokova, Irina V. Sung, Kai-Feng Lugea, Aurelia Fischer, Lars Wang, Yan-Ling Gukovsky, Ilya Pandol, Stephen J. TI Cell death in pancreatitis: Effects of alcohol SO JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article DE alcoholic pancreatitis; caspases; cytochrome c release; RIP; XIAP ID RECEPTOR-INTERACTING PROTEIN; INDUCED LIVER APOPTOSIS; ACINAR-CELLS; INFLAMMATORY MEDIATORS; AKT PHOSPHORYLATION; SIGNALING PATHWAYS; APAF-1 APOPTOSOME; NECROSIS; SEVERITY; XIAP AB Pancreatitis is a severe and frequently lethal disorder, a major cause of which is alcohol abuse. Parenchymal cell death is a major complication of pancreatitis. In experimental models of (non-alcoholic) acute pancreatitis, acinar cells have been shown to die through both necrosis and apoptosis, the two principal pathways of cell death. The severity of experimental acute pancreatitis correlates directly with the extent of necrosis and inversely with apoptosis. Thus, understanding the regulation of apoptosis and necrosis, and whether it is possible to manipulate the pattern of death responses, is becoming exceedingly important in investigations of the pathogenesis and treatment of pancreatitis. The effects of alcohol on cell death responses of pancreatitis, and the mechanisms that may mediate these effects, are just starting to be explored. This paper reviews the signaling pathways mediating the balance between apoptosis and necrosis in acute pancreatitis, and alcohol's effects on cell death responses in pancreatitis. C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Med,VAGLAHS,W Los Angeles VA Healthcare Ctr, USC UCLA Res Ctr Alcohol Liver & Pancreat Dis, Los Angeles, CA 90073 USA. RP Gukovskaya, AS (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med,VAGLAHS,W Los Angeles VA Healthcare Ctr, USC UCLA Res Ctr Alcohol Liver & Pancreat Dis, 11301 Wilshire Blvd,Bldg 258,Room 340, Los Angeles, CA 90073 USA. EM agukovsk@ucla.edu FU NIDDK NIH HHS [DK 59936]; PHS HHS [P50-A11999] NR 52 TC 24 Z9 26 U1 0 U2 2 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0815-9319 J9 J GASTROEN HEPATOL JI J. Gastroenterol. Hepatol. PD OCT PY 2006 VL 21 SU 3 BP S10 EP S13 DI 10.1111/j.1440-1746.2006.04571.x PG 4 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 075XC UT WOS:000239919600005 PM 16958657 ER PT J AU Pandol, SJ Tsukamoto, H AF Pandol, Steve J. Tsukamoto, Hide TI Action plan for enhancing global collaboration on alcoholic liver and pancreatic diseases: White paper SO JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article C1 Univ Calif Los Angeles, VA Greater LA Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Los Angeles, CA 90073 USA. Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90089 USA. Univ Calif Los Angeles, Res Ctr Alcohol Liver & Pancreat Dis, Los Angeles, CA USA. RP Pandol, SJ (reprint author), Univ Calif Los Angeles, VA Greater LA Healthcare Syst, Bldg 258,Room 340,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM stephen.pandol@med.va.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0815-9319 J9 J GASTROEN HEPATOL JI J. Gastroenterol. Hepatol. PD OCT PY 2006 VL 21 SU 3 BP S109 EP S110 DI 10.1111/j.1440-1746.2006.04598.x PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 075XC UT WOS:000239919600029 PM 16958661 ER PT J AU Rubenstein, LV Meredith, LS Parker, LE Gordon, NP Hickey, SC Oken, C Lee, ML AF Rubenstein, Lisa V. Meredith, Lisa S. Parker, Louise E. Gordon, Nancy P. Hickey, Scot C. Oken, Carole Lee, Martin L. TI Impacts of evidence-based quality improvement on depression in primary care: A randomized experiment SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE quality improvement; depression; continuous quality management; social function ID MANAGED PRIMARY-CARE; CONTROLLED-TRIAL; COLLABORATIVE CARE; COST-EFFECTIVENESS; HEALTH-CARE; CLINICAL-PRACTICE; MAJOR DEPRESSION; GUIDELINES; OUTCOMES; ORGANIZATIONS AB CONTEXT: Previous studies testing continuous quality improvement (CQI) for depression showed no effects. Methods for practices to self-improve depression care performance are needed. We assessed the impacts of evidence-based quality improvement (EBQI), a modification of CQI, as carried out by 2 different health care systems, and collected qualitative data on the design and implementation process. OBJECTIVE: Evaluate impacts of EBQI on practice-wide depression care and outcomes. DESIGN: Practice-level randomized experiment comparing EBQI with usual care. SETTING: Six Kaiser Permanente of Northern California and 3 Veterans Administration primary care practices randomly assigned to EBQI teams (6 practices) or usual care (3 practices). Practices included 245 primary care clinicians and 250,000 patients. INTERVENTION: Researchers assisted system senior leaders to identify priorities for EBQI teams; initiated the manual-based EBQI process; and provided references and tools. EVALUATION PARTICIPANTS: Five hundred and sixty-seven representative patients with major depression. MAIN OUTCOME MEASURES: Appropriate treatment, depression, functional status, and satisfaction. RESULTS: Depressed patients in EBQI practices showed a trend toward more appropriate treatment compared with those in usual care (46.0% vs 39.9% at 6 months, P=.07), but no significant improvement in 12-month depression symptom outcomes (27.0% vs 36.1% poor depression outcome, P=.18). Social functioning improved significantly (mean score 65.0 vs 56.8 at 12 months, P=.02); physical functioning did not. CONCLUSION: Evidence-based quality improvement had perceptible, but modest, effects on practice performance for patients with depression. The modest improvements, along with qualitative data, identify potential future directions for improving CQI research and practice. C1 VA Greater Los Angeles, North Hills, CA 91343 USA. RAND Hlth Program, Santa Monica, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA USA. Kaiser Permanente, Div Res, Oakland, CA USA. Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA. RP Rubenstein, LV (reprint author), VA Greater Los Angeles, 16111 Plummer 152, North Hills, CA 91343 USA. EM lisa_rubenstein@rand.org NR 66 TC 42 Z9 42 U1 2 U2 9 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD OCT PY 2006 VL 21 IS 10 BP 1027 EP 1035 DI 10.1111/j.1525-1497.2006.00549.x PG 9 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 081BH UT WOS:000240291700003 PM 16836631 ER PT J AU Kinder, LS Katon, WJ Ludman, E Russo, J Simon, G Lin, EHB Ciechanowski, P Von Korff, M Young, B AF Kinder, Leslie S. Katon, Wayne J. Ludman, Evette Russo, Joan Simon, Greg Lin, Elizabeth H. B. Ciechanowski, Paul Von Korff, Michael Young, Bessie TI Improving depression care in patients with diabetes and multiple complications SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE depression; diabetes mellitus; primary care ID COMORBID MEDICAL ILLNESS; COLLABORATIVE CARE; COMPETING DEMANDS; MAJOR DEPRESSION; CONTROLLED-TRIAL; SELF-CARE; MANAGEMENT; OUTCOMES; METAANALYSIS; MELLITUS AB BACKGROUND: Depression is common in patients with diabetes, but it is often inadequately treated within primary care. Competing clinical demands and treatment resistance may make it especially difficult to improve depressive symptoms in patients with diabetes who have multiple complications. OBJECTIVE: To determine whether a collaborative care intervention for depression would be as effective in patients with diabetes who had 2 or more complications as in patients with diabetes who had fewer complications. DESIGN: The Pathways Study was a randomized control trial comparing collaborative care case management for depression and usual primary care. This secondary analysis compared outcomes in patients with 2 or more complications to patients with fewer complications. PATIENTS: Three hundred and twenty-nine patients with diabetes and comorbid depression were recruited through primary care clinics of a large prepaid health plan. MEASUREMENTS: Depression was assessed at baseline, 3, 6, and 12 months with the 20-item depression scale from the Hopkins Symptom Checklist. Diabetes complications were determined from automated patient records. RESULTS: The Pathways collaborative care intervention was significantly more successful at reducing depressive symptoms than usual primary care in patients with diabetes who had 2 or more complications. Patients with fewer than 2 complications experienced similar reductions in depressive symptoms in both intervention and usual care. CONCLUSIONS: Patients with depression and diabetes who have multiple complications may benefit most from collaborative care for depression. These findings suggest that with appropriate intervention depression can be successfully treated in patients with diabetes who have the highest severity of medical problems. C1 Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98101 USA. Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA 98101 USA. RP Kinder, LS (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM lskinder@stanfordalumni.org FU NIMH NIH HHS [MH01643, MH073686, MH4-1739, R01 MH073686] NR 36 TC 36 Z9 38 U1 2 U2 6 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD OCT PY 2006 VL 21 IS 10 BP 1036 EP 1041 DI 10.1111/j.1525-1497.2006.00552.x PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 081BH UT WOS:000240291700004 PM 16836628 ER PT J AU Bean-Mayberry, B Chang, CC Scholle, SH AF Bean-Mayberry, Bevanne Chang, Chung-Chou Scholle, Sarah Hudson TI Brief report: Lack of a race effect in primary care ratings among women veterans SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE patient satisfaction; primary care; race; veterans; women ID HEALTH-CARE; PATIENT SATISFACTION; SERVICES; RACE/ETHNICITY; ASSESSMENTS; ATTRIBUTES; QUALITY; SYSTEM AB OBJECTIVE: To explore the effect of race on primary care quality and satisfaction among women in the Department of Veterans Affairs (VA). METHODS: We used a mail survey to measure primary care quality and satisfaction. We focused on 4 primary care domains: patient preference for provider, interpersonal communication, accumulated knowledge, and coordination. We performed univariate analyses to compare variables by race and multiple logistic regression analysis to examine the effect of race on the probability of reporting a perfect score on each domain, while adjusting for patient characteristics and site. RESULTS: Black women were younger, unmarried, educated, of higher income, and reported female providers and gynecological care in VA more often. In regression analysis, race was not significantly associated with any primary care domain or satisfaction. Gynecological care from VA provider was associated with perfect ratings on patient preference for provider (odds ratio [OR] 2.0, 95% confidence intervals [CI] 1.3, 3.1), and satisfaction (OR 1.6, 95% CI 1.2, 2.3), while female provider was associated with interpersonal communication (OR 1.9, 95% CI 1.4, 2.6). CONCLUSIONS: While demographics and health experiences vary by race among veterans, race had no effect on primary care ratings. Future studies need to determine whether this racial equity persists in health outcomes among women veterans. C1 VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA USA. Univ Pittsburgh, Dept Hlth Policy & Management, Pittsburgh, PA USA. Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. Natl Comm Qual Assurance, Res & Anal Div, Washington, DC USA. RP Bean-Mayberry, B (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 151C-U,Univ Dr C, Pittsburgh, PA 15240 USA. EM bevanne.bean-mayberry@va.gov NR 18 TC 5 Z9 5 U1 1 U2 2 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD OCT PY 2006 VL 21 IS 10 BP 1105 EP 1108 DI 10.1111/j.1525-1497.2006.00517.x PG 4 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 081BH UT WOS:000240291700016 PM 16970560 ER PT J AU Hunt, PW Harrigan, PR Huang, W Bates, M Williamson, DW McCune, JM Price, RW Spudich, SS Lampiris, H Hoh, R Leigler, T Martin, JN Deeks, SG AF Hunt, Peter W. Harrigan, P. Richard Huang, Wei Bates, Michael Williamson, David W. McCune, Joseph M. Price, Richard W. Spudich, Serena S. Lampiris, Harry Hoh, Rebecca Leigler, Teri Martin, Jeffrey N. Deeks, Steven G. TI Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1 - Infected patients with detectable viremia SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT 13th Conference on Retroviruses and Opportunistic Infections CY FEB 05-09, 2006 CL Denver, CO ID IMMUNODEFICIENCY-VIRUS TYPE-1; BIOLOGICAL PHENOTYPE; INDIVIDUALS; PROGRESSION; CORECEPTOR; THERAPY; DISEASE AB Although CXCR4-tropic viruses are relatively uncommon among untreated human immunodeficiency virus (HIV) infected individuals except during advanced immunodeficiency, the prevalence of CXCR4-tropic viruses among treated patients with detectable viremia is unknown. To address this issue, viral coreceptor usage was measured with a single-cycle recombinant-virus phenotypic entry assay in treatment-naive and treated HIV-infected participants with detectable viremia sampled from 2 clinic-based cohorts. Of 182 treated participants, 75 (41%) harbored dual/ mixed or X4-tropic viruses, compared with 178 (18%) of the 976 treatment-naive participants (P < .001). This difference remained significant after adjustment for CD4(+) T cell count and CCR5 Delta 32 genotype. Enrichment for dual/mixed/X4-tropic viruses among treated participants was largely but incompletely explained by lower pretreatment nadir CD4(+) T cell counts. CCR5 inhibitors may thus be best strategically used before salvage therapy and before significant CD4(+) T cell depletion. C1 Univ San Francisco, Posit Hlth Program, San Francisco Gen Hosp, San Francisco, CA 94110 USA. Univ San Francisco, Dept Neurol, San Francisco Gen Hosp, San Francisco, CA 94110 USA. Univ San Francisco, Grad Program Biol & Med Informat, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94110 USA. Univ San Francisco, Dept Internal Med, San Francisco Vet Affairs Med Ctr, Div Expt Med, San Francisco, CA 94110 USA. Univ San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94110 USA. Gladstone Inst Virol & Immunol, San Francisco, CA USA. Monogram Biosci Inc, San Francisco, CA USA. Univ British Columbia, Fac Med, Vancouver, BC V5Z 1M9, Canada. Univ British Columbia, British Columbia Ctr Excellence HIV AIDS, Vancouver, BC V5Z 1M9, Canada. Univ British Columbia, Fac Med, Vancouver, BC V5Z 1M9, Canada. RP Hunt, PW (reprint author), Univ San Francisco, Posit Hlth Program, San Francisco Gen Hosp, Bldg 80,Ward 84,995 Potrero Ave, San Francisco, CA 94110 USA. EM phunt@php.ucsf.edu FU NCRR NIH HHS [5-M01-RR00083-37]; NIAID NIH HHS [R01 AI52745, R37 AI40312, K23 AI65244, P30 AI27763]; NIH HHS [DPI OD00329]; NIMH NIH HHS [P30 MH62246, P30 MH59037]; NINDS NIH HHS [NS 37660] NR 15 TC 109 Z9 110 U1 0 U2 1 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD OCT 1 PY 2006 VL 194 IS 7 BP 926 EP 930 DI 10.1086/507312 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 081LE UT WOS:000240318300009 PM 16960780 ER PT J AU Rumsfeld, JS AF Rumsfeld, John S. TI Introduction: Managing patients with chronic angina: Emerging therapeutic options for improving clinical efficacy and outcomes SO JOURNAL OF MANAGED CARE PHARMACY LA English DT Editorial Material ID QUALITY-OF-LIFE; ACUTE CORONARY SYNDROMES; STABLE ANGINA; MEDICAL-TREATMENT; PECTORIS; DISEASE C1 Denver VA Med Ctr, Denver, CO 80220 USA. Univ Colorado, Hlth Sci Ctr, Denver, CO USA. RP Rumsfeld, JS (reprint author), Denver VA Med Ctr, 1055 Clermont St, Denver, CO 80220 USA. EM john.rumsfeld@va.gov NR 12 TC 0 Z9 0 U1 0 U2 0 PU ACADEMY MANAGED CARE PHARMACY PI ALEXANDRIA PA 100 N PITT ST, 400, ALEXANDRIA, VA 22314-3134 USA SN 1083-4087 J9 J MANAG CARE PHARM JI J. Manag. Care Pharm. PD OCT PY 2006 VL 12 IS 8 SU S BP S2 EP S3 PG 2 WC Health Care Sciences & Services; Pharmacology & Pharmacy SC Health Care Sciences & Services; Pharmacology & Pharmacy GA 109ZP UT WOS:000242348400001 PM 23577421 ER PT J AU Balasubramanian, S Mani, S Shiraishi, H Johnston, RK Yamane, K Willey, CD Cooper, G Tuxworth, WJ Kuppuswamy, D AF Balasubramanian, Sundaravadivel Mani, Santhoshkumar Shiraishi, Hirokazu Johnston, Rebecca K. Yamane, Kentaro Willey, Christopher D. Cooper, George Tuxworth, William J. Kuppuswamy, Dhandapani TI Enhanced ubiquitination of cytoskeletal proteins in pressure overloaded myocardium. is accompanied by changes in specific E3 ligases SO JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY LA English DT Article DE ubiquitination; E3 ligases; Cbl; cardiac hypertrophy ID FOCAL COMPLEX-FORMATION; NF-KAPPA-B; C-CBL; CARDIAC-HYPERTROPHY; PROTEASOME SYSTEM; INSULIN-RECEPTOR; TYROSINE KINASE; GENE-EXPRESSION; MUSCLE-CELLS; DEGRADATION AB Ubiquitin conjugation of proteins is critical for cell homeostasis and contributes to both cell survival and death. Here we studied ubiquitination of proteins in pressure overloaded (PO) myocardium in the context of cardiomyocyte survival. Analysis using a feline right ventricular pressure overload (RVPO) model revealed a robust and transient increase in ubiquitination of proteins present in the Triton X-100-insoluble fraction in 24 to 48 h PO myocardium, and confocal micrographs indicate this increase in ubiquitination occurs subsarcolemmaly near the intercalated disc area of cardiomyocytes. The ubiquitination was accompanied by changes in E3 ligases including Cbl, E6AP, Mdm2 and cIAP in the same period of PO, although atrophy-related E3 ligases, MuRF1 and MuRF3 were unaltered. Furthermore, Cbl displayed a substantial increase in both levels of expression and tyrosine phosphorylation in 48 It PO myocardium. Confocal studies revealed enrichment of Cbl at the intercalated discs of 48 h PO cardiomyocytes, as evidenced by its colocalization with N-cadherin. Although apoptosis was observed in 48 It PO myocardium by TUNEL staining, cardiomyocytes showing ubiquitin staining were not positive for TUNEL staining. Furthennore, 48 It PO resulted in the phosphorylation of inhibitor of nuclear factor kappa B (I kappa B), suggesting its ubiquitin-mediated degradation and the nuclear localization of NF kappa B for the expression of specific cell survival factors such as cIAPs. Together these data indicate that increased levels of E3 ligases that regulate cell homeostasis and promote cell survival could ubiquitinate multiple cytoskeletal protein targets and that these events that occur during the early phase of PO may contribute to both cardiomyocyte survival and hypertrophy. (c) 2006 Elsevier Inc. All rights reserved. C1 Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Div Cardiol, Charleston, SC 29425 USA. Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC 29425 USA. RP Kuppuswamy, D (reprint author), Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Div Cardiol, 114 Doughty St, Charleston, SC 29425 USA. EM kuppusd@musc.edu OI Willey, Christopher/0000-0001-9953-0279 FU NHLBI NIH HHS [HL-48788]; NIGMS NIH HHS [GM08716] NR 61 TC 29 Z9 31 U1 0 U2 0 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 0022-2828 EI 1095-8584 J9 J MOL CELL CARDIOL JI J. Mol. Cell. Cardiol. PD OCT PY 2006 VL 41 IS 4 BP 669 EP 679 DI 10.1016/j.yjmcc.2006.04.022 PG 11 WC Cardiac & Cardiovascular Systems; Cell Biology SC Cardiovascular System & Cardiology; Cell Biology GA 096VC UT WOS:000241403900012 PM 16928382 ER PT J AU Fontana, A Rosenheck, R Ruzek, J McFall, M AF Fontana, Alan Rosenheck, Robert Ruzek, Josef McFall, Miles TI Specificity of patients' satisfaction with the delivery and outcome of treatment SO JOURNAL OF NERVOUS AND MENTAL DISEASE LA English DT Article DE satisfaction with treatment; delivery of care; clinical outcomes; veterans; posttraumatic stress disorder ID POSTTRAUMATIC-STRESS-DISORDER; CONSUMER SATISFACTION; PSYCHIATRIC-CARE; ISSUES AB This study investigated the hypotheses that the gener disposition to be satisfied is more influential than the nature of service delivery in determining satisfaction with treatment, and that there is a specificity to satisfaction with the delivery of care and with clinical outcome of care that makes their ratings distinct. Data were obtained by questionnaire at intake into treatment and 4 months later from 154 male veterans. There were statistically significant relationships between the general disposition to be satisfied and satisfaction with treatment, but they had only a trivial effect on the relationships between treatment satisfaction and other variables. There was, however, a specificity to satisfaction ratings such that a major feature of the delivery of care, the experience of friendliness and caring from staff, was related more highly to satisfaction with care than to satisfaction with outcome, while measures of clinical outcome were related more highly to satisfaction with outcome than to satisfaction with care. A general disposition to be satisfied, therefore, appears not to have a major biasing effect on satisfaction with treatment. Further, patients appear to make valid differentiations between satisfaction with the delivery of care and the clinical outcome of care when their attention is focused specifically on satisfaction with these features. C1 Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. VA Natl Ctr PTSD, Evaluat Div, West Haven, CT USA. VA Natl Ctr PTSD, Educ Div, Menlo Pk, CA USA. VA Puget Sound Healthcare Syst, NW Network Mental Illness Res Educ & Clin Ctr, Seattle, WA USA. RP Fontana, A (reprint author), VA Connecticut Healthcare Syst, W Haven Campus,950 Campbell Ave,NEPEC 182, West Haven, CT 06516 USA. NR 21 TC 4 Z9 5 U1 2 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-3018 J9 J NERV MENT DIS JI J. Nerv. Ment. Dis. PD OCT PY 2006 VL 194 IS 10 BP 780 EP 784 DI 10.1097/01.nmd.0000240036.45462.e6 PG 5 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 096FZ UT WOS:000241364300009 PM 17041291 ER PT J AU Sharp, ND Greiner, GT Li, YF Mitchell, PH Sochalski, JA Cournoyer, PR Sales, AE AF Sharp, Nancy D. Greiner, Gwendolyn T. Li, Yu-Fang Mitchell, Pamela H. Sochalski, Julie A. Cournoyer, Paulette R. Sales, Anne E. TI Nurse executive and staff nurse perceptions of the effects of reorganization in veterans health administration hospitals SO JOURNAL OF NURSING ADMINISTRATION LA English DT Article ID QUALITY-OF-CARE; PATIENT; IMPACT; LEADERSHIP; MORTALITY; OUTCOMES; SYSTEM; WORK AB Objective: To examine nurse executive perceptions of effects of service line reorganization on nurse executive roles, nursing staff and patient care, and compare nurse executive responses to staff nurse reports of job satisfaction and quality of care in the same types of Veterans Health Administration facilities. Background: Although a growing body of research focuses on the association between nurse staffing structures, nurse satisfaction, and patient outcomes, relatively little attention has been paid to the effects of hospital restructuring on nursing management and nursing staff. Methods: Data on hospital and nursing service organization and nurse executive perceptions were collected through structured interviews with 125 nurse executives conducted from December 2002 through May 2003. Staff nurse data were derived from a survey of Veterans Health Administration nursing staff conducted from February through June 2003 at the same facilities. Results: Nurse executives in Veterans Health Administration described significant changes in the nurse executive role, and new challenges for managing nursing practice and achieving consistent quality of nursing care. Although nursing management perceived differences in the overall effects of restructuring on nursing staff depending on the type of reorganization, staff nurses reported significant differences in perceived quality of patient care across organization types. C1 VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev 152, Seattle, WA 98101 USA. Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. Univ Washington, Sch Nursing, Seattle, WA 98195 USA. Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. Dept Vet Affairs, Off Nursing Serv, Washington, DC USA. RP Sharp, ND (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev 152, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM nancy.sharp@med.va.gov RI Sales, Anne/D-9678-2012 OI Sales, Anne/0000-0001-9360-3334 NR 26 TC 5 Z9 6 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0002-0443 J9 J NURS ADMIN JI J. Nurs. Adm. PD OCT PY 2006 VL 36 IS 10 BP 471 EP 478 DI 10.1097/00005110-200610000-00008 PG 8 WC Nursing SC Nursing GA 098UF UT WOS:000241547600008 PM 17035882 ER PT J AU Wang, H Khaoustov, VI Krishnan, B Cai, W Stoll, B Burrin, DG Yoffe, B AF Wang, Hui Khaoustov, Vladimir I. Krishnan, Buvaneswari Cai, Wei Stoll, Barbara Burrin, Douglas G. Yoffe, Boris TI Total parenteral nutrition induces liver steatosis and apoptosis in neonatal piglets SO JOURNAL OF NUTRITION LA English DT Article ID INDUCED HEPATOBILIARY DYSFUNCTION; NF-KAPPA-B; HEPATOCYTE APOPTOSIS; NONALCOHOLIC STEATOHEPATITIS; FATTY LIVER; CELL-DEATH; PATHOGENESIS; ACTIVATION; NECROSIS; INJURY AB Total parenteral nutrition (TPN) induces a high rate of liver disease in infants, yet the pathogenesis remains elusive. We used neonatal piglets as an animal model to assess early events leading to TPN-mediated liver injury. Newborn piglets (n = 7) were nourished for 7 d on TPN or enteral nutrition (EN) and the liver tissue and isolated hepatocytes were subjected to morphologic and molecular analysis. Histological analysis revealed prominent steatosis (grade > 2) in 6 of 7 TPN pigs, whereas minimal steatosis (grade : 1) was observed in only 2 EN pigs. Abundant cytosolic cytochrome C and DNA fragmentation were observed in hepatocytes from TPN compared with EN piglets. Markers of mitochondrial and Fas-mediated apoptosis were altered in TPN liver tissue, as indicated by a lower ATP concentration (P < 0.05), accumulation of ubiquitin, 9.9-fold activation of caspase-3 activity (P < 0.01), and increased cleavage of poly-(ADP-ribose) polymerase, caspase-8, -9, and -7 when compared with EN livers. Bcl-2 and proliferating cell nuclear antigen expression was downregulated, whereas Fas and Bax were upregulated in TPN livers. However, levels of caspase-12 and Bip/GRP78, both markers of endoplasmic reticulum-mediated apoptosis, did not differ between the groups. Short-term TPN induces steatosis and oxidative stress, which results in apoptosis mediated by the mitochondrial and Fas pathways. Thus, TPN-induced steatosis in newborn piglets may serve as a novel animal model to assess the pathogenesis of fatty liver and apoptosis-mediated liver injury in infants. C1 Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. Baylor Univ, USDA ARS, Childrens Nutr Res Ctr, Dept Pediat, Houston, TX 77030 USA. Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA. RP Yoffe, B (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. EM byoffe@bcm.tmc.edu FU NICHD NIH HHS [HD33920]; NIDDK NIH HHS [P30 DK56338] NR 36 TC 33 Z9 35 U1 1 U2 4 PU AMER SOCIETY NUTRITIONAL SCIENCE PI BETHESDA PA 9650 ROCKVILLE PIKE, RM L-2407A, BETHESDA, MD 20814 USA SN 0022-3166 J9 J NUTR JI J. Nutr. PD OCT PY 2006 VL 136 IS 10 BP 2547 EP 2552 PG 6 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 089OH UT WOS:000240889600016 PM 16988124 ER PT J AU Wu, SM Compton, P Bolus, R Schieffer, B Pham, Q Baria, A Van Vort, W Davis, F Shekelle, P Naliboff, BD AF Wu, Stephen M. Compton, Peggy Bolus, Roger Schieffer, Beatrix Pham, Quynh Baria, Ariel Van Vort, Walter Davis, Frederick Shekelle, Paul Naliboff, Bruce D. TI The Addiction Behaviors Checklist: Validation of a new clinician-based measure of inappropriate opioid use in chronic pain SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE chronic noncancer pain; opioid medications; substance abuse; addiction; medication misuse ID MEDICATION MISUSE; ASSESSMENT-TOOL; OPIATE ABUSE; PSEUDOADDICTION; THERAPY; ISSUES AB This study introduces the Addiction Behaviors Checklist (ABC), which is a brief (20-item) instrument designed to track behaviors characteristic of addiction related to prescription opioid medications in chronic pain populations. Items are focused on observable behaviors noted both during and between clinic visits. One hundred thirty-six consecutive veterans in a multidisciplinary Veterans Affairs Chronic Pain Clinic who were receiving long-term opioid medication treatment were included in this study. This study represents one of the first to follow a sample of chronic pain patients on opioid therapy over time, using a structured assessment tool to evaluate and track behaviors suggestive of addiction. Interrater reliability and concurrent validity data are presented, as well as a cut-Off scare for use in determining inappropriate medication use. The psychometric findings support the ABC as a viable assessment tool that can increase a provider's confidence in determinations of appropriate vs. inappropriate opioid use. C1 Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Nursing, Acute Care Sect, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurovisceral Sci & Womens Hlth, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA USA. RP Naliboff, BD (reprint author), VAGLAHS, Ctr Neurovisceral Sci & Womens Hlth, Bldg 115,Room 223,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM naliboff@ucla.edu NR 22 TC 76 Z9 77 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD OCT PY 2006 VL 32 IS 4 BP 342 EP 351 DI 10.1016/j.jpainsymman.2006.05.010 PG 10 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 094BZ UT WOS:000241215600007 PM 17000351 ER PT J AU Jung, SR Kim, K Hille, B Nguyen, TD Koh, DS AF Jung, Seung-Ryoung Kim, Kyungjin Hille, Bertil Nguyen, Toan D. Koh, Duk-Su TI Pattern of Ca2+ increase determines the type of secretory mechanism activated in dog pancreatic duct epithelial cells SO JOURNAL OF PHYSIOLOGY-LONDON LA English DT Article ID INTERMEDIATE CONDUCTANCE; CALCIUM OSCILLATIONS; CYSTIC-FIBROSIS; MATHEMATICAL-MODEL; POTASSIUM CHANNELS; GANGLION NEURONS; GENE-EXPRESSION; HCO3-TRANSPORT; CL-SECRETION; ATP RELEASE AB Intracellular calcium concentration ([Ca2+](i)) is a key factor controlling secretion from various cell types. We investigated how different patterns of [Ca2+](i) signals evoke salt secretion via ion transport mechanisms and mucin secretion via exocytosis in dog pancreatic duct epithelial cells (PDEC). Activation of epithelial P2Y(2) receptors by UTP generated two patterns of [Ca2+](i) change: 2-10 mu M UTP induced [Ca2+](i) oscillations, whereas 100 mu M UTP induced a sustained [Ca2+](i) increase, both in the micromolar range. As monitored by carbon-fibre amperometry, the sustained [Ca2+](i) increase stimulated a larger increase in exocytosis than [Ca2+](i) oscillations, despite their similar amplitude. In contrast, patch-clamp recordings revealed that [Ca2+](i) oscillations synchronously activated a K+ current as efficiently as the sustained [Ca2+](i) increase. This K+ current was mediated by intermediate-conductance Ca2+-activated K+ channels (32 pS at -100 mV) which were sensitive to charybdotoxin and resistant to TEA. Activation of these Ca2+-dependent K+ channels hyperpolarized the plasma membrane from a resting potential of - 40 mV to - 90 mV, as monitored in perforated whole-cell configuration, in turn enhancing Na+-independent, Cl--dependent and DIDS-sensitive HCO3-secretion, as monitored through changes in intracellular pH. PDEC therefore encode concentrations of purinergic agonists as different patterns of [Ca2+](i) changes, which differentially stimulate K+ channels, the Cl--HCO3- exchanger, and exocytosis. Thus, in addition to amplitude, the temporal pattern of [Ca2+](i) increases is an important mechanism for transducing extracellular stimuli into different physiological effects. C1 Univ Washington, Dept Physiol & Biophys, Sch Med, Seattle, WA 98195 USA. Univ Washington, Dept Med, Sch Med, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. Pohang Univ Sci & Technol, Dept Phys, Pohang, South Korea. Seoul Natl Univ, Dept Life Sci, Seoul, South Korea. RP Koh, DS (reprint author), Univ Washington, Dept Physiol & Biophys, Sch Med, Hlth Sci Bldg, Seattle, WA 98195 USA. EM koh@u.washington.edu FU NIAMS NIH HHS [AR17803, R01 AR017803]; NIDDK NIH HHS [DK55885, R01 DK055885] NR 53 TC 17 Z9 18 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-3751 EI 1469-7793 J9 J PHYSIOL-LONDON JI J. Physiol.-London PD OCT 1 PY 2006 VL 576 IS 1 BP 163 EP 178 DI 10.1113/jphysiol.2006.114876 PG 16 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA 093IU UT WOS:000241162800018 PM 16857709 ER PT J AU Roumanas, ED Garrett, N Blackwell, KE Freymiller, E Abemayor, E Wong, WK Reumer, J Fueki, K Fueki, W Kapur, KK AF Roumanas, Eleni D. Garrett, Neal Blackwell, Keith E. Freymiller, Earl Abemayor, Elliot Wong, Weng Kee Reumer, John, III Fueki, Kenji Fueki, Warawan Kapur, Krishan K. TI Masticatory and swallowing threshold performances with conventional and implant-supported prostheses after mandibular fibula free-flap reconstruction SO JOURNAL OF PROSTHETIC DENTISTRY LA English DT Article; Proceedings Paper CT 87th Annual Meeting of the Academy-of-Prosthodontics CY MAY, 2005 CL Scottsdale, AZ SP Acad Prosthodont ID MASSETER MUSCLE-ACTIVITY; OSSEOINTEGRATED IMPLANTS; OROMANDIBULAR RECONSTRUCTION; NATURAL DENTITION; DENTURE WEARERS; FUNCTIONAL-EVALUATION; CANCER PATIENT; BONE-GRAFTS; NECK-CANCER; HEAD AB Statement of problem. Significant strides in rnicrovascular surgical techniques allow predictable restoration of bony and soft tissue orofacial defects. In combination with prosthetic rehabilitation, varying degrees of improvement in esthetics, speech intelligibility, and swallowing have been noted; however, the relative impact of conventional and implant-supported prostheses on restoration of masticatory function arc not known. Purpose. The purpose of this study was to determine whether conventional or implant-supported dental prostheses and current surgical reconstructive procedures restore patients' masticatory function to presurgical levels. Material and methods. Of the 46 subjects enrolled in this study, 23 (7 edentulous and 16 partially dentate) completed conventional prosthesis (CP) treatment and masticatory evaluation, and of these, 15 (3 edentulous and 12 partially dentate) completed treatment and evaluation with an implant-supported prosthesis (IP). Standardized masticatory performance tests with peanuts and carrots as the test food were made on the defect and nondefect sides. Tests of swallowing threshold performance were made with carrots as the test food. Statistical analysis included repeated-measures analysis of variance (ANOVA) with post hoc Tukey HSD tests (alpha=.05). Results. Masticatory function at entry was markedly compromised. Further performance declines were noted following surgery (PS) on both the defect and nondefect sides. Restoration with CP and IP produced improvements (significant for defect side only, P<.05) in performance over the PS interval and were not significantly different from performances at entry prior to surgery. In addition, the performance on the defect side with the IP was significantly greater than the performance with the CP (P<.001). Conclusion. impairment in masticatory ability remains following free-flap reconstruction prior to prosthetic rehabilitation. Both CP and IP may provide improved masticatory ability, permitting patients to regain the functional level they possessed prior to surgical intervention. The IP may contribute to greater support and stability of the prosthesis, resulting in increased use for mastication and superior performance on the defect side compared to the CP. C1 Univ Calif Los Angeles, David Geffen Sch Med, Div Head & Neck Surg, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA USA. Vet Adm Greater Los Angeles Healthcare Syst, Dent Res Lab, Los Angeles, CA USA. Tokyo Med & Dent Univ, Dept Removeable Prosthodont, Tokyo, Japan. Univ Calif Los Angeles, Sch Dent, Div Diagnost & Surg Sci, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Sch Dent, Sect Oral & Maxillofacial Surg, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Sch Dent, Div Adv Prosthodont Biomat & Hosp Dent, Los Angeles, CA 90095 USA. RP Roumanas, ED (reprint author), Univ Calif Los Angeles, Sch Dent, Jane & Jerry Weintraub Ctr Reconstruct Biotechnol, Div Adv Prosthodont Biomat & Hosp Dent, 10833 Le Conte Ave,B3-087 CHS, Los Angeles, CA 90095 USA. EM eroumana@ucla.edu RI Fueki, Kenji/A-9909-2008 OI Fueki, Kenji/0000-0002-5885-2447 FU NCRR NIH HHS [C06 RR-14529-01]; NIDCR NIH HHS [1R01DE11255] NR 42 TC 35 Z9 35 U1 0 U2 3 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0022-3913 J9 J PROSTHET DENT JI J. Prosthet. Dent. PD OCT PY 2006 VL 96 IS 4 BP 289 EP 297 DI 10.1016/j.prosdent.2006.08.015 PG 9 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 099CF UT WOS:000241569400010 PM 17052474 ER EF